Microinjection of LCChemicalEntity into the CA1 region of hippocampus improves LCChemicalEntity - induced LCOTHER in adult male LCOTHER .	3
Microinjection of LCChemicalEntity into the CA1 region of hippocampus improves LCOTHER - induced LCDiseaseOrPhenotypicFeature in adult male LCOTHER .	3
Microinjection of LCOTHER into the CA1 region of hippocampus improves LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature in adult male LCOTHER .	2
The effect of LCChemicalEntity ( LCGeneOrGeneProduct - LCGeneOrGeneProduct antagonist ) on LCOTHER ( LCOTHER LCOTHER antagonist ) - induced LCOTHER in Morris water maze ( MWM ) was investigated .	3
The effect of LCChemicalEntity ( LCOTHER - LCOTHER antagonist ) on LCChemicalEntity ( LCOTHER LCOTHER antagonist ) - induced LCOTHER in Morris water maze ( MWM ) was investigated .	3
The effect of LCChemicalEntity ( LCOTHER - LCOTHER antagonist ) on LCOTHER ( LCOTHER LCOTHER antagonist ) - induced LCDiseaseOrPhenotypicFeature in Morris water maze ( MWM ) was investigated .	3
The effect of LCOTHER ( LCOTHER - LCOTHER antagonist ) on LCChemicalEntity ( LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist ) - induced LCOTHER in Morris water maze ( MWM ) was investigated .	3
The effect of LCOTHER ( LCOTHER - LCOTHER antagonist ) on LCChemicalEntity ( LCOTHER LCOTHER antagonist ) - induced LCDiseaseOrPhenotypicFeature in Morris water maze ( MWM ) was investigated .	2
One week later , they received repeatedly vehicles ( saline , LCOTHER , saline + LCOTHER ) , LCOTHER ( 2 microg / 0 . 5 microl saline / side ; 30 min before training ) , LCChemicalEntity ( 2 , 4 and 8 microg / 0 . 5 microl LCOTHER / side ; 20 min before training ) and LCChemicalEntity ( 2 microg / 0 . 5 microl ; 30 min before LCOTHER injection ) + LCOTHER ( 4 microg / 0 . 5 microl LCOTHER ) through cannulae each day .	3
However , LCOTHER and LCChemicalEntity co - administration resulted in a significant decrease in escape latencies and traveled distances as compared to the LCChemicalEntity - treated LCOTHER .	3
Our findings show that microinjection of LCChemicalEntity into the CA1 region of the hippocampus improves the LCChemicalEntity - induced LCOTHER . LCOTHER : A LCOTHER LCOTHER LCOTHER LCOTHER candidate susceptibility gene? The chromosomal region 12q24 has been previously implicated by linkage studies of both LCOTHER LCOTHER and LCOTHER LCOTHER LCOTHER and we have reported two pedigrees segregating both LCOTHER LCOTHER and LCOTHER ' LCOTHER LCOTHER that show linkage across this region .	3
Our findings show that microinjection of LCChemicalEntity into the CA1 region of the hippocampus improves the LCOTHER - induced LCDiseaseOrPhenotypicFeature . LCOTHER : A LCOTHER LCOTHER LCOTHER LCOTHER candidate susceptibility gene? The chromosomal region 12q24 has been previously implicated by linkage studies of both LCOTHER LCOTHER and LCOTHER LCOTHER LCOTHER and we have reported two pedigrees segregating both LCOTHER LCOTHER and LCOTHER ' LCOTHER LCOTHER that show linkage across this region .	3
Our findings show that microinjection of LCOTHER into the CA1 region of the hippocampus improves the LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature . LCOTHER : A LCOTHER LCOTHER LCOTHER LCOTHER candidate susceptibility gene? The chromosomal region 12q24 has been previously implicated by linkage studies of both LCOTHER LCOTHER and LCOTHER LCOTHER LCOTHER and we have reported two pedigrees segregating both LCOTHER LCOTHER and LCOTHER ' LCOTHER LCOTHER that show linkage across this region .	2
The gene LCGeneOrGeneProduct is located in this chromosomal region and has been recently reported as a susceptibility gene for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER .	1
The gene LCGeneOrGeneProduct is located in this chromosomal region and has been recently reported as a susceptibility gene for LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
LCChemicalEntity on either day induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ; LCOTHER LCOTHER at P45 resulted in LCOTHER cell loss and spontaneous LCOTHER , whereas P20 LCOTHER had no cell loss or spontaneous LCOTHER .	2
LCChemicalEntity on either day induced LCOTHER LCOTHER ; LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature at P45 resulted in LCOTHER cell loss and spontaneous LCOTHER , whereas P20 LCOTHER had no cell loss or spontaneous LCOTHER .	2
LCChemicalEntity on either day induced LCOTHER LCOTHER ; LCOTHER LCOTHER at P45 resulted in LCOTHER cell loss and spontaneous LCDiseaseOrPhenotypicFeature , whereas P20 LCOTHER had no cell loss or spontaneous LCOTHER .	2
LCChemicalEntity on either day induced LCOTHER LCOTHER ; LCOTHER LCOTHER at P45 resulted in LCOTHER cell loss and spontaneous LCOTHER , whereas P20 LCOTHER had no cell loss or spontaneous LCDiseaseOrPhenotypicFeature .	2
This new LCGeneOrGeneProduct homozygous mutation ( LCOTHER . LCOTHER - LCOTHER > LCOTHER ) was identified in three LCOTHER from two North - African consanguineous families with combined LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER in the liver .	1
This new LCGeneOrGeneProduct homozygous mutation ( LCOTHER . LCOTHER - LCOTHER > LCOTHER ) was identified in three LCOTHER from two North - African consanguineous families with combined LCOTHER LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in the liver .	1
This new LCOTHER homozygous mutation ( LCSequenceVariant . LCSequenceVariant - LCSequenceVariant > LCSequenceVariant ) was identified in three LCOTHER from two North - African consanguineous families with combined LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER in the liver .	1
This new LCOTHER homozygous mutation ( LCSequenceVariant . LCSequenceVariant - LCSequenceVariant > LCSequenceVariant ) was identified in three LCOTHER from two North - African consanguineous families with combined LCOTHER LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in the liver .	1
BACKGROUND / AIMS : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER may result from aberrations of the LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	1
BACKGROUND / AIMS : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER may result from aberrations of the LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	1
BACKGROUND / AIMS : LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature may result from aberrations of the LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	1
BACKGROUND / AIMS : LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature may result from aberrations of the LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	1
CONCLUSION : Mutations affecting the intracellular domain of the LCOTHER can result in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER , despite normal serum concentrations of LCGeneOrGeneProduct .	1
CONCLUSION : Mutations affecting the intracellular domain of the LCOTHER can result in LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , despite normal serum concentrations of LCGeneOrGeneProduct .	1
IMPORTANCE OF THE FIELD : LCOTHER , in particular LCChemicalEntity - LCChemicalEntity ( LCOTHER - LCOTHER ) , have been the mainstay of treatment for several solid LCDiseaseOrPhenotypicFeature , including LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , for > 40 years .	3
IMPORTANCE OF THE FIELD : LCOTHER , in particular LCOTHER - LCOTHER ( LCChemicalEntity - LCChemicalEntity ) , have been the mainstay of treatment for several solid LCDiseaseOrPhenotypicFeature , including LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , for > 40 years .	3
WHAT THE READER WILL GAIN : The reader will gain better insight into the safety of LCChemicalEntity in special populations such as LCOTHER with advanced age , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
The most commonly reported toxic effects of LCChemicalEntity are LCDiseaseOrPhenotypicFeature , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER LCOTHER .	2
The most commonly reported toxic effects of LCChemicalEntity are LCOTHER , LCDiseaseOrPhenotypicFeature , LCOTHER , LCOTHER and LCOTHER - LCOTHER LCOTHER .	2
The most commonly reported toxic effects of LCChemicalEntity are LCOTHER , LCOTHER , LCDiseaseOrPhenotypicFeature , LCOTHER and LCOTHER - LCOTHER LCOTHER .	2
The most commonly reported toxic effects of LCChemicalEntity are LCOTHER , LCOTHER , LCOTHER , LCDiseaseOrPhenotypicFeature and LCOTHER - LCOTHER LCOTHER .	2
The most commonly reported toxic effects of LCChemicalEntity are LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
In this investigation the behavioural effects of chronic ( two week ) treatment with LCOTHER - LCOTHER and ( three weeks ) with LCChemicalEntity either separately or in combination with LCChemicalEntity - LCChemicalEntity were tested on adult Lister hooded LCOTHER .	3
This reduction was eliminated when LCChemicalEntity was co administered with LCChemicalEntity - LCChemicalEntity .	3
The LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) plays a crucial role in modulating cell apoptosis and proliferation in a number of diseases , including LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER and LCOTHER .	1
The LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) plays a crucial role in modulating cell apoptosis and proliferation in a number of diseases , including LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature and LCOTHER .	1
The LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) plays a crucial role in modulating cell apoptosis and proliferation in a number of diseases , including LCOTHER LCOTHER , LCOTHER and LCDiseaseOrPhenotypicFeature .	1
The LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER - LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) plays a crucial role in modulating cell apoptosis and proliferation in a number of diseases , including LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER and LCOTHER .	1
The LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER - LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) plays a crucial role in modulating cell apoptosis and proliferation in a number of diseases , including LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature and LCOTHER .	1
The LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER - LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) plays a crucial role in modulating cell apoptosis and proliferation in a number of diseases , including LCOTHER LCOTHER , LCOTHER and LCDiseaseOrPhenotypicFeature .	1
In this study , we first investigated the role of LCGeneOrGeneProduct in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
Histological analyses of apoptosis , proliferation , angiogenesis and LCOTHER zone assessments were performed using LCGeneOrGeneProduct LCGeneOrGeneProduct - mediated LCChemicalEntity nick - end labelling ( TUNEL ) staining , BrdU immunostaining , LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) / LCOTHER immunostaining and Masson ' s trichrome staining , respectively .	1
Improved cardiac function and less scar formation were observed in LCGeneOrGeneProduct KO LCOTHER , and we also observed the altered expression of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER and LCOTHER - LCOTHER / LCOTHER , as well as LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
Improved cardiac function and less scar formation were observed in LCGeneOrGeneProduct KO LCOTHER , and we also observed the altered expression of LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER and LCOTHER - LCOTHER / LCOTHER , as well as LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
Improved cardiac function and less scar formation were observed in LCGeneOrGeneProduct KO LCOTHER , and we also observed the altered expression of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct and LCOTHER - LCOTHER / LCOTHER , as well as LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
Improved cardiac function and less scar formation were observed in LCGeneOrGeneProduct KO LCOTHER , and we also observed the altered expression of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCOTHER , as well as LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
Improved cardiac function and less scar formation were observed in LCGeneOrGeneProduct KO LCOTHER , and we also observed the altered expression of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER and LCOTHER - LCOTHER / LCGeneOrGeneProduct , as well as LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
Improved cardiac function and less scar formation were observed in LCGeneOrGeneProduct KO LCOTHER , and we also observed the altered expression of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER and LCOTHER - LCOTHER / LCOTHER , as well as LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	1
Improved cardiac function and less scar formation were observed in LCGeneOrGeneProduct KO LCOTHER , and we also observed the altered expression of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER and LCOTHER - LCOTHER / LCOTHER , as well as LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	1
Improved cardiac function and less scar formation were observed in LCOTHER KO LCOTHER , and we also observed the altered expression of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCGeneOrGeneProduct and LCOTHER - LCOTHER / LCOTHER , as well as LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
Improved cardiac function and less scar formation were observed in LCOTHER KO LCOTHER , and we also observed the altered expression of LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCGeneOrGeneProduct and LCOTHER - LCOTHER / LCOTHER , as well as LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
On the whole , our findings indicate that the absence of LCGeneOrGeneProduct plays a cardioprotective role in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature by promoting changes in LCOTHER / LCOTHER signalling . Long - Lived LCOTHER + LCOTHER - LCOTHER + T Cells rather than Short - Lived LCOTHER + LCOTHER - LCOTHER + LCOTHER - LCOTHER + T Cells Initiate Rapid LCOTHER - LCOTHER Production To Suppress Anamnestic T Cell Responses during Secondary LCOTHER LCOTHER .	1
On the whole , our findings indicate that the absence of LCGeneOrGeneProduct plays a cardioprotective role in LCOTHER LCOTHER LCOTHER by promoting changes in LCGeneOrGeneProduct / LCOTHER signalling . Long - Lived LCOTHER + LCOTHER - LCOTHER + T Cells rather than Short - Lived LCOTHER + LCOTHER - LCOTHER + LCOTHER - LCOTHER + T Cells Initiate Rapid LCOTHER - LCOTHER Production To Suppress Anamnestic T Cell Responses during Secondary LCOTHER LCOTHER .	1
On the whole , our findings indicate that the absence of LCGeneOrGeneProduct plays a cardioprotective role in LCOTHER LCOTHER LCOTHER by promoting changes in LCOTHER / LCGeneOrGeneProduct signalling . Long - Lived LCOTHER + LCOTHER - LCOTHER + T Cells rather than Short - Lived LCOTHER + LCOTHER - LCOTHER + LCOTHER - LCOTHER + T Cells Initiate Rapid LCOTHER - LCOTHER Production To Suppress Anamnestic T Cell Responses during Secondary LCOTHER LCOTHER .	1
On the whole , our findings indicate that the absence of LCOTHER plays a cardioprotective role in LCOTHER LCOTHER LCOTHER by promoting changes in LCGeneOrGeneProduct / LCGeneOrGeneProduct signalling . Long - Lived LCOTHER + LCOTHER - LCOTHER + T Cells rather than Short - Lived LCOTHER + LCOTHER - LCOTHER + LCOTHER - LCOTHER + T Cells Initiate Rapid LCOTHER - LCOTHER Production To Suppress Anamnestic T Cell Responses during Secondary LCOTHER LCOTHER .	1
LCGeneOrGeneProduct ( + ) T cells that produce LCGeneOrGeneProduct - LCGeneOrGeneProduct are the source of host - protective LCOTHER - LCOTHER during primary LCOTHER with a number of different pathogens , including Plasmodium spp .	1
LCGeneOrGeneProduct ( + ) T cells that produce LCOTHER - LCOTHER are the source of host - protective LCGeneOrGeneProduct - LCGeneOrGeneProduct during primary LCOTHER with a number of different pathogens , including Plasmodium spp .	1
The fate of these LCGeneOrGeneProduct ( + ) LCGeneOrGeneProduct - LCGeneOrGeneProduct ( + ) LCOTHER - LCOTHER ( + ) T cells following clearance of primary LCOTHER and their subsequent influence on the course of repeated infections is , however , presently unknown .	1
The fate of these LCGeneOrGeneProduct ( + ) LCOTHER - LCOTHER ( + ) LCGeneOrGeneProduct - LCGeneOrGeneProduct ( + ) T cells following clearance of primary LCOTHER and their subsequent influence on the course of repeated infections is , however , presently unknown .	1
In this study , utilizing LCGeneOrGeneProduct - LCGeneOrGeneProduct - yellow fluorescent protein ( YFP ) and LCOTHER - LCOTHER - GFP dual reporter LCOTHER , we show that primary LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - induced LCOTHER ( + ) YFP ( + ) GFP ( + ) T cells have limited memory potential , do not stably express LCOTHER - LCOTHER , and are disproportionately lost from the Ag - experienced LCOTHER ( + ) T cell memory population during the maintenance phase postinfection .	1
In this study , utilizing LCOTHER - LCOTHER - yellow fluorescent protein ( YFP ) and LCGeneOrGeneProduct - LCGeneOrGeneProduct - GFP dual reporter LCOTHER , we show that primary LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - induced LCOTHER ( + ) YFP ( + ) GFP ( + ) T cells have limited memory potential , do not stably express LCOTHER - LCOTHER , and are disproportionately lost from the Ag - experienced LCOTHER ( + ) T cell memory population during the maintenance phase postinfection .	1
In this study , utilizing LCOTHER - LCOTHER - yellow fluorescent protein ( YFP ) and LCOTHER - LCOTHER - GFP dual reporter LCOTHER , we show that primary LCOTHER LCOTHER - induced LCGeneOrGeneProduct ( + ) YFP ( + ) GFP ( + ) T cells have limited memory potential , do not stably express LCGeneOrGeneProduct - LCGeneOrGeneProduct , and are disproportionately lost from the Ag - experienced LCOTHER ( + ) T cell memory population during the maintenance phase postinfection .	1
LCGeneOrGeneProduct ( + ) YFP ( + ) GFP ( + ) T cells generally exhibited a short - lived effector rather than effector memory T cell phenotype postinfection and expressed high levels of LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , and LCOTHER , indicative of cellular exhaustion .	1
LCGeneOrGeneProduct ( + ) YFP ( + ) GFP ( + ) T cells generally exhibited a short - lived effector rather than effector memory T cell phenotype postinfection and expressed high levels of LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , and LCOTHER , indicative of cellular exhaustion .	1
LCGeneOrGeneProduct ( + ) YFP ( + ) GFP ( + ) T cells generally exhibited a short - lived effector rather than effector memory T cell phenotype postinfection and expressed high levels of LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCGeneOrGeneProduct , indicative of cellular exhaustion .	1
In contrast , LCGeneOrGeneProduct ( + ) YFP ( + ) GFP ( - ) T cell - derived cells expanded rapidly and upregulated LCGeneOrGeneProduct - LCGeneOrGeneProduct expression during secondary LCOTHER .	1
Correspondingly , LCGeneOrGeneProduct ( + ) T cells were the major producers within an accelerated and amplified LCGeneOrGeneProduct - LCGeneOrGeneProduct response during the early stage of secondary LCOTHER LCOTHER .	1
Correspondingly , LCGeneOrGeneProduct ( + ) T cells were the major producers within an accelerated and amplified LCOTHER - LCOTHER response during the early stage of secondary LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
Correspondingly , LCOTHER ( + ) T cells were the major producers within an accelerated and amplified LCGeneOrGeneProduct - LCGeneOrGeneProduct response during the early stage of secondary LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
The results in this study significantly improve our understanding of the durability of LCGeneOrGeneProduct - LCGeneOrGeneProduct - producing LCOTHER ( + ) T cells postinfection and provide information on how LCOTHER - LCOTHER may contribute to optimized parasite control and prevention of immune - mediated pathology during repeated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER as a LCOTHER LCOTHER : the role of critical LCOTHER groups in LCOTHER LCOTHER .	1
The results in this study significantly improve our understanding of the durability of LCOTHER - LCOTHER - producing LCGeneOrGeneProduct ( + ) T cells postinfection and provide information on how LCGeneOrGeneProduct - LCGeneOrGeneProduct may contribute to optimized parasite control and prevention of immune - mediated pathology during repeated LCOTHER LCOTHER . LCOTHER as a LCOTHER LCOTHER : the role of critical LCOTHER groups in LCOTHER LCOTHER .	1
The results in this study significantly improve our understanding of the durability of LCOTHER - LCOTHER - producing LCGeneOrGeneProduct ( + ) T cells postinfection and provide information on how LCOTHER - LCOTHER may contribute to optimized parasite control and prevention of immune - mediated pathology during repeated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER as a LCOTHER LCOTHER : the role of critical LCOTHER groups in LCOTHER LCOTHER .	1
The results in this study significantly improve our understanding of the durability of LCOTHER - LCOTHER - producing LCOTHER ( + ) T cells postinfection and provide information on how LCGeneOrGeneProduct - LCGeneOrGeneProduct may contribute to optimized parasite control and prevention of immune - mediated pathology during repeated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER as a LCOTHER LCOTHER : the role of critical LCOTHER groups in LCOTHER LCOTHER .	1
LCChemicalEntity ( LCOTHER ) is a metabolite of the LCOTHER LCOTHER LCOTHER ( LCOTHER ) and putatively responsible for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature following anti - LCOTHER therapy with LCOTHER .	2
LCOTHER ( LCChemicalEntity ) is a metabolite of the LCOTHER LCOTHER LCOTHER ( LCOTHER ) and putatively responsible for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature following anti - LCOTHER therapy with LCOTHER .	2
LCOTHER ( LCOTHER ) is a metabolite of the LCOTHER LCOTHER LCOTHER ( LCOTHER ) and putatively responsible for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature following anti - LCOTHER therapy with LCChemicalEntity .	2
LCOTHER ( LCOTHER ) is a metabolite of the LCOTHER LCOTHER LCOTHER ( LCOTHER ) and putatively responsible for LCOTHER LCOTHER following anti - LCDiseaseOrPhenotypicFeature therapy with LCChemicalEntity .	3
LCOTHER of LCChemicalEntity was determined by protein content , cell number , LCOTHER release , LCOTHER LCOTHER exclusion assay and LCGeneOrGeneProduct - LCGeneOrGeneProduct activity .	3
LCChemicalEntity reduced LCOTHER cell number and protein , induced a loss in free intracellular LCChemicalEntity and an increase in LCOTHER markers .	3
LCChemicalEntity reduced LCOTHER cell number and protein , induced a loss in free intracellular LCOTHER and an increase in LCDiseaseOrPhenotypicFeature markers .	2
LCChemicalEntity but not LCOTHER inhibited the LCOTHER LCOTHER LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER and LCOTHER LCOTHER .	3
LCChemicalEntity but not LCOTHER inhibited the LCOTHER LCOTHER LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER LCOTHER .	3
LCChemicalEntity but not LCOTHER inhibited the LCOTHER LCOTHER LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCGeneOrGeneProduct LCGeneOrGeneProduct .	3
LCOTHER activation by LCChemicalEntity was inhibited by LCChemicalEntity .	3
The effects of LCChemicalEntity on LCOTHER LCOTHER activities and LCChemicalEntity could be reproduced in cell lysate .	3
Acidification , which slowed the reaction of LCChemicalEntity with LCChemicalEntity donors , could also attenuate effects of LCOTHER on LCOTHER markers , LCOTHER depletion and LCOTHER LCOTHER inhibition in living cells .	3
Acidification , which slowed the reaction of LCChemicalEntity with LCOTHER donors , could also attenuate effects of LCOTHER on LCDiseaseOrPhenotypicFeature markers , LCOTHER depletion and LCOTHER LCOTHER inhibition in living cells .	2
Acidification , which slowed the reaction of LCChemicalEntity with LCOTHER donors , could also attenuate effects of LCOTHER on LCOTHER markers , LCChemicalEntity depletion and LCOTHER LCOTHER inhibition in living cells .	3
Acidification , which slowed the reaction of LCOTHER with LCOTHER donors , could also attenuate effects of LCChemicalEntity on LCDiseaseOrPhenotypicFeature markers , LCOTHER depletion and LCOTHER LCOTHER inhibition in living cells .	2
Acidification , which slowed the reaction of LCOTHER with LCOTHER donors , could also attenuate effects of LCChemicalEntity on LCOTHER markers , LCChemicalEntity depletion and LCOTHER LCOTHER inhibition in living cells .	3
Thus , LCChemicalEntity directly reacts with cellular protein and non - protein LCChemicalEntity , mediating its LCOTHER on LCOTHER .	3
LCChemicalEntity , an effective antipsychotic , induces LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) in 40% of LCOTHER .	2
LCChemicalEntity , an effective antipsychotic , induces LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) in 40% of LCOTHER .	2
The decreased capacity to concentrate urine is likely due to LCChemicalEntity acutely disrupting the LCOTHER pathway and chronically reducing LCOTHER LCOTHER ( LCOTHER - LCOTHER ) and water channel ( LCGeneOrGeneProduct ) expression in the inner medulla .	3
Targeting an alternative signaling pathway , such as LCGeneOrGeneProduct - mediated signaling , may be an effective method of treating LCChemicalEntity - induced LCOTHER .	2
Targeting an alternative signaling pathway , such as LCOTHER - mediated signaling , may be an effective method of treating LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature .	2
LCGeneOrGeneProduct - LCGeneOrGeneProduct null LCOTHER ( LCOTHER KO ) and strain - matched wild type ( WT ) controls were treated with LCChemicalEntity for 0 , 3 or 5 days .	2
LCOTHER - LCOTHER null LCOTHER ( LCGeneOrGeneProduct KO ) and strain - matched wild type ( WT ) controls were treated with LCChemicalEntity for 0 , 3 or 5 days .	2
Western blot analysis revealed that LCGeneOrGeneProduct expression in medullary tissues was lowered after 3 and 5 days in WT LCOTHER ; however , LCOTHER was unchanged in LCGeneOrGeneProduct KO .	3
Western blot analysis revealed that LCOTHER expression in medullary tissues was lowered after 3 and 5 days in WT LCOTHER ; however , LCGeneOrGeneProduct was unchanged in LCGeneOrGeneProduct KO .	3
LCGeneOrGeneProduct and LCOTHER - LCOTHER expression was lowered in 6 week LCOTHER - treated WT animals whereas in treated LCGeneOrGeneProduct KO LCOTHER , LCOTHER was only reduced by 2 - fold and LCOTHER - LCOTHER expression was unaffected .	3
LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct expression was lowered in 6 week LCChemicalEntity - treated WT animals whereas in treated LCOTHER KO LCOTHER , LCOTHER was only reduced by 2 - fold and LCOTHER - LCOTHER expression was unaffected .	3
LCOTHER and LCOTHER - LCOTHER expression was lowered in 6 week LCChemicalEntity - treated WT animals whereas in treated LCOTHER KO LCOTHER , LCGeneOrGeneProduct was only reduced by 2 - fold and LCOTHER - LCOTHER expression was unaffected .	3
LCOTHER and LCOTHER - LCOTHER expression was lowered in 6 week LCOTHER - treated WT animals whereas in treated LCGeneOrGeneProduct KO LCOTHER , LCOTHER was only reduced by 2 - fold and LCGeneOrGeneProduct - LCGeneOrGeneProduct expression was unaffected .	3
Urinary LCOTHER , LCOTHER and LCChemicalEntity were elevated in LCChemicalEntity - fed WT but not in LCOTHER - fed LCOTHER KO LCOTHER .	1
Urinary LCOTHER , LCOTHER and LCChemicalEntity were elevated in LCOTHER - fed WT but not in LCChemicalEntity - fed LCOTHER KO LCOTHER .	1
Our data show that ablation of LCGeneOrGeneProduct preserves LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct protein expression and localization in LCOTHER - induced LCOTHER , and prevents the development of the severe LCOTHER associated with LCOTHER therapy . LCOTHER LCOTHER LCOTHER - mediated activation of LCOTHER LCOTHER LCOTHER inhibits the growth of LCOTHER in vitro and in vivo .	3
Our data show that ablation of LCGeneOrGeneProduct preserves LCOTHER and LCOTHER - LCOTHER protein expression and localization in LCChemicalEntity - induced LCOTHER , and prevents the development of the severe LCOTHER associated with LCOTHER therapy . LCOTHER LCOTHER LCOTHER - mediated activation of LCOTHER LCOTHER LCOTHER inhibits the growth of LCOTHER in vitro and in vivo .	2
Our data show that ablation of LCGeneOrGeneProduct preserves LCOTHER and LCOTHER - LCOTHER protein expression and localization in LCOTHER - induced LCDiseaseOrPhenotypicFeature , and prevents the development of the severe LCOTHER associated with LCOTHER therapy . LCOTHER LCOTHER LCOTHER - mediated activation of LCOTHER LCOTHER LCOTHER inhibits the growth of LCOTHER in vitro and in vivo .	2
Our data show that ablation of LCGeneOrGeneProduct preserves LCOTHER and LCOTHER - LCOTHER protein expression and localization in LCOTHER - induced LCOTHER , and prevents the development of the severe LCOTHER associated with LCChemicalEntity therapy . LCOTHER LCOTHER LCOTHER - mediated activation of LCOTHER LCOTHER LCOTHER inhibits the growth of LCOTHER in vitro and in vivo .	2
Our data show that ablation of LCOTHER preserves LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct protein expression and localization in LCChemicalEntity - induced LCOTHER , and prevents the development of the severe LCOTHER associated with LCOTHER therapy . LCOTHER LCOTHER LCOTHER - mediated activation of LCOTHER LCOTHER LCOTHER inhibits the growth of LCOTHER in vitro and in vivo .	3
Our data show that ablation of LCOTHER preserves LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct protein expression and localization in LCOTHER - induced LCOTHER , and prevents the development of the severe LCOTHER associated with LCChemicalEntity therapy . LCOTHER LCOTHER LCOTHER - mediated activation of LCOTHER LCOTHER LCOTHER inhibits the growth of LCOTHER in vitro and in vivo .	3
Our data show that ablation of LCOTHER preserves LCOTHER and LCOTHER - LCOTHER protein expression and localization in LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature , and prevents the development of the severe LCOTHER associated with LCOTHER therapy . LCOTHER LCOTHER LCOTHER - mediated activation of LCOTHER LCOTHER LCOTHER inhibits the growth of LCOTHER in vitro and in vivo .	2
Our data show that ablation of LCOTHER preserves LCOTHER and LCOTHER - LCOTHER protein expression and localization in LCChemicalEntity - induced LCOTHER , and prevents the development of the severe LCDiseaseOrPhenotypicFeature associated with LCOTHER therapy . LCOTHER LCOTHER LCOTHER - mediated activation of LCOTHER LCOTHER LCOTHER inhibits the growth of LCOTHER in vitro and in vivo .	2
LCChemicalEntity regulates functions via four receptors ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER ) .	4
LCChemicalEntity regulates functions via four receptors ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER ) .	4
LCChemicalEntity regulates functions via four receptors ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER ) .	4
LCChemicalEntity regulates functions via four receptors ( LCOTHER , LCOTHER , LCOTHER , and LCGeneOrGeneProduct ) .	4
The LCChemicalEntity - LCChemicalEntity - LCChemicalEntity LCChemicalEntity , LCChemicalEntity , LCChemicalEntity - LCChemicalEntity ( LCOTHER ( LCOTHER ) ) / LCOTHER ( LCOTHER + ) / LCOTHER LCOTHER LCOTHER ( LCOTHER ) / LCOTHER - LCOTHER LCOTHER LCOTHER pathway regulates LCDiseaseOrPhenotypicFeature growth .	1
The LCOTHER - LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER - LCOTHER ( LCChemicalEntity ( LCChemicalEntity ) ) / LCOTHER ( LCOTHER + ) / LCOTHER LCOTHER LCOTHER ( LCOTHER ) / LCOTHER - LCOTHER LCOTHER LCOTHER pathway regulates LCDiseaseOrPhenotypicFeature growth .	1
The LCOTHER - LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER - LCOTHER ( LCOTHER ( LCOTHER ) ) / LCChemicalEntity ( LCChemicalEntity + ) / LCOTHER LCOTHER LCOTHER ( LCOTHER ) / LCOTHER - LCOTHER LCOTHER LCOTHER pathway regulates LCDiseaseOrPhenotypicFeature growth .	1
The LCOTHER - LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER - LCOTHER ( LCOTHER ( LCOTHER ) ) / LCOTHER ( LCOTHER + ) / LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) / LCOTHER - LCOTHER LCOTHER LCOTHER pathway regulates LCDiseaseOrPhenotypicFeature growth .	3
The LCOTHER - LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER - LCOTHER ( LCOTHER ( LCOTHER ) ) / LCOTHER ( LCOTHER + ) / LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) / LCOTHER - LCOTHER LCOTHER LCOTHER pathway regulates LCDiseaseOrPhenotypicFeature growth .	3
We evaluated the role of LCGeneOrGeneProduct in the regulation of LCDiseaseOrPhenotypicFeature growth .	1
In LCOTHER - LCOTHER - LCOTHER cells stimulated with ( LCOTHER ) - ( LCOTHER ) - ( - ) - LCOTHER LCOTHER ( LCChemicalEntity ) , we measured ( a ) cell growth , ( b ) LCChemicalEntity ( LCChemicalEntity ) and LCOTHER LCOTHER levels , and ( c ) phosphorylation of LCOTHER and LCOTHER - LCOTHER LCOTHER LCOTHER isoforms .	2
Following knockdown of LCGeneOrGeneProduct , LCOTHER - LCOTHER - LCOTHER cells were stimulated with LCChemicalEntity before evaluating cell growth and LCOTHER LCOTHER - LCOTHER LCOTHER ( LCOTHER ) - LCOTHER / LCOTHER phosphorylation .	2
LCOTHER were treated with saline or LCChemicalEntity for 44 days and LCDiseaseOrPhenotypicFeature volume was measured .	3
LCChemicalEntity inhibited the growth of LCDiseaseOrPhenotypicFeature cells .	3
LCChemicalEntity increased LCChemicalEntity ( LCChemicalEntity ) levels and LCOTHER phosphorylation and decreased LCOTHER / LCOTHER phosphorylation .	2
Silencing of LCGeneOrGeneProduct prevented LCChemicalEntity inhibition of LCOTHER - LCOTHER - LCOTHER cell growth and ablated LCOTHER effects on LCOTHER / LCOTHER phosphorylation .	2
Silencing of LCGeneOrGeneProduct prevented LCOTHER inhibition of LCOTHER - LCOTHER - LCOTHER cell growth and ablated LCChemicalEntity effects on LCOTHER / LCOTHER phosphorylation .	2
In vivo , LCChemicalEntity decreased LCDiseaseOrPhenotypicFeature growth and expression of LCOTHER and its receptors ; LCOTHER expression was increased .	3
LCChemicalEntity inhibits LCDiseaseOrPhenotypicFeature growth by LCOTHER - dependent LCOTHER / LCOTHER dephosphorylation .	3
Modulation of LCGeneOrGeneProduct by LCOTHER LCOTHER may be important in regulating LCDiseaseOrPhenotypicFeature growth . The LCOTHER LCOTHER LCOTHER LCOTHER polymorphism is associated with LCOTHER LCOTHER in LCOTHER ' LCOTHER LCOTHER LCOTHER .	3
In this report the distribution of the exonic LCSequenceVariant / LCSequenceVariant single nucleotide polymorphism ( SNP ) in LCOTHER LCOTHER LCOTHER ( LCOTHER ) gene , resulting in the amino acid substitution LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , was investigated in a large population of LCDiseaseOrPhenotypicFeature LCOTHER ( n = 321 ) and non - demented control ( n = 208 ) .	1
In this report the distribution of the exonic LCOTHER / LCOTHER single nucleotide polymorphism ( SNP ) in LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) gene , resulting in the amino acid substitution LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , was investigated in a large population of LCDiseaseOrPhenotypicFeature LCOTHER ( n = 321 ) and non - demented control ( n = 208 ) .	1
In this report the distribution of the exonic LCOTHER / LCOTHER single nucleotide polymorphism ( SNP ) in LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene , resulting in the amino acid substitution LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , was investigated in a large population of LCDiseaseOrPhenotypicFeature LCOTHER ( n = 321 ) and non - demented control ( n = 208 ) .	1
In this report the distribution of the exonic LCOTHER / LCOTHER single nucleotide polymorphism ( SNP ) in LCOTHER LCOTHER LCOTHER ( LCOTHER ) gene , resulting in the amino acid substitution LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant ( LCOTHER ) , was investigated in a large population of LCDiseaseOrPhenotypicFeature LCOTHER ( n = 321 ) and non - demented control ( n = 208 ) .	1
In this report the distribution of the exonic LCOTHER / LCOTHER single nucleotide polymorphism ( SNP ) in LCOTHER LCOTHER LCOTHER ( LCOTHER ) gene , resulting in the amino acid substitution LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCSequenceVariant ) , was investigated in a large population of LCDiseaseOrPhenotypicFeature LCOTHER ( n = 321 ) and non - demented control ( n = 208 ) .	1
An increased representation of the LCGeneOrGeneProduct AA genotype was observed in LCDiseaseOrPhenotypicFeature LCOTHER with fast LCOTHER LCOTHER in comparison with that from LCOTHER with slow deterioration rate .	1
Our findings suggest that the LCSequenceVariant LCOTHER polymorphism is associated with a faster rate of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER LCOTHER , highlighting the important role of purine metabolism in the progression of this LCOTHER LCOTHER . LCOTHER LCOTHER use , LCOTHER LCOTHER , and LCOTHER LCOTHER : a systematic review of published and unpublished studies .	2
Our findings suggest that the LCSequenceVariant LCOTHER polymorphism is associated with a faster rate of LCOTHER LCOTHER in LCDiseaseOrPhenotypicFeature LCOTHER , highlighting the important role of purine metabolism in the progression of this LCOTHER LCOTHER . LCOTHER LCOTHER use , LCOTHER LCOTHER , and LCOTHER LCOTHER : a systematic review of published and unpublished studies .	1
Our findings suggest that the LCOTHER LCGeneOrGeneProduct polymorphism is associated with a faster rate of LCOTHER LCOTHER in LCDiseaseOrPhenotypicFeature LCOTHER , highlighting the important role of purine metabolism in the progression of this LCOTHER LCOTHER . LCOTHER LCOTHER use , LCOTHER LCOTHER , and LCOTHER LCOTHER : a systematic review of published and unpublished studies .	1
RESULTS : In a pooled analysis of 1460 LCDiseaseOrPhenotypicFeature and 3817 LCOTHER / LCOTHER , LCOTHER were more frequent in LCOTHER vs LCOTHER / LCOTHER in all treatment groups , but the excess increased from 2 . 8 ( odds ratio ; range , 2 . 3 - 3 . 5 ) in nonantithrombotic users to 5 . 7 ( range , 3 . 4 - 9 . 7 ) in antiplatelet users and 8 . 0 ( range , 3 . 5 - 17 . 8 ) in LCChemicalEntity users ( P difference = 0 . 01 ) .	1
RESULTS : In a pooled analysis of 1460 LCOTHER and 3817 LCOTHER / LCOTHER , LCDiseaseOrPhenotypicFeature were more frequent in LCOTHER vs LCOTHER / LCOTHER in all treatment groups , but the excess increased from 2 . 8 ( odds ratio ; range , 2 . 3 - 3 . 5 ) in nonantithrombotic users to 5 . 7 ( range , 3 . 4 - 9 . 7 ) in antiplatelet users and 8 . 0 ( range , 3 . 5 - 17 . 8 ) in LCChemicalEntity users ( P difference = 0 . 01 ) .	1
RESULTS : In a pooled analysis of 1460 LCOTHER and 3817 LCOTHER / LCOTHER , LCOTHER were more frequent in LCDiseaseOrPhenotypicFeature vs LCOTHER / LCOTHER in all treatment groups , but the excess increased from 2 . 8 ( odds ratio ; range , 2 . 3 - 3 . 5 ) in nonantithrombotic users to 5 . 7 ( range , 3 . 4 - 9 . 7 ) in antiplatelet users and 8 . 0 ( range , 3 . 5 - 17 . 8 ) in LCChemicalEntity users ( P difference = 0 . 01 ) .	1
There was also an excess of LCDiseaseOrPhenotypicFeature in LCChemicalEntity users vs nonusers with LCOTHER ( OR , 2 . 7 ; 95% CI , 1 . 6 - 4 . 4 ; P < 0 . 001 ) but none in LCOTHER users with LCOTHER / LCOTHER ( OR , 1 . 3 ; 95% CI , 0 . 9 - 1 . 7 ; P = 0 . 33 ; P difference = 0 . 01 ) .	1
There was also an excess of LCDiseaseOrPhenotypicFeature in LCOTHER users vs nonusers with LCOTHER ( OR , 2 . 7 ; 95% CI , 1 . 6 - 4 . 4 ; P < 0 . 001 ) but none in LCChemicalEntity users with LCOTHER / LCOTHER ( OR , 1 . 3 ; 95% CI , 0 . 9 - 1 . 7 ; P = 0 . 33 ; P difference = 0 . 01 ) .	1
There was also an excess of LCOTHER in LCOTHER users vs nonusers with LCDiseaseOrPhenotypicFeature ( OR , 2 . 7 ; 95% CI , 1 . 6 - 4 . 4 ; P < 0 . 001 ) but none in LCChemicalEntity users with LCOTHER / LCOTHER ( OR , 1 . 3 ; 95% CI , 0 . 9 - 1 . 7 ; P = 0 . 33 ; P difference = 0 . 01 ) .	1
CONCLUSIONS : The excess of LCDiseaseOrPhenotypicFeature in LCChemicalEntity users with LCOTHER compared to other groups suggests that LCOTHER increase the risk of LCOTHER - associated LCOTHER .	1
CONCLUSIONS : The excess of LCDiseaseOrPhenotypicFeature in LCOTHER users with LCOTHER compared to other groups suggests that LCOTHER increase the risk of LCChemicalEntity - associated LCOTHER .	1
CONCLUSIONS : The excess of LCOTHER in LCOTHER users with LCDiseaseOrPhenotypicFeature compared to other groups suggests that LCOTHER increase the risk of LCChemicalEntity - associated LCOTHER .	1
CONCLUSIONS : The excess of LCOTHER in LCOTHER users with LCOTHER compared to other groups suggests that LCDiseaseOrPhenotypicFeature increase the risk of LCChemicalEntity - associated LCOTHER .	1
LCChemicalEntity , an oral inhibitor of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , has shown phase I efficacy in LCOTHER .	3
LCChemicalEntity , an oral inhibitor of the LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , has shown phase I efficacy in LCOTHER .	3
LCChemicalEntity , an oral inhibitor of the LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , has shown phase I efficacy in LCDiseaseOrPhenotypicFeature .	3
LCOTHER , an oral inhibitor of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , has shown phase I efficacy in LCDiseaseOrPhenotypicFeature .	1
LCOTHER , an oral inhibitor of the LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , has shown phase I efficacy in LCDiseaseOrPhenotypicFeature .	1
CONCLUSIONS : LCChemicalEntity 10 mg / day was well tolerated , showing modest clinical activity in pretreated LCDiseaseOrPhenotypicFeature .	3
Evaluation of LCChemicalEntity plus standard therapy for metastatic LCDiseaseOrPhenotypicFeature continues . Decreased Whole - Body Fat Mass Produced by Chronic LCOTHER Consumption is Associated with Activation of LCOTHER - Mediated Protein Synthesis and Increased Autophagy in Epididymal White Adipose Tissue .	3
LCChemicalEntity increased LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct , and LCOTHER LCOTHER phosphorylation , suggesting increased autophagy , while markers of apoptosis ( cleaved LCOTHER - LCOTHER LCOTHER - LCOTHER , and LCOTHER ) were unchanged .	2
LCChemicalEntity increased LCOTHER - LCOTHER , LCOTHER - LCOTHER LCOTHER - LCOTHER , and LCGeneOrGeneProduct LCOTHER phosphorylation , suggesting increased autophagy , while markers of apoptosis ( cleaved LCOTHER - LCOTHER LCOTHER - LCOTHER , and LCOTHER ) were unchanged .	2
Although LCChemicalEntity increased LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , and LCOTHER - LCOTHER mRNA , no change in key components of the LCOTHER inflammasome ( LCOTHER , LCOTHER , and cleaved LCOTHER - LCOTHER ) was detected suggesting LCOTHER did not increase pyroptosis .	2
Although LCChemicalEntity increased LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , and LCOTHER - LCOTHER mRNA , no change in key components of the LCOTHER inflammasome ( LCOTHER , LCOTHER , and cleaved LCOTHER - LCOTHER ) was detected suggesting LCOTHER did not increase pyroptosis .	2
Although LCChemicalEntity increased LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCGeneOrGeneProduct - LCGeneOrGeneProduct mRNA , no change in key components of the LCOTHER inflammasome ( LCOTHER , LCOTHER , and cleaved LCOTHER - LCOTHER ) was detected suggesting LCOTHER did not increase pyroptosis .	2
CONCLUSIONS : These results demonstrate that the LCChemicalEntity - induced decrease in whole - body fat mass resulted in part from activation of autophagy in eWAT as protein synthesis was increased and mediated by the specific increase in the activity of LCGeneOrGeneProduct . A potential regulatory single nucleotide polymorphism in the promoter of the LCOTHER gene may be associated with LCOTHER LCOTHER in the Chinese Han population .	1
BACKGROUND : LCOTHER with defects in the LCGeneOrGeneProduct gene exhibit multiple aging phenotypes including LCDiseaseOrPhenotypicFeature .	1
We hypothesised that the LCSequenceVariant - LCSequenceVariant polymorphism in the promoter region of the LCOTHER LCOTHER gene may contribute to the prevalence of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	2
We hypothesised that the LCSequenceVariant - LCSequenceVariant polymorphism in the promoter region of the LCOTHER LCOTHER gene may contribute to the prevalence of LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	2
We hypothesised that the LCOTHER - LCOTHER polymorphism in the promoter region of the LCOTHER LCGeneOrGeneProduct gene may contribute to the prevalence of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
We hypothesised that the LCOTHER - LCOTHER polymorphism in the promoter region of the LCOTHER LCGeneOrGeneProduct gene may contribute to the prevalence of LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
METHODS : We investigate whether the LCSequenceVariant - LCSequenceVariant polymorphism of LCOTHER is associated with LCDiseaseOrPhenotypicFeature in a population consisting of 215 LCOTHER with LCOTHER and 220 non - LCOTHER subjects .	2
METHODS : We investigate whether the LCSequenceVariant - LCSequenceVariant polymorphism of LCOTHER is associated with LCOTHER in a population consisting of 215 LCOTHER with LCDiseaseOrPhenotypicFeature and 220 non - LCOTHER subjects .	2
METHODS : We investigate whether the LCOTHER - LCOTHER polymorphism of LCGeneOrGeneProduct is associated with LCDiseaseOrPhenotypicFeature in a population consisting of 215 LCOTHER with LCOTHER and 220 non - LCOTHER subjects .	1
METHODS : We investigate whether the LCOTHER - LCOTHER polymorphism of LCGeneOrGeneProduct is associated with LCOTHER in a population consisting of 215 LCOTHER with LCDiseaseOrPhenotypicFeature and 220 non - LCOTHER subjects .	1
RESULTS : Differences in the genotype distributions of the LCSequenceVariant - LCSequenceVariant polymorphism between the LCDiseaseOrPhenotypicFeature and non - LCOTHER groups are statistically significant ( P = 0 . 032 ) .	2
There are differential effects of age , gender and smoking status on the association of the LCSequenceVariant - LCSequenceVariant polymorphism with LCDiseaseOrPhenotypicFeature ; the LCOTHER - LCOTHER polymorphism is significantly associated with LCOTHER in subjects over 60years old , in females and in nonsmokers .	2
There are differential effects of age , gender and smoking status on the association of the LCSequenceVariant - LCSequenceVariant polymorphism with LCOTHER ; the LCOTHER - LCOTHER polymorphism is significantly associated with LCDiseaseOrPhenotypicFeature in subjects over 60years old , in females and in nonsmokers .	2
There are differential effects of age , gender and smoking status on the association of the LCOTHER - LCOTHER polymorphism with LCOTHER ; the LCSequenceVariant - LCSequenceVariant polymorphism is significantly associated with LCDiseaseOrPhenotypicFeature in subjects over 60years old , in females and in nonsmokers .	2
CONCLUSIONS : The LCSequenceVariant - LCSequenceVariant polymorphism of the LCOTHER LCOTHER gene is associated with LCDiseaseOrPhenotypicFeature and may be a potential regulatory site . Protective effects of LCOTHER on LCOTHER LCOTHER LCOTHER in LCOTHER .	2
CONCLUSIONS : The LCOTHER - LCOTHER polymorphism of the LCOTHER LCGeneOrGeneProduct gene is associated with LCDiseaseOrPhenotypicFeature and may be a potential regulatory site . Protective effects of LCOTHER on LCOTHER LCOTHER LCOTHER in LCOTHER .	1
We investigated the effects of LCChemicalEntity , a plasma inhibitor of coagulation factors , in LCOTHER with LCChemicalEntity LCChemicalEntity - induced LCOTHER , which is an experimental model of LCOTHER LCOTHER LCOTHER .	3
We investigated the effects of LCChemicalEntity , a plasma inhibitor of coagulation factors , in LCOTHER with LCOTHER LCOTHER - induced LCDiseaseOrPhenotypicFeature , which is an experimental model of LCOTHER LCOTHER LCOTHER .	3
We investigated the effects of LCChemicalEntity , a plasma inhibitor of coagulation factors , in LCOTHER with LCOTHER LCOTHER - induced LCOTHER , which is an experimental model of LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
We investigated the effects of LCOTHER , a plasma inhibitor of coagulation factors , in LCOTHER with LCChemicalEntity LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature , which is an experimental model of LCOTHER LCOTHER LCOTHER .	2
We investigated the effects of LCOTHER , a plasma inhibitor of coagulation factors , in LCOTHER with LCChemicalEntity LCChemicalEntity - induced LCOTHER , which is an experimental model of LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
LCChemicalEntity ( 50 or 500 IU / kg / i . v . ) was administered to LCOTHER once a day for 10 days immediately after the injection of LCChemicalEntity LCChemicalEntity ( 50 mg / kg / i . v . ) .	3
Treatment with LCChemicalEntity attenuated the LCChemicalEntity LCChemicalEntity - induced LCOTHER LCOTHER .	3
Treatment with LCChemicalEntity attenuated the LCOTHER LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
Treatment with LCOTHER attenuated the LCChemicalEntity LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
LCChemicalEntity LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER were also suppressed .	2
LCChemicalEntity LCChemicalEntity - induced LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature were also suppressed .	2
In addition , LCChemicalEntity treatment markedly suppressed LCChemicalEntity LCChemicalEntity - induced apoptosis of renal tubular epithelial cells .	3
These findings suggest that LCGeneOrGeneProduct plays an important role in the pathogenesis of LCChemicalEntity LCChemicalEntity - induced LCOTHER LCOTHER .	1
These findings suggest that LCGeneOrGeneProduct plays an important role in the pathogenesis of LCOTHER LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
These findings suggest that LCOTHER plays an important role in the pathogenesis of LCChemicalEntity LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
Treatment with LCChemicalEntity may be clinically effective in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . A single amino acid substitution confers B - cell clonogenic activity to the LCOTHER - LCOTHER matrix protein LCOTHER .	3
Recent data highlight the presence , in LCOTHER - LCOTHER - LCOTHER LCOTHER with LCOTHER , of LCGeneOrGeneProduct variants ( vp17s ) endowed with B - cell clonogenicity , suggesting a role of vp17s in LCDiseaseOrPhenotypicFeature .	1
Here , we show that a single LCSequenceVariant ( LCSequenceVariant ) LCSequenceVariant LCSequenceVariant ( LCSequenceVariant ) LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCDiseaseOrPhenotypicFeature progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCDiseaseOrPhenotypicFeature progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCGeneOrGeneProduct ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCSequenceVariant variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCDiseaseOrPhenotypicFeature progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCDiseaseOrPhenotypicFeature progression ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCDiseaseOrPhenotypicFeature progression ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCDiseaseOrPhenotypicFeature progression ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCDiseaseOrPhenotypicFeature progression ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCDiseaseOrPhenotypicFeature progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCDiseaseOrPhenotypicFeature progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCDiseaseOrPhenotypicFeature progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCDiseaseOrPhenotypicFeature progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER ) .	1
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCDiseaseOrPhenotypicFeature progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct ) .	1
Previously , we and others reported that recessive mutations in the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) can cause both lethal and nonlethal LCDiseaseOrPhenotypicFeature , thus demonstrating that pterygia resulted from LCOTHER LCOTHER .	1
Previously , we and others reported that recessive mutations in the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) can cause both lethal and nonlethal LCDiseaseOrPhenotypicFeature , thus demonstrating that pterygia resulted from LCOTHER LCOTHER .	1
No LCOTHER , LCOTHER , or LCOTHER mutations were detected , but a homozygous LCGeneOrGeneProduct frameshift mutation , LCOTHER . LCOTHER - LCOTHER , was identified in a family with three children affected with lethal LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
No LCOTHER , LCOTHER , or LCOTHER mutations were detected , but a homozygous LCOTHER frameshift mutation , LCSequenceVariant . LCSequenceVariant - LCSequenceVariant , was identified in a family with three children affected with lethal LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
Previously , LCGeneOrGeneProduct mutations have been reported in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
Functional studies were consistent with the hypothesis that whereas incomplete loss of LCGeneOrGeneProduct function may cause LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , more severe loss of function can result in a lethal LCOTHER LCOTHER phenotype . Comparison of sequential LCOTHER isolates in a LCOTHER with LCOTHER and failing antiviral therapy .	3
Functional studies were consistent with the hypothesis that whereas incomplete loss of LCGeneOrGeneProduct function may cause LCOTHER LCOTHER , more severe loss of function can result in a lethal LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature phenotype . Comparison of sequential LCOTHER isolates in a LCOTHER with LCOTHER and failing antiviral therapy .	3
In parallel , we used LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) genotyping , and a - and UL10 - 13 - sequence analysis to study LCDiseaseOrPhenotypicFeature interstrain variability .	1
In parallel , we used LCOTHER LCOTHER ( LCGeneOrGeneProduct ) genotyping , and a - and UL10 - 13 - sequence analysis to study LCDiseaseOrPhenotypicFeature interstrain variability .	1
LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct changes responsible for resistance to LCChemicalEntity were initially detected at residues 591 and 592 , and then at position 594 .	1
Decreased sensitivity to LCChemicalEntity coincided with the appearance of amino acid substitution LCSequenceVariant in DNA polymerase , whereas cross - resistance to LCOTHER and LCOTHER was due to the LCOTHER substitution .	3
Decreased sensitivity to LCOTHER coincided with the appearance of amino acid substitution LCOTHER in DNA polymerase , whereas cross - resistance to LCChemicalEntity and LCOTHER was due to the LCSequenceVariant substitution .	3
Decreased sensitivity to LCOTHER coincided with the appearance of amino acid substitution LCOTHER in DNA polymerase , whereas cross - resistance to LCOTHER and LCChemicalEntity was due to the LCSequenceVariant substitution .	3
LCChemicalEntity ( LCOTHER ) - LCChemicalEntity ( LCOTHER ) is an effective therapy for relapsed / refractory ( R / R ) LCOTHER LCOTHER ( LCOTHER ) .	5
LCChemicalEntity ( LCOTHER ) - LCOTHER ( LCChemicalEntity ) is an effective therapy for relapsed / refractory ( R / R ) LCOTHER LCOTHER ( LCOTHER ) .	5
LCChemicalEntity ( LCOTHER ) - LCOTHER ( LCOTHER ) is an effective therapy for relapsed / refractory ( R / R ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	3
LCChemicalEntity ( LCOTHER ) - LCOTHER ( LCOTHER ) is an effective therapy for relapsed / refractory ( R / R ) LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	3
LCOTHER ( LCChemicalEntity ) - LCChemicalEntity ( LCOTHER ) is an effective therapy for relapsed / refractory ( R / R ) LCOTHER LCOTHER ( LCOTHER ) .	5
LCOTHER ( LCChemicalEntity ) - LCOTHER ( LCChemicalEntity ) is an effective therapy for relapsed / refractory ( R / R ) LCOTHER LCOTHER ( LCOTHER ) .	5
LCOTHER ( LCChemicalEntity ) - LCOTHER ( LCOTHER ) is an effective therapy for relapsed / refractory ( R / R ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	3
LCOTHER ( LCChemicalEntity ) - LCOTHER ( LCOTHER ) is an effective therapy for relapsed / refractory ( R / R ) LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	3
LCOTHER ( LCOTHER ) - LCChemicalEntity ( LCOTHER ) is an effective therapy for relapsed / refractory ( R / R ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	3
LCOTHER ( LCOTHER ) - LCChemicalEntity ( LCOTHER ) is an effective therapy for relapsed / refractory ( R / R ) LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	3
LCOTHER ( LCOTHER ) - LCOTHER ( LCChemicalEntity ) is an effective therapy for relapsed / refractory ( R / R ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	3
LCOTHER ( LCOTHER ) - LCOTHER ( LCChemicalEntity ) is an effective therapy for relapsed / refractory ( R / R ) LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	3
This retrospective study investigated the combination of LCChemicalEntity ( 1 . 3 mg / m ( 2 ) on days 1 , 4 , 8 , and 11 every 3 weeks ) and LCChemicalEntity ( 20 mg on the day of and the day after LCOTHER ) as salvage treatment in 85 LCOTHER with R / R LCOTHER after prior autologous stem cell transplantation or conventional chemotherapy .	5
This retrospective study investigated the combination of LCChemicalEntity ( 1 . 3 mg / m ( 2 ) on days 1 , 4 , 8 , and 11 every 3 weeks ) and LCOTHER ( 20 mg on the day of and the day after LCOTHER ) as salvage treatment in 85 LCOTHER with R / R LCDiseaseOrPhenotypicFeature after prior autologous stem cell transplantation or conventional chemotherapy .	3
This retrospective study investigated the combination of LCOTHER ( 1 . 3 mg / m ( 2 ) on days 1 , 4 , 8 , and 11 every 3 weeks ) and LCChemicalEntity ( 20 mg on the day of and the day after LCOTHER ) as salvage treatment in 85 LCOTHER with R / R LCDiseaseOrPhenotypicFeature after prior autologous stem cell transplantation or conventional chemotherapy .	3
This retrospective study investigated the combination of LCOTHER ( 1 . 3 mg / m ( 2 ) on days 1 , 4 , 8 , and 11 every 3 weeks ) and LCOTHER ( 20 mg on the day of and the day after LCChemicalEntity ) as salvage treatment in 85 LCOTHER with R / R LCDiseaseOrPhenotypicFeature after prior autologous stem cell transplantation or conventional chemotherapy .	3
Eighty - seven percent of the LCOTHER had received immunomodulatory drugs included in some line of therapy before LCChemicalEntity - LCChemicalEntity .	5
The median number of LCChemicalEntity - LCChemicalEntity cycles was 6 , up to a maximum of 12 cycles .	5
Prolonged PFS and OS were observed in LCOTHER achieving CR and receiving LCChemicalEntity - LCChemicalEntity a single line of prior therapy .	5
LCChemicalEntity - LCChemicalEntity was an effective salvage treatment for LCOTHER LCOTHER , particularly for those in first relapse . LCOTHER LCOTHER ( LCOTHER ) LCOTHER gene ( LCOTHER ) variants may increase LCOTHER LCOTHER and LCOTHER in LCOTHER LCOTHER LCOTHER .	5
LCChemicalEntity - LCOTHER was an effective salvage treatment for LCDiseaseOrPhenotypicFeature LCOTHER , particularly for those in first relapse . LCOTHER LCOTHER ( LCOTHER ) LCOTHER gene ( LCOTHER ) variants may increase LCOTHER LCOTHER and LCOTHER in LCOTHER LCOTHER LCOTHER .	3
LCOTHER - LCChemicalEntity was an effective salvage treatment for LCDiseaseOrPhenotypicFeature LCOTHER , particularly for those in first relapse . LCOTHER LCOTHER ( LCOTHER ) LCOTHER gene ( LCOTHER ) variants may increase LCOTHER LCOTHER and LCOTHER in LCOTHER LCOTHER LCOTHER .	3
The LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct gene ( LCOTHER ) is associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and is located on chromosome 22q11 . 23 .	1
The LCOTHER LCOTHER ( LCOTHER ) LCOTHER gene ( LCGeneOrGeneProduct ) is associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and is located on chromosome 22q11 . 23 .	1
Its gene product , the LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct , is strongly expressed in the caudate nucleus , which also is involved in LCDiseaseOrPhenotypicFeature .	1
In addition , association of LCGeneOrGeneProduct variants with LCDiseaseOrPhenotypicFeature was replicated for individuals with LCOTHER .	1
In addition , association of LCGeneOrGeneProduct variants with LCOTHER was replicated for individuals with LCDiseaseOrPhenotypicFeature .	1
Findings point toward a possible mediating role of LCGeneOrGeneProduct variants on phenotypic expression in LCDiseaseOrPhenotypicFeature that need to be replicated in a larger sample . LCOTHER in LCOTHER LCOTHER with LCOTHER and / or glomerular LCOTHER .	1
In this study , we developed a new LCDiseaseOrPhenotypicFeature - responsive reporter vector using a LCOTHER - responsive element of the 5 ' LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct untranslated region and generated a novel LCOTHER - sensing transgenic LCOTHER .	1
In this study , we developed a new LCOTHER - responsive reporter vector using a LCDiseaseOrPhenotypicFeature - responsive element of the 5 ' LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct untranslated region and generated a novel LCOTHER - sensing transgenic LCOTHER .	1
With this model , we were able to identify diffuse cortical LCDiseaseOrPhenotypicFeature in the LCChemicalEntity LCChemicalEntity - induced LCOTHER LCOTHER and focal and segmental LCOTHER in the remnant kidney model .	1
With this model , we were able to identify diffuse cortical LCOTHER in the LCChemicalEntity LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and focal and segmental LCOTHER in the remnant kidney model .	2
Expression of the LCDiseaseOrPhenotypicFeature - responsive transgene increased throughout the observation period , reaching 2 . 2 - fold at 2 weeks in the LCChemicalEntity LCChemicalEntity model and 2 . 6 - fold at 4 weeks in the remnant kidney model , whereas that of LCOTHER LCOTHER LCOTHER LCOTHER showed a mild decrease , reflecting distinct behaviors of the two genes .	1
Expression of the LCDiseaseOrPhenotypicFeature - responsive transgene increased throughout the observation period , reaching 2 . 2 - fold at 2 weeks in the LCOTHER LCOTHER model and 2 . 6 - fold at 4 weeks in the remnant kidney model , whereas that of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct showed a mild decrease , reflecting distinct behaviors of the two genes .	1
Finally , we identified the localization of proliferating cell nuclear antigen - positive , LCGeneOrGeneProduct - LCGeneOrGeneProduct - positive , and terminal LCOTHER nick - end labeled - positive cells in the LCDiseaseOrPhenotypicFeature cortical area in the remnant kidney model .	1
Finally , we identified the localization of proliferating cell nuclear antigen - positive , LCOTHER - LCOTHER - positive , and terminal LCChemicalEntity nick - end labeled - positive cells in the LCDiseaseOrPhenotypicFeature cortical area in the remnant kidney model .	1
INTRODUCTION : The possible LCDiseaseOrPhenotypicFeature effects of LCChemicalEntity , namely LCOTHER and LCOTHER , were investigated in adult Charles Foster albino LCOTHER of either sex , weighing 150 - 200 g .	2
RESULTS : The results indicate that LCChemicalEntity - and LCOTHER - treated LCOTHER showed LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in comparison to control LCOTHER in all the parameters studied .	2
RESULTS : The results indicate that LCOTHER - and LCChemicalEntity - treated LCOTHER showed LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in comparison to control LCOTHER in all the parameters studied .	2
To evaluate this phenomenon , the association between two single nucleotide polymorphisms ( LCSequenceVariant LCSequenceVariant LCSequenceVariant transition in exon7 leading to amino acid substitution LCOTHER and LCOTHER at 3 ' UTR ) of LCOTHER gene in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature were analyzed in a case - control study of 100 individuals in South Indian population .	3
To evaluate this phenomenon , the association between two single nucleotide polymorphisms ( LCOTHER LCOTHER LCOTHER transition in exon7 leading to amino acid substitution LCSequenceVariant and LCOTHER at 3 ' UTR ) of LCOTHER gene in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature were analyzed in a case - control study of 100 individuals in South Indian population .	3
The estimated relative risk was significantly high for individuals with w1 / m1 genotype at 3 ' UTR of LCOTHER gene ( OR - 4 . 64 ; 95%CI = 1 . 51 - 14 . 86 ; P < 0 . 01 ) whereas the LCOTHER LCSequenceVariant / LCSequenceVariant genotype ( w2 / m2 ) on exon 7 was found to be associated with a decreased risk for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( OR - 0 . 17 ; 95%CI = 0 . 02 - 0 . 89 ; P = 0 . 03 ) .	3
BACKGROUND : LCOTHER ' LCOTHER LCOTHER ( LCOTHER ) is an LCOTHER LCOTHER LCOTHER resulting from inactivating mutations in the LCChemicalEntity - sensitive LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) gene .	2
BACKGROUND : LCOTHER ' LCOTHER LCOTHER ( LCOTHER ) is an LCOTHER LCOTHER LCOTHER resulting from inactivating mutations in the LCChemicalEntity - sensitive LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) gene .	2
In this study , we analysed mutations in the LCGeneOrGeneProduct gene of seven Japanese LCOTHER with LCDiseaseOrPhenotypicFeature .	1
Five of them [ LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCOTHER . LCOTHER ] have been reported in Japanese LCOTHER , but not in LCDiseaseOrPhenotypicFeature LCOTHER from other ethnic groups .	2
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCSequenceVariant ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCOTHER . LCOTHER ] have been reported in Japanese LCOTHER , but not in LCDiseaseOrPhenotypicFeature LCOTHER from other ethnic groups .	2
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCOTHER . LCOTHER ] have been reported in Japanese LCOTHER , but not in LCDiseaseOrPhenotypicFeature LCOTHER from other ethnic groups .	2
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCSequenceVariant ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCOTHER . LCOTHER ] have been reported in Japanese LCOTHER , but not in LCDiseaseOrPhenotypicFeature LCOTHER from other ethnic groups .	2
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCOTHER . LCOTHER ] have been reported in Japanese LCOTHER , but not in LCDiseaseOrPhenotypicFeature LCOTHER from other ethnic groups .	2
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCSequenceVariant ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCOTHER . LCOTHER ] have been reported in Japanese LCOTHER , but not in LCDiseaseOrPhenotypicFeature LCOTHER from other ethnic groups .	2
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER ) and LCOTHER . LCOTHER ] have been reported in Japanese LCOTHER , but not in LCDiseaseOrPhenotypicFeature LCOTHER from other ethnic groups .	2
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCSequenceVariant ) and LCOTHER . LCOTHER ] have been reported in Japanese LCOTHER , but not in LCDiseaseOrPhenotypicFeature LCOTHER from other ethnic groups .	2
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCSequenceVariant . LCSequenceVariant ] have been reported in Japanese LCOTHER , but not in LCDiseaseOrPhenotypicFeature LCOTHER from other ethnic groups .	2
CONCLUSIONS : We found four novel mutations in the LCGeneOrGeneProduct gene in seven Japanese LCOTHER with LCDiseaseOrPhenotypicFeature .	1
Moreover , our study suggests that the distribution of mutations in the LCGeneOrGeneProduct gene in Japanese LCDiseaseOrPhenotypicFeature LCOTHER potentially differs from that in other populations . Autosomal dominant mutation in the signal peptide of LCOTHER in a kindred with LCOTHER , LCOTHER , and LCOTHER .	1
Homozygous or compound heterozygous mutations in LCGeneOrGeneProduct ( LCOTHER ) cause LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , which is characterized by LCOTHER in utero due to LCOTHER LCOTHER and LCOTHER LCOTHER .	1
Homozygous or compound heterozygous mutations in LCOTHER ( LCGeneOrGeneProduct ) cause LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , which is characterized by LCOTHER in utero due to LCOTHER LCOTHER and LCOTHER LCOTHER .	1
The phenotype resembles the LCDiseaseOrPhenotypicFeature caused by LCChemicalEntity - LCChemicalEntity LCChemicalEntity LCChemicalEntity or LCOTHER LCOTHER LCOTHER intake during pregnancy .	2
The phenotype resembles the LCDiseaseOrPhenotypicFeature caused by LCOTHER - LCOTHER LCOTHER LCOTHER or LCChemicalEntity LCChemicalEntity LCChemicalEntity intake during pregnancy .	2
Recently , heterozygous LCGeneOrGeneProduct mutations were shown to result in early - onset LCDiseaseOrPhenotypicFeature , LCOTHER , and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
Recently , heterozygous LCGeneOrGeneProduct mutations were shown to result in early - onset LCOTHER , LCDiseaseOrPhenotypicFeature , and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
Recently , heterozygous LCGeneOrGeneProduct mutations were shown to result in early - onset LCOTHER , LCOTHER , and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
Recently , heterozygous LCGeneOrGeneProduct mutations were shown to result in early - onset LCOTHER , LCOTHER , and LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
We report mutation analysis of the LCGeneOrGeneProduct gene in 39 kindreds with LCDiseaseOrPhenotypicFeature and LCOTHER who previously tested negative for mutations in the LCOTHER ( LCOTHER ) and LCOTHER ( LCOTHER LCOTHER LCOTHER LCOTHER ) genes .	1
We report mutation analysis of the LCGeneOrGeneProduct gene in 39 kindreds with LCOTHER and LCDiseaseOrPhenotypicFeature who previously tested negative for mutations in the LCOTHER ( LCOTHER ) and LCOTHER ( LCOTHER LCOTHER LCOTHER LCOTHER ) genes .	1
On this basis , we conclude that LCGeneOrGeneProduct mutations are rare events in LCOTHER with LCDiseaseOrPhenotypicFeature .	1
Within the kindred , we found affected individuals over 4 generations who carried the novel LCGeneOrGeneProduct mutation and were characterized by significant LCDiseaseOrPhenotypicFeature , LCOTHER , and LCOTHER .	1
Within the kindred , we found affected individuals over 4 generations who carried the novel LCGeneOrGeneProduct mutation and were characterized by significant LCOTHER , LCDiseaseOrPhenotypicFeature , and LCOTHER .	1
Within the kindred , we found affected individuals over 4 generations who carried the novel LCGeneOrGeneProduct mutation and were characterized by significant LCOTHER , LCOTHER , and LCDiseaseOrPhenotypicFeature .	1
Because all heterozygous LCGeneOrGeneProduct mutations that have been described are localized in the signal sequence , screening of the LCOTHER gene for LCOTHER with LCDiseaseOrPhenotypicFeature with LCOTHER and LCOTHER may best be focused on sequencing of exon 1 , which encodes the signal peptide . A Critical Role for the LCOTHER LCOTHER LCOTHER LCOTHER in Virus - Induced LCOTHER LCOTHER in LCOTHER .	1
Because all heterozygous LCGeneOrGeneProduct mutations that have been described are localized in the signal sequence , screening of the LCOTHER gene for LCOTHER with LCOTHER with LCDiseaseOrPhenotypicFeature and LCOTHER may best be focused on sequencing of exon 1 , which encodes the signal peptide . A Critical Role for the LCOTHER LCOTHER LCOTHER LCOTHER in Virus - Induced LCOTHER LCOTHER in LCOTHER .	1
Because all heterozygous LCGeneOrGeneProduct mutations that have been described are localized in the signal sequence , screening of the LCOTHER gene for LCOTHER with LCOTHER with LCOTHER and LCDiseaseOrPhenotypicFeature may best be focused on sequencing of exon 1 , which encodes the signal peptide . A Critical Role for the LCOTHER LCOTHER LCOTHER LCOTHER in Virus - Induced LCOTHER LCOTHER in LCOTHER .	1
Because all heterozygous LCOTHER mutations that have been described are localized in the signal sequence , screening of the LCGeneOrGeneProduct gene for LCOTHER with LCDiseaseOrPhenotypicFeature with LCOTHER and LCOTHER may best be focused on sequencing of exon 1 , which encodes the signal peptide . A Critical Role for the LCOTHER LCOTHER LCOTHER LCOTHER in Virus - Induced LCOTHER LCOTHER in LCOTHER .	1
Because all heterozygous LCOTHER mutations that have been described are localized in the signal sequence , screening of the LCGeneOrGeneProduct gene for LCOTHER with LCOTHER with LCDiseaseOrPhenotypicFeature and LCOTHER may best be focused on sequencing of exon 1 , which encodes the signal peptide . A Critical Role for the LCOTHER LCOTHER LCOTHER LCOTHER in Virus - Induced LCOTHER LCOTHER in LCOTHER .	1
Because all heterozygous LCOTHER mutations that have been described are localized in the signal sequence , screening of the LCGeneOrGeneProduct gene for LCOTHER with LCOTHER with LCOTHER and LCDiseaseOrPhenotypicFeature may best be focused on sequencing of exon 1 , which encodes the signal peptide . A Critical Role for the LCOTHER LCOTHER LCOTHER LCOTHER in Virus - Induced LCOTHER LCOTHER in LCOTHER .	1
The pathogenesis of LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , characterized by immune - mediated damage of LCGeneOrGeneProduct - producing b - cells of pancreatic islets , may involve LCOTHER LCOTHER .	1
Essential components of the innate immune antiviral response , including LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) and LCOTHER LCOTHER - mediated signaling pathways , are candidates for determining susceptibility to LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
Essential components of the innate immune antiviral response , including LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCGeneOrGeneProduct LCGeneOrGeneProduct - mediated signaling pathways , are candidates for determining susceptibility to LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
LCDiseaseOrPhenotypicFeature can be induced in LEW . 1WR1 weanling LCOTHER challenged with virus or with the viral mimetic LCChemicalEntity : LCChemicalEntity LCChemicalEntity ( LCOTHER LCOTHER : LCOTHER ) .	2
LCDiseaseOrPhenotypicFeature can be induced in LEW . 1WR1 weanling LCOTHER challenged with virus or with the viral mimetic LCOTHER : LCOTHER LCOTHER ( LCChemicalEntity LCChemicalEntity : LCChemicalEntity ) .	2
LCOTHER deficiency significantly delayed the onset and frequency of LCDiseaseOrPhenotypicFeature and greatly reduced the intensity of LCOTHER after LCChemicalEntity LCChemicalEntity : LCChemicalEntity treatment .	2
The occurrence of LCOTHER LCOTHER LCOTHER - induced LCDiseaseOrPhenotypicFeature was also diminished in LCGeneOrGeneProduct - deficient animals .	1
LCChemicalEntity LCChemicalEntity ( LCOTHER LCOTHER - LCOTHER , LCOTHER - ( - ) - LCOTHER - LCOTHER - LCOTHER , LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER , LCOTHER / LCOTHER - LCOTHER - LCOTHER ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCChemicalEntity ( LCOTHER ) and LCOTHER ( LCOTHER ) .	6
LCChemicalEntity LCChemicalEntity ( LCOTHER LCOTHER - LCOTHER , LCOTHER - ( - ) - LCOTHER - LCOTHER - LCOTHER , LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER , LCOTHER / LCOTHER - LCOTHER - LCOTHER ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCOTHER ( LCChemicalEntity ) and LCOTHER ( LCOTHER ) .	6
LCChemicalEntity LCChemicalEntity ( LCOTHER LCOTHER - LCOTHER , LCOTHER - ( - ) - LCOTHER - LCOTHER - LCOTHER , LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER , LCOTHER / LCOTHER - LCOTHER - LCOTHER ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCOTHER ( LCOTHER ) and LCChemicalEntity ( LCOTHER ) .	6
LCChemicalEntity LCChemicalEntity ( LCOTHER LCOTHER - LCOTHER , LCOTHER - ( - ) - LCOTHER - LCOTHER - LCOTHER , LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER , LCOTHER / LCOTHER - LCOTHER - LCOTHER ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCOTHER ( LCOTHER ) and LCOTHER ( LCChemicalEntity ) .	6
LCOTHER LCOTHER ( LCChemicalEntity LCChemicalEntity - LCChemicalEntity , LCOTHER - ( - ) - LCOTHER - LCOTHER - LCOTHER , LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER , LCOTHER / LCOTHER - LCOTHER - LCOTHER ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCChemicalEntity ( LCOTHER ) and LCOTHER ( LCOTHER ) .	6
LCOTHER LCOTHER ( LCChemicalEntity LCChemicalEntity - LCChemicalEntity , LCOTHER - ( - ) - LCOTHER - LCOTHER - LCOTHER , LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER , LCOTHER / LCOTHER - LCOTHER - LCOTHER ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCOTHER ( LCChemicalEntity ) and LCOTHER ( LCOTHER ) .	6
LCOTHER LCOTHER ( LCChemicalEntity LCChemicalEntity - LCChemicalEntity , LCOTHER - ( - ) - LCOTHER - LCOTHER - LCOTHER , LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER , LCOTHER / LCOTHER - LCOTHER - LCOTHER ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCOTHER ( LCOTHER ) and LCChemicalEntity ( LCOTHER ) .	6
LCOTHER LCOTHER ( LCChemicalEntity LCChemicalEntity - LCChemicalEntity , LCOTHER - ( - ) - LCOTHER - LCOTHER - LCOTHER , LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER , LCOTHER / LCOTHER - LCOTHER - LCOTHER ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCOTHER ( LCOTHER ) and LCOTHER ( LCChemicalEntity ) .	6
LCOTHER LCOTHER ( LCOTHER LCOTHER - LCOTHER , LCChemicalEntity - ( - ) - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity , LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity / LCChemicalEntity , LCChemicalEntity / LCChemicalEntity - LCChemicalEntity - LCChemicalEntity ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCChemicalEntity ( LCOTHER ) and LCOTHER ( LCOTHER ) .	6
LCOTHER LCOTHER ( LCOTHER LCOTHER - LCOTHER , LCChemicalEntity - ( - ) - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity , LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity / LCChemicalEntity , LCChemicalEntity / LCChemicalEntity - LCChemicalEntity - LCChemicalEntity ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCOTHER ( LCChemicalEntity ) and LCOTHER ( LCOTHER ) .	6
LCOTHER LCOTHER ( LCOTHER LCOTHER - LCOTHER , LCChemicalEntity - ( - ) - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity , LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity / LCChemicalEntity , LCChemicalEntity / LCChemicalEntity - LCChemicalEntity - LCChemicalEntity ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCOTHER ( LCOTHER ) and LCChemicalEntity ( LCOTHER ) .	6
LCOTHER LCOTHER ( LCOTHER LCOTHER - LCOTHER , LCChemicalEntity - ( - ) - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity , LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity / LCChemicalEntity , LCChemicalEntity / LCChemicalEntity - LCChemicalEntity - LCChemicalEntity ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCOTHER ( LCOTHER ) and LCOTHER ( LCChemicalEntity ) .	6
LCOTHER LCOTHER ( LCOTHER LCOTHER - LCOTHER , LCOTHER - ( - ) - LCOTHER - LCOTHER - LCOTHER , LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER , LCOTHER / LCOTHER - LCOTHER - LCOTHER ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCChemicalEntity ( LCOTHER ) and LCChemicalEntity ( LCOTHER ) .	6
LCOTHER LCOTHER ( LCOTHER LCOTHER - LCOTHER , LCOTHER - ( - ) - LCOTHER - LCOTHER - LCOTHER , LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER , LCOTHER / LCOTHER - LCOTHER - LCOTHER ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCChemicalEntity ( LCOTHER ) and LCOTHER ( LCChemicalEntity ) .	6
LCOTHER LCOTHER ( LCOTHER LCOTHER - LCOTHER , LCOTHER - ( - ) - LCOTHER - LCOTHER - LCOTHER , LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER , LCOTHER / LCOTHER - LCOTHER - LCOTHER ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCOTHER ( LCChemicalEntity ) and LCChemicalEntity ( LCOTHER ) .	6
LCOTHER LCOTHER ( LCOTHER LCOTHER - LCOTHER , LCOTHER - ( - ) - LCOTHER - LCOTHER - LCOTHER , LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER , LCOTHER / LCOTHER - LCOTHER - LCOTHER ) is a novel LCOTHER LCOTHER , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCOTHER ( LCChemicalEntity ) and LCOTHER ( LCChemicalEntity ) .	6
We have studied the effects of oral treatment with LCChemicalEntity LCChemicalEntity on a whole - animal model in which partial LCDiseaseOrPhenotypicFeature can be elicited repeatedly on different days without changes in threshold or LCOTHER patterns .	3
We have studied the effects of oral treatment with LCChemicalEntity LCChemicalEntity on a whole - animal model in which partial LCOTHER can be elicited repeatedly on different days without changes in threshold or LCDiseaseOrPhenotypicFeature patterns .	3
Mutations of LCGeneOrGeneProduct / LCOTHER , found recently in LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER , are predominantly truncating mutations .	1
Mutations of LCGeneOrGeneProduct / LCOTHER , found recently in LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , are predominantly truncating mutations .	1
Mutations of LCOTHER / LCGeneOrGeneProduct , found recently in LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER , are predominantly truncating mutations .	1
Mutations of LCOTHER / LCGeneOrGeneProduct , found recently in LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , are predominantly truncating mutations .	1
Additionally , mutation analysis for LCGeneOrGeneProduct / LCOTHER in 120 LCOTHER with LCDiseaseOrPhenotypicFeature yielded seven different ( four novel ) mutations in five LCOTHER , four of whom also presented with congenital LCOTHER LCOTHER .	1
Additionally , mutation analysis for LCGeneOrGeneProduct / LCOTHER in 120 LCOTHER with LCOTHER yielded seven different ( four novel ) mutations in five LCOTHER , four of whom also presented with congenital LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
Additionally , mutation analysis for LCOTHER / LCGeneOrGeneProduct in 120 LCOTHER with LCDiseaseOrPhenotypicFeature yielded seven different ( four novel ) mutations in five LCOTHER , four of whom also presented with congenital LCOTHER LCOTHER .	1
Additionally , mutation analysis for LCOTHER / LCGeneOrGeneProduct in 120 LCOTHER with LCOTHER yielded seven different ( four novel ) mutations in five LCOTHER , four of whom also presented with congenital LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
CONCLUSIONS : Hypomorphic LCGeneOrGeneProduct / LCOTHER mutations cause LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
CONCLUSIONS : Hypomorphic LCGeneOrGeneProduct / LCOTHER mutations cause LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
CONCLUSIONS : Hypomorphic LCOTHER / LCGeneOrGeneProduct mutations cause LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
CONCLUSIONS : Hypomorphic LCOTHER / LCGeneOrGeneProduct mutations cause LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
OBJECTIVE : Genetic association of the sequence variants for LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER genes with LCDiseaseOrPhenotypicFeature in an African American population was investigated .	1
RESULTS : In the case - control design , the frequencies of the TT genotype for SNP LCSequenceVariant and the homozygous deletion variant ( LCOTHER ) in the fourth exon of the LCOTHER - LCOTHER gene were higher among LCOTHER with LCOTHER with LCDiseaseOrPhenotypicFeature compared with the controls ( odds ratio [ OR ] , 2 . 779 , P = . 016 ; and OR , 3 . 09 , P = . 022 , respectively ) .	2
RESULTS : In the case - control design , the frequencies of the TT genotype for SNP LCOTHER and the homozygous deletion variant ( LCSequenceVariant ) in the fourth exon of the LCOTHER - LCOTHER gene were higher among LCOTHER with LCOTHER with LCDiseaseOrPhenotypicFeature compared with the controls ( odds ratio [ OR ] , 2 . 779 , P = . 016 ; and OR , 3 . 09 , P = . 022 , respectively ) .	2
RESULTS : In the case - control design , the frequencies of the TT genotype for SNP LCOTHER and the homozygous deletion variant ( LCOTHER ) in the fourth exon of the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene were higher among LCOTHER with LCOTHER with LCDiseaseOrPhenotypicFeature compared with the controls ( odds ratio [ OR ] , 2 . 779 , P = . 016 ; and OR , 3 . 09 , P = . 022 , respectively ) .	1
CONCLUSION : Our findings suggest that the genetic variants of the LCGeneOrGeneProduct - LCGeneOrGeneProduct but not the LCOTHER - LCOTHER gene contribute to LCDiseaseOrPhenotypicFeature susceptibility in this African - American population . Identification of a gain - of - function mutation of the LCOTHER LCOTHER in LCOTHER with LCOTHER LCOTHER LCOTHER .	1
There is currently no known LCOTHER LCOTHER linked to LCGeneOrGeneProduct ( LCOTHER ) or its receptor ( LCGeneOrGeneProduct ) in LCOTHER .	4
There is currently no known LCOTHER LCOTHER linked to LCOTHER ( LCGeneOrGeneProduct ) or its receptor ( LCGeneOrGeneProduct ) in LCOTHER .	4
Given the essential role of this hormonal system in breast physiology , we reasoned that genetic anomalies of LCGeneOrGeneProduct / LCGeneOrGeneProduct genes may be related to the occurrence of LCOTHER LCOTHER with high proliferative potential .	4
Given the essential role of this hormonal system in breast physiology , we reasoned that genetic anomalies of LCGeneOrGeneProduct / LCOTHER genes may be related to the occurrence of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with high proliferative potential .	1
Given the essential role of this hormonal system in breast physiology , we reasoned that genetic anomalies of LCOTHER / LCGeneOrGeneProduct genes may be related to the occurrence of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with high proliferative potential .	1
In a prospective study involving 74 LCDiseaseOrPhenotypicFeature LCOTHER and 170 control subjects , we identified four LCOTHER harboring a heterozygous single nucleotide polymorphism in exon 6 of the LCGeneOrGeneProduct gene , encoding LCOTHER ( LCOTHER ) - - > LCOTHER substitution in its extracellular domain .	1
In a prospective study involving 74 LCDiseaseOrPhenotypicFeature LCOTHER and 170 control subjects , we identified four LCOTHER harboring a heterozygous single nucleotide polymorphism in exon 6 of the LCOTHER gene , encoding LCSequenceVariant ( LCSequenceVariant ) - - > LCSequenceVariant substitution in its extracellular domain .	2
This sole substitution was sufficient to confer constitutive activity to the receptor variant ( LCOTHER ( LCOTHER ) ) , as assessed in three reconstituted cell models ( LCOTHER / LCOTHER , LCOTHER and LCOTHER - LCOTHER cells ) by LCGeneOrGeneProduct - independent ( i ) LCGeneOrGeneProduct tyrosine phosphorylation , ( ii ) activation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) signaling , ( iii ) transcriptional activity toward a LCOTHER - responsive reporter gene , and ( iv ) cell proliferation and protection from cell death .	4
This sole substitution was sufficient to confer constitutive activity to the receptor variant ( LCOTHER ( LCOTHER ) ) , as assessed in three reconstituted cell models ( LCOTHER / LCOTHER , LCOTHER and LCOTHER - LCOTHER cells ) by LCOTHER - independent ( i ) LCGeneOrGeneProduct tyrosine phosphorylation , ( ii ) activation of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) signaling , ( iii ) transcriptional activity toward a LCOTHER - responsive reporter gene , and ( iv ) cell proliferation and protection from cell death .	1
This sole substitution was sufficient to confer constitutive activity to the receptor variant ( LCOTHER ( LCOTHER ) ) , as assessed in three reconstituted cell models ( LCOTHER / LCOTHER , LCOTHER and LCOTHER - LCOTHER cells ) by LCOTHER - independent ( i ) LCGeneOrGeneProduct tyrosine phosphorylation , ( ii ) activation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) signaling , ( iii ) transcriptional activity toward a LCOTHER - responsive reporter gene , and ( iv ) cell proliferation and protection from cell death .	1
Constitutive activity of LCGeneOrGeneProduct ( LCOTHER ) in the breast sample from a LCOTHER was supported by increased LCGeneOrGeneProduct signaling .	1
We found that depletion of LCGeneOrGeneProduct and LCOTHER using small interfering RNA led to LCGeneOrGeneProduct remodeling .	1
We found that depletion of LCOTHER and LCGeneOrGeneProduct using small interfering RNA led to LCGeneOrGeneProduct remodeling .	1
Depletion of LCGeneOrGeneProduct also induced the formation of invadopodia containing LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) .	1
Depletion of LCGeneOrGeneProduct also induced the formation of invadopodia containing LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) .	1
LCGeneOrGeneProduct depletion caused increased LCGeneOrGeneProduct - LCGeneOrGeneProduct trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of LCOTHER - LCOTHER with membranes containing the endosomal markers LCOTHER and LCOTHER but increased localization with the exocytic LCOTHER .	1
LCGeneOrGeneProduct depletion caused increased LCOTHER - LCOTHER trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of LCGeneOrGeneProduct - LCGeneOrGeneProduct with membranes containing the endosomal markers LCOTHER and LCOTHER but increased localization with the exocytic LCOTHER .	1
LCGeneOrGeneProduct depletion caused increased LCOTHER - LCOTHER trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of LCOTHER - LCOTHER with membranes containing the endosomal markers LCOTHER and LCOTHER but increased localization with the exocytic LCGeneOrGeneProduct .	1
LCOTHER depletion caused increased LCGeneOrGeneProduct - LCGeneOrGeneProduct trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of LCOTHER - LCOTHER with membranes containing the endosomal markers LCGeneOrGeneProduct and LCOTHER but increased localization with the exocytic LCOTHER .	1
LCOTHER depletion caused increased LCGeneOrGeneProduct - LCGeneOrGeneProduct trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of LCOTHER - LCOTHER with membranes containing the endosomal markers LCOTHER and LCGeneOrGeneProduct but increased localization with the exocytic LCOTHER .	1
LCOTHER depletion caused increased LCGeneOrGeneProduct - LCGeneOrGeneProduct trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of LCOTHER - LCOTHER with membranes containing the endosomal markers LCOTHER and LCOTHER but increased localization with the exocytic LCGeneOrGeneProduct .	1
LCOTHER depletion caused increased LCOTHER - LCOTHER trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of LCGeneOrGeneProduct - LCGeneOrGeneProduct with membranes containing the endosomal markers LCGeneOrGeneProduct and LCOTHER but increased localization with the exocytic LCOTHER .	1
LCOTHER depletion caused increased LCOTHER - LCOTHER trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of LCGeneOrGeneProduct - LCGeneOrGeneProduct with membranes containing the endosomal markers LCOTHER and LCGeneOrGeneProduct but increased localization with the exocytic LCOTHER .	1
LCOTHER depletion caused increased LCOTHER - LCOTHER trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of LCGeneOrGeneProduct - LCGeneOrGeneProduct with membranes containing the endosomal markers LCOTHER and LCOTHER but increased localization with the exocytic LCGeneOrGeneProduct .	1
Mining oncogenomic databases revealed that loss of the LCGeneOrGeneProduct allele and underexpression of LCOTHER mRNA are associated with LCOTHER LCDiseaseOrPhenotypicFeature .	3
Mining oncogenomic databases revealed that loss of the LCOTHER allele and underexpression of LCGeneOrGeneProduct mRNA are associated with LCOTHER LCDiseaseOrPhenotypicFeature .	3
We propose that LCGeneOrGeneProduct synthesizes a pool of LCChemicalEntity ( LCChemicalEntity ) LCChemicalEntity that maintains LCOTHER - LCOTHER traffic in the degradative pathway and suppresses the formation of invadopodia . Common germline genetic variation in antioxidant defense genes and survival after diagnosis of LCOTHER LCOTHER .	1
We propose that LCGeneOrGeneProduct synthesizes a pool of LCOTHER ( LCOTHER ) LCOTHER that maintains LCGeneOrGeneProduct - LCGeneOrGeneProduct traffic in the degradative pathway and suppresses the formation of invadopodia . Common germline genetic variation in antioxidant defense genes and survival after diagnosis of LCOTHER LCOTHER .	1
We propose that LCOTHER synthesizes a pool of LCChemicalEntity ( LCChemicalEntity ) LCChemicalEntity that maintains LCGeneOrGeneProduct - LCGeneOrGeneProduct traffic in the degradative pathway and suppresses the formation of invadopodia . Common germline genetic variation in antioxidant defense genes and survival after diagnosis of LCOTHER LCOTHER .	1
Of particular interest are genes involved in defense against LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCOTHER ) because LCOTHER are thought to cause DNA damage and contribute to the pathogenesis of LCDiseaseOrPhenotypicFeature .	2
Of particular interest are genes involved in defense against LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) because LCOTHER are thought to cause DNA damage and contribute to the pathogenesis of LCDiseaseOrPhenotypicFeature .	2
Of particular interest are genes involved in defense against LCOTHER LCOTHER LCOTHER ( LCOTHER ) because LCChemicalEntity are thought to cause DNA damage and contribute to the pathogenesis of LCDiseaseOrPhenotypicFeature .	2
LCOTHER AND METHODS : We examined associations between 54 polymorphisms that tag the known common variants ( minor allele frequency > 0 . 05 ) in 10 genes involved in oxidative damage repair ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) and survival in 4 , 470 LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
LCGeneOrGeneProduct LCOTHER is located near the LCOTHER insertion sequence element in the LCOTHER 3 ' untranslated region , and the rare allele of this SNP is associated with an increased risk of LCDiseaseOrPhenotypicFeature , with a hazard ratio of 1 . 27 per rare allele carried ( 95% CI , 1 . 13 to 11 . 43 ) .	1
LCOTHER LCSequenceVariant is located near the LCOTHER insertion sequence element in the LCOTHER 3 ' untranslated region , and the rare allele of this SNP is associated with an increased risk of LCDiseaseOrPhenotypicFeature , with a hazard ratio of 1 . 27 per rare allele carried ( 95% CI , 1 . 13 to 11 . 43 ) .	2
LCOTHER LCOTHER is located near the LCOTHER insertion sequence element in the LCGeneOrGeneProduct 3 ' untranslated region , and the rare allele of this SNP is associated with an increased risk of LCDiseaseOrPhenotypicFeature , with a hazard ratio of 1 . 27 per rare allele carried ( 95% CI , 1 . 13 to 11 . 43 ) .	1
CONCLUSION : These data provide strong support for the hypothesis that common variation in LCGeneOrGeneProduct is associated with prognosis after a diagnosis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . A novel LCOTHER nonsense mutation ( LCOTHER ) in a German family with LCOTHER LCOTHER LCOTHER LCOTHER .	1
Very recently , mutations of the LCGeneOrGeneProduct gene in exons 2 - 9 have been found in LCDiseaseOrPhenotypicFeature LCOTHER , suggesting that this gene plays an important role in orofacial development .	1
The premature stop codon was responsible for a truncated protein lacking parts of the DNA - binding domain and the complete LCOTHER - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - binding domain probably essential for interactions with the LCGeneOrGeneProduct transcription factors . Late - onset LCOTHER LCOTHER : molecular pathology in two siblings .	4
We report on a new allele at the LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) locus causing late - onset LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
We report on a new allele at the LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) locus causing late - onset LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
We report on a new allele at the LCOTHER LCOTHER ( LCGeneOrGeneProduct ) locus causing late - onset LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
We report on a new allele at the LCOTHER LCOTHER ( LCGeneOrGeneProduct ) locus causing late - onset LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
A comparison of genotypes , LCGeneOrGeneProduct activities , and clinical data on 4 individuals carrying the allele of 81 LCOTHER with LCDiseaseOrPhenotypicFeature examined , further validates the concept that different degrees of residual LCOTHER activity are the basis of phenotypical variation in LCOTHER . Families with the risk allele of LCOTHER reveal a link between LCOTHER and another component of the same molecular pathway , LCOTHER .	1
A comparison of genotypes , LCGeneOrGeneProduct activities , and clinical data on 4 individuals carrying the allele of 81 LCOTHER with LCOTHER examined , further validates the concept that different degrees of residual LCOTHER activity are the basis of phenotypical variation in LCDiseaseOrPhenotypicFeature . Families with the risk allele of LCOTHER reveal a link between LCOTHER and another component of the same molecular pathway , LCOTHER .	1
A comparison of genotypes , LCOTHER activities , and clinical data on 4 individuals carrying the allele of 81 LCOTHER with LCOTHER examined , further validates the concept that different degrees of residual LCGeneOrGeneProduct activity are the basis of phenotypical variation in LCDiseaseOrPhenotypicFeature . Families with the risk allele of LCOTHER reveal a link between LCOTHER and another component of the same molecular pathway , LCOTHER .	1
We have previously reported a robust association between an allelic haplotype of ' LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ' ( LCOTHER ) and LCDiseaseOrPhenotypicFeature in a nationwide collection of Finnish LCOTHER families .	1
We have previously reported a robust association between an allelic haplotype of ' LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ' ( LCOTHER ) and LCOTHER in a nationwide collection of Finnish LCDiseaseOrPhenotypicFeature families .	1
We have previously reported a robust association between an allelic haplotype of ' LCOTHER LCOTHER LCOTHER LCOTHER ' ( LCGeneOrGeneProduct ) and LCDiseaseOrPhenotypicFeature in a nationwide collection of Finnish LCOTHER families .	1
We have previously reported a robust association between an allelic haplotype of ' LCOTHER LCOTHER LCOTHER LCOTHER ' ( LCGeneOrGeneProduct ) and LCOTHER in a nationwide collection of Finnish LCDiseaseOrPhenotypicFeature families .	1
LCGeneOrGeneProduct association to LCDiseaseOrPhenotypicFeature has since been replicated in multiple independent study samples from different populations .	1
Notably , this and other converging lines of evidence underline the importance of LCGeneOrGeneProduct - related functional pathways in the etiology of LCDiseaseOrPhenotypicFeature . LCOTHER regulates meiotic G2 / M transition by modulating the LCOTHER / LCOTHER - LCOTHER LCOTHER pathway in oocytes .	1
Depletion of LCGeneOrGeneProduct by LCChemicalEntity injection decreased LCOTHER LCOTHER levels , resulting in attenuation of LCOTHER - LCOTHER LCOTHER ( LCOTHER ) activation , and severely compromised meiotic resumption .	3
Depletion of LCGeneOrGeneProduct by LCOTHER injection decreased LCGeneOrGeneProduct LCGeneOrGeneProduct levels , resulting in attenuation of LCOTHER - LCOTHER LCOTHER ( LCOTHER ) activation , and severely compromised meiotic resumption .	2
Depletion of LCGeneOrGeneProduct by LCOTHER injection decreased LCOTHER LCOTHER levels , resulting in attenuation of LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) activation , and severely compromised meiotic resumption .	2
Depletion of LCGeneOrGeneProduct by LCOTHER injection decreased LCOTHER LCOTHER levels , resulting in attenuation of LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) activation , and severely compromised meiotic resumption .	2
Depletion of LCOTHER by LCChemicalEntity injection decreased LCGeneOrGeneProduct LCGeneOrGeneProduct levels , resulting in attenuation of LCOTHER - LCOTHER LCOTHER ( LCOTHER ) activation , and severely compromised meiotic resumption .	3
Depletion of LCOTHER by LCChemicalEntity injection decreased LCOTHER LCOTHER levels , resulting in attenuation of LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) activation , and severely compromised meiotic resumption .	3
Depletion of LCOTHER by LCChemicalEntity injection decreased LCOTHER LCOTHER levels , resulting in attenuation of LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) activation , and severely compromised meiotic resumption .	3
LCGeneOrGeneProduct protects LCGeneOrGeneProduct LCGeneOrGeneProduct from destruction by competing with the action of LCOTHER / LCOTHER ( LCOTHER ) Impaired G2 / M transition after LCOTHER depletion could be rescued by expression of exogenous LCOTHER LCOTHER .	2
LCGeneOrGeneProduct protects LCOTHER LCOTHER from destruction by competing with the action of LCGeneOrGeneProduct / LCGeneOrGeneProduct ( LCOTHER ) Impaired G2 / M transition after LCOTHER depletion could be rescued by expression of exogenous LCOTHER LCOTHER .	1
LCGeneOrGeneProduct protects LCOTHER LCOTHER from destruction by competing with the action of LCOTHER / LCOTHER ( LCGeneOrGeneProduct ) Impaired G2 / M transition after LCOTHER depletion could be rescued by expression of exogenous LCOTHER LCOTHER .	1
LCGeneOrGeneProduct protects LCOTHER LCOTHER from destruction by competing with the action of LCOTHER / LCOTHER ( LCOTHER ) Impaired G2 / M transition after LCOTHER depletion could be rescued by expression of exogenous LCGeneOrGeneProduct LCGeneOrGeneProduct .	2
LCOTHER protects LCGeneOrGeneProduct LCGeneOrGeneProduct from destruction by competing with the action of LCGeneOrGeneProduct / LCGeneOrGeneProduct ( LCOTHER ) Impaired G2 / M transition after LCOTHER depletion could be rescued by expression of exogenous LCOTHER LCOTHER .	1
LCOTHER protects LCGeneOrGeneProduct LCGeneOrGeneProduct from destruction by competing with the action of LCOTHER / LCOTHER ( LCGeneOrGeneProduct ) Impaired G2 / M transition after LCOTHER depletion could be rescued by expression of exogenous LCOTHER LCOTHER .	1
LCOTHER protects LCOTHER LCOTHER from destruction by competing with the action of LCOTHER / LCOTHER ( LCOTHER ) Impaired G2 / M transition after LCGeneOrGeneProduct depletion could be rescued by expression of exogenous LCGeneOrGeneProduct LCGeneOrGeneProduct .	2
Our findings reveal a novel role of LCGeneOrGeneProduct in regulating meiotic G2 / M transition by acting via the LCGeneOrGeneProduct / LCGeneOrGeneProduct ( LCOTHER ) - LCOTHER LCOTHER pathway . The LCOTHER LCOTHER LCOTHER > LCOTHER polymorphism is not associated with LCOTHER LCOTHER LCOTHER .	1
Our findings reveal a novel role of LCGeneOrGeneProduct in regulating meiotic G2 / M transition by acting via the LCOTHER / LCOTHER ( LCGeneOrGeneProduct ) - LCOTHER LCOTHER pathway . The LCOTHER LCOTHER LCOTHER > LCOTHER polymorphism is not associated with LCOTHER LCOTHER LCOTHER .	1
Our findings reveal a novel role of LCGeneOrGeneProduct in regulating meiotic G2 / M transition by acting via the LCOTHER / LCOTHER ( LCOTHER ) - LCGeneOrGeneProduct LCGeneOrGeneProduct pathway . The LCOTHER LCOTHER LCOTHER > LCOTHER polymorphism is not associated with LCOTHER LCOTHER LCOTHER .	2
A functional single nucleotide polymorphism ( SNP ) in the 3 ' untranslated region of the LCGeneOrGeneProduct gene ( LCOTHER LCOTHER > LCOTHER , LCOTHER ) has been associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER .	1
A functional single nucleotide polymorphism ( SNP ) in the 3 ' untranslated region of the LCGeneOrGeneProduct gene ( LCOTHER LCOTHER > LCOTHER , LCOTHER ) has been associated with LCOTHER LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
A functional single nucleotide polymorphism ( SNP ) in the 3 ' untranslated region of the LCOTHER gene ( LCGeneOrGeneProduct LCOTHER > LCOTHER , LCOTHER ) has been associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER .	1
A functional single nucleotide polymorphism ( SNP ) in the 3 ' untranslated region of the LCOTHER gene ( LCGeneOrGeneProduct LCOTHER > LCOTHER , LCOTHER ) has been associated with LCOTHER LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
A functional single nucleotide polymorphism ( SNP ) in the 3 ' untranslated region of the LCOTHER gene ( LCOTHER LCSequenceVariant > LCSequenceVariant , LCOTHER ) has been associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER .	1
A functional single nucleotide polymorphism ( SNP ) in the 3 ' untranslated region of the LCOTHER gene ( LCOTHER LCSequenceVariant > LCSequenceVariant , LCOTHER ) has been associated with LCOTHER LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
A functional single nucleotide polymorphism ( SNP ) in the 3 ' untranslated region of the LCOTHER gene ( LCOTHER LCOTHER > LCOTHER , LCSequenceVariant ) has been associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER .	1
A functional single nucleotide polymorphism ( SNP ) in the 3 ' untranslated region of the LCOTHER gene ( LCOTHER LCOTHER > LCOTHER , LCSequenceVariant ) has been associated with LCOTHER LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
BACKGROUND : LCGeneOrGeneProduct mutations are expected to be potential therapeutic targets for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
BACKGROUND : LCGeneOrGeneProduct mutations are expected to be potential therapeutic targets for LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
METHODS : We examined five hotspot mutations in the LCGeneOrGeneProduct gene ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) in LCOTHER - fixed and LCOTHER - embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 LCOTHER undergoing curative resection for LCDiseaseOrPhenotypicFeature between 2000 and 2011 using a Luminex technology - based multiplex gene mutation detection kit .	1
METHODS : We examined five hotspot mutations in the LCOTHER gene ( LCSequenceVariant , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) in LCOTHER - fixed and LCOTHER - embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 LCOTHER undergoing curative resection for LCDiseaseOrPhenotypicFeature between 2000 and 2011 using a Luminex technology - based multiplex gene mutation detection kit .	1
METHODS : We examined five hotspot mutations in the LCOTHER gene ( LCOTHER , LCSequenceVariant , LCOTHER , LCOTHER , and LCOTHER ) in LCOTHER - fixed and LCOTHER - embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 LCOTHER undergoing curative resection for LCDiseaseOrPhenotypicFeature between 2000 and 2011 using a Luminex technology - based multiplex gene mutation detection kit .	1
METHODS : We examined five hotspot mutations in the LCOTHER gene ( LCOTHER , LCOTHER , LCSequenceVariant , LCOTHER , and LCOTHER ) in LCOTHER - fixed and LCOTHER - embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 LCOTHER undergoing curative resection for LCDiseaseOrPhenotypicFeature between 2000 and 2011 using a Luminex technology - based multiplex gene mutation detection kit .	1
METHODS : We examined five hotspot mutations in the LCOTHER gene ( LCOTHER , LCOTHER , LCOTHER , LCSequenceVariant , and LCOTHER ) in LCOTHER - fixed and LCOTHER - embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 LCOTHER undergoing curative resection for LCDiseaseOrPhenotypicFeature between 2000 and 2011 using a Luminex technology - based multiplex gene mutation detection kit .	1
METHODS : We examined five hotspot mutations in the LCOTHER gene ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCSequenceVariant ) in LCOTHER - fixed and LCOTHER - embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 LCOTHER undergoing curative resection for LCDiseaseOrPhenotypicFeature between 2000 and 2011 using a Luminex technology - based multiplex gene mutation detection kit .	1
CONCLUSIONS : The LCGeneOrGeneProduct mutation status was highly concordant between endoscopic biopsy and surgically resected specimens from the same LCOTHER , suggesting that endoscopic biopsy specimens can be clinically used to detect LCOTHER mutations in LCOTHER with LCDiseaseOrPhenotypicFeature . LCOTHER LCOTHER polymorphisms and survival .	1
CONCLUSIONS : The LCOTHER mutation status was highly concordant between endoscopic biopsy and surgically resected specimens from the same LCOTHER , suggesting that endoscopic biopsy specimens can be clinically used to detect LCGeneOrGeneProduct mutations in LCOTHER with LCDiseaseOrPhenotypicFeature . LCOTHER LCOTHER polymorphisms and survival .	1
The antioxidant enzyme LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) has previously been suggested to confer protection against LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) , one of the main causes of LCOTHER in the Western world .	1
The antioxidant enzyme LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) has previously been suggested to confer protection against LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , one of the main causes of LCOTHER in the Western world .	1
The antioxidant enzyme LCOTHER LCOTHER ( LCGeneOrGeneProduct ) has previously been suggested to confer protection against LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) , one of the main causes of LCOTHER in the Western world .	1
The antioxidant enzyme LCOTHER LCOTHER ( LCGeneOrGeneProduct ) has previously been suggested to confer protection against LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , one of the main causes of LCOTHER in the Western world .	1
Two coding polymorphisms , LCSequenceVariant / LCSequenceVariant and LCOTHER / LCOTHER , and a promoter variant , - LCOTHER / LCOTHER , has been extensively studied with respect to susceptibility to LCDiseaseOrPhenotypicFeature .	1
Two coding polymorphisms , LCOTHER / LCOTHER and LCSequenceVariant / LCSequenceVariant , and a promoter variant , - LCSequenceVariant / LCSequenceVariant , has been extensively studied with respect to susceptibility to LCDiseaseOrPhenotypicFeature .	1
Using self - reported data on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature to evaluate the impact of the LCGeneOrGeneProduct LCOTHER / LCOTHER polymorphism on susceptibility to LCOTHER , we found only a nonsignificant trend of LCOTHER homozygosity in LCOTHER being a risk factor .	1
Using self - reported data on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature to evaluate the impact of the LCOTHER LCSequenceVariant / LCSequenceVariant polymorphism on susceptibility to LCOTHER , we found only a nonsignificant trend of LCOTHER homozygosity in LCOTHER being a risk factor .	1
Using self - reported data on LCOTHER LCOTHER LCOTHER to evaluate the impact of the LCGeneOrGeneProduct LCOTHER / LCOTHER polymorphism on susceptibility to LCDiseaseOrPhenotypicFeature , we found only a nonsignificant trend of LCOTHER homozygosity in LCOTHER being a risk factor .	1
Using self - reported data on LCOTHER LCOTHER LCOTHER to evaluate the impact of the LCOTHER LCSequenceVariant / LCSequenceVariant polymorphism on susceptibility to LCDiseaseOrPhenotypicFeature , we found only a nonsignificant trend of LCOTHER homozygosity in LCOTHER being a risk factor .	1
Our results thus indicates that LCGeneOrGeneProduct LCOTHER homozygosity is associated with increased mortality in LCOTHER in the second half of life and that this increased mortality is possibly related to LCDiseaseOrPhenotypicFeature severity and survival after LCOTHER rather than susceptibility to development of LCOTHER . The antiarrhythmic effect and possible ionic mechanisms of LCOTHER on animal models .	1
Our results thus indicates that LCGeneOrGeneProduct LCOTHER homozygosity is associated with increased mortality in LCOTHER in the second half of life and that this increased mortality is possibly related to LCOTHER severity and survival after LCDiseaseOrPhenotypicFeature rather than susceptibility to development of LCOTHER . The antiarrhythmic effect and possible ionic mechanisms of LCOTHER on animal models .	1
Our results thus indicates that LCGeneOrGeneProduct LCOTHER homozygosity is associated with increased mortality in LCOTHER in the second half of life and that this increased mortality is possibly related to LCOTHER severity and survival after LCOTHER rather than susceptibility to development of LCDiseaseOrPhenotypicFeature . The antiarrhythmic effect and possible ionic mechanisms of LCOTHER on animal models .	1
Our results thus indicates that LCOTHER LCSequenceVariant homozygosity is associated with increased mortality in LCOTHER in the second half of life and that this increased mortality is possibly related to LCDiseaseOrPhenotypicFeature severity and survival after LCOTHER rather than susceptibility to development of LCOTHER . The antiarrhythmic effect and possible ionic mechanisms of LCOTHER on animal models .	1
Our results thus indicates that LCOTHER LCSequenceVariant homozygosity is associated with increased mortality in LCOTHER in the second half of life and that this increased mortality is possibly related to LCOTHER severity and survival after LCDiseaseOrPhenotypicFeature rather than susceptibility to development of LCOTHER . The antiarrhythmic effect and possible ionic mechanisms of LCOTHER on animal models .	1
Our results thus indicates that LCOTHER LCSequenceVariant homozygosity is associated with increased mortality in LCOTHER in the second half of life and that this increased mortality is possibly related to LCOTHER severity and survival after LCOTHER rather than susceptibility to development of LCDiseaseOrPhenotypicFeature . The antiarrhythmic effect and possible ionic mechanisms of LCOTHER on animal models .	1
This study was designed to evaluate the effects of LCChemicalEntity and explore the underlying ionic mechanism , using both LCChemicalEntity - induced LCOTHER and LCOTHER - induced LCOTHER LCOTHER LCOTHER models .	3
This study was designed to evaluate the effects of LCChemicalEntity and explore the underlying ionic mechanism , using both LCOTHER - induced LCOTHER and LCChemicalEntity - induced LCOTHER LCOTHER LCOTHER models .	3
This study was designed to evaluate the effects of LCChemicalEntity and explore the underlying ionic mechanism , using both LCOTHER - induced LCOTHER and LCOTHER - induced LCOTHER LCOTHER LCDiseaseOrPhenotypicFeature models .	3
The current data showed that LCChemicalEntity significantly delayed onset of LCDiseaseOrPhenotypicFeature , decreased the time course of LCOTHER LCOTHER LCOTHER LCOTHER , reduced LCOTHER score , and increased the survival time of LCOTHER LCOTHER and LCOTHER LCOTHER .	3
The current data showed that LCChemicalEntity significantly delayed onset of LCOTHER , decreased the time course of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , reduced LCOTHER score , and increased the survival time of LCOTHER LCOTHER and LCOTHER LCOTHER .	3
The current data showed that LCChemicalEntity significantly delayed onset of LCOTHER , decreased the time course of LCOTHER LCOTHER LCOTHER LCOTHER , reduced LCDiseaseOrPhenotypicFeature score , and increased the survival time of LCOTHER LCOTHER and LCOTHER LCOTHER .	3
The current data showed that LCChemicalEntity significantly delayed onset of LCOTHER , decreased the time course of LCOTHER LCOTHER LCOTHER LCOTHER , reduced LCOTHER score , and increased the survival time of LCDiseaseOrPhenotypicFeature LCOTHER and LCOTHER LCOTHER .	3
[ LCChemicalEntity ( LCChemicalEntity + ) ] ( i ) overload induced by LCChemicalEntity or LCOTHER was reduced in isolated myocytes pretreated with LCOTHER .	2
[ LCChemicalEntity ( LCChemicalEntity + ) ] ( i ) overload induced by LCOTHER or LCChemicalEntity was reduced in isolated myocytes pretreated with LCOTHER .	2
[ LCChemicalEntity ( LCChemicalEntity + ) ] ( i ) overload induced by LCOTHER or LCOTHER was reduced in isolated myocytes pretreated with LCChemicalEntity .	3
Moreover , LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) antagonist LCChemicalEntity - LCChemicalEntity ( LCOTHER - LCOTHER - LCOTHER - LCOTHER - LCOTHER ) partially abolished the beneficial effects of LCChemicalEntity .	3
Moreover , LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) antagonist LCOTHER - LCOTHER ( LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity ) partially abolished the beneficial effects of LCChemicalEntity .	3
These data suggest that LCChemicalEntity produced antiarrhythmic actions on LCDiseaseOrPhenotypicFeature LCOTHER and LCOTHER LCOTHER models induced by LCOTHER or LCOTHER via stimulating the cardiac LCOTHER ( LCOTHER ) - LCOTHER .	3
These data suggest that LCChemicalEntity produced antiarrhythmic actions on LCOTHER LCOTHER and LCOTHER LCOTHER models induced by LCChemicalEntity or LCOTHER via stimulating the cardiac LCOTHER ( LCOTHER ) - LCOTHER .	3
These data suggest that LCChemicalEntity produced antiarrhythmic actions on LCOTHER LCOTHER and LCOTHER LCOTHER models induced by LCOTHER or LCChemicalEntity via stimulating the cardiac LCOTHER ( LCOTHER ) - LCOTHER .	3
These data suggest that LCOTHER produced antiarrhythmic actions on LCDiseaseOrPhenotypicFeature LCOTHER and LCOTHER LCOTHER models induced by LCChemicalEntity or LCOTHER via stimulating the cardiac LCOTHER ( LCOTHER ) - LCOTHER .	2
These data suggest that LCOTHER produced antiarrhythmic actions on LCDiseaseOrPhenotypicFeature LCOTHER and LCOTHER LCOTHER models induced by LCOTHER or LCChemicalEntity via stimulating the cardiac LCOTHER ( LCOTHER ) - LCOTHER .	2
BACKGROUND : ( Over - ) expression of LCGeneOrGeneProduct may limit local availability of arginine for LCChemicalEntity LCChemicalEntity synthesis .	1
We investigated the significance of LCGeneOrGeneProduct ( LCOTHER ) for the development of airway hyperresponsiveness ( AHR ) and LCOTHER LCOTHER in female LCOTHER with LCGeneOrGeneProduct ( LCOTHER ) - induced allergic LCOTHER .	2
We investigated the significance of LCGeneOrGeneProduct ( LCOTHER ) for the development of airway hyperresponsiveness ( AHR ) and LCOTHER LCOTHER in female LCOTHER with LCOTHER ( LCGeneOrGeneProduct ) - induced allergic LCOTHER .	2
We investigated the significance of LCGeneOrGeneProduct ( LCOTHER ) for the development of airway hyperresponsiveness ( AHR ) and LCOTHER LCOTHER in female LCOTHER with LCOTHER ( LCOTHER ) - induced allergic LCDiseaseOrPhenotypicFeature .	1
We investigated the significance of LCOTHER ( LCGeneOrGeneProduct ) for the development of airway hyperresponsiveness ( AHR ) and LCOTHER LCOTHER in female LCOTHER with LCGeneOrGeneProduct ( LCOTHER ) - induced allergic LCOTHER .	2
We investigated the significance of LCOTHER ( LCGeneOrGeneProduct ) for the development of airway hyperresponsiveness ( AHR ) and LCOTHER LCOTHER in female LCOTHER with LCOTHER ( LCGeneOrGeneProduct ) - induced allergic LCOTHER .	2
We investigated the significance of LCOTHER ( LCGeneOrGeneProduct ) for the development of airway hyperresponsiveness ( AHR ) and LCOTHER LCOTHER in female LCOTHER with LCOTHER ( LCOTHER ) - induced allergic LCDiseaseOrPhenotypicFeature .	1
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCGeneOrGeneProduct and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCGeneOrGeneProduct ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCGeneOrGeneProduct , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCGeneOrGeneProduct and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCGeneOrGeneProduct ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCGeneOrGeneProduct and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCGeneOrGeneProduct and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCGeneOrGeneProduct ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCGeneOrGeneProduct - specific LCOTHER .	2
RESULTS : LCGeneOrGeneProduct ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCGeneOrGeneProduct .	2
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCGeneOrGeneProduct and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCGeneOrGeneProduct ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCGeneOrGeneProduct , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCGeneOrGeneProduct and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCGeneOrGeneProduct ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCGeneOrGeneProduct and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCGeneOrGeneProduct and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCGeneOrGeneProduct ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCGeneOrGeneProduct and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCOTHER and LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCOTHER and LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCGeneOrGeneProduct ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCGeneOrGeneProduct , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCGeneOrGeneProduct and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCGeneOrGeneProduct ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCGeneOrGeneProduct and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCGeneOrGeneProduct and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCGeneOrGeneProduct ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	2
LCGeneOrGeneProduct elimination also decreased number and tightness of correlations between adaptive changes in lung function and LCDiseaseOrPhenotypicFeature parameters in LCOTHER / LCOTHER - treated female LCOTHER .	1
LCGeneOrGeneProduct elimination also decreased number and tightness of correlations between adaptive changes in lung function and LCOTHER parameters in LCGeneOrGeneProduct / LCOTHER - treated female LCOTHER .	2
LCGeneOrGeneProduct elimination also decreased number and tightness of correlations between adaptive changes in lung function and LCOTHER parameters in LCOTHER / LCGeneOrGeneProduct - treated female LCOTHER .	2
LCGeneOrGeneProduct - deficient LCGeneOrGeneProduct / LCOTHER - treated females differed from males in a more pronounced decline of arginine - metabolizing and - transporting genes , higher plasma arginine levels , a smaller LCOTHER - specific LCOTHER response , and no improvement of peripheral lung function .	2
LCGeneOrGeneProduct - deficient LCOTHER / LCGeneOrGeneProduct - treated females differed from males in a more pronounced decline of arginine - metabolizing and - transporting genes , higher plasma arginine levels , a smaller LCOTHER - specific LCOTHER response , and no improvement of peripheral lung function .	2
LCGeneOrGeneProduct - deficient LCOTHER / LCOTHER - treated females differed from males in a more pronounced decline of arginine - metabolizing and - transporting genes , higher plasma arginine levels , a smaller LCGeneOrGeneProduct - specific LCOTHER response , and no improvement of peripheral lung function .	2
LCGeneOrGeneProduct - deficient LCOTHER / LCOTHER - treated females differed from males in a more pronounced decline of arginine - metabolizing and - transporting genes , higher plasma arginine levels , a smaller LCOTHER - specific LCGeneOrGeneProduct response , and no improvement of peripheral lung function .	2
CONCLUSION : Complete ablation of LCGeneOrGeneProduct in the lung affects mRNA abundance of arginine - transporting and - metabolizing genes , and pro - LCDiseaseOrPhenotypicFeature genes , but not LCOTHER responsiveness or accumulation of LCOTHER cells . LCOTHER LCOTHER I : time course of LCOTHER peroxidation biomarkers , LCOTHER LCOTHER , and LCOTHER LCOTHER metabolite levels in LCOTHER .	1
CONCLUSION : Complete ablation of LCGeneOrGeneProduct in the lung affects mRNA abundance of arginine - transporting and - metabolizing genes , and pro - LCOTHER genes , but not LCOTHER responsiveness or accumulation of LCDiseaseOrPhenotypicFeature cells . LCOTHER LCOTHER I : time course of LCOTHER peroxidation biomarkers , LCOTHER LCOTHER , and LCOTHER LCOTHER metabolite levels in LCOTHER .	1
To determine whether there was a temporal relationship between LCChemicalEntity - associated oxidative stress and LCDiseaseOrPhenotypicFeature , adult male Sprague - Dawley LCOTHER were treated ip with LCOTHER ( 500 mg / kg ) or 0 . 9% saline ( vehicle ) once daily for 2 , 4 , 7 , 10 , or 14 days .	1
Plasma and liver LCChemicalEntity - LCChemicalEntity ( LCChemicalEntity ) - LCChemicalEntity were elevated and reached a plateau after day 2 of LCChemicalEntity treatment compared to control .	2
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature was evaluated based on serum levels of LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) and by histology .	2
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature was evaluated based on serum levels of LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) and by histology .	2
Serum LCGeneOrGeneProduct - LCGeneOrGeneProduct levels were significantly elevated by day 4 , which corresponded to LCOTHER as shown by the increasing incidence of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER , and LCOTHER throughout the study .	2
Serum LCGeneOrGeneProduct - LCGeneOrGeneProduct levels were significantly elevated by day 4 , which corresponded to LCOTHER as shown by the increasing incidence of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature , and LCOTHER throughout the study .	2
Serum LCGeneOrGeneProduct - LCGeneOrGeneProduct levels were significantly elevated by day 4 , which corresponded to LCOTHER as shown by the increasing incidence of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER , and LCDiseaseOrPhenotypicFeature throughout the study .	2
Overall , these findings indicate that LCChemicalEntity treatment results in oxidative stress , as measured by levels of LCOTHER - LCOTHER ( LCOTHER ) - LCOTHER , which precedes the onset of LCDiseaseOrPhenotypicFeature , LCOTHER , and elevated levels of serum LCOTHER - LCOTHER . Delineation of the clinical phenotype associated with LCOTHER mutations based on the clinical and neuropsychological evaluation of three families .	2
Overall , these findings indicate that LCChemicalEntity treatment results in oxidative stress , as measured by levels of LCOTHER - LCOTHER ( LCOTHER ) - LCOTHER , which precedes the onset of LCOTHER , LCDiseaseOrPhenotypicFeature , and elevated levels of serum LCOTHER - LCOTHER . Delineation of the clinical phenotype associated with LCOTHER mutations based on the clinical and neuropsychological evaluation of three families .	2
Overall , these findings indicate that LCChemicalEntity treatment results in oxidative stress , as measured by levels of LCOTHER - LCOTHER ( LCOTHER ) - LCOTHER , which precedes the onset of LCOTHER , LCOTHER , and elevated levels of serum LCGeneOrGeneProduct - LCGeneOrGeneProduct . Delineation of the clinical phenotype associated with LCOTHER mutations based on the clinical and neuropsychological evaluation of three families .	2
The prognostic value of serum LCDiseaseOrPhenotypicFeature markers LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) and LCOTHER - LCOTHER - LCOTHER LCOTHER ( LCOTHER ) is limited .	1
The prognostic value of serum LCDiseaseOrPhenotypicFeature markers LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) and LCOTHER - LCOTHER - LCOTHER LCOTHER ( LCOTHER ) is limited .	1
The prognostic value of serum LCDiseaseOrPhenotypicFeature markers LCOTHER - LCOTHER ( LCOTHER ) and LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is limited .	1
The prognostic value of serum LCDiseaseOrPhenotypicFeature markers LCOTHER - LCOTHER ( LCOTHER ) and LCOTHER - LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is limited .	1
Serum concentrations of LCGeneOrGeneProduct , LCOTHER and LCOTHER - LCOTHER as markers of LCDiseaseOrPhenotypicFeature and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	1
Serum concentrations of LCOTHER , LCChemicalEntity and LCOTHER - LCOTHER as markers of LCDiseaseOrPhenotypicFeature and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	1
Serum concentrations of LCOTHER , LCOTHER and LCOTHER - LCOTHER as markers of LCDiseaseOrPhenotypicFeature and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	1
Serum concentrations of LCOTHER , LCOTHER and LCOTHER - LCOTHER as markers of LCDiseaseOrPhenotypicFeature and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	1
Serum concentrations of LCOTHER , LCOTHER and LCOTHER - LCOTHER as markers of LCDiseaseOrPhenotypicFeature and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	1
Serum concentrations of LCOTHER , LCOTHER and LCOTHER - LCOTHER as markers of LCDiseaseOrPhenotypicFeature and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER - LCOTHER ) were measured .	1
Serum concentrations of LCOTHER , LCOTHER and LCOTHER - LCOTHER as markers of LCDiseaseOrPhenotypicFeature and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER - LCOTHER ) were measured .	1
Serum concentrations of LCOTHER , LCOTHER and LCOTHER - LCOTHER as markers of LCDiseaseOrPhenotypicFeature and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct ) were measured .	1
RESULTS : LCOTHER with LCDiseaseOrPhenotypicFeature had higher serum LCGeneOrGeneProduct and LCOTHER ( P < 0 . 001 for LCOTHER , LCOTHER , LCOTHER and LCOTHER ) and lower LCOTHER ( P = 0 . 008 ) levels than LCOTHER LCOTHER without LCOTHER .	2
RESULTS : LCOTHER with LCDiseaseOrPhenotypicFeature had higher serum LCOTHER and LCOTHER ( P < 0 . 001 for LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER ) and lower LCOTHER ( P = 0 . 008 ) levels than LCOTHER LCOTHER without LCOTHER .	2
RESULTS : LCOTHER with LCDiseaseOrPhenotypicFeature had higher serum LCOTHER and LCOTHER ( P < 0 . 001 for LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER ) and lower LCOTHER ( P = 0 . 008 ) levels than LCOTHER LCOTHER without LCOTHER .	2
RESULTS : LCOTHER with LCDiseaseOrPhenotypicFeature had higher serum LCOTHER and LCOTHER ( P < 0 . 001 for LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER ) and lower LCOTHER ( P = 0 . 008 ) levels than LCOTHER LCOTHER without LCOTHER .	2
RESULTS : LCOTHER with LCDiseaseOrPhenotypicFeature had higher serum LCOTHER and LCOTHER ( P < 0 . 001 for LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct ) and lower LCOTHER ( P = 0 . 008 ) levels than LCOTHER LCOTHER without LCOTHER .	2
RESULTS : LCOTHER with LCDiseaseOrPhenotypicFeature had higher serum LCOTHER and LCOTHER ( P < 0 . 001 for LCOTHER , LCOTHER , LCOTHER and LCOTHER ) and lower LCGeneOrGeneProduct ( P = 0 . 008 ) levels than LCOTHER LCOTHER without LCOTHER .	2
RESULTS : LCOTHER with LCOTHER had higher serum LCGeneOrGeneProduct and LCOTHER ( P < 0 . 001 for LCOTHER , LCOTHER , LCOTHER and LCOTHER ) and lower LCOTHER ( P = 0 . 008 ) levels than LCDiseaseOrPhenotypicFeature LCOTHER without LCOTHER .	1
RESULTS : LCOTHER with LCOTHER had higher serum LCOTHER and LCOTHER ( P < 0 . 001 for LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER ) and lower LCOTHER ( P = 0 . 008 ) levels than LCDiseaseOrPhenotypicFeature LCOTHER without LCOTHER .	1
RESULTS : LCOTHER with LCOTHER had higher serum LCOTHER and LCOTHER ( P < 0 . 001 for LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER ) and lower LCOTHER ( P = 0 . 008 ) levels than LCDiseaseOrPhenotypicFeature LCOTHER without LCOTHER .	1
RESULTS : LCOTHER with LCOTHER had higher serum LCOTHER and LCOTHER ( P < 0 . 001 for LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER ) and lower LCOTHER ( P = 0 . 008 ) levels than LCDiseaseOrPhenotypicFeature LCOTHER without LCOTHER .	1
RESULTS : LCOTHER with LCOTHER had higher serum LCOTHER and LCOTHER ( P < 0 . 001 for LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct ) and lower LCOTHER ( P = 0 . 008 ) levels than LCDiseaseOrPhenotypicFeature LCOTHER without LCOTHER .	1
RESULTS : LCOTHER with LCOTHER had higher serum LCOTHER and LCOTHER ( P < 0 . 001 for LCOTHER , LCOTHER , LCOTHER and LCOTHER ) and lower LCGeneOrGeneProduct ( P = 0 . 008 ) levels than LCDiseaseOrPhenotypicFeature LCOTHER without LCOTHER .	1
Serum levels of LCGeneOrGeneProduct and LCOTHER were lower , whereas M30 was significantly higher in LCDiseaseOrPhenotypicFeature LCOTHER than in HCs .	1
CONCLUSIONS : High serum levels of LCDiseaseOrPhenotypicFeature LCOTHER such as LCGeneOrGeneProduct and LCOTHER in the serum of LCOTHER LCOTHER indicate the presence of LCOTHER . Over - expression of LCOTHER and LCOTHER in a child with LCOTHER LCOTHER LCOTHER and LCOTHER LCOTHER : a new syndrome .	1
CONCLUSIONS : High serum levels of LCDiseaseOrPhenotypicFeature LCOTHER such as LCOTHER and LCGeneOrGeneProduct in the serum of LCOTHER LCOTHER indicate the presence of LCOTHER . Over - expression of LCOTHER and LCOTHER in a child with LCOTHER LCOTHER LCOTHER and LCOTHER LCOTHER : a new syndrome .	1
CONCLUSIONS : High serum levels of LCOTHER LCOTHER such as LCGeneOrGeneProduct and LCOTHER in the serum of LCDiseaseOrPhenotypicFeature LCOTHER indicate the presence of LCOTHER . Over - expression of LCOTHER and LCOTHER in a child with LCOTHER LCOTHER LCOTHER and LCOTHER LCOTHER : a new syndrome .	1
CONCLUSIONS : High serum levels of LCOTHER LCOTHER such as LCOTHER and LCGeneOrGeneProduct in the serum of LCDiseaseOrPhenotypicFeature LCOTHER indicate the presence of LCOTHER . Over - expression of LCOTHER and LCOTHER in a child with LCOTHER LCOTHER LCOTHER and LCOTHER LCOTHER : a new syndrome .	1
Dysregulated expression of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is found in the cells of LCOTHER who have LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) , a genetic disorder of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER and progressive LCOTHER LCOTHER .	1
Dysregulated expression of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is found in the cells of LCOTHER who have LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , a genetic disorder of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER and progressive LCOTHER LCOTHER .	1
Dysregulated expression of LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is found in the cells of LCOTHER who have LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) , a genetic disorder of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER and progressive LCOTHER LCOTHER .	1
Dysregulated expression of LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is found in the cells of LCOTHER who have LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , a genetic disorder of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER and progressive LCOTHER LCOTHER .	1
Loss of function mutations in the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) gene leading to under - expression of LCOTHER cause the LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , characterized by small malformed ears and a broad range of LCOTHER LCOTHER LCOTHER .	1
Loss of function mutations in the LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene leading to under - expression of LCOTHER cause the LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , characterized by small malformed ears and a broad range of LCOTHER LCOTHER LCOTHER .	1
Loss of function mutations in the LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) gene leading to under - expression of LCGeneOrGeneProduct cause the LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , characterized by small malformed ears and a broad range of LCOTHER LCOTHER LCOTHER .	1
Our data suggest that dysregulated expression of LCGeneOrGeneProduct and LCOTHER genes is associated with an array of LCOTHER LCOTHER LCOTHER LCOTHER similar to the short ear LCOTHER and LCDiseaseOrPhenotypicFeature . The activation of spinal LCOTHER - LCOTHER - LCOTHER - LCOTHER LCOTHER may contribute to degeneration of spinal motor neurons induced by neuraxial LCOTHER after a noninjurious interval of LCOTHER LCOTHER LCOTHER .	1
Our data suggest that dysregulated expression of LCOTHER and LCGeneOrGeneProduct genes is associated with an array of LCOTHER LCOTHER LCOTHER LCOTHER similar to the short ear LCOTHER and LCDiseaseOrPhenotypicFeature . The activation of spinal LCOTHER - LCOTHER - LCOTHER - LCOTHER LCOTHER may contribute to degeneration of spinal motor neurons induced by neuraxial LCOTHER after a noninjurious interval of LCOTHER LCOTHER LCOTHER .	1
Second , we investigated the effect of IT LCChemicalEntity - LCChemicalEntity ( 30 mug ) on the histopathologic changes in the spinal cord after LCChemicalEntity - induced LCOTHER LCOTHER .	1
Second , we investigated the effect of IT LCChemicalEntity - LCChemicalEntity ( 30 mug ) on the histopathologic changes in the spinal cord after LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
Second , we investigated the effect of IT LCOTHER - LCOTHER ( 30 mug ) on the histopathologic changes in the spinal cord after LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
After IT LCChemicalEntity , the cerebrospinal fluid ( CSF ) LCChemicalEntity concentration was increased in group M relative to both baseline and group C ( P < 0 . 05 ) .	2
IT LCChemicalEntity - LCChemicalEntity significantly reduced the number of dark - stained alpha - motoneurons after LCChemicalEntity - induced LCOTHER LCOTHER compared with the saline group .	1
IT LCChemicalEntity - LCChemicalEntity significantly reduced the number of dark - stained alpha - motoneurons after LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature compared with the saline group .	1
IT LCOTHER - LCOTHER significantly reduced the number of dark - stained alpha - motoneurons after LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature compared with the saline group .	2
These data indicate that IT LCChemicalEntity induces LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with a concomitant increase in CSF LCOTHER , which is involved in LCOTHER LCOTHER activation .	2
These data indicate that IT LCChemicalEntity induces LCOTHER LCOTHER with a concomitant increase in CSF LCChemicalEntity , which is involved in LCOTHER LCOTHER activation .	2
These data indicate that IT LCChemicalEntity induces LCOTHER LCOTHER with a concomitant increase in CSF LCOTHER , which is involved in LCGeneOrGeneProduct LCGeneOrGeneProduct activation .	1
These data indicate that IT LCOTHER induces LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with a concomitant increase in CSF LCOTHER , which is involved in LCGeneOrGeneProduct LCGeneOrGeneProduct activation .	1
These data indicate that IT LCOTHER induces LCOTHER LCOTHER with a concomitant increase in CSF LCChemicalEntity , which is involved in LCGeneOrGeneProduct LCGeneOrGeneProduct activation .	1
We suggest that LCChemicalEntity may be LCDiseaseOrPhenotypicFeature in the setting of LCOTHER LCOTHER LCOTHER via LCOTHER LCOTHER activation . Association of LCOTHER polymorphisms and LCOTHER - induced LCOTHER LCOTHER in Chinese LCOTHER LCOTHER .	2
We suggest that LCChemicalEntity may be LCOTHER in the setting of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature via LCOTHER LCOTHER activation . Association of LCOTHER polymorphisms and LCOTHER - induced LCOTHER LCOTHER in Chinese LCOTHER LCOTHER .	1
We suggest that LCChemicalEntity may be LCOTHER in the setting of LCOTHER LCOTHER LCOTHER via LCGeneOrGeneProduct LCGeneOrGeneProduct activation . Association of LCOTHER polymorphisms and LCOTHER - induced LCOTHER LCOTHER in Chinese LCOTHER LCOTHER .	1
We suggest that LCOTHER may be LCDiseaseOrPhenotypicFeature in the setting of LCOTHER LCOTHER LCOTHER via LCGeneOrGeneProduct LCGeneOrGeneProduct activation . Association of LCOTHER polymorphisms and LCOTHER - induced LCOTHER LCOTHER in Chinese LCOTHER LCOTHER .	1
We suggest that LCOTHER may be LCOTHER in the setting of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature via LCGeneOrGeneProduct LCGeneOrGeneProduct activation . Association of LCOTHER polymorphisms and LCOTHER - induced LCOTHER LCOTHER in Chinese LCOTHER LCOTHER .	1
AIM : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is most commonly affected by typical LCChemicalEntity LCChemicalEntity that have a high affinity with the LCOTHER LCOTHER .	2
AIM : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is most commonly affected by typical LCOTHER LCOTHER that have a high affinity with the LCGeneOrGeneProduct LCGeneOrGeneProduct .	1
AIM : LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is most commonly affected by typical LCChemicalEntity LCChemicalEntity that have a high affinity with the LCOTHER LCOTHER .	2
AIM : LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is most commonly affected by typical LCOTHER LCOTHER that have a high affinity with the LCGeneOrGeneProduct LCGeneOrGeneProduct .	1
AIM : LCOTHER LCOTHER ( LCOTHER ) is most commonly affected by typical LCChemicalEntity LCChemicalEntity that have a high affinity with the LCGeneOrGeneProduct LCGeneOrGeneProduct .	1
Recently , many research groups have reported on the positive relationship between the genetic variations in the LCGeneOrGeneProduct gene and the therapeutic response in LCDiseaseOrPhenotypicFeature LCOTHER as a result of the role of variations in the receptor in modulating receptor expression .	1
In this study , we evaluate the role LCGeneOrGeneProduct plays in LCOTHER - induced LCOTHER in LCDiseaseOrPhenotypicFeature LCOTHER .	1
In this study , we evaluate the role LCOTHER plays in LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature in LCOTHER LCOTHER .	2
METHODS : We identified seven SNP ( single nucleotide polymorphism ) ( - 141Cins > del , TaqIB , TaqID , LCOTHER , LCOTHER , LCOTHER and TaqIA ) in the LCGeneOrGeneProduct gene in 146 LCDiseaseOrPhenotypicFeature LCOTHER ( 59 with LCOTHER and 87 without LCOTHER according to the Simpson - Angus Scale ) treated with LCOTHER after 8 weeks .	1
METHODS : We identified seven SNP ( single nucleotide polymorphism ) ( - 141Cins > del , TaqIB , TaqID , LCOTHER , LCOTHER , LCOTHER and TaqIA ) in the LCOTHER gene in 146 LCDiseaseOrPhenotypicFeature LCOTHER ( 59 with LCOTHER and 87 without LCOTHER according to the Simpson - Angus Scale ) treated with LCChemicalEntity after 8 weeks .	3
CONCLUSION : Our results did not lend strong support to the view that the genetic variation of the LCGeneOrGeneProduct gene plays a major role in the individually variable adverse effect induced by LCOTHER , at least in Chinese LCOTHER with LCDiseaseOrPhenotypicFeature .	1
For example , the symptoms of LCDiseaseOrPhenotypicFeature can be dramatically improved by LCChemicalEntity and LCOTHER agonists , whereas central LCOTHER LCOTHER LCOTHER LCOTHER can induce or aggravate LCOTHER symptoms .	3
For example , the symptoms of LCOTHER can be dramatically improved by LCOTHER and LCOTHER agonists , whereas central LCChemicalEntity LCChemicalEntity LCChemicalEntity LCChemicalEntity can induce or aggravate LCDiseaseOrPhenotypicFeature symptoms .	2
To our knowledge , there is no previous report regarding whether LCChemicalEntity , a peripheral LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist , can also induce or aggravate symptoms of LCOTHER .	3
LCChemicalEntity , the first LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , has been associated with LCDiseaseOrPhenotypicFeature in several recent publications .	2
LCOTHER , the first LCChemicalEntity LCChemicalEntity LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCOTHER ) , has been associated with LCDiseaseOrPhenotypicFeature in several recent publications .	1
LCOTHER , the first LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) , has been associated with LCDiseaseOrPhenotypicFeature in several recent publications .	1
The authors report here a LCOTHER LCOTHER comorbid with LCOTHER LCOTHER who developed LCDiseaseOrPhenotypicFeature after LCOTHER had been added to his LCChemicalEntity therapy .	2
Our LCOTHER started to have symptoms of LCOTHER only after he had been treated with LCChemicalEntity , and his LCDiseaseOrPhenotypicFeature symptoms resolved completely upon discontinuation of his LCOTHER .	2
Such a temporal relationship between the use of LCChemicalEntity and the symptoms of LCDiseaseOrPhenotypicFeature in our LCOTHER did not support a potentiating effect of LCOTHER on LCOTHER - associated LCOTHER .	2
Such a temporal relationship between the use of LCChemicalEntity and the symptoms of LCOTHER in our LCOTHER did not support a potentiating effect of LCOTHER on LCOTHER - associated LCDiseaseOrPhenotypicFeature .	2
Such a temporal relationship between the use of LCOTHER and the symptoms of LCDiseaseOrPhenotypicFeature in our LCOTHER did not support a potentiating effect of LCChemicalEntity on LCOTHER - associated LCOTHER .	2
Such a temporal relationship between the use of LCOTHER and the symptoms of LCOTHER in our LCOTHER did not support a potentiating effect of LCChemicalEntity on LCChemicalEntity - associated LCOTHER .	7
Such a temporal relationship between the use of LCOTHER and the symptoms of LCOTHER in our LCOTHER did not support a potentiating effect of LCOTHER on LCChemicalEntity - associated LCDiseaseOrPhenotypicFeature .	2
However , physicians should be aware of the possibility that LCChemicalEntity can be associated with LCDiseaseOrPhenotypicFeature in some individuals , especially those receiving concomitant LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) after orthotopic liver transplantation ( OLTX ) using LCOTHER - based immunotherapy : risk of development and treatment .	2
BACKGROUND : The LCGeneOrGeneProduct inhibitors LCChemicalEntity and LCOTHER are both known to be LCOTHER .	3
BACKGROUND : The LCGeneOrGeneProduct inhibitors LCOTHER and LCChemicalEntity are both known to be LCOTHER .	3
BACKGROUND : The LCOTHER inhibitors LCChemicalEntity and LCOTHER are both known to be LCDiseaseOrPhenotypicFeature .	2
BACKGROUND : The LCOTHER inhibitors LCOTHER and LCChemicalEntity are both known to be LCDiseaseOrPhenotypicFeature .	2
LCOTHER were divided into three groups : Controls , no LCDiseaseOrPhenotypicFeature or LCOTHER , n = 748 ; LCOTHER , sustained serum LCChemicalEntity > 2 . 5 mg / dl , n = 41 ; and LCOTHER , n = 45 .	2
LCOTHER were divided into three groups : Controls , no LCOTHER or LCDiseaseOrPhenotypicFeature , n = 748 ; LCOTHER , sustained serum LCChemicalEntity > 2 . 5 mg / dl , n = 41 ; and LCOTHER , n = 45 .	2
LCOTHER were divided into three groups : Controls , no LCOTHER or LCOTHER , n = 748 ; LCDiseaseOrPhenotypicFeature , sustained serum LCChemicalEntity > 2 . 5 mg / dl , n = 41 ; and LCOTHER , n = 45 .	2
Compared with control LCOTHER , LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER had higher preoperative serum LCChemicalEntity levels , a greater percentage of LCOTHER with LCOTHER LCOTHER , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum LCOTHER .	2
Compared with control LCOTHER , LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER had higher preoperative serum LCOTHER levels , a greater percentage of LCOTHER with LCOTHER LCOTHER , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum LCChemicalEntity .	2
Compared with control LCOTHER , LCOTHER and LCDiseaseOrPhenotypicFeature LCOTHER had higher preoperative serum LCChemicalEntity levels , a greater percentage of LCOTHER with LCOTHER LCOTHER , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum LCOTHER .	2
Compared with control LCOTHER , LCOTHER and LCDiseaseOrPhenotypicFeature LCOTHER had higher preoperative serum LCOTHER levels , a greater percentage of LCOTHER with LCOTHER LCOTHER , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum LCChemicalEntity .	2
Compared with control LCOTHER , LCOTHER and LCOTHER LCOTHER had higher preoperative serum LCOTHER levels , a greater percentage of LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum LCChemicalEntity .	2
LCOTHER who develop LCDiseaseOrPhenotypicFeature have a higher preoperative and 1 - year serum LCChemicalEntity and are more likely to have LCOTHER LCOTHER .	2
We identified such a mechanism as the origin of the mild to asymptomatic phenotype observed in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER homozygous for the LCSequenceVariant mutation ( LCOTHER > LCOTHER ) in the LCOTHER gene .	1
We identified such a mechanism as the origin of the mild to asymptomatic phenotype observed in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER homozygous for the LCOTHER mutation ( LCSequenceVariant > LCSequenceVariant ) in the LCOTHER gene .	1
We identified such a mechanism as the origin of the mild to asymptomatic phenotype observed in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER homozygous for the LCOTHER mutation ( LCOTHER > LCOTHER ) in the LCGeneOrGeneProduct gene .	1
We therefore systematically analyzed the functional impact of the most prevalent immune escape variants , the sG145R and sP120T mutants , on the viral replication efficacy and antiviral drug susceptibility of common treatment - associated mutants with resistance to LCChemicalEntity ( LCOTHER ) and / or LCChemicalEntity negativity .	1
We therefore systematically analyzed the functional impact of the most prevalent immune escape variants , the sG145R and sP120T mutants , on the viral replication efficacy and antiviral drug susceptibility of common treatment - associated mutants with resistance to LCOTHER ( LCChemicalEntity ) and / or LCChemicalEntity negativity .	1
Replication - competent LCOTHER strains with sG145R or sP120T and LCChemicalEntity resistance ( rtM204I or rtL180M / rtM204V ) were generated on an LCChemicalEntity - positive and an LCOTHER - negative background with LCOTHER ( LCOTHER ) and basal core promoter ( BCP ) mutants .	1
Replication - competent LCOTHER strains with sG145R or sP120T and LCChemicalEntity resistance ( rtM204I or rtL180M / rtM204V ) were generated on an LCOTHER - positive and an LCChemicalEntity - negative background with LCOTHER ( LCOTHER ) and basal core promoter ( BCP ) mutants .	1
However , the concomitant occurrence of LCOTHER negativity ( LCGeneOrGeneProduct / BCP ) , sP120T , and LCChemicalEntity resistance resulted in the restoration of replication to levels of wild - type LCOTHER .	1
Drug - related LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature are most often associated with LCChemicalEntity .	2
Bilateral LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature after the use of LCOTHER , without concurrent LCChemicalEntity use , have never been reported .	2
In our LCOTHER , transient LCOTHER LCOTHER or LCOTHER LCOTHER related to LCChemicalEntity and / or LCOTHER use were the most likely causes of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Detailed spectral profile analysis of LCOTHER - induced LCOTHER LCOTHER in anesthetized LCOTHER .	2
In our LCOTHER , transient LCOTHER LCOTHER or LCOTHER LCOTHER related to LCOTHER and / or LCChemicalEntity use were the most likely causes of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Detailed spectral profile analysis of LCOTHER - induced LCOTHER LCOTHER in anesthetized LCOTHER .	2
LCChemicalEntity model is a widely used experimental model for LCDiseaseOrPhenotypicFeature research .	2
In the present study we aimed to portray a detailed spectral analysis of LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in comparison with basal brain activity in anesthetized Wistar LCOTHER .	2
After a short period of basal activity recording , LCDiseaseOrPhenotypicFeature focus was induced by injecting 400IU / 2 microl LCChemicalEntity - LCChemicalEntity LCChemicalEntity into the left lateral ventricle while the cortical activity was continuously recorded .	2
Basal activity , latent period and the LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature periods were then analyzed using both conventional methods and spectral analysis .	2
LCGeneOrGeneProduct ( - / - ) LCOTHER exhibit altered bladder function and neurochemical properties in micturition pathways after LCChemicalEntity ( LCOTHER ) - induced LCOTHER .	1
LCGeneOrGeneProduct ( - / - ) LCOTHER exhibit altered bladder function and neurochemical properties in micturition pathways after LCOTHER ( LCChemicalEntity ) - induced LCOTHER .	1
LCGeneOrGeneProduct ( - / - ) LCOTHER exhibit altered bladder function and neurochemical properties in micturition pathways after LCOTHER ( LCOTHER ) - induced LCDiseaseOrPhenotypicFeature .	3
LCOTHER ( - / - ) LCOTHER exhibit altered bladder function and neurochemical properties in micturition pathways after LCChemicalEntity ( LCOTHER ) - induced LCDiseaseOrPhenotypicFeature .	2
LCOTHER ( - / - ) LCOTHER exhibit altered bladder function and neurochemical properties in micturition pathways after LCOTHER ( LCChemicalEntity ) - induced LCDiseaseOrPhenotypicFeature .	2
Given LCGeneOrGeneProduct ' s role as an anti - LCDiseaseOrPhenotypicFeature mediator , we hypothesized that LCOTHER ( - / - ) LCOTHER would exhibit enhanced LCOTHER mediator expression after LCOTHER .	3
Given LCGeneOrGeneProduct ' s role as an anti - LCOTHER mediator , we hypothesized that LCOTHER ( - / - ) LCOTHER would exhibit enhanced LCDiseaseOrPhenotypicFeature mediator expression after LCOTHER .	3
Given LCGeneOrGeneProduct ' s role as an anti - LCOTHER mediator , we hypothesized that LCOTHER ( - / - ) LCOTHER would exhibit enhanced LCOTHER mediator expression after LCDiseaseOrPhenotypicFeature .	3
Given LCOTHER ' s role as an anti - LCOTHER mediator , we hypothesized that LCGeneOrGeneProduct ( - / - ) LCOTHER would exhibit enhanced LCDiseaseOrPhenotypicFeature mediator expression after LCOTHER .	3
Given LCOTHER ' s role as an anti - LCOTHER mediator , we hypothesized that LCGeneOrGeneProduct ( - / - ) LCOTHER would exhibit enhanced LCOTHER mediator expression after LCDiseaseOrPhenotypicFeature .	3
A LCOTHER LCOTHER cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type ( WT ) and LCGeneOrGeneProduct ( - / - ) LCOTHER with or without LCChemicalEntity - induced LCOTHER ( 150 mg / kg ; i . p . ; 48 h ) .	1
A LCOTHER LCOTHER cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type ( WT ) and LCGeneOrGeneProduct ( - / - ) LCOTHER with or without LCOTHER - induced LCDiseaseOrPhenotypicFeature ( 150 mg / kg ; i . p . ; 48 h ) .	3
A LCOTHER LCOTHER cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type ( WT ) and LCOTHER ( - / - ) LCOTHER with or without LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature ( 150 mg / kg ; i . p . ; 48 h ) .	2
Four binary comparisons were made : WT control versus LCOTHER treatment ( 48 h ) , LCGeneOrGeneProduct ( - / - ) control versus LCChemicalEntity treatment ( 48 h ) , WT control versus LCOTHER ( - / - ) control , and WT with LCOTHER treatment ( 48 h ) versus LCOTHER ( - / - ) with LCOTHER treatment ( 48 h ) .	1
Four binary comparisons were made : WT control versus LCOTHER treatment ( 48 h ) , LCGeneOrGeneProduct ( - / - ) control versus LCOTHER treatment ( 48 h ) , WT control versus LCOTHER ( - / - ) control , and WT with LCChemicalEntity treatment ( 48 h ) versus LCOTHER ( - / - ) with LCOTHER treatment ( 48 h ) .	1
Four binary comparisons were made : WT control versus LCOTHER treatment ( 48 h ) , LCGeneOrGeneProduct ( - / - ) control versus LCOTHER treatment ( 48 h ) , WT control versus LCOTHER ( - / - ) control , and WT with LCOTHER treatment ( 48 h ) versus LCOTHER ( - / - ) with LCChemicalEntity treatment ( 48 h ) .	1
Four binary comparisons were made : WT control versus LCOTHER treatment ( 48 h ) , LCOTHER ( - / - ) control versus LCOTHER treatment ( 48 h ) , WT control versus LCGeneOrGeneProduct ( - / - ) control , and WT with LCChemicalEntity treatment ( 48 h ) versus LCOTHER ( - / - ) with LCOTHER treatment ( 48 h ) .	1
Four binary comparisons were made : WT control versus LCOTHER treatment ( 48 h ) , LCOTHER ( - / - ) control versus LCOTHER treatment ( 48 h ) , WT control versus LCGeneOrGeneProduct ( - / - ) control , and WT with LCOTHER treatment ( 48 h ) versus LCOTHER ( - / - ) with LCChemicalEntity treatment ( 48 h ) .	1
Four binary comparisons were made : WT control versus LCOTHER treatment ( 48 h ) , LCOTHER ( - / - ) control versus LCOTHER treatment ( 48 h ) , WT control versus LCOTHER ( - / - ) control , and WT with LCOTHER treatment ( 48 h ) versus LCGeneOrGeneProduct ( - / - ) with LCChemicalEntity treatment ( 48 h ) .	1
LCChemicalEntity treatment significantly ( p < or = 0 . 001 ) increased expression of LCGeneOrGeneProduct and LCOTHER - LCOTHER in the urinary bladder of WT and LCOTHER ( - / - ) LCOTHER , but expression in LCOTHER ( - / - ) LCOTHER with LCOTHER treatment was significantly ( p < or = 0 . 001 ) greater ( 4 . 2 - to 13 - fold increase ) than that observed in WT urinary bladder ( 3 . 6 - to 5 - fold increase ) .	2
LCChemicalEntity treatment significantly ( p < or = 0 . 001 ) increased expression of LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct in the urinary bladder of WT and LCOTHER ( - / - ) LCOTHER , but expression in LCOTHER ( - / - ) LCOTHER with LCOTHER treatment was significantly ( p < or = 0 . 001 ) greater ( 4 . 2 - to 13 - fold increase ) than that observed in WT urinary bladder ( 3 . 6 - to 5 - fold increase ) .	2
LCOTHER treatment significantly ( p < or = 0 . 001 ) increased expression of LCOTHER and LCOTHER - LCOTHER in the urinary bladder of WT and LCGeneOrGeneProduct ( - / - ) LCOTHER , but expression in LCOTHER ( - / - ) LCOTHER with LCChemicalEntity treatment was significantly ( p < or = 0 . 001 ) greater ( 4 . 2 - to 13 - fold increase ) than that observed in WT urinary bladder ( 3 . 6 - to 5 - fold increase ) .	1
LCOTHER treatment significantly ( p < or = 0 . 001 ) increased expression of LCOTHER and LCOTHER - LCOTHER in the urinary bladder of WT and LCOTHER ( - / - ) LCOTHER , but expression in LCGeneOrGeneProduct ( - / - ) LCOTHER with LCChemicalEntity treatment was significantly ( p < or = 0 . 001 ) greater ( 4 . 2 - to 13 - fold increase ) than that observed in WT urinary bladder ( 3 . 6 - to 5 - fold increase ) .	1
The data suggest that in LCGeneOrGeneProduct ( - / - ) LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER mediators are increased above that observed in WT with LCOTHER .	3
The data suggest that in LCGeneOrGeneProduct ( - / - ) LCOTHER with LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature mediators are increased above that observed in WT with LCOTHER .	3
The data suggest that in LCGeneOrGeneProduct ( - / - ) LCOTHER with LCOTHER LCOTHER , LCOTHER mediators are increased above that observed in WT with LCChemicalEntity .	1
This shift in balance may contribute to increased LCOTHER LCOTHER in LCGeneOrGeneProduct ( - / - ) LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and altered neurochemical expression in micturition pathways . LCOTHER associated with LCOTHER : case presentation and literature review .	3
PURPOSE : We present a case of a LCOTHER who developed LCDiseaseOrPhenotypicFeature shortly after initiating treatment with LCChemicalEntity and to discuss the potential drug - drug interactions related to the inhibition of LCOTHER LCOTHER ( LCOTHER ) LCOTHER in this case , as well as in other cases , of LCOTHER - induced LCOTHER .	2
PURPOSE : We present a case of a LCOTHER who developed LCDiseaseOrPhenotypicFeature shortly after initiating treatment with LCOTHER and to discuss the potential drug - drug interactions related to the inhibition of LCOTHER LCOTHER ( LCOTHER ) LCOTHER in this case , as well as in other cases , of LCChemicalEntity - induced LCOTHER .	2
PURPOSE : We present a case of a LCOTHER who developed LCOTHER shortly after initiating treatment with LCOTHER and to discuss the potential drug - drug interactions related to the inhibition of LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct in this case , as well as in other cases , of LCChemicalEntity - induced LCOTHER .	1
Drug - drug interactions related to the inhibition of LCGeneOrGeneProduct by LCChemicalEntity are likely involved in the clinical outcome of these cases .	1
Detailed history obtained retrospectively revealed that the LCOTHER took LCChemicalEntity sparingly only when she had LCDiseaseOrPhenotypicFeature .	3
But before this event , she was taking LCChemicalEntity 2 - 3 times daily for several days because of a persistent LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
Extensive literature search revealed multiple cases of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature secondary to LCChemicalEntity , but none of the cases were associated with LCOTHER . Characterization of LCOTHER LCOTHER LCOTHER LCOTHER with LCOTHER mutations .	2
LCOTHER LCOTHER ( LCOTHER ) - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct are pattern - recognition molecules of the respiratory tract that activate LCDiseaseOrPhenotypicFeature and phagocytic defences after binding to microbial LCOTHER .	1
LCOTHER LCOTHER ( LCOTHER ) - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct are pattern - recognition molecules of the respiratory tract that activate LCOTHER and phagocytic defences after binding to microbial LCChemicalEntity .	4
METHODS : Allele frequencies of LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , and LCOTHER - LCOTHER were determined by polymerase chain reaction in 303 LCOTHER with microbiologically proven LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , including 18 LCOTHER who LCOTHER , and 222 healthy control subjects .	1
METHODS : Allele frequencies of LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , and LCOTHER - LCOTHER were determined by polymerase chain reaction in 303 LCOTHER with microbiologically proven LCOTHER LCOTHER , including 18 LCOTHER who LCDiseaseOrPhenotypicFeature , and 222 healthy control subjects .	1
RESULTS : Homozygosity of allele 1A1 of LCGeneOrGeneProduct - LCGeneOrGeneProduct increased the risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( odds ratio [ OR ] , 7 . 4 ; 95% confidence interval [ CI ] , 1 . 3 - 42 . 4 ) ; carriage of 1A5 reduced the risk ( OR , 0 . 3 ; 95% CI , 0 . 1 - 0 . 97 ) .	1
An analysis of the multiple single - nucleotide polymorphisms in LCOTHER - LCOTHER demonstrated that homozygosity for alleles encoding LCSequenceVariant ( LCSequenceVariant LCSequenceVariant ) LCSequenceVariant LCSequenceVariant LCSequenceVariant ( LCSequenceVariant LCSequenceVariant ) LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant in the LCChemicalEntity recognition domain was associated with an increased risk of LCOTHER LCOTHER ( OR , 6 . 7 ; 95% CI , 1 . 4 - 31 . 5 ) .	1
An analysis of the multiple single - nucleotide polymorphisms in LCOTHER - LCOTHER demonstrated that homozygosity for alleles encoding LCSequenceVariant ( LCSequenceVariant LCSequenceVariant ) LCSequenceVariant LCSequenceVariant LCSequenceVariant ( LCSequenceVariant LCSequenceVariant ) LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant in the LCOTHER recognition domain was associated with an increased risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( OR , 6 . 7 ; 95% CI , 1 . 4 - 31 . 5 ) .	2
Carriage of alleles encoding LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant was found in 61% of LCOTHER who LCDiseaseOrPhenotypicFeature , compared with 35% of those who survived ( OR adjusted for age , 2 . 9 ; 95% CI , 1 . 1 - 7 . 7 ) .	1
CONCLUSIONS : Gene polymorphism resulting in the substitution of LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant in the LCChemicalEntity recognition domain of LCOTHER - LCOTHER increases susceptibility to LCOTHER LCOTHER , as well as the risk of LCOTHER . Risk factors and predictors of LCOTHER - induced LCOTHER among multiethnic Malaysians with LCOTHER ' LCOTHER LCOTHER .	1
CONCLUSIONS : Gene polymorphism resulting in the substitution of LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant in the LCOTHER recognition domain of LCOTHER - LCOTHER increases susceptibility to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , as well as the risk of LCOTHER . Risk factors and predictors of LCOTHER - induced LCOTHER among multiethnic Malaysians with LCOTHER ' LCOTHER LCOTHER .	2
CONCLUSIONS : Gene polymorphism resulting in the substitution of LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant in the LCOTHER recognition domain of LCOTHER - LCOTHER increases susceptibility to LCOTHER LCOTHER , as well as the risk of LCDiseaseOrPhenotypicFeature . Risk factors and predictors of LCOTHER - induced LCOTHER among multiethnic Malaysians with LCOTHER ' LCOTHER LCOTHER .	2
CONCLUSIONS : Gene polymorphism resulting in the substitution of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in the LCChemicalEntity recognition domain of LCGeneOrGeneProduct - LCGeneOrGeneProduct increases susceptibility to LCOTHER LCOTHER , as well as the risk of LCOTHER . Risk factors and predictors of LCOTHER - induced LCOTHER among multiethnic Malaysians with LCOTHER ' LCOTHER LCOTHER .	1
CONCLUSIONS : Gene polymorphism resulting in the substitution of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in the LCOTHER recognition domain of LCGeneOrGeneProduct - LCGeneOrGeneProduct increases susceptibility to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , as well as the risk of LCOTHER . Risk factors and predictors of LCOTHER - induced LCOTHER among multiethnic Malaysians with LCOTHER ' LCOTHER LCOTHER .	1
CONCLUSIONS : Gene polymorphism resulting in the substitution of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in the LCOTHER recognition domain of LCGeneOrGeneProduct - LCGeneOrGeneProduct increases susceptibility to LCOTHER LCOTHER , as well as the risk of LCDiseaseOrPhenotypicFeature . Risk factors and predictors of LCOTHER - induced LCOTHER among multiethnic Malaysians with LCOTHER ' LCOTHER LCOTHER .	1
Chronic pulsatile LCChemicalEntity therapy for LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) leads to the development of motor fluctuations and LCOTHER .	3
Chronic pulsatile LCChemicalEntity therapy for LCOTHER ' LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) leads to the development of motor fluctuations and LCOTHER .	3
Chronic pulsatile LCChemicalEntity therapy for LCOTHER ' LCOTHER LCOTHER ( LCOTHER ) leads to the development of motor fluctuations and LCDiseaseOrPhenotypicFeature .	2
We studied the prevalence and predictors of LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature among multiethnic Malaysian LCOTHER with LCOTHER .	2
We studied the prevalence and predictors of LCChemicalEntity - induced LCOTHER among multiethnic Malaysian LCOTHER with LCDiseaseOrPhenotypicFeature .	3
LCOTHER with LCOTHER had lower onset age ( p < 0 . 001 ) , longer duration of LCChemicalEntity therapy ( p < 0 . 001 ) , longer disease duration ( p < 0 . 001 ) , higher total daily LCOTHER dose ( p < 0 . 001 ) , and higher total UPDRS scores ( p = 0 . 005 ) than LCOTHER without LCDiseaseOrPhenotypicFeature .	2
LCOTHER with LCOTHER had lower onset age ( p < 0 . 001 ) , longer duration of LCOTHER therapy ( p < 0 . 001 ) , longer disease duration ( p < 0 . 001 ) , higher total daily LCChemicalEntity dose ( p < 0 . 001 ) , and higher total UPDRS scores ( p = 0 . 005 ) than LCOTHER without LCDiseaseOrPhenotypicFeature .	2
CONCLUSIONS : The prevalence of LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature in our LCOTHER was 44% .	2
LCOTHER LCOTHER LCOTHER ( LCOTHER ) is an LCOTHER LCOTHER LCOTHER , which is characterized by periodic attacks of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature associated with a decrease in the serum LCChemicalEntity level .	1
A major disease - causing gene for LCDiseaseOrPhenotypicFeature has been identified as LCGeneOrGeneProduct , which encodes the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER with four transmembrane domains ( I - IV ) , each with six transmembrane segments ( S1 - S6 ) .	1
A major disease - causing gene for LCDiseaseOrPhenotypicFeature has been identified as LCOTHER , which encodes the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct with four transmembrane domains ( I - IV ) , each with six transmembrane segments ( S1 - S6 ) .	1
Genetic analysis identified a novel LCSequenceVariant mutation in all LCDiseaseOrPhenotypicFeature LCOTHER in the family , but not in normal family members or 160 control people .	2
PURPOSE : This study was designed to establish a LCOTHER model of LCOTHER LCOTHER LCOTHER ( LCOTHER ) by LCChemicalEntity LCChemicalEntity ( LCOTHER ( LCOTHER ) ) - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and to explore the potential role of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER ( LCOTHER ) and their endogenous inhibitors ( TIMPs ) in LCOTHER formation .	2
PURPOSE : This study was designed to establish a LCOTHER model of LCOTHER LCOTHER LCOTHER ( LCOTHER ) by LCChemicalEntity LCChemicalEntity ( LCOTHER ( LCOTHER ) ) - induced LCOTHER LCOTHER and to explore the potential role of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER ( LCOTHER ) and their endogenous inhibitors ( TIMPs ) in LCDiseaseOrPhenotypicFeature formation .	2
PURPOSE : This study was designed to establish a LCOTHER model of LCOTHER LCOTHER LCOTHER ( LCOTHER ) by LCOTHER LCOTHER ( LCChemicalEntity ( LCChemicalEntity ) ) - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and to explore the potential role of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER ( LCOTHER ) and their endogenous inhibitors ( TIMPs ) in LCOTHER formation .	2
PURPOSE : This study was designed to establish a LCOTHER model of LCOTHER LCOTHER LCOTHER ( LCOTHER ) by LCOTHER LCOTHER ( LCChemicalEntity ( LCChemicalEntity ) ) - induced LCOTHER LCOTHER and to explore the potential role of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER ( LCOTHER ) and their endogenous inhibitors ( TIMPs ) in LCDiseaseOrPhenotypicFeature formation .	2
LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCOTHER mRNA levels were increased in LCChemicalEntity ( LCChemicalEntity ) - treated segments ( all p < 0 . 01 ) , with trends of elevation in LCOTHER ( LCOTHER ) - untreated segments , as compared with LCOTHER - treated segments .	2
LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCOTHER mRNA levels were increased in LCOTHER ( LCOTHER ) - treated segments ( all p < 0 . 01 ) , with trends of elevation in LCChemicalEntity ( LCChemicalEntity ) - untreated segments , as compared with LCOTHER - treated segments .	2
LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER and LCOTHER - LCOTHER mRNA levels were increased in LCChemicalEntity ( LCChemicalEntity ) - treated segments ( all p < 0 . 01 ) , with trends of elevation in LCOTHER ( LCOTHER ) - untreated segments , as compared with LCOTHER - treated segments .	2
LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER and LCOTHER - LCOTHER mRNA levels were increased in LCOTHER ( LCOTHER ) - treated segments ( all p < 0 . 01 ) , with trends of elevation in LCChemicalEntity ( LCChemicalEntity ) - untreated segments , as compared with LCOTHER - treated segments .	2
LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER mRNA levels were increased in LCChemicalEntity ( LCChemicalEntity ) - treated segments ( all p < 0 . 01 ) , with trends of elevation in LCOTHER ( LCOTHER ) - untreated segments , as compared with LCOTHER - treated segments .	2
LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER mRNA levels were increased in LCOTHER ( LCOTHER ) - treated segments ( all p < 0 . 01 ) , with trends of elevation in LCChemicalEntity ( LCChemicalEntity ) - untreated segments , as compared with LCOTHER - treated segments .	2
LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct mRNA levels were increased in LCChemicalEntity ( LCChemicalEntity ) - treated segments ( all p < 0 . 01 ) , with trends of elevation in LCOTHER ( LCOTHER ) - untreated segments , as compared with LCOTHER - treated segments .	2
LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct mRNA levels were increased in LCOTHER ( LCOTHER ) - treated segments ( all p < 0 . 01 ) , with trends of elevation in LCChemicalEntity ( LCChemicalEntity ) - untreated segments , as compared with LCOTHER - treated segments .	2
Immunohistochemistry displayed significantly increased expressions of LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCOTHER ( all p < 0 . 01 ) in intima and media for LCChemicalEntity ( LCChemicalEntity ) - treated segments .	2
Immunohistochemistry displayed significantly increased expressions of LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER and LCOTHER - LCOTHER ( all p < 0 . 01 ) in intima and media for LCChemicalEntity ( LCChemicalEntity ) - treated segments .	2
Immunohistochemistry displayed significantly increased expressions of LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER ( all p < 0 . 01 ) in intima and media for LCChemicalEntity ( LCChemicalEntity ) - treated segments .	2
Immunohistochemistry displayed significantly increased expressions of LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct ( all p < 0 . 01 ) in intima and media for LCChemicalEntity ( LCChemicalEntity ) - treated segments .	2
OBJECTIVE : To describe clinical and genetic features of a Thai family with LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) caused by an activating germline mutation in the LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) gene .	1
OBJECTIVE : To describe clinical and genetic features of a Thai family with LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) caused by an activating germline mutation in the LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene .	1
OBJECTIVE : To describe clinical and genetic features of a Thai family with LCOTHER - LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) caused by an activating germline mutation in the LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) gene .	1
OBJECTIVE : To describe clinical and genetic features of a Thai family with LCOTHER - LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) caused by an activating germline mutation in the LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene .	1
CONCLUSIONS : LCOTHER and bilateral shortening of the fifth metacarpal bones and the middle phalanges of the fifth fingers might be characteristic features of LCDiseaseOrPhenotypicFeature because of an activating LCGeneOrGeneProduct germline mutation .	1
PURPOSE : To identify the mutation in the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene ( LCOTHER ) in a Chinese family with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
PURPOSE : To identify the mutation in the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene ( LCOTHER ) in a Chinese family with LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
PURPOSE : To identify the mutation in the LCOTHER - LCOTHER gene ( LCGeneOrGeneProduct ) in a Chinese family with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
PURPOSE : To identify the mutation in the LCOTHER - LCOTHER gene ( LCGeneOrGeneProduct ) in a Chinese family with LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
CONCLUSIONS : We indentified a novel LCOTHER . LCOTHER mutation in LCGeneOrGeneProduct , which is the causative mutation for LCDiseaseOrPhenotypicFeature in this family .	1
Our result expands the mutation spectrum of LCGeneOrGeneProduct and contributes to the study of the molecular pathogenesis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER polymorphisms associated with alternative splicing modify susceptibility to LCOTHER LCOTHER LCOTHER LCOTHER through epistatic interaction with LCOTHER .	1
We previously reported association of LCGeneOrGeneProduct - LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) in three Asian populations .	1
We previously reported association of LCGeneOrGeneProduct - LCOTHER with LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) in three Asian populations .	1
We previously reported association of LCOTHER - LCSequenceVariant with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) in three Asian populations .	2
We previously reported association of LCOTHER - LCSequenceVariant with LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) in three Asian populations .	2
Because polymorphism of LCGeneOrGeneProduct , another inhibitory receptor of B cells , was associated with LCOTHER LCDiseaseOrPhenotypicFeature , we identified LCOTHER LCOTHER polymorphisms , tested their association with LCOTHER and examined genetic interaction with LCOTHER in the Japanese ( 160 LCOTHER , 277 controls ) , Thais ( 87 LCOTHER , 187 controls ) and Caucasians ( 94 families containing LCOTHER members ) .	1
Because polymorphism of LCGeneOrGeneProduct , another inhibitory receptor of B cells , was associated with LCOTHER LCOTHER , we identified LCOTHER LCOTHER polymorphisms , tested their association with LCDiseaseOrPhenotypicFeature and examined genetic interaction with LCOTHER in the Japanese ( 160 LCOTHER , 277 controls ) , Thais ( 87 LCOTHER , 187 controls ) and Caucasians ( 94 families containing LCOTHER members ) .	1
Because polymorphism of LCGeneOrGeneProduct , another inhibitory receptor of B cells , was associated with LCOTHER LCOTHER , we identified LCOTHER LCOTHER polymorphisms , tested their association with LCOTHER and examined genetic interaction with LCOTHER in the Japanese ( 160 LCDiseaseOrPhenotypicFeature , 277 controls ) , Thais ( 87 LCOTHER , 187 controls ) and Caucasians ( 94 families containing LCOTHER members ) .	1
Because polymorphism of LCGeneOrGeneProduct , another inhibitory receptor of B cells , was associated with LCOTHER LCOTHER , we identified LCOTHER LCOTHER polymorphisms , tested their association with LCOTHER and examined genetic interaction with LCOTHER in the Japanese ( 160 LCOTHER , 277 controls ) , Thais ( 87 LCDiseaseOrPhenotypicFeature , 187 controls ) and Caucasians ( 94 families containing LCOTHER members ) .	1
Because polymorphism of LCGeneOrGeneProduct , another inhibitory receptor of B cells , was associated with LCOTHER LCOTHER , we identified LCOTHER LCOTHER polymorphisms , tested their association with LCOTHER and examined genetic interaction with LCOTHER in the Japanese ( 160 LCOTHER , 277 controls ) , Thais ( 87 LCOTHER , 187 controls ) and Caucasians ( 94 families containing LCDiseaseOrPhenotypicFeature members ) .	1
Because polymorphism of LCOTHER , another inhibitory receptor of B cells , was associated with LCOTHER LCDiseaseOrPhenotypicFeature , we identified LCOTHER LCGeneOrGeneProduct polymorphisms , tested their association with LCOTHER and examined genetic interaction with LCOTHER in the Japanese ( 160 LCOTHER , 277 controls ) , Thais ( 87 LCOTHER , 187 controls ) and Caucasians ( 94 families containing LCOTHER members ) .	1
Because polymorphism of LCOTHER , another inhibitory receptor of B cells , was associated with LCOTHER LCOTHER , we identified LCOTHER LCGeneOrGeneProduct polymorphisms , tested their association with LCOTHER and examined genetic interaction with LCGeneOrGeneProduct in the Japanese ( 160 LCOTHER , 277 controls ) , Thais ( 87 LCOTHER , 187 controls ) and Caucasians ( 94 families containing LCOTHER members ) .	1
Because polymorphism of LCOTHER , another inhibitory receptor of B cells , was associated with LCOTHER LCOTHER , we identified LCOTHER LCOTHER polymorphisms , tested their association with LCOTHER and examined genetic interaction with LCGeneOrGeneProduct in the Japanese ( 160 LCDiseaseOrPhenotypicFeature , 277 controls ) , Thais ( 87 LCOTHER , 187 controls ) and Caucasians ( 94 families containing LCOTHER members ) .	1
Because polymorphism of LCOTHER , another inhibitory receptor of B cells , was associated with LCOTHER LCOTHER , we identified LCOTHER LCOTHER polymorphisms , tested their association with LCOTHER and examined genetic interaction with LCGeneOrGeneProduct in the Japanese ( 160 LCOTHER , 277 controls ) , Thais ( 87 LCDiseaseOrPhenotypicFeature , 187 controls ) and Caucasians ( 94 families containing LCOTHER members ) .	1
Because polymorphism of LCOTHER , another inhibitory receptor of B cells , was associated with LCOTHER LCOTHER , we identified LCOTHER LCOTHER polymorphisms , tested their association with LCOTHER and examined genetic interaction with LCGeneOrGeneProduct in the Japanese ( 160 LCOTHER , 277 controls ) , Thais ( 87 LCOTHER , 187 controls ) and Caucasians ( 94 families containing LCDiseaseOrPhenotypicFeature members ) .	1
Using the two Asian cohorts , significant association of LCGeneOrGeneProduct - LCOTHER / Thr with LCDiseaseOrPhenotypicFeature was observed only in the presence of LCOTHER - * 1 / * 1 genotype ( OR 4 . 63 , 95% CI 1 . 47 - 14 . 6 , P = 0 . 009 versus LCOTHER - LCOTHER / Ile plus LCOTHER - * 2 / * 2 ) .	1
Using the two Asian cohorts , significant association of LCOTHER - LCSequenceVariant / Thr with LCDiseaseOrPhenotypicFeature was observed only in the presence of LCOTHER - * 1 / * 1 genotype ( OR 4 . 63 , 95% CI 1 . 47 - 14 . 6 , P = 0 . 009 versus LCOTHER - LCOTHER / Ile plus LCOTHER - * 2 / * 2 ) .	2
Using the two Asian cohorts , significant association of LCOTHER - LCOTHER / Thr with LCDiseaseOrPhenotypicFeature was observed only in the presence of LCGeneOrGeneProduct - * 1 / * 1 genotype ( OR 4 . 63 , 95% CI 1 . 47 - 14 . 6 , P = 0 . 009 versus LCOTHER - LCOTHER / Ile plus LCOTHER - * 2 / * 2 ) .	1
Using the two Asian cohorts , significant association of LCOTHER - LCOTHER / Thr with LCDiseaseOrPhenotypicFeature was observed only in the presence of LCOTHER - * 1 / * 1 genotype ( OR 4 . 63 , 95% CI 1 . 47 - 14 . 6 , P = 0 . 009 versus LCOTHER - LCOTHER / Ile plus LCGeneOrGeneProduct - * 2 / * 2 ) .	1
Using the two Asian cohorts , significant association of LCOTHER - LCOTHER / Thr with LCOTHER was observed only in the presence of LCGeneOrGeneProduct - * 1 / * 1 genotype ( OR 4 . 63 , 95% CI 1 . 47 - 14 . 6 , P = 0 . 009 versus LCGeneOrGeneProduct - LCOTHER / Ile plus LCOTHER - * 2 / * 2 ) .	1
The AS isoform lacks exon 8 , and is deduced to contain 49 amino acid changes in the membrane - distal portion of the extracellular domain , where considerable amino acid changes are known in LCGeneOrGeneProduct ( c ) allele associated with LCOTHER LCDiseaseOrPhenotypicFeature .	1
These results indicated that the presence of LCGeneOrGeneProduct - * 2 allele decreases risk for LCOTHER LCOTHER conferred by LCGeneOrGeneProduct - LCOTHER , possibly by increasing the AS isoform of LCOTHER . Vaccine candidates derived from a novel infectious cDNA clone of an American genotype LCOTHER LCOTHER LCOTHER LCOTHER .	1
These results indicated that the presence of LCOTHER - * 2 allele decreases risk for LCOTHER LCDiseaseOrPhenotypicFeature conferred by LCOTHER - LCOTHER , possibly by increasing the AS isoform of LCGeneOrGeneProduct . Vaccine candidates derived from a novel infectious cDNA clone of an American genotype LCOTHER LCOTHER LCOTHER LCOTHER .	1
BACKGROUND : Markers of fibrinolysis , LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) levels were studied for the evaluation of short - term effects of LCChemicalEntity administration in postmenopausal LCOTHER .	1
BACKGROUND : Markers of fibrinolysis , LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , and LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) levels were studied for the evaluation of short - term effects of LCChemicalEntity administration in postmenopausal LCOTHER .	1
RESULTS : Three months of LCChemicalEntity treatment was associated with a significant decrease in the plasma LCGeneOrGeneProduct antigen concentrations ( 16% change , P < 0 . 01 ) , and a significant increase in LCOTHER antigen concentrations ( 25% change , P < 0 . 05 ) .	3
RESULTS : Three months of LCChemicalEntity treatment was associated with a significant decrease in the plasma LCOTHER antigen concentrations ( 16% change , P < 0 . 01 ) , and a significant increase in LCGeneOrGeneProduct antigen concentrations ( 25% change , P < 0 . 05 ) .	2
CONCLUSION : We suggest that the increased risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature due to LCChemicalEntity treatment may be related to increased LCOTHER levels , but not LCOTHER levels . LCOTHER serves as a prognostic biomarker for LCOTHER LCOTHER .	2
CONCLUSION : We suggest that the increased risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature due to LCOTHER treatment may be related to increased LCGeneOrGeneProduct levels , but not LCOTHER levels . LCOTHER serves as a prognostic biomarker for LCOTHER LCOTHER .	2
CONCLUSION : We suggest that the increased risk of LCOTHER LCOTHER due to LCChemicalEntity treatment may be related to increased LCGeneOrGeneProduct levels , but not LCOTHER levels . LCOTHER serves as a prognostic biomarker for LCOTHER LCOTHER .	2
CONCLUSION : We suggest that the increased risk of LCOTHER LCOTHER due to LCChemicalEntity treatment may be related to increased LCOTHER levels , but not LCGeneOrGeneProduct levels . LCOTHER serves as a prognostic biomarker for LCOTHER LCOTHER .	3
LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is a LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct that regulates spindle assembly in LCOTHER cells and is overexpressed in various LCOTHER .	2
LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is a LCOTHER - LCOTHER LCOTHER that regulates spindle assembly in LCOTHER cells and is overexpressed in various LCDiseaseOrPhenotypicFeature .	1
LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is a LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct that regulates spindle assembly in LCOTHER cells and is overexpressed in various LCOTHER .	2
LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is a LCOTHER - LCOTHER LCOTHER that regulates spindle assembly in LCOTHER cells and is overexpressed in various LCDiseaseOrPhenotypicFeature .	1
However , the role of LCGeneOrGeneProduct in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) remains undetermined .	1
However , the role of LCGeneOrGeneProduct in LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) remains undetermined .	1
LCGeneOrGeneProduct expression was detected using quantitative reverse transcription polymerase chain reaction in two cell lines and 5 matched LCDiseaseOrPhenotypicFeature and adjacent non - tumorous liver tissues .	1
The correlation between survival and LCGeneOrGeneProduct expression was analyzed in 359 LCOTHER with LCDiseaseOrPhenotypicFeature using RNASeqV2 data available from The LCOTHER Genome Atlas ( TCGA ) website ( https : / / tcga - data . nci . nih . gov / tcga / ) .	1
The correlation between survival and LCGeneOrGeneProduct expression was analyzed in 359 LCOTHER with LCOTHER using RNASeqV2 data available from The LCDiseaseOrPhenotypicFeature Genome Atlas ( TCGA ) website ( https : / / tcga - data . nci . nih . gov / tcga / ) .	1
The expression of LCGeneOrGeneProduct , phospho - LCGeneOrGeneProduct and LCOTHER - LCOTHER was evaluated by immunohistochemistry in 63 cases of LCOTHER and matched adjacent non - tumorous liver tissues .	2
The expression of LCGeneOrGeneProduct , phospho - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct was evaluated by immunohistochemistry in 63 cases of LCOTHER and matched adjacent non - tumorous liver tissues .	2
The expression of LCGeneOrGeneProduct , phospho - LCOTHER and LCOTHER - LCOTHER was evaluated by immunohistochemistry in 63 cases of LCDiseaseOrPhenotypicFeature and matched adjacent non - tumorous liver tissues .	1
The expression of LCOTHER , phospho - LCGeneOrGeneProduct and LCOTHER - LCOTHER was evaluated by immunohistochemistry in 63 cases of LCDiseaseOrPhenotypicFeature and matched adjacent non - tumorous liver tissues .	1
The expression of LCOTHER , phospho - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct was evaluated by immunohistochemistry in 63 cases of LCDiseaseOrPhenotypicFeature and matched adjacent non - tumorous liver tissues .	1
Relationships between protein expression and clinicopathological parameters were assessed , and the correlations between LCGeneOrGeneProduct with phospho - LCGeneOrGeneProduct and LCOTHER - LCOTHER expressions were evaluated .	2
Relationships between protein expression and clinicopathological parameters were assessed , and the correlations between LCGeneOrGeneProduct with phospho - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct expressions were evaluated .	2
LCGeneOrGeneProduct , as the most obviously different DEG in cells and tissues from the RNA - seq data , was listed as an LCDiseaseOrPhenotypicFeature candidate biomarker for further verification .	1
LCGeneOrGeneProduct was overexpressed in LCDiseaseOrPhenotypicFeature cells and tissues ( P = 0 . 002 , P = 0 . 013 ) and LCOTHER LCOTHER with a high expression of LCOTHER had a poor prognosis ( P = 0 . 0145 ) .	1
LCGeneOrGeneProduct was overexpressed in LCOTHER cells and tissues ( P = 0 . 002 , P = 0 . 013 ) and LCDiseaseOrPhenotypicFeature LCOTHER with a high expression of LCOTHER had a poor prognosis ( P = 0 . 0145 ) .	1
Clinical analysis indicated that the overexpression of LCGeneOrGeneProduct in LCDiseaseOrPhenotypicFeature was significantly correlated with diolame complete ( P < 0 . 001 ) , LCOTHER nodule number ( P = 0 . 012 ) and recurrence ( P = 0 . 004 ) .	1
Clinical analysis indicated that the overexpression of LCGeneOrGeneProduct in LCOTHER was significantly correlated with diolame complete ( P < 0 . 001 ) , LCDiseaseOrPhenotypicFeature nodule number ( P = 0 . 012 ) and recurrence ( P = 0 . 004 ) .	1
LCGeneOrGeneProduct expression was positively correlated with the expression of phospho - LCGeneOrGeneProduct ( r = 0 . 883 , P < 0 . 01 ) and LCOTHER - LCOTHER ( r = 0 . 781 , P < 0 . 01 ) .	2
LCGeneOrGeneProduct expression was positively correlated with the expression of phospho - LCOTHER ( r = 0 . 883 , P < 0 . 01 ) and LCGeneOrGeneProduct - LCGeneOrGeneProduct ( r = 0 . 781 , P < 0 . 01 ) .	2
Overexpression of LCGeneOrGeneProduct was associated with clinicopathological characteristics and poor LCOTHER outcomes , suggesting that LCOTHER serves as a prognostic biomarker for LCDiseaseOrPhenotypicFeature .	1
Overexpression of LCOTHER was associated with clinicopathological characteristics and poor LCOTHER outcomes , suggesting that LCGeneOrGeneProduct serves as a prognostic biomarker for LCDiseaseOrPhenotypicFeature .	1
Alteration of LCGeneOrGeneProduct protein levels may contribute to invasion and LCOTHER LCOTHER LCOTHER , which may occur through activation of LCGeneOrGeneProduct signaling and promotion of LCOTHER - LCOTHER expression . The number of LCOTHER LCOTHER LCOTHER in LCOTHER LCOTHER correlates with the LCOTHER LCOTHER - LCOTHER LCOTHER gene insertion / deletion polymorphism .	2
Alteration of LCGeneOrGeneProduct protein levels may contribute to invasion and LCOTHER LCOTHER LCOTHER , which may occur through activation of LCOTHER signaling and promotion of LCGeneOrGeneProduct - LCGeneOrGeneProduct expression . The number of LCOTHER LCOTHER LCOTHER in LCOTHER LCOTHER correlates with the LCOTHER LCOTHER - LCOTHER LCOTHER gene insertion / deletion polymorphism .	2
Alteration of LCGeneOrGeneProduct protein levels may contribute to invasion and LCOTHER LCOTHER LCOTHER , which may occur through activation of LCOTHER signaling and promotion of LCOTHER - LCOTHER expression . The number of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER LCOTHER correlates with the LCOTHER LCOTHER - LCOTHER LCOTHER gene insertion / deletion polymorphism .	1
PURPOSE : In the present study , we aimed to substantiate the putative significance of LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature biology by investigating the influence of its gene polymorphism on LCOTHER LCOTHER progression .	1
PURPOSE : In the present study , we aimed to substantiate the putative significance of LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) on LCOTHER LCOTHER biology by investigating the influence of its gene polymorphism on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature progression .	1
PURPOSE : In the present study , we aimed to substantiate the putative significance of LCOTHER LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature biology by investigating the influence of its gene polymorphism on LCOTHER LCOTHER progression .	1
PURPOSE : In the present study , we aimed to substantiate the putative significance of LCOTHER LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) on LCOTHER LCOTHER biology by investigating the influence of its gene polymorphism on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature progression .	1
Amplified LCGeneOrGeneProduct gene fragments were separated on LCChemicalEntity gels .	1
The distribution of the LCGeneOrGeneProduct genotypes did not differ significantly from the control group of 189 LCOTHER without LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
However , the LCGeneOrGeneProduct genotypes correlated with the number of LCOTHER LCOTHER LCOTHER and the Unio Internationale Contra Cancrum ( UICC ) LCDiseaseOrPhenotypicFeature stage .	1
No correlation was found between LCOTHER type , LCOTHER location , local LCOTHER growth , distant LCDiseaseOrPhenotypicFeature , and the LCGeneOrGeneProduct genotype .	1
The expression of LCGeneOrGeneProduct in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature was investigated by immunohistochemistry in 100 of 113 LCOTHER .	1
LCGeneOrGeneProduct was expressed by endothelial cells in all ( 100% ) specimens and by LCDiseaseOrPhenotypicFeature cells in 56 ( 56% ) specimens .	1
CONCLUSIONS : Our study shows that LCGeneOrGeneProduct is expressed locally in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and that the gene polymorphism influences metastatic behavior . LCOTHER mutations associated with LCOTHER ' LCOTHER and LCOTHER LCOTHER LCOTHER .	1
In two unrelated pedigrees of LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature , each affected child was found to carry a homozygous mutation in exon 17 of the LCOTHER locus that led to a LCSequenceVariant mutation just upstream of the polymerase domain of the protein .	1
LCGeneOrGeneProduct is the prototype of a group of LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER that bind and modulate signaling of various LCGeneOrGeneProduct - like ligands .	1
The LCGeneOrGeneProduct gene is on a region of chromosome 21 syntenic with the area of LCOTHER chromosome 7 bearing the LCGeneOrGeneProduct gene .	1
Inability to identify a separate LCOTHER gene corresponding to the mammalian LCOTHER gene suggests that LCGeneOrGeneProduct may serve roles in LCOTHER distributed between LCGeneOrGeneProduct and LCOTHER in other species .	1
Inability to identify a separate LCOTHER gene corresponding to the mammalian LCOTHER gene suggests that LCGeneOrGeneProduct may serve roles in LCOTHER distributed between LCOTHER and LCGeneOrGeneProduct in other species .	1
LCGeneOrGeneProduct , like LCOTHER , dorsalizes embryos upon overexpression and is cleaved by LCGeneOrGeneProduct , which antagonizes this activity .	3
LCOTHER , like LCGeneOrGeneProduct , dorsalizes embryos upon overexpression and is cleaved by LCGeneOrGeneProduct , which antagonizes this activity .	3
Loss - of - function experiments demonstrate that LCGeneOrGeneProduct serves as a LCGeneOrGeneProduct antagonist with functions that overlap and are redundant with those of LCOTHER in forming the dorsoventral axis . Polymorphic forms of LCOTHER LCOTHER LCOTHER and their interaction with LCOTHER LCOTHER trinucleotide repeats in LCOTHER LCOTHER .	3
The LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) gene has polymorphic regions containing variable length glutamine and glycine repeats and these are believed to be associated with LCDiseaseOrPhenotypicFeature risk .	1
The LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene has polymorphic regions containing variable length glutamine and glycine repeats and these are believed to be associated with LCDiseaseOrPhenotypicFeature risk .	1
The effect on LCDiseaseOrPhenotypicFeature risks from LCGeneOrGeneProduct polymorphisms alone and synergistically with the LCOTHER gene was examined in this report .	1
The effect on LCOTHER risks from LCGeneOrGeneProduct polymorphisms alone and synergistically with the LCGeneOrGeneProduct gene was examined in this report .	1
Moreover , we confirm previous results that a short LCSequenceVariant LCSequenceVariant in conjunction with GG genotype significantly increases the risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . A homozygous mutation in LCOTHER / LCOTHER associated with early onset LCOTHER , LCOTHER LCOTHER , and severe LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER activity .	2
Mutations in nuclear genes associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature respiratory chain are rare , having been found in only two LCGeneOrGeneProduct assembly factors and , as private changes in single families , three LCOTHER structural subunits .	3
Mutations in nuclear genes associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature respiratory chain are rare , having been found in only two LCOTHER assembly factors and , as private changes in single families , three LCGeneOrGeneProduct structural subunits .	3
Recently , LCOTHER LCGeneOrGeneProduct / LCOTHER , the ortholog of LCOTHER LCOTHER , has been identified as a new assembly factor for LCGeneOrGeneProduct .	1
Recently , LCOTHER LCOTHER / LCGeneOrGeneProduct , the ortholog of LCOTHER LCOTHER , has been identified as a new assembly factor for LCGeneOrGeneProduct .	1
Recently , LCOTHER LCOTHER / LCOTHER , the ortholog of LCOTHER LCGeneOrGeneProduct , has been identified as a new assembly factor for LCGeneOrGeneProduct .	3
In a baby LCOTHER with early onset , severe LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and profound , isolated LCOTHER LCOTHER in skeletal muscle , we identified a disease - segregating homozygous mutation ( LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ) in LCOTHER / LCOTHER , predicting a drastic change in a highly conserved amino - acid residue ( LCOTHER . LCOTHER ) .	2
In a baby LCOTHER with early onset , severe LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and profound , isolated LCOTHER LCOTHER in skeletal muscle , we identified a disease - segregating homozygous mutation ( LCOTHER . LCOTHER > LCOTHER ) in LCOTHER / LCOTHER , predicting a drastic change in a highly conserved amino - acid residue ( LCSequenceVariant . LCSequenceVariant ) .	2
In a baby LCOTHER with early onset , severe LCOTHER , LCOTHER LCOTHER and profound , isolated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in skeletal muscle , we identified a disease - segregating homozygous mutation ( LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ) in LCOTHER / LCOTHER , predicting a drastic change in a highly conserved amino - acid residue ( LCOTHER . LCOTHER ) .	2
In a baby LCOTHER with early onset , severe LCOTHER , LCOTHER LCOTHER and profound , isolated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in skeletal muscle , we identified a disease - segregating homozygous mutation ( LCOTHER . LCOTHER > LCOTHER ) in LCOTHER / LCOTHER , predicting a drastic change in a highly conserved amino - acid residue ( LCSequenceVariant . LCSequenceVariant ) .	2
In a LCGeneOrGeneProduct LCOTHER strain , the expression of a LCOTHER ( LCOTHER ) mutant allele caused temperature - sensitive LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , decreased LCOTHER consumption , impaired maturation / stabilization of the LCOTHER LCOTHER - LCOTHER LCOTHER , and reduced LCOTHER LCOTHER activity and amount .	1
In a LCGeneOrGeneProduct LCOTHER strain , the expression of a LCOTHER ( LCOTHER ) mutant allele caused temperature - sensitive LCOTHER LCOTHER LCOTHER , decreased LCChemicalEntity consumption , impaired maturation / stabilization of the LCOTHER LCOTHER - LCOTHER LCOTHER , and reduced LCOTHER LCOTHER activity and amount .	1
In a LCGeneOrGeneProduct LCOTHER strain , the expression of a LCOTHER ( LCOTHER ) mutant allele caused temperature - sensitive LCOTHER LCOTHER LCOTHER , decreased LCOTHER consumption , impaired maturation / stabilization of the LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct , and reduced LCOTHER LCOTHER activity and amount .	1
In a LCGeneOrGeneProduct LCOTHER strain , the expression of a LCOTHER ( LCOTHER ) mutant allele caused temperature - sensitive LCOTHER LCOTHER LCOTHER , decreased LCOTHER consumption , impaired maturation / stabilization of the LCOTHER LCOTHER - LCOTHER LCOTHER , and reduced LCGeneOrGeneProduct LCGeneOrGeneProduct activity and amount .	3
In a LCOTHER LCOTHER strain , the expression of a LCGeneOrGeneProduct ( LCOTHER ) mutant allele caused temperature - sensitive LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , decreased LCOTHER consumption , impaired maturation / stabilization of the LCOTHER LCOTHER - LCOTHER LCOTHER , and reduced LCOTHER LCOTHER activity and amount .	1
In a LCOTHER LCOTHER strain , the expression of a LCGeneOrGeneProduct ( LCOTHER ) mutant allele caused temperature - sensitive LCOTHER LCOTHER LCOTHER , decreased LCChemicalEntity consumption , impaired maturation / stabilization of the LCOTHER LCOTHER - LCOTHER LCOTHER , and reduced LCOTHER LCOTHER activity and amount .	1
In a LCOTHER LCOTHER strain , the expression of a LCGeneOrGeneProduct ( LCOTHER ) mutant allele caused temperature - sensitive LCOTHER LCOTHER LCOTHER , decreased LCOTHER consumption , impaired maturation / stabilization of the LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct , and reduced LCOTHER LCOTHER activity and amount .	1
In a LCOTHER LCOTHER strain , the expression of a LCGeneOrGeneProduct ( LCOTHER ) mutant allele caused temperature - sensitive LCOTHER LCOTHER LCOTHER , decreased LCOTHER consumption , impaired maturation / stabilization of the LCOTHER LCOTHER - LCOTHER LCOTHER , and reduced LCGeneOrGeneProduct LCGeneOrGeneProduct activity and amount .	3
In a LCOTHER LCOTHER strain , the expression of a LCOTHER ( LCSequenceVariant ) mutant allele caused temperature - sensitive LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , decreased LCOTHER consumption , impaired maturation / stabilization of the LCOTHER LCOTHER - LCOTHER LCOTHER , and reduced LCOTHER LCOTHER activity and amount .	2
In a LCOTHER LCOTHER strain , the expression of a LCOTHER ( LCSequenceVariant ) mutant allele caused temperature - sensitive LCOTHER LCOTHER LCOTHER , decreased LCChemicalEntity consumption , impaired maturation / stabilization of the LCOTHER LCOTHER - LCOTHER LCOTHER , and reduced LCOTHER LCOTHER activity and amount .	1
In a LCOTHER LCOTHER strain , the expression of a LCOTHER ( LCSequenceVariant ) mutant allele caused temperature - sensitive LCOTHER LCOTHER LCOTHER , decreased LCOTHER consumption , impaired maturation / stabilization of the LCOTHER LCOTHER - LCOTHER LCOTHER , and reduced LCGeneOrGeneProduct LCGeneOrGeneProduct activity and amount .	3
LCGeneOrGeneProduct / LCOTHER is a novel disease gene , causing LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , early onset , severe LCOTHER LCOTHER . cDNA sequence and chromosomal localization of the remaining three LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER : the LCOTHER LCOTHER fraction is completed .	1
LCGeneOrGeneProduct / LCOTHER is a novel disease gene , causing LCOTHER - LCOTHER , early onset , severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . cDNA sequence and chromosomal localization of the remaining three LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER : the LCOTHER LCOTHER fraction is completed .	1
LCOTHER / LCGeneOrGeneProduct is a novel disease gene , causing LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , early onset , severe LCOTHER LCOTHER . cDNA sequence and chromosomal localization of the remaining three LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER : the LCOTHER LCOTHER fraction is completed .	1
LCOTHER / LCGeneOrGeneProduct is a novel disease gene , causing LCOTHER - LCOTHER , early onset , severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . cDNA sequence and chromosomal localization of the remaining three LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER : the LCOTHER LCOTHER fraction is completed .	1
We cloned the cDNA of three remaining LCOTHER LCOTHER : LCOTHER LCOTHER LCOTHER of this LCOTHER fraction : the LCGeneOrGeneProduct ( 49 kDa ) , LCGeneOrGeneProduct ( 30 kDa ) , and LCOTHER ( 13 kDa ) subunits .	4
We cloned the cDNA of three remaining LCOTHER LCOTHER : LCOTHER LCOTHER LCOTHER of this LCOTHER fraction : the LCGeneOrGeneProduct ( 49 kDa ) , LCOTHER ( 30 kDa ) , and LCGeneOrGeneProduct ( 13 kDa ) subunits .	4
We cloned the cDNA of three remaining LCOTHER LCOTHER : LCOTHER LCOTHER LCOTHER of this LCOTHER fraction : the LCOTHER ( 49 kDa ) , LCGeneOrGeneProduct ( 30 kDa ) , and LCGeneOrGeneProduct ( 13 kDa ) subunits .	4
Polymerase chain reaction performed with DNA isolated from somatic LCOTHER - rodent cell hybrids containing defined LCOTHER chromosomes as template gave a LCOTHER - specific signal which mapped the LCGeneOrGeneProduct and LCGeneOrGeneProduct subunits to chromosomes 1 and 11 , respectively .	4
The LCGeneOrGeneProduct contains a highly conserved LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct phosphorylation site and the LCOTHER subunit contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site which make them strong candidates for future mutation detection studies in LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER . The LCOTHER mutation database : an online database of LCOTHER LCOTHER mutations involved in the LCOTHER ( LCOTHER ) LCOTHER LCOTHER and congenital LCOTHER LCOTHER .	1
The LCGeneOrGeneProduct contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site and the LCGeneOrGeneProduct subunit contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site which make them strong candidates for future mutation detection studies in LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER . The LCOTHER mutation database : an online database of LCOTHER LCOTHER mutations involved in the LCOTHER ( LCOTHER ) LCOTHER LCOTHER and congenital LCOTHER LCOTHER .	4
The LCGeneOrGeneProduct contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site and the LCOTHER subunit contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site which make them strong candidates for future mutation detection studies in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER . The LCOTHER mutation database : an online database of LCOTHER LCOTHER mutations involved in the LCOTHER ( LCOTHER ) LCOTHER LCOTHER and congenital LCOTHER LCOTHER .	1
The LCOTHER contains a highly conserved LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct phosphorylation site and the LCOTHER subunit contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site which make them strong candidates for future mutation detection studies in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER . The LCOTHER mutation database : an online database of LCOTHER LCOTHER mutations involved in the LCOTHER ( LCOTHER ) LCOTHER LCOTHER and congenital LCOTHER LCOTHER .	1
The LCOTHER contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site and the LCGeneOrGeneProduct subunit contains a highly conserved LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct phosphorylation site which make them strong candidates for future mutation detection studies in LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER . The LCOTHER mutation database : an online database of LCOTHER LCOTHER mutations involved in the LCOTHER ( LCOTHER ) LCOTHER LCOTHER and congenital LCOTHER LCOTHER .	1
The LCOTHER contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site and the LCGeneOrGeneProduct subunit contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site which make them strong candidates for future mutation detection studies in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER . The LCOTHER mutation database : an online database of LCOTHER LCOTHER mutations involved in the LCOTHER ( LCOTHER ) LCOTHER LCOTHER and congenital LCOTHER LCOTHER .	1
The LCOTHER contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site and the LCOTHER subunit contains a highly conserved LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct phosphorylation site which make them strong candidates for future mutation detection studies in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER . The LCOTHER mutation database : an online database of LCOTHER LCOTHER mutations involved in the LCOTHER ( LCOTHER ) LCOTHER LCOTHER and congenital LCOTHER LCOTHER .	1
BACKGROUND : LCGeneOrGeneProduct LCGeneOrGeneProduct ( HGNC approved gene symbol - LCOTHER ) , also known as LCOTHER , is an enzyme of the LCChemicalEntity LCChemicalEntity ( LCOTHER ) cycle , involved in fundamental cellular energy production .	1
BACKGROUND : LCGeneOrGeneProduct LCGeneOrGeneProduct ( HGNC approved gene symbol - LCOTHER ) , also known as LCOTHER , is an enzyme of the LCOTHER LCOTHER ( LCChemicalEntity ) cycle , involved in fundamental cellular energy production .	1
BACKGROUND : LCOTHER LCOTHER ( HGNC approved gene symbol - LCGeneOrGeneProduct ) , also known as LCOTHER , is an enzyme of the LCChemicalEntity LCChemicalEntity ( LCOTHER ) cycle , involved in fundamental cellular energy production .	1
BACKGROUND : LCOTHER LCOTHER ( HGNC approved gene symbol - LCGeneOrGeneProduct ) , also known as LCOTHER , is an enzyme of the LCOTHER LCOTHER ( LCChemicalEntity ) cycle , involved in fundamental cellular energy production .	1
BACKGROUND : LCOTHER LCOTHER ( HGNC approved gene symbol - LCOTHER ) , also known as LCGeneOrGeneProduct , is an enzyme of the LCChemicalEntity LCChemicalEntity ( LCOTHER ) cycle , involved in fundamental cellular energy production .	1
BACKGROUND : LCOTHER LCOTHER ( HGNC approved gene symbol - LCOTHER ) , also known as LCGeneOrGeneProduct , is an enzyme of the LCOTHER LCOTHER ( LCChemicalEntity ) cycle , involved in fundamental cellular energy production .	1
In 2002 , the Multiple LCOTHER Consortium identified heterozygous germline mutations of LCGeneOrGeneProduct in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , ( LCOTHER : LCOTHER LCOTHER ) .	1
In 2002 , the Multiple LCOTHER Consortium identified heterozygous germline mutations of LCGeneOrGeneProduct in LCOTHER with LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( LCDiseaseOrPhenotypicFeature : LCOTHER LCOTHER ) .	1
In 2002 , the Multiple LCOTHER Consortium identified heterozygous germline mutations of LCGeneOrGeneProduct in LCOTHER with LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( LCOTHER : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	1
The identification of LCGeneOrGeneProduct as a LCDiseaseOrPhenotypicFeature suppressor was an unexpected finding and following the identification of subunits of succinate dehydrogenase in 2000 and 2001 , was only the second description of the involvement of an enzyme of intermediary metabolism in LCOTHER .	1
The identification of LCGeneOrGeneProduct as a LCOTHER suppressor was an unexpected finding and following the identification of subunits of succinate dehydrogenase in 2000 and 2001 , was only the second description of the involvement of an enzyme of intermediary metabolism in LCDiseaseOrPhenotypicFeature .	1
DESCRIPTION : The LCGeneOrGeneProduct mutation database is a part of the LCChemicalEntity cycle gene mutation database ( formerly the succinate dehydrogenase gene mutation database ) and is based on the Leiden Open ( source ) Variation Database ( LOVD ) system .	1
Since the first molecular characterization of an LCGeneOrGeneProduct mutation by Bourgeron et al in 1994 , a series of reports of both LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER and LCOTHER with LCOTHER / LCOTHER have described 107 variants , of which 93 are thought to be pathogenic .	1
Since the first molecular characterization of an LCGeneOrGeneProduct mutation by Bourgeron et al in 1994 , a series of reports of both LCOTHER LCOTHER LCOTHER and LCOTHER with LCDiseaseOrPhenotypicFeature / LCOTHER have described 107 variants , of which 93 are thought to be pathogenic .	1
Since the first molecular characterization of an LCGeneOrGeneProduct mutation by Bourgeron et al in 1994 , a series of reports of both LCOTHER LCOTHER LCOTHER and LCOTHER with LCOTHER / LCDiseaseOrPhenotypicFeature have described 107 variants , of which 93 are thought to be pathogenic .	1
There is considerable interest in identifying the molecular mechanisms that relate early - life LCChemicalEntity exposure to the development of these latent diseases , particularly in relationship to LCDiseaseOrPhenotypicFeature .	2
DISCUSSION : Epigenetic reprogramming that imparts functional changes in gene expression , the development of LCOTHER stem cells , and immunomodulation are plausible underlying mechanisms by which early - life LCChemicalEntity exposure elicits latent LCDiseaseOrPhenotypicFeature effects .	2
CONCLUSIONS : Evidence is mounting that relates early - life LCChemicalEntity exposure and LCDiseaseOrPhenotypicFeature development later in life .	2
Here , we described the screening of 10 LCOTHER who presented with LCDiseaseOrPhenotypicFeature , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature for mutations in open reading frame ( ORF ) of LCGeneOrGeneProduct gene .	1
STUDY DESIGN : Wild - type ( WT ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCGeneOrGeneProduct / LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCGeneOrGeneProduct / LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCGeneOrGeneProduct transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCGeneOrGeneProduct / LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCGeneOrGeneProduct transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCGeneOrGeneProduct transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCGeneOrGeneProduct transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCGeneOrGeneProduct transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCGeneOrGeneProduct transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCGeneOrGeneProduct transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCGeneOrGeneProduct transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCGeneOrGeneProduct transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCGeneOrGeneProduct transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCGeneOrGeneProduct transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCDiseaseOrPhenotypicFeature WT female with LCGeneOrGeneProduct transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCGeneOrGeneProduct transgenic male were analyzed for ER stress markers : LCGeneOrGeneProduct / LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCGeneOrGeneProduct transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCGeneOrGeneProduct transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCGeneOrGeneProduct transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCGeneOrGeneProduct transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCGeneOrGeneProduct transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCGeneOrGeneProduct transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCGeneOrGeneProduct transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCGeneOrGeneProduct transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCGeneOrGeneProduct transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) messenger RNA ( mRNA ) splicing .	1
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCGeneOrGeneProduct transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) messenger RNA ( mRNA ) splicing .	1
RESULTS : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature significantly increased the levels of LCGeneOrGeneProduct , LCOTHER , phosphorylated ( p ) - LCOTHER , p - LCOTHER , and p - LCOTHER ; triggered LCOTHER mRNA splicing ; and enhanced ER chaperone gene expression in WT embryos .	2
CONCLUSION : Mitigating oxidative stress via LCGeneOrGeneProduct overexpression blocks LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - induced ER stress in vivo . The LCOTHER LCOTHER : identification of single nucleotide polymorphisms from six ethnic populations .	1
BACKGROUND : The effects of LCChemicalEntity , LCChemicalEntity , LCChemicalEntity , LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity and related LCChemicalEntity - like chemicals are mediated through binding - dependent activation of the cytosolic LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
BACKGROUND : The effects of LCChemicalEntity , LCChemicalEntity , LCChemicalEntity , LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity and related LCOTHER - like chemicals are mediated through binding - dependent activation of the cytosolic LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	1
BACKGROUND : The effects of LCChemicalEntity , LCChemicalEntity , LCChemicalEntity , LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity and related LCOTHER - like chemicals are mediated through binding - dependent activation of the cytosolic LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	1
BACKGROUND : The effects of LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER - LCOTHER - LCOTHER and related LCChemicalEntity - like chemicals are mediated through binding - dependent activation of the cytosolic LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	1
BACKGROUND : The effects of LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER - LCOTHER - LCOTHER and related LCChemicalEntity - like chemicals are mediated through binding - dependent activation of the cytosolic LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	1
We hypothesized that LCSequenceVariant LCSequenceVariant LCSequenceVariant influences weight regulation in females with LCDiseaseOrPhenotypicFeature .	1
Our data provide evidence that LCSequenceVariant LCSequenceVariant LCSequenceVariant mediates severity of weight regulation disturbances in females with LCDiseaseOrPhenotypicFeature , and the gene - dose effect - like differences suggest a direct functional role of LCOTHER LCOTHER LCOTHER in the behavioral regulation of body weight . LCOTHER , a new member of the LCOTHER gene family , is involved in drug resistance in LCOTHER / LCOTHER cells .	1
LCOTHER / LCOTHER cells expressing the exogenous LCGeneOrGeneProduct exhibited less resistance to several anti - cancer drugs , such as LCChemicalEntity ( LCOTHER ) , LCOTHER , LCOTHER , and LCOTHER , than the control cells containing the empty vector .	2
LCOTHER / LCOTHER cells expressing the exogenous LCGeneOrGeneProduct exhibited less resistance to several anti - cancer drugs , such as LCOTHER ( LCChemicalEntity ) , LCOTHER , LCOTHER , and LCOTHER , than the control cells containing the empty vector .	2
LCOTHER / LCOTHER cells expressing the exogenous LCGeneOrGeneProduct exhibited less resistance to several anti - cancer drugs , such as LCOTHER ( LCOTHER ) , LCChemicalEntity , LCOTHER , and LCOTHER , than the control cells containing the empty vector .	2
LCOTHER / LCOTHER cells expressing the exogenous LCGeneOrGeneProduct exhibited less resistance to several anti - cancer drugs , such as LCOTHER ( LCOTHER ) , LCOTHER , LCChemicalEntity , and LCOTHER , than the control cells containing the empty vector .	2
LCOTHER / LCOTHER cells expressing the exogenous LCGeneOrGeneProduct exhibited less resistance to several anti - cancer drugs , such as LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER , and LCChemicalEntity , than the control cells containing the empty vector .	2
LCChemicalEntity - LCChemicalEntity is a critical chemotherapeutic agent for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	3
LCChemicalEntity - LCChemicalEntity is a critical chemotherapeutic agent for LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	3
It hydrolyzes plasma LCChemicalEntity into LCChemicalEntity and LCOTHER , causing LCOTHER LCOTHER and inhibition of protein synthesis and eventually , LCOTHER cell death .	1
It hydrolyzes plasma LCChemicalEntity into LCOTHER and LCChemicalEntity , causing LCOTHER LCOTHER and inhibition of protein synthesis and eventually , LCOTHER cell death .	1
Therefore , we sought to identify genes that are involved in LCChemicalEntity - LCChemicalEntity resistance in primary LCDiseaseOrPhenotypicFeature cells .	3
We also found that LCGeneOrGeneProduct is expressed in all LCDiseaseOrPhenotypicFeature cells tested .	1
Specific knockdown of LCGeneOrGeneProduct confers LCChemicalEntity - LCChemicalEntity resistance , validating our genome - wide retroviral shRNA library screening data .	2
LCChemicalEntity , an agonist of LCGeneOrGeneProduct , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	2
LCChemicalEntity , an agonist of LCOTHER , enhances the sensitivity of parental LCDiseaseOrPhenotypicFeature cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	1
LCChemicalEntity , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCGeneOrGeneProduct - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	2
LCChemicalEntity , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCGeneOrGeneProduct is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	2
LCChemicalEntity , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCGeneOrGeneProduct loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	2
LCChemicalEntity , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCDiseaseOrPhenotypicFeature cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	1
LCChemicalEntity , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCGeneOrGeneProduct - mediated apoptotic pathway .	2
LCOTHER , an agonist of LCGeneOrGeneProduct , enhances the sensitivity of parental LCDiseaseOrPhenotypicFeature cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	1
LCOTHER , an agonist of LCGeneOrGeneProduct , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCChemicalEntity - LCChemicalEntity treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	2
LCOTHER , an agonist of LCGeneOrGeneProduct , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCChemicalEntity - LCChemicalEntity and LCOTHER , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	2
LCOTHER , an agonist of LCGeneOrGeneProduct , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCDiseaseOrPhenotypicFeature cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	1
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCGeneOrGeneProduct - depleted cells , to LCChemicalEntity - LCChemicalEntity treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	2
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCGeneOrGeneProduct - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCChemicalEntity - LCChemicalEntity and LCOTHER , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	2
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCGeneOrGeneProduct - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCDiseaseOrPhenotypicFeature cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	1
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCChemicalEntity - LCChemicalEntity treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCChemicalEntity , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	5
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCChemicalEntity - LCChemicalEntity treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCDiseaseOrPhenotypicFeature cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	3
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCGeneOrGeneProduct is required for the synergistic action of LCChemicalEntity - LCChemicalEntity and LCOTHER , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	2
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCGeneOrGeneProduct is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCDiseaseOrPhenotypicFeature cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	1
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCChemicalEntity - LCChemicalEntity and LCChemicalEntity , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	5
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCChemicalEntity - LCChemicalEntity and LCOTHER , and that LCOTHER loss promotes LCDiseaseOrPhenotypicFeature cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	3
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCChemicalEntity , and that LCGeneOrGeneProduct loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	2
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCChemicalEntity , and that LCOTHER loss promotes LCDiseaseOrPhenotypicFeature cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	1
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCChemicalEntity , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCGeneOrGeneProduct - mediated apoptotic pathway .	2
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCGeneOrGeneProduct loss promotes LCDiseaseOrPhenotypicFeature cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	1
Consistent with this premise , LCOTHER LCOTHER cells with relatively high levels of LCGeneOrGeneProduct are more sensitive to LCChemicalEntity - LCChemicalEntity treatment compared to LCOTHER - depleted LCOTHER cells , further indicating that LCOTHER loss has a crucial role in LCOTHER - LCOTHER resistance in LCOTHER LCOTHER .	2
Consistent with this premise , LCOTHER LCOTHER cells with relatively high levels of LCGeneOrGeneProduct are more sensitive to LCOTHER - LCOTHER treatment compared to LCOTHER - depleted LCDiseaseOrPhenotypicFeature cells , further indicating that LCOTHER loss has a crucial role in LCOTHER - LCOTHER resistance in LCOTHER LCOTHER .	1
Consistent with this premise , LCOTHER LCOTHER cells with relatively high levels of LCGeneOrGeneProduct are more sensitive to LCOTHER - LCOTHER treatment compared to LCOTHER - depleted LCOTHER cells , further indicating that LCOTHER loss has a crucial role in LCChemicalEntity - LCChemicalEntity resistance in LCOTHER LCOTHER .	2
Consistent with this premise , LCOTHER LCOTHER cells with relatively high levels of LCGeneOrGeneProduct are more sensitive to LCOTHER - LCOTHER treatment compared to LCOTHER - depleted LCOTHER cells , further indicating that LCOTHER loss has a crucial role in LCOTHER - LCOTHER resistance in LCDiseaseOrPhenotypicFeature LCOTHER .	1
Consistent with this premise , LCOTHER LCOTHER cells with relatively high levels of LCOTHER are more sensitive to LCChemicalEntity - LCChemicalEntity treatment compared to LCOTHER - depleted LCDiseaseOrPhenotypicFeature cells , further indicating that LCOTHER loss has a crucial role in LCOTHER - LCOTHER resistance in LCOTHER LCOTHER .	3
Consistent with this premise , LCOTHER LCOTHER cells with relatively high levels of LCOTHER are more sensitive to LCChemicalEntity - LCChemicalEntity treatment compared to LCOTHER - depleted LCOTHER cells , further indicating that LCOTHER loss has a crucial role in LCOTHER - LCOTHER resistance in LCDiseaseOrPhenotypicFeature LCOTHER .	3
Consistent with this premise , LCOTHER LCOTHER cells with relatively high levels of LCOTHER are more sensitive to LCOTHER - LCOTHER treatment compared to LCGeneOrGeneProduct - depleted LCDiseaseOrPhenotypicFeature cells , further indicating that LCOTHER loss has a crucial role in LCOTHER - LCOTHER resistance in LCOTHER LCOTHER .	1
Consistent with this premise , LCOTHER LCOTHER cells with relatively high levels of LCOTHER are more sensitive to LCOTHER - LCOTHER treatment compared to LCGeneOrGeneProduct - depleted LCOTHER cells , further indicating that LCOTHER loss has a crucial role in LCChemicalEntity - LCChemicalEntity resistance in LCOTHER LCOTHER .	2
Consistent with this premise , LCOTHER LCOTHER cells with relatively high levels of LCOTHER are more sensitive to LCOTHER - LCOTHER treatment compared to LCGeneOrGeneProduct - depleted LCOTHER cells , further indicating that LCOTHER loss has a crucial role in LCOTHER - LCOTHER resistance in LCDiseaseOrPhenotypicFeature LCOTHER .	1
Consistent with this premise , LCOTHER LCOTHER cells with relatively high levels of LCOTHER are more sensitive to LCOTHER - LCOTHER treatment compared to LCOTHER - depleted LCOTHER cells , further indicating that LCGeneOrGeneProduct loss has a crucial role in LCChemicalEntity - LCChemicalEntity resistance in LCOTHER LCOTHER .	2
Consistent with this premise , LCOTHER LCOTHER cells with relatively high levels of LCOTHER are more sensitive to LCOTHER - LCOTHER treatment compared to LCOTHER - depleted LCOTHER cells , further indicating that LCGeneOrGeneProduct loss has a crucial role in LCOTHER - LCOTHER resistance in LCDiseaseOrPhenotypicFeature LCOTHER .	1
Consistent with this premise , LCOTHER LCOTHER cells with relatively high levels of LCOTHER are more sensitive to LCOTHER - LCOTHER treatment compared to LCOTHER - depleted LCOTHER cells , further indicating that LCOTHER loss has a crucial role in LCChemicalEntity - LCChemicalEntity resistance in LCDiseaseOrPhenotypicFeature LCOTHER .	3
Thus , our study demonstrates for the first time , a novel LCGeneOrGeneProduct - mediated mechanism for LCChemicalEntity - LCChemicalEntity resistance in LCOTHER , and identifies LCOTHER as a functional biomarker for defining high - risk subpopulations and for the detection of evolving resistant clones .	2
Thus , our study demonstrates for the first time , a novel LCGeneOrGeneProduct - mediated mechanism for LCOTHER - LCOTHER resistance in LCDiseaseOrPhenotypicFeature , and identifies LCOTHER as a functional biomarker for defining high - risk subpopulations and for the detection of evolving resistant clones .	3
Thus , our study demonstrates for the first time , a novel LCOTHER - mediated mechanism for LCChemicalEntity - LCChemicalEntity resistance in LCDiseaseOrPhenotypicFeature , and identifies LCOTHER as a functional biomarker for defining high - risk subpopulations and for the detection of evolving resistant clones .	3
LCGeneOrGeneProduct may also be utilized for effective treatment of LCChemicalEntity - LCChemicalEntity - resistant LCOTHER . Oncogene advance online publication , 26 June 2017 ; doi : 10 . 1038 / onc . 2017 . 211 . rTMS of supplementary motor area modulates therapy - induced LCOTHER in LCOTHER LCOTHER .	2
LCGeneOrGeneProduct may also be utilized for effective treatment of LCOTHER - LCOTHER - resistant LCDiseaseOrPhenotypicFeature . Oncogene advance online publication , 26 June 2017 ; doi : 10 . 1038 / onc . 2017 . 211 . rTMS of supplementary motor area modulates therapy - induced LCOTHER in LCOTHER LCOTHER .	3
LCOTHER may also be utilized for effective treatment of LCChemicalEntity - LCChemicalEntity - resistant LCDiseaseOrPhenotypicFeature . Oncogene advance online publication , 26 June 2017 ; doi : 10 . 1038 / onc . 2017 . 211 . rTMS of supplementary motor area modulates therapy - induced LCOTHER in LCOTHER LCOTHER .	3
The neural mechanisms and circuitry involved in LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature are unclear .	2
BACKGROUND : The LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) gene was reported as a susceptibility gene to LCDiseaseOrPhenotypicFeature .	1
BACKGROUND : The LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene was reported as a susceptibility gene to LCDiseaseOrPhenotypicFeature .	1
LCSequenceVariant at the LCOTHER gene was selected because it conferred a risk for young LCDiseaseOrPhenotypicFeature in our previous report .	2
LCOTHER at the LCGeneOrGeneProduct gene was selected because it conferred a risk for young LCDiseaseOrPhenotypicFeature in our previous report .	1
Similarly , SNP LCSequenceVariant was only significant in young LCDiseaseOrPhenotypicFeature LCOTHER ( OR = 1 . 8 , p = 0 . 025 ) but not in LCOTHER ( p = 0 . 27 ) .	2
CONCLUSIONS : The present study demonstrates a sex - differential effect of LCGeneOrGeneProduct on IMT , plaque index and LCDiseaseOrPhenotypicFeature , which highlights its influence on various aspects of LCOTHER . Reduced LCOTHER expression after high - fat diet is associated with selective up - regulation of LCOTHER and further LCOTHER LCOTHER LCOTHER signaling in adipose tissue .	1
CONCLUSIONS : The present study demonstrates a sex - differential effect of LCGeneOrGeneProduct on IMT , plaque index and LCOTHER , which highlights its influence on various aspects of LCDiseaseOrPhenotypicFeature . Reduced LCOTHER expression after high - fat diet is associated with selective up - regulation of LCOTHER and further LCOTHER LCOTHER LCOTHER signaling in adipose tissue .	1
LCGeneOrGeneProduct is an adipocyte - derived LCOTHER with potent antidiabetic , anti - LCDiseaseOrPhenotypicFeature , and antiatherogenic activity .	3
LCOTHER is an adipocyte - derived LCGeneOrGeneProduct with potent antidiabetic , anti - LCDiseaseOrPhenotypicFeature , and antiatherogenic activity .	3
In this study , we examined LCGeneOrGeneProduct expression as a function of dietary high - fat and high - LCChemicalEntity LCChemicalEntity conditions in LCOTHER .	3
A decrease of LCGeneOrGeneProduct expression in addition to an up - regulation of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , retinoid signaling , and LCOTHER LCOTHER response element signaling was selectively observed in WAT of LCOTHER fed a normal - LCOTHER LCOTHER , high - fat diet .	3
A decrease of LCGeneOrGeneProduct expression in addition to an up - regulation of LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , retinoid signaling , and LCOTHER LCOTHER response element signaling was selectively observed in WAT of LCOTHER fed a normal - LCOTHER LCOTHER , high - fat diet .	3
A decrease of LCGeneOrGeneProduct expression in addition to an up - regulation of LCOTHER LCOTHER LCOTHER ( LCOTHER ) , retinoid signaling , and LCChemicalEntity LCChemicalEntity response element signaling was selectively observed in WAT of LCOTHER fed a normal - LCOTHER LCOTHER , high - fat diet .	3
A decrease of LCGeneOrGeneProduct expression in addition to an up - regulation of LCOTHER LCOTHER LCOTHER ( LCOTHER ) , retinoid signaling , and LCOTHER LCOTHER response element signaling was selectively observed in WAT of LCOTHER fed a normal - LCChemicalEntity LCChemicalEntity , high - fat diet .	3
A decrease of LCOTHER expression in addition to an up - regulation of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , retinoid signaling , and LCOTHER LCOTHER response element signaling was selectively observed in WAT of LCOTHER fed a normal - LCChemicalEntity LCChemicalEntity , high - fat diet .	2
A decrease of LCOTHER expression in addition to an up - regulation of LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , retinoid signaling , and LCOTHER LCOTHER response element signaling was selectively observed in WAT of LCOTHER fed a normal - LCChemicalEntity LCChemicalEntity , high - fat diet .	2
A decrease of LCOTHER expression in addition to an up - regulation of LCOTHER LCOTHER LCOTHER ( LCOTHER ) , retinoid signaling , and LCChemicalEntity LCChemicalEntity response element signaling was selectively observed in WAT of LCOTHER fed a normal - LCChemicalEntity LCChemicalEntity , high - fat diet .	1
Reduced LCGeneOrGeneProduct expression in WAT was also observed in LCOTHER fed a high - LCChemicalEntity LCChemicalEntity diet .	3
Adipocyte cell culture revealed that endogenous and synthetic LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct - and LCOTHER - selective agonists , as well as a synthetic LCOTHER LCOTHER LCOTHER agonist , efficiently reduced LCGeneOrGeneProduct expression , whereas LCOTHER expression only increased with LCOTHER agonists .	3
Adipocyte cell culture revealed that endogenous and synthetic LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER - and LCGeneOrGeneProduct - selective agonists , as well as a synthetic LCOTHER LCOTHER LCOTHER agonist , efficiently reduced LCGeneOrGeneProduct expression , whereas LCOTHER expression only increased with LCOTHER agonists .	3
Adipocyte cell culture revealed that endogenous and synthetic LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER - and LCOTHER - selective agonists , as well as a synthetic LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct agonist , efficiently reduced LCGeneOrGeneProduct expression , whereas LCOTHER expression only increased with LCOTHER agonists .	3
Adipocyte cell culture revealed that endogenous and synthetic LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER - and LCOTHER - selective agonists , as well as a synthetic LCOTHER LCOTHER LCOTHER agonist , efficiently reduced LCGeneOrGeneProduct expression , whereas LCGeneOrGeneProduct expression only increased with LCOTHER agonists .	3
We conclude that reduced LCGeneOrGeneProduct expression under high - fat dietary conditions is dependent on 1 ) increased LCGeneOrGeneProduct expression in adipocytes , which does not increase all - trans - LCOTHER LCOTHER levels ; 2 ) further LCOTHER ligand - induced , WAT - selective , increased LCOTHER LCOTHER response element - mediated signaling ; and 3 ) LCOTHER ligand - dependent reduction of LCOTHER expression . - Landrier , J . - F . , Kasiri , E . , Karkeni , E . , Mihaly , J . , Beke , G . , Weiss , K . , Lucas , R . , Aydemir , G . , Salles , J . , Walrand , S . , de Lera , A .	3
We conclude that reduced LCGeneOrGeneProduct expression under high - fat dietary conditions is dependent on 1 ) increased LCOTHER expression in adipocytes , which does not increase all - trans - LCChemicalEntity LCChemicalEntity levels ; 2 ) further LCOTHER ligand - induced , WAT - selective , increased LCOTHER LCOTHER response element - mediated signaling ; and 3 ) LCOTHER ligand - dependent reduction of LCOTHER expression . - Landrier , J . - F . , Kasiri , E . , Karkeni , E . , Mihaly , J . , Beke , G . , Weiss , K . , Lucas , R . , Aydemir , G . , Salles , J . , Walrand , S . , de Lera , A .	3
We conclude that reduced LCGeneOrGeneProduct expression under high - fat dietary conditions is dependent on 1 ) increased LCOTHER expression in adipocytes , which does not increase all - trans - LCOTHER LCOTHER levels ; 2 ) further LCOTHER ligand - induced , WAT - selective , increased LCChemicalEntity LCChemicalEntity response element - mediated signaling ; and 3 ) LCOTHER ligand - dependent reduction of LCOTHER expression . - Landrier , J . - F . , Kasiri , E . , Karkeni , E . , Mihaly , J . , Beke , G . , Weiss , K . , Lucas , R . , Aydemir , G . , Salles , J . , Walrand , S . , de Lera , A .	3
Reduced LCGeneOrGeneProduct expression after high - fat diet is associated with selective up - regulation of LCGeneOrGeneProduct and further LCOTHER LCOTHER LCOTHER signaling in adipose tissue . Effect of the abrogation of LCOTHER - LCOTHER by antisense LCOTHER on the expression of LCOTHER - LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in isolated fibroblasts from LCOTHER LCOTHER .	3
The isoforms LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCGeneOrGeneProduct - LCGeneOrGeneProduct have profibrotic properties , whereas LCOTHER - LCOTHER may have antifibrotic functions .	2
The aim of this study was to investigate the effect of LCGeneOrGeneProduct - LCGeneOrGeneProduct targeting by antisense LCChemicalEntity on the RNA synthesis and protein expression of LCOTHER - LCOTHER isoforms and their receptors in LCOTHER - derived fibroblasts .	1
The aim of this study was to investigate the effect of LCGeneOrGeneProduct - LCGeneOrGeneProduct targeting by antisense LCOTHER on the RNA synthesis and protein expression of LCOTHER - LCOTHER isoforms and their receptors in LCDiseaseOrPhenotypicFeature - derived fibroblasts .	2
In tissue samples with normal fibroblasts ( NFs ) serving as control samples , expression of LCOTHER - LCOTHER LCOTHER - LCOTHER was decreased when compared to LCDiseaseOrPhenotypicFeature fibroblasts ( KFs ) , while expression of LCGeneOrGeneProduct - LCGeneOrGeneProduct and of LCOTHER - LCOTHER was significantly higher in NFs .	3
In tissue samples with normal fibroblasts ( NFs ) serving as control samples , expression of LCOTHER - LCOTHER LCOTHER - LCOTHER was decreased when compared to LCOTHER fibroblasts ( KFs ) , while expression of LCGeneOrGeneProduct - LCGeneOrGeneProduct and of LCGeneOrGeneProduct - LCGeneOrGeneProduct was significantly higher in NFs .	4
Expression of LCGeneOrGeneProduct - LCGeneOrGeneProduct mRNA revealed contrary patterns in KFs from different LCOTHER while expression of LCGeneOrGeneProduct - LCGeneOrGeneProduct was found to be equal during the measurement period .	4
To analyse the in vivo function of LCGeneOrGeneProduct in cartilage , we generated LCOTHER with a conditional deletion of LCOTHER driven by the LCGeneOrGeneProduct LCGeneOrGeneProduct promoter .	1
To analyse the in vivo function of LCOTHER in cartilage , we generated LCOTHER with a conditional deletion of LCGeneOrGeneProduct driven by the LCGeneOrGeneProduct LCGeneOrGeneProduct promoter .	1
LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCOTHER displayed severe LCOTHER with runting , impaired formation of secondary centres of ossification , and LCOTHER LCOTHER including LCOTHER LCOTHER and LCOTHER LCOTHER .	1
LCGeneOrGeneProduct ( LCOTHER ) LCOTHER displayed severe LCDiseaseOrPhenotypicFeature with runting , impaired formation of secondary centres of ossification , and LCOTHER LCOTHER including LCOTHER LCOTHER and LCOTHER LCOTHER .	1
LCGeneOrGeneProduct ( LCOTHER ) LCOTHER displayed severe LCOTHER with runting , impaired formation of secondary centres of ossification , and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature including LCOTHER LCOTHER and LCOTHER LCOTHER .	1
LCGeneOrGeneProduct ( LCOTHER ) LCOTHER displayed severe LCOTHER with runting , impaired formation of secondary centres of ossification , and LCOTHER LCOTHER including LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER .	1
LCGeneOrGeneProduct ( LCOTHER ) LCOTHER displayed severe LCOTHER with runting , impaired formation of secondary centres of ossification , and LCOTHER LCOTHER including LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
LCOTHER ( LCGeneOrGeneProduct ) LCOTHER displayed severe LCDiseaseOrPhenotypicFeature with runting , impaired formation of secondary centres of ossification , and LCOTHER LCOTHER including LCOTHER LCOTHER and LCOTHER LCOTHER .	1
LCOTHER ( LCGeneOrGeneProduct ) LCOTHER displayed severe LCOTHER with runting , impaired formation of secondary centres of ossification , and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature including LCOTHER LCOTHER and LCOTHER LCOTHER .	1
LCOTHER ( LCGeneOrGeneProduct ) LCOTHER displayed severe LCOTHER with runting , impaired formation of secondary centres of ossification , and LCOTHER LCOTHER including LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER .	1
LCOTHER ( LCGeneOrGeneProduct ) LCOTHER displayed severe LCOTHER with runting , impaired formation of secondary centres of ossification , and LCOTHER LCOTHER including LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
LCGeneOrGeneProduct signalling was markedly impaired in LCGeneOrGeneProduct - deficient chondrocytes as evidenced by reduced expression of known LCOTHER target genes as well as reduced phosphorylation of LCOTHER / LCOTHER / LCOTHER and LCOTHER / LCOTHER / LCOTHER LCOTHER LCOTHER .	1
LCGeneOrGeneProduct signalling was markedly impaired in LCOTHER - deficient chondrocytes as evidenced by reduced expression of known LCGeneOrGeneProduct target genes as well as reduced phosphorylation of LCOTHER / LCOTHER / LCOTHER and LCOTHER / LCOTHER / LCOTHER LCOTHER LCOTHER .	4
LCGeneOrGeneProduct signalling was markedly impaired in LCOTHER - deficient chondrocytes as evidenced by reduced expression of known LCOTHER target genes as well as reduced phosphorylation of LCOTHER / LCOTHER / LCOTHER and LCGeneOrGeneProduct / LCOTHER / LCOTHER LCOTHER LCOTHER .	1
LCGeneOrGeneProduct signalling was markedly impaired in LCOTHER - deficient chondrocytes as evidenced by reduced expression of known LCOTHER target genes as well as reduced phosphorylation of LCOTHER / LCOTHER / LCOTHER and LCOTHER / LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER .	1
LCGeneOrGeneProduct signalling was markedly impaired in LCOTHER - deficient chondrocytes as evidenced by reduced expression of known LCOTHER target genes as well as reduced phosphorylation of LCOTHER / LCOTHER / LCOTHER and LCOTHER / LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER .	1
LCOTHER signalling was markedly impaired in LCGeneOrGeneProduct - deficient chondrocytes as evidenced by reduced expression of known LCGeneOrGeneProduct target genes as well as reduced phosphorylation of LCOTHER / LCOTHER / LCOTHER and LCOTHER / LCOTHER / LCOTHER LCOTHER LCOTHER .	2
LCOTHER signalling was markedly impaired in LCGeneOrGeneProduct - deficient chondrocytes as evidenced by reduced expression of known LCOTHER target genes as well as reduced phosphorylation of LCOTHER / LCOTHER / LCOTHER and LCGeneOrGeneProduct / LCOTHER / LCOTHER LCOTHER LCOTHER .	1
LCOTHER signalling was markedly impaired in LCGeneOrGeneProduct - deficient chondrocytes as evidenced by reduced expression of known LCOTHER target genes as well as reduced phosphorylation of LCOTHER / LCOTHER / LCOTHER and LCOTHER / LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER .	1
LCOTHER signalling was markedly impaired in LCGeneOrGeneProduct - deficient chondrocytes as evidenced by reduced expression of known LCOTHER target genes as well as reduced phosphorylation of LCOTHER / LCOTHER / LCOTHER and LCOTHER / LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER .	1
LCOTHER signalling was markedly impaired in LCOTHER - deficient chondrocytes as evidenced by reduced expression of known LCGeneOrGeneProduct target genes as well as reduced phosphorylation of LCOTHER / LCOTHER / LCOTHER and LCGeneOrGeneProduct / LCOTHER / LCOTHER LCOTHER LCOTHER .	1
LCOTHER signalling was markedly impaired in LCOTHER - deficient chondrocytes as evidenced by reduced expression of known LCGeneOrGeneProduct target genes as well as reduced phosphorylation of LCOTHER / LCOTHER / LCOTHER and LCOTHER / LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER .	1
LCOTHER signalling was markedly impaired in LCOTHER - deficient chondrocytes as evidenced by reduced expression of known LCGeneOrGeneProduct target genes as well as reduced phosphorylation of LCOTHER / LCOTHER / LCOTHER and LCOTHER / LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER .	1
LCGeneOrGeneProduct mediates LCGeneOrGeneProduct phosphorylation at C - terminal serine residues .	1
These findings provide the first in vivo evidence in a mammalian system that LCGeneOrGeneProduct is required for LCGeneOrGeneProduct signalling and functions as an upstream activating kinase for LCOTHER / LCOTHER / LCOTHER in addition to its known role in regulating LCOTHER LCOTHER pathways .	2
RESULTS : The promoter indel and LCOTHER had independent genetic effects , which accounted for the association of LCSequenceVariant and LCSequenceVariant .	1
CONCLUSION : We corroborated the association of the promoter indel with LCDiseaseOrPhenotypicFeature in 5 different populations and revealed that LCSequenceVariant is the main single - nucleotide polymorphism responsible for altered LCOTHER expression in PBMC . Tissue - Specific Ablation of the LCOTHER LCOTHER in the LCOTHER Uterine Epithelium Results in Implantation Failure .	1
CONCLUSION : We corroborated the association of the promoter indel with LCDiseaseOrPhenotypicFeature in 5 different populations and revealed that LCOTHER is the main single - nucleotide polymorphism responsible for altered LCGeneOrGeneProduct expression in PBMC . Tissue - Specific Ablation of the LCOTHER LCOTHER in the LCOTHER Uterine Epithelium Results in Implantation Failure .	1
LCGeneOrGeneProduct , secreted from the endometrial glands ( GEs ) , binds to the LCGeneOrGeneProduct , activating the LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER ( LCOTHER - LCOTHER ) signaling pathway in the LE .	4
LCOTHER , secreted from the endometrial glands ( GEs ) , binds to the LCOTHER , activating the LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) signaling pathway in the LE .	1
LCOTHER , secreted from the endometrial glands ( GEs ) , binds to the LCOTHER , activating the LCGeneOrGeneProduct LCGeneOrGeneProduct - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER ( LCOTHER - LCGeneOrGeneProduct ) signaling pathway in the LE .	1
LCOTHER , secreted from the endometrial glands ( GEs ) , binds to the LCOTHER , activating the LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) signaling pathway in the LE .	1
LCGeneOrGeneProduct - LCGeneOrGeneProduct activation converts the LE to a receptive state so that juxtaposed blastocysts begin to implant .	1
Crossing LCGeneOrGeneProduct - Cre LCOTHER with LCGeneOrGeneProduct flx / flx LCOTHER generated LCOTHER flx / D : LCOTHER Cre / + females that were overtly normal but infertile .	4
Crossing LCGeneOrGeneProduct - Cre LCOTHER with LCOTHER flx / flx LCOTHER generated LCGeneOrGeneProduct flx / D : LCOTHER Cre / + females that were overtly normal but infertile .	4
The loss of LCGeneOrGeneProduct results in both the failure for LCOTHER to translocate to the LE nuclei and a reduction in the expression of the LCOTHER regulated gene LCGeneOrGeneProduct that regulates uterine receptivity .	2
The loss of LCOTHER results in both the failure for LCGeneOrGeneProduct to translocate to the LE nuclei and a reduction in the expression of the LCGeneOrGeneProduct regulated gene LCOTHER that regulates uterine receptivity .	1
The loss of LCOTHER results in both the failure for LCOTHER to translocate to the LE nuclei and a reduction in the expression of the LCGeneOrGeneProduct regulated gene LCGeneOrGeneProduct that regulates uterine receptivity .	1
LCGeneOrGeneProduct ( LCOTHER ) is an 11 - kDa small LCOTHER LCOTHER LCOTHER initially isolated from LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
LCOTHER ( LCGeneOrGeneProduct ) is an 11 - kDa small LCOTHER LCOTHER LCOTHER initially isolated from LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
LCOTHER ( LCOTHER ) is an 11 - kDa small LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct initially isolated from LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
Aberrant LCGeneOrGeneProduct expression has been implicated in a range of LCDiseaseOrPhenotypicFeature and is often associated with poor prognosis .	1
This study examined the role of LCGeneOrGeneProduct on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell functions and the implication in progression of the disease .	2
Expression of LCGeneOrGeneProduct was determined in a cohort of pancreatic tissues comprised of 126 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and 114 adjacent non - tumour pancreatic tissues .	2
Knockdown and overexpression of LCGeneOrGeneProduct in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cells was performed using specifically constructed plasmids , which either had anti - LCOTHER ribozyme transgene or the full length LCOTHER LCOTHER coding sequence .	2
The effect of manipulating LCGeneOrGeneProduct expression on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell functions was assessed using several in vitro cell function assays .	2
Local invasive LCOTHER LCOTHER extended beyond the pancreas expressed higher levels of LCGeneOrGeneProduct transcripts compared with the LCDiseaseOrPhenotypicFeature confined to the pancreas .	1
In addition , LCGeneOrGeneProduct overexpression resulted in increased LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell invasion which was associated with upregulation of LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) and LCOTHER - LCOTHER .	2
In addition , LCGeneOrGeneProduct overexpression resulted in increased LCOTHER LCOTHER cell invasion which was associated with upregulation of LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) and LCOTHER - LCOTHER .	2
In addition , LCGeneOrGeneProduct overexpression resulted in increased LCOTHER LCOTHER cell invasion which was associated with upregulation of LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) and LCOTHER - LCOTHER .	2
In addition , LCGeneOrGeneProduct overexpression resulted in increased LCOTHER LCOTHER cell invasion which was associated with upregulation of LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) and LCGeneOrGeneProduct - LCGeneOrGeneProduct .	2
In addition , LCOTHER overexpression resulted in increased LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell invasion which was associated with upregulation of LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) and LCOTHER - LCOTHER .	2
In addition , LCOTHER overexpression resulted in increased LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell invasion which was associated with upregulation of LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) and LCOTHER - LCOTHER .	2
In addition , LCOTHER overexpression resulted in increased LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell invasion which was associated with upregulation of LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) and LCGeneOrGeneProduct - LCGeneOrGeneProduct .	2
Overexpression of LCGeneOrGeneProduct also promoted aggregation and survival of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cells when they lost anchorage .	2
Taken together , higher expression of LCGeneOrGeneProduct was associated with local invasion in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
LCGeneOrGeneProduct expression is associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell growth , migration , cell - matrix adhesion , and invasion via regulation of LCOTHER .	2
However , LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER with high baseline LCDiseaseOrPhenotypicFeature carrying the LCGeneOrGeneProduct 3 ' - UTR LCOTHER - LCOTHER - allele showed significantly higher sustained virologic response ( SVR ) rates ( 25 . 3% vs .	1
However , LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER with high baseline LCDiseaseOrPhenotypicFeature carrying the LCOTHER 3 ' - UTR LCSequenceVariant - LCSequenceVariant - allele showed significantly higher sustained virologic response ( SVR ) rates ( 25 . 3% vs .	1
Mutations of LCGeneOrGeneProduct and dysfunction of the LCOTHER and / or LCOTHER LCDiseaseOrPhenotypicFeature - suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of LCOTHER , but frequent somatic mutations in other well - established LCOTHER - suppressor genes have not been identified .	1
Mutations of LCGeneOrGeneProduct and dysfunction of the LCOTHER and / or LCOTHER LCOTHER - suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of LCDiseaseOrPhenotypicFeature , but frequent somatic mutations in other well - established LCOTHER - suppressor genes have not been identified .	1
Mutations of LCGeneOrGeneProduct and dysfunction of the LCOTHER and / or LCOTHER LCOTHER - suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of LCOTHER , but frequent somatic mutations in other well - established LCDiseaseOrPhenotypicFeature - suppressor genes have not been identified .	1
Mutations of LCOTHER and dysfunction of the LCGeneOrGeneProduct and / or LCOTHER LCOTHER - suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of LCDiseaseOrPhenotypicFeature , but frequent somatic mutations in other well - established LCOTHER - suppressor genes have not been identified .	1
Mutations of LCOTHER and dysfunction of the LCOTHER and / or LCGeneOrGeneProduct LCOTHER - suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of LCDiseaseOrPhenotypicFeature , but frequent somatic mutations in other well - established LCOTHER - suppressor genes have not been identified .	1
Using a genome - wide screen of DNA copy number alterations in 36 primary LCDiseaseOrPhenotypicFeature , we identified two LCOTHER with apparent homozygous deletions of the LCGeneOrGeneProduct gene .	1
Using a genome - wide screen of DNA copy number alterations in 36 primary LCOTHER , we identified two LCDiseaseOrPhenotypicFeature with apparent homozygous deletions of the LCGeneOrGeneProduct gene .	1
Subsequently , 18 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - derived cell lines and 41 primary LCOTHER were evaluated for LCGeneOrGeneProduct alterations .	1
Subsequently , 18 LCOTHER LCOTHER - derived cell lines and 41 primary LCDiseaseOrPhenotypicFeature were evaluated for LCGeneOrGeneProduct alterations .	1
As expected , LCDiseaseOrPhenotypicFeature and cell lines with LCGeneOrGeneProduct defects lacked mutations in LCOTHER or LCOTHER but showed LCOTHER pathway activation based on immunohistochemical detection of phosphorylated LCOTHER ( primary LCOTHER ) or increased levels of LCOTHER - bound LCOTHER ( cell lines ) .	1
As expected , LCDiseaseOrPhenotypicFeature and cell lines with LCOTHER defects lacked mutations in LCGeneOrGeneProduct or LCOTHER but showed LCOTHER pathway activation based on immunohistochemical detection of phosphorylated LCOTHER ( primary LCOTHER ) or increased levels of LCOTHER - bound LCOTHER ( cell lines ) .	1
As expected , LCDiseaseOrPhenotypicFeature and cell lines with LCOTHER defects lacked mutations in LCOTHER or LCOTHER but showed LCGeneOrGeneProduct pathway activation based on immunohistochemical detection of phosphorylated LCOTHER ( primary LCOTHER ) or increased levels of LCOTHER - bound LCOTHER ( cell lines ) .	1
As expected , LCDiseaseOrPhenotypicFeature and cell lines with LCOTHER defects lacked mutations in LCOTHER or LCOTHER but showed LCOTHER pathway activation based on immunohistochemical detection of phosphorylated LCOTHER ( primary LCOTHER ) or increased levels of LCOTHER - bound LCGeneOrGeneProduct ( cell lines ) .	1
As expected , LCOTHER and cell lines with LCOTHER defects lacked mutations in LCOTHER or LCOTHER but showed LCOTHER pathway activation based on immunohistochemical detection of phosphorylated LCGeneOrGeneProduct ( primary LCDiseaseOrPhenotypicFeature ) or increased levels of LCOTHER - bound LCOTHER ( cell lines ) .	1
As expected , LCOTHER and cell lines with LCOTHER defects lacked mutations in LCOTHER or LCOTHER but showed LCOTHER pathway activation based on immunohistochemical detection of phosphorylated LCOTHER ( primary LCDiseaseOrPhenotypicFeature ) or increased levels of LCOTHER - bound LCGeneOrGeneProduct ( cell lines ) .	1
As expected , LCOTHER and cell lines with LCOTHER defects lacked mutations in LCOTHER or LCOTHER but showed LCOTHER pathway activation based on immunohistochemical detection of phosphorylated LCOTHER ( primary LCOTHER ) or increased levels of LCChemicalEntity - bound LCGeneOrGeneProduct ( cell lines ) .	4
The LCGeneOrGeneProduct LCDiseaseOrPhenotypicFeature - suppressor gene was mutated in all LCOTHER with documented LCOTHER mutation , suggesting that the pathways regulated by these two LCOTHER - suppressor proteins often cooperate in the development of LCOTHER LCOTHER with serous differentiation . Drug - induced LCOTHER LCOTHER LCOTHER in injection drug users receiving LCOTHER : high frequency in hospitalized LCOTHER and risk factors .	1
The LCGeneOrGeneProduct LCOTHER - suppressor gene was mutated in all LCDiseaseOrPhenotypicFeature with documented LCOTHER mutation , suggesting that the pathways regulated by these two LCOTHER - suppressor proteins often cooperate in the development of LCOTHER LCOTHER with serous differentiation . Drug - induced LCOTHER LCOTHER LCOTHER in injection drug users receiving LCOTHER : high frequency in hospitalized LCOTHER and risk factors .	1
The LCGeneOrGeneProduct LCOTHER - suppressor gene was mutated in all LCOTHER with documented LCOTHER mutation , suggesting that the pathways regulated by these two LCDiseaseOrPhenotypicFeature - suppressor proteins often cooperate in the development of LCOTHER LCOTHER with serous differentiation . Drug - induced LCOTHER LCOTHER LCOTHER in injection drug users receiving LCOTHER : high frequency in hospitalized LCOTHER and risk factors .	1
The LCGeneOrGeneProduct LCOTHER - suppressor gene was mutated in all LCOTHER with documented LCOTHER mutation , suggesting that the pathways regulated by these two LCOTHER - suppressor proteins often cooperate in the development of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with serous differentiation . Drug - induced LCOTHER LCOTHER LCOTHER in injection drug users receiving LCOTHER : high frequency in hospitalized LCOTHER and risk factors .	1
The LCOTHER LCDiseaseOrPhenotypicFeature - suppressor gene was mutated in all LCOTHER with documented LCGeneOrGeneProduct mutation , suggesting that the pathways regulated by these two LCOTHER - suppressor proteins often cooperate in the development of LCOTHER LCOTHER with serous differentiation . Drug - induced LCOTHER LCOTHER LCOTHER in injection drug users receiving LCOTHER : high frequency in hospitalized LCOTHER and risk factors .	1
The LCOTHER LCOTHER - suppressor gene was mutated in all LCDiseaseOrPhenotypicFeature with documented LCGeneOrGeneProduct mutation , suggesting that the pathways regulated by these two LCOTHER - suppressor proteins often cooperate in the development of LCOTHER LCOTHER with serous differentiation . Drug - induced LCOTHER LCOTHER LCOTHER in injection drug users receiving LCOTHER : high frequency in hospitalized LCOTHER and risk factors .	1
In addition to LCChemicalEntity dose , 15 demographic , biological , and pharmacological variables were considered as potential risk factors for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
RESULTS : Among 167 LCChemicalEntity maintenance LCOTHER , the prevalence of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature to 0 . 50 second ( ( 1 / 2 ) ) or longer was 16 . 2% compared with 0% in 80 control subjects .	2
Six LCOTHER ( 3 . 6% ) in the LCChemicalEntity group presented LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
LCChemicalEntity dose , presence of LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER , LCOTHER level , and liver function contribute to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
LCOTHER dose , presence of LCChemicalEntity LCChemicalEntity - LCChemicalEntity LCChemicalEntity LCChemicalEntity , LCOTHER level , and liver function contribute to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
LCOTHER dose , presence of LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER , LCChemicalEntity level , and liver function contribute to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is a cell cycle regulator implicated in development of certain LCDiseaseOrPhenotypicFeature .	2
LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is a cell cycle regulator implicated in development of certain LCDiseaseOrPhenotypicFeature .	2
However , characteristics of LCGeneOrGeneProduct expression and its clinical / prognostic significance are unclear in LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
However , characteristics of LCGeneOrGeneProduct expression and its clinical / prognostic significance are unclear in LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
Therefore , we investigated the expression and clinicopathological significance of LCGeneOrGeneProduct in LCOTHER with LCDiseaseOrPhenotypicFeature and its role in regulating invasion and LCOTHER LCOTHER LCOTHER cell lines .	1
Therefore , we investigated the expression and clinicopathological significance of LCGeneOrGeneProduct in LCOTHER with LCOTHER and its role in regulating invasion and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell lines .	2
LCGeneOrGeneProduct was significantly upregulated in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell lines and lesions compared with normal cells and adjacent noncancerous ovarian tissues .	2
In the 213 LCOTHER samples , LCGeneOrGeneProduct protein levels were positively correlated with clinical stage ( P < 0 . 001 ) , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( P < 0 . 001 ) , LCOTHER LCOTHER ( P < 0 . 001 ) , LCOTHER recurrence ( P < 0 . 001 ) , differentiation grade ( P < 0 . 001 ) , residual LCOTHER size ( P < 0 . 001 ) , LCOTHER see LCOTHER cells ( P = 0 . 020 ) , and serum LCOTHER level ( P < 0 . 001 ) .	2
In the 213 LCOTHER samples , LCGeneOrGeneProduct protein levels were positively correlated with clinical stage ( P < 0 . 001 ) , LCOTHER LCOTHER LCOTHER ( P < 0 . 001 ) , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( P < 0 . 001 ) , LCOTHER recurrence ( P < 0 . 001 ) , differentiation grade ( P < 0 . 001 ) , residual LCOTHER size ( P < 0 . 001 ) , LCOTHER see LCOTHER cells ( P = 0 . 020 ) , and serum LCOTHER level ( P < 0 . 001 ) .	2
In the 213 LCOTHER samples , LCGeneOrGeneProduct protein levels were positively correlated with clinical stage ( P < 0 . 001 ) , LCOTHER LCOTHER LCOTHER ( P < 0 . 001 ) , LCOTHER LCOTHER ( P < 0 . 001 ) , LCDiseaseOrPhenotypicFeature recurrence ( P < 0 . 001 ) , differentiation grade ( P < 0 . 001 ) , residual LCOTHER size ( P < 0 . 001 ) , LCOTHER see LCOTHER cells ( P = 0 . 020 ) , and serum LCOTHER level ( P < 0 . 001 ) .	2
In the 213 LCOTHER samples , LCGeneOrGeneProduct protein levels were positively correlated with clinical stage ( P < 0 . 001 ) , LCOTHER LCOTHER LCOTHER ( P < 0 . 001 ) , LCOTHER LCOTHER ( P < 0 . 001 ) , LCOTHER recurrence ( P < 0 . 001 ) , differentiation grade ( P < 0 . 001 ) , residual LCDiseaseOrPhenotypicFeature size ( P < 0 . 001 ) , LCOTHER see LCOTHER cells ( P = 0 . 020 ) , and serum LCOTHER level ( P < 0 . 001 ) .	2
In the 213 LCOTHER samples , LCGeneOrGeneProduct protein levels were positively correlated with clinical stage ( P < 0 . 001 ) , LCOTHER LCOTHER LCOTHER ( P < 0 . 001 ) , LCOTHER LCOTHER ( P < 0 . 001 ) , LCOTHER recurrence ( P < 0 . 001 ) , differentiation grade ( P < 0 . 001 ) , residual LCOTHER size ( P < 0 . 001 ) , LCOTHER see LCDiseaseOrPhenotypicFeature cells ( P = 0 . 020 ) , and serum LCOTHER level ( P < 0 . 001 ) .	2
In the 213 LCOTHER samples , LCGeneOrGeneProduct protein levels were positively correlated with clinical stage ( P < 0 . 001 ) , LCOTHER LCOTHER LCOTHER ( P < 0 . 001 ) , LCOTHER LCOTHER ( P < 0 . 001 ) , LCOTHER recurrence ( P < 0 . 001 ) , differentiation grade ( P < 0 . 001 ) , residual LCOTHER size ( P < 0 . 001 ) , LCOTHER see LCOTHER cells ( P = 0 . 020 ) , and serum LCGeneOrGeneProduct level ( P < 0 . 001 ) .	2
Multivariate analysis implicated LCGeneOrGeneProduct as an independent prognostic indicator for LCDiseaseOrPhenotypicFeature LCOTHER .	1
Additionally , downregulation of LCGeneOrGeneProduct in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cells remarkably inhibited cellular motility and invasion .	2
Aberrant LCGeneOrGeneProduct expression may predict unfavorable clinical outcomes in LCDiseaseOrPhenotypicFeature LCOTHER and play an important role in regulating invasion in LCOTHER LCOTHER cells .	1
Aberrant LCGeneOrGeneProduct expression may predict unfavorable clinical outcomes in LCOTHER LCOTHER and play an important role in regulating invasion in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cells .	2
Thus , LCGeneOrGeneProduct may serve as a prognostic marker and therapeutic target for LCDiseaseOrPhenotypicFeature . Identification of novel susceptibility genes in childhood - onset LCOTHER LCOTHER LCOTHER using a uniquely designed candidate gene pathway platform .	1
RESULTS : Family - based TDT showed a significant association of LCDiseaseOrPhenotypicFeature with a LCSequenceVariant polymorphism in the LCOTHER - LCOTHER gene ( LCOTHER ) ( P = 5 . 74 x 10 ( - 6 ) ) and a LCOTHER polymorphism in the LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER gene ( LCOTHER ) ( P = 9 . 58 x 10 ( - 6 ) ) .	2
RESULTS : Family - based TDT showed a significant association of LCDiseaseOrPhenotypicFeature with a LCOTHER polymorphism in the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene ( LCOTHER ) ( P = 5 . 74 x 10 ( - 6 ) ) and a LCOTHER polymorphism in the LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER gene ( LCOTHER ) ( P = 9 . 58 x 10 ( - 6 ) ) .	1
RESULTS : Family - based TDT showed a significant association of LCDiseaseOrPhenotypicFeature with a LCOTHER polymorphism in the LCOTHER - LCOTHER gene ( LCGeneOrGeneProduct ) ( P = 5 . 74 x 10 ( - 6 ) ) and a LCOTHER polymorphism in the LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER gene ( LCOTHER ) ( P = 9 . 58 x 10 ( - 6 ) ) .	1
RESULTS : Family - based TDT showed a significant association of LCDiseaseOrPhenotypicFeature with a LCOTHER polymorphism in the LCOTHER - LCOTHER gene ( LCOTHER ) ( P = 5 . 74 x 10 ( - 6 ) ) and a LCSequenceVariant polymorphism in the LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER gene ( LCOTHER ) ( P = 9 . 58 x 10 ( - 6 ) ) .	2
RESULTS : Family - based TDT showed a significant association of LCDiseaseOrPhenotypicFeature with a LCOTHER polymorphism in the LCOTHER - LCOTHER gene ( LCOTHER ) ( P = 5 . 74 x 10 ( - 6 ) ) and a LCOTHER polymorphism in the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene ( LCOTHER ) ( P = 9 . 58 x 10 ( - 6 ) ) .	1
RESULTS : Family - based TDT showed a significant association of LCDiseaseOrPhenotypicFeature with a LCOTHER polymorphism in the LCOTHER - LCOTHER gene ( LCOTHER ) ( P = 5 . 74 x 10 ( - 6 ) ) and a LCOTHER polymorphism in the LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER gene ( LCGeneOrGeneProduct ) ( P = 9 . 58 x 10 ( - 6 ) ) .	1
To develop a novel and effective drug that could enhance cognitive function and neuroprotection , we newly synthesized LCChemicalEntity LCChemicalEntity - LCChemicalEntity by the esterification of LCChemicalEntity and LCOTHER - LCOTHER LCOTHER .	1
To develop a novel and effective drug that could enhance cognitive function and neuroprotection , we newly synthesized LCChemicalEntity LCChemicalEntity - LCChemicalEntity by the esterification of LCOTHER and LCChemicalEntity - LCChemicalEntity LCChemicalEntity .	1
To develop a novel and effective drug that could enhance cognitive function and neuroprotection , we newly synthesized LCOTHER LCOTHER - LCOTHER by the esterification of LCChemicalEntity and LCChemicalEntity - LCChemicalEntity LCChemicalEntity .	1
In the present study , we investigated whether LCChemicalEntity LCChemicalEntity - LCChemicalEntity could improve LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER - injected LCOTHER and in LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - infused LCOTHER .	3
In the present study , we investigated whether LCChemicalEntity LCChemicalEntity - LCChemicalEntity could improve LCOTHER LCOTHER in LCOTHER - injected LCOTHER and in LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCChemicalEntity - LCChemicalEntity ) - infused LCOTHER .	1
In the present study , we investigated whether LCOTHER LCOTHER - LCOTHER could improve LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCChemicalEntity - injected LCOTHER and in LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - infused LCOTHER .	2
In the present study , we investigated whether LCOTHER LCOTHER - LCOTHER could improve LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER - injected LCOTHER and in LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCChemicalEntity - LCChemicalEntity ) - infused LCOTHER .	2
LCChemicalEntity LCChemicalEntity - LCChemicalEntity was found to attenuate LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in both LCOTHER models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - infused LCOTHER .	3
LCChemicalEntity LCChemicalEntity - LCChemicalEntity was found to attenuate LCOTHER LCOTHER in both LCOTHER models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCChemicalEntity - LCChemicalEntity ) - infused LCOTHER .	1
LCOTHER LCOTHER - LCOTHER was found to attenuate LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in both LCOTHER models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCChemicalEntity - LCChemicalEntity ) - infused LCOTHER .	2
Cells were pretreated with LCChemicalEntity LCChemicalEntity - LCChemicalEntity , before exposed to LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCChemicalEntity - LCChemicalEntity ) , LCOTHER or LCOTHER .	1
We found that LCChemicalEntity LCChemicalEntity - LCChemicalEntity significantly decreased apoptotic cell death and reduced LCChemicalEntity LCChemicalEntity LCChemicalEntity , LCOTHER LCOTHER release , and LCOTHER LCOTHER activation .	3
We found that LCChemicalEntity LCChemicalEntity - LCChemicalEntity significantly decreased apoptotic cell death and reduced LCOTHER LCOTHER LCOTHER , LCChemicalEntity LCChemicalEntity release , and LCOTHER LCOTHER activation .	3
We found that LCChemicalEntity LCChemicalEntity - LCChemicalEntity significantly decreased apoptotic cell death and reduced LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER release , and LCGeneOrGeneProduct LCGeneOrGeneProduct activation .	3
Taking these in vitro and in vivo results together , our study suggests that LCChemicalEntity LCChemicalEntity - LCChemicalEntity is a potentially effective candidate against LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature that is characterized by wide spread LCOTHER LCOTHER and progressive LCOTHER LCOTHER LCOTHER LCOTHER . Anticipation in familial LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER with LCOTHER mutation in the LCOTHER ( LCOTHER ) gene .	3
Taking these in vitro and in vivo results together , our study suggests that LCChemicalEntity LCChemicalEntity - LCChemicalEntity is a potentially effective candidate against LCOTHER ' LCOTHER LCOTHER that is characterized by wide spread LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and progressive LCOTHER LCOTHER LCOTHER LCOTHER . Anticipation in familial LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER with LCOTHER mutation in the LCOTHER ( LCOTHER ) gene .	3
Taking these in vitro and in vivo results together , our study suggests that LCChemicalEntity LCChemicalEntity - LCChemicalEntity is a potentially effective candidate against LCOTHER ' LCOTHER LCOTHER that is characterized by wide spread LCOTHER LCOTHER and progressive LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Anticipation in familial LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER with LCOTHER mutation in the LCOTHER ( LCOTHER ) gene .	3
CONCLUSIONS : The LCSequenceVariant mutation in LCOTHER cosegregated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in the investigated family .	1
CONCLUSIONS : The LCOTHER mutation in LCGeneOrGeneProduct cosegregated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in the investigated family .	1
OBJECTIVE : The aim of the present study was to investigate the effect of LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature on trabecular bone mineral density ( BMD ) in children and adolescents .	2
Of 13 documented LCDiseaseOrPhenotypicFeature , 3 occurred after LCChemicalEntity and LCOTHER were started , and none occurred in LCOTHER with LCOTHER .	2
Of 13 documented LCDiseaseOrPhenotypicFeature , 3 occurred after LCOTHER and LCChemicalEntity were started , and none occurred in LCOTHER with LCOTHER .	2
Of 13 documented LCOTHER , 3 occurred after LCChemicalEntity and LCOTHER were started , and none occurred in LCOTHER with LCDiseaseOrPhenotypicFeature .	2
CONCLUSIONS : This is the first study to link LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature and LCOTHER treatment to lower BMD in children and adolescents .	2
The present study aimed to evaluate the LCChemicalEntity effects at doses of 25 , 50 or 75 mg / kg on LCDiseaseOrPhenotypicFeature parameters to determine their anticonvulsant activity and its effects on amino acid ( LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ) levels as well as on LCOTHER ( LCOTHER ) activity in LCOTHER hippocampus after LCOTHER .	3
The present study aimed to evaluate the LCChemicalEntity effects at doses of 25 , 50 or 75 mg / kg on LCOTHER parameters to determine their anticonvulsant activity and its effects on amino acid ( LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ) levels as well as on LCGeneOrGeneProduct ( LCOTHER ) activity in LCOTHER hippocampus after LCOTHER .	2
The present study aimed to evaluate the LCChemicalEntity effects at doses of 25 , 50 or 75 mg / kg on LCOTHER parameters to determine their anticonvulsant activity and its effects on amino acid ( LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ) levels as well as on LCOTHER ( LCGeneOrGeneProduct ) activity in LCOTHER hippocampus after LCOTHER .	2
The present study aimed to evaluate the LCChemicalEntity effects at doses of 25 , 50 or 75 mg / kg on LCOTHER parameters to determine their anticonvulsant activity and its effects on amino acid ( LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ) levels as well as on LCOTHER ( LCOTHER ) activity in LCOTHER hippocampus after LCDiseaseOrPhenotypicFeature .	3
LCChemicalEntity produced an increased latency to first LCDiseaseOrPhenotypicFeature , at doses 25mg / kg ( 20 . 12 + 2 . 20 min ) , 50mg / kg ( 20 . 95 + 2 . 21 min ) or 75 mg / kg ( 23 . 43 + 1 . 99 min ) when compared with seized LCOTHER .	3
In addition , LCChemicalEntity content of LCOTHER hippocampus treated with LCChemicalEntity plus LCOTHER showed an increase of 46 . 90% when compared with seized LCOTHER .	2
In addition , LCChemicalEntity content of LCOTHER hippocampus treated with LCOTHER plus LCChemicalEntity showed an increase of 46 . 90% when compared with seized LCOTHER .	2
In addition , LCOTHER content of LCOTHER hippocampus treated with LCChemicalEntity plus LCChemicalEntity showed an increase of 46 . 90% when compared with seized LCOTHER .	5
In LCChemicalEntity , LCOTHER and LCOTHER levels detected a decrease of 5 . 21% , 13 . 55% and 21 . 80% , respectively in LCOTHER hippocampus treated with LCChemicalEntity plus LCOTHER when compared with seized LCOTHER .	3
In LCChemicalEntity , LCOTHER and LCOTHER levels detected a decrease of 5 . 21% , 13 . 55% and 21 . 80% , respectively in LCOTHER hippocampus treated with LCOTHER plus LCChemicalEntity when compared with seized LCOTHER .	3
In LCOTHER , LCChemicalEntity and LCOTHER levels detected a decrease of 5 . 21% , 13 . 55% and 21 . 80% , respectively in LCOTHER hippocampus treated with LCChemicalEntity plus LCOTHER when compared with seized LCOTHER .	3
In LCOTHER , LCChemicalEntity and LCOTHER levels detected a decrease of 5 . 21% , 13 . 55% and 21 . 80% , respectively in LCOTHER hippocampus treated with LCOTHER plus LCChemicalEntity when compared with seized LCOTHER .	3
In LCOTHER , LCOTHER and LCChemicalEntity levels detected a decrease of 5 . 21% , 13 . 55% and 21 . 80% , respectively in LCOTHER hippocampus treated with LCChemicalEntity plus LCOTHER when compared with seized LCOTHER .	3
In LCOTHER , LCOTHER and LCChemicalEntity levels detected a decrease of 5 . 21% , 13 . 55% and 21 . 80% , respectively in LCOTHER hippocampus treated with LCOTHER plus LCChemicalEntity when compared with seized LCOTHER .	3
In LCOTHER , LCOTHER and LCOTHER levels detected a decrease of 5 . 21% , 13 . 55% and 21 . 80% , respectively in LCOTHER hippocampus treated with LCChemicalEntity plus LCChemicalEntity when compared with seized LCOTHER .	5
Hippocampus LCOTHER treated with LCChemicalEntity plus LCChemicalEntity showed an increase in LCOTHER activity ( 63 . 30% ) when compared with seized LCOTHER .	5
Hippocampus LCOTHER treated with LCChemicalEntity plus LCOTHER showed an increase in LCGeneOrGeneProduct activity ( 63 . 30% ) when compared with seized LCOTHER .	2
Hippocampus LCOTHER treated with LCOTHER plus LCChemicalEntity showed an increase in LCGeneOrGeneProduct activity ( 63 . 30% ) when compared with seized LCOTHER .	2
The results indicate that LCChemicalEntity can exert anticonvulsant activity and reduce the frequency of installation of LCChemicalEntity - induced LCOTHER LCOTHER , as demonstrated by increase in latency to first LCOTHER and decrease in mortality rate of animals .	5
The results indicate that LCChemicalEntity can exert anticonvulsant activity and reduce the frequency of installation of LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , as demonstrated by increase in latency to first LCOTHER and decrease in mortality rate of animals .	3
The results indicate that LCChemicalEntity can exert anticonvulsant activity and reduce the frequency of installation of LCOTHER - induced LCOTHER LCOTHER , as demonstrated by increase in latency to first LCDiseaseOrPhenotypicFeature and decrease in mortality rate of animals .	3
The results indicate that LCOTHER can exert anticonvulsant activity and reduce the frequency of installation of LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , as demonstrated by increase in latency to first LCOTHER and decrease in mortality rate of animals .	2
The results indicate that LCOTHER can exert anticonvulsant activity and reduce the frequency of installation of LCChemicalEntity - induced LCOTHER LCOTHER , as demonstrated by increase in latency to first LCDiseaseOrPhenotypicFeature and decrease in mortality rate of animals .	2
In conclusion , our data suggest that LCChemicalEntity may influence in epileptogenesis and promote anticonvulsant actions in LCChemicalEntity model by modulating the LCOTHER and LCOTHER contents and of LCOTHER activity in seized LCOTHER hippocampus .	5
In conclusion , our data suggest that LCChemicalEntity may influence in epileptogenesis and promote anticonvulsant actions in LCOTHER model by modulating the LCOTHER and LCOTHER contents and of LCGeneOrGeneProduct activity in seized LCOTHER hippocampus .	2
In conclusion , our data suggest that LCOTHER may influence in epileptogenesis and promote anticonvulsant actions in LCChemicalEntity model by modulating the LCOTHER and LCOTHER contents and of LCGeneOrGeneProduct activity in seized LCOTHER hippocampus .	2
LCGeneOrGeneProduct was activated by some LCOTHER LCOTHER - LCOTHER [ LCGeneOrGeneProduct , LCOTHER , LCOTHER ] , by secretagogues activating LCOTHER - LCOTHER ( LCOTHER ) [ LCOTHER , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCOTHER [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	2
LCGeneOrGeneProduct was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCGeneOrGeneProduct , LCOTHER ] , by secretagogues activating LCOTHER - LCOTHER ( LCOTHER ) [ LCOTHER , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCOTHER [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	2
LCGeneOrGeneProduct was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCOTHER , LCGeneOrGeneProduct ] , by secretagogues activating LCOTHER - LCOTHER ( LCOTHER ) [ LCOTHER , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCOTHER [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	2
LCGeneOrGeneProduct was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCOTHER , LCOTHER ] , by secretagogues activating LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) [ LCOTHER , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCOTHER [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	2
LCGeneOrGeneProduct was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCOTHER , LCOTHER ] , by secretagogues activating LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) [ LCOTHER , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCOTHER [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	2
LCGeneOrGeneProduct was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCOTHER , LCOTHER ] , by secretagogues activating LCOTHER - LCOTHER ( LCOTHER ) [ LCGeneOrGeneProduct , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCOTHER [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	2
LCGeneOrGeneProduct was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCOTHER , LCOTHER ] , by secretagogues activating LCOTHER - LCOTHER ( LCOTHER ) [ LCOTHER , LCChemicalEntity , LCOTHER ] and by post - receptor stimulants activating LCOTHER [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	2
LCGeneOrGeneProduct was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCOTHER , LCOTHER ] , by secretagogues activating LCOTHER - LCOTHER ( LCOTHER ) [ LCOTHER , LCOTHER , LCChemicalEntity ] and by post - receptor stimulants activating LCOTHER [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	2
LCGeneOrGeneProduct was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCOTHER , LCOTHER ] , by secretagogues activating LCOTHER - LCOTHER ( LCOTHER ) [ LCOTHER , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCGeneOrGeneProduct [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	2
LCGeneOrGeneProduct was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCOTHER , LCOTHER ] , by secretagogues activating LCOTHER - LCOTHER ( LCOTHER ) [ LCOTHER , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCOTHER [ LCChemicalEntity ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	2
LCOTHER was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCOTHER , LCOTHER ] , by secretagogues activating LCOTHER - LCOTHER ( LCOTHER ) [ LCGeneOrGeneProduct , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCGeneOrGeneProduct [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	1
LCOTHER - activation of LCGeneOrGeneProduct required both high - and low - affinity - LCGeneOrGeneProduct - LCGeneOrGeneProduct - state activation .	1
It was partially reduced by LCOTHER - or LCOTHER - inhibition , but not with LCGeneOrGeneProduct - inhibitors ( LCChemicalEntity , LCOTHER ) or LCOTHER .	3
It was partially reduced by LCOTHER - or LCOTHER - inhibition , but not with LCGeneOrGeneProduct - inhibitors ( LCOTHER , LCChemicalEntity ) or LCOTHER .	3
LCChemicalEntity - LCChemicalEntity , which prevents LCGeneOrGeneProduct binding to LCOTHER - LCOTHER partially inhibited LCOTHER - activation , as well as reduced LCOTHER - induced LCOTHER / LCOTHER activation and LCOTHER release induced by LCOTHER or LCOTHER .	3
LCChemicalEntity - LCChemicalEntity , which prevents LCOTHER binding to LCOTHER - LCOTHER partially inhibited LCGeneOrGeneProduct - activation , as well as reduced LCOTHER - induced LCOTHER / LCOTHER activation and LCOTHER release induced by LCOTHER or LCOTHER .	3
LCChemicalEntity - LCChemicalEntity , which prevents LCOTHER binding to LCOTHER - LCOTHER partially inhibited LCOTHER - activation , as well as reduced LCGeneOrGeneProduct - induced LCOTHER / LCOTHER activation and LCOTHER release induced by LCOTHER or LCOTHER .	3
LCChemicalEntity - LCChemicalEntity , which prevents LCOTHER binding to LCOTHER - LCOTHER partially inhibited LCOTHER - activation , as well as reduced LCOTHER - induced LCOTHER / LCOTHER activation and LCGeneOrGeneProduct release induced by LCOTHER or LCOTHER .	3
LCChemicalEntity - LCChemicalEntity , which prevents LCOTHER binding to LCOTHER - LCOTHER partially inhibited LCOTHER - activation , as well as reduced LCOTHER - induced LCOTHER / LCOTHER activation and LCOTHER release induced by LCGeneOrGeneProduct or LCOTHER .	3
LCChemicalEntity - LCChemicalEntity , which prevents LCOTHER binding to LCOTHER - LCOTHER partially inhibited LCOTHER - activation , as well as reduced LCOTHER - induced LCOTHER / LCOTHER activation and LCOTHER release induced by LCOTHER or LCChemicalEntity .	1
LCOTHER - LCOTHER , which prevents LCGeneOrGeneProduct binding to LCOTHER - LCOTHER partially inhibited LCOTHER - activation , as well as reduced LCGeneOrGeneProduct - induced LCOTHER / LCOTHER activation and LCOTHER release induced by LCOTHER or LCOTHER .	2
LCOTHER - LCOTHER , which prevents LCGeneOrGeneProduct binding to LCOTHER - LCOTHER partially inhibited LCOTHER - activation , as well as reduced LCOTHER - induced LCOTHER / LCOTHER activation and LCOTHER release induced by LCGeneOrGeneProduct or LCOTHER .	2
LCOTHER - LCOTHER , which prevents LCGeneOrGeneProduct binding to LCOTHER - LCOTHER partially inhibited LCOTHER - activation , as well as reduced LCOTHER - induced LCOTHER / LCOTHER activation and LCOTHER release induced by LCOTHER or LCChemicalEntity .	2
LCOTHER - LCOTHER , which prevents LCOTHER binding to LCOTHER - LCOTHER partially inhibited LCGeneOrGeneProduct - activation , as well as reduced LCGeneOrGeneProduct - induced LCOTHER / LCOTHER activation and LCOTHER release induced by LCOTHER or LCOTHER .	2
LCOTHER - LCOTHER , which prevents LCOTHER binding to LCOTHER - LCOTHER partially inhibited LCGeneOrGeneProduct - activation , as well as reduced LCOTHER - induced LCOTHER / LCOTHER activation and LCOTHER release induced by LCGeneOrGeneProduct or LCOTHER .	2
LCOTHER - LCOTHER , which prevents LCOTHER binding to LCOTHER - LCOTHER partially inhibited LCGeneOrGeneProduct - activation , as well as reduced LCOTHER - induced LCOTHER / LCOTHER activation and LCOTHER release induced by LCOTHER or LCChemicalEntity .	2
LCOTHER - LCOTHER , which prevents LCOTHER binding to LCOTHER - LCOTHER partially inhibited LCOTHER - activation , as well as reduced LCOTHER - induced LCOTHER / LCOTHER activation and LCGeneOrGeneProduct release induced by LCGeneOrGeneProduct or LCOTHER .	2
LCGeneOrGeneProduct and other LCOTHER - LCOTHER / LCOTHER / growth - factors activate LCOTHER via LCOTHER LCOTHER ( LCGeneOrGeneProduct / LCOTHER ) , LCOTHER and LCOTHER but not cytosolic LCOTHER or LCOTHER .	1
LCGeneOrGeneProduct and other LCOTHER - LCOTHER / LCOTHER / growth - factors activate LCOTHER via LCOTHER LCOTHER ( LCOTHER / LCGeneOrGeneProduct ) , LCOTHER and LCOTHER but not cytosolic LCOTHER or LCOTHER .	1
LCGeneOrGeneProduct and other LCOTHER - LCOTHER / LCOTHER / growth - factors activate LCOTHER via LCOTHER LCOTHER ( LCOTHER / LCOTHER ) , LCGeneOrGeneProduct and LCOTHER but not cytosolic LCOTHER or LCOTHER .	1
LCGeneOrGeneProduct and other LCOTHER - LCOTHER / LCOTHER / growth - factors activate LCOTHER via LCOTHER LCOTHER ( LCOTHER / LCOTHER ) , LCOTHER and LCGeneOrGeneProduct but not cytosolic LCOTHER or LCOTHER .	1
LCOTHER and other LCChemicalEntity - LCChemicalEntity / LCOTHER / growth - factors activate LCGeneOrGeneProduct via LCOTHER LCOTHER ( LCOTHER / LCOTHER ) , LCOTHER and LCOTHER but not cytosolic LCOTHER or LCOTHER .	2
LCOTHER and other LCChemicalEntity - LCChemicalEntity / LCOTHER / growth - factors activate LCOTHER via LCOTHER LCOTHER ( LCGeneOrGeneProduct / LCOTHER ) , LCOTHER and LCOTHER but not cytosolic LCOTHER or LCOTHER .	1
LCOTHER and other LCChemicalEntity - LCChemicalEntity / LCOTHER / growth - factors activate LCOTHER via LCOTHER LCOTHER ( LCOTHER / LCGeneOrGeneProduct ) , LCOTHER and LCOTHER but not cytosolic LCOTHER or LCOTHER .	1
LCOTHER and other LCChemicalEntity - LCChemicalEntity / LCOTHER / growth - factors activate LCOTHER via LCOTHER LCOTHER ( LCOTHER / LCOTHER ) , LCGeneOrGeneProduct and LCOTHER but not cytosolic LCOTHER or LCOTHER .	1
LCOTHER and other LCChemicalEntity - LCChemicalEntity / LCOTHER / growth - factors activate LCOTHER via LCOTHER LCOTHER ( LCOTHER / LCOTHER ) , LCOTHER and LCGeneOrGeneProduct but not cytosolic LCOTHER or LCOTHER .	1
LCOTHER and other LCOTHER - LCOTHER / LCChemicalEntity / growth - factors activate LCGeneOrGeneProduct via LCOTHER LCOTHER ( LCOTHER / LCOTHER ) , LCOTHER and LCOTHER but not cytosolic LCOTHER or LCOTHER .	2
LCOTHER and other LCOTHER - LCOTHER / LCChemicalEntity / growth - factors activate LCOTHER via LCOTHER LCOTHER ( LCGeneOrGeneProduct / LCOTHER ) , LCOTHER and LCOTHER but not cytosolic LCOTHER or LCOTHER .	1
LCOTHER and other LCOTHER - LCOTHER / LCChemicalEntity / growth - factors activate LCOTHER via LCOTHER LCOTHER ( LCOTHER / LCGeneOrGeneProduct ) , LCOTHER and LCOTHER but not cytosolic LCOTHER or LCOTHER .	1
LCOTHER and other LCOTHER - LCOTHER / LCChemicalEntity / growth - factors activate LCOTHER via LCOTHER LCOTHER ( LCOTHER / LCOTHER ) , LCGeneOrGeneProduct and LCOTHER but not cytosolic LCOTHER or LCOTHER .	1
LCOTHER and other LCOTHER - LCOTHER / LCChemicalEntity / growth - factors activate LCOTHER via LCOTHER LCOTHER ( LCOTHER / LCOTHER ) , LCOTHER and LCGeneOrGeneProduct but not cytosolic LCOTHER or LCOTHER .	1
LCOTHER and other LCOTHER - LCOTHER / LCOTHER / growth - factors activate LCGeneOrGeneProduct via LCOTHER LCOTHER ( LCGeneOrGeneProduct / LCOTHER ) , LCOTHER and LCOTHER but not cytosolic LCOTHER or LCOTHER .	4
LCOTHER and other LCOTHER - LCOTHER / LCOTHER / growth - factors activate LCGeneOrGeneProduct via LCOTHER LCOTHER ( LCOTHER / LCGeneOrGeneProduct ) , LCOTHER and LCOTHER but not cytosolic LCOTHER or LCOTHER .	4
LCOTHER and other LCOTHER - LCOTHER / LCOTHER / growth - factors activate LCGeneOrGeneProduct via LCOTHER LCOTHER ( LCOTHER / LCOTHER ) , LCGeneOrGeneProduct and LCOTHER but not cytosolic LCOTHER or LCOTHER .	2
LCOTHER and other LCOTHER - LCOTHER / LCOTHER / growth - factors activate LCGeneOrGeneProduct via LCOTHER LCOTHER ( LCOTHER / LCOTHER ) , LCOTHER and LCGeneOrGeneProduct but not cytosolic LCOTHER or LCOTHER .	1
LCGeneOrGeneProduct - activation of LCOTHER showed several novel features being dependent on both receptor - activation states , having LCGeneOrGeneProduct - and LCOTHER - dependent / independent components and LCOTHER - LCOTHER - dependent / independent components .	1
LCGeneOrGeneProduct - activation of LCOTHER showed several novel features being dependent on both receptor - activation states , having LCOTHER - and LCGeneOrGeneProduct - dependent / independent components and LCOTHER - LCOTHER - dependent / independent components .	1
LCOTHER - activation of LCGeneOrGeneProduct showed several novel features being dependent on both receptor - activation states , having LCGeneOrGeneProduct - and LCOTHER - dependent / independent components and LCOTHER - LCOTHER - dependent / independent components .	2
LCOTHER - activation of LCGeneOrGeneProduct showed several novel features being dependent on both receptor - activation states , having LCOTHER - and LCGeneOrGeneProduct - dependent / independent components and LCOTHER - LCOTHER - dependent / independent components .	2
These results show that LCGeneOrGeneProduct is important in signaling cascades activated by numerous pancreatic stimuli which mediate their various physiological / pathophysiological responses and thus could be a promising target for the development of therapies in some LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature such as LCOTHER .	1
These results show that LCGeneOrGeneProduct is important in signaling cascades activated by numerous pancreatic stimuli which mediate their various physiological / pathophysiological responses and thus could be a promising target for the development of therapies in some LCOTHER LCOTHER such as LCDiseaseOrPhenotypicFeature .	1
OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of LCChemicalEntity and LCChemicalEntity in LCOTHER with LCOTHER LCOTHER ( LCOTHER ) .	6
OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of LCChemicalEntity and LCOTHER in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	3
OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of LCChemicalEntity and LCOTHER in LCOTHER with LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	3
OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of LCOTHER and LCChemicalEntity in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	3
OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of LCOTHER and LCChemicalEntity in LCOTHER with LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	3
LCOTHER AND METHODS : A total of 4086 LCOTHER ( mean age 60 . 8 years ) diagnosed with LCOTHER were enrolled and received LCChemicalEntity 90 mg daily ( n = 2032 ) or LCChemicalEntity 75 mg twice daily ( n = 2054 ) .	6
RESULTS : Mean ( SD ; maximum ) duration of treatment was 19 . 3 ( 10 . 3 ; 32 . 9 ) and 19 . 1 ( 10 . 4 ; 33 . 1 ) months in the LCChemicalEntity and LCChemicalEntity groups , respectively .	6
The cumulative discontinuation rate due to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature was significantly lower with LCChemicalEntity than LCOTHER ( 5 . 2 vs 8 . 5 events per 100 LCOTHER - years , respectively ; hazard ratio 0 . 62 ( 95% CI : 0 . 47 , 0 . 81 ; p < or = 0 . 001 ) ) .	2
The cumulative discontinuation rate due to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature was significantly lower with LCOTHER than LCChemicalEntity ( 5 . 2 vs 8 . 5 events per 100 LCOTHER - years , respectively ; hazard ratio 0 . 62 ( 95% CI : 0 . 47 , 0 . 81 ; p < or = 0 . 001 ) ) .	2
The cumulative discontinuation rate due to LCOTHER LCOTHER was significantly lower with LCChemicalEntity than LCChemicalEntity ( 5 . 2 vs 8 . 5 events per 100 LCOTHER - years , respectively ; hazard ratio 0 . 62 ( 95% CI : 0 . 47 , 0 . 81 ; p < or = 0 . 001 ) ) .	6
The incidence of discontinuations for LCDiseaseOrPhenotypicFeature - related and LCOTHER - related AEs were significantly higher with LCChemicalEntity ( 2 . 5% and 1 . 1% respectively ) compared with LCOTHER ( 1 . 5% and 0 . 4% respectively ; p < 0 . 001 for LCOTHER and p < 0 . 01 for LCOTHER ) .	2
The incidence of discontinuations for LCDiseaseOrPhenotypicFeature - related and LCOTHER - related AEs were significantly higher with LCOTHER ( 2 . 5% and 1 . 1% respectively ) compared with LCChemicalEntity ( 1 . 5% and 0 . 4% respectively ; p < 0 . 001 for LCOTHER and p < 0 . 01 for LCOTHER ) .	2
The incidence of discontinuations for LCOTHER - related and LCDiseaseOrPhenotypicFeature - related AEs were significantly higher with LCChemicalEntity ( 2 . 5% and 1 . 1% respectively ) compared with LCOTHER ( 1 . 5% and 0 . 4% respectively ; p < 0 . 001 for LCOTHER and p < 0 . 01 for LCOTHER ) .	2
The incidence of discontinuations for LCOTHER - related and LCDiseaseOrPhenotypicFeature - related AEs were significantly higher with LCOTHER ( 2 . 5% and 1 . 1% respectively ) compared with LCChemicalEntity ( 1 . 5% and 0 . 4% respectively ; p < 0 . 001 for LCOTHER and p < 0 . 01 for LCOTHER ) .	2
The incidence of discontinuations for LCOTHER - related and LCOTHER - related AEs were significantly higher with LCChemicalEntity ( 2 . 5% and 1 . 1% respectively ) compared with LCChemicalEntity ( 1 . 5% and 0 . 4% respectively ; p < 0 . 001 for LCOTHER and p < 0 . 01 for LCOTHER ) .	6
LCChemicalEntity and LCChemicalEntity treatment resulted in similar efficacy ( PGADS mean changes from baseline - 0 . 62 vs - 0 . 58 , respectively ) .	6
CONCLUSIONS : LCChemicalEntity 90 mg demonstrated a significantly lower risk for discontinuing treatment due to LCOTHER LCOTHER compared with LCChemicalEntity 150 mg .	6
CONCLUSIONS : LCOTHER 90 mg demonstrated a significantly lower risk for discontinuing treatment due to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature compared with LCChemicalEntity 150 mg .	2
Discontinuations from renovascular AEs , although less common than discontinuations from LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , were significantly higher with LCChemicalEntity . Putative LCOTHER LCOTHER Risk SNP in an LCOTHER LCOTHER - Binding Site of the LCOTHER Gene Illustrates Enrichment of Risk SNPs in LCOTHER LCOTHER Target Sites .	2
We integrated chromatin - immunoprecipitation - coupled sequencing and microarray expression profiling in LCGeneOrGeneProduct - LCGeneOrGeneProduct gene rearrangement positive LCOTHER cells with the GWAS LCOTHER risk SNPs catalog to identify disease susceptibility SNPs localized within functional LCOTHER LCOTHER - binding sites ( LCOTHER ) .	1
Of these , LCOTHER : LCOTHER > LCOTHER in an intron of the LCGeneOrGeneProduct gene ( LCOTHER ) was within a novel putative auxiliary LCGeneOrGeneProduct - binding motif , which is enriched in the neighborhood of canonical LCOTHER - responsive elements .	4
Of these , LCOTHER : LCOTHER > LCOTHER in an intron of the LCGeneOrGeneProduct gene ( LCOTHER ) was within a novel putative auxiliary LCOTHER - binding motif , which is enriched in the neighborhood of canonical LCChemicalEntity - responsive elements .	1
Of these , LCOTHER : LCOTHER > LCOTHER in an intron of the LCOTHER gene ( LCGeneOrGeneProduct ) was within a novel putative auxiliary LCGeneOrGeneProduct - binding motif , which is enriched in the neighborhood of canonical LCOTHER - responsive elements .	4
Of these , LCOTHER : LCOTHER > LCOTHER in an intron of the LCOTHER gene ( LCGeneOrGeneProduct ) was within a novel putative auxiliary LCOTHER - binding motif , which is enriched in the neighborhood of canonical LCChemicalEntity - responsive elements .	1
Of these , LCOTHER : LCOTHER > LCOTHER in an intron of the LCOTHER gene ( LCOTHER ) was within a novel putative auxiliary LCGeneOrGeneProduct - binding motif , which is enriched in the neighborhood of canonical LCChemicalEntity - responsive elements .	1
The expression of LCGeneOrGeneProduct in primary LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature was significantly lower in those with the G compared with the T allele and correlated significantly with LCOTHER protein .	1
The expression of LCGeneOrGeneProduct in primary LCOTHER LCOTHER was significantly lower in those with the G compared with the T allele and correlated significantly with LCGeneOrGeneProduct protein .	4
Higher LCGeneOrGeneProduct level in prostate tissue of LCOTHER with a favorable LCDiseaseOrPhenotypicFeature risk profile points out a LCOTHER - suppressive effect .	1
These results unravel a hidden link between LCGeneOrGeneProduct and a functional putative LCDiseaseOrPhenotypicFeature risk SNP , whose allele alteration affects LCOTHER regulation of its host gene LCOTHER . LCOTHER LCOTHER LCOTHER LCOTHER protects liver sinusoidal endothelial cells in acute LCOTHER LCOTHER LCOTHER .	1
These results unravel a hidden link between LCGeneOrGeneProduct and a functional putative LCOTHER risk SNP , whose allele alteration affects LCChemicalEntity regulation of its host gene LCOTHER . LCOTHER LCOTHER LCOTHER LCOTHER protects liver sinusoidal endothelial cells in acute LCOTHER LCOTHER LCOTHER .	1
Compared to that in the normal control , more severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and hepatocyte apoptosis , worse hepatic LCChemicalEntity peroxidation demonstrated by the increased ASAFR , . LCChemicalEntity and LCOTHER , but decreased LCOTHER and LCOTHER , increased LCOTHER - LCOTHER / LCOTHER activities and LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER expressions , which revealed obvious LCOTHER LCOTHER and scaffold structure broken , were shown in the model control .	1
Compared to that in the normal control , more severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and hepatocyte apoptosis , worse hepatic LCOTHER peroxidation demonstrated by the increased ASAFR , . LCOTHER and LCChemicalEntity , but decreased LCOTHER and LCOTHER , increased LCOTHER - LCOTHER / LCOTHER activities and LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER expressions , which revealed obvious LCOTHER LCOTHER and scaffold structure broken , were shown in the model control .	2
Compared to that in the normal control , more severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and hepatocyte apoptosis , worse hepatic LCOTHER peroxidation demonstrated by the increased ASAFR , . LCOTHER and LCOTHER , but decreased LCGeneOrGeneProduct and LCOTHER , increased LCOTHER - LCOTHER / LCOTHER activities and LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER expressions , which revealed obvious LCOTHER LCOTHER and scaffold structure broken , were shown in the model control .	1
Compared to that in the normal control , more severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and hepatocyte apoptosis , worse hepatic LCOTHER peroxidation demonstrated by the increased ASAFR , . LCOTHER and LCOTHER , but decreased LCOTHER and LCGeneOrGeneProduct , increased LCOTHER - LCOTHER / LCOTHER activities and LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER expressions , which revealed obvious LCOTHER LCOTHER and scaffold structure broken , were shown in the model control .	1
Compared to that in the normal control , more severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and hepatocyte apoptosis , worse hepatic LCOTHER peroxidation demonstrated by the increased ASAFR , . LCOTHER and LCOTHER , but decreased LCOTHER and LCOTHER , increased LCOTHER - LCOTHER / LCOTHER activities and LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER and LCOTHER expressions , which revealed obvious LCOTHER LCOTHER and scaffold structure broken , were shown in the model control .	1
Compared to that in the normal control , more severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and hepatocyte apoptosis , worse hepatic LCOTHER peroxidation demonstrated by the increased ASAFR , . LCOTHER and LCOTHER , but decreased LCOTHER and LCOTHER , increased LCOTHER - LCOTHER / LCOTHER activities and LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER expressions , which revealed obvious LCOTHER LCOTHER and scaffold structure broken , were shown in the model control .	1
Compared to that in the normal control , more severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and hepatocyte apoptosis , worse hepatic LCOTHER peroxidation demonstrated by the increased ASAFR , . LCOTHER and LCOTHER , but decreased LCOTHER and LCOTHER , increased LCOTHER - LCOTHER / LCOTHER activities and LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCGeneOrGeneProduct expressions , which revealed obvious LCOTHER LCOTHER and scaffold structure broken , were shown in the model control .	1
Compared with the model group , LCOTHER and LCChemicalEntity , LCChemicalEntity - LCChemicalEntity significantly improved serum LCGeneOrGeneProduct / LCOTHER , attenuated LCOTHER LCOTHER and improved peroxidative LCOTHER LCOTHER LCOTHER , decreased LCOTHER - LCOTHER / LCOTHER activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of LCOTHER - LCOTHER and LCOTHER - LCOTHER .	2
Compared with the model group , LCOTHER and LCChemicalEntity , LCChemicalEntity - LCChemicalEntity significantly improved serum LCOTHER / LCGeneOrGeneProduct , attenuated LCOTHER LCOTHER and improved peroxidative LCOTHER LCOTHER LCOTHER , decreased LCOTHER - LCOTHER / LCOTHER activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of LCOTHER - LCOTHER and LCOTHER - LCOTHER .	2
Compared with the model group , LCOTHER and LCChemicalEntity , LCChemicalEntity - LCChemicalEntity significantly improved serum LCOTHER / LCOTHER , attenuated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and improved peroxidative LCOTHER LCOTHER LCOTHER , decreased LCOTHER - LCOTHER / LCOTHER activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of LCOTHER - LCOTHER and LCOTHER - LCOTHER .	3
Compared with the model group , LCOTHER and LCChemicalEntity , LCChemicalEntity - LCChemicalEntity significantly improved serum LCOTHER / LCOTHER , attenuated LCOTHER LCOTHER and improved peroxidative LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , decreased LCOTHER - LCOTHER / LCOTHER activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of LCOTHER - LCOTHER and LCOTHER - LCOTHER .	3
Compared with the model group , LCOTHER and LCChemicalEntity , LCChemicalEntity - LCChemicalEntity significantly improved serum LCOTHER / LCOTHER , attenuated LCOTHER LCOTHER and improved peroxidative LCOTHER LCOTHER LCOTHER , decreased LCOTHER - LCOTHER / LCOTHER activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER .	3
Compared with the model group , LCOTHER and LCChemicalEntity , LCChemicalEntity - LCChemicalEntity significantly improved serum LCOTHER / LCOTHER , attenuated LCOTHER LCOTHER and improved peroxidative LCOTHER LCOTHER LCOTHER , decreased LCOTHER - LCOTHER / LCOTHER activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct .	3
Compared with the model group , LCOTHER and LCOTHER , LCOTHER - LCOTHER significantly improved serum LCGeneOrGeneProduct / LCOTHER , attenuated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and improved peroxidative LCOTHER LCOTHER LCOTHER , decreased LCOTHER - LCOTHER / LCOTHER activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of LCOTHER - LCOTHER and LCOTHER - LCOTHER .	1
Compared with the model group , LCOTHER and LCOTHER , LCOTHER - LCOTHER significantly improved serum LCGeneOrGeneProduct / LCOTHER , attenuated LCOTHER LCOTHER and improved peroxidative LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , decreased LCOTHER - LCOTHER / LCOTHER activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of LCOTHER - LCOTHER and LCOTHER - LCOTHER .	1
Compared with the model group , LCOTHER and LCOTHER , LCOTHER - LCOTHER significantly improved serum LCOTHER / LCGeneOrGeneProduct , attenuated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and improved peroxidative LCOTHER LCOTHER LCOTHER , decreased LCOTHER - LCOTHER / LCOTHER activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of LCOTHER - LCOTHER and LCOTHER - LCOTHER .	1
Compared with the model group , LCOTHER and LCOTHER , LCOTHER - LCOTHER significantly improved serum LCOTHER / LCGeneOrGeneProduct , attenuated LCOTHER LCOTHER and improved peroxidative LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , decreased LCOTHER - LCOTHER / LCOTHER activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of LCOTHER - LCOTHER and LCOTHER - LCOTHER .	1
Compared with the model group , LCOTHER and LCOTHER , LCOTHER - LCOTHER significantly improved serum LCOTHER / LCOTHER , attenuated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and improved peroxidative LCOTHER LCOTHER LCOTHER , decreased LCOTHER - LCOTHER / LCOTHER activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER .	1
Compared with the model group , LCOTHER and LCOTHER , LCOTHER - LCOTHER significantly improved serum LCOTHER / LCOTHER , attenuated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and improved peroxidative LCOTHER LCOTHER LCOTHER , decreased LCOTHER - LCOTHER / LCOTHER activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct .	1
Compared with the model group , LCOTHER and LCOTHER , LCOTHER - LCOTHER significantly improved serum LCOTHER / LCOTHER , attenuated LCOTHER LCOTHER and improved peroxidative LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , decreased LCOTHER - LCOTHER / LCOTHER activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER .	1
Compared with the model group , LCOTHER and LCOTHER , LCOTHER - LCOTHER significantly improved serum LCOTHER / LCOTHER , attenuated LCOTHER LCOTHER and improved peroxidative LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , decreased LCOTHER - LCOTHER / LCOTHER activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct .	1
LCOTHER could protect LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and maintain the microvasculature integration in acute LCOTHER LCOTHER of LCOTHER induced by LCChemicalEntity / LCOTHER - LCOTHER .	2
LCOTHER could protect LCOTHER LCOTHER LCOTHER and maintain the microvasculature integration in acute LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature of LCOTHER induced by LCChemicalEntity / LCOTHER - LCOTHER .	2
Certain concepts concerning LCGeneOrGeneProduct / LCGeneOrGeneProduct action modes have been challenged by in vivo studies : LCOTHER - LCOTHER levels are elevated in maturing erythroblasts , but not in their progenitors ; truncated LCOTHER alleles that lack a major LCOTHER / LCOTHER recruitment site nonetheless promote LCOTHER ; and LCOTHER disruption unexpectedly bolsters erythropoiesis .	4
Certain concepts concerning LCGeneOrGeneProduct / LCOTHER action modes have been challenged by in vivo studies : LCOTHER - LCOTHER levels are elevated in maturing erythroblasts , but not in their progenitors ; truncated LCGeneOrGeneProduct alleles that lack a major LCOTHER / LCOTHER recruitment site nonetheless promote LCOTHER ; and LCOTHER disruption unexpectedly bolsters erythropoiesis .	4
Certain concepts concerning LCOTHER / LCGeneOrGeneProduct action modes have been challenged by in vivo studies : LCOTHER - LCOTHER levels are elevated in maturing erythroblasts , but not in their progenitors ; truncated LCOTHER alleles that lack a major LCGeneOrGeneProduct / LCGeneOrGeneProduct recruitment site nonetheless promote LCOTHER ; and LCOTHER disruption unexpectedly bolsters erythropoiesis .	1
Certain concepts concerning LCOTHER / LCGeneOrGeneProduct action modes have been challenged by in vivo studies : LCOTHER - LCOTHER levels are elevated in maturing erythroblasts , but not in their progenitors ; truncated LCOTHER alleles that lack a major LCOTHER / LCOTHER recruitment site nonetheless promote LCDiseaseOrPhenotypicFeature ; and LCOTHER disruption unexpectedly bolsters erythropoiesis .	1
Certain concepts concerning LCOTHER / LCOTHER action modes have been challenged by in vivo studies : LCOTHER - LCOTHER levels are elevated in maturing erythroblasts , but not in their progenitors ; truncated LCGeneOrGeneProduct alleles that lack a major LCGeneOrGeneProduct / LCGeneOrGeneProduct recruitment site nonetheless promote LCOTHER ; and LCOTHER disruption unexpectedly bolsters erythropoiesis .	1
Certain concepts concerning LCOTHER / LCOTHER action modes have been challenged by in vivo studies : LCOTHER - LCOTHER levels are elevated in maturing erythroblasts , but not in their progenitors ; truncated LCGeneOrGeneProduct alleles that lack a major LCOTHER / LCOTHER recruitment site nonetheless promote LCDiseaseOrPhenotypicFeature ; and LCOTHER disruption unexpectedly bolsters erythropoiesis .	1
To discover novel LCGeneOrGeneProduct / LCGeneOrGeneProduct action routes , global transcriptome analyses presently are applied to interrogate LCOTHER / LCOTHER effects on primary bone marrow - derived CFUe - like progenitors .	4
To discover novel LCGeneOrGeneProduct / LCOTHER action routes , global transcriptome analyses presently are applied to interrogate LCOTHER / LCGeneOrGeneProduct effects on primary bone marrow - derived CFUe - like progenitors .	4
To discover novel LCOTHER / LCOTHER action routes , global transcriptome analyses presently are applied to interrogate LCGeneOrGeneProduct / LCGeneOrGeneProduct effects on primary bone marrow - derived CFUe - like progenitors .	4
Overall , 160 LCGeneOrGeneProduct / LCGeneOrGeneProduct target transcripts were significantly modulated 2 - to 21 . 8 - fold .	4
A unique set of LCGeneOrGeneProduct - regulated survival factors included LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER LCOTHER .	1
A unique set of LCGeneOrGeneProduct - regulated survival factors included LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER LCOTHER .	1
A unique set of LCGeneOrGeneProduct - regulated survival factors included LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER and LCOTHER LCOTHER .	1
A unique set of LCGeneOrGeneProduct - regulated survival factors included LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER LCOTHER .	1
A unique set of LCGeneOrGeneProduct - regulated survival factors included LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER LCOTHER .	1
A unique set of LCGeneOrGeneProduct - regulated survival factors included LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER LCOTHER .	1
A unique set of LCGeneOrGeneProduct - regulated survival factors included LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct LCGeneOrGeneProduct .	1
LCGeneOrGeneProduct / LCGeneOrGeneProduct - modulated cell cycle mediators included LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCOTHER - LCOTHER .	4
LCGeneOrGeneProduct / LCOTHER - modulated cell cycle mediators included LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCOTHER - LCOTHER .	1
LCGeneOrGeneProduct / LCOTHER - modulated cell cycle mediators included LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCOTHER - LCOTHER .	1
LCGeneOrGeneProduct / LCOTHER - modulated cell cycle mediators included LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCOTHER - LCOTHER .	1
LCGeneOrGeneProduct / LCOTHER - modulated cell cycle mediators included LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER and LCOTHER - LCOTHER - LCOTHER .	1
LCGeneOrGeneProduct / LCOTHER - modulated cell cycle mediators included LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER - LCOTHER .	1
LCGeneOrGeneProduct / LCOTHER - modulated cell cycle mediators included LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct .	1
LCOTHER / LCGeneOrGeneProduct - modulated cell cycle mediators included LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCOTHER - LCOTHER .	1
LCOTHER / LCGeneOrGeneProduct - modulated cell cycle mediators included LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCOTHER - LCOTHER .	1
LCOTHER / LCGeneOrGeneProduct - modulated cell cycle mediators included LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCOTHER - LCOTHER .	1
LCOTHER / LCGeneOrGeneProduct - modulated cell cycle mediators included LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER and LCOTHER - LCOTHER - LCOTHER .	1
LCOTHER / LCGeneOrGeneProduct - modulated cell cycle mediators included LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER - LCOTHER .	1
LCOTHER / LCGeneOrGeneProduct - modulated cell cycle mediators included LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct .	1
For example , not only LCGeneOrGeneProduct plus LCOTHER but also LCOTHER , LCOTHER and LCOTHER were LCGeneOrGeneProduct - induced as negative - feedback components .	2
For example , not only LCOTHER plus LCGeneOrGeneProduct but also LCOTHER , LCOTHER and LCOTHER were LCGeneOrGeneProduct - induced as negative - feedback components .	2
For example , not only LCOTHER plus LCOTHER but also LCGeneOrGeneProduct , LCOTHER and LCOTHER were LCGeneOrGeneProduct - induced as negative - feedback components .	2
For example , not only LCOTHER plus LCOTHER but also LCOTHER , LCGeneOrGeneProduct and LCOTHER were LCGeneOrGeneProduct - induced as negative - feedback components .	2
For example , not only LCOTHER plus LCOTHER but also LCOTHER , LCOTHER and LCGeneOrGeneProduct were LCGeneOrGeneProduct - induced as negative - feedback components .	2
LCGeneOrGeneProduct , plus five additional targets , further proved to comprise new LCOTHER / LCOTHER / LCOTHER response genes ( which are important for erythropoiesis during LCDiseaseOrPhenotypicFeature ) .	1
LCOTHER , plus five additional targets , further proved to comprise new LCGeneOrGeneProduct / LCOTHER / LCOTHER response genes ( which are important for erythropoiesis during LCDiseaseOrPhenotypicFeature ) .	1
LCOTHER , plus five additional targets , further proved to comprise new LCOTHER / LCGeneOrGeneProduct / LCOTHER response genes ( which are important for erythropoiesis during LCDiseaseOrPhenotypicFeature ) .	1
LCOTHER , plus five additional targets , further proved to comprise new LCOTHER / LCOTHER / LCGeneOrGeneProduct response genes ( which are important for erythropoiesis during LCDiseaseOrPhenotypicFeature ) .	1
Among receptors , an atypical LCGeneOrGeneProduct - LCGeneOrGeneProduct LCOTHER - LCOTHER was up - modulated > 5 - fold by LCGeneOrGeneProduct .	2
Among receptors , an atypical LCOTHER - LCOTHER LCGeneOrGeneProduct - LCGeneOrGeneProduct was up - modulated > 5 - fold by LCGeneOrGeneProduct .	2
The LCGeneOrGeneProduct therefore engages a sophisticated set of transcriptome response circuits , with LCGeneOrGeneProduct - LCGeneOrGeneProduct deployed as one novel positive regulator of proerythroblast formation . Novel LCOTHER gene mutations in LCOTHER with LCOTHER LCOTHER LCOTHER .	1
LCGeneOrGeneProduct gene , a novel cell adhesion molecule , is a candidate gene for LCDiseaseOrPhenotypicFeature .	1
RESULTS : In a LCOTHER , a LCOTHER - LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in exon 8 that resulted in a substitution of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in the first LCChemicalEntity - binding LCGeneOrGeneProduct domain .	4
The heterozygous LCOTHER . LCOTHER > LCOTHER transition in exon 9 resulted in a substitution of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) in the second LCChemicalEntity - binding LCGeneOrGeneProduct domain .	4
CONCLUSIONS : Two novel LCGeneOrGeneProduct mutations were identified in the LCChemicalEntity - binding LCOTHER domain in LCOTHER with LCOTHER .	1
CONCLUSIONS : Two novel LCGeneOrGeneProduct mutations were identified in the LCOTHER - binding LCGeneOrGeneProduct domain in LCOTHER with LCOTHER .	1
CONCLUSIONS : Two novel LCGeneOrGeneProduct mutations were identified in the LCOTHER - binding LCOTHER domain in LCOTHER with LCDiseaseOrPhenotypicFeature .	1
CONCLUSIONS : Two novel LCOTHER mutations were identified in the LCChemicalEntity - binding LCGeneOrGeneProduct domain in LCOTHER with LCOTHER .	4
CONCLUSIONS : Two novel LCOTHER mutations were identified in the LCOTHER - binding LCGeneOrGeneProduct domain in LCOTHER with LCDiseaseOrPhenotypicFeature .	1
LCGeneOrGeneProduct is likely to be an LCDiseaseOrPhenotypicFeature - susceptibility gene and LCOTHER mutations may increase the risk of developing a LCOTHER LCOTHER rather than being a direct causative mutation . The differential effects of LCOTHER and LCOTHER on LCOTHER LCOTHER release , LCOTHER gene expression and LCOTHER in a clinical LCOTHER model .	1
LCGeneOrGeneProduct is likely to be an LCOTHER - susceptibility gene and LCOTHER mutations may increase the risk of developing a LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature rather than being a direct causative mutation . The differential effects of LCOTHER and LCOTHER on LCOTHER LCOTHER release , LCOTHER gene expression and LCOTHER in a clinical LCOTHER model .	1
LCOTHER is likely to be an LCOTHER - susceptibility gene and LCGeneOrGeneProduct mutations may increase the risk of developing a LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature rather than being a direct causative mutation . The differential effects of LCOTHER and LCOTHER on LCOTHER LCOTHER release , LCOTHER gene expression and LCOTHER in a clinical LCOTHER model .	1
In the present study , we describe the proinflammatory effects of LCChemicalEntity on local LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) production and LCOTHER ( LCOTHER ) gene expression that increases LCOTHER LCOTHER in LCOTHER subjects .	2
In the present study , we describe the proinflammatory effects of LCChemicalEntity on local LCOTHER LCOTHER ( LCGeneOrGeneProduct ) production and LCOTHER ( LCOTHER ) gene expression that increases LCOTHER LCOTHER in LCOTHER subjects .	2
In the present study , we describe the proinflammatory effects of LCChemicalEntity on local LCOTHER LCOTHER ( LCOTHER ) production and LCOTHER ( LCOTHER ) gene expression that increases LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER subjects .	2
In the present study , we describe the proinflammatory effects of LCOTHER on local LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) production and LCOTHER ( LCOTHER ) gene expression that increases LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER subjects .	2
In the present study , we describe the proinflammatory effects of LCOTHER on local LCOTHER LCOTHER ( LCGeneOrGeneProduct ) production and LCOTHER ( LCOTHER ) gene expression that increases LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER subjects .	2
METHODS : Subjects ( n = 114 ) undergoing extraction of impacted third molars received either 2% LCOTHER or 0 . 5% LCChemicalEntity before surgery and either LCChemicalEntity 50 mg or placebo orally 90 min before surgery and for the following 48 h .	5
RESULTS : The LCChemicalEntity / LCChemicalEntity group reported significantly less LCOTHER , as assessed by a visual analog scale , compared with the other three treatment groups over the first 4 h .	5
RESULTS : The LCChemicalEntity / LCOTHER group reported significantly less LCDiseaseOrPhenotypicFeature , as assessed by a visual analog scale , compared with the other three treatment groups over the first 4 h .	2
RESULTS : The LCOTHER / LCChemicalEntity group reported significantly less LCDiseaseOrPhenotypicFeature , as assessed by a visual analog scale , compared with the other three treatment groups over the first 4 h .	3
However , the LCChemicalEntity / placebo group reported significantly more LCDiseaseOrPhenotypicFeature at 24 h and LCOTHER levels during the first 4 h were significantly higher than the other three treatment groups .	2
However , the LCChemicalEntity / placebo group reported significantly more LCOTHER at 24 h and LCGeneOrGeneProduct levels during the first 4 h were significantly higher than the other three treatment groups .	2
Moreover , LCChemicalEntity significantly increased LCGeneOrGeneProduct - LCGeneOrGeneProduct gene expression at 48 h as compared with the LCOTHER / placebo group .	2
Moreover , LCChemicalEntity significantly increased LCOTHER - LCOTHER gene expression at 48 h as compared with the LCChemicalEntity / placebo group .	6
LCChemicalEntity levels were not significantly affected by any of the treatments , indicating that the effects seen were attributable to inhibition of LCGeneOrGeneProduct - LCGeneOrGeneProduct , but not LCOTHER - LCOTHER .	3
CONCLUSIONS : These results suggest that LCChemicalEntity stimulates LCGeneOrGeneProduct - LCGeneOrGeneProduct gene expression after LCOTHER LCOTHER , which is associated with higher LCOTHER production and LCOTHER after the local anesthetic effect dissipates . LCOTHER and LCOTHER LCOTHER among LCOTHER treated with LCOTHER for LCOTHER LCOTHER in the city of Copenhagen .	2
CONCLUSIONS : These results suggest that LCChemicalEntity stimulates LCOTHER - LCOTHER gene expression after LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , which is associated with higher LCOTHER production and LCOTHER after the local anesthetic effect dissipates . LCOTHER and LCOTHER LCOTHER among LCOTHER treated with LCOTHER for LCOTHER LCOTHER in the city of Copenhagen .	1
CONCLUSIONS : These results suggest that LCChemicalEntity stimulates LCOTHER - LCOTHER gene expression after LCOTHER LCOTHER , which is associated with higher LCGeneOrGeneProduct production and LCOTHER after the local anesthetic effect dissipates . LCOTHER and LCOTHER LCOTHER among LCOTHER treated with LCOTHER for LCOTHER LCOTHER in the city of Copenhagen .	2
CONCLUSIONS : These results suggest that LCChemicalEntity stimulates LCOTHER - LCOTHER gene expression after LCOTHER LCOTHER , which is associated with higher LCOTHER production and LCDiseaseOrPhenotypicFeature after the local anesthetic effect dissipates . LCOTHER and LCOTHER LCOTHER among LCOTHER treated with LCOTHER for LCOTHER LCOTHER in the city of Copenhagen .	2
CONCLUSIONS : These results suggest that LCOTHER stimulates LCGeneOrGeneProduct - LCGeneOrGeneProduct gene expression after LCOTHER LCOTHER , which is associated with higher LCGeneOrGeneProduct production and LCOTHER after the local anesthetic effect dissipates . LCOTHER and LCOTHER LCOTHER among LCOTHER treated with LCOTHER for LCOTHER LCOTHER in the city of Copenhagen .	2
CONCLUSIONS : These results suggest that LCOTHER stimulates LCGeneOrGeneProduct - LCGeneOrGeneProduct gene expression after LCOTHER LCOTHER , which is associated with higher LCOTHER production and LCDiseaseOrPhenotypicFeature after the local anesthetic effect dissipates . LCOTHER and LCOTHER LCOTHER among LCOTHER treated with LCOTHER for LCOTHER LCOTHER in the city of Copenhagen .	1
BACKGROUND : LCChemicalEntity is prescribed to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature to decrease illicit LCOTHER use .	3
BACKGROUND : LCChemicalEntity is prescribed to LCOTHER LCOTHER to decrease illicit LCChemicalEntity use .	1
LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in the ECG of LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) has been reported in LCChemicalEntity users .	2
LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in the ECG of LCOTHER with LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) has been reported in LCChemicalEntity users .	2
As LCOTHER LCOTHER sometimes faint while using illicit drugs , doctors might attribute too many episodes of LCOTHER to illicit drug use and thereby underestimate the incidence of LCDiseaseOrPhenotypicFeature in this special population , and the high mortality in this population may , in part , be caused by the proarrhythmic effect of LCChemicalEntity .	2
The association between LCOTHER dose and QT , and LCChemicalEntity dose and reporting of LCDiseaseOrPhenotypicFeature was assessed using multivariate linear regression and logistic regression , respectively .	2
RESULTS : LCChemicalEntity dose was associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature of 0 . 140 ms / mg ( p = 0 . 002 ) .	2
Among the subjects treated with LCChemicalEntity , 28% LCOTHER and 32% LCOTHER had LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
A 50 mg higher LCChemicalEntity dose was associated with a 1 . 2 ( 95% CI 1 . 1 to 1 . 4 ) times higher odds for LCDiseaseOrPhenotypicFeature .	2
CONCLUSIONS : LCChemicalEntity is associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and higher reporting of LCOTHER in a population of LCOTHER LCOTHER . Clusters of multidrug - resistant LCOTHER LCOTHER cases , Europe .	2
CONCLUSIONS : LCChemicalEntity is associated with LCOTHER LCOTHER and higher reporting of LCDiseaseOrPhenotypicFeature in a population of LCOTHER LCOTHER . Clusters of multidrug - resistant LCOTHER LCOTHER cases , Europe .	2
CONCLUSIONS : LCChemicalEntity is associated with LCOTHER LCOTHER and higher reporting of LCOTHER in a population of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Clusters of multidrug - resistant LCOTHER LCOTHER cases , Europe .	3
This study investigated the possible association between three functional polymorphisms in the promoter region of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) gene and LCDiseaseOrPhenotypicFeature , LCOTHER , and LCOTHER LCOTHER .	1
This study investigated the possible association between three functional polymorphisms in the promoter region of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) gene and LCOTHER , LCOTHER , and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
This study investigated the possible association between three functional polymorphisms in the promoter region of the LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene and LCDiseaseOrPhenotypicFeature , LCOTHER , and LCOTHER LCOTHER .	1
This study investigated the possible association between three functional polymorphisms in the promoter region of the LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene and LCOTHER , LCOTHER , and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
These observations strongly suggest that the - 120 - bp duplication polymorphism of LCGeneOrGeneProduct is associated with LCDiseaseOrPhenotypicFeature and that the - LCSequenceVariant LCSequenceVariant / LCSequenceVariant polymorphism is associated with LCOTHER LCOTHER . Lack of major involvement of LCOTHER LCOTHER genes in LCOTHER LCOTHER : implications for disease heterogeneity .	1
These observations strongly suggest that the - 120 - bp duplication polymorphism of LCGeneOrGeneProduct is associated with LCOTHER and that the - LCOTHER LCOTHER / LCOTHER polymorphism is associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Lack of major involvement of LCOTHER LCOTHER genes in LCOTHER LCOTHER : implications for disease heterogeneity .	1
Recent studies indicate that genetic ablation of LCOTHER LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct gene , which encodes a 47 kD urothelial - specific integral membrane protein forming urothelial plaques , causes LCDiseaseOrPhenotypicFeature and LCOTHER .	1
Recent studies indicate that genetic ablation of LCOTHER LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct gene , which encodes a 47 kD urothelial - specific integral membrane protein forming urothelial plaques , causes LCOTHER and LCDiseaseOrPhenotypicFeature .	1
However , SNP1 of LCGeneOrGeneProduct LCGeneOrGeneProduct gene affecting a LCOTHER LCOTHER LCOTHER conversion and an LCOTHER change , and SNP7 of LCOTHER LCOTHER affecting a LCOTHER LCOTHER LCOTHER conversion and a LCOTHER change , were marginally associated with LCDiseaseOrPhenotypicFeature ( both P = 0 . 08 ) .	1
However , SNP1 of LCOTHER LCOTHER gene affecting a LCSequenceVariant LCSequenceVariant LCSequenceVariant conversion and an LCOTHER change , and SNP7 of LCOTHER LCOTHER affecting a LCOTHER LCOTHER LCOTHER conversion and a LCOTHER change , were marginally associated with LCDiseaseOrPhenotypicFeature ( both P = 0 . 08 ) .	1
However , SNP1 of LCOTHER LCOTHER gene affecting a LCOTHER LCOTHER LCOTHER conversion and an LCSequenceVariant change , and SNP7 of LCOTHER LCOTHER affecting a LCOTHER LCOTHER LCOTHER conversion and a LCOTHER change , were marginally associated with LCDiseaseOrPhenotypicFeature ( both P = 0 . 08 ) .	1
However , SNP1 of LCOTHER LCOTHER gene affecting a LCOTHER LCOTHER LCOTHER conversion and an LCOTHER change , and SNP7 of LCGeneOrGeneProduct LCGeneOrGeneProduct affecting a LCOTHER LCOTHER LCOTHER conversion and a LCOTHER change , were marginally associated with LCDiseaseOrPhenotypicFeature ( both P = 0 . 08 ) .	1
However , SNP1 of LCOTHER LCOTHER gene affecting a LCOTHER LCOTHER LCOTHER conversion and an LCOTHER change , and SNP7 of LCOTHER LCOTHER affecting a LCSequenceVariant LCSequenceVariant LCSequenceVariant conversion and a LCOTHER change , were marginally associated with LCDiseaseOrPhenotypicFeature ( both P = 0 . 08 ) .	1
However , SNP1 of LCOTHER LCOTHER gene affecting a LCOTHER LCOTHER LCOTHER conversion and an LCOTHER change , and SNP7 of LCOTHER LCOTHER affecting a LCOTHER LCOTHER LCOTHER conversion and a LCSequenceVariant change , were marginally associated with LCDiseaseOrPhenotypicFeature ( both P = 0 . 08 ) .	1
Studies of additional cases yielded a second set of data that , in combination with the first set , confirmed a weak association of LCGeneOrGeneProduct LCGeneOrGeneProduct SNP7 in LCDiseaseOrPhenotypicFeature ( P = 0 . 036 adjusted for both subsets of cases vs .	1
The fact that no truncation or frame shift mutations have been found in any of the LCOTHER LCOTHER , coupled with our recent finding that some breeding pairs of LCGeneOrGeneProduct LCGeneOrGeneProduct knockout LCOTHER yield litters that show not only LCDiseaseOrPhenotypicFeature , but also severe LCOTHER and LCOTHER LCOTHER , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOTHER . Midline B3 LCOTHER nerves in LCOTHER medulla are involved in LCOTHER effect of LCOTHER .	1
The fact that no truncation or frame shift mutations have been found in any of the LCOTHER LCOTHER , coupled with our recent finding that some breeding pairs of LCGeneOrGeneProduct LCGeneOrGeneProduct knockout LCOTHER yield litters that show not only LCOTHER , but also severe LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOTHER . Midline B3 LCOTHER nerves in LCOTHER medulla are involved in LCOTHER effect of LCOTHER .	1
Previous experiments in this laboratory have shown that microinjection of LCChemicalEntity onto the ventrolateral cells of the B3 LCOTHER neurons in the medulla elicits a LCDiseaseOrPhenotypicFeature response mediated by a projection descending into the spinal cord .	2
Previous experiments in this laboratory have shown that microinjection of LCOTHER onto the ventrolateral cells of the B3 LCChemicalEntity neurons in the medulla elicits a LCDiseaseOrPhenotypicFeature response mediated by a projection descending into the spinal cord .	2
In spontaneously LCOTHER , LCOTHER - prone LCOTHER , microinjection of LCChemicalEntity into the area of the midline B3 LCOTHER cell group in the ventral medulla caused a potent LCDiseaseOrPhenotypicFeature of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the LCOTHER neurotoxin LCOTHER , LCOTHER - LCOTHER ( LCOTHER , LCOTHER - LCOTHER ) injected intracerebroventricularly .	2
In spontaneously LCOTHER , LCOTHER - prone LCOTHER , microinjection of LCOTHER into the area of the midline B3 LCChemicalEntity cell group in the ventral medulla caused a potent LCDiseaseOrPhenotypicFeature of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the LCOTHER neurotoxin LCOTHER , LCOTHER - LCOTHER ( LCOTHER , LCOTHER - LCOTHER ) injected intracerebroventricularly .	2
In spontaneously LCOTHER , LCOTHER - prone LCOTHER , microinjection of LCOTHER into the area of the midline B3 LCChemicalEntity cell group in the ventral medulla caused a potent LCOTHER of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the LCOTHER neurotoxin LCChemicalEntity , LCChemicalEntity - LCChemicalEntity ( LCOTHER , LCOTHER - LCOTHER ) injected intracerebroventricularly .	1
In spontaneously LCOTHER , LCOTHER - prone LCOTHER , microinjection of LCOTHER into the area of the midline B3 LCChemicalEntity cell group in the ventral medulla caused a potent LCOTHER of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the LCOTHER neurotoxin LCOTHER , LCOTHER - LCOTHER ( LCChemicalEntity , LCChemicalEntity - LCChemicalEntity ) injected intracerebroventricularly .	1
In spontaneously LCOTHER , LCOTHER - prone LCOTHER , microinjection of LCOTHER into the area of the midline B3 LCOTHER cell group in the ventral medulla caused a potent LCOTHER of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the LCChemicalEntity neurotoxin LCChemicalEntity , LCChemicalEntity - LCChemicalEntity ( LCOTHER , LCOTHER - LCOTHER ) injected intracerebroventricularly .	1
In spontaneously LCOTHER , LCOTHER - prone LCOTHER , microinjection of LCOTHER into the area of the midline B3 LCOTHER cell group in the ventral medulla caused a potent LCOTHER of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the LCChemicalEntity neurotoxin LCOTHER , LCOTHER - LCOTHER ( LCChemicalEntity , LCChemicalEntity - LCChemicalEntity ) injected intracerebroventricularly .	1
However , intraspinal injection of LCOTHER , LCOTHER - LCOTHER to produce a more selective lesion of only descending LCChemicalEntity projections in the spinal cord did not affect this LCDiseaseOrPhenotypicFeature .	2
Further , LCOTHER , LCOTHER - LCOTHER lesion of LCChemicalEntity nerves travelling in the median forebrain bundle , one of the main ascending pathways from the B3 LCOTHER cells , did not affect the fall in blood pressure associated with a midline B3 LCOTHER LCChemicalEntity injection .	2
Further , LCOTHER , LCOTHER - LCOTHER lesion of LCOTHER nerves travelling in the median forebrain bundle , one of the main ascending pathways from the B3 LCChemicalEntity cells , did not affect the fall in blood pressure associated with a midline B3 LCOTHER LCChemicalEntity injection .	2
Further , LCOTHER , LCOTHER - LCOTHER lesion of LCOTHER nerves travelling in the median forebrain bundle , one of the main ascending pathways from the B3 LCOTHER cells , did not affect the fall in blood pressure associated with a midline B3 LCChemicalEntity LCChemicalEntity injection .	2
It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature via descending projections , the midline LCOTHER B3 cells in the medulla contribute to the LCOTHER action of LCOTHER , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem . A novel mutation screening system for LCOTHER - LCOTHER LCOTHER , LCOTHER LCOTHER by high - resolution melting curve analysis in combination with small amplicon genotyping using genomic DNA .	2
It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a LCChemicalEntity - induced LCOTHER via descending projections , the midline LCOTHER B3 cells in the medulla contribute to the LCDiseaseOrPhenotypicFeature action of LCOTHER , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem . A novel mutation screening system for LCOTHER - LCOTHER LCOTHER , LCOTHER LCOTHER by high - resolution melting curve analysis in combination with small amplicon genotyping using genomic DNA .	2
It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a LCOTHER - induced LCOTHER via descending projections , the midline LCChemicalEntity B3 cells in the medulla contribute to the LCDiseaseOrPhenotypicFeature action of LCOTHER , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem . A novel mutation screening system for LCOTHER - LCOTHER LCOTHER , LCOTHER LCOTHER by high - resolution melting curve analysis in combination with small amplicon genotyping using genomic DNA .	2
It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a LCOTHER - induced LCOTHER via descending projections , the midline LCChemicalEntity B3 cells in the medulla contribute to the LCOTHER action of LCChemicalEntity , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem . A novel mutation screening system for LCOTHER - LCOTHER LCOTHER , LCOTHER LCOTHER by high - resolution melting curve analysis in combination with small amplicon genotyping using genomic DNA .	2
LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) ( LCOTHER # LCOTHER ) is an LCOTHER LCOTHER LCOTHER caused by LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene ( LCOTHER ) mutations .	1
LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) ( LCOTHER # LCOTHER ) is an LCOTHER LCOTHER LCOTHER caused by LCOTHER LCOTHER LCOTHER gene ( LCGeneOrGeneProduct ) mutations .	1
LCOTHER - LCOTHER LCOTHER , LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) ( LCOTHER # LCOTHER ) is an LCOTHER LCOTHER LCOTHER caused by LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene ( LCOTHER ) mutations .	1
LCOTHER - LCOTHER LCOTHER , LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) ( LCOTHER # LCOTHER ) is an LCOTHER LCOTHER LCOTHER caused by LCOTHER LCOTHER LCOTHER gene ( LCGeneOrGeneProduct ) mutations .	1
LCOTHER - LCOTHER LCOTHER , LCOTHER LCOTHER ( LCOTHER ) ( LCDiseaseOrPhenotypicFeature # LCDiseaseOrPhenotypicFeature ) is an LCOTHER LCOTHER LCOTHER caused by LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene ( LCOTHER ) mutations .	1
LCOTHER - LCOTHER LCOTHER , LCOTHER LCOTHER ( LCOTHER ) ( LCDiseaseOrPhenotypicFeature # LCDiseaseOrPhenotypicFeature ) is an LCOTHER LCOTHER LCOTHER caused by LCOTHER LCOTHER LCOTHER gene ( LCGeneOrGeneProduct ) mutations .	1
It was reported that there was a case of LCOTHER LCOTHER patient with LCDiseaseOrPhenotypicFeature who presented with LCOTHER ( LCOTHER LCOTHER LCOTHER ) while getting LCChemicalEntity infusion was reported .	3
On admission , laboratory examination showed LCOTHER LCOTHER ( + + + + ) , total LCOTHER 8 . 25 mg / dL , conjugated LCOTHER 4 . 36 mg / dL , unconjugated LCOTHER 3 . 89 mg / dL , LCOTHER 3 . 52 meq / L Patient was diagnosed as LCOTHER LCOTHER with LCDiseaseOrPhenotypicFeature and got LCChemicalEntity infusion in LCOTHER 5% 500 mg / 8 hour .	3
After 30 hours of LCChemicalEntity infusion the patient felt LCDiseaseOrPhenotypicFeature and electrocardiography ( ECG ) recording showed LCOTHER LCOTHER LCOTHER ( LCOTHER ) > 5 x / minute , trigemini , constant type - - LCOTHER LCOTHER , positive U wave .	2
After 30 hours of LCChemicalEntity infusion the patient felt LCOTHER and electrocardiography ( ECG ) recording showed LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) > 5 x / minute , trigemini , constant type - - LCOTHER LCOTHER , positive U wave .	2
After 30 hours of LCChemicalEntity infusion the patient felt LCOTHER and electrocardiography ( ECG ) recording showed LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) > 5 x / minute , trigemini , constant type - - LCOTHER LCOTHER , positive U wave .	2
After 30 hours of LCChemicalEntity infusion the patient felt LCOTHER and electrocardiography ( ECG ) recording showed LCOTHER LCOTHER LCOTHER ( LCOTHER ) > 5 x / minute , trigemini , constant type - - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , positive U wave .	2
LCChemicalEntity , like LCOTHER , is a LCOTHER LCOTHER that has anti - LCDiseaseOrPhenotypicFeature property , although it also pro - LCOTHER that can cause various LCOTHER , including severe LCOTHER such as multiple LCOTHER .	2
LCChemicalEntity , like LCOTHER , is a LCOTHER LCOTHER that has anti - LCOTHER property , although it also pro - LCDiseaseOrPhenotypicFeature that can cause various LCOTHER , including severe LCOTHER such as multiple LCOTHER .	2
LCChemicalEntity , like LCOTHER , is a LCOTHER LCOTHER that has anti - LCOTHER property , although it also pro - LCOTHER that can cause various LCDiseaseOrPhenotypicFeature , including severe LCOTHER such as multiple LCOTHER .	2
LCChemicalEntity , like LCOTHER , is a LCOTHER LCOTHER that has anti - LCOTHER property , although it also pro - LCOTHER that can cause various LCOTHER , including severe LCDiseaseOrPhenotypicFeature such as multiple LCOTHER .	2
LCChemicalEntity , like LCOTHER , is a LCOTHER LCOTHER that has anti - LCOTHER property , although it also pro - LCOTHER that can cause various LCOTHER , including severe LCOTHER such as multiple LCDiseaseOrPhenotypicFeature .	2
Administration of parenteral LCChemicalEntity must be done carefully and with good observation because of its pro - LCDiseaseOrPhenotypicFeature effect , especially in older patients who have LCOTHER LCOTHER or patients with LCOTHER LCOTHER ( LCOTHER ) which frequently occurs due to LCOTHER and or LCOTHER in LCOTHER cases . Low frequency of LCOTHER - associated LCOTHER variants in Kenya and Sudan and novel LCOTHER variants .	2
Administration of parenteral LCChemicalEntity must be done carefully and with good observation because of its pro - LCOTHER effect , especially in older patients who have LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature or patients with LCOTHER LCOTHER ( LCOTHER ) which frequently occurs due to LCOTHER and or LCOTHER in LCOTHER cases . Low frequency of LCOTHER - associated LCOTHER variants in Kenya and Sudan and novel LCOTHER variants .	2
CONTEXT : Generalized LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature syndrome is a rare familial or sporadic condition characterized by partial insensitivity to LCChemicalEntity , caused by mutations in the LCOTHER LCOTHER ( LCOTHER ) gene .	3
She also had LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER , whereas LCChemicalEntity effectively suppressed these clinical manifestations .	3
She also had LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , whereas LCChemicalEntity effectively suppressed these clinical manifestations .	3
CONCLUSIONS : LCChemicalEntity treatment is effective in controlling the LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature , LCOTHER , and LCOTHER in this child case , wherein LCOTHER LCOTHER plays a key role in the proper formation of the ligand - binding pocket and the AF - 2 surface of the LCOTHER LCOTHER LBD . Inactivation of LCOTHER / LCOTHER / LCOTHER LCOTHER LCOTHER LCOTHER triggers senescence and inhibits LCOTHER - induced immortalization .	3
CONCLUSIONS : LCChemicalEntity treatment is effective in controlling the LCOTHER LCOTHER , LCOTHER , LCOTHER , and LCDiseaseOrPhenotypicFeature in this child case , wherein LCOTHER LCOTHER plays a key role in the proper formation of the ligand - binding pocket and the AF - 2 surface of the LCOTHER LCOTHER LBD . Inactivation of LCOTHER / LCOTHER / LCOTHER LCOTHER LCOTHER LCOTHER triggers senescence and inhibits LCOTHER - induced immortalization .	3
CONCLUSIONS : LCOTHER treatment is effective in controlling the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER , LCOTHER , and LCOTHER in this child case , wherein LCSequenceVariant LCSequenceVariant plays a key role in the proper formation of the ligand - binding pocket and the AF - 2 surface of the LCOTHER LCOTHER LBD . Inactivation of LCOTHER / LCOTHER / LCOTHER LCOTHER LCOTHER LCOTHER triggers senescence and inhibits LCOTHER - induced immortalization .	1
CONCLUSIONS : LCOTHER treatment is effective in controlling the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER , LCOTHER , and LCOTHER in this child case , wherein LCOTHER LCOTHER plays a key role in the proper formation of the ligand - binding pocket and the AF - 2 surface of the LCGeneOrGeneProduct LCGeneOrGeneProduct LBD . Inactivation of LCOTHER / LCOTHER / LCOTHER LCOTHER LCOTHER LCOTHER triggers senescence and inhibits LCOTHER - induced immortalization .	1
Our recent study showed that LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCGeneOrGeneProduct and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCGeneOrGeneProduct , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCGeneOrGeneProduct to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	2
Our recent study showed that LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCGeneOrGeneProduct and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCDiseaseOrPhenotypicFeature suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER .	1
Our recent study showed that LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER .	1
Our recent study showed that LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct .	1
Our recent study showed that LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCGeneOrGeneProduct and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCGeneOrGeneProduct , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCGeneOrGeneProduct to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	2
Our recent study showed that LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCGeneOrGeneProduct and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCDiseaseOrPhenotypicFeature suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER .	1
Our recent study showed that LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct .	1
Our recent study showed that LCOTHER / LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct regulates apoptosis and vasculogenesis by promoting degradation of LCGeneOrGeneProduct and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCGeneOrGeneProduct , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCGeneOrGeneProduct to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	2
Our recent study showed that LCOTHER / LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCGeneOrGeneProduct and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCDiseaseOrPhenotypicFeature suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER .	1
Our recent study showed that LCOTHER / LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct .	1
Our recent study showed that LCOTHER / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCGeneOrGeneProduct to promote LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCGeneOrGeneProduct to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCDiseaseOrPhenotypicFeature suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Our recent study showed that LCOTHER / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCGeneOrGeneProduct and LCOTHER pathways via targeted degradation of LCDiseaseOrPhenotypicFeature suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	3
Here we investigated the role of LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER in cellular senescence and immortalization of LCOTHER embryonic fibroblasts ( MEFs ) and report that LCOTHER is required for proper cell proliferation and LCGeneOrGeneProduct ( LCOTHER ) - induced immortalization .	2
Here we investigated the role of LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER in cellular senescence and immortalization of LCOTHER embryonic fibroblasts ( MEFs ) and report that LCOTHER is required for proper cell proliferation and LCGeneOrGeneProduct ( LCOTHER ) - induced immortalization .	2
Here we investigated the role of LCOTHER / LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct in cellular senescence and immortalization of LCOTHER embryonic fibroblasts ( MEFs ) and report that LCOTHER is required for proper cell proliferation and LCGeneOrGeneProduct ( LCOTHER ) - induced immortalization .	2
Here we investigated the role of LCOTHER / LCOTHER LCOTHER LCOTHER in cellular senescence and immortalization of LCOTHER embryonic fibroblasts ( MEFs ) and report that LCGeneOrGeneProduct is required for proper cell proliferation and LCGeneOrGeneProduct ( LCOTHER ) - induced immortalization .	2
LCGeneOrGeneProduct inactivation by genetic deletion remarkably suppresses cell proliferation by inducing senescence , which is associated with accumulation of LCGeneOrGeneProduct , but not LCOTHER .	3
Mechanistically , LCGeneOrGeneProduct deletion caused accumulation of LCGeneOrGeneProduct - LCGeneOrGeneProduct , a substrate of LCOTHER - LCOTHER LCOTHER LCOTHER and a transcription factor that drives LCOTHER transcription .	1
Mechanistically , LCGeneOrGeneProduct deletion caused accumulation of LCOTHER - LCOTHER , a substrate of LCOTHER - LCOTHER LCOTHER LCOTHER and a transcription factor that drives LCGeneOrGeneProduct transcription .	3
Mechanistically , LCOTHER deletion caused accumulation of LCGeneOrGeneProduct - LCGeneOrGeneProduct , a substrate of LCOTHER - LCGeneOrGeneProduct LCOTHER LCOTHER and a transcription factor that drives LCOTHER transcription .	1
Mechanistically , LCOTHER deletion caused accumulation of LCGeneOrGeneProduct - LCGeneOrGeneProduct , a substrate of LCOTHER - LCOTHER LCOTHER LCOTHER and a transcription factor that drives LCGeneOrGeneProduct transcription .	1
Mechanistically , LCOTHER deletion caused accumulation of LCOTHER - LCOTHER , a substrate of LCGeneOrGeneProduct - LCOTHER LCOTHER LCOTHER and a transcription factor that drives LCGeneOrGeneProduct transcription .	3
Mechanistically , LCOTHER deletion caused accumulation of LCOTHER - LCOTHER , a substrate of LCOTHER - LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct and a transcription factor that drives LCGeneOrGeneProduct transcription .	3
Importantly , senescence triggered by LCGeneOrGeneProduct deletion can be largely rescued by simultaneous deletion of LCGeneOrGeneProduct , the LCOTHER encoding gene , indicating its causal role .	3
Importantly , senescence triggered by LCGeneOrGeneProduct deletion can be largely rescued by simultaneous deletion of LCOTHER , the LCGeneOrGeneProduct encoding gene , indicating its causal role .	3
Furthermore , LCOTHER ( LCOTHER ) - induced immortalization can also be abrogated by LCGeneOrGeneProduct deletion via senescence induction , which is again rescued by simultaneous deletion of LCGeneOrGeneProduct .	3
Finally , we found that LCGeneOrGeneProduct deletion inactivates LCGeneOrGeneProduct ( LCOTHER ) activity and block the LCOTHER signaling pathway , together with accumulated LCOTHER , to induce senescence .	2
Finally , we found that LCGeneOrGeneProduct deletion inactivates LCOTHER ( LCOTHER ) activity and block the LCGeneOrGeneProduct signaling pathway , together with accumulated LCOTHER , to induce senescence .	2
Finally , we found that LCGeneOrGeneProduct deletion inactivates LCOTHER ( LCOTHER ) activity and block the LCOTHER signaling pathway , together with accumulated LCGeneOrGeneProduct , to induce senescence .	3
Taken together , our results demonstrated that LCGeneOrGeneProduct is a LCGeneOrGeneProduct ( LCOTHER ) - cooperating oncogene required for LCOTHER ( LCOTHER ) - induced immortalization and transformation , and targeting LCOTHER - LCOTHER LCOTHER LCOTHER may , therefore , have therapeutic value for senescence - based LCOTHER treatment . In vivo evidences suggesting the role of oxidative stress in pathogenesis of LCOTHER - induced LCOTHER : protection by LCOTHER .	2
Taken together , our results demonstrated that LCGeneOrGeneProduct is a LCOTHER ( LCOTHER ) - cooperating oncogene required for LCGeneOrGeneProduct ( LCOTHER ) - induced immortalization and transformation , and targeting LCOTHER - LCOTHER LCOTHER LCOTHER may , therefore , have therapeutic value for senescence - based LCOTHER treatment . In vivo evidences suggesting the role of oxidative stress in pathogenesis of LCOTHER - induced LCOTHER : protection by LCOTHER .	2
Taken together , our results demonstrated that LCGeneOrGeneProduct is a LCOTHER ( LCOTHER ) - cooperating oncogene required for LCOTHER ( LCOTHER ) - induced immortalization and transformation , and targeting LCOTHER - LCOTHER LCOTHER LCOTHER may , therefore , have therapeutic value for senescence - based LCDiseaseOrPhenotypicFeature treatment . In vivo evidences suggesting the role of oxidative stress in pathogenesis of LCOTHER - induced LCOTHER : protection by LCOTHER .	1
Taken together , our results demonstrated that LCOTHER is a LCGeneOrGeneProduct ( LCOTHER ) - cooperating oncogene required for LCOTHER ( LCOTHER ) - induced immortalization and transformation , and targeting LCOTHER - LCOTHER LCOTHER LCOTHER may , therefore , have therapeutic value for senescence - based LCDiseaseOrPhenotypicFeature treatment . In vivo evidences suggesting the role of oxidative stress in pathogenesis of LCOTHER - induced LCOTHER : protection by LCOTHER .	1
Taken together , our results demonstrated that LCOTHER is a LCOTHER ( LCSequenceVariant ) - cooperating oncogene required for LCOTHER ( LCOTHER ) - induced immortalization and transformation , and targeting LCOTHER - LCOTHER LCOTHER LCOTHER may , therefore , have therapeutic value for senescence - based LCDiseaseOrPhenotypicFeature treatment . In vivo evidences suggesting the role of oxidative stress in pathogenesis of LCOTHER - induced LCOTHER : protection by LCOTHER .	1
Taken together , our results demonstrated that LCOTHER is a LCOTHER ( LCOTHER ) - cooperating oncogene required for LCGeneOrGeneProduct ( LCOTHER ) - induced immortalization and transformation , and targeting LCOTHER - LCOTHER LCOTHER LCOTHER may , therefore , have therapeutic value for senescence - based LCDiseaseOrPhenotypicFeature treatment . In vivo evidences suggesting the role of oxidative stress in pathogenesis of LCOTHER - induced LCOTHER : protection by LCOTHER .	1
Taken together , our results demonstrated that LCOTHER is a LCOTHER ( LCOTHER ) - cooperating oncogene required for LCOTHER ( LCSequenceVariant ) - induced immortalization and transformation , and targeting LCOTHER - LCOTHER LCOTHER LCOTHER may , therefore , have therapeutic value for senescence - based LCDiseaseOrPhenotypicFeature treatment . In vivo evidences suggesting the role of oxidative stress in pathogenesis of LCOTHER - induced LCOTHER : protection by LCOTHER .	1
Taken together , our results demonstrated that LCOTHER is a LCOTHER ( LCOTHER ) - cooperating oncogene required for LCOTHER ( LCOTHER ) - induced immortalization and transformation , and targeting LCGeneOrGeneProduct - LCOTHER LCOTHER LCOTHER may , therefore , have therapeutic value for senescence - based LCDiseaseOrPhenotypicFeature treatment . In vivo evidences suggesting the role of oxidative stress in pathogenesis of LCOTHER - induced LCOTHER : protection by LCOTHER .	1
Taken together , our results demonstrated that LCOTHER is a LCOTHER ( LCOTHER ) - cooperating oncogene required for LCOTHER ( LCOTHER ) - induced immortalization and transformation , and targeting LCOTHER - LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct may , therefore , have therapeutic value for senescence - based LCDiseaseOrPhenotypicFeature treatment . In vivo evidences suggesting the role of oxidative stress in pathogenesis of LCOTHER - induced LCOTHER : protection by LCOTHER .	1
The aims of this study were to examine LCChemicalEntity ( LCOTHER ) - induced oxidative stress that promotes production of LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCOTHER ) and to investigate the role of LCOTHER , an expectorant agent , which has also LCOTHER properties , on kidney tissue against the possible LCOTHER - induced LCOTHER LCOTHER in LCOTHER .	1
The aims of this study were to examine LCChemicalEntity ( LCOTHER ) - induced oxidative stress that promotes production of LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) and to investigate the role of LCOTHER , an expectorant agent , which has also LCOTHER properties , on kidney tissue against the possible LCOTHER - induced LCOTHER LCOTHER in LCOTHER .	1
The aims of this study were to examine LCChemicalEntity ( LCOTHER ) - induced oxidative stress that promotes production of LCOTHER LCOTHER LCOTHER ( LCOTHER ) and to investigate the role of LCChemicalEntity , an expectorant agent , which has also LCOTHER properties , on kidney tissue against the possible LCOTHER - induced LCOTHER LCOTHER in LCOTHER .	3
The aims of this study were to examine LCChemicalEntity ( LCOTHER ) - induced oxidative stress that promotes production of LCOTHER LCOTHER LCOTHER ( LCOTHER ) and to investigate the role of LCOTHER , an expectorant agent , which has also LCOTHER properties , on kidney tissue against the possible LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER .	2
The aims of this study were to examine LCOTHER ( LCChemicalEntity ) - induced oxidative stress that promotes production of LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCOTHER ) and to investigate the role of LCOTHER , an expectorant agent , which has also LCOTHER properties , on kidney tissue against the possible LCOTHER - induced LCOTHER LCOTHER in LCOTHER .	1
The aims of this study were to examine LCOTHER ( LCChemicalEntity ) - induced oxidative stress that promotes production of LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) and to investigate the role of LCOTHER , an expectorant agent , which has also LCOTHER properties , on kidney tissue against the possible LCOTHER - induced LCOTHER LCOTHER in LCOTHER .	1
The aims of this study were to examine LCOTHER ( LCChemicalEntity ) - induced oxidative stress that promotes production of LCOTHER LCOTHER LCOTHER ( LCOTHER ) and to investigate the role of LCChemicalEntity , an expectorant agent , which has also LCOTHER properties , on kidney tissue against the possible LCOTHER - induced LCOTHER LCOTHER in LCOTHER .	3
The aims of this study were to examine LCOTHER ( LCChemicalEntity ) - induced oxidative stress that promotes production of LCOTHER LCOTHER LCOTHER ( LCOTHER ) and to investigate the role of LCOTHER , an expectorant agent , which has also LCOTHER properties , on kidney tissue against the possible LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER .	2
The aims of this study were to examine LCOTHER ( LCOTHER ) - induced oxidative stress that promotes production of LCOTHER LCOTHER LCOTHER ( LCOTHER ) and to investigate the role of LCChemicalEntity , an expectorant agent , which has also LCOTHER properties , on kidney tissue against the possible LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER .	3
The aims of this study were to examine LCOTHER ( LCOTHER ) - induced oxidative stress that promotes production of LCOTHER LCOTHER LCOTHER ( LCOTHER ) and to investigate the role of LCOTHER , an expectorant agent , which has also LCOTHER properties , on kidney tissue against the possible LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER .	2
LCOTHER were divided into three groups : sham , LCChemicalEntity and LCOTHER plus LCChemicalEntity .	3
LCOTHER were divided into three groups : sham , LCOTHER and LCChemicalEntity plus LCChemicalEntity .	3
LCChemicalEntity administration to control LCOTHER significantly increased renal LCChemicalEntity ( LCOTHER ) and urinary LCOTHER - LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCOTHER , a marker of LCOTHER LCOTHER LCOTHER ) excretion but decreased LCOTHER LCOTHER ( LCOTHER ) and LCOTHER ( LCOTHER ) activities .	2
LCChemicalEntity administration to control LCOTHER significantly increased renal LCOTHER ( LCChemicalEntity ) and urinary LCOTHER - LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCOTHER , a marker of LCOTHER LCOTHER LCOTHER ) excretion but decreased LCOTHER LCOTHER ( LCOTHER ) and LCOTHER ( LCOTHER ) activities .	2
LCChemicalEntity administration to control LCOTHER significantly increased renal LCOTHER ( LCOTHER ) and urinary LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER , a marker of LCOTHER LCOTHER LCOTHER ) excretion but decreased LCOTHER LCOTHER ( LCOTHER ) and LCOTHER ( LCOTHER ) activities .	2
LCChemicalEntity administration to control LCOTHER significantly increased renal LCOTHER ( LCOTHER ) and urinary LCOTHER - LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCGeneOrGeneProduct , a marker of LCOTHER LCOTHER LCOTHER ) excretion but decreased LCOTHER LCOTHER ( LCOTHER ) and LCOTHER ( LCOTHER ) activities .	2
LCChemicalEntity administration to control LCOTHER significantly increased renal LCOTHER ( LCOTHER ) and urinary LCOTHER - LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCOTHER , a marker of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) excretion but decreased LCOTHER LCOTHER ( LCOTHER ) and LCOTHER ( LCOTHER ) activities .	2
LCChemicalEntity administration to control LCOTHER significantly increased renal LCOTHER ( LCOTHER ) and urinary LCOTHER - LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCOTHER , a marker of LCOTHER LCOTHER LCOTHER ) excretion but decreased LCChemicalEntity LCChemicalEntity ( LCOTHER ) and LCOTHER ( LCOTHER ) activities .	3
LCChemicalEntity administration to control LCOTHER significantly increased renal LCOTHER ( LCOTHER ) and urinary LCOTHER - LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCOTHER , a marker of LCOTHER LCOTHER LCOTHER ) excretion but decreased LCOTHER LCOTHER ( LCChemicalEntity ) and LCOTHER ( LCOTHER ) activities .	3
LCOTHER administration to control LCOTHER significantly increased renal LCOTHER ( LCOTHER ) and urinary LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER , a marker of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) excretion but decreased LCOTHER LCOTHER ( LCOTHER ) and LCOTHER ( LCOTHER ) activities .	1
LCOTHER administration to control LCOTHER significantly increased renal LCOTHER ( LCOTHER ) and urinary LCOTHER - LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCGeneOrGeneProduct , a marker of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) excretion but decreased LCOTHER LCOTHER ( LCOTHER ) and LCOTHER ( LCOTHER ) activities .	1
LCChemicalEntity administration with LCOTHER injections caused significantly decreased renal LCChemicalEntity and urinary LCOTHER excretion , and increased LCOTHER activity , but not LCOTHER activity in renal tissue when compared with LCOTHER alone .	3
LCChemicalEntity administration with LCOTHER injections caused significantly decreased renal LCOTHER and urinary LCGeneOrGeneProduct excretion , and increased LCOTHER activity , but not LCOTHER activity in renal tissue when compared with LCOTHER alone .	3
LCOTHER administration with LCChemicalEntity injections caused significantly decreased renal LCChemicalEntity and urinary LCOTHER excretion , and increased LCOTHER activity , but not LCOTHER activity in renal tissue when compared with LCOTHER alone .	2
LCOTHER administration with LCChemicalEntity injections caused significantly decreased renal LCOTHER and urinary LCGeneOrGeneProduct excretion , and increased LCOTHER activity , but not LCOTHER activity in renal tissue when compared with LCOTHER alone .	2
LCOTHER administration with LCChemicalEntity injections caused significantly decreased renal LCOTHER and urinary LCOTHER excretion , and increased LCChemicalEntity activity , but not LCOTHER activity in renal tissue when compared with LCOTHER alone .	3
LCOTHER administration with LCOTHER injections caused significantly decreased renal LCOTHER and urinary LCOTHER excretion , and increased LCOTHER activity , but not LCGeneOrGeneProduct activity in renal tissue when compared with LCChemicalEntity alone .	3
LCChemicalEntity showed histopathological protection against LCOTHER - induced LCDiseaseOrPhenotypicFeature .	3
LCOTHER showed histopathological protection against LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature .	2
There were a significant dilatation of tubular lumens , extensive epithelial cell vacuolization , LCOTHER , LCOTHER , and LCOTHER in LCChemicalEntity - treated LCOTHER more than those of the control and the LCChemicalEntity groups .	3
It is concluded that oxidative tubular damage plays an important role in the LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature and the modulation of oxidative stress with LCOTHER reduces the LCOTHER - induced LCOTHER LCOTHER both at the biochemical and histological levels . LCOTHER LCOTHER LCOTHER - LCOTHER interacts with LCOTHER and LCOTHER to modulate LCOTHER secretion in LCOTHER gonadotrophs .	2
It is concluded that oxidative tubular damage plays an important role in the LCChemicalEntity - induced LCOTHER and the modulation of oxidative stress with LCChemicalEntity reduces the LCOTHER - induced LCOTHER LCOTHER both at the biochemical and histological levels . LCOTHER LCOTHER LCOTHER - LCOTHER interacts with LCOTHER and LCOTHER to modulate LCOTHER secretion in LCOTHER gonadotrophs .	3
It is concluded that oxidative tubular damage plays an important role in the LCChemicalEntity - induced LCOTHER and the modulation of oxidative stress with LCOTHER reduces the LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature both at the biochemical and histological levels . LCOTHER LCOTHER LCOTHER - LCOTHER interacts with LCOTHER and LCOTHER to modulate LCOTHER secretion in LCOTHER gonadotrophs .	2
It is concluded that oxidative tubular damage plays an important role in the LCOTHER - induced LCOTHER and the modulation of oxidative stress with LCChemicalEntity reduces the LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature both at the biochemical and histological levels . LCOTHER LCOTHER LCOTHER - LCOTHER interacts with LCOTHER and LCOTHER to modulate LCOTHER secretion in LCOTHER gonadotrophs .	3
It is concluded that oxidative tubular damage plays an important role in the LCOTHER - induced LCOTHER and the modulation of oxidative stress with LCOTHER reduces the LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature both at the biochemical and histological levels . LCOTHER LCOTHER LCOTHER - LCOTHER interacts with LCOTHER and LCOTHER to modulate LCOTHER secretion in LCOTHER gonadotrophs .	2
We have shown previously that , in LCOTHER primary pituitary cells , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct inhibits LCGeneOrGeneProduct mRNA expression and LCOTHER release .	3
In contrast , in LCOTHER LCOTHER gonadotrophs , others have shown a stimulatory effect of LCGeneOrGeneProduct on basal or LCGeneOrGeneProduct - stimulated LCOTHER promoter - driven transcription .	2
In contrast , in LCOTHER LCOTHER gonadotrophs , others have shown a stimulatory effect of LCGeneOrGeneProduct on basal or LCOTHER - stimulated LCGeneOrGeneProduct promoter - driven transcription .	1
In contrast , in LCOTHER LCOTHER gonadotrophs , others have shown a stimulatory effect of LCOTHER on basal or LCGeneOrGeneProduct - stimulated LCGeneOrGeneProduct promoter - driven transcription .	2
As a species comparison with our previous results , we used LCOTHER cells to investigate the effects of LCGeneOrGeneProduct - LCGeneOrGeneProduct on LCOTHER mRNA and secretion modulated by LCGeneOrGeneProduct and LCOTHER .	2
As a species comparison with our previous results , we used LCOTHER cells to investigate the effects of LCGeneOrGeneProduct - LCGeneOrGeneProduct on LCOTHER mRNA and secretion modulated by LCOTHER and LCGeneOrGeneProduct .	2
As a species comparison with our previous results , we used LCOTHER cells to investigate the effects of LCOTHER - LCOTHER on LCOTHER mRNA and secretion modulated by LCGeneOrGeneProduct and LCGeneOrGeneProduct .	1
LCGeneOrGeneProduct - LCGeneOrGeneProduct alone had no effect on LCOTHER production , but enhanced the LCGeneOrGeneProduct + LCOTHER - induced stimulation of LCOTHER mRNA and LCOTHER secretion , without any effect on LCOTHER mRNA .	2
LCGeneOrGeneProduct - LCGeneOrGeneProduct alone had no effect on LCOTHER production , but enhanced the LCOTHER + LCGeneOrGeneProduct - induced stimulation of LCOTHER mRNA and LCOTHER secretion , without any effect on LCOTHER mRNA .	2
LCGeneOrGeneProduct - LCGeneOrGeneProduct alone had no effect on LCOTHER production , but enhanced the LCOTHER + LCOTHER - induced stimulation of LCGeneOrGeneProduct mRNA and LCOTHER secretion , without any effect on LCOTHER mRNA .	1
LCOTHER - LCOTHER alone had no effect on LCOTHER production , but enhanced the LCGeneOrGeneProduct + LCGeneOrGeneProduct - induced stimulation of LCOTHER mRNA and LCOTHER secretion , without any effect on LCOTHER mRNA .	1
LCOTHER - LCOTHER alone had no effect on LCOTHER production , but enhanced the LCGeneOrGeneProduct + LCOTHER - induced stimulation of LCGeneOrGeneProduct mRNA and LCOTHER secretion , without any effect on LCOTHER mRNA .	2
LCOTHER - LCOTHER alone had no effect on LCOTHER production , but enhanced the LCOTHER + LCGeneOrGeneProduct - induced stimulation of LCGeneOrGeneProduct mRNA and LCOTHER secretion , without any effect on LCOTHER mRNA .	2
LCGeneOrGeneProduct - LCGeneOrGeneProduct reduced LCGeneOrGeneProduct mRNA up - regulation in response to LCOTHER ( + / - LCOTHER ) and decreased LCOTHER LCOTHER expression , which would favour LCOTHER , rather than LCOTHER , synthesis and secretion .	3
LCGeneOrGeneProduct - LCGeneOrGeneProduct reduced LCOTHER mRNA up - regulation in response to LCGeneOrGeneProduct ( + / - LCOTHER ) and decreased LCOTHER LCOTHER expression , which would favour LCOTHER , rather than LCOTHER , synthesis and secretion .	2
LCGeneOrGeneProduct - LCGeneOrGeneProduct reduced LCOTHER mRNA up - regulation in response to LCOTHER ( + / - LCGeneOrGeneProduct ) and decreased LCOTHER LCOTHER expression , which would favour LCOTHER , rather than LCOTHER , synthesis and secretion .	2
LCGeneOrGeneProduct - LCGeneOrGeneProduct reduced LCOTHER mRNA up - regulation in response to LCOTHER ( + / - LCOTHER ) and decreased LCGeneOrGeneProduct LCGeneOrGeneProduct expression , which would favour LCOTHER , rather than LCOTHER , synthesis and secretion .	3
LCOTHER - LCOTHER reduced LCGeneOrGeneProduct mRNA up - regulation in response to LCGeneOrGeneProduct ( + / - LCOTHER ) and decreased LCOTHER LCOTHER expression , which would favour LCOTHER , rather than LCOTHER , synthesis and secretion .	2
LCOTHER / LCOTHER phosphorylation induced by LCGeneOrGeneProduct - LCGeneOrGeneProduct , indicating activation of LCOTHER signalling , was the same whether LCOTHER - LCOTHER was used alone or combined with LCGeneOrGeneProduct + / - LCOTHER .	2
LCOTHER / LCOTHER phosphorylation induced by LCGeneOrGeneProduct - LCGeneOrGeneProduct , indicating activation of LCOTHER signalling , was the same whether LCOTHER - LCOTHER was used alone or combined with LCOTHER + / - LCGeneOrGeneProduct .	2
LCOTHER / LCOTHER phosphorylation induced by LCOTHER - LCOTHER , indicating activation of LCOTHER signalling , was the same whether LCGeneOrGeneProduct - LCGeneOrGeneProduct was used alone or combined with LCGeneOrGeneProduct + / - LCOTHER .	2
LCOTHER / LCOTHER phosphorylation induced by LCOTHER - LCOTHER , indicating activation of LCOTHER signalling , was the same whether LCGeneOrGeneProduct - LCGeneOrGeneProduct was used alone or combined with LCOTHER + / - LCGeneOrGeneProduct .	2
LCOTHER / LCOTHER phosphorylation induced by LCOTHER - LCOTHER , indicating activation of LCOTHER signalling , was the same whether LCOTHER - LCOTHER was used alone or combined with LCGeneOrGeneProduct + / - LCGeneOrGeneProduct .	1
We hypothesized that LCGeneOrGeneProduct and / or LCGeneOrGeneProduct pathways may be modulated by LCOTHER - LCOTHER , but neither the LCOTHER - stimulated phosphorylation of LCOTHER / LCOTHER nor the LCOTHER - induced LCOTHER / LCOTHER or LCOTHER LCOTHER LCOTHER - LCOTHER phosphorylation were modified .	1
We hypothesized that LCGeneOrGeneProduct and / or LCOTHER pathways may be modulated by LCOTHER - LCOTHER , but neither the LCOTHER - stimulated phosphorylation of LCOTHER / LCOTHER nor the LCGeneOrGeneProduct - induced LCOTHER / LCOTHER or LCOTHER LCOTHER LCOTHER - LCOTHER phosphorylation were modified .	1
We hypothesized that LCOTHER and / or LCGeneOrGeneProduct pathways may be modulated by LCOTHER - LCOTHER , but neither the LCOTHER - stimulated phosphorylation of LCOTHER / LCOTHER nor the LCOTHER - induced LCOTHER / LCOTHER or LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct phosphorylation were modified .	1
We hypothesized that LCOTHER and / or LCOTHER pathways may be modulated by LCGeneOrGeneProduct - LCGeneOrGeneProduct , but neither the LCGeneOrGeneProduct - stimulated phosphorylation of LCOTHER / LCOTHER nor the LCOTHER - induced LCOTHER / LCOTHER or LCOTHER LCOTHER LCOTHER - LCOTHER phosphorylation were modified .	2
We hypothesized that LCOTHER and / or LCOTHER pathways may be modulated by LCGeneOrGeneProduct - LCGeneOrGeneProduct , but neither the LCOTHER - stimulated phosphorylation of LCOTHER / LCOTHER nor the LCGeneOrGeneProduct - induced LCOTHER / LCOTHER or LCOTHER LCOTHER LCOTHER - LCOTHER phosphorylation were modified .	2
We hypothesized that LCOTHER and / or LCOTHER pathways may be modulated by LCOTHER - LCOTHER , but neither the LCGeneOrGeneProduct - stimulated phosphorylation of LCOTHER / LCOTHER nor the LCGeneOrGeneProduct - induced LCOTHER / LCOTHER or LCOTHER LCOTHER LCOTHER - LCOTHER phosphorylation were modified .	1
We hypothesized that LCOTHER and / or LCOTHER pathways may be modulated by LCOTHER - LCOTHER , but neither the LCOTHER - stimulated phosphorylation of LCOTHER / LCOTHER nor the LCGeneOrGeneProduct - induced LCOTHER / LCOTHER or LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct phosphorylation were modified .	1
However , the LCGeneOrGeneProduct - induced activation of LCGeneOrGeneProduct LCGeneOrGeneProduct was decreased by LCOTHER - LCOTHER .	2
However , the LCOTHER - induced activation of LCGeneOrGeneProduct LCGeneOrGeneProduct was decreased by LCGeneOrGeneProduct - LCGeneOrGeneProduct .	3
LCGeneOrGeneProduct as important modulators of LCGeneOrGeneProduct and / or LCOTHER - stimulated LCOTHER synthesis and release and 2 .	2
LCGeneOrGeneProduct as important modulators of LCOTHER and / or LCGeneOrGeneProduct - stimulated LCOTHER synthesis and release and 2 .	2
LCOTHER as important modulators of LCGeneOrGeneProduct and / or LCGeneOrGeneProduct - stimulated LCOTHER synthesis and release and 2 .	1
We investigated whether single nucleotide polymorphisms ( SNPs ) of LCGeneOrGeneProduct , encoding LCOTHER , influenced the conversion from LCOTHER LCOTHER LCOTHER ( LCOTHER ) to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in subjects of the STOP - NIDDM trial .	1
We investigated whether single nucleotide polymorphisms ( SNPs ) of LCOTHER , encoding LCGeneOrGeneProduct , influenced the conversion from LCOTHER LCOTHER LCOTHER ( LCOTHER ) to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in subjects of the STOP - NIDDM trial .	1
This trial aimed at evaluating the effect of LCChemicalEntity compared to placebo in the prevention of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
Female carriers of the less frequent C allele of LCSequenceVariant had a 1 . 7 - fold elevated risk [ 95% confidence interval ( CI ) 1 . 09 - 2 . 66 ; P = 0 . 020 ] for the conversion to LCDiseaseOrPhenotypicFeature compared to LCOTHER with the common genotype after the adjustment for age , treatment group ( placebo or LCOTHER ) , smoking , weight at baseline , and weight change .	2
Haplotype analysis based on three SNPs ( LCSequenceVariant , LCSequenceVariant , and LCOTHER ) representing the linkage disequilibrium blocks in our study population indicated that the conversion to LCOTHER LCOTHER LCOTHER LCOTHER was dependent on the number of risk alleles in different haplotypes in LCOTHER .	1
Haplotype analysis based on three SNPs ( LCSequenceVariant , LCOTHER , and LCSequenceVariant ) representing the linkage disequilibrium blocks in our study population indicated that the conversion to LCOTHER LCOTHER LCOTHER LCOTHER was dependent on the number of risk alleles in different haplotypes in LCOTHER .	1
Haplotype analysis based on three SNPs ( LCOTHER , LCSequenceVariant , and LCSequenceVariant ) representing the linkage disequilibrium blocks in our study population indicated that the conversion to LCOTHER LCOTHER LCOTHER LCOTHER was dependent on the number of risk alleles in different haplotypes in LCOTHER .	1
Our results suggest that SNPs of LCGeneOrGeneProduct and their haplotypes predispose to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in female subjects of the STOP - NIDDM study population . Identification of three LCOTHER gene mutations associated with LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in two Chinese pedigrees .	1
Three LCGeneOrGeneProduct gene mutations , LCOTHER - LCOTHER > LCOTHER , LCOTHER - LCOTHER LCOTHER and LCOTHER , have been identified in two Chinese pedigree with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , respectively . Gene therapy for LCOTHER LCOTHER airway disease - is clinical success imminent? LCOTHER LCOTHER ( LCOTHER ) was one of the first LCOTHER LCOTHER for which gene therapy was seriously considered as a realistic option for treatment , and as such , it has long provided a paradigm for gene therapy of LCOTHER LCOTHER .	1
Three LCOTHER gene mutations , LCSequenceVariant - LCSequenceVariant > LCSequenceVariant , LCOTHER - LCOTHER LCOTHER and LCOTHER , have been identified in two Chinese pedigree with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , respectively . Gene therapy for LCOTHER LCOTHER airway disease - is clinical success imminent? LCOTHER LCOTHER ( LCOTHER ) was one of the first LCOTHER LCOTHER for which gene therapy was seriously considered as a realistic option for treatment , and as such , it has long provided a paradigm for gene therapy of LCOTHER LCOTHER .	1
Three LCOTHER gene mutations , LCOTHER - LCOTHER > LCOTHER , LCSequenceVariant - LCSequenceVariant LCSequenceVariant and LCOTHER , have been identified in two Chinese pedigree with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , respectively . Gene therapy for LCOTHER LCOTHER airway disease - is clinical success imminent? LCOTHER LCOTHER ( LCOTHER ) was one of the first LCOTHER LCOTHER for which gene therapy was seriously considered as a realistic option for treatment , and as such , it has long provided a paradigm for gene therapy of LCOTHER LCOTHER .	1
Three LCOTHER gene mutations , LCOTHER - LCOTHER > LCOTHER , LCOTHER - LCOTHER LCOTHER and LCSequenceVariant , have been identified in two Chinese pedigree with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , respectively . Gene therapy for LCOTHER LCOTHER airway disease - is clinical success imminent? LCOTHER LCOTHER ( LCOTHER ) was one of the first LCOTHER LCOTHER for which gene therapy was seriously considered as a realistic option for treatment , and as such , it has long provided a paradigm for gene therapy of LCOTHER LCOTHER .	1
However , despite the cloning of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene in 1989 , over 15 years later a practical gene therapy for LCDiseaseOrPhenotypicFeature has not eventuated .	1
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature can be effectively treated by atypical LCChemicalEntity such as LCOTHER , LCOTHER and LCOTHER .	3
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature can be effectively treated by atypical LCOTHER such as LCChemicalEntity , LCOTHER and LCOTHER .	3
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature can be effectively treated by atypical LCOTHER such as LCOTHER , LCChemicalEntity and LCOTHER .	3
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature can be effectively treated by atypical LCOTHER such as LCOTHER , LCOTHER and LCChemicalEntity .	3
We present a 15 - year - old girl LCOTHER who developed frequent LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature after 5 months of LCChemicalEntity treatment ( 1000 mg per day ) .	2
LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is a ligand of the LCGeneOrGeneProduct pathway family which has been widely studied in the context of LCOTHER angiogenesis , its blockade shown to result in non - productive angiogenesis and halted LCOTHER growth .	1
LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is a ligand of the LCOTHER pathway family which has been widely studied in the context of LCDiseaseOrPhenotypicFeature angiogenesis , its blockade shown to result in non - productive angiogenesis and halted LCOTHER growth .	1
LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is a ligand of the LCOTHER pathway family which has been widely studied in the context of LCOTHER angiogenesis , its blockade shown to result in non - productive angiogenesis and halted LCDiseaseOrPhenotypicFeature growth .	1
LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is a ligand of the LCGeneOrGeneProduct pathway family which has been widely studied in the context of LCOTHER angiogenesis , its blockade shown to result in non - productive angiogenesis and halted LCOTHER growth .	1
LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is a ligand of the LCOTHER pathway family which has been widely studied in the context of LCDiseaseOrPhenotypicFeature angiogenesis , its blockade shown to result in non - productive angiogenesis and halted LCOTHER growth .	1
LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is a ligand of the LCOTHER pathway family which has been widely studied in the context of LCOTHER angiogenesis , its blockade shown to result in non - productive angiogenesis and halted LCDiseaseOrPhenotypicFeature growth .	1
As LCGeneOrGeneProduct inhibitors enter the clinic , there is an emerging need to understand their side effects , namely the systemic consequences of LCOTHER : LCGeneOrGeneProduct blockade in tissues other than LCOTHER .	1
As LCGeneOrGeneProduct inhibitors enter the clinic , there is an emerging need to understand their side effects , namely the systemic consequences of LCOTHER : LCOTHER blockade in tissues other than LCDiseaseOrPhenotypicFeature .	1
As LCOTHER inhibitors enter the clinic , there is an emerging need to understand their side effects , namely the systemic consequences of LCGeneOrGeneProduct : LCGeneOrGeneProduct blockade in tissues other than LCOTHER .	1
As LCOTHER inhibitors enter the clinic , there is an emerging need to understand their side effects , namely the systemic consequences of LCGeneOrGeneProduct : LCOTHER blockade in tissues other than LCDiseaseOrPhenotypicFeature .	1
Here we show that LCGeneOrGeneProduct blockade with monoclonal antibodies perturbs the BM vascular niche of sub - lethally irradiated LCOTHER , resulting in increased LCGeneOrGeneProduct ( + ) , LCOTHER - LCOTHER ( + ) and LCOTHER - LCOTHER ( + ) vessel density , and also increased megakaryocytes , whereas LCOTHER ( + ) , LCOTHER ( + ) , LCOTHER ( + ) and LCOTHER ( + ) vessel density remained unaltered .	1
Here we show that LCGeneOrGeneProduct blockade with monoclonal antibodies perturbs the BM vascular niche of sub - lethally irradiated LCOTHER , resulting in increased LCOTHER ( + ) , LCGeneOrGeneProduct - LCGeneOrGeneProduct ( + ) and LCOTHER - LCOTHER ( + ) vessel density , and also increased megakaryocytes , whereas LCOTHER ( + ) , LCOTHER ( + ) , LCOTHER ( + ) and LCOTHER ( + ) vessel density remained unaltered .	1
Here we show that LCGeneOrGeneProduct blockade with monoclonal antibodies perturbs the BM vascular niche of sub - lethally irradiated LCOTHER , resulting in increased LCOTHER ( + ) , LCOTHER - LCOTHER ( + ) and LCGeneOrGeneProduct - LCGeneOrGeneProduct ( + ) vessel density , and also increased megakaryocytes , whereas LCOTHER ( + ) , LCOTHER ( + ) , LCOTHER ( + ) and LCOTHER ( + ) vessel density remained unaltered .	1
We investigated also the expression of angiocrine genes upon LCGeneOrGeneProduct treatment in vivo , and demonstrate that LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER are upregulated , while LCOTHER and LCOTHER are reduced .	2
We investigated also the expression of angiocrine genes upon LCGeneOrGeneProduct treatment in vivo , and demonstrate that LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER are upregulated , while LCOTHER and LCOTHER are reduced .	2
We investigated also the expression of angiocrine genes upon LCGeneOrGeneProduct treatment in vivo , and demonstrate that LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER - LCOTHER are upregulated , while LCOTHER and LCOTHER are reduced .	2
We investigated also the expression of angiocrine genes upon LCGeneOrGeneProduct treatment in vivo , and demonstrate that LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER - LCOTHER are upregulated , while LCOTHER and LCOTHER are reduced .	2
We investigated also the expression of angiocrine genes upon LCGeneOrGeneProduct treatment in vivo , and demonstrate that LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct are upregulated , while LCOTHER and LCOTHER are reduced .	2
We investigated also the expression of angiocrine genes upon LCGeneOrGeneProduct treatment in vivo , and demonstrate that LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER are upregulated , while LCGeneOrGeneProduct and LCOTHER are reduced .	2
We investigated also the expression of angiocrine genes upon LCGeneOrGeneProduct treatment in vivo , and demonstrate that LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER are upregulated , while LCOTHER and LCGeneOrGeneProduct are reduced .	2
We investigated also the expression of angiocrine genes upon LCOTHER treatment in vivo , and demonstrate that LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct and LCOTHER - LCOTHER are upregulated , while LCOTHER and LCOTHER are reduced .	2
We investigated also the expression of angiocrine genes upon LCOTHER treatment in vivo , and demonstrate that LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct are upregulated , while LCOTHER and LCOTHER are reduced .	2
We investigated also the expression of angiocrine genes upon LCOTHER treatment in vivo , and demonstrate that LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER - LCOTHER are upregulated , while LCGeneOrGeneProduct and LCOTHER are reduced .	2
We investigated also the expression of angiocrine genes upon LCOTHER treatment in vivo , and demonstrate that LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER - LCOTHER are upregulated , while LCOTHER and LCGeneOrGeneProduct are reduced .	2
In vitro treatment of endothelial cells with anti - LCGeneOrGeneProduct reduced LCGeneOrGeneProduct phosphorylation while maintaining similar levels of LCOTHER LCOTHER / LCOTHER phosphorylation .	1
Besides its effects in the BM vascular niche , anti - LCGeneOrGeneProduct treatment perturbed hematopoiesis , as evidenced by increased myeloid ( LCGeneOrGeneProduct ( + ) ) , decreased B ( LCOTHER ( + ) ) and T ( LCOTHER ( + ) ) lymphoid BM content of treated LCOTHER , with a corresponding increase in myeloid circulating cells .	3
Besides its effects in the BM vascular niche , anti - LCGeneOrGeneProduct treatment perturbed hematopoiesis , as evidenced by increased myeloid ( LCOTHER ( + ) ) , decreased B ( LCGeneOrGeneProduct ( + ) ) and T ( LCOTHER ( + ) ) lymphoid BM content of treated LCOTHER , with a corresponding increase in myeloid circulating cells .	2
Besides its effects in the BM vascular niche , anti - LCGeneOrGeneProduct treatment perturbed hematopoiesis , as evidenced by increased myeloid ( LCOTHER ( + ) ) , decreased B ( LCOTHER ( + ) ) and T ( LCGeneOrGeneProduct ( + ) ) lymphoid BM content of treated LCOTHER , with a corresponding increase in myeloid circulating cells .	2
Moreover , anti - LCGeneOrGeneProduct treatment also increased the number of CFU - M and - G colonies in methylcellulose assays , independently of LCGeneOrGeneProduct .	1
To clarify the role of LCGeneOrGeneProduct host genetic background and disease progression on viral evolutionary patterns , we obtain LCOTHER envelope sequences from clonal LCOTHER - LCOTHER variants isolated at multiple time points in the course of LCOTHER from populations of LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature individuals who only harbored LCOTHER - using LCOTHER - LCOTHER variants at all time points .	1
We describe the effect of LCChemicalEntity and LCChemicalEntity on frontal lobe oxygenation ( S ( c ) O ( 2 ) ) following anesthesia - induced LCOTHER .	6
We describe the effect of LCChemicalEntity and LCOTHER on frontal lobe oxygenation ( S ( c ) O ( 2 ) ) following anesthesia - induced LCDiseaseOrPhenotypicFeature .	3
We describe the effect of LCOTHER and LCChemicalEntity on frontal lobe oxygenation ( S ( c ) O ( 2 ) ) following anesthesia - induced LCDiseaseOrPhenotypicFeature .	3
METHODS : Following induction of anesthesia by LCOTHER ( 0 . 15 mg kg ( - 1 ) ) and LCOTHER ( 2 . 0 mg kg ( - 1 ) ) , 13 LCOTHER received LCChemicalEntity ( 0 . 1 mg iv ) and 12 LCOTHER received LCChemicalEntity ( 10 mg iv ) to restore mean arterial pressure ( MAP ) .	6
CONCLUSIONS : The utilization of LCChemicalEntity to correct LCDiseaseOrPhenotypicFeature induced by anesthesia has a negative impact on S ( c ) O ( 2 ) while LCOTHER maintains frontal lobe oxygenation potentially related to an increase in CO . LCOTHER LCOTHER ( LCOTHER - LCOTHER ) and LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) Single Nucleotide Polymorphisms ( SNPs ) , LCOTHER and Metabolism in LCOTHER LCOTHER LCOTHER in Inner Mongolia .	3
CONCLUSIONS : The utilization of LCChemicalEntity to correct LCOTHER induced by anesthesia has a negative impact on S ( c ) O ( 2 ) while LCChemicalEntity maintains frontal lobe oxygenation potentially related to an increase in CO . LCOTHER LCOTHER ( LCOTHER - LCOTHER ) and LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) Single Nucleotide Polymorphisms ( SNPs ) , LCOTHER and Metabolism in LCOTHER LCOTHER LCOTHER in Inner Mongolia .	6
However , few studies have focused on the association of LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCSequenceVariant / LCSequenceVariant and LCOTHER - LCOTHER - LCOTHER / LCOTHER single nucleotide polymorphisms ( SNPs ) , LCOTHER biomarkers , and metabolic indexes in LCOTHER with LCDiseaseOrPhenotypicFeature , especially in the Inner Mongolia population .	1
However , few studies have focused on the association of LCOTHER - LCOTHER - LCOTHER / LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCSequenceVariant / LCSequenceVariant single nucleotide polymorphisms ( SNPs ) , LCOTHER biomarkers , and metabolic indexes in LCOTHER with LCDiseaseOrPhenotypicFeature , especially in the Inner Mongolia population .	1
The aim of this study was to investigate the associations of LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCSequenceVariant / LCSequenceVariant and LCOTHER - LCOTHER - LCOTHER / LCOTHER SNPs , and LCOTHER and metabolic biomarkers in LCOTHER with LCDiseaseOrPhenotypicFeature pregnancies .	1
The aim of this study was to investigate the associations of LCOTHER - LCOTHER - LCOTHER / LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCSequenceVariant / LCSequenceVariant SNPs , and LCOTHER and metabolic biomarkers in LCOTHER with LCDiseaseOrPhenotypicFeature pregnancies .	1
RESULTS Distribution frequency of LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCSequenceVariant ( OR = 3 . 316 , 95% CI = 1 . 092 - 8 . 304 , p = 0 . 025 ) in LCOTHER with LCDiseaseOrPhenotypicFeature pregnancies were obviously higher than that in LCOTHER with healthy pregnancies .	1
LCDiseaseOrPhenotypicFeature biomarkers in serum ( hs - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	1
LCDiseaseOrPhenotypicFeature biomarkers in serum ( hs - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	1
LCDiseaseOrPhenotypicFeature biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	1
LCDiseaseOrPhenotypicFeature biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	1
LCDiseaseOrPhenotypicFeature biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	1
LCDiseaseOrPhenotypicFeature biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	1
LCDiseaseOrPhenotypicFeature biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	1
LCDiseaseOrPhenotypicFeature biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	1
LCDiseaseOrPhenotypicFeature biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	1
LCDiseaseOrPhenotypicFeature biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	1
LCDiseaseOrPhenotypicFeature biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	1
LCDiseaseOrPhenotypicFeature biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	1
LCOTHER biomarkers in serum ( hs - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCDiseaseOrPhenotypicFeature and LCOTHER with healthy pregnancies .	1
LCOTHER biomarkers in serum ( hs - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCDiseaseOrPhenotypicFeature and LCOTHER with healthy pregnancies .	1
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCDiseaseOrPhenotypicFeature and LCOTHER with healthy pregnancies .	1
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCDiseaseOrPhenotypicFeature and LCOTHER with healthy pregnancies .	1
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCDiseaseOrPhenotypicFeature and LCOTHER with healthy pregnancies .	1
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCDiseaseOrPhenotypicFeature and LCOTHER with healthy pregnancies .	1
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCDiseaseOrPhenotypicFeature and LCOTHER with healthy pregnancies .	1
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCDiseaseOrPhenotypicFeature and LCOTHER with healthy pregnancies .	1
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCDiseaseOrPhenotypicFeature and LCOTHER with healthy pregnancies .	1
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCDiseaseOrPhenotypicFeature and LCOTHER with healthy pregnancies .	1
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCDiseaseOrPhenotypicFeature and LCOTHER with healthy pregnancies .	1
CONCLUSIONS LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCSequenceVariant / LCSequenceVariant SNP , hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER / LCOTHER - LCOTHER were associated with LCDiseaseOrPhenotypicFeature in LCOTHER from Inner Mongolia , as was serious LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER prevents LCOTHER LCOTHER accumulation in macrophages induced by the LCOTHER LCOTHER inhibitor LCOTHER .	1
CONCLUSIONS LCOTHER - LCOTHER - LCOTHER / LCOTHER SNP , hs - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER / LCOTHER - LCOTHER were associated with LCDiseaseOrPhenotypicFeature in LCOTHER from Inner Mongolia , as was serious LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER prevents LCOTHER LCOTHER accumulation in macrophages induced by the LCOTHER LCOTHER inhibitor LCOTHER .	1
CONCLUSIONS LCOTHER - LCOTHER - LCOTHER / LCOTHER SNP , hs - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , and LCOTHER - LCOTHER / LCOTHER - LCOTHER were associated with LCDiseaseOrPhenotypicFeature in LCOTHER from Inner Mongolia , as was serious LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER prevents LCOTHER LCOTHER accumulation in macrophages induced by the LCOTHER LCOTHER inhibitor LCOTHER .	1
CONCLUSIONS LCOTHER - LCOTHER - LCOTHER / LCOTHER SNP , hs - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , and LCOTHER - LCOTHER / LCOTHER - LCOTHER were associated with LCDiseaseOrPhenotypicFeature in LCOTHER from Inner Mongolia , as was serious LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER prevents LCOTHER LCOTHER accumulation in macrophages induced by the LCOTHER LCOTHER inhibitor LCOTHER .	1
CONCLUSIONS LCOTHER - LCOTHER - LCOTHER / LCOTHER SNP , hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCOTHER - LCOTHER were associated with LCDiseaseOrPhenotypicFeature in LCOTHER from Inner Mongolia , as was serious LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER prevents LCOTHER LCOTHER accumulation in macrophages induced by the LCOTHER LCOTHER inhibitor LCOTHER .	1
CONCLUSIONS LCOTHER - LCOTHER - LCOTHER / LCOTHER SNP , hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct were associated with LCDiseaseOrPhenotypicFeature in LCOTHER from Inner Mongolia , as was serious LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER prevents LCOTHER LCOTHER accumulation in macrophages induced by the LCOTHER LCOTHER inhibitor LCOTHER .	1
We have previously demonstrated that LCChemicalEntity treatment increases LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature formation in male LCOTHER to a greater extent than in female LCOTHER .	2
Furthermore , peripheral blood monocytes isolated from LCChemicalEntity - treated females had less LCChemicalEntity LCChemicalEntity accumulation .	3
LCChemicalEntity decreased the accumulation of LCChemicalEntity LCChemicalEntity in macrophages following LCOTHER treatment .	3
LCChemicalEntity increased the expression of the scavenger receptor , LCGeneOrGeneProduct mRNA , responsible for the uptake of LDL .	2
Additionally , LCChemicalEntity treatment selectively increased the relative levels of LCGeneOrGeneProduct mRNA , a transcription factor responsible for the regulation of LCOTHER mRNA expression .	2
Additionally , LCChemicalEntity treatment selectively increased the relative levels of LCOTHER mRNA , a transcription factor responsible for the regulation of LCGeneOrGeneProduct mRNA expression .	2
Additionally , LCOTHER treatment selectively increased the relative levels of LCGeneOrGeneProduct mRNA , a transcription factor responsible for the regulation of LCGeneOrGeneProduct mRNA expression .	1
LCChemicalEntity did , however , significantly suppress LCGeneOrGeneProduct protein levels as measured by fluorescent immunocytochemistry .	3
This data suggests that LCChemicalEntity modifies the expression of LCGeneOrGeneProduct at the level of protein expression in monocyte - derived macrophages resulting in reduced LCOTHER LCOTHER accumulation following LCOTHER treatment . Single - strand conformation polymorphism analysis of the LCOTHER gene in LCOTHER and LCOTHER LCOTHER children in Japan .	3
This data suggests that LCChemicalEntity modifies the expression of LCOTHER at the level of protein expression in monocyte - derived macrophages resulting in reduced LCChemicalEntity LCChemicalEntity accumulation following LCOTHER treatment . Single - strand conformation polymorphism analysis of the LCOTHER gene in LCOTHER and LCOTHER LCOTHER children in Japan .	3
This data suggests that LCOTHER modifies the expression of LCGeneOrGeneProduct at the level of protein expression in monocyte - derived macrophages resulting in reduced LCChemicalEntity LCChemicalEntity accumulation following LCOTHER treatment . Single - strand conformation polymorphism analysis of the LCOTHER gene in LCOTHER and LCOTHER LCOTHER children in Japan .	1
We screened all 17 exons of the LCGeneOrGeneProduct gene for mutations in 90 LCDiseaseOrPhenotypicFeature or LCOTHER LCOTHER children using polymerase chain reaction ( PCR ) - single strand conformation polymorphism ( SSCP ) analysis .	1
We screened all 17 exons of the LCGeneOrGeneProduct gene for mutations in 90 LCOTHER or LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature children using polymerase chain reaction ( PCR ) - single strand conformation polymorphism ( SSCP ) analysis .	1
Although uncommon , point mutations in the LCGeneOrGeneProduct gene may be a cause of LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER in Japanese LCOTHER . Homozygously deleted gene LCOTHER regulates LCOTHER - initiating activity of LCOTHER cells .	1
Although uncommon , point mutations in the LCGeneOrGeneProduct gene may be a cause of LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in Japanese LCOTHER . Homozygously deleted gene LCOTHER regulates LCOTHER - initiating activity of LCOTHER cells .	1
LCOTHER - LCGeneOrGeneProduct - low cells form spheroids with LCGeneOrGeneProduct and LCOTHER expression in serum - free medium but LCOTHER - LCOTHER - high cells do not .	1
LCOTHER - LCGeneOrGeneProduct - low cells form spheroids with LCOTHER and LCGeneOrGeneProduct expression in serum - free medium but LCOTHER - LCOTHER - high cells do not .	1
Compared with spheroid - forming LCOTHER - LCGeneOrGeneProduct - low cells , adherent LCOTHER - LCOTHER - high cells display lower tumorigenicity , indicating LCOTHER decreases the number of LCDiseaseOrPhenotypicFeature - initiating cells .	1
Compared with spheroid - forming LCOTHER - LCOTHER - low cells , adherent LCOTHER - LCGeneOrGeneProduct - high cells display lower tumorigenicity , indicating LCOTHER decreases the number of LCDiseaseOrPhenotypicFeature - initiating cells .	1
Compared with spheroid - forming LCOTHER - LCOTHER - low cells , adherent LCOTHER - LCOTHER - high cells display lower tumorigenicity , indicating LCGeneOrGeneProduct decreases the number of LCDiseaseOrPhenotypicFeature - initiating cells .	1
Gene expression analysis and chromatin immunoprecipitation assay reveal that LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER / LCOTHER ) is transcriptionally repressed by LCGeneOrGeneProduct , especially in cells cultured in serum - free medium .	3
Gene expression analysis and chromatin immunoprecipitation assay reveal that LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct / LCOTHER ) is transcriptionally repressed by LCGeneOrGeneProduct , especially in cells cultured in serum - free medium .	3
Gene expression analysis and chromatin immunoprecipitation assay reveal that LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER / LCGeneOrGeneProduct ) is transcriptionally repressed by LCGeneOrGeneProduct , especially in cells cultured in serum - free medium .	3
Exogenous LCGeneOrGeneProduct rescues spheroid - forming activity and tumorigenicity of the LCOTHER - LCGeneOrGeneProduct - high cells , suggesting that loss of LCOTHER increases the number of LCOTHER - initiating cells through transcriptional activation of LCOTHER .	3
Exogenous LCGeneOrGeneProduct rescues spheroid - forming activity and tumorigenicity of the LCOTHER - LCOTHER - high cells , suggesting that loss of LCGeneOrGeneProduct increases the number of LCOTHER - initiating cells through transcriptional activation of LCOTHER .	3
Exogenous LCGeneOrGeneProduct rescues spheroid - forming activity and tumorigenicity of the LCOTHER - LCOTHER - high cells , suggesting that loss of LCOTHER increases the number of LCDiseaseOrPhenotypicFeature - initiating cells through transcriptional activation of LCOTHER .	1
Exogenous LCOTHER rescues spheroid - forming activity and tumorigenicity of the LCOTHER - LCGeneOrGeneProduct - high cells , suggesting that loss of LCOTHER increases the number of LCDiseaseOrPhenotypicFeature - initiating cells through transcriptional activation of LCOTHER .	1
Exogenous LCOTHER rescues spheroid - forming activity and tumorigenicity of the LCOTHER - LCOTHER - high cells , suggesting that loss of LCGeneOrGeneProduct increases the number of LCDiseaseOrPhenotypicFeature - initiating cells through transcriptional activation of LCOTHER .	1
These results illustrate that LCGeneOrGeneProduct is a distinctive LCDiseaseOrPhenotypicFeature suppressor , which does not only suppress growth of LCOTHER cells but also regulates LCOTHER - mediated LCOTHER - initiating activity of LCOTHER cells . LCOTHER LCOTHER LCOTHER resulting from a new nonsense mutation , LCOTHER . LCOTHER , in the LCOTHER gene .	1
These results illustrate that LCGeneOrGeneProduct is a distinctive LCOTHER suppressor , which does not only suppress growth of LCDiseaseOrPhenotypicFeature cells but also regulates LCOTHER - mediated LCOTHER - initiating activity of LCOTHER cells . LCOTHER LCOTHER LCOTHER resulting from a new nonsense mutation , LCOTHER . LCOTHER , in the LCOTHER gene .	1
These results illustrate that LCGeneOrGeneProduct is a distinctive LCOTHER suppressor , which does not only suppress growth of LCOTHER cells but also regulates LCOTHER - mediated LCDiseaseOrPhenotypicFeature - initiating activity of LCOTHER cells . LCOTHER LCOTHER LCOTHER resulting from a new nonsense mutation , LCOTHER . LCOTHER , in the LCOTHER gene .	1
These results illustrate that LCGeneOrGeneProduct is a distinctive LCOTHER suppressor , which does not only suppress growth of LCOTHER cells but also regulates LCOTHER - mediated LCOTHER - initiating activity of LCDiseaseOrPhenotypicFeature cells . LCOTHER LCOTHER LCOTHER resulting from a new nonsense mutation , LCOTHER . LCOTHER , in the LCOTHER gene .	1
These results illustrate that LCOTHER is a distinctive LCOTHER suppressor , which does not only suppress growth of LCOTHER cells but also regulates LCGeneOrGeneProduct - mediated LCDiseaseOrPhenotypicFeature - initiating activity of LCOTHER cells . LCOTHER LCOTHER LCOTHER resulting from a new nonsense mutation , LCOTHER . LCOTHER , in the LCOTHER gene .	1
These results illustrate that LCOTHER is a distinctive LCOTHER suppressor , which does not only suppress growth of LCOTHER cells but also regulates LCGeneOrGeneProduct - mediated LCOTHER - initiating activity of LCDiseaseOrPhenotypicFeature cells . LCOTHER LCOTHER LCOTHER resulting from a new nonsense mutation , LCOTHER . LCOTHER , in the LCOTHER gene .	1
The molecular basis of LCDiseaseOrPhenotypicFeature involves mutations in the LCGeneOrGeneProduct gene , which encodes an enzyme that allows membrane targeting and secretion of several Wnt proteins critical for normal tissue development .	1
CONCLUSION : Identification of this new de novo nonsense mutation confirms the diagnosis of LCDiseaseOrPhenotypicFeature in this child and highlights the clinical importance of LCGeneOrGeneProduct and Wnt signalling pathways in embryogenesis . LCOTHER LCOTHER LCOTHER LCOTHER .	1
The expressed LCGeneOrGeneProduct LCGeneOrGeneProduct recognized tested LCChemicalEntity drugs and LCOTHER LCOTHER in a LCOTHER - and LCOTHER - sensitive fashion with affinities virtually identical to those displayed by the LCOTHER LCOTHER LCOTHER LCOTHER .	1
The expressed LCGeneOrGeneProduct LCGeneOrGeneProduct recognized tested LCOTHER drugs and LCChemicalEntity LCChemicalEntity in a LCOTHER - and LCOTHER - sensitive fashion with affinities virtually identical to those displayed by the LCOTHER LCOTHER LCOTHER LCOTHER .	1
The expressed LCOTHER LCOTHER recognized tested LCOTHER drugs and LCOTHER LCOTHER in a LCChemicalEntity - and LCOTHER - sensitive fashion with affinities virtually identical to those displayed by the LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct .	1
The expressed LCOTHER LCOTHER recognized tested LCOTHER drugs and LCOTHER LCOTHER in a LCOTHER - and LCChemicalEntity - sensitive fashion with affinities virtually identical to those displayed by the LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct .	1
Effects on LCChemicalEntity LCChemicalEntity are similar to those noted for the LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct .	1
METHODS : LCGeneOrGeneProduct - LCGeneOrGeneProduct gene sequencing was performed on genomic DNA isolated from a total of 75 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER , including 31 b ( 0 ) 39 / b ( 0 ) 39 , 33 b ( 0 ) 39 / b ( + ) IVSI - 110 , 9 b ( + ) IVSI - 110 / b ( + ) IVSI - 110 , one b ( 0 ) IVSI - 1 / b ( + ) IVSI - 6 and one b ( 0 ) 39 / b ( + ) IVSI - 6 .	1
RESULTS : The results show that the LCSequenceVariant polymorphism is present in LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER in the 5 ' UTR sequence ( + 25 ) of the LCOTHER - LCOTHER gene , known to affect the LCOTHER ( LCOTHER homologue of LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ) binding site 5 ' - GGTTAT - 3 ' .	1
RESULTS : The results show that the LCOTHER polymorphism is present in LCOTHER - LCOTHER LCOTHER in the 5 ' UTR sequence ( + 25 ) of the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene , known to affect the LCGeneOrGeneProduct ( LCOTHER homologue of LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ) binding site 5 ' - GGTTAT - 3 ' .	1
RESULTS : The results show that the LCOTHER polymorphism is present in LCOTHER - LCOTHER LCOTHER in the 5 ' UTR sequence ( + 25 ) of the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene , known to affect the LCOTHER ( LCOTHER homologue of LCOTHER LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ) binding site 5 ' - GGTTAT - 3 ' .	1
This LCGeneOrGeneProduct ( + LCSequenceVariant LCSequenceVariant - > LCSequenceVariant ) polymorphism is associated with the LCGeneOrGeneProduct - LCGeneOrGeneProduct - XmnI polymorphism and both are linked with the LCOTHER ( LCOTHER ) LCOTHER - LCOTHER gene , but not with the LCOTHER ( + ) LCOTHER - LCOTHER - LCOTHER gene .	1
This LCGeneOrGeneProduct ( + LCSequenceVariant LCSequenceVariant - > LCSequenceVariant ) polymorphism is associated with the LCOTHER - LCOTHER - XmnI polymorphism and both are linked with the LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct - LCGeneOrGeneProduct gene , but not with the LCOTHER ( + ) LCOTHER - LCOTHER - LCOTHER gene .	1
This LCGeneOrGeneProduct ( + LCSequenceVariant LCSequenceVariant - > LCSequenceVariant ) polymorphism is associated with the LCOTHER - LCOTHER - XmnI polymorphism and both are linked with the LCOTHER ( LCOTHER ) LCOTHER - LCOTHER gene , but not with the LCGeneOrGeneProduct ( + ) LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct gene .	1
This LCOTHER ( + LCOTHER LCOTHER - > LCOTHER ) polymorphism is associated with the LCGeneOrGeneProduct - LCGeneOrGeneProduct - XmnI polymorphism and both are linked with the LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct - LCGeneOrGeneProduct gene , but not with the LCOTHER ( + ) LCOTHER - LCOTHER - LCOTHER gene .	1
This LCOTHER ( + LCOTHER LCOTHER - > LCOTHER ) polymorphism is associated with the LCGeneOrGeneProduct - LCGeneOrGeneProduct - XmnI polymorphism and both are linked with the LCOTHER ( LCOTHER ) LCOTHER - LCOTHER gene , but not with the LCGeneOrGeneProduct ( + ) LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct gene .	1
In agreement with the expectation that this mutation alters the LCOTHER binding activity , we found that the LCGeneOrGeneProduct ( + LCSequenceVariant LCSequenceVariant - > LCSequenceVariant ) and LCGeneOrGeneProduct - LCGeneOrGeneProduct - XmnI polymorphisms are associated with high LCOTHER in erythroid precursor cells isolated from LCOTHER ( LCOTHER ) LCOTHER / LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER .	1
In agreement with the expectation that this mutation alters the LCOTHER binding activity , we found that the LCGeneOrGeneProduct ( + LCSequenceVariant LCSequenceVariant - > LCSequenceVariant ) and LCOTHER - LCOTHER - XmnI polymorphisms are associated with high LCOTHER in erythroid precursor cells isolated from LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature / LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER .	1
In agreement with the expectation that this mutation alters the LCOTHER binding activity , we found that the LCOTHER ( + LCOTHER LCOTHER - > LCOTHER ) and LCGeneOrGeneProduct - LCGeneOrGeneProduct - XmnI polymorphisms are associated with high LCOTHER in erythroid precursor cells isolated from LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature / LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER .	1
CONCLUSIONS : As a potential explanation of our findings , we hypothesize that in LCOTHER - LCOTHER the LCGeneOrGeneProduct - LCGeneOrGeneProduct - XmnI / LCOTHER - LCOTHER - ( LCOTHER - > LCOTHER ) genotype is frequently under genetic linkage with LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) - LCDiseaseOrPhenotypicFeature mutations , but not with the LCOTHER ( + ) - LCOTHER mutation here studied ( i . e .	1
CONCLUSIONS : As a potential explanation of our findings , we hypothesize that in LCOTHER - LCOTHER the LCGeneOrGeneProduct - LCGeneOrGeneProduct - XmnI / LCOTHER - LCOTHER - ( LCOTHER - > LCOTHER ) genotype is frequently under genetic linkage with LCOTHER ( LCOTHER ) - LCOTHER mutations , but not with the LCDiseaseOrPhenotypicFeature ( + ) - LCDiseaseOrPhenotypicFeature mutation here studied ( i . e .	1
CONCLUSIONS : As a potential explanation of our findings , we hypothesize that in LCOTHER - LCOTHER the LCOTHER - LCOTHER - XmnI / LCGeneOrGeneProduct - LCGeneOrGeneProduct - ( LCOTHER - > LCOTHER ) genotype is frequently under genetic linkage with LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) - LCDiseaseOrPhenotypicFeature mutations , but not with the LCOTHER ( + ) - LCOTHER mutation here studied ( i . e .	1
CONCLUSIONS : As a potential explanation of our findings , we hypothesize that in LCOTHER - LCOTHER the LCOTHER - LCOTHER - XmnI / LCGeneOrGeneProduct - LCGeneOrGeneProduct - ( LCOTHER - > LCOTHER ) genotype is frequently under genetic linkage with LCOTHER ( LCOTHER ) - LCOTHER mutations , but not with the LCDiseaseOrPhenotypicFeature ( + ) - LCDiseaseOrPhenotypicFeature mutation here studied ( i . e .	1
CONCLUSIONS : As a potential explanation of our findings , we hypothesize that in LCOTHER - LCOTHER the LCOTHER - LCOTHER - XmnI / LCOTHER - LCOTHER - ( LCSequenceVariant - > LCSequenceVariant ) genotype is frequently under genetic linkage with LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) - LCDiseaseOrPhenotypicFeature mutations , but not with the LCOTHER ( + ) - LCOTHER mutation here studied ( i . e .	1
CONCLUSIONS : As a potential explanation of our findings , we hypothesize that in LCOTHER - LCOTHER the LCOTHER - LCOTHER - XmnI / LCOTHER - LCOTHER - ( LCSequenceVariant - > LCSequenceVariant ) genotype is frequently under genetic linkage with LCOTHER ( LCOTHER ) - LCOTHER mutations , but not with the LCDiseaseOrPhenotypicFeature ( + ) - LCDiseaseOrPhenotypicFeature mutation here studied ( i . e .	1
Here we describe the characterization of the LCSequenceVariant ( + LCSequenceVariant LCSequenceVariant - > LCSequenceVariant ) polymorphism of the LCOTHER - LCOTHER gene associated in LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER with high LCOTHER in erythroid precursor cells . LCOTHER consumption and LCOTHER LCOTHER incidence and progression : A Mendelian randomisation study .	1
Here we describe the characterization of the LCOTHER ( + LCOTHER LCOTHER - > LCOTHER ) polymorphism of the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene associated in LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER with high LCOTHER in erythroid precursor cells . LCOTHER consumption and LCOTHER LCOTHER incidence and progression : A Mendelian randomisation study .	1
The effects of LCChemicalEntity consumption on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature incidence and survival remain unclear , potentially due to methodological limitations of observational studies .	1
In this study , we investigated the associations of genetic variants in LCChemicalEntity - metabolising genes with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature incidence and survival .	1
Study - specific associations of 68 single nucleotide polymorphisms ( SNPs ) in 8 LCChemicalEntity - metabolising genes ( LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) and LCOTHER LCOTHER ( LCOTHER ) ) with LCOTHER LCOTHER diagnosis and LCOTHER LCOTHER - specific mortality , by grade , were assessed using logistic and Cox regression models , respectively .	1
Study - specific associations of 68 single nucleotide polymorphisms ( SNPs ) in 8 LCChemicalEntity - metabolising genes ( LCOTHER LCOTHER ( LCGeneOrGeneProduct ) and LCOTHER LCOTHER ( LCOTHER ) ) with LCOTHER LCOTHER diagnosis and LCOTHER LCOTHER - specific mortality , by grade , were assessed using logistic and Cox regression models , respectively .	1
Study - specific associations of 68 single nucleotide polymorphisms ( SNPs ) in 8 LCChemicalEntity - metabolising genes ( LCOTHER LCOTHER ( LCOTHER ) and LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) ) with LCOTHER LCOTHER diagnosis and LCOTHER LCOTHER - specific mortality , by grade , were assessed using logistic and Cox regression models , respectively .	1
Study - specific associations of 68 single nucleotide polymorphisms ( SNPs ) in 8 LCChemicalEntity - metabolising genes ( LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER ( LCGeneOrGeneProduct ) ) with LCOTHER LCOTHER diagnosis and LCOTHER LCOTHER - specific mortality , by grade , were assessed using logistic and Cox regression models , respectively .	1
Study - specific associations of 68 single nucleotide polymorphisms ( SNPs ) in 8 LCChemicalEntity - metabolising genes ( LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER ( LCOTHER ) ) with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature diagnosis and LCOTHER LCOTHER - specific mortality , by grade , were assessed using logistic and Cox regression models , respectively .	1
Study - specific associations of 68 single nucleotide polymorphisms ( SNPs ) in 8 LCChemicalEntity - metabolising genes ( LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER ( LCOTHER ) ) with LCOTHER LCOTHER diagnosis and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - specific mortality , by grade , were assessed using logistic and Cox regression models , respectively .	1
Study - specific associations of 68 single nucleotide polymorphisms ( SNPs ) in 8 LCOTHER - metabolising genes ( LCOTHER LCOTHER ( LCOTHER ) and LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) ) with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature diagnosis and LCOTHER LCOTHER - specific mortality , by grade , were assessed using logistic and Cox regression models , respectively .	1
Study - specific associations of 68 single nucleotide polymorphisms ( SNPs ) in 8 LCOTHER - metabolising genes ( LCOTHER LCOTHER ( LCOTHER ) and LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) ) with LCOTHER LCOTHER diagnosis and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - specific mortality , by grade , were assessed using logistic and Cox regression models , respectively .	1
Study - specific associations of 68 single nucleotide polymorphisms ( SNPs ) in 8 LCOTHER - metabolising genes ( LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER ( LCGeneOrGeneProduct ) ) with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature diagnosis and LCOTHER LCOTHER - specific mortality , by grade , were assessed using logistic and Cox regression models , respectively .	1
Study - specific associations of 68 single nucleotide polymorphisms ( SNPs ) in 8 LCOTHER - metabolising genes ( LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER ( LCGeneOrGeneProduct ) ) with LCOTHER LCOTHER diagnosis and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - specific mortality , by grade , were assessed using logistic and Cox regression models , respectively .	1
We found little evidence that variants in LCChemicalEntity metabolising genes were associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature diagnosis .	1
SNPs within LCGeneOrGeneProduct associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature mortality were LCOTHER ( fixed effects hazard ratio , HRfixed = 0 . 78 ; 95% confidence interval ( 95%CI ) : 0 . 66 , 0 . 91 ; p values = 0 . 002 ) ; LCOTHER , HRfixed = 0 . 76 ; 95%CI : 0 . 64 , 0 . 91 ; p values = 0 . 003 ) ; and LCOTHER ( HRfixed = 0 . 76 ; 95%CI : 0 . 64 , 0 . 91 ; p values = 0 . 002 ) .	1
In LCGeneOrGeneProduct , LCOTHER ( HRfixed = 1 . 43 ; 95%CI : 1 . 14 , 1 . 79 ; p values = 0 . 002 ) was associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature mortality in LCOTHER with low - grade LCOTHER LCOTHER .	1
In LCGeneOrGeneProduct , LCOTHER ( HRfixed = 1 . 43 ; 95%CI : 1 . 14 , 1 . 79 ; p values = 0 . 002 ) was associated with LCOTHER LCOTHER mortality in LCOTHER with low - grade LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
In LCOTHER , LCSequenceVariant ( HRfixed = 1 . 43 ; 95%CI : 1 . 14 , 1 . 79 ; p values = 0 . 002 ) was associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature mortality in LCOTHER with low - grade LCOTHER LCOTHER .	2
In LCOTHER , LCSequenceVariant ( HRfixed = 1 . 43 ; 95%CI : 1 . 14 , 1 . 79 ; p values = 0 . 002 ) was associated with LCOTHER LCOTHER mortality in LCOTHER with low - grade LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
These results suggest that LCChemicalEntity consumption is unlikely to affect LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature incidence , but it may influence disease progression . Novel somatic LCOTHER gene alterations in sporadic LCOTHER LCOTHER and correlation with clinical characteristics .	1
Somatic mutations of LCGeneOrGeneProduct gene have also been described in sporadic LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
In our study , we examined the presence of alterations in LCGeneOrGeneProduct gene in a series of 39 LCOTHER who had undergone surgery for sporadic LCDiseaseOrPhenotypicFeature ( 35 with LCOTHER LCOTHER LCOTHER LCOTHER , 4 with a LCOTHER ) .	1
In our study , we examined the presence of alterations in LCGeneOrGeneProduct gene in a series of 39 LCOTHER who had undergone surgery for sporadic LCOTHER ( 35 with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , 4 with a LCOTHER ) .	1
Somatic LCGeneOrGeneProduct mutations were detected in 6 of the 35 LCOTHER with a LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature examined ( 17 . 1% ) , whereas no alterations were found in the LCOTHER .	1
Moreover , two polymorphisms were also found : one allele carried a LCSequenceVariant polymorphism ( 1 / 39 LCDiseaseOrPhenotypicFeature ) , while a LCOTHER polymorphism ( LCOTHER / LCOTHER ) was found in 15 and 8 LCOTHER in hetero ( CT ) and homozygosity ( TT ) , respectively .	1
Moreover , two polymorphisms were also found : one allele carried a LCSequenceVariant polymorphism ( 1 / 39 LCOTHER ) , while a LCOTHER polymorphism ( LCOTHER / LCOTHER ) was found in 15 and 8 LCDiseaseOrPhenotypicFeature in hetero ( CT ) and homozygosity ( TT ) , respectively .	1
Moreover , two polymorphisms were also found : one allele carried a LCOTHER polymorphism ( 1 / 39 LCOTHER ) , while a LCSequenceVariant polymorphism ( LCOTHER / LCOTHER ) was found in 15 and 8 LCDiseaseOrPhenotypicFeature in hetero ( CT ) and homozygosity ( TT ) , respectively .	1
Moreover , two polymorphisms were also found : one allele carried a LCOTHER polymorphism ( 1 / 39 LCOTHER ) , while a LCOTHER polymorphism ( LCSequenceVariant / LCSequenceVariant ) was found in 15 and 8 LCDiseaseOrPhenotypicFeature in hetero ( CT ) and homozygosity ( TT ) , respectively .	1
In conclusion , our data demonstrate the presence of somatic alterations of the LCGeneOrGeneProduct LCDiseaseOrPhenotypicFeature suppressor gene in about one fifth of benign sporadic LCOTHER LCOTHER .	1
In conclusion , our data demonstrate the presence of somatic alterations of the LCGeneOrGeneProduct LCOTHER suppressor gene in about one fifth of benign sporadic LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature predisposition ( PAP ) has been recently associated with germline mutations in the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) gene .	1
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature predisposition ( PAP ) has been recently associated with germline mutations in the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene .	1
RESULTS : A heterozygous in - frame deletion LCSequenceVariant ( LCOTHER . LCOTHER ) was identified in one LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER .	1
RESULTS : A heterozygous in - frame deletion LCOTHER ( LCSequenceVariant . LCSequenceVariant ) was identified in one LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER .	1
CONCLUSIONS : While mutations were absent in non - LCOTHER - LCOTHER LCOTHER LCOTHER , germline LCGeneOrGeneProduct mutations can be found in children and adolescents with LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , even in the absence of family history .	1
Finally , the IKr blockers , LCChemicalEntity and LCOTHER , which are reported to cause LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) in clinical practice , produced early afterdepolarization ( EAD ) .	2
Finally , the IKr blockers , LCChemicalEntity and LCOTHER , which are reported to cause LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) in clinical practice , produced early afterdepolarization ( EAD ) .	2
Finally , the IKr blockers , LCOTHER and LCChemicalEntity , which are reported to cause LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) in clinical practice , produced early afterdepolarization ( EAD ) .	2
Finally , the IKr blockers , LCOTHER and LCChemicalEntity , which are reported to cause LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) in clinical practice , produced early afterdepolarization ( EAD ) .	2
However , mutation analysis showed that the proband is a compound heterozygote for 2 mutations in LCGeneOrGeneProduct : a substitution of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER . LCOTHER ) and a novel LCOTHER LCOTHER LCOTHER transition at the 5 ' splice site of intron 22 ( LCOTHER . LCOTHER + LCOTHER > LCOTHER ) , providing the molecular diagnosis of LCDiseaseOrPhenotypicFeature .	1
However , mutation analysis showed that the proband is a compound heterozygote for 2 mutations in LCOTHER : a substitution of LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant ( LCOTHER . LCOTHER ) and a novel LCOTHER LCOTHER LCOTHER transition at the 5 ' splice site of intron 22 ( LCOTHER . LCOTHER + LCOTHER > LCOTHER ) , providing the molecular diagnosis of LCDiseaseOrPhenotypicFeature .	1
However , mutation analysis showed that the proband is a compound heterozygote for 2 mutations in LCOTHER : a substitution of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCSequenceVariant . LCSequenceVariant ) and a novel LCOTHER LCOTHER LCOTHER transition at the 5 ' splice site of intron 22 ( LCOTHER . LCOTHER + LCOTHER > LCOTHER ) , providing the molecular diagnosis of LCDiseaseOrPhenotypicFeature .	1
However , mutation analysis showed that the proband is a compound heterozygote for 2 mutations in LCOTHER : a substitution of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER . LCOTHER ) and a novel LCSequenceVariant LCSequenceVariant LCSequenceVariant transition at the 5 ' splice site of intron 22 ( LCOTHER . LCOTHER + LCOTHER > LCOTHER ) , providing the molecular diagnosis of LCDiseaseOrPhenotypicFeature .	1
However , mutation analysis showed that the proband is a compound heterozygote for 2 mutations in LCOTHER : a substitution of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER . LCOTHER ) and a novel LCOTHER LCOTHER LCOTHER transition at the 5 ' splice site of intron 22 ( LCSequenceVariant . LCSequenceVariant + LCSequenceVariant > LCSequenceVariant ) , providing the molecular diagnosis of LCDiseaseOrPhenotypicFeature .	1
Supplementation with LCChemicalEntity and LCChemicalEntity improved clinical symptoms and resulted in catch - up growth , but vision remained impaired .	5
We investigated effects of LCChemicalEntity on pulmonary endothelial cell ( EC ) permeability and LCDiseaseOrPhenotypicFeature activation and identified a receptor mediating these effects .	3
LCChemicalEntity enhanced the EC barrier and protected against barrier dysfunction caused by vasoactive peptide LCGeneOrGeneProduct and LCOTHER bacterial wall LCOTHER ( LCOTHER ) .	1
LCChemicalEntity enhanced the EC barrier and protected against barrier dysfunction caused by vasoactive peptide LCOTHER and LCDiseaseOrPhenotypicFeature bacterial wall LCOTHER ( LCOTHER ) .	3
LCChemicalEntity enhanced the EC barrier and protected against barrier dysfunction caused by vasoactive peptide LCOTHER and LCOTHER bacterial wall LCChemicalEntity ( LCOTHER ) .	3
LCChemicalEntity enhanced the EC barrier and protected against barrier dysfunction caused by vasoactive peptide LCOTHER and LCOTHER bacterial wall LCOTHER ( LCChemicalEntity ) .	3
LCGeneOrGeneProduct mediated barrier - protective effects of LCOTHER by activating LCOTHER / LCOTHER LCOTHER and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct targets at cell adhesions and cytoskeleton : LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , and LCOTHER .	2
LCOTHER mediated barrier - protective effects of LCChemicalEntity by activating LCOTHER / LCOTHER LCOTHER and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct targets at cell adhesions and cytoskeleton : LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , and LCOTHER .	1
LCChemicalEntity also suppressed LCChemicalEntity - induced LCOTHER signaling by inhibiting the LCOTHER pathway and expression of LCOTHER LCOTHER LCOTHER LCOTHER and LCOTHER .	3
LCChemicalEntity also suppressed LCOTHER - induced LCDiseaseOrPhenotypicFeature signaling by inhibiting the LCOTHER pathway and expression of LCOTHER LCOTHER LCOTHER LCOTHER and LCOTHER .	3
LCChemicalEntity also suppressed LCOTHER - induced LCOTHER signaling by inhibiting the LCOTHER pathway and expression of LCOTHER LCOTHER LCOTHER LCGeneOrGeneProduct and LCOTHER .	3
LCChemicalEntity also suppressed LCOTHER - induced LCOTHER signaling by inhibiting the LCOTHER pathway and expression of LCOTHER LCOTHER LCOTHER LCOTHER and LCGeneOrGeneProduct .	3
LCOTHER also suppressed LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature signaling by inhibiting the LCOTHER pathway and expression of LCOTHER LCOTHER LCOTHER LCOTHER and LCOTHER .	2
LCOTHER also suppressed LCOTHER - induced LCDiseaseOrPhenotypicFeature signaling by inhibiting the LCOTHER pathway and expression of LCOTHER LCOTHER LCOTHER LCGeneOrGeneProduct and LCOTHER .	1
LCOTHER also suppressed LCOTHER - induced LCDiseaseOrPhenotypicFeature signaling by inhibiting the LCOTHER pathway and expression of LCOTHER LCOTHER LCOTHER LCOTHER and LCGeneOrGeneProduct .	1
In vivo , LCChemicalEntity was protective in two distinct models of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) : LCOTHER - induced LCOTHER LCOTHER and two - hit LCOTHER caused by suboptimal mechanical ventilation and injection of LCOTHER LCOTHER - activating peptide .	1
In vivo , LCChemicalEntity was protective in two distinct models of LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) : LCOTHER - induced LCOTHER LCOTHER and two - hit LCOTHER caused by suboptimal mechanical ventilation and injection of LCOTHER LCOTHER - activating peptide .	1
In vivo , LCChemicalEntity was protective in two distinct models of LCOTHER LCOTHER LCOTHER ( LCOTHER ) : LCChemicalEntity - induced LCOTHER LCOTHER and two - hit LCOTHER caused by suboptimal mechanical ventilation and injection of LCOTHER LCOTHER - activating peptide .	3
In vivo , LCChemicalEntity was protective in two distinct models of LCOTHER LCOTHER LCOTHER ( LCOTHER ) : LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and two - hit LCOTHER caused by suboptimal mechanical ventilation and injection of LCOTHER LCOTHER - activating peptide .	3
In vivo , LCChemicalEntity was protective in two distinct models of LCOTHER LCOTHER LCOTHER ( LCOTHER ) : LCOTHER - induced LCOTHER LCOTHER and two - hit LCDiseaseOrPhenotypicFeature caused by suboptimal mechanical ventilation and injection of LCOTHER LCOTHER - activating peptide .	1
In vivo , LCOTHER was protective in two distinct models of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) : LCOTHER - induced LCOTHER LCOTHER and two - hit LCOTHER caused by suboptimal mechanical ventilation and injection of LCGeneOrGeneProduct LCGeneOrGeneProduct - activating peptide .	1
In vivo , LCOTHER was protective in two distinct models of LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) : LCOTHER - induced LCOTHER LCOTHER and two - hit LCOTHER caused by suboptimal mechanical ventilation and injection of LCGeneOrGeneProduct LCGeneOrGeneProduct - activating peptide .	1
In vivo , LCOTHER was protective in two distinct models of LCOTHER LCOTHER LCOTHER ( LCOTHER ) : LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and two - hit LCOTHER caused by suboptimal mechanical ventilation and injection of LCOTHER LCOTHER - activating peptide .	2
In vivo , LCOTHER was protective in two distinct models of LCOTHER LCOTHER LCOTHER ( LCOTHER ) : LCOTHER - induced LCOTHER LCOTHER and two - hit LCDiseaseOrPhenotypicFeature caused by suboptimal mechanical ventilation and injection of LCGeneOrGeneProduct LCGeneOrGeneProduct - activating peptide .	1
The results suggest a novel role for the LCChemicalEntity - LCGeneOrGeneProduct axis in vascular EC protection that is critical for improvement of pathological states associated with increased vascular leakage and LCOTHER . Genetic polymorphisms in the LCOTHER LCOTHER LCOTHER gene LCOTHER and the LCOTHER ( LCOTHER ) LCOTHER : LCOTHER LCOTHER LCOTHER gene LCOTHER in LCOTHER who developed LCOTHER - related LCOTHER LCOTHER LCOTHER after childhood LCOTHER .	4
The results suggest a novel role for the LCChemicalEntity - LCOTHER axis in vascular EC protection that is critical for improvement of pathological states associated with increased vascular leakage and LCDiseaseOrPhenotypicFeature . Genetic polymorphisms in the LCOTHER LCOTHER LCOTHER gene LCOTHER and the LCOTHER ( LCOTHER ) LCOTHER : LCOTHER LCOTHER LCOTHER gene LCOTHER in LCOTHER who developed LCOTHER - related LCOTHER LCOTHER LCOTHER after childhood LCOTHER .	3
The results suggest a novel role for the LCOTHER - LCGeneOrGeneProduct axis in vascular EC protection that is critical for improvement of pathological states associated with increased vascular leakage and LCDiseaseOrPhenotypicFeature . Genetic polymorphisms in the LCOTHER LCOTHER LCOTHER gene LCOTHER and the LCOTHER ( LCOTHER ) LCOTHER : LCOTHER LCOTHER LCOTHER gene LCOTHER in LCOTHER who developed LCOTHER - related LCOTHER LCOTHER LCOTHER after childhood LCOTHER .	1
BACKGROUND : Exposure to LCChemicalEntity as part of LCDiseaseOrPhenotypicFeature therapy has been associated with the development of LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	3
BACKGROUND : Exposure to LCChemicalEntity as part of LCOTHER therapy has been associated with the development of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	2
BACKGROUND : Exposure to LCChemicalEntity as part of LCOTHER therapy has been associated with the development of LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	2
The potential role of genetic risk factors in LCChemicalEntity - related LCDiseaseOrPhenotypicFeature remains to be defined .	2
Thus , in this study , the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of LCChemicalEntity ( in particular , the LCOTHER LCOTHER LCOTHER LCOTHER : LCOTHER LCOTHER LCOTHER gene LCOTHER and the LCOTHER LCOTHER LCOTHER gene LCOTHER ) had an impact on the risk of LCOTHER - related LCDiseaseOrPhenotypicFeature .	2
Thus , in this study , the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of LCOTHER ( in particular , the LCOTHER LCOTHER LCOTHER LCOTHER : LCOTHER LCOTHER LCOTHER gene LCOTHER and the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene LCOTHER ) had an impact on the risk of LCChemicalEntity - related LCOTHER .	1
Thus , in this study , the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of LCOTHER ( in particular , the LCOTHER LCOTHER LCOTHER LCOTHER : LCOTHER LCOTHER LCOTHER gene LCOTHER and the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene LCOTHER ) had an impact on the risk of LCOTHER - related LCDiseaseOrPhenotypicFeature .	1
Thus , in this study , the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of LCOTHER ( in particular , the LCOTHER LCOTHER LCOTHER LCOTHER : LCOTHER LCOTHER LCOTHER gene LCOTHER and the LCOTHER LCOTHER LCOTHER gene LCGeneOrGeneProduct ) had an impact on the risk of LCChemicalEntity - related LCOTHER .	1
Thus , in this study , the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of LCOTHER ( in particular , the LCOTHER LCOTHER LCOTHER LCOTHER : LCOTHER LCOTHER LCOTHER gene LCOTHER and the LCOTHER LCOTHER LCOTHER gene LCGeneOrGeneProduct ) had an impact on the risk of LCOTHER - related LCDiseaseOrPhenotypicFeature .	1
Thus , in this study , the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of LCOTHER ( in particular , the LCOTHER LCOTHER LCOTHER LCOTHER : LCOTHER LCOTHER LCOTHER gene LCOTHER and the LCOTHER LCOTHER LCOTHER gene LCOTHER ) had an impact on the risk of LCChemicalEntity - related LCDiseaseOrPhenotypicFeature .	2
Enzyme activity assays with recombinant LCGeneOrGeneProduct isoforms ( LCOTHER LCOTHER and LCOTHER LCOTHER ) and the LCChemicalEntity substrate LCOTHER were used to investigate the functional impact of the LCOTHER LCOTHER polymorphism .	1
Enzyme activity assays with recombinant LCOTHER isoforms ( LCGeneOrGeneProduct LCOTHER and LCOTHER LCOTHER ) and the LCChemicalEntity substrate LCOTHER were used to investigate the functional impact of the LCOTHER LCOTHER polymorphism .	1
Enzyme activity assays with recombinant LCOTHER isoforms ( LCOTHER LCSequenceVariant and LCOTHER LCOTHER ) and the LCChemicalEntity substrate LCOTHER were used to investigate the functional impact of the LCOTHER LCOTHER polymorphism .	1
Enzyme activity assays with recombinant LCOTHER isoforms ( LCOTHER LCOTHER and LCGeneOrGeneProduct LCOTHER ) and the LCChemicalEntity substrate LCOTHER were used to investigate the functional impact of the LCOTHER LCOTHER polymorphism .	1
Enzyme activity assays with recombinant LCOTHER isoforms ( LCOTHER LCOTHER and LCOTHER LCSequenceVariant ) and the LCChemicalEntity substrate LCOTHER were used to investigate the functional impact of the LCOTHER LCOTHER polymorphism .	1
RESULTS : Multivariate analyses adjusted for sex and primary disease recurrence were used to test for associations between the candidate genetic polymorphisms ( LCOTHER * 2 and LCGeneOrGeneProduct LCOTHER ) and the risk of LCDiseaseOrPhenotypicFeature .	1
RESULTS : Multivariate analyses adjusted for sex and primary disease recurrence were used to test for associations between the candidate genetic polymorphisms ( LCOTHER * 2 and LCOTHER LCSequenceVariant ) and the risk of LCDiseaseOrPhenotypicFeature .	2
Analyses indicated no association between the LCOTHER * 2 polymorphism and the risk of LCChemicalEntity - related LCDiseaseOrPhenotypicFeature ( odds ratio [ OR ] , 1 . 04 ; P = . 97 ) .	2
There was a trend toward an association between the LCGeneOrGeneProduct LCOTHER polymorphism and the risk of LCDiseaseOrPhenotypicFeature ( OR , 8 . 16 ; P = . 056 for G / G vs A / A ; OR , 5 . 44 ; P = . 092 for G / A vs A / A ) .	1
There was a trend toward an association between the LCOTHER LCSequenceVariant polymorphism and the risk of LCDiseaseOrPhenotypicFeature ( OR , 8 . 16 ; P = . 056 for G / G vs A / A ; OR , 5 . 44 ; P = . 092 for G / A vs A / A ) .	2
In line , recombinant LCGeneOrGeneProduct LCOTHER ( G allele ) synthesized 2 . 6 - fold more LCDiseaseOrPhenotypicFeature LCOTHER per unit of time than LCOTHER LCOTHER ( A allele ; LCOTHER LCOTHER [ 8 . 26 + / - 3 . 57 nmol / hour . mg ] vs LCOTHER LCOTHER [ 3 . 22 + / - 0 . 67 nmol / hour . mg ] ; P = . 01 ) .	1
In line , recombinant LCGeneOrGeneProduct LCOTHER ( G allele ) synthesized 2 . 6 - fold more LCOTHER LCChemicalEntity per unit of time than LCOTHER LCOTHER ( A allele ; LCOTHER LCOTHER [ 8 . 26 + / - 3 . 57 nmol / hour . mg ] vs LCOTHER LCOTHER [ 3 . 22 + / - 0 . 67 nmol / hour . mg ] ; P = . 01 ) .	1
In line , recombinant LCOTHER LCSequenceVariant ( G allele ) synthesized 2 . 6 - fold more LCOTHER LCChemicalEntity per unit of time than LCOTHER LCOTHER ( A allele ; LCOTHER LCOTHER [ 8 . 26 + / - 3 . 57 nmol / hour . mg ] vs LCOTHER LCOTHER [ 3 . 22 + / - 0 . 67 nmol / hour . mg ] ; P = . 01 ) .	1
In line , recombinant LCOTHER LCOTHER ( G allele ) synthesized 2 . 6 - fold more LCDiseaseOrPhenotypicFeature LCChemicalEntity per unit of time than LCOTHER LCOTHER ( A allele ; LCOTHER LCOTHER [ 8 . 26 + / - 3 . 57 nmol / hour . mg ] vs LCOTHER LCOTHER [ 3 . 22 + / - 0 . 67 nmol / hour . mg ] ; P = . 01 ) .	2
CONCLUSIONS : The functional LCGeneOrGeneProduct LCOTHER polymorphism may have an impact on the risk of LCChemicalEntity - related LCOTHER among childhood LCOTHER survivors by modulating the intracardiac formation of LCOTHER LCOTHER LCOTHER metabolites .	1
CONCLUSIONS : The functional LCGeneOrGeneProduct LCOTHER polymorphism may have an impact on the risk of LCOTHER - related LCDiseaseOrPhenotypicFeature among childhood LCOTHER survivors by modulating the intracardiac formation of LCOTHER LCOTHER LCOTHER metabolites .	1
CONCLUSIONS : The functional LCGeneOrGeneProduct LCOTHER polymorphism may have an impact on the risk of LCOTHER - related LCOTHER among childhood LCOTHER survivors by modulating the intracardiac formation of LCDiseaseOrPhenotypicFeature LCOTHER LCOTHER metabolites .	1
CONCLUSIONS : The functional LCOTHER LCSequenceVariant polymorphism may have an impact on the risk of LCChemicalEntity - related LCOTHER among childhood LCOTHER survivors by modulating the intracardiac formation of LCOTHER LCOTHER LCOTHER metabolites .	1
CONCLUSIONS : The functional LCOTHER LCSequenceVariant polymorphism may have an impact on the risk of LCOTHER - related LCDiseaseOrPhenotypicFeature among childhood LCOTHER survivors by modulating the intracardiac formation of LCOTHER LCOTHER LCOTHER metabolites .	2
CONCLUSIONS : The functional LCOTHER LCOTHER polymorphism may have an impact on the risk of LCChemicalEntity - related LCDiseaseOrPhenotypicFeature among childhood LCOTHER survivors by modulating the intracardiac formation of LCOTHER LCOTHER LCOTHER metabolites .	2
CONCLUSIONS : The functional LCOTHER LCOTHER polymorphism may have an impact on the risk of LCChemicalEntity - related LCOTHER among childhood LCDiseaseOrPhenotypicFeature survivors by modulating the intracardiac formation of LCOTHER LCOTHER LCOTHER metabolites .	3
CONCLUSIONS : The functional LCOTHER LCOTHER polymorphism may have an impact on the risk of LCChemicalEntity - related LCOTHER among childhood LCOTHER survivors by modulating the intracardiac formation of LCDiseaseOrPhenotypicFeature LCOTHER LCOTHER metabolites .	2
LCGeneOrGeneProduct LCGeneOrGeneProduct gene polymorphisms have been demonstrated to associate with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk , of which LCOTHER - LCOTHER / LCOTHER and - LCOTHER / LCOTHER changes have been well investigated due to the possibility that they may alter the LCOTHER transcription .	1
The signal transduction target upon LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) stimulation , the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) activation , supports LCOTHER development , signal transduction in which is mediated by LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) signaling .	1
The signal transduction target upon LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) stimulation , the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) activation , supports LCOTHER development , signal transduction in which is mediated by LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) signaling .	1
The signal transduction target upon LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) stimulation , the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) activation , supports LCDiseaseOrPhenotypicFeature development , signal transduction in which is mediated by LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) signaling .	1
The signal transduction target upon LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) stimulation , the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) activation , supports LCOTHER development , signal transduction in which is mediated by LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) signaling .	1
The signal transduction target upon LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) stimulation , the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) activation , supports LCOTHER development , signal transduction in which is mediated by LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) signaling .	1
The signal transduction target upon LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) stimulation , the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) activation , supports LCDiseaseOrPhenotypicFeature development , signal transduction in which is mediated by LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) signaling .	1
The signal transduction target upon LCOTHER LCOTHER LCOTHER ( LCOTHER ) stimulation , the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) activation , supports LCDiseaseOrPhenotypicFeature development , signal transduction in which is mediated by LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) signaling .	1
The signal transduction target upon LCOTHER LCOTHER LCOTHER ( LCOTHER ) stimulation , the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) activation , supports LCDiseaseOrPhenotypicFeature development , signal transduction in which is mediated by LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) signaling .	1
Based on recent papers describing the prognostic roles of the polymorphisms and the LCGeneOrGeneProduct functions on LCDiseaseOrPhenotypicFeature development , we sought to determine if Japanese LCOTHER LCOTHER LCOTHER were affected by the LCOTHER - 31 / - 511 and LCOTHER - 670 polymorphisms .	1
We observed strong linkage disequilibrium between the LCSequenceVariant LCSequenceVariant LCSequenceVariant - LCSequenceVariant and the LCSequenceVariant LCSequenceVariant LCSequenceVariant - LCSequenceVariant and between the LCOTHER LCOTHER LCOTHER - LCOTHER and the LCOTHER LCOTHER LCOTHER - LCOTHER in LCOTHER in both the cases and controls ( R ( 2 ) = 0 . 94 ) .	1
We observed strong linkage disequilibrium between the LCSequenceVariant LCSequenceVariant LCSequenceVariant - LCSequenceVariant and the LCOTHER LCOTHER LCOTHER - LCOTHER and between the LCOTHER LCOTHER LCOTHER - LCOTHER and the LCSequenceVariant LCSequenceVariant LCSequenceVariant - LCSequenceVariant in LCOTHER in both the cases and controls ( R ( 2 ) = 0 . 94 ) .	1
We observed strong linkage disequilibrium between the LCOTHER LCOTHER LCOTHER - LCOTHER and the LCOTHER LCOTHER LCOTHER - LCOTHER and between the LCSequenceVariant LCSequenceVariant LCSequenceVariant - LCSequenceVariant and the LCSequenceVariant LCSequenceVariant LCSequenceVariant - LCSequenceVariant in LCOTHER in both the cases and controls ( R ( 2 ) = 0 . 94 ) .	1
Neither LCGeneOrGeneProduct - 31 , - 511 nor LCOTHER - 670 polymorphisms showed significantly different risks of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
Compared with a normoxic , chow - fed control LCOTHER heart , LCDiseaseOrPhenotypicFeature decreased LCGeneOrGeneProduct expression , LCOTHER LCOTHER oxidation , and LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) levels , while increasing glycolysis , all of which served to maintain normal LCOTHER concentrations ( [ LCOTHER ] ) and thereby , ejection fractions .	3
Compared with a normoxic , chow - fed control LCOTHER heart , LCDiseaseOrPhenotypicFeature decreased LCOTHER expression , LCChemicalEntity LCChemicalEntity oxidation , and LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) levels , while increasing glycolysis , all of which served to maintain normal LCOTHER concentrations ( [ LCOTHER ] ) and thereby , ejection fractions .	3
Compared with a normoxic , chow - fed control LCOTHER heart , LCDiseaseOrPhenotypicFeature decreased LCOTHER expression , LCOTHER LCOTHER oxidation , and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) levels , while increasing glycolysis , all of which served to maintain normal LCOTHER concentrations ( [ LCOTHER ] ) and thereby , ejection fractions .	3
Compared with a normoxic , chow - fed control LCOTHER heart , LCDiseaseOrPhenotypicFeature decreased LCOTHER expression , LCOTHER LCOTHER oxidation , and LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) levels , while increasing glycolysis , all of which served to maintain normal LCOTHER concentrations ( [ LCOTHER ] ) and thereby , ejection fractions .	3
Compared with a normoxic , chow - fed control LCOTHER heart , LCDiseaseOrPhenotypicFeature decreased LCOTHER expression , LCOTHER LCOTHER oxidation , and LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) levels , while increasing glycolysis , all of which served to maintain normal LCChemicalEntity concentrations ( [ LCOTHER ] ) and thereby , ejection fractions .	3
Compared with a normoxic , chow - fed control LCOTHER heart , LCDiseaseOrPhenotypicFeature decreased LCOTHER expression , LCOTHER LCOTHER oxidation , and LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) levels , while increasing glycolysis , all of which served to maintain normal LCOTHER concentrations ( [ LCChemicalEntity ] ) and thereby , ejection fractions .	3
Compared with a normoxic , chow - fed control LCOTHER heart , LCOTHER decreased LCGeneOrGeneProduct expression , LCOTHER LCOTHER oxidation , and LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) levels , while increasing glycolysis , all of which served to maintain normal LCChemicalEntity concentrations ( [ LCOTHER ] ) and thereby , ejection fractions .	1
Compared with a normoxic , chow - fed control LCOTHER heart , LCOTHER decreased LCGeneOrGeneProduct expression , LCOTHER LCOTHER oxidation , and LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) levels , while increasing glycolysis , all of which served to maintain normal LCOTHER concentrations ( [ LCChemicalEntity ] ) and thereby , ejection fractions .	1
Compared with a normoxic , chow - fed control LCOTHER heart , LCOTHER decreased LCOTHER expression , LCChemicalEntity LCChemicalEntity oxidation , and LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) levels , while increasing glycolysis , all of which served to maintain normal LCChemicalEntity concentrations ( [ LCOTHER ] ) and thereby , ejection fractions .	1
Compared with a normoxic , chow - fed control LCOTHER heart , LCOTHER decreased LCOTHER expression , LCChemicalEntity LCChemicalEntity oxidation , and LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) levels , while increasing glycolysis , all of which served to maintain normal LCOTHER concentrations ( [ LCChemicalEntity ] ) and thereby , ejection fractions .	1
Compared with a normoxic , chow - fed control LCOTHER heart , LCOTHER decreased LCOTHER expression , LCOTHER LCOTHER oxidation , and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) levels , while increasing glycolysis , all of which served to maintain normal LCChemicalEntity concentrations ( [ LCOTHER ] ) and thereby , ejection fractions .	1
Compared with a normoxic , chow - fed control LCOTHER heart , LCOTHER decreased LCOTHER expression , LCOTHER LCOTHER oxidation , and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) levels , while increasing glycolysis , all of which served to maintain normal LCOTHER concentrations ( [ LCChemicalEntity ] ) and thereby , ejection fractions .	1
Compared with a normoxic , chow - fed control LCOTHER heart , LCOTHER decreased LCOTHER expression , LCOTHER LCOTHER oxidation , and LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) levels , while increasing glycolysis , all of which served to maintain normal LCChemicalEntity concentrations ( [ LCOTHER ] ) and thereby , ejection fractions .	1
Compared with a normoxic , chow - fed control LCOTHER heart , LCOTHER decreased LCOTHER expression , LCOTHER LCOTHER oxidation , and LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) levels , while increasing glycolysis , all of which served to maintain normal LCOTHER concentrations ( [ LCChemicalEntity ] ) and thereby , ejection fractions .	1
LCDiseaseOrPhenotypicFeature was unable to alter the high LCGeneOrGeneProduct expression or reverse the metabolic changes caused by the high - fat diet , with the result that [ LCOTHER ] and contractile function decreased significantly .	3
LCDiseaseOrPhenotypicFeature was unable to alter the high LCOTHER expression or reverse the metabolic changes caused by the high - fat diet , with the result that [ LCChemicalEntity ] and contractile function decreased significantly .	3
LCOTHER was unable to alter the high LCGeneOrGeneProduct expression or reverse the metabolic changes caused by the high - fat diet , with the result that [ LCChemicalEntity ] and contractile function decreased significantly .	1
The adaptive metabolic changes caused by LCDiseaseOrPhenotypicFeature in control LCOTHER hearts were found to have occurred already in LCGeneOrGeneProduct - deficient ( LCOTHER ( - / - ) ) LCOTHER hearts and sustained function in LCOTHER despite an inability for further metabolic remodeling .	3
The adaptive metabolic changes caused by LCDiseaseOrPhenotypicFeature in control LCOTHER hearts were found to have occurred already in LCOTHER - deficient ( LCGeneOrGeneProduct ( - / - ) ) LCOTHER hearts and sustained function in LCOTHER despite an inability for further metabolic remodeling .	3
The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between LCChemicalEntity usage and LCDiseaseOrPhenotypicFeature after cardiac surgery .	2
CONCLUSION : Our results suggest that use of high - dose LCChemicalEntity in older LCOTHER in conjunction with cardiopulmonary bypass and open - chamber cardiac surgery is associated with clinical LCDiseaseOrPhenotypicFeature in susceptible LCOTHER . Cardioprotective effect of LCOTHER LCOTHER LCOTHER on LCOTHER - induced LCOTHER LCOTHER in LCOTHER .	2
The present study was done to investigate the protective effect of LCChemicalEntity on experimentally induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER .	3
Pretreatment of LCChemicalEntity , at a dose of 0 . 5 mL / 100 g bodyweight per day , orally for 30 days , prevented the increase in LCChemicalEntity peroxidation and activity of marker enzymes observed in LCOTHER - induced LCOTHER ( 85 mg kg ( - 1 ) s .	1
Pretreatment of LCChemicalEntity , at a dose of 0 . 5 mL / 100 g bodyweight per day , orally for 30 days , prevented the increase in LCOTHER peroxidation and activity of marker enzymes observed in LCChemicalEntity - induced LCOTHER ( 85 mg kg ( - 1 ) s .	3
LCChemicalEntity prevented the LCChemicalEntity - induced decrease in antioxidant enzymes in the heart and increased the rate of LCOTHER - stimulated LCOTHER uptake and respiratory coupling ratio .	3
LCChemicalEntity prevented the LCOTHER - induced decrease in antioxidant enzymes in the heart and increased the rate of LCChemicalEntity - stimulated LCOTHER uptake and respiratory coupling ratio .	2
LCChemicalEntity prevented the LCOTHER - induced decrease in antioxidant enzymes in the heart and increased the rate of LCOTHER - stimulated LCChemicalEntity uptake and respiratory coupling ratio .	2
LCOTHER prevented the LCOTHER - induced decrease in antioxidant enzymes in the heart and increased the rate of LCChemicalEntity - stimulated LCChemicalEntity uptake and respiratory coupling ratio .	2
LCChemicalEntity protected against pathological changes induced by LCChemicalEntity in LCOTHER heart .	3
The results show that pretreatment with LCChemicalEntity may be useful in preventing the damage induced by LCChemicalEntity in LCOTHER heart . LCOTHER increases metastatic potential of LCOTHER LCOTHER cells in vivo and alters expression of genes involved in cell motility .	3
Although the role of LCGeneOrGeneProduct in LCDiseaseOrPhenotypicFeature is controversial , a number of studies have shown that elevated levels correlate with aggressive LCOTHER behavior , advanced stage , and poor prognosis .	1
Although the role of LCGeneOrGeneProduct in LCOTHER is controversial , a number of studies have shown that elevated levels correlate with aggressive LCDiseaseOrPhenotypicFeature behavior , advanced stage , and poor prognosis .	1
Here we sought to determine the role of LCGeneOrGeneProduct more directly by determining whether experimental manipulation of LCGeneOrGeneProduct levels in LCOTHER LCOTHER ( LCOTHER ) cells led to changes in metastatic potential in vivo .	1
Here we sought to determine the role of LCGeneOrGeneProduct more directly by determining whether experimental manipulation of LCOTHER levels in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) cells led to changes in metastatic potential in vivo .	1
Here we sought to determine the role of LCGeneOrGeneProduct more directly by determining whether experimental manipulation of LCOTHER levels in LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) cells led to changes in metastatic potential in vivo .	1
Here we sought to determine the role of LCOTHER more directly by determining whether experimental manipulation of LCGeneOrGeneProduct levels in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) cells led to changes in metastatic potential in vivo .	1
Here we sought to determine the role of LCOTHER more directly by determining whether experimental manipulation of LCGeneOrGeneProduct levels in LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) cells led to changes in metastatic potential in vivo .	1
Investigation of mRNA expression patterns showed that LCGeneOrGeneProduct overexpression altered the levels of approximately 250 other transcripts , with over - representation of genes that affect function of LCGeneOrGeneProduct or other LCOTHER LCOTHER .	1
CONCLUSIONS : Increases or decreases in LCGeneOrGeneProduct levels have reciprocal effects on LCDiseaseOrPhenotypicFeature cell behavior , with higher expression promoting metastasis .	1
AIMS : Individuals with both LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) and the LCGeneOrGeneProduct ( LCOTHER ) 2 - 2 genotype are at increased risk of LCOTHER LCOTHER .	1
AIMS : Individuals with both LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) and the LCOTHER ( LCGeneOrGeneProduct ) 2 - 2 genotype are at increased risk of LCOTHER LCOTHER .	1
AIMS : Individuals with both LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) and the LCGeneOrGeneProduct ( LCOTHER ) 2 - 2 genotype are at increased risk of LCOTHER LCOTHER .	1
AIMS : Individuals with both LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) and the LCOTHER ( LCGeneOrGeneProduct ) 2 - 2 genotype are at increased risk of LCOTHER LCOTHER .	1
AIMS : Individuals with both LCOTHER LCOTHER ( LCOTHER ) and the LCGeneOrGeneProduct ( LCOTHER ) 2 - 2 genotype are at increased risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
AIMS : Individuals with both LCOTHER LCOTHER ( LCOTHER ) and the LCOTHER ( LCGeneOrGeneProduct ) 2 - 2 genotype are at increased risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
As the antioxidant function of the LCOTHER 2 - 2 protein is impaired , we sought to test the pharmacogenomic hypothesis that LCOTHER LCChemicalEntity LCChemicalEntity supplementation would provide cardiovascular protection to LCGeneOrGeneProduct 2 - 2 LCOTHER individuals .	1
As the antioxidant function of the LCOTHER 2 - 2 protein is impaired , we sought to test the pharmacogenomic hypothesis that LCOTHER LCChemicalEntity LCChemicalEntity supplementation would provide cardiovascular protection to LCOTHER 2 - 2 LCDiseaseOrPhenotypicFeature individuals .	3
MATERIALS & METHODS : We determined the LCGeneOrGeneProduct genotype on LCOTHER participants from two trials ( HOPE and ICARE ) and assessed the effect of LCOTHER LCOTHER by LCOTHER genotype on their common prespecified outcome , the composite of LCOTHER , LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
MATERIALS & METHODS : We determined the LCOTHER genotype on LCDiseaseOrPhenotypicFeature participants from two trials ( HOPE and ICARE ) and assessed the effect of LCOTHER LCOTHER by LCGeneOrGeneProduct genotype on their common prespecified outcome , the composite of LCOTHER , LCOTHER LCOTHER and LCOTHER LCOTHER .	1
MATERIALS & METHODS : We determined the LCOTHER genotype on LCOTHER participants from two trials ( HOPE and ICARE ) and assessed the effect of LCChemicalEntity LCChemicalEntity by LCGeneOrGeneProduct genotype on their common prespecified outcome , the composite of LCOTHER , LCOTHER LCOTHER and LCOTHER LCOTHER .	1
MATERIALS & METHODS : We determined the LCOTHER genotype on LCOTHER participants from two trials ( HOPE and ICARE ) and assessed the effect of LCChemicalEntity LCChemicalEntity by LCOTHER genotype on their common prespecified outcome , the composite of LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER and LCOTHER LCOTHER .	3
MATERIALS & METHODS : We determined the LCOTHER genotype on LCOTHER participants from two trials ( HOPE and ICARE ) and assessed the effect of LCChemicalEntity LCChemicalEntity by LCOTHER genotype on their common prespecified outcome , the composite of LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER .	3
MATERIALS & METHODS : We determined the LCOTHER genotype on LCOTHER participants from two trials ( HOPE and ICARE ) and assessed the effect of LCChemicalEntity LCChemicalEntity by LCOTHER genotype on their common prespecified outcome , the composite of LCOTHER , LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
MATERIALS & METHODS : We determined the LCOTHER genotype on LCOTHER participants from two trials ( HOPE and ICARE ) and assessed the effect of LCOTHER LCOTHER by LCGeneOrGeneProduct genotype on their common prespecified outcome , the composite of LCOTHER , LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
In these trials , LCGeneOrGeneProduct typing of 69 LCOTHER individuals and treating those with the LCOTHER 2 - 2 with LCOTHER LCOTHER prevented one LCOTHER LCOTHER , LCOTHER or LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
In these trials , LCOTHER typing of 69 LCDiseaseOrPhenotypicFeature individuals and treating those with the LCGeneOrGeneProduct 2 - 2 with LCOTHER LCOTHER prevented one LCOTHER LCOTHER , LCOTHER or LCOTHER LCOTHER .	1
In these trials , LCOTHER typing of 69 LCOTHER individuals and treating those with the LCGeneOrGeneProduct 2 - 2 with LCOTHER LCOTHER prevented one LCOTHER LCOTHER , LCOTHER or LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
In these trials , LCOTHER typing of 69 LCOTHER individuals and treating those with the LCOTHER 2 - 2 with LCChemicalEntity LCChemicalEntity prevented one LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER or LCOTHER LCOTHER .	3
In these trials , LCOTHER typing of 69 LCOTHER individuals and treating those with the LCOTHER 2 - 2 with LCChemicalEntity LCChemicalEntity prevented one LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature or LCOTHER LCOTHER .	3
In these trials , LCOTHER typing of 69 LCOTHER individuals and treating those with the LCOTHER 2 - 2 with LCChemicalEntity LCChemicalEntity prevented one LCOTHER LCOTHER , LCOTHER or LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
Lifelong administration of LCChemicalEntity LCChemicalEntity to LCGeneOrGeneProduct 2 - 2 LCOTHER individuals in the Kaiser population would increase their life expectancy by 3 years .	1
Lifelong administration of LCChemicalEntity LCChemicalEntity to LCOTHER 2 - 2 LCDiseaseOrPhenotypicFeature individuals in the Kaiser population would increase their life expectancy by 3 years .	3
CONCLUSION : A pharmacogenomic strategy of screening LCDiseaseOrPhenotypicFeature individuals for the LCGeneOrGeneProduct genotype and treating those with LCOTHER 2 - 2 with LCOTHER LCOTHER appears to be highly clinically effective . LCOTHER pharmacogenomics and risk of inadequate platelet inhibition : US FDA recommendations .	1
CONCLUSION : A pharmacogenomic strategy of screening LCDiseaseOrPhenotypicFeature individuals for the LCOTHER genotype and treating those with LCGeneOrGeneProduct 2 - 2 with LCOTHER LCOTHER appears to be highly clinically effective . LCOTHER pharmacogenomics and risk of inadequate platelet inhibition : US FDA recommendations .	1
Antiplatelet therapy with LCChemicalEntity is the current standard of care for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER undergoing a percutaneous coronary intervention .	3
LCChemicalEntity is a prodrug that undergoes hepatic biotransformation by LCGeneOrGeneProduct into its active metabolite .	1
Consequently , the US FDA has recently changed LCChemicalEntity ' s prescribing information to highlight the impact of LCGeneOrGeneProduct genotype on LCOTHER pharmacokinetics , pharmacodynamics and clinical response .	1
Dysregulation of the oncogenic transcription factor LCGeneOrGeneProduct induces B - cell transformation and is a driver for LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER - LCOTHER ) .	1
Dysregulation of the oncogenic transcription factor LCGeneOrGeneProduct induces B - cell transformation and is a driver for LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature ) .	1
LCGeneOrGeneProduct overexpression in LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature is associated with more aggressive phenotypes and poor prognosis .	1
Although genomic studies suggest a link between LCGeneOrGeneProduct overexpression and LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) signaling molecules in LCOTHER - LCOTHER , signaling pathways essential to LCOTHER - mediated B - cell transformation have not been fully elucidated .	2
Although genomic studies suggest a link between LCGeneOrGeneProduct overexpression and LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) signaling molecules in LCOTHER - LCOTHER , signaling pathways essential to LCOTHER - mediated B - cell transformation have not been fully elucidated .	2
Although genomic studies suggest a link between LCGeneOrGeneProduct overexpression and LCOTHER - LCOTHER LCOTHER ( LCOTHER ) signaling molecules in LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , signaling pathways essential to LCOTHER - mediated B - cell transformation have not been fully elucidated .	1
We utilized intracellular phospho - flow cytometry to investigate the relationship between LCGeneOrGeneProduct and LCGeneOrGeneProduct signaling in pre - malignant B cells .	2
Utilizing the Eu - LCGeneOrGeneProduct LCOTHER model , where LCOTHER is overexpressed specifically in B cells , both basal and stimulated LCGeneOrGeneProduct signaling were increased in LCOTHER B lymphocytes from Eu - LCOTHER LCOTHER compared with wild - type littermates .	2
Utilizing the Eu - LCGeneOrGeneProduct LCOTHER model , where LCOTHER is overexpressed specifically in B cells , both basal and stimulated LCOTHER signaling were increased in LCDiseaseOrPhenotypicFeature B lymphocytes from Eu - LCOTHER LCOTHER compared with wild - type littermates .	1
Utilizing the Eu - LCOTHER LCOTHER model , where LCGeneOrGeneProduct is overexpressed specifically in B cells , both basal and stimulated LCGeneOrGeneProduct signaling were increased in LCOTHER B lymphocytes from Eu - LCOTHER LCOTHER compared with wild - type littermates .	2
Utilizing the Eu - LCOTHER LCOTHER model , where LCGeneOrGeneProduct is overexpressed specifically in B cells , both basal and stimulated LCOTHER signaling were increased in LCDiseaseOrPhenotypicFeature B lymphocytes from Eu - LCOTHER LCOTHER compared with wild - type littermates .	1
Utilizing the Eu - LCOTHER LCOTHER model , where LCOTHER is overexpressed specifically in B cells , both basal and stimulated LCGeneOrGeneProduct signaling were increased in LCDiseaseOrPhenotypicFeature B lymphocytes from Eu - LCOTHER LCOTHER compared with wild - type littermates .	1
B cells overexpressing LCGeneOrGeneProduct displayed constitutively higher levels of activated LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER / LCOTHER .	2
B cells overexpressing LCGeneOrGeneProduct displayed constitutively higher levels of activated LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER / LCOTHER .	2
B cells overexpressing LCGeneOrGeneProduct displayed constitutively higher levels of activated LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER / LCOTHER .	2
Notably , LCGeneOrGeneProduct - overexpressing B cells maintained elevated LCGeneOrGeneProduct signaling despite treatment with LCOTHER , a LCOTHER ' LCOTHER LCOTHER LCOTHER inhibitor .	2
Notably , LCOTHER - overexpressing B cells maintained elevated LCGeneOrGeneProduct signaling despite treatment with LCChemicalEntity , a LCOTHER ' LCOTHER LCOTHER LCOTHER inhibitor .	1
Notably , LCOTHER - overexpressing B cells maintained elevated LCOTHER signaling despite treatment with LCChemicalEntity , a LCGeneOrGeneProduct ' LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct inhibitor .	3
Furthermore , LCGeneOrGeneProduct / LCGeneOrGeneProduct pathway signaling was also increased in Eu - LCOTHER B cells , and this increase was partially suppressed with LCOTHER .	1
Furthermore , LCGeneOrGeneProduct / LCOTHER pathway signaling was also increased in Eu - LCGeneOrGeneProduct B cells , and this increase was partially suppressed with LCOTHER .	2
Furthermore , LCGeneOrGeneProduct / LCOTHER pathway signaling was also increased in Eu - LCOTHER B cells , and this increase was partially suppressed with LCChemicalEntity .	3
Furthermore , LCOTHER / LCGeneOrGeneProduct pathway signaling was also increased in Eu - LCGeneOrGeneProduct B cells , and this increase was partially suppressed with LCOTHER .	2
Furthermore , LCOTHER / LCGeneOrGeneProduct pathway signaling was also increased in Eu - LCOTHER B cells , and this increase was partially suppressed with LCChemicalEntity .	3
Our data show that in pre - malignant B cells , LCGeneOrGeneProduct overexpression is sufficient to activate LCGeneOrGeneProduct and LCOTHER / LCOTHER signaling pathways and further enhances signaling following LCOTHER ligation .	2
Our data show that in pre - malignant B cells , LCGeneOrGeneProduct overexpression is sufficient to activate LCOTHER and LCOTHER / LCOTHER signaling pathways and further enhances signaling following LCGeneOrGeneProduct ligation .	2
Our data show that in pre - malignant B cells , LCOTHER overexpression is sufficient to activate LCOTHER and LCGeneOrGeneProduct / LCGeneOrGeneProduct signaling pathways and further enhances signaling following LCOTHER ligation .	1
Therefore , our results indicate that LCOTHER B cells have already acquired enhanced survival and growth capabilities before transformation , and that elevated LCGeneOrGeneProduct levels confer resistance to pharmacologic inhibitors of LCGeneOrGeneProduct signaling , which has significant implications for LCOTHER - LCOTHER treatment . Genetic investigation of four meiotic genes in LCOTHER with LCOTHER LCOTHER LCOTHER .	2
Therefore , our results indicate that LCOTHER B cells have already acquired enhanced survival and growth capabilities before transformation , and that elevated LCGeneOrGeneProduct levels confer resistance to pharmacologic inhibitors of LCOTHER signaling , which has significant implications for LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature treatment . Genetic investigation of four meiotic genes in LCOTHER with LCOTHER LCOTHER LCOTHER .	1
RESULTS : A single heterozygous missense mutation , substitution of a LCOTHER LCOTHER LCOTHER LCOTHER in exon 2 of LCGeneOrGeneProduct , was found in two Caucasian LCOTHER in whom LCDiseaseOrPhenotypicFeature developed at 18 and 36 years of age .	1
CONCLUSIONS : The symptoms of LCDiseaseOrPhenotypicFeature observed in the LCOTHER homozygote mutation carrier and in both LCOTHER with a heterozygous substitution in exon 2 of the LCGeneOrGeneProduct gene provide indirect evidence of the role of genes involved in meiotic recombination in the regulation of ovarian function .	1
LCGeneOrGeneProduct and LCOTHER mutations may be one explanation for LCDiseaseOrPhenotypicFeature , albeit uncommon . LCOTHER antagonizes LCOTHER - but not LCOTHER - induced LCOTHER LCOTHER in LCOTHER .	1
LCOTHER and LCGeneOrGeneProduct mutations may be one explanation for LCDiseaseOrPhenotypicFeature , albeit uncommon . LCOTHER antagonizes LCOTHER - but not LCOTHER - induced LCOTHER LCOTHER in LCOTHER .	1
RATIONALE : LCChemicalEntity and LCChemicalEntity are widely consumed licit LCOTHER LCOTHER worldwide .	3
OBJECTIVES : The present study investigates the effects of LCChemicalEntity on LCDiseaseOrPhenotypicFeature induced by LCOTHER and another LCOTHER LCOTHER , LCOTHER , in LCOTHER .	3
OBJECTIVES : The present study investigates the effects of LCChemicalEntity on LCOTHER induced by LCChemicalEntity and another LCOTHER LCOTHER , LCOTHER , in LCOTHER .	3
METHODS : Adult male Swiss Webster LCOTHER ( 25 - 32 g ) were given LCChemicalEntity ( 0 . 05 - 0 . 25 mg / kg s . c . ) or saline 10 min before LCChemicalEntity ( 70 mg / kg i . p . ) or LCOTHER ( 15 and 30 mg / kg i . p . ) injections .	3
RESULTS : LCChemicalEntity ( 0 . 05 - 0 . 25 mg / kg ) itself did not produce any significant effect in the EPM test , whereas LCChemicalEntity ( 70 mg / kg ) and LCOTHER ( 30 mg / kg ) produced an LCOTHER LCOTHER , apparent with decreases in open - arm time and entry .	3
RESULTS : LCChemicalEntity ( 0 . 05 - 0 . 25 mg / kg ) itself did not produce any significant effect in the EPM test , whereas LCOTHER ( 70 mg / kg ) and LCOTHER ( 30 mg / kg ) produced an LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , apparent with decreases in open - arm time and entry .	3
RESULTS : LCOTHER ( 0 . 05 - 0 . 25 mg / kg ) itself did not produce any significant effect in the EPM test , whereas LCChemicalEntity ( 70 mg / kg ) and LCOTHER ( 30 mg / kg ) produced an LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , apparent with decreases in open - arm time and entry .	2
RESULTS : LCOTHER ( 0 . 05 - 0 . 25 mg / kg ) itself did not produce any significant effect in the EPM test , whereas LCOTHER ( 70 mg / kg ) and LCChemicalEntity ( 30 mg / kg ) produced an LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , apparent with decreases in open - arm time and entry .	2
LCChemicalEntity ( 0 . 25 mg / kg ) pretreatment blocked the LCChemicalEntity - but not LCOTHER - induced LCOTHER .	3
LCChemicalEntity ( 0 . 25 mg / kg ) pretreatment blocked the LCOTHER - but not LCOTHER - induced LCDiseaseOrPhenotypicFeature .	3
LCOTHER ( 0 . 25 mg / kg ) pretreatment blocked the LCChemicalEntity - but not LCOTHER - induced LCDiseaseOrPhenotypicFeature .	2
LCOTHER ( 0 . 25 mg / kg ) pretreatment blocked the LCOTHER - but not LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature .	2
CONCLUSIONS : Our results suggest that the antagonistic effect of LCChemicalEntity on LCChemicalEntity - induced LCOTHER is specific to LCOTHER , instead of a non - specific anxiolytic effect .	3
CONCLUSIONS : Our results suggest that the antagonistic effect of LCChemicalEntity on LCOTHER - induced LCDiseaseOrPhenotypicFeature is specific to LCOTHER , instead of a non - specific anxiolytic effect .	3
CONCLUSIONS : Our results suggest that the antagonistic effect of LCChemicalEntity on LCOTHER - induced LCOTHER is specific to LCChemicalEntity , instead of a non - specific anxiolytic effect .	3
CONCLUSIONS : Our results suggest that the antagonistic effect of LCOTHER on LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature is specific to LCOTHER , instead of a non - specific anxiolytic effect .	2
Thus , it may extend the current findings on the interaction between LCChemicalEntity and LCChemicalEntity . Behavioral effects of pubertal LCOTHER LCOTHER LCOTHER exposure in male LCOTHER with low LCOTHER .	3
The goal of this study was to assess the interactive effects of chronic LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCOTHER ) exposure and brain LCChemicalEntity ( LCOTHER - LCOTHER , LCOTHER - LCOTHER ) depletion on behavior of pubertal male LCOTHER .	1
The goal of this study was to assess the interactive effects of chronic LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCOTHER ) exposure and brain LCOTHER ( LCChemicalEntity - LCChemicalEntity , LCOTHER - LCOTHER ) depletion on behavior of pubertal male LCOTHER .	1
The goal of this study was to assess the interactive effects of chronic LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCOTHER ) exposure and brain LCOTHER ( LCOTHER - LCOTHER , LCChemicalEntity - LCChemicalEntity ) depletion on behavior of pubertal male LCOTHER .	1
The goal of this study was to assess the interactive effects of chronic LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) exposure and brain LCChemicalEntity ( LCOTHER - LCOTHER , LCOTHER - LCOTHER ) depletion on behavior of pubertal male LCOTHER .	1
The goal of this study was to assess the interactive effects of chronic LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) exposure and brain LCOTHER ( LCChemicalEntity - LCChemicalEntity , LCOTHER - LCOTHER ) depletion on behavior of pubertal male LCOTHER .	1
The goal of this study was to assess the interactive effects of chronic LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) exposure and brain LCOTHER ( LCOTHER - LCOTHER , LCChemicalEntity - LCChemicalEntity ) depletion on behavior of pubertal male LCOTHER .	1
LCChemicalEntity significantly and substantially depleted LCChemicalEntity - LCChemicalEntity and LCOTHER - LCOTHER in all brain regions examined .	3
LCChemicalEntity significantly and substantially depleted LCOTHER - LCOTHER and LCChemicalEntity - LCChemicalEntity in all brain regions examined .	3
Chronic LCChemicalEntity treatment significantly decreased LCChemicalEntity - LCChemicalEntity and LCOTHER - LCOTHER in certain brain areas , but to a much lesser extent than LCOTHER .	3
Chronic LCChemicalEntity treatment significantly decreased LCOTHER - LCOTHER and LCChemicalEntity - LCChemicalEntity in certain brain areas , but to a much lesser extent than LCOTHER .	3
Chronic LCChemicalEntity treatment significantly decreased LCOTHER - LCOTHER and LCOTHER - LCOTHER in certain brain areas , but to a much lesser extent than LCChemicalEntity .	1
Chronic exposure to LCChemicalEntity alone significantly decreased locomotor activity and increased LCDiseaseOrPhenotypicFeature but had no effect on sexual behavior , partner preference , or LCOTHER .	2
Chronic exposure to LCChemicalEntity alone significantly decreased locomotor activity and increased LCOTHER but had no effect on sexual behavior , partner preference , or LCDiseaseOrPhenotypicFeature .	2
LCChemicalEntity alone had no effect on locomotion , LCDiseaseOrPhenotypicFeature , or sexual behavior but increased partner preference and LCOTHER .	2
LCChemicalEntity alone had no effect on locomotion , LCOTHER , or sexual behavior but increased partner preference and LCDiseaseOrPhenotypicFeature .	2
The most striking effect of combining LCChemicalEntity + LCChemicalEntity was a significant increase in attack frequency as well as a significant decrease in the latency to attack , particularly following physical provocation .	1
Based on these data , it can be speculated that pubertal LCChemicalEntity users with low central LCChemicalEntity - LCChemicalEntity may be especially prone to exhibit LCOTHER LCOTHER . DNA damage and repair in LCOTHER LCOTHER - - a correlation with the LCOTHER and LCOTHER genes polymorphisms .	1
Based on these data , it can be speculated that pubertal LCChemicalEntity users with low central LCOTHER - LCOTHER may be especially prone to exhibit LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . DNA damage and repair in LCOTHER LCOTHER - - a correlation with the LCOTHER and LCOTHER genes polymorphisms .	2
Based on these data , it can be speculated that pubertal LCOTHER users with low central LCChemicalEntity - LCChemicalEntity may be especially prone to exhibit LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . DNA damage and repair in LCOTHER LCOTHER - - a correlation with the LCOTHER and LCOTHER genes polymorphisms .	1
We observed a strong association between LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature occurrence , impaired DNA repair in LCOTHER lymphocytes and the LCOTHER / LCOTHER genotype of the LCOTHER polymorphism of the LCGeneOrGeneProduct gene .	1
We did not observe any correlation between the LCOTHER polymorphism of the LCGeneOrGeneProduct gene and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , including subjects with impaired DNA repair and / or high levels of endogenous oxidative DNA lesions .	1
Therefore , our result suggest that the LCSequenceVariant polymorphism of the LCOTHER gene may be linked with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature by the modulation of the cellular response to oxidative stress and this polymorphism may be a useful additional marker in this disease along with the genetic or / and environmental indicators of oxidative stress . LCOTHER + dependence of the LCOTHER + - selective LCOTHER channel .	1
Microfluorimetry and patch - clamp experiments were performed on LCGeneOrGeneProduct - expressing LCOTHER cells to determine whether this LCChemicalEntity ( LCChemicalEntity + ) - sensing LCOTHER ( LCOTHER + ) channel is constitutively active .	3
Microfluorimetry and patch - clamp experiments were performed on LCGeneOrGeneProduct - expressing LCOTHER cells to determine whether this LCOTHER ( LCOTHER + ) - sensing LCChemicalEntity ( LCChemicalEntity + ) channel is constitutively active .	3
Intact cells loaded with LCChemicalEntity - LCChemicalEntity had an elevated intracellular free LCChemicalEntity ( LCChemicalEntity + ) concentration ( ( i ) ) , which decreased to the same level such as in non - transfected cells if external LCOTHER ( LCOTHER + ) was chelated by LCOTHER .	2
Intact cells loaded with LCChemicalEntity - LCChemicalEntity had an elevated intracellular free LCOTHER ( LCOTHER + ) concentration ( ( i ) ) , which decreased to the same level such as in non - transfected cells if external LCChemicalEntity ( LCChemicalEntity + ) was chelated by LCOTHER .	2
Whole cell recordings from non - transfected LCOTHER cells and cells expressing LCOTHER LCGeneOrGeneProduct revealed the presence of a basal inward current in both types of cells when the internal solution contained 0 . 1 mm LCOTHER and 100 nm ( i ) or if the cytosolic LCChemicalEntity ( LCChemicalEntity + ) buffering remained undisturbed in perforated patch - clamp experiments .	3
Whole cell recordings from non - transfected LCOTHER cells and cells expressing LCOTHER LCOTHER revealed the presence of a basal inward current in both types of cells when the internal solution contained 0 . 1 mm LCChemicalEntity and 100 nm ( i ) or if the cytosolic LCChemicalEntity ( LCChemicalEntity + ) buffering remained undisturbed in perforated patch - clamp experiments .	1
If recombinantly expressed LCGeneOrGeneProduct forms open channels , one would expect LCChemicalEntity ( LCChemicalEntity + ) - induced current inhibition , because LCOTHER is negatively regulated by internal LCOTHER ( LCOTHER + ) .	3
If recombinantly expressed LCGeneOrGeneProduct forms open channels , one would expect LCOTHER ( LCOTHER + ) - induced current inhibition , because LCOTHER is negatively regulated by internal LCChemicalEntity ( LCChemicalEntity + ) .	3
If recombinantly expressed LCOTHER forms open channels , one would expect LCOTHER ( LCOTHER + ) - induced current inhibition , because LCGeneOrGeneProduct is negatively regulated by internal LCChemicalEntity ( LCChemicalEntity + ) .	3
In contrast , dialyzing 0 . 5 mm LCChemicalEntity into LCGeneOrGeneProduct - expressing cells readily activated LCOTHER ( LCOTHER + ) inward currents , which were undetectable in non - transfected cells .	1
In contrast , dialyzing 0 . 5 mm LCChemicalEntity into LCOTHER - expressing cells readily activated LCChemicalEntity ( LCChemicalEntity + ) inward currents , which were undetectable in non - transfected cells .	1
In contrast , dialyzing 0 . 5 mm LCOTHER into LCGeneOrGeneProduct - expressing cells readily activated LCChemicalEntity ( LCChemicalEntity + ) inward currents , which were undetectable in non - transfected cells .	3
Interestingly , monovalent cations permeated the LCGeneOrGeneProduct channels under conditions where no LCChemicalEntity ( LCChemicalEntity + ) permeation was detectable , indicating that divalent cations block LCOTHER channels from the extracellular side .	3
Like LCOTHER LCGeneOrGeneProduct , the truncated LCOTHER LCOTHER ( LCOTHER - LCOTHER ) , which lacks the C - terminal domain required for LCChemicalEntity ( LCChemicalEntity + ) - calmodulin binding , does not form constitutive active channels , whereas the LCOTHER LCOTHER ( LCOTHER ) , carrying a point mutation in the presumed pore region , does not function as a channel .	3
Like LCOTHER LCOTHER , the truncated LCOTHER LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) , which lacks the C - terminal domain required for LCChemicalEntity ( LCChemicalEntity + ) - calmodulin binding , does not form constitutive active channels , whereas the LCOTHER LCOTHER ( LCOTHER ) , carrying a point mutation in the presumed pore region , does not function as a channel .	3
Like LCOTHER LCOTHER , the truncated LCOTHER LCOTHER ( LCSequenceVariant - LCSequenceVariant ) , which lacks the C - terminal domain required for LCChemicalEntity ( LCChemicalEntity + ) - calmodulin binding , does not form constitutive active channels , whereas the LCOTHER LCOTHER ( LCOTHER ) , carrying a point mutation in the presumed pore region , does not function as a channel .	1
Although LCChemicalEntity , LCChemicalEntity - LCChemicalEntity ( LCOTHER or LCOTHER ) has been shown to damage brain LCChemicalEntity ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCOTHER - LCOTHER LCOTHER LCOTHER on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCChemicalEntity , LCChemicalEntity - LCChemicalEntity ( LCOTHER or LCOTHER ) has been shown to damage brain LCOTHER ( LCChemicalEntity - LCChemicalEntity ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCOTHER - LCOTHER LCOTHER LCOTHER on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCChemicalEntity , LCChemicalEntity - LCChemicalEntity ( LCOTHER or LCOTHER ) has been shown to damage brain LCOTHER ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCChemicalEntity - LCChemicalEntity LCOTHER LCOTHER on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCChemicalEntity , LCChemicalEntity - LCChemicalEntity ( LCOTHER or LCOTHER ) has been shown to damage brain LCOTHER ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCOTHER - LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCChemicalEntity , LCChemicalEntity - LCChemicalEntity ( LCOTHER or LCOTHER ) has been shown to damage brain LCOTHER ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCOTHER - LCOTHER LCOTHER LCOTHER on functions in which LCChemicalEntity - LCChemicalEntity is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCChemicalEntity or LCOTHER ) has been shown to damage brain LCChemicalEntity ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCOTHER - LCOTHER LCOTHER LCOTHER on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCChemicalEntity or LCOTHER ) has been shown to damage brain LCOTHER ( LCChemicalEntity - LCChemicalEntity ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCOTHER - LCOTHER LCOTHER LCOTHER on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCChemicalEntity or LCOTHER ) has been shown to damage brain LCOTHER ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCChemicalEntity - LCChemicalEntity LCOTHER LCOTHER on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCChemicalEntity or LCOTHER ) has been shown to damage brain LCOTHER ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCOTHER - LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCChemicalEntity or LCOTHER ) has been shown to damage brain LCOTHER ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCOTHER - LCOTHER LCOTHER LCOTHER on functions in which LCChemicalEntity - LCChemicalEntity is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCOTHER or LCChemicalEntity ) has been shown to damage brain LCChemicalEntity ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCOTHER - LCOTHER LCOTHER LCOTHER on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCOTHER or LCChemicalEntity ) has been shown to damage brain LCOTHER ( LCChemicalEntity - LCChemicalEntity ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCOTHER - LCOTHER LCOTHER LCOTHER on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCOTHER or LCChemicalEntity ) has been shown to damage brain LCOTHER ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCChemicalEntity - LCChemicalEntity LCOTHER LCOTHER on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCOTHER or LCChemicalEntity ) has been shown to damage brain LCOTHER ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCOTHER - LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCOTHER or LCChemicalEntity ) has been shown to damage brain LCOTHER ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCOTHER - LCOTHER LCOTHER LCOTHER on functions in which LCChemicalEntity - LCChemicalEntity is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCOTHER or LCOTHER ) has been shown to damage brain LCChemicalEntity ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCOTHER - LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCOTHER or LCOTHER ) has been shown to damage brain LCOTHER ( LCChemicalEntity - LCChemicalEntity ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCOTHER - LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCOTHER or LCOTHER ) has been shown to damage brain LCOTHER ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCChemicalEntity - induced LCChemicalEntity - LCChemicalEntity LCOTHER LCOTHER on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCOTHER or LCOTHER ) has been shown to damage brain LCOTHER ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCChemicalEntity - induced LCOTHER - LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCOTHER or LCOTHER ) has been shown to damage brain LCOTHER ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCChemicalEntity - induced LCOTHER - LCOTHER LCOTHER LCOTHER on functions in which LCChemicalEntity - LCChemicalEntity is involved , such as cognitive function .	2
Although LCOTHER , LCOTHER - LCOTHER ( LCOTHER or LCOTHER ) has been shown to damage brain LCOTHER ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCChemicalEntity - LCChemicalEntity LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	2
Because LCChemicalEntity - LCChemicalEntity transporters play a key element in the regulation of synaptic LCOTHER - LCOTHER transmission it may be important to control for the potential covariance effect of a polymorphism in the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) when studying the effects of LCOTHER as well as cognitive functioning .	1
Because LCChemicalEntity - LCChemicalEntity transporters play a key element in the regulation of synaptic LCOTHER - LCOTHER transmission it may be important to control for the potential covariance effect of a polymorphism in the LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) when studying the effects of LCOTHER as well as cognitive functioning .	1
Because LCOTHER - LCOTHER transporters play a key element in the regulation of synaptic LCChemicalEntity - LCChemicalEntity transmission it may be important to control for the potential covariance effect of a polymorphism in the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) when studying the effects of LCOTHER as well as cognitive functioning .	1
Because LCOTHER - LCOTHER transporters play a key element in the regulation of synaptic LCChemicalEntity - LCChemicalEntity transmission it may be important to control for the potential covariance effect of a polymorphism in the LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) when studying the effects of LCOTHER as well as cognitive functioning .	1
Because LCOTHER - LCOTHER transporters play a key element in the regulation of synaptic LCOTHER - LCOTHER transmission it may be important to control for the potential covariance effect of a polymorphism in the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) when studying the effects of LCChemicalEntity as well as cognitive functioning .	1
Because LCOTHER - LCOTHER transporters play a key element in the regulation of synaptic LCOTHER - LCOTHER transmission it may be important to control for the potential covariance effect of a polymorphism in the LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) when studying the effects of LCChemicalEntity as well as cognitive functioning .	1
"While the use of LCChemicalEntity in quantities that may be considered """""""" moderate """""""" is not associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , heavy use of LCOTHER use may lead to long lasting LCOTHER LCOTHER ."	2
"While the use of LCChemicalEntity in quantities that may be considered """""""" moderate """""""" is not associated with LCOTHER LCOTHER LCOTHER , heavy use of LCOTHER use may lead to long lasting LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ."	2
"While the use of LCOTHER in quantities that may be considered """""""" moderate """""""" is not associated with LCOTHER LCOTHER LCOTHER , heavy use of LCChemicalEntity use may lead to long lasting LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ."	2
No effect of LCGeneOrGeneProduct - LCGeneOrGeneProduct or gender on memory function or LCChemicalEntity use was observed . Effects of common germline genetic variation in cell cycle control genes on LCOTHER LCOTHER survival : results from a population - based cohort .	1
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	1
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature study .	1
RESULTS : The rare allele of the tagging single nucleotide polymorphism ( SNP ) LCSequenceVariant is associated with an increased risk of LCDiseaseOrPhenotypicFeature ( hazard ratio = 1 . 26 per rare allele carried , 95% confidence interval : 1 . 12 to 1 . 42 ; P = 0 . 0001 ) , which was not attenuated after adjusting for LCOTHER stage , grade , and treatment .	2
This SNP is part of a large linkage disequilibrium block , which contains LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
This SNP is part of a large linkage disequilibrium block , which contains LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
This SNP is part of a large linkage disequilibrium block , which contains LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER .	1
This SNP is part of a large linkage disequilibrium block , which contains LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER .	1
This SNP is part of a large linkage disequilibrium block , which contains LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER .	1
This SNP is part of a large linkage disequilibrium block , which contains LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCGeneOrGeneProduct .	1
Elevated expression of the LCGeneOrGeneProduct transcript was associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature survival , adding biological interest to the finding .	1
CONCLUSION : It is possible that LCGeneOrGeneProduct LCOTHER , or another variant it tags , is associated with prognosis after a diagnosis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
CONCLUSION : It is possible that LCOTHER LCSequenceVariant , or another variant it tags , is associated with prognosis after a diagnosis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
Because members of the LCGeneOrGeneProduct family of proteins function as sensors that link changes in LCChemicalEntity levels with a variety of biological processes , including neurotransmission and hormone - responsiveness , LCOTHER is an intriguing candidate gene for the abnormal development in this child .	1
To assess the LCOTHER effects of LCChemicalEntity ( LCOTHER ) on LCChemicalEntity ( LCOTHER ) - induced LCOTHER , 60 male Sprague - Dawley LCOTHER were treated with LCOTHER 30 mg / kg / day or tap water for 15 days .	3
To assess the LCOTHER effects of LCChemicalEntity ( LCOTHER ) on LCOTHER ( LCChemicalEntity ) - induced LCOTHER , 60 male Sprague - Dawley LCOTHER were treated with LCOTHER 30 mg / kg / day or tap water for 15 days .	3
To assess the LCOTHER effects of LCChemicalEntity ( LCOTHER ) on LCOTHER ( LCOTHER ) - induced LCDiseaseOrPhenotypicFeature , 60 male Sprague - Dawley LCOTHER were treated with LCOTHER 30 mg / kg / day or tap water for 15 days .	3
To assess the LCOTHER effects of LCOTHER ( LCChemicalEntity ) on LCChemicalEntity ( LCOTHER ) - induced LCOTHER , 60 male Sprague - Dawley LCOTHER were treated with LCOTHER 30 mg / kg / day or tap water for 15 days .	3
To assess the LCOTHER effects of LCOTHER ( LCChemicalEntity ) on LCOTHER ( LCChemicalEntity ) - induced LCOTHER , 60 male Sprague - Dawley LCOTHER were treated with LCOTHER 30 mg / kg / day or tap water for 15 days .	3
To assess the LCOTHER effects of LCOTHER ( LCChemicalEntity ) on LCOTHER ( LCOTHER ) - induced LCDiseaseOrPhenotypicFeature , 60 male Sprague - Dawley LCOTHER were treated with LCOTHER 30 mg / kg / day or tap water for 15 days .	3
To assess the LCOTHER effects of LCOTHER ( LCOTHER ) on LCChemicalEntity ( LCOTHER ) - induced LCDiseaseOrPhenotypicFeature , 60 male Sprague - Dawley LCOTHER were treated with LCOTHER 30 mg / kg / day or tap water for 15 days .	2
To assess the LCOTHER effects of LCOTHER ( LCOTHER ) on LCOTHER ( LCChemicalEntity ) - induced LCDiseaseOrPhenotypicFeature , 60 male Sprague - Dawley LCOTHER were treated with LCOTHER 30 mg / kg / day or tap water for 15 days .	2
LCChemicalEntity increased systolic blood pressure ( SBP ) from 109 + / - 1 . 8 to 135 + / - 0 . 6 mmHg and plasma LCChemicalEntity ( 5711 + / - 284 . 9 saline , 7931 + / - 392 . 8 U / ml LCOTHER , P < 0 . 001 ) .	2
In this prevention study , SBP in the LCChemicalEntity + LCChemicalEntity group was increased from 115 + / - 0 . 4 to 124 + / - 1 . 5 mmHg , but this was significantly lower than in the LCOTHER - only group ( P ' < 0 . 05 ) .	3
In this prevention study , SBP in the LCChemicalEntity + LCOTHER group was increased from 115 + / - 0 . 4 to 124 + / - 1 . 5 mmHg , but this was significantly lower than in the LCChemicalEntity - only group ( P ' < 0 . 05 ) .	3
LCChemicalEntity reversed LCChemicalEntity - induced LCOTHER ( 129 + / - 0 . 6 mmHg , vs .	3
LCChemicalEntity reversed LCOTHER - induced LCDiseaseOrPhenotypicFeature ( 129 + / - 0 . 6 mmHg , vs .	3
LCOTHER reversed LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature ( 129 + / - 0 . 6 mmHg , vs .	2
135 + / - 0 . 6 mmHg P ' < 0 . 05 ) and decreased plasma LCOTHER ( 7931 + / - 392 . 8 LCOTHER , 1187 + / - 441 . 2 LCChemicalEntity + LCChemicalEntity , P < 0 . 0001 ) .	3
Plasma LCChemicalEntity / LCOTHER ( LCOTHER ) was decreased in LCChemicalEntity - treated LCOTHER compared to saline - treated LCOTHER ( 11 . 2 + / - 1 . 08 microm , 15 . 3 + / - 1 . 17 microm , respectively , P < 0 . 05 ) .	3
Plasma LCOTHER / LCChemicalEntity ( LCOTHER ) was decreased in LCChemicalEntity - treated LCOTHER compared to saline - treated LCOTHER ( 11 . 2 + / - 1 . 08 microm , 15 . 3 + / - 1 . 17 microm , respectively , P < 0 . 05 ) .	3
Plasma LCOTHER / LCOTHER ( LCChemicalEntity ) was decreased in LCChemicalEntity - treated LCOTHER compared to saline - treated LCOTHER ( 11 . 2 + / - 1 . 08 microm , 15 . 3 + / - 1 . 17 microm , respectively , P < 0 . 05 ) .	3
Thus , LCChemicalEntity prevented and reversed LCChemicalEntity - induced LCOTHER in the LCOTHER . Comparison of unilateral pallidotomy and subthalamotomy findings in advanced LCOTHER LCOTHER ' LCOTHER LCOTHER .	3
Thus , LCChemicalEntity prevented and reversed LCOTHER - induced LCDiseaseOrPhenotypicFeature in the LCOTHER . Comparison of unilateral pallidotomy and subthalamotomy findings in advanced LCOTHER LCOTHER ' LCOTHER LCOTHER .	3
Thus , LCOTHER prevented and reversed LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature in the LCOTHER . Comparison of unilateral pallidotomy and subthalamotomy findings in advanced LCOTHER LCOTHER ' LCOTHER LCOTHER .	2
Ten consecutive LCOTHER ( mean age , 58 . 4 + / - 6 . 8 years ; 7 LCOTHER , 3 LCOTHER ) with similar characteristics at the duration of disease ( mean disease time , 8 . 4 + / - 3 . 5 years ) , disabling motor fluctuations ( Hoehn _ Yahr stage 3 - 5 in off - drug phases ) and LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature were selected .	2
We have previously reported that LCChemicalEntity - LCChemicalEntity significantly alleviated LCChemicalEntity - induced LCOTHER and reversed spine density decreases in the CA1 region of the hippocampus in LCOTHER - treated animals .	3
We have previously reported that LCChemicalEntity - LCChemicalEntity significantly alleviated LCOTHER - induced LCDiseaseOrPhenotypicFeature and reversed spine density decreases in the CA1 region of the hippocampus in LCOTHER - treated animals .	3
We have previously reported that LCChemicalEntity - LCChemicalEntity significantly alleviated LCOTHER - induced LCOTHER and reversed spine density decreases in the CA1 region of the hippocampus in LCChemicalEntity - treated animals .	3
We have previously reported that LCOTHER - LCOTHER significantly alleviated LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature and reversed spine density decreases in the CA1 region of the hippocampus in LCOTHER - treated animals .	2
Here , we investigated the effects of LCChemicalEntity - LCChemicalEntity on long - term potentiation ( LTP ) in the lateral perforant path ( LPP ) - granule cell synapse of LCOTHER dentate gyrus ( DG ) in acute saline or LCChemicalEntity - treated LCOTHER .	3
Acute LCOTHER ( 30mg / kg , s . c . ) treatment significantly attenuated hippocampal LTP and LCChemicalEntity - LCChemicalEntity ( 1ug , i . c . v . ) restored the amplitude of PS that was attenuated by LCChemicalEntity injection .	3
Pre - treatment of the LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist LCChemicalEntity - LCChemicalEntity , LCChemicalEntity ( 10ug , i . c . v ) reversed the effects of LCOTHER - LCOTHER , but the LCOTHER LCOTHER antagonist LCOTHER - LCOTHER , LCOTHER ( 10ug , i . c . v ) did not .	3
Pre - treatment of the LCOTHER LCOTHER antagonist LCChemicalEntity - LCChemicalEntity , LCChemicalEntity ( 10ug , i . c . v ) reversed the effects of LCChemicalEntity - LCChemicalEntity , but the LCOTHER LCOTHER antagonist LCOTHER - LCOTHER , LCOTHER ( 10ug , i . c . v ) did not .	3
Pre - treatment of the LCOTHER LCOTHER antagonist LCOTHER - LCOTHER , LCOTHER ( 10ug , i . c . v ) reversed the effects of LCOTHER - LCOTHER , but the LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist LCChemicalEntity - LCChemicalEntity , LCChemicalEntity ( 10ug , i . c . v ) did not .	3
The present results demonstrate that LCChemicalEntity - LCChemicalEntity attenuates the effect of LCChemicalEntity on hippocampal LTP through LCOTHER LCOTHER and suggest an ameliorative function of LCOTHER - LCOTHER on LCOTHER - induced LCOTHER LCOTHER . Distinct patterns of germ - line deletions in LCOTHER and LCOTHER : the implication of Alu repetitive element in the genetic etiology of LCOTHER LCOTHER ( LCOTHER ) .	3
The present results demonstrate that LCChemicalEntity - LCChemicalEntity attenuates the effect of LCOTHER on hippocampal LTP through LCGeneOrGeneProduct LCGeneOrGeneProduct and suggest an ameliorative function of LCOTHER - LCOTHER on LCOTHER - induced LCOTHER LCOTHER . Distinct patterns of germ - line deletions in LCOTHER and LCOTHER : the implication of Alu repetitive element in the genetic etiology of LCOTHER LCOTHER ( LCOTHER ) .	1
The present results demonstrate that LCChemicalEntity - LCChemicalEntity attenuates the effect of LCOTHER on hippocampal LTP through LCOTHER LCOTHER and suggest an ameliorative function of LCOTHER - LCOTHER on LCChemicalEntity - induced LCOTHER LCOTHER . Distinct patterns of germ - line deletions in LCOTHER and LCOTHER : the implication of Alu repetitive element in the genetic etiology of LCOTHER LCOTHER ( LCOTHER ) .	3
The present results demonstrate that LCChemicalEntity - LCChemicalEntity attenuates the effect of LCOTHER on hippocampal LTP through LCOTHER LCOTHER and suggest an ameliorative function of LCOTHER - LCOTHER on LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Distinct patterns of germ - line deletions in LCOTHER and LCOTHER : the implication of Alu repetitive element in the genetic etiology of LCOTHER LCOTHER ( LCOTHER ) .	3
The present results demonstrate that LCOTHER - LCOTHER attenuates the effect of LCChemicalEntity on hippocampal LTP through LCGeneOrGeneProduct LCGeneOrGeneProduct and suggest an ameliorative function of LCOTHER - LCOTHER on LCOTHER - induced LCOTHER LCOTHER . Distinct patterns of germ - line deletions in LCOTHER and LCOTHER : the implication of Alu repetitive element in the genetic etiology of LCOTHER LCOTHER ( LCOTHER ) .	1
The present results demonstrate that LCOTHER - LCOTHER attenuates the effect of LCChemicalEntity on hippocampal LTP through LCOTHER LCOTHER and suggest an ameliorative function of LCOTHER - LCOTHER on LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Distinct patterns of germ - line deletions in LCOTHER and LCOTHER : the implication of Alu repetitive element in the genetic etiology of LCOTHER LCOTHER ( LCOTHER ) .	2
The present results demonstrate that LCOTHER - LCOTHER attenuates the effect of LCOTHER on hippocampal LTP through LCOTHER LCOTHER and suggest an ameliorative function of LCChemicalEntity - LCChemicalEntity on LCChemicalEntity - induced LCOTHER LCOTHER . Distinct patterns of germ - line deletions in LCOTHER and LCOTHER : the implication of Alu repetitive element in the genetic etiology of LCOTHER LCOTHER ( LCOTHER ) .	3
The present results demonstrate that LCOTHER - LCOTHER attenuates the effect of LCOTHER on hippocampal LTP through LCOTHER LCOTHER and suggest an ameliorative function of LCChemicalEntity - LCChemicalEntity on LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Distinct patterns of germ - line deletions in LCOTHER and LCOTHER : the implication of Alu repetitive element in the genetic etiology of LCOTHER LCOTHER ( LCOTHER ) .	3
The present results demonstrate that LCOTHER - LCOTHER attenuates the effect of LCOTHER on hippocampal LTP through LCOTHER LCOTHER and suggest an ameliorative function of LCOTHER - LCOTHER on LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Distinct patterns of germ - line deletions in LCOTHER and LCOTHER : the implication of Alu repetitive element in the genetic etiology of LCOTHER LCOTHER ( LCOTHER ) .	2
A relatively high frequency of germ - line genomic rearrangements in LCGeneOrGeneProduct and LCOTHER has been reported among LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) LCOTHER from different ethnic populations .	1
A relatively high frequency of germ - line genomic rearrangements in LCGeneOrGeneProduct and LCOTHER has been reported among LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) LCOTHER from different ethnic populations .	1
A relatively high frequency of germ - line genomic rearrangements in LCOTHER and LCGeneOrGeneProduct has been reported among LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) LCOTHER from different ethnic populations .	1
A relatively high frequency of germ - line genomic rearrangements in LCOTHER and LCGeneOrGeneProduct has been reported among LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) LCOTHER from different ethnic populations .	1
LCChemicalEntity LCChemicalEntity is associated with decreased risks of various LCDiseaseOrPhenotypicFeature , including LCOTHER LCOTHER .	3
LCChemicalEntity LCChemicalEntity is associated with decreased risks of various LCOTHER , including LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
A link between LCGeneOrGeneProduct and the LCGeneOrGeneProduct - LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) or LCOTHER LCOTHER - LCOTHER ( LCOTHER ) - LCOTHER pathway has been suggested .	1
A link between LCGeneOrGeneProduct and the LCOTHER - LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) or LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) - LCOTHER pathway has been suggested .	1
A link between LCGeneOrGeneProduct and the LCOTHER - LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) or LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) - LCOTHER pathway has been suggested .	1
A link between LCOTHER and the LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) or LCOTHER LCOTHER - LCOTHER ( LCOTHER ) - LCOTHER pathway has been suggested .	1
A link between LCOTHER and the LCGeneOrGeneProduct - LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) or LCOTHER LCOTHER - LCOTHER ( LCOTHER ) - LCOTHER pathway has been suggested .	1
A link between LCOTHER and the LCOTHER - LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) or LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) - LCGeneOrGeneProduct pathway has been suggested .	1
A link between LCOTHER and the LCOTHER - LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) or LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct pathway has been suggested .	1
However , the prognostic role of LCGeneOrGeneProduct expression or its relationship with LCGeneOrGeneProduct or LCOTHER mutation remains uncertain .	1
However , the prognostic role of LCGeneOrGeneProduct expression or its relationship with LCOTHER or LCGeneOrGeneProduct mutation remains uncertain .	1
Among 619 LCOTHER LCOTHER in two prospective cohort studies , 233 ( 38% ) LCDiseaseOrPhenotypicFeature showed LCGeneOrGeneProduct overexpression by immunohistochemistry .	2
LCGeneOrGeneProduct overexpression was significantly associated with LCGeneOrGeneProduct mutation ( odds ratio , 1 . 55 ; 95% confidence interval , 1 . 11 - 2 . 16 ) and LCOTHER mutation ( odds ratio , 2 . 17 ; 95% confidence interval , 1 . 36 - 3 . 47 ) , both of which persisted in multivariate logistic regression analysis .	1
LCGeneOrGeneProduct overexpression was significantly associated with LCOTHER mutation ( odds ratio , 1 . 55 ; 95% confidence interval , 1 . 11 - 2 . 16 ) and LCGeneOrGeneProduct mutation ( odds ratio , 2 . 17 ; 95% confidence interval , 1 . 36 - 3 . 47 ) , both of which persisted in multivariate logistic regression analysis .	1
LCGeneOrGeneProduct was not independently associated with body mass index , family history of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER location ( colon versus rectum ) , stage , LCOTHER grade , signet ring cells , CIMP , MSI , LINE - 1 hypomethylation , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER , or LCOTHER - LCOTHER .	2
In conclusion , LCGeneOrGeneProduct overexpression in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature is independently associated with LCOTHER and LCOTHER mutations .	2
In conclusion , LCGeneOrGeneProduct overexpression in LCOTHER LCOTHER is independently associated with LCGeneOrGeneProduct and LCOTHER mutations .	1
In conclusion , LCGeneOrGeneProduct overexpression in LCOTHER LCOTHER is independently associated with LCOTHER and LCGeneOrGeneProduct mutations .	1
Our data support potential interactions between the LCGeneOrGeneProduct , LCGeneOrGeneProduct - LCOTHER and LCOTHER - LCOTHER pathways , and possible influence by LCOTHER or LCOTHER mutation on therapy or chemoprevention targeting LCOTHER . Identification of novel type LCOTHER LCOTHER gene mutations resulting in severe LCOTHER LCOTHER LCOTHER LCOTHER .	1
Our data support potential interactions between the LCGeneOrGeneProduct , LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCOTHER pathways , and possible influence by LCOTHER or LCOTHER mutation on therapy or chemoprevention targeting LCOTHER . Identification of novel type LCOTHER LCOTHER gene mutations resulting in severe LCOTHER LCOTHER LCOTHER LCOTHER .	1
Our data support potential interactions between the LCGeneOrGeneProduct , LCOTHER - LCOTHER and LCOTHER - LCOTHER pathways , and possible influence by LCGeneOrGeneProduct or LCOTHER mutation on therapy or chemoprevention targeting LCOTHER . Identification of novel type LCOTHER LCOTHER gene mutations resulting in severe LCOTHER LCOTHER LCOTHER LCOTHER .	1
Our data support potential interactions between the LCGeneOrGeneProduct , LCOTHER - LCOTHER and LCOTHER - LCOTHER pathways , and possible influence by LCOTHER or LCGeneOrGeneProduct mutation on therapy or chemoprevention targeting LCOTHER . Identification of novel type LCOTHER LCOTHER gene mutations resulting in severe LCOTHER LCOTHER LCOTHER LCOTHER .	1
Our data support potential interactions between the LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER pathways , and possible influence by LCOTHER or LCOTHER mutation on therapy or chemoprevention targeting LCOTHER . Identification of novel type LCOTHER LCOTHER gene mutations resulting in severe LCOTHER LCOTHER LCOTHER LCOTHER .	1
Our data support potential interactions between the LCOTHER , LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct pathways , and possible influence by LCOTHER or LCOTHER mutation on therapy or chemoprevention targeting LCOTHER . Identification of novel type LCOTHER LCOTHER gene mutations resulting in severe LCOTHER LCOTHER LCOTHER LCOTHER .	1
In this work , we studied the proband in a small nuclear family of Chinese and Dutch / German descent and identified two novel mutations in the type LCGeneOrGeneProduct LCGeneOrGeneProduct gene leading to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER - LCOTHER variant ( LCOTHER - LCOTHER ) .	1
In this work , we studied the proband in a small nuclear family of Chinese and Dutch / German descent and identified two novel mutations in the type LCGeneOrGeneProduct LCGeneOrGeneProduct gene leading to LCOTHER LCOTHER LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature variant ( LCOTHER - LCOTHER ) .	1
In this work , we studied the proband in a small nuclear family of Chinese and Dutch / German descent and identified two novel mutations in the type LCGeneOrGeneProduct LCGeneOrGeneProduct gene leading to LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER - LCOTHER variant ( LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature ) .	1
AIMS : LCGeneOrGeneProduct mutations now guide the clinical use of LCOTHER - targeted therapy in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
AIMS : LCOTHER mutations now guide the clinical use of LCGeneOrGeneProduct - targeted therapy in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
However , standard LCGeneOrGeneProduct mutation analysis requires a minimum amount of LCDiseaseOrPhenotypicFeature tissue , which may not be available in certain situations .	1
In this study , we combined a mass spectrometry genotyping assay ( Sequenom ) with a mutant - enriched PCR ( ME - PCR ) to detect LCGeneOrGeneProduct mutations in free plasma DNA from LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
Results in plasma DNA samples were compared with LCGeneOrGeneProduct mutation status obtained in LCDiseaseOrPhenotypicFeature DNA ( 18 / 31 LCOTHER mutant ) .	1
The relationship of LCGeneOrGeneProduct mutation status in LCDiseaseOrPhenotypicFeature and / or plasma samples to overall survival was assessed .	1
RESULTS : The LCGeneOrGeneProduct mutation status in plasma DNA was identical to the primary LCDiseaseOrPhenotypicFeature in 61% of LCOTHER ( 19 / 31 ) .	1
By mass spectrometry genotyping , the plasma samples contained mutant DNA corresponding to 5 / 14 LCGeneOrGeneProduct Exon 19 deletions and 3 / 4 LCOTHER LCOTHER mutations previously diagnosed in the matched LCDiseaseOrPhenotypicFeature .	1
By mass spectrometry genotyping , the plasma samples contained mutant DNA corresponding to 5 / 14 LCOTHER Exon 19 deletions and 3 / 4 LCGeneOrGeneProduct LCOTHER mutations previously diagnosed in the matched LCDiseaseOrPhenotypicFeature .	1
By mass spectrometry genotyping , the plasma samples contained mutant DNA corresponding to 5 / 14 LCOTHER Exon 19 deletions and 3 / 4 LCOTHER LCSequenceVariant mutations previously diagnosed in the matched LCDiseaseOrPhenotypicFeature .	1
For LCOTHER treated with LCChemicalEntity , overall survival was correlated with the presence of LCGeneOrGeneProduct mutation in plasma and / or LCOTHER tissue ( p = 0 . 002 ) , with the two LCOTHER positive only in plasma DNA showing responses and favorable outcomes .	1
For LCOTHER treated with LCChemicalEntity , overall survival was correlated with the presence of LCOTHER mutation in plasma and / or LCDiseaseOrPhenotypicFeature tissue ( p = 0 . 002 ) , with the two LCOTHER positive only in plasma DNA showing responses and favorable outcomes .	3
For LCOTHER treated with LCOTHER , overall survival was correlated with the presence of LCGeneOrGeneProduct mutation in plasma and / or LCDiseaseOrPhenotypicFeature tissue ( p = 0 . 002 ) , with the two LCOTHER positive only in plasma DNA showing responses and favorable outcomes .	1
A positive LCGeneOrGeneProduct result in plasma DNA has a high predictive value for LCDiseaseOrPhenotypicFeature LCOTHER status and for favorable clinical course on LCOTHER - targeted therapy and could therefore be useful in guiding clinical decisions in LCOTHER with insufficient or unavailable LCOTHER specimens . Dynamic subunit turnover in LCOTHER - LCOTHER assemblies is regulated by LCOTHER to mediate membrane remodelling during cytokinesis .	1
A positive LCGeneOrGeneProduct result in plasma DNA has a high predictive value for LCOTHER LCOTHER status and for favorable clinical course on LCOTHER - targeted therapy and could therefore be useful in guiding clinical decisions in LCOTHER with insufficient or unavailable LCDiseaseOrPhenotypicFeature specimens . Dynamic subunit turnover in LCOTHER - LCOTHER assemblies is regulated by LCOTHER to mediate membrane remodelling during cytokinesis .	1
A positive LCOTHER result in plasma DNA has a high predictive value for LCOTHER LCGeneOrGeneProduct status and for favorable clinical course on LCOTHER - targeted therapy and could therefore be useful in guiding clinical decisions in LCOTHER with insufficient or unavailable LCDiseaseOrPhenotypicFeature specimens . Dynamic subunit turnover in LCOTHER - LCOTHER assemblies is regulated by LCOTHER to mediate membrane remodelling during cytokinesis .	1
A positive LCOTHER result in plasma DNA has a high predictive value for LCOTHER LCOTHER status and for favorable clinical course on LCGeneOrGeneProduct - targeted therapy and could therefore be useful in guiding clinical decisions in LCOTHER with insufficient or unavailable LCDiseaseOrPhenotypicFeature specimens . Dynamic subunit turnover in LCOTHER - LCOTHER assemblies is regulated by LCOTHER to mediate membrane remodelling during cytokinesis .	1
The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters ( LCOTHER , LCOTHER , LCOTHER and LCOTHER ) of LCChemicalEntity - ( LCChemicalEntity - LCChemicalEntity ) LCChemicalEntity ( LCOTHER ) in comparison to its parent compound , LCChemicalEntity LCChemicalEntity ( LCOTHER ) .	6
The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters ( LCOTHER , LCOTHER , LCOTHER and LCOTHER ) of LCChemicalEntity - ( LCChemicalEntity - LCChemicalEntity ) LCChemicalEntity ( LCOTHER ) in comparison to its parent compound , LCOTHER LCOTHER ( LCChemicalEntity ) .	6
The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters ( LCOTHER , LCOTHER , LCOTHER and LCOTHER ) of LCOTHER - ( LCOTHER - LCOTHER ) LCOTHER ( LCChemicalEntity ) in comparison to its parent compound , LCChemicalEntity LCChemicalEntity ( LCOTHER ) .	6
The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters ( LCOTHER , LCOTHER , LCOTHER and LCOTHER ) of LCOTHER - ( LCOTHER - LCOTHER ) LCOTHER ( LCChemicalEntity ) in comparison to its parent compound , LCOTHER LCOTHER ( LCChemicalEntity ) .	6
LCChemicalEntity was more potent than LCChemicalEntity , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting LCOTHER against LCOTHER - induced LCOTHER whereas the corresponding value for LCOTHER was 322 mg / kg .	6
LCChemicalEntity was more potent than LCOTHER , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting LCOTHER against LCChemicalEntity - induced LCOTHER whereas the corresponding value for LCOTHER was 322 mg / kg .	3
LCChemicalEntity was more potent than LCOTHER , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting LCOTHER against LCOTHER - induced LCDiseaseOrPhenotypicFeature whereas the corresponding value for LCOTHER was 322 mg / kg .	3
LCChemicalEntity was more potent than LCOTHER , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting LCOTHER against LCOTHER - induced LCOTHER whereas the corresponding value for LCChemicalEntity was 322 mg / kg .	6
LCOTHER was more potent than LCChemicalEntity , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting LCOTHER against LCChemicalEntity - induced LCOTHER whereas the corresponding value for LCOTHER was 322 mg / kg .	3
LCOTHER was more potent than LCOTHER , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting LCOTHER against LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature whereas the corresponding value for LCOTHER was 322 mg / kg .	2
LCOTHER was more potent than LCOTHER , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting LCOTHER against LCOTHER - induced LCDiseaseOrPhenotypicFeature whereas the corresponding value for LCChemicalEntity was 322 mg / kg .	3
In vivo microdialysis demonstrated that an intraperitoneal administration of LCChemicalEntity induced a pronounced increment of hippocampal LCChemicalEntity and LCOTHER whereas no significant change was observed on the level of LCOTHER and LCOTHER .	2
In vivo microdialysis demonstrated that an intraperitoneal administration of LCChemicalEntity induced a pronounced increment of hippocampal LCOTHER and LCChemicalEntity whereas no significant change was observed on the level of LCOTHER and LCOTHER .	2
Pretreatment with either LCChemicalEntity ( 50 and 100 mg / kg ) or LCChemicalEntity ( 300 and 600 mg / kg ) completely abolished LCOTHER - evoked increases in extracellular LCOTHER and LCOTHER .	6
Pretreatment with either LCChemicalEntity ( 50 and 100 mg / kg ) or LCOTHER ( 300 and 600 mg / kg ) completely abolished LCChemicalEntity - evoked increases in extracellular LCOTHER and LCOTHER .	3
Pretreatment with either LCChemicalEntity ( 50 and 100 mg / kg ) or LCOTHER ( 300 and 600 mg / kg ) completely abolished LCOTHER - evoked increases in extracellular LCChemicalEntity and LCOTHER .	3
Pretreatment with either LCChemicalEntity ( 50 and 100 mg / kg ) or LCOTHER ( 300 and 600 mg / kg ) completely abolished LCOTHER - evoked increases in extracellular LCOTHER and LCChemicalEntity .	3
Pretreatment with either LCOTHER ( 50 and 100 mg / kg ) or LCChemicalEntity ( 300 and 600 mg / kg ) completely abolished LCChemicalEntity - evoked increases in extracellular LCOTHER and LCOTHER .	3
Pretreatment with either LCOTHER ( 50 and 100 mg / kg ) or LCChemicalEntity ( 300 and 600 mg / kg ) completely abolished LCOTHER - evoked increases in extracellular LCChemicalEntity and LCOTHER .	3
Pretreatment with either LCOTHER ( 50 and 100 mg / kg ) or LCChemicalEntity ( 300 and 600 mg / kg ) completely abolished LCOTHER - evoked increases in extracellular LCOTHER and LCChemicalEntity .	3
Pretreatment with either LCOTHER ( 50 and 100 mg / kg ) or LCOTHER ( 300 and 600 mg / kg ) completely abolished LCChemicalEntity - evoked increases in extracellular LCChemicalEntity and LCOTHER .	2
Pretreatment with either LCOTHER ( 50 and 100 mg / kg ) or LCOTHER ( 300 and 600 mg / kg ) completely abolished LCChemicalEntity - evoked increases in extracellular LCOTHER and LCChemicalEntity .	2
Based on the finding that LCChemicalEntity and LCChemicalEntity could protect the animals against LCOTHER - induced LCOTHER it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of LCOTHER and LCOTHER .	6
Based on the finding that LCChemicalEntity and LCOTHER could protect the animals against LCChemicalEntity - induced LCOTHER it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of LCOTHER and LCOTHER .	3
Based on the finding that LCChemicalEntity and LCOTHER could protect the animals against LCOTHER - induced LCDiseaseOrPhenotypicFeature it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of LCOTHER and LCOTHER .	3
Based on the finding that LCChemicalEntity and LCOTHER could protect the animals against LCOTHER - induced LCOTHER it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of LCChemicalEntity and LCOTHER .	3
Based on the finding that LCChemicalEntity and LCOTHER could protect the animals against LCOTHER - induced LCOTHER it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of LCOTHER and LCChemicalEntity .	3
Based on the finding that LCOTHER and LCChemicalEntity could protect the animals against LCChemicalEntity - induced LCOTHER it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of LCOTHER and LCOTHER .	3
Based on the finding that LCOTHER and LCChemicalEntity could protect the animals against LCOTHER - induced LCOTHER it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of LCChemicalEntity and LCOTHER .	3
Based on the finding that LCOTHER and LCChemicalEntity could protect the animals against LCOTHER - induced LCOTHER it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of LCOTHER and LCChemicalEntity .	3
Based on the finding that LCOTHER and LCOTHER could protect the animals against LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of LCOTHER and LCOTHER .	2
Based on the finding that LCOTHER and LCOTHER could protect the animals against LCChemicalEntity - induced LCOTHER it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of LCChemicalEntity and LCOTHER .	2
Based on the finding that LCOTHER and LCOTHER could protect the animals against LCChemicalEntity - induced LCOTHER it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of LCOTHER and LCChemicalEntity .	2
Therefore , like LCChemicalEntity , the finding that LCOTHER could drastically reduce LCChemicalEntity - induced increases in LCOTHER and LCOTHER should account , at least partly , for its anticonvulsant activity observed in LCOTHER - induced LCOTHER in experimental animals .	3
Therefore , like LCChemicalEntity , the finding that LCOTHER could drastically reduce LCOTHER - induced increases in LCChemicalEntity and LCOTHER should account , at least partly , for its anticonvulsant activity observed in LCOTHER - induced LCOTHER in experimental animals .	3
Therefore , like LCChemicalEntity , the finding that LCOTHER could drastically reduce LCOTHER - induced increases in LCOTHER and LCChemicalEntity should account , at least partly , for its anticonvulsant activity observed in LCOTHER - induced LCOTHER in experimental animals .	3
Therefore , like LCChemicalEntity , the finding that LCOTHER could drastically reduce LCOTHER - induced increases in LCOTHER and LCOTHER should account , at least partly , for its anticonvulsant activity observed in LCChemicalEntity - induced LCOTHER in experimental animals .	3
Therefore , like LCOTHER , the finding that LCChemicalEntity could drastically reduce LCChemicalEntity - induced increases in LCOTHER and LCOTHER should account , at least partly , for its anticonvulsant activity observed in LCOTHER - induced LCOTHER in experimental animals .	3
Therefore , like LCOTHER , the finding that LCChemicalEntity could drastically reduce LCOTHER - induced increases in LCChemicalEntity and LCOTHER should account , at least partly , for its anticonvulsant activity observed in LCOTHER - induced LCOTHER in experimental animals .	3
Therefore , like LCOTHER , the finding that LCChemicalEntity could drastically reduce LCOTHER - induced increases in LCOTHER and LCChemicalEntity should account , at least partly , for its anticonvulsant activity observed in LCOTHER - induced LCOTHER in experimental animals .	3
Therefore , like LCOTHER , the finding that LCChemicalEntity could drastically reduce LCOTHER - induced increases in LCOTHER and LCOTHER should account , at least partly , for its anticonvulsant activity observed in LCChemicalEntity - induced LCOTHER in experimental animals .	3
Therefore , like LCOTHER , the finding that LCChemicalEntity could drastically reduce LCOTHER - induced increases in LCOTHER and LCOTHER should account , at least partly , for its anticonvulsant activity observed in LCOTHER - induced LCDiseaseOrPhenotypicFeature in experimental animals .	3
Therefore , like LCOTHER , the finding that LCOTHER could drastically reduce LCChemicalEntity - induced increases in LCChemicalEntity and LCOTHER should account , at least partly , for its anticonvulsant activity observed in LCOTHER - induced LCOTHER in experimental animals .	2
Therefore , like LCOTHER , the finding that LCOTHER could drastically reduce LCChemicalEntity - induced increases in LCOTHER and LCChemicalEntity should account , at least partly , for its anticonvulsant activity observed in LCOTHER - induced LCOTHER in experimental animals .	2
Therefore , like LCOTHER , the finding that LCOTHER could drastically reduce LCChemicalEntity - induced increases in LCOTHER and LCOTHER should account , at least partly , for its anticonvulsant activity observed in LCOTHER - induced LCDiseaseOrPhenotypicFeature in experimental animals .	2
Therefore , like LCOTHER , the finding that LCOTHER could drastically reduce LCOTHER - induced increases in LCOTHER and LCOTHER should account , at least partly , for its anticonvulsant activity observed in LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature in experimental animals .	2
Recently , significantly higher frequencies of heterozygous carriers of the Slavic founder LCGeneOrGeneProduct mutation , LCOTHER , were found in Russian children with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and in Polish adults with LCOTHER - LCOTHER LCOTHER ( LCOTHER ) .	1
Recently , significantly higher frequencies of heterozygous carriers of the Slavic founder LCGeneOrGeneProduct mutation , LCOTHER , were found in Russian children with LCOTHER LCOTHER LCOTHER , and in Polish adults with LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
Recently , significantly higher frequencies of heterozygous carriers of the Slavic founder LCGeneOrGeneProduct mutation , LCOTHER , were found in Russian children with LCOTHER LCOTHER LCOTHER , and in Polish adults with LCOTHER - LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
Recently , significantly higher frequencies of heterozygous carriers of the Slavic founder LCOTHER mutation , LCSequenceVariant , were found in Russian children with LCOTHER LCOTHER LCOTHER , and in Polish adults with LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
Recently , significantly higher frequencies of heterozygous carriers of the Slavic founder LCOTHER mutation , LCSequenceVariant , were found in Russian children with LCOTHER LCOTHER LCOTHER , and in Polish adults with LCOTHER - LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
The LCGeneOrGeneProduct mutation LCOTHER on one allele was found in 3 of 270 LCOTHER with LCDiseaseOrPhenotypicFeature and 2 of 212 children and adolescents with LCOTHER ; no carrier was found among 63 LCOTHER with LCOTHER LCOTHER ( LCOTHER ) .	1
The LCGeneOrGeneProduct mutation LCOTHER on one allele was found in 3 of 270 LCOTHER with LCOTHER and 2 of 212 children and adolescents with LCDiseaseOrPhenotypicFeature ; no carrier was found among 63 LCOTHER with LCOTHER LCOTHER ( LCOTHER ) .	1
The LCOTHER mutation LCSequenceVariant on one allele was found in 3 of 270 LCOTHER with LCOTHER and 2 of 212 children and adolescents with LCDiseaseOrPhenotypicFeature ; no carrier was found among 63 LCOTHER with LCOTHER LCOTHER ( LCOTHER ) .	1
In the analyzed population with LCDiseaseOrPhenotypicFeature , an increased odds ratio for the occurrence of mutation LCSequenceVariant was found in comparison with the control Polish population ( OR range 1 . 48 - 1 . 85 , 95% confidence interval 1 . 18 - 2 . 65 ) .	1
Nonetheless , LCGeneOrGeneProduct gene heterozygosity is not a major risk factor for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in childhood and adolescence . LCOTHER - LCOTHER LCOTHER LCOTHER deficiency in B lymphocytes predisposes to LCOTHER LCOTHER LCOTHER / LCOTHER LCOTHER LCOTHER in LCOTHER .	1
We have previously shown that transgenic ( tg ) LCOTHER expressing in B lymphocytes both LCGeneOrGeneProduct - LCGeneOrGeneProduct and a LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) mutant lacking the really interesting new gene and zinc finger domains ( TRAF2DN ) develop LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER with high incidence ( Zapata et al .	1
We have previously shown that transgenic ( tg ) LCOTHER expressing in B lymphocytes both LCGeneOrGeneProduct - LCGeneOrGeneProduct and a LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) mutant lacking the really interesting new gene and zinc finger domains ( TRAF2DN ) develop LCOTHER LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with high incidence ( Zapata et al .	1
We have previously shown that transgenic ( tg ) LCOTHER expressing in B lymphocytes both LCOTHER - LCOTHER and a LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) mutant lacking the really interesting new gene and zinc finger domains ( TRAF2DN ) develop LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER with high incidence ( Zapata et al .	3
We have previously shown that transgenic ( tg ) LCOTHER expressing in B lymphocytes both LCOTHER - LCOTHER and a LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) mutant lacking the really interesting new gene and zinc finger domains ( TRAF2DN ) develop LCOTHER LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with high incidence ( Zapata et al .	3
We have previously shown that transgenic ( tg ) LCOTHER expressing in B lymphocytes both LCOTHER - LCOTHER and a LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) mutant lacking the really interesting new gene and zinc finger domains ( TRAF2DN ) develop LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER with high incidence ( Zapata et al .	3
We have previously shown that transgenic ( tg ) LCOTHER expressing in B lymphocytes both LCOTHER - LCOTHER and a LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) mutant lacking the really interesting new gene and zinc finger domains ( TRAF2DN ) develop LCOTHER LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with high incidence ( Zapata et al .	3
Moreover , consistent with previous results , we also show that LCGeneOrGeneProduct was required for efficient LCGeneOrGeneProduct and LCOTHER activation in response to LCOTHER engagement .	2
Moreover , consistent with previous results , we also show that LCGeneOrGeneProduct was required for efficient LCOTHER and LCGeneOrGeneProduct activation in response to LCOTHER engagement .	2
Moreover , consistent with previous results , we also show that LCGeneOrGeneProduct was required for efficient LCOTHER and LCOTHER activation in response to LCGeneOrGeneProduct engagement .	1
Moreover , consistent with previous results , we also show that LCOTHER was required for efficient LCGeneOrGeneProduct and LCOTHER activation in response to LCGeneOrGeneProduct engagement .	1
Moreover , consistent with previous results , we also show that LCOTHER was required for efficient LCOTHER and LCGeneOrGeneProduct activation in response to LCGeneOrGeneProduct engagement .	1
However , LCGeneOrGeneProduct was deleterious for LCGeneOrGeneProduct - mediated activation of these kinases .	1
In contrast , LCGeneOrGeneProduct deficiency had no effect on LCGeneOrGeneProduct - mediated LCOTHER LCOTHER activation but significantly reduced LCOTHER - mediated LCOTHER activation .	1
In contrast , LCGeneOrGeneProduct deficiency had no effect on LCOTHER - mediated LCGeneOrGeneProduct LCGeneOrGeneProduct activation but significantly reduced LCOTHER - mediated LCOTHER activation .	2
In contrast , LCGeneOrGeneProduct deficiency had no effect on LCOTHER - mediated LCOTHER LCOTHER activation but significantly reduced LCGeneOrGeneProduct - mediated LCOTHER activation .	1
In contrast , LCGeneOrGeneProduct deficiency had no effect on LCOTHER - mediated LCOTHER LCOTHER activation but significantly reduced LCOTHER - mediated LCGeneOrGeneProduct activation .	2
In contrast , LCOTHER deficiency had no effect on LCGeneOrGeneProduct - mediated LCGeneOrGeneProduct LCGeneOrGeneProduct activation but significantly reduced LCOTHER - mediated LCOTHER activation .	1
In contrast , LCOTHER deficiency had no effect on LCGeneOrGeneProduct - mediated LCOTHER LCOTHER activation but significantly reduced LCOTHER - mediated LCGeneOrGeneProduct activation .	1
In contrast , LCOTHER deficiency had no effect on LCOTHER - mediated LCOTHER LCOTHER activation but significantly reduced LCGeneOrGeneProduct - mediated LCGeneOrGeneProduct activation .	1
Finally , we further confirm that LCGeneOrGeneProduct was required for LCGeneOrGeneProduct - mediated proliferation , but its absence relieved B cells of the need for LCOTHER LCOTHER LCOTHER LCOTHER for survival .	1
Finally , we further confirm that LCGeneOrGeneProduct was required for LCOTHER - mediated proliferation , but its absence relieved B cells of the need for LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct for survival .	1
Altogether , our results suggest that LCGeneOrGeneProduct deficiency cooperates with LCGeneOrGeneProduct - LCGeneOrGeneProduct in promoting LCOTHER LCOTHER LCOTHER / LCOTHER LCOTHER LCOTHER in LCOTHER , possibly by specifically enforcing marginal zone B cell accumulation , increasing LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER expression , and rendering B cells independent of LCOTHER LCOTHER LCOTHER LCOTHER for survival . Association of adipocyte genes with LCOTHER expression : a microarray analysis of subcutaneous and omental adipose tissue in morbidly LCOTHER subjects .	1
Altogether , our results suggest that LCGeneOrGeneProduct deficiency cooperates with LCOTHER - LCOTHER in promoting LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature / LCOTHER LCOTHER LCOTHER in LCOTHER , possibly by specifically enforcing marginal zone B cell accumulation , increasing LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER expression , and rendering B cells independent of LCOTHER LCOTHER LCOTHER LCOTHER for survival . Association of adipocyte genes with LCOTHER expression : a microarray analysis of subcutaneous and omental adipose tissue in morbidly LCOTHER subjects .	3
Altogether , our results suggest that LCGeneOrGeneProduct deficiency cooperates with LCOTHER - LCOTHER in promoting LCOTHER LCOTHER LCOTHER / LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER , possibly by specifically enforcing marginal zone B cell accumulation , increasing LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER expression , and rendering B cells independent of LCOTHER LCOTHER LCOTHER LCOTHER for survival . Association of adipocyte genes with LCOTHER expression : a microarray analysis of subcutaneous and omental adipose tissue in morbidly LCOTHER subjects .	3
Altogether , our results suggest that LCGeneOrGeneProduct deficiency cooperates with LCOTHER - LCOTHER in promoting LCOTHER LCOTHER LCOTHER / LCOTHER LCOTHER LCOTHER in LCOTHER , possibly by specifically enforcing marginal zone B cell accumulation , increasing LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct expression , and rendering B cells independent of LCOTHER LCOTHER LCOTHER LCOTHER for survival . Association of adipocyte genes with LCOTHER expression : a microarray analysis of subcutaneous and omental adipose tissue in morbidly LCOTHER subjects .	3
Altogether , our results suggest that LCGeneOrGeneProduct deficiency cooperates with LCOTHER - LCOTHER in promoting LCOTHER LCOTHER LCOTHER / LCOTHER LCOTHER LCOTHER in LCOTHER , possibly by specifically enforcing marginal zone B cell accumulation , increasing LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER expression , and rendering B cells independent of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct for survival . Association of adipocyte genes with LCOTHER expression : a microarray analysis of subcutaneous and omental adipose tissue in morbidly LCOTHER subjects .	1
Altogether , our results suggest that LCOTHER deficiency cooperates with LCGeneOrGeneProduct - LCGeneOrGeneProduct in promoting LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature / LCOTHER LCOTHER LCOTHER in LCOTHER , possibly by specifically enforcing marginal zone B cell accumulation , increasing LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER expression , and rendering B cells independent of LCOTHER LCOTHER LCOTHER LCOTHER for survival . Association of adipocyte genes with LCOTHER expression : a microarray analysis of subcutaneous and omental adipose tissue in morbidly LCOTHER subjects .	1
Altogether , our results suggest that LCOTHER deficiency cooperates with LCGeneOrGeneProduct - LCGeneOrGeneProduct in promoting LCOTHER LCOTHER LCOTHER / LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER , possibly by specifically enforcing marginal zone B cell accumulation , increasing LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER expression , and rendering B cells independent of LCOTHER LCOTHER LCOTHER LCOTHER for survival . Association of adipocyte genes with LCOTHER expression : a microarray analysis of subcutaneous and omental adipose tissue in morbidly LCOTHER subjects .	1
Altogether , our results suggest that LCOTHER deficiency cooperates with LCGeneOrGeneProduct - LCGeneOrGeneProduct in promoting LCOTHER LCOTHER LCOTHER / LCOTHER LCOTHER LCOTHER in LCOTHER , possibly by specifically enforcing marginal zone B cell accumulation , increasing LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct expression , and rendering B cells independent of LCOTHER LCOTHER LCOTHER LCOTHER for survival . Association of adipocyte genes with LCOTHER expression : a microarray analysis of subcutaneous and omental adipose tissue in morbidly LCOTHER subjects .	1
However , LCDiseaseOrPhenotypicFeature subjects differ in LCOTHER LCOTHER , LCGeneOrGeneProduct production and co - morbidities .	1
Based on fasting plasma analysis , LCDiseaseOrPhenotypicFeature subjects were grouped as Low LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LAT ) vs High LCOTHER and LCOTHER ( HAT ) .	1
Based on fasting plasma analysis , LCDiseaseOrPhenotypicFeature subjects were grouped as Low LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) and LCOTHER ( LCOTHER ) ( LAT ) vs High LCOTHER and LCOTHER ( HAT ) .	1
Based on fasting plasma analysis , LCDiseaseOrPhenotypicFeature subjects were grouped as Low LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCChemicalEntity ( LCOTHER ) ( LAT ) vs High LCOTHER and LCOTHER ( HAT ) .	2
Based on fasting plasma analysis , LCDiseaseOrPhenotypicFeature subjects were grouped as Low LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER ( LCChemicalEntity ) ( LAT ) vs High LCOTHER and LCOTHER ( HAT ) .	2
Based on fasting plasma analysis , LCDiseaseOrPhenotypicFeature subjects were grouped as Low LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LAT ) vs High LCGeneOrGeneProduct and LCOTHER ( HAT ) .	1
Based on fasting plasma analysis , LCDiseaseOrPhenotypicFeature subjects were grouped as Low LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LAT ) vs High LCOTHER and LCChemicalEntity ( HAT ) .	2
Based on fasting plasma analysis , LCOTHER subjects were grouped as Low LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) and LCChemicalEntity ( LCOTHER ) ( LAT ) vs High LCOTHER and LCOTHER ( HAT ) .	2
Based on fasting plasma analysis , LCOTHER subjects were grouped as Low LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) and LCOTHER ( LCChemicalEntity ) ( LAT ) vs High LCOTHER and LCOTHER ( HAT ) .	2
Based on fasting plasma analysis , LCOTHER subjects were grouped as Low LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LAT ) vs High LCOTHER and LCChemicalEntity ( HAT ) .	2
Based on fasting plasma analysis , LCOTHER subjects were grouped as Low LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) and LCChemicalEntity ( LCOTHER ) ( LAT ) vs High LCOTHER and LCOTHER ( HAT ) .	2
Based on fasting plasma analysis , LCOTHER subjects were grouped as Low LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) and LCOTHER ( LCChemicalEntity ) ( LAT ) vs High LCOTHER and LCOTHER ( HAT ) .	2
Based on fasting plasma analysis , LCOTHER subjects were grouped as Low LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) and LCOTHER ( LCOTHER ) ( LAT ) vs High LCOTHER and LCChemicalEntity ( HAT ) .	2
Based on fasting plasma analysis , LCOTHER subjects were grouped as Low LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LAT ) vs High LCGeneOrGeneProduct and LCChemicalEntity ( HAT ) .	2
METHODS : LAT and HAT groups were matched in age , LCOTHER , LCGeneOrGeneProduct , and LCOTHER , and had similar expression of LCOTHER - related genes ( LCGeneOrGeneProduct , LCOTHER - LCOTHER ) .	1
METHODS : LAT and HAT groups were matched in age , LCOTHER , LCGeneOrGeneProduct , and LCOTHER , and had similar expression of LCOTHER - related genes ( LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct ) .	1
METHODS : LAT and HAT groups were matched in age , LCOTHER , LCOTHER , and LCOTHER , and had similar expression of LCGeneOrGeneProduct - related genes ( LCGeneOrGeneProduct , LCOTHER - LCOTHER ) .	1
METHODS : LAT and HAT groups were matched in age , LCOTHER , LCOTHER , and LCOTHER , and had similar expression of LCGeneOrGeneProduct - related genes ( LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct ) .	1
LCOTHER related genes tended to be increased in the HAT group and were correlated ( LCGeneOrGeneProduct LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER LCOTHER , p < 0 . 01 each ) .	2
LCOTHER related genes tended to be increased in the HAT group and were correlated ( LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct , p < 0 . 01 each ) .	2
LCOTHER related genes tended to be increased in the HAT group and were correlated ( LCOTHER LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct LCGeneOrGeneProduct , p < 0 . 01 each ) .	2
Increased LCGeneOrGeneProduct ( p < 0 . 01 ) , an LCOTHER LCOTHER , in HAT suggests a compensatory LCGeneOrGeneProduct pathway , associated with increased LCOTHER storage .	4
Increased LCGeneOrGeneProduct ( p < 0 . 01 ) , an LCOTHER LCOTHER , in HAT suggests a compensatory LCOTHER pathway , associated with increased LCChemicalEntity storage .	2
Increased LCOTHER ( p < 0 . 01 ) , an LCGeneOrGeneProduct LCGeneOrGeneProduct , in HAT suggests a compensatory LCGeneOrGeneProduct pathway , associated with increased LCOTHER storage .	4
Increased LCOTHER ( p < 0 . 01 ) , an LCGeneOrGeneProduct LCGeneOrGeneProduct , in HAT suggests a compensatory LCOTHER pathway , associated with increased LCChemicalEntity storage .	2
Increased LCOTHER ( p < 0 . 01 ) , an LCOTHER LCOTHER , in HAT suggests a compensatory LCGeneOrGeneProduct pathway , associated with increased LCChemicalEntity storage .	2
RESULTS : HAT adipose tissue demonstrated increased LCChemicalEntity related genes for storage ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	1
RESULTS : HAT adipose tissue demonstrated increased LCChemicalEntity related genes for storage ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	1
RESULTS : HAT adipose tissue demonstrated increased LCChemicalEntity related genes for storage ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	1
RESULTS : HAT adipose tissue demonstrated increased LCChemicalEntity related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	1
RESULTS : HAT adipose tissue demonstrated increased LCChemicalEntity related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	1
RESULTS : HAT adipose tissue demonstrated increased LCChemicalEntity related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCGeneOrGeneProduct ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	1
RESULTS : HAT adipose tissue demonstrated increased LCChemicalEntity related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCGeneOrGeneProduct , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	1
RESULTS : HAT adipose tissue demonstrated increased LCChemicalEntity related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCGeneOrGeneProduct , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	1
RESULTS : HAT adipose tissue demonstrated increased LCChemicalEntity related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCGeneOrGeneProduct ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	1
RESULTS : HAT adipose tissue demonstrated increased LCChemicalEntity related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	1
RESULTS : HAT adipose tissue demonstrated increased LCChemicalEntity related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCGeneOrGeneProduct ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	1
RESULTS : HAT adipose tissue demonstrated increased LCChemicalEntity related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCGeneOrGeneProduct , LCOTHER , LCOTHER ) .	1
RESULTS : HAT adipose tissue demonstrated increased LCChemicalEntity related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCGeneOrGeneProduct , LCOTHER ) .	1
RESULTS : HAT adipose tissue demonstrated increased LCChemicalEntity related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCGeneOrGeneProduct ) .	1
HAT subjects had increased anti - LCDiseaseOrPhenotypicFeature genes LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER while LCOTHER LCOTHER and LCOTHER were also significantly increased ; all genes , p < 0 . 025 .	1
HAT subjects had increased anti - LCDiseaseOrPhenotypicFeature genes LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER while LCOTHER LCOTHER and LCOTHER were also significantly increased ; all genes , p < 0 . 025 .	1
HAT subjects had increased anti - LCDiseaseOrPhenotypicFeature genes LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER while LCOTHER LCOTHER and LCOTHER were also significantly increased ; all genes , p < 0 . 025 .	1
HAT subjects had increased anti - LCDiseaseOrPhenotypicFeature genes LCOTHER , LCOTHER , LCOTHER , and LCGeneOrGeneProduct while LCOTHER LCOTHER and LCOTHER were also significantly increased ; all genes , p < 0 . 025 .	1
HAT subjects had increased anti - LCDiseaseOrPhenotypicFeature genes LCOTHER , LCOTHER , LCOTHER , and LCOTHER while LCOTHER LCGeneOrGeneProduct and LCOTHER were also significantly increased ; all genes , p < 0 . 025 .	1
HAT subjects had increased anti - LCDiseaseOrPhenotypicFeature genes LCOTHER , LCOTHER , LCOTHER , and LCOTHER while LCOTHER LCOTHER and LCGeneOrGeneProduct were also significantly increased ; all genes , p < 0 . 025 .	1
HAT subjects had increased anti - LCOTHER genes LCOTHER , LCOTHER , LCOTHER , and LCOTHER while LCDiseaseOrPhenotypicFeature LCGeneOrGeneProduct and LCOTHER were also significantly increased ; all genes , p < 0 . 025 .	1
HAT subjects had increased anti - LCOTHER genes LCOTHER , LCOTHER , LCOTHER , and LCOTHER while LCDiseaseOrPhenotypicFeature LCOTHER and LCGeneOrGeneProduct were also significantly increased ; all genes , p < 0 . 025 .	1
CONCLUSION : Taken together , the profile of LCGeneOrGeneProduct receptor , LCGeneOrGeneProduct gene expression and metabolic factors in adipose tissue from morbidly LCOTHER HAT subjects suggests a compensatory response associated with the increased plasma LCOTHER and LCOTHER . LCOTHER region and risk of LCOTHER LCOTHER LCOTHER in African American LCOTHER .	4
CONCLUSION : Taken together , the profile of LCGeneOrGeneProduct receptor , LCOTHER gene expression and metabolic factors in adipose tissue from morbidly LCOTHER HAT subjects suggests a compensatory response associated with the increased plasma LCGeneOrGeneProduct and LCOTHER . LCOTHER region and risk of LCOTHER LCOTHER LCOTHER in African American LCOTHER .	4
CONCLUSION : Taken together , the profile of LCGeneOrGeneProduct receptor , LCOTHER gene expression and metabolic factors in adipose tissue from morbidly LCOTHER HAT subjects suggests a compensatory response associated with the increased plasma LCOTHER and LCChemicalEntity . LCOTHER region and risk of LCOTHER LCOTHER LCOTHER in African American LCOTHER .	2
CONCLUSION : Taken together , the profile of LCOTHER receptor , LCGeneOrGeneProduct gene expression and metabolic factors in adipose tissue from morbidly LCOTHER HAT subjects suggests a compensatory response associated with the increased plasma LCOTHER and LCChemicalEntity . LCOTHER region and risk of LCOTHER LCOTHER LCOTHER in African American LCOTHER .	2
CONCLUSION : Taken together , the profile of LCOTHER receptor , LCOTHER gene expression and metabolic factors in adipose tissue from morbidly LCDiseaseOrPhenotypicFeature HAT subjects suggests a compensatory response associated with the increased plasma LCGeneOrGeneProduct and LCOTHER . LCOTHER region and risk of LCOTHER LCOTHER LCOTHER in African American LCOTHER .	1
CONCLUSION : Taken together , the profile of LCOTHER receptor , LCOTHER gene expression and metabolic factors in adipose tissue from morbidly LCDiseaseOrPhenotypicFeature HAT subjects suggests a compensatory response associated with the increased plasma LCOTHER and LCChemicalEntity . LCOTHER region and risk of LCOTHER LCOTHER LCOTHER in African American LCOTHER .	2
CONCLUSION : Taken together , the profile of LCOTHER receptor , LCOTHER gene expression and metabolic factors in adipose tissue from morbidly LCOTHER HAT subjects suggests a compensatory response associated with the increased plasma LCGeneOrGeneProduct and LCChemicalEntity . LCOTHER region and risk of LCOTHER LCOTHER LCOTHER in African American LCOTHER .	2
We conducted a screening of the LCOTHER region for 1 , 536 single nucleotide polymorphisms ( SNPs ) and the deletion of the LCGeneOrGeneProduct gene in a LCDiseaseOrPhenotypicFeature case - control study ( 380 cases , 765 age - matched controls ) nested within the prospective Black LCOTHER ' s Health Study .	1
The most strongly associated SNP with LCDiseaseOrPhenotypicFeature was the LCSequenceVariant ( odds ratio , OR = 1 . 70 , p = 5 . 6 10 ( - 5 ) ) near the LCOTHER - LCOTHER gene .	2
Conditional haplotype analysis revealed three other SNPs , LCSequenceVariant ( OR = 1 . 86 , p = 1 . 2 10 ( - 4 ) ) , LCOTHER ( OR = 1 . 53 , p = 1 . 0 10 ( - 3 ) ) , and LCOTHER ( OR = 1 . 43 , p = 1 . 3 10 ( - 3 ) ) , to be associated with LCDiseaseOrPhenotypicFeature independent of the LCOTHER SNP .	2
Conditional haplotype analysis revealed three other SNPs , LCOTHER ( OR = 1 . 86 , p = 1 . 2 10 ( - 4 ) ) , LCSequenceVariant ( OR = 1 . 53 , p = 1 . 0 10 ( - 3 ) ) , and LCOTHER ( OR = 1 . 43 , p = 1 . 3 10 ( - 3 ) ) , to be associated with LCDiseaseOrPhenotypicFeature independent of the LCOTHER SNP .	2
Conditional haplotype analysis revealed three other SNPs , LCOTHER ( OR = 1 . 86 , p = 1 . 2 10 ( - 4 ) ) , LCOTHER ( OR = 1 . 53 , p = 1 . 0 10 ( - 3 ) ) , and LCSequenceVariant ( OR = 1 . 43 , p = 1 . 3 10 ( - 3 ) ) , to be associated with LCDiseaseOrPhenotypicFeature independent of the LCOTHER SNP .	2
Conditional haplotype analysis revealed three other SNPs , LCOTHER ( OR = 1 . 86 , p = 1 . 2 10 ( - 4 ) ) , LCOTHER ( OR = 1 . 53 , p = 1 . 0 10 ( - 3 ) ) , and LCOTHER ( OR = 1 . 43 , p = 1 . 3 10 ( - 3 ) ) , to be associated with LCDiseaseOrPhenotypicFeature independent of the LCSequenceVariant SNP .	2
We hypothesised that a common substitution in the basal promoter of LCGeneOrGeneProduct ( position - 93 , LCOTHER ) modifies the risk of LCDiseaseOrPhenotypicFeature after methylating chemotherapy .	1
We hypothesised that a common substitution in the basal promoter of LCOTHER ( position - 93 , LCSequenceVariant ) modifies the risk of LCDiseaseOrPhenotypicFeature after methylating chemotherapy .	2
RESULTS : Carrier frequency of the LCGeneOrGeneProduct - 93 variant was higher in LCOTHER who developed therapy related LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( t - LCOTHER ) ( 75 . 0% , n = 12 ) or LCOTHER LCOTHER ( 53 . 3% .	1
RESULTS : Carrier frequency of the LCGeneOrGeneProduct - 93 variant was higher in LCOTHER who developed therapy related LCOTHER LCOTHER LCOTHER ( t - LCDiseaseOrPhenotypicFeature ) ( 75 . 0% , n = 12 ) or LCOTHER LCOTHER ( 53 . 3% .	1
RESULTS : Carrier frequency of the LCGeneOrGeneProduct - 93 variant was higher in LCOTHER who developed therapy related LCOTHER LCOTHER LCOTHER ( t - LCOTHER ) ( 75 . 0% , n = 12 ) or LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( 53 . 3% .	1
The LCGeneOrGeneProduct - 93 variant allele was also over - represented in t - LCDiseaseOrPhenotypicFeature cases when compared to de novo LCOTHER cases ( 36 . 9% , n = 420 ) and healthy controls ( 36 . 3% , n = 952 ) , and was associated with a significantly increased risk of developing t - LCOTHER ( odds ratio 5 . 31 , 95% confidence interval 1 . 40 to 20 . 15 ) , but only in LCOTHER previously treated with a methylating agent .	1
The LCGeneOrGeneProduct - 93 variant allele was also over - represented in t - LCOTHER cases when compared to de novo LCDiseaseOrPhenotypicFeature cases ( 36 . 9% , n = 420 ) and healthy controls ( 36 . 3% , n = 952 ) , and was associated with a significantly increased risk of developing t - LCOTHER ( odds ratio 5 . 31 , 95% confidence interval 1 . 40 to 20 . 15 ) , but only in LCOTHER previously treated with a methylating agent .	1
The LCGeneOrGeneProduct - 93 variant allele was also over - represented in t - LCOTHER cases when compared to de novo LCOTHER cases ( 36 . 9% , n = 420 ) and healthy controls ( 36 . 3% , n = 952 ) , and was associated with a significantly increased risk of developing t - LCDiseaseOrPhenotypicFeature ( odds ratio 5 . 31 , 95% confidence interval 1 . 40 to 20 . 15 ) , but only in LCOTHER previously treated with a methylating agent .	1
CONCLUSIONS : These data support the hypothesis that the common polymorphism at position - 93 in the core promoter of LCGeneOrGeneProduct defines a risk allele for the development of LCDiseaseOrPhenotypicFeature after methylating chemotherapy for LCOTHER LCOTHER .	1
CONCLUSIONS : These data support the hypothesis that the common polymorphism at position - 93 in the core promoter of LCGeneOrGeneProduct defines a risk allele for the development of LCOTHER after methylating chemotherapy for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
LCGeneOrGeneProduct - LCGeneOrGeneProduct is a key enzyme in the conversion of LCChemicalEntity LCChemicalEntity to LCOTHER .	1
LCGeneOrGeneProduct - LCGeneOrGeneProduct is a key enzyme in the conversion of LCOTHER LCOTHER to LCChemicalEntity .	2
LCOTHER - LCOTHER is a key enzyme in the conversion of LCChemicalEntity LCChemicalEntity to LCChemicalEntity .	8
The LCChemicalEntity produced by LCOTHER - LCOTHER are involved in LCDiseaseOrPhenotypicFeature and LCOTHER response in different tissues in the body .	1
The LCChemicalEntity produced by LCOTHER - LCOTHER are involved in LCOTHER and LCDiseaseOrPhenotypicFeature response in different tissues in the body .	1
The LCOTHER produced by LCGeneOrGeneProduct - LCGeneOrGeneProduct are involved in LCDiseaseOrPhenotypicFeature and LCOTHER response in different tissues in the body .	1
The LCOTHER produced by LCGeneOrGeneProduct - LCGeneOrGeneProduct are involved in LCOTHER and LCDiseaseOrPhenotypicFeature response in different tissues in the body .	1
Accumulating evidence from epidemiologic studies , chemical carcinogen - induced rodent models and clinical trials indicate that LCGeneOrGeneProduct - LCGeneOrGeneProduct plays a role in LCOTHER LCDiseaseOrPhenotypicFeature and is overexpressed in LCOTHER LCOTHER tissue .	1
Accumulating evidence from epidemiologic studies , chemical carcinogen - induced rodent models and clinical trials indicate that LCGeneOrGeneProduct - LCGeneOrGeneProduct plays a role in LCOTHER LCOTHER and is overexpressed in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature tissue .	2
We examined whether sequence variants in the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene are associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk .	2
This study supports the hypothesis that LCOTHER is involved in LCOTHER LCOTHER and that sequence variation within the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene influence the risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Glutamatergic neurotransmission mediated by LCOTHER LCOTHER in the inferior colliculus can modulate LCOTHER - induced LCOTHER .	2
The present study examined the influence of excitatory amino acid - mediated mechanisms in the IC on the LCOTHER induced by the LCGeneOrGeneProduct LCGeneOrGeneProduct blocker LCChemicalEntity administered systemically ( 1 or 0 . 5 mg / kg ) in LCOTHER .	3
LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature was challenged with prior intracollicular microinjections of LCOTHER LCOTHER LCOTHER antagonists , LCOTHER - LCOTHER ( 15 or 30 mmol / 0 . 5 microl ) and LCOTHER ( 10 or 20 nmol / 0 . 5 microl ) , or of the LCOTHER LCOTHER agonist LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCOTHER , 20 or 30 nmol / 0 . 5 microl ) .	2
LCOTHER - induced LCOTHER was challenged with prior intracollicular microinjections of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct antagonists , LCChemicalEntity - LCChemicalEntity ( 15 or 30 mmol / 0 . 5 microl ) and LCOTHER ( 10 or 20 nmol / 0 . 5 microl ) , or of the LCOTHER LCOTHER agonist LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCOTHER , 20 or 30 nmol / 0 . 5 microl ) .	3
LCOTHER - induced LCOTHER was challenged with prior intracollicular microinjections of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct antagonists , LCOTHER - LCOTHER ( 15 or 30 mmol / 0 . 5 microl ) and LCChemicalEntity ( 10 or 20 nmol / 0 . 5 microl ) , or of the LCOTHER LCOTHER agonist LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCOTHER , 20 or 30 nmol / 0 . 5 microl ) .	3
LCOTHER - induced LCOTHER was challenged with prior intracollicular microinjections of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct antagonists , LCOTHER - LCOTHER ( 15 or 30 mmol / 0 . 5 microl ) and LCOTHER ( 10 or 20 nmol / 0 . 5 microl ) , or of the LCOTHER LCOTHER agonist LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity ( LCOTHER , 20 or 30 nmol / 0 . 5 microl ) .	2
LCOTHER - induced LCOTHER was challenged with prior intracollicular microinjections of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct antagonists , LCOTHER - LCOTHER ( 15 or 30 mmol / 0 . 5 microl ) and LCOTHER ( 10 or 20 nmol / 0 . 5 microl ) , or of the LCOTHER LCOTHER agonist LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCChemicalEntity , 20 or 30 nmol / 0 . 5 microl ) .	2
LCOTHER - induced LCOTHER was challenged with prior intracollicular microinjections of LCOTHER LCOTHER LCOTHER antagonists , LCOTHER - LCOTHER ( 15 or 30 mmol / 0 . 5 microl ) and LCOTHER ( 10 or 20 nmol / 0 . 5 microl ) , or of the LCGeneOrGeneProduct LCGeneOrGeneProduct agonist LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity ( LCOTHER , 20 or 30 nmol / 0 . 5 microl ) .	2
LCOTHER - induced LCOTHER was challenged with prior intracollicular microinjections of LCOTHER LCOTHER LCOTHER antagonists , LCOTHER - LCOTHER ( 15 or 30 mmol / 0 . 5 microl ) and LCOTHER ( 10 or 20 nmol / 0 . 5 microl ) , or of the LCGeneOrGeneProduct LCGeneOrGeneProduct agonist LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCChemicalEntity , 20 or 30 nmol / 0 . 5 microl ) .	2
The results showed that intracollicular microinjection of LCChemicalEntity - LCChemicalEntity and LCOTHER previous to systemic injections of LCChemicalEntity significantly attenuated the LCOTHER , as indicated by a reduced latency to step down from a horizontal bar .	3
The results showed that intracollicular microinjection of LCChemicalEntity - LCChemicalEntity and LCOTHER previous to systemic injections of LCOTHER significantly attenuated the LCDiseaseOrPhenotypicFeature , as indicated by a reduced latency to step down from a horizontal bar .	3
The results showed that intracollicular microinjection of LCOTHER - LCOTHER and LCChemicalEntity previous to systemic injections of LCChemicalEntity significantly attenuated the LCOTHER , as indicated by a reduced latency to step down from a horizontal bar .	3
The results showed that intracollicular microinjection of LCOTHER - LCOTHER and LCChemicalEntity previous to systemic injections of LCOTHER significantly attenuated the LCDiseaseOrPhenotypicFeature , as indicated by a reduced latency to step down from a horizontal bar .	3
The results showed that intracollicular microinjection of LCOTHER - LCOTHER and LCOTHER previous to systemic injections of LCChemicalEntity significantly attenuated the LCDiseaseOrPhenotypicFeature , as indicated by a reduced latency to step down from a horizontal bar .	2
These findings suggest that LCChemicalEntity - mediated mechanisms in the neural circuits at the IC level influence LCChemicalEntity - induced LCOTHER and participate in the regulation of motor activity . LCOTHER effects of LCOTHER LCOTHER on LCOTHER - induced LCOTHER in LCOTHER .	1
These findings suggest that LCChemicalEntity - mediated mechanisms in the neural circuits at the IC level influence LCOTHER - induced LCDiseaseOrPhenotypicFeature and participate in the regulation of motor activity . LCOTHER effects of LCOTHER LCOTHER on LCOTHER - induced LCOTHER in LCOTHER .	1
These findings suggest that LCOTHER - mediated mechanisms in the neural circuits at the IC level influence LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature and participate in the regulation of motor activity . LCOTHER effects of LCOTHER LCOTHER on LCOTHER - induced LCOTHER in LCOTHER .	2
LCChemicalEntity - ( LCOTHER - ) induced LCDiseaseOrPhenotypicFeature is associated with enhanced oxidative stress .	2
LCOTHER - ( LCChemicalEntity - ) induced LCDiseaseOrPhenotypicFeature is associated with enhanced oxidative stress .	2
In this study , we investigated the effect of chronic administration of LCGeneOrGeneProduct on oxidative stress and LCDiseaseOrPhenotypicFeature upon LCOTHER administration .	3
In this study , we investigated the effect of chronic administration of LCGeneOrGeneProduct on oxidative stress and LCOTHER upon LCChemicalEntity administration .	3
In a prevention study , LCOTHER received 4 days of LCGeneOrGeneProduct treatment followed by LCChemicalEntity and continued during the test period .	3
LCChemicalEntity significantly increased SBP and plasma LCChemicalEntity level and decreased thymus and body weights .	2
LCGeneOrGeneProduct lowered ( P < 0 . 01 ) and dose dependently prevented ( P < 0 . 001 ) LCChemicalEntity - induced LCOTHER .	3
LCGeneOrGeneProduct lowered ( P < 0 . 01 ) and dose dependently prevented ( P < 0 . 001 ) LCOTHER - induced LCDiseaseOrPhenotypicFeature .	3
LCOTHER lowered ( P < 0 . 01 ) and dose dependently prevented ( P < 0 . 001 ) LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature .	2
LCGeneOrGeneProduct prevented body LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and significantly reduced the elevated plasma LCOTHER and increased FRAP values .	3
LCGeneOrGeneProduct prevented body LCOTHER LCOTHER and significantly reduced the elevated plasma LCChemicalEntity and increased FRAP values .	3
Chronic administration of LCGeneOrGeneProduct strongly reduced the blood pressure and production of LCChemicalEntity and improved antioxidant capacity in LCOTHER - induced LCOTHER , suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LCOTHER . Role of LCOTHER LCOTHER LCOTHER LCOTHER in LCOTHER and migration of fibroblast - like synoviocytes in LCOTHER LCOTHER .	3
Chronic administration of LCGeneOrGeneProduct strongly reduced the blood pressure and production of LCOTHER and improved antioxidant capacity in LCChemicalEntity - induced LCOTHER , suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LCOTHER . Role of LCOTHER LCOTHER LCOTHER LCOTHER in LCOTHER and migration of fibroblast - like synoviocytes in LCOTHER LCOTHER .	3
Chronic administration of LCGeneOrGeneProduct strongly reduced the blood pressure and production of LCOTHER and improved antioxidant capacity in LCOTHER - induced LCDiseaseOrPhenotypicFeature , suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LCOTHER . Role of LCOTHER LCOTHER LCOTHER LCOTHER in LCOTHER and migration of fibroblast - like synoviocytes in LCOTHER LCOTHER .	3
Chronic administration of LCOTHER strongly reduced the blood pressure and production of LCOTHER and improved antioxidant capacity in LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature , suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LCOTHER . Role of LCOTHER LCOTHER LCOTHER LCOTHER in LCOTHER and migration of fibroblast - like synoviocytes in LCOTHER LCOTHER .	2
To probe the role of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) in regulating LCDiseaseOrPhenotypicFeature , cell proliferation , migration and invasion of fibroblast - like synoviocytes ( FLSs ) from LCOTHER with LCOTHER LCOTHER ( LCOTHER ) .	1
To probe the role of LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) in regulating LCDiseaseOrPhenotypicFeature , cell proliferation , migration and invasion of fibroblast - like synoviocytes ( FLSs ) from LCOTHER with LCOTHER LCOTHER ( LCOTHER ) .	1
An inhibitor of LCOTHER ( LCChemicalEntity ) and short interference RNA ( siRNA ) against LCGeneOrGeneProduct were used to inhibit LCOTHER expression .	3
An inhibitor of LCOTHER ( LCChemicalEntity ) and short interference RNA ( siRNA ) against LCOTHER were used to inhibit LCGeneOrGeneProduct expression .	3
In LCDiseaseOrPhenotypicFeature FLSs , the level of LCGeneOrGeneProduct was up - regulated by stimulation with LCOTHER - LCOTHER and LCOTHER - LCOTHER .	1
In LCOTHER FLSs , the level of LCGeneOrGeneProduct was up - regulated by stimulation with LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER .	2
In LCOTHER FLSs , the level of LCGeneOrGeneProduct was up - regulated by stimulation with LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct .	2
Inhibition of LCGeneOrGeneProduct by LCOTHER and siRNA - mediated knockdown reduced LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER production , and proliferation of LCOTHER FLSs .	2
Inhibition of LCGeneOrGeneProduct by LCOTHER and siRNA - mediated knockdown reduced LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct production , and proliferation of LCOTHER FLSs .	2
Inhibition of LCOTHER by LCChemicalEntity and siRNA - mediated knockdown reduced LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER production , and proliferation of LCOTHER FLSs .	3
Inhibition of LCOTHER by LCChemicalEntity and siRNA - mediated knockdown reduced LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct production , and proliferation of LCOTHER FLSs .	3
Inhibition of LCOTHER by LCChemicalEntity and siRNA - mediated knockdown reduced LCOTHER - LCOTHER and LCOTHER - LCOTHER production , and proliferation of LCDiseaseOrPhenotypicFeature FLSs .	1
Furthermore , LCChemicalEntity restrained the phosphorylation of LCGeneOrGeneProduct LCGeneOrGeneProduct and LCOTHER , as well as nucleus transsituation of LCOTHER as well as LCOTHER in FLSs .	1
Furthermore , LCChemicalEntity restrained the phosphorylation of LCOTHER LCOTHER and LCGeneOrGeneProduct , as well as nucleus transsituation of LCOTHER as well as LCOTHER in FLSs .	1
Furthermore , LCChemicalEntity restrained the phosphorylation of LCOTHER LCOTHER and LCOTHER , as well as nucleus transsituation of LCGeneOrGeneProduct as well as LCOTHER in FLSs .	1
Furthermore , LCChemicalEntity restrained the phosphorylation of LCOTHER LCOTHER and LCOTHER , as well as nucleus transsituation of LCOTHER as well as LCGeneOrGeneProduct in FLSs .	1
LCGeneOrGeneProduct regulated the production of LCDiseaseOrPhenotypicFeature factors , cell proliferation , migration and invasion of LCOTHER FLS , which was mediated by the LCOTHER - LCOTHER and LCOTHER pathways .	1
LCGeneOrGeneProduct regulated the production of LCOTHER factors , cell proliferation , migration and invasion of LCOTHER FLS , which was mediated by the LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER pathways .	1
LCGeneOrGeneProduct regulated the production of LCOTHER factors , cell proliferation , migration and invasion of LCOTHER FLS , which was mediated by the LCOTHER - LCOTHER and LCGeneOrGeneProduct pathways .	1
LCOTHER regulated the production of LCOTHER factors , cell proliferation , migration and invasion of LCDiseaseOrPhenotypicFeature FLS , which was mediated by the LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER pathways .	1
LCOTHER regulated the production of LCOTHER factors , cell proliferation , migration and invasion of LCDiseaseOrPhenotypicFeature FLS , which was mediated by the LCOTHER - LCOTHER and LCGeneOrGeneProduct pathways .	1
Our data suggested that targeting LCGeneOrGeneProduct to prevent LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and destruction might be a promising therapy for LCOTHER . LCOTHER LCOTHER LCOTHER LCOTHER - dependent signaling mediates LCOTHER LCOTHER cell growth and LCOTHER .	1
LCOTHER cells depleted of LCGeneOrGeneProduct protein grew slower , formed fewer colonies in anchorage - independent growth assays and exhibited impaired xenograft LCDiseaseOrPhenotypicFeature formation in nude LCOTHER .	1
Consistent with impaired growth , LCGeneOrGeneProduct knockdown increased levels of the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) inhibitors LCOTHER ( LCOTHER / LCOTHER ) ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LCOTHER ) .	1
Consistent with impaired growth , LCGeneOrGeneProduct knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) inhibitors LCOTHER ( LCOTHER / LCOTHER ) ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LCOTHER ) .	1
Consistent with impaired growth , LCGeneOrGeneProduct knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCOTHER ) inhibitors LCGeneOrGeneProduct ( LCOTHER / LCOTHER ) ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LCOTHER ) .	3
Consistent with impaired growth , LCGeneOrGeneProduct knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCOTHER ) inhibitors LCOTHER ( LCGeneOrGeneProduct / LCOTHER ) ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LCOTHER ) .	3
Consistent with impaired growth , LCGeneOrGeneProduct knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCOTHER ) inhibitors LCOTHER ( LCOTHER / LCGeneOrGeneProduct ) ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LCOTHER ) .	3
Consistent with impaired growth , LCGeneOrGeneProduct knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCOTHER ) inhibitors LCOTHER ( LCOTHER / LCOTHER ) ( LCGeneOrGeneProduct ) and LCOTHER ( LCOTHER ) ( LCOTHER ) .	3
Consistent with impaired growth , LCGeneOrGeneProduct knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCOTHER ) inhibitors LCOTHER ( LCOTHER / LCOTHER ) ( LCOTHER ) and LCGeneOrGeneProduct ( LCOTHER ) ( LCOTHER ) .	3
Consistent with impaired growth , LCGeneOrGeneProduct knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCOTHER ) inhibitors LCOTHER ( LCOTHER / LCOTHER ) ( LCOTHER ) and LCOTHER ( LCGeneOrGeneProduct ) ( LCOTHER ) .	3
Consistent with impaired growth , LCGeneOrGeneProduct knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCOTHER ) inhibitors LCOTHER ( LCOTHER / LCOTHER ) ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LCGeneOrGeneProduct ) .	3
Consistent with impaired growth , LCOTHER knockdown increased levels of the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) inhibitors LCGeneOrGeneProduct ( LCOTHER / LCOTHER ) ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LCOTHER ) .	3
Consistent with impaired growth , LCOTHER knockdown increased levels of the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) inhibitors LCOTHER ( LCGeneOrGeneProduct / LCOTHER ) ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LCOTHER ) .	3
Consistent with impaired growth , LCOTHER knockdown increased levels of the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) inhibitors LCOTHER ( LCOTHER / LCGeneOrGeneProduct ) ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LCOTHER ) .	3
Consistent with impaired growth , LCOTHER knockdown increased levels of the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) inhibitors LCOTHER ( LCOTHER / LCOTHER ) ( LCGeneOrGeneProduct ) and LCOTHER ( LCOTHER ) ( LCOTHER ) .	3
Consistent with impaired growth , LCOTHER knockdown increased levels of the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) inhibitors LCOTHER ( LCOTHER / LCOTHER ) ( LCOTHER ) and LCGeneOrGeneProduct ( LCOTHER ) ( LCOTHER ) .	3
Consistent with impaired growth , LCOTHER knockdown increased levels of the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) inhibitors LCOTHER ( LCOTHER / LCOTHER ) ( LCOTHER ) and LCOTHER ( LCGeneOrGeneProduct ) ( LCOTHER ) .	3
Consistent with impaired growth , LCOTHER knockdown increased levels of the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) inhibitors LCOTHER ( LCOTHER / LCOTHER ) ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LCGeneOrGeneProduct ) .	3
Consistent with impaired growth , LCOTHER knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) inhibitors LCGeneOrGeneProduct ( LCOTHER / LCOTHER ) ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LCOTHER ) .	3
Consistent with impaired growth , LCOTHER knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) inhibitors LCOTHER ( LCGeneOrGeneProduct / LCOTHER ) ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LCOTHER ) .	3
Consistent with impaired growth , LCOTHER knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) inhibitors LCOTHER ( LCOTHER / LCGeneOrGeneProduct ) ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LCOTHER ) .	3
Consistent with impaired growth , LCOTHER knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) inhibitors LCOTHER ( LCOTHER / LCOTHER ) ( LCGeneOrGeneProduct ) and LCOTHER ( LCOTHER ) ( LCOTHER ) .	3
Consistent with impaired growth , LCOTHER knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) inhibitors LCOTHER ( LCOTHER / LCOTHER ) ( LCOTHER ) and LCGeneOrGeneProduct ( LCOTHER ) ( LCOTHER ) .	3
Consistent with impaired growth , LCOTHER knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) inhibitors LCOTHER ( LCOTHER / LCOTHER ) ( LCOTHER ) and LCOTHER ( LCGeneOrGeneProduct ) ( LCOTHER ) .	3
Consistent with impaired growth , LCOTHER knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) inhibitors LCOTHER ( LCOTHER / LCOTHER ) ( LCOTHER ) and LCOTHER ( LCOTHER ) ( LCGeneOrGeneProduct ) .	3
Despite the absence of functional LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) protein in LCOTHER cells , LCGeneOrGeneProduct knockdown reduced LCGeneOrGeneProduct phosphorylation at LCOTHER LCOTHER and concomitantly inhibited phosphorylation of the LCOTHER target , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) .	1
Despite the absence of functional LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) protein in LCOTHER cells , LCGeneOrGeneProduct knockdown reduced LCOTHER phosphorylation at LCOTHER LCOTHER and concomitantly inhibited phosphorylation of the LCGeneOrGeneProduct target , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) .	1
Despite the absence of functional LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) protein in LCOTHER cells , LCGeneOrGeneProduct knockdown reduced LCOTHER phosphorylation at LCOTHER LCOTHER and concomitantly inhibited phosphorylation of the LCOTHER target , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) .	1
Despite the absence of functional LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) protein in LCOTHER cells , LCGeneOrGeneProduct knockdown reduced LCOTHER phosphorylation at LCOTHER LCOTHER and concomitantly inhibited phosphorylation of the LCOTHER target , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) .	1
Despite the absence of functional LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) protein in LCOTHER cells , LCOTHER knockdown reduced LCGeneOrGeneProduct phosphorylation at LCOTHER LCOTHER and concomitantly inhibited phosphorylation of the LCOTHER target , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) .	1
Despite the absence of functional LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) protein in LCOTHER cells , LCOTHER knockdown reduced LCGeneOrGeneProduct phosphorylation at LCOTHER LCOTHER and concomitantly inhibited phosphorylation of the LCOTHER target , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) .	1
Despite the absence of functional LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) protein in LCOTHER cells , LCOTHER knockdown reduced LCOTHER phosphorylation at LCOTHER LCOTHER and concomitantly inhibited phosphorylation of the LCGeneOrGeneProduct target , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) .	1
Despite the absence of functional LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) protein in LCOTHER cells , LCOTHER knockdown reduced LCOTHER phosphorylation at LCOTHER LCOTHER and concomitantly inhibited phosphorylation of the LCGeneOrGeneProduct target , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) .	1
LCGeneOrGeneProduct knockdown also resulted in decreased basal LCGeneOrGeneProduct phosphorylation and attenuated LCOTHER activation following LCOTHER stimulation .	2
LCGeneOrGeneProduct knockdown also resulted in decreased basal LCOTHER phosphorylation and attenuated LCGeneOrGeneProduct activation following LCOTHER stimulation .	2
LCGeneOrGeneProduct knockdown also resulted in decreased basal LCOTHER phosphorylation and attenuated LCOTHER activation following LCGeneOrGeneProduct stimulation .	1
LCGeneOrGeneProduct and LCOTHER expression was not increased by treatment of LCOTHER cells with LCGeneOrGeneProduct and LCOTHER inhibitors , suggesting that LCOTHER regulates LCOTHER expression independently of LCOTHER and LCOTHER .	1
LCGeneOrGeneProduct and LCOTHER expression was not increased by treatment of LCOTHER cells with LCOTHER and LCGeneOrGeneProduct inhibitors , suggesting that LCOTHER regulates LCOTHER expression independently of LCOTHER and LCOTHER .	1
LCGeneOrGeneProduct and LCOTHER expression was not increased by treatment of LCOTHER cells with LCOTHER and LCOTHER inhibitors , suggesting that LCOTHER regulates LCOTHER expression independently of LCGeneOrGeneProduct and LCOTHER .	1
LCGeneOrGeneProduct and LCOTHER expression was not increased by treatment of LCOTHER cells with LCOTHER and LCOTHER inhibitors , suggesting that LCOTHER regulates LCOTHER expression independently of LCOTHER and LCGeneOrGeneProduct .	1
LCOTHER and LCGeneOrGeneProduct expression was not increased by treatment of LCOTHER cells with LCGeneOrGeneProduct and LCOTHER inhibitors , suggesting that LCOTHER regulates LCOTHER expression independently of LCOTHER and LCOTHER .	1
LCOTHER and LCGeneOrGeneProduct expression was not increased by treatment of LCOTHER cells with LCOTHER and LCGeneOrGeneProduct inhibitors , suggesting that LCOTHER regulates LCOTHER expression independently of LCOTHER and LCOTHER .	1
LCOTHER and LCGeneOrGeneProduct expression was not increased by treatment of LCOTHER cells with LCOTHER and LCOTHER inhibitors , suggesting that LCOTHER regulates LCOTHER expression independently of LCGeneOrGeneProduct and LCOTHER .	1
LCOTHER and LCGeneOrGeneProduct expression was not increased by treatment of LCOTHER cells with LCOTHER and LCOTHER inhibitors , suggesting that LCOTHER regulates LCOTHER expression independently of LCOTHER and LCGeneOrGeneProduct .	1
LCOTHER and LCOTHER expression was not increased by treatment of LCOTHER cells with LCOTHER and LCOTHER inhibitors , suggesting that LCGeneOrGeneProduct regulates LCGeneOrGeneProduct expression independently of LCOTHER and LCOTHER .	1
LCOTHER and LCOTHER expression was not increased by treatment of LCOTHER cells with LCOTHER and LCOTHER inhibitors , suggesting that LCGeneOrGeneProduct regulates LCOTHER expression independently of LCGeneOrGeneProduct and LCOTHER .	1
LCOTHER and LCOTHER expression was not increased by treatment of LCOTHER cells with LCOTHER and LCOTHER inhibitors , suggesting that LCGeneOrGeneProduct regulates LCOTHER expression independently of LCOTHER and LCGeneOrGeneProduct .	2
Immunohistochemical analysis of Grade 1 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature revealed aberrant LCGeneOrGeneProduct expression , with foci of elevated LCOTHER staining , not observed in normal endometrium .	1
Immunohistochemical analysis of Grade 1 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature revealed aberrant LCOTHER expression , with foci of elevated LCGeneOrGeneProduct staining , not observed in normal endometrium .	1
These studies demonstrate a critical role for LCGeneOrGeneProduct signaling in endometrial LCDiseaseOrPhenotypicFeature by regulating expression of LCOTHER inhibitors LCOTHER and LCOTHER and activation of LCOTHER and LCOTHER - dependent proliferative pathways .	1
These studies demonstrate a critical role for LCGeneOrGeneProduct signaling in endometrial LCOTHER by regulating expression of LCGeneOrGeneProduct inhibitors LCOTHER and LCOTHER and activation of LCOTHER and LCOTHER - dependent proliferative pathways .	1
These studies demonstrate a critical role for LCGeneOrGeneProduct signaling in endometrial LCOTHER by regulating expression of LCOTHER inhibitors LCGeneOrGeneProduct and LCOTHER and activation of LCOTHER and LCOTHER - dependent proliferative pathways .	3
These studies demonstrate a critical role for LCGeneOrGeneProduct signaling in endometrial LCOTHER by regulating expression of LCOTHER inhibitors LCOTHER and LCGeneOrGeneProduct and activation of LCOTHER and LCOTHER - dependent proliferative pathways .	3
These studies demonstrate a critical role for LCGeneOrGeneProduct signaling in endometrial LCOTHER by regulating expression of LCOTHER inhibitors LCOTHER and LCOTHER and activation of LCGeneOrGeneProduct and LCOTHER - dependent proliferative pathways .	1
These studies demonstrate a critical role for LCGeneOrGeneProduct signaling in endometrial LCOTHER by regulating expression of LCOTHER inhibitors LCOTHER and LCOTHER and activation of LCOTHER and LCGeneOrGeneProduct - dependent proliferative pathways .	2
These studies demonstrate a critical role for LCOTHER signaling in endometrial LCDiseaseOrPhenotypicFeature by regulating expression of LCGeneOrGeneProduct inhibitors LCOTHER and LCOTHER and activation of LCOTHER and LCOTHER - dependent proliferative pathways .	1
These studies demonstrate a critical role for LCOTHER signaling in endometrial LCDiseaseOrPhenotypicFeature by regulating expression of LCOTHER inhibitors LCGeneOrGeneProduct and LCOTHER and activation of LCOTHER and LCOTHER - dependent proliferative pathways .	1
These studies demonstrate a critical role for LCOTHER signaling in endometrial LCDiseaseOrPhenotypicFeature by regulating expression of LCOTHER inhibitors LCOTHER and LCGeneOrGeneProduct and activation of LCOTHER and LCOTHER - dependent proliferative pathways .	1
These studies demonstrate a critical role for LCOTHER signaling in endometrial LCDiseaseOrPhenotypicFeature by regulating expression of LCOTHER inhibitors LCOTHER and LCOTHER and activation of LCGeneOrGeneProduct and LCOTHER - dependent proliferative pathways .	1
These studies demonstrate a critical role for LCOTHER signaling in endometrial LCDiseaseOrPhenotypicFeature by regulating expression of LCOTHER inhibitors LCOTHER and LCOTHER and activation of LCOTHER and LCGeneOrGeneProduct - dependent proliferative pathways .	1
These studies demonstrate a critical role for LCOTHER signaling in endometrial LCOTHER by regulating expression of LCGeneOrGeneProduct inhibitors LCGeneOrGeneProduct and LCOTHER and activation of LCOTHER and LCOTHER - dependent proliferative pathways .	3
These studies demonstrate a critical role for LCOTHER signaling in endometrial LCOTHER by regulating expression of LCGeneOrGeneProduct inhibitors LCOTHER and LCGeneOrGeneProduct and activation of LCOTHER and LCOTHER - dependent proliferative pathways .	3
These studies demonstrate a critical role for LCOTHER signaling in endometrial LCOTHER by regulating expression of LCOTHER inhibitors LCGeneOrGeneProduct and LCOTHER and activation of LCGeneOrGeneProduct and LCOTHER - dependent proliferative pathways .	1
These studies demonstrate a critical role for LCOTHER signaling in endometrial LCOTHER by regulating expression of LCOTHER inhibitors LCGeneOrGeneProduct and LCOTHER and activation of LCOTHER and LCGeneOrGeneProduct - dependent proliferative pathways .	1
These studies demonstrate a critical role for LCOTHER signaling in endometrial LCOTHER by regulating expression of LCOTHER inhibitors LCOTHER and LCGeneOrGeneProduct and activation of LCGeneOrGeneProduct and LCOTHER - dependent proliferative pathways .	1
These studies demonstrate a critical role for LCOTHER signaling in endometrial LCOTHER by regulating expression of LCOTHER inhibitors LCOTHER and LCGeneOrGeneProduct and activation of LCOTHER and LCGeneOrGeneProduct - dependent proliferative pathways .	1
In respect of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk , we also saw no effect with the LCOTHER variant but we did observe a borderline association with the 5 ' - untranslated region LCSequenceVariant allele ( hazard ratio , 1 . 43 ; CI , 1 . 01 - 2 . 00 ) .	1
In this study , sequence abnormalities of the LCGeneOrGeneProduct gene were assessed by polymerase chain reaction with specific primers and automated sequencing analysis in DNA samples from 20 LCOTHER with suspected LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature from 18 Brazilian families .	1
LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature ( LCOTHER ) is characterized by nociceptive sensitization caused by the cessation of chronic LCOTHER use .	2
LCChemicalEntity - induced LCOTHER ( LCDiseaseOrPhenotypicFeature ) is characterized by nociceptive sensitization caused by the cessation of chronic LCOTHER use .	2
LCChemicalEntity ( 300 mg / kg ) inhibited LCDiseaseOrPhenotypicFeature in both the thermal sensitivity test and the LCOTHER LCOTHER - induced writhing test .	3
Furthermore , LCChemicalEntity showed a tendency to aggravate LCDiseaseOrPhenotypicFeature in the LCOTHER LCOTHER - induced writhing test .	2
Our data suggested that the LCChemicalEntity LCChemicalEntity , but not LCOTHER or LCOTHER , may contribute toward reversal of LCDiseaseOrPhenotypicFeature . Association study of LCOTHER LCOTHER LCOTHER , LCOTHER , LCOTHER , and LCOTHER and LCOTHER - LCOTHER LCOTHER LCOTHER in a Han Chinese population .	3
Our data suggested that the LCOTHER LCOTHER , but not LCChemicalEntity or LCOTHER , may contribute toward reversal of LCDiseaseOrPhenotypicFeature . Association study of LCOTHER LCOTHER LCOTHER , LCOTHER , LCOTHER , and LCOTHER and LCOTHER - LCOTHER LCOTHER LCOTHER in a Han Chinese population .	2
PURPOSE : Genes in the complement pathway , including LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER / LCOTHER , and LCOTHER , have been reported to be associated with LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
PURPOSE : Genes in the complement pathway , including LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER / LCOTHER , and LCOTHER , have been reported to be associated with LCOTHER - LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
PURPOSE : Genes in the complement pathway , including LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER / LCOTHER , and LCOTHER , have been reported to be associated with LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
PURPOSE : Genes in the complement pathway , including LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER / LCOTHER , and LCOTHER , have been reported to be associated with LCOTHER - LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
RESULTS : Four SNPs , including LCSequenceVariant ( P = 0 . 0276 ) , LCOTHER ( P = 0 . 0266 ) , LCOTHER ( P = 0 . 00514 ) , and LCOTHER ( P = 0 . 0089 ) , in LCOTHER showed a significant association with wet LCDiseaseOrPhenotypicFeature in the cohort of this study .	2
RESULTS : Four SNPs , including LCOTHER ( P = 0 . 0276 ) , LCSequenceVariant ( P = 0 . 0266 ) , LCOTHER ( P = 0 . 00514 ) , and LCOTHER ( P = 0 . 0089 ) , in LCOTHER showed a significant association with wet LCDiseaseOrPhenotypicFeature in the cohort of this study .	2
RESULTS : Four SNPs , including LCOTHER ( P = 0 . 0276 ) , LCOTHER ( P = 0 . 0266 ) , LCSequenceVariant ( P = 0 . 00514 ) , and LCOTHER ( P = 0 . 0089 ) , in LCOTHER showed a significant association with wet LCDiseaseOrPhenotypicFeature in the cohort of this study .	2
RESULTS : Four SNPs , including LCOTHER ( P = 0 . 0276 ) , LCOTHER ( P = 0 . 0266 ) , LCOTHER ( P = 0 . 00514 ) , and LCSequenceVariant ( P = 0 . 0089 ) , in LCOTHER showed a significant association with wet LCDiseaseOrPhenotypicFeature in the cohort of this study .	2
RESULTS : Four SNPs , including LCOTHER ( P = 0 . 0276 ) , LCOTHER ( P = 0 . 0266 ) , LCOTHER ( P = 0 . 00514 ) , and LCOTHER ( P = 0 . 0089 ) , in LCGeneOrGeneProduct showed a significant association with wet LCDiseaseOrPhenotypicFeature in the cohort of this study .	1
None of the SNPs in LCGeneOrGeneProduct showed a significant association with LCOTHER , and none of the SNPs in LCOTHER , LCOTHER , LCOTHER , and LCOTHER showed a significant association with either wet LCDiseaseOrPhenotypicFeature or LCOTHER in the cohort of this study .	1
None of the SNPs in LCOTHER showed a significant association with LCOTHER , and none of the SNPs in LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER showed a significant association with either wet LCDiseaseOrPhenotypicFeature or LCOTHER in the cohort of this study .	1
None of the SNPs in LCOTHER showed a significant association with LCOTHER , and none of the SNPs in LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER showed a significant association with either wet LCDiseaseOrPhenotypicFeature or LCOTHER in the cohort of this study .	1
None of the SNPs in LCOTHER showed a significant association with LCOTHER , and none of the SNPs in LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER showed a significant association with either wet LCDiseaseOrPhenotypicFeature or LCOTHER in the cohort of this study .	1
CONCLUSION : This study showed that SNPs LCSequenceVariant ( P = 0 . 0276 ) , LCOTHER ( P = 0 . 0266 ) , LCOTHER ( P = 0 . 00514 ) , and LCOTHER ( P = 0 . 0089 ) , but not LCOTHER , LCOTHER , or LCOTHER , in LCOTHER were significantly associated with wet LCDiseaseOrPhenotypicFeature in a mainland Han Chinese population .	2
CONCLUSION : This study showed that SNPs LCOTHER ( P = 0 . 0276 ) , LCSequenceVariant ( P = 0 . 0266 ) , LCOTHER ( P = 0 . 00514 ) , and LCOTHER ( P = 0 . 0089 ) , but not LCOTHER , LCOTHER , or LCOTHER , in LCOTHER were significantly associated with wet LCDiseaseOrPhenotypicFeature in a mainland Han Chinese population .	2
CONCLUSION : This study showed that SNPs LCOTHER ( P = 0 . 0276 ) , LCOTHER ( P = 0 . 0266 ) , LCSequenceVariant ( P = 0 . 00514 ) , and LCOTHER ( P = 0 . 0089 ) , but not LCOTHER , LCOTHER , or LCOTHER , in LCOTHER were significantly associated with wet LCDiseaseOrPhenotypicFeature in a mainland Han Chinese population .	2
CONCLUSION : This study showed that SNPs LCOTHER ( P = 0 . 0276 ) , LCOTHER ( P = 0 . 0266 ) , LCOTHER ( P = 0 . 00514 ) , and LCSequenceVariant ( P = 0 . 0089 ) , but not LCOTHER , LCOTHER , or LCOTHER , in LCOTHER were significantly associated with wet LCDiseaseOrPhenotypicFeature in a mainland Han Chinese population .	2
CONCLUSION : This study showed that SNPs LCOTHER ( P = 0 . 0276 ) , LCOTHER ( P = 0 . 0266 ) , LCOTHER ( P = 0 . 00514 ) , and LCOTHER ( P = 0 . 0089 ) , but not LCOTHER , LCOTHER , or LCOTHER , in LCGeneOrGeneProduct were significantly associated with wet LCDiseaseOrPhenotypicFeature in a mainland Han Chinese population .	1
This study showed that LCGeneOrGeneProduct was more likely to be LCDiseaseOrPhenotypicFeature susceptibility gene at Chr . 1q31 based on the finding that the LCOTHER and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCOTHER in a white population in LCOTHER , LCOTHER , and LCOTHER genes showed a significant association with LCOTHER . Seven novel and six de novo LCOTHER gene mutations in LCOTHER with LCOTHER LCOTHER .	1
This study showed that LCGeneOrGeneProduct was more likely to be LCOTHER susceptibility gene at Chr . 1q31 based on the finding that the LCOTHER and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCDiseaseOrPhenotypicFeature in a white population in LCOTHER , LCOTHER , and LCOTHER genes showed a significant association with LCOTHER . Seven novel and six de novo LCOTHER gene mutations in LCOTHER with LCOTHER LCOTHER .	1
This study showed that LCGeneOrGeneProduct was more likely to be LCOTHER susceptibility gene at Chr . 1q31 based on the finding that the LCOTHER and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCOTHER in a white population in LCOTHER , LCOTHER , and LCOTHER genes showed a significant association with LCDiseaseOrPhenotypicFeature . Seven novel and six de novo LCOTHER gene mutations in LCOTHER with LCOTHER LCOTHER .	1
This study showed that LCOTHER was more likely to be LCDiseaseOrPhenotypicFeature susceptibility gene at Chr . 1q31 based on the finding that the LCOTHER and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCOTHER in a white population in LCOTHER , LCOTHER , and LCGeneOrGeneProduct genes showed a significant association with LCOTHER . Seven novel and six de novo LCOTHER gene mutations in LCOTHER with LCOTHER LCOTHER .	1
This study showed that LCOTHER was more likely to be LCOTHER susceptibility gene at Chr . 1q31 based on the finding that the LCOTHER and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCDiseaseOrPhenotypicFeature in a white population in LCOTHER , LCOTHER , and LCGeneOrGeneProduct genes showed a significant association with LCOTHER . Seven novel and six de novo LCOTHER gene mutations in LCOTHER with LCOTHER LCOTHER .	1
This study showed that LCOTHER was more likely to be LCOTHER susceptibility gene at Chr . 1q31 based on the finding that the LCOTHER and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCOTHER in a white population in LCGeneOrGeneProduct , LCOTHER , and LCOTHER genes showed a significant association with LCDiseaseOrPhenotypicFeature . Seven novel and six de novo LCOTHER gene mutations in LCOTHER with LCOTHER LCOTHER .	1
This study showed that LCOTHER was more likely to be LCOTHER susceptibility gene at Chr . 1q31 based on the finding that the LCOTHER and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCOTHER in a white population in LCOTHER , LCGeneOrGeneProduct , and LCOTHER genes showed a significant association with LCDiseaseOrPhenotypicFeature . Seven novel and six de novo LCOTHER gene mutations in LCOTHER with LCOTHER LCOTHER .	1
Inactivating mutations in LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) have been identified as a cause of LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ; LCOTHER LCOTHER ) .	3
Inactivating mutations in LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) have been identified as a cause of LCOTHER - LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ; LCOTHER LCOTHER ) .	3
Inactivating mutations in LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) have been identified as a cause of LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ; LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	3
Inactivating mutations in LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) have been identified as a cause of LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ; LCOTHER LCOTHER ) .	3
Inactivating mutations in LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) have been identified as a cause of LCOTHER - LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ; LCOTHER LCOTHER ) .	3
Inactivating mutations in LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) have been identified as a cause of LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ; LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	3
The transcription factor LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct is an upstream regulator of several genes involved in the pathogenesis of LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature of the young .	1
We therefore tested the hypothesis that variability in the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene is associated with subsets of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and estimates of LCOTHER secretion in LCOTHER tolerant subjects .	1
Moreover , in studies of 238 middle - aged LCChemicalEntity tolerant subjects , of 226 LCOTHER tolerant offspring of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER and of 367 young healthy subjects , the carriers of the polymorphism did not differ from non - carriers in LCOTHER induced serum LCOTHER or LCOTHER - LCOTHER responses .	1
Moreover , in studies of 238 middle - aged LCChemicalEntity tolerant subjects , of 226 LCOTHER tolerant offspring of LCOTHER LCOTHER LCOTHER LCOTHER and of 367 young healthy subjects , the carriers of the polymorphism did not differ from non - carriers in LCOTHER induced serum LCGeneOrGeneProduct or LCOTHER - LCOTHER responses .	2
Moreover , in studies of 238 middle - aged LCChemicalEntity tolerant subjects , of 226 LCOTHER tolerant offspring of LCOTHER LCOTHER LCOTHER LCOTHER and of 367 young healthy subjects , the carriers of the polymorphism did not differ from non - carriers in LCOTHER induced serum LCOTHER or LCGeneOrGeneProduct - LCGeneOrGeneProduct responses .	2
Moreover , in studies of 238 middle - aged LCOTHER tolerant subjects , of 226 LCChemicalEntity tolerant offspring of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER and of 367 young healthy subjects , the carriers of the polymorphism did not differ from non - carriers in LCOTHER induced serum LCOTHER or LCOTHER - LCOTHER responses .	1
Moreover , in studies of 238 middle - aged LCOTHER tolerant subjects , of 226 LCChemicalEntity tolerant offspring of LCOTHER LCOTHER LCOTHER LCOTHER and of 367 young healthy subjects , the carriers of the polymorphism did not differ from non - carriers in LCOTHER induced serum LCGeneOrGeneProduct or LCOTHER - LCOTHER responses .	2
Moreover , in studies of 238 middle - aged LCOTHER tolerant subjects , of 226 LCChemicalEntity tolerant offspring of LCOTHER LCOTHER LCOTHER LCOTHER and of 367 young healthy subjects , the carriers of the polymorphism did not differ from non - carriers in LCOTHER induced serum LCOTHER or LCGeneOrGeneProduct - LCGeneOrGeneProduct responses .	2
Moreover , in studies of 238 middle - aged LCOTHER tolerant subjects , of 226 LCOTHER tolerant offspring of LCOTHER LCOTHER LCOTHER LCOTHER and of 367 young healthy subjects , the carriers of the polymorphism did not differ from non - carriers in LCChemicalEntity induced serum LCGeneOrGeneProduct or LCOTHER - LCOTHER responses .	2
Moreover , in studies of 238 middle - aged LCOTHER tolerant subjects , of 226 LCOTHER tolerant offspring of LCOTHER LCOTHER LCOTHER LCOTHER and of 367 young healthy subjects , the carriers of the polymorphism did not differ from non - carriers in LCChemicalEntity induced serum LCOTHER or LCGeneOrGeneProduct - LCGeneOrGeneProduct responses .	2
Mutations in the coding region of the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene are not associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature or with changes in LCOTHER responses to LCOTHER among the Caucasians examined . LCOTHER - associated LCOTHER in a healthy adolescent receiving LCOTHER for LCOTHER LCOTHER control .	1
A healthy 17 - year - old male received standard intermittent doses of LCChemicalEntity via a LCOTHER - controlled analgesia ( PCA ) pump for management of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature control .	3
The routine use of LCChemicalEntity via PCA even for a brief LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature should be reconsidered . Smoking of LCOTHER LCOTHER as a risk factor for LCOTHER LCOTHER among people who use injection drugs .	3
BACKGROUND : Little is known about the possible role that smoking LCChemicalEntity LCChemicalEntity has on the incidence of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
Given the increasing use of LCChemicalEntity LCChemicalEntity , we sought to examine whether use of this illicit drug has become a risk factor for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
To determine whether the risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature among daily smokers of LCChemicalEntity LCChemicalEntity changed over time , we used Cox proportional hazards regression and divided the study into 3 periods : May 1 , 1996 - Nov .	2
After adjusting for potential confounders , we found that the risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature among participants who were daily smokers of LCChemicalEntity LCChemicalEntity increased over time ( period 1 : hazard ratio [ HR ] 1 . 03 , 95% confidence interval [ CI ] 0 . 57 - 1 . 85 ; period 2 : HR 1 . 68 , 95% CI 1 . 01 - 2 . 80 ; and period 3 : HR 2 . 74 , 95% CI 1 . 06 - 7 . 11 ) .	2
LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is required to convert the LCChemicalEntity LCChemicalEntity used in supplements and for food fortification and the LCOTHER produced by LCOTHER LCOTHER during DNA synthesis to the reduced LCOTHER forms used by the cell .	1
LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is required to convert the LCOTHER LCOTHER used in supplements and for food fortification and the LCChemicalEntity produced by LCOTHER LCOTHER during DNA synthesis to the reduced LCOTHER forms used by the cell .	1
LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is required to convert the LCOTHER LCOTHER used in supplements and for food fortification and the LCOTHER produced by LCOTHER LCOTHER during DNA synthesis to the reduced LCChemicalEntity forms used by the cell .	1
LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is required to convert the LCChemicalEntity LCChemicalEntity used in supplements and for food fortification and the LCOTHER produced by LCOTHER LCOTHER during DNA synthesis to the reduced LCOTHER forms used by the cell .	1
LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is required to convert the LCOTHER LCOTHER used in supplements and for food fortification and the LCChemicalEntity produced by LCOTHER LCOTHER during DNA synthesis to the reduced LCOTHER forms used by the cell .	1
LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is required to convert the LCOTHER LCOTHER used in supplements and for food fortification and the LCOTHER produced by LCOTHER LCOTHER during DNA synthesis to the reduced LCChemicalEntity forms used by the cell .	1
LCOTHER LCOTHER ( LCOTHER ) is required to convert the LCOTHER LCOTHER used in supplements and for food fortification and the LCChemicalEntity produced by LCGeneOrGeneProduct LCGeneOrGeneProduct during DNA synthesis to the reduced LCOTHER forms used by the cell .	2
OBJECTIVE : We aimed to determine whether a common , recently discovered deletion polymorphism in the LCGeneOrGeneProduct gene is a risk factor for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature or low birth weight .	1
LCOTHER with both a LCGeneOrGeneProduct deletion allele and low LCChemicalEntity intake ( < 400 microg / d from diet plus supplements ) had a significantly greater risk of LCOTHER LCOTHER ( AOR : 5 . 5 ; 95% CI : 1 . 5 , 20 . 4 ; P = 0 . 01 ) and a significantly greater risk of having an infant with a low birth weight ( AOR : 8 . 3 ; 95% CI : 1 . 8 , 38 . 6 ; P = 0 . 01 ) than did LCOTHER without a deletion allele and with a LCOTHER intake > / = 400 microg / d .	1
LCOTHER with both a LCGeneOrGeneProduct deletion allele and low LCOTHER intake ( < 400 microg / d from diet plus supplements ) had a significantly greater risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( AOR : 5 . 5 ; 95% CI : 1 . 5 , 20 . 4 ; P = 0 . 01 ) and a significantly greater risk of having an infant with a low birth weight ( AOR : 8 . 3 ; 95% CI : 1 . 8 , 38 . 6 ; P = 0 . 01 ) than did LCOTHER without a deletion allele and with a LCOTHER intake > / = 400 microg / d .	1
LCOTHER with both a LCGeneOrGeneProduct deletion allele and low LCOTHER intake ( < 400 microg / d from diet plus supplements ) had a significantly greater risk of LCOTHER LCOTHER ( AOR : 5 . 5 ; 95% CI : 1 . 5 , 20 . 4 ; P = 0 . 01 ) and a significantly greater risk of having an infant with a low birth weight ( AOR : 8 . 3 ; 95% CI : 1 . 8 , 38 . 6 ; P = 0 . 01 ) than did LCOTHER without a deletion allele and with a LCChemicalEntity intake > / = 400 microg / d .	1
LCOTHER with both a LCOTHER deletion allele and low LCChemicalEntity intake ( < 400 microg / d from diet plus supplements ) had a significantly greater risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( AOR : 5 . 5 ; 95% CI : 1 . 5 , 20 . 4 ; P = 0 . 01 ) and a significantly greater risk of having an infant with a low birth weight ( AOR : 8 . 3 ; 95% CI : 1 . 8 , 38 . 6 ; P = 0 . 01 ) than did LCOTHER without a deletion allele and with a LCOTHER intake > / = 400 microg / d .	3
CONCLUSIONS : The LCGeneOrGeneProduct LCOTHER - LCOTHER LCOTHER LCOTHER allele may be a risk factor for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
CONCLUSIONS : The LCOTHER LCSequenceVariant - LCSequenceVariant LCSequenceVariant LCSequenceVariant allele may be a risk factor for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
LCChemicalEntity is a novel LCOTHER derivative which attenuates LCChemicalEntity - induced LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER .	3
LCChemicalEntity is a novel LCOTHER derivative which attenuates LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
LCOTHER is a novel LCOTHER derivative which attenuates LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
Given that LCOTHER inhibits passive avoidance retention when given during training or in a defined 10 - 12h post - training period , we evaluated the ability of LCChemicalEntity to attenuate LCDiseaseOrPhenotypicFeature induced by LCOTHER LCOTHER .	3
Given that LCOTHER inhibits passive avoidance retention when given during training or in a defined 10 - 12h post - training period , we evaluated the ability of LCChemicalEntity to attenuate LCOTHER induced by LCChemicalEntity LCChemicalEntity .	3
A step - down passive avoidance paradigm was employed and LCChemicalEntity ( 3 mg / kg ) and LCChemicalEntity ( 0 . 5 mg / kg ) were given alone or in combination during training and at the 10 - 12h post - training period of consolidation .	3
Co - administration of LCChemicalEntity and LCChemicalEntity during training or 10h thereafter produced no significant anti - LCOTHER effect .	3
Co - administration of LCChemicalEntity and LCOTHER during training or 10h thereafter produced no significant anti - LCDiseaseOrPhenotypicFeature effect .	3
However , administration of LCChemicalEntity during training completely reversed the LCDiseaseOrPhenotypicFeature induced by LCOTHER at the 10h post - training time and the converse was also true .	3
However , administration of LCChemicalEntity during training completely reversed the LCOTHER induced by LCChemicalEntity at the 10h post - training time and the converse was also true .	3
However , administration of LCOTHER during training completely reversed the LCDiseaseOrPhenotypicFeature induced by LCChemicalEntity at the 10h post - training time and the converse was also true .	2
The LCGeneOrGeneProduct - LCGeneOrGeneProduct system is involved in LCOTHER growth and LCOTHER .	1
The LCGeneOrGeneProduct - LCOTHER system is involved in LCDiseaseOrPhenotypicFeature growth and LCOTHER .	1
The LCGeneOrGeneProduct - LCOTHER system is involved in LCOTHER growth and LCDiseaseOrPhenotypicFeature .	1
The LCOTHER - LCGeneOrGeneProduct system is involved in LCDiseaseOrPhenotypicFeature growth and LCOTHER .	1
The LCOTHER - LCGeneOrGeneProduct system is involved in LCOTHER growth and LCDiseaseOrPhenotypicFeature .	1
This study was designed to evaluate the role of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) in the formation of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER .	1
This study was designed to evaluate the role of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) in the formation of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER .	1
The mRNA levels of LCGeneOrGeneProduct , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) , and LCOTHER / LCOTHER were suppressed in LCGeneOrGeneProduct compared with WT .	2
The mRNA levels of LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) , and LCOTHER / LCOTHER were suppressed in LCGeneOrGeneProduct compared with WT .	2
The mRNA levels of LCOTHER , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) , and LCOTHER / LCOTHER were suppressed in LCGeneOrGeneProduct compared with WT .	2
The mRNA levels of LCOTHER , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) , and LCGeneOrGeneProduct / LCGeneOrGeneProduct were suppressed in LCGeneOrGeneProduct compared with WT .	2
Double immunofluorescence analysis showed that the number of accumulated LCGeneOrGeneProduct / LCGeneOrGeneProduct ( + ) cells expressing LCOTHER - LCOTHER in metastatic areas was higher in WT than in LCGeneOrGeneProduct .	2
Double immunofluorescence analysis showed that the number of accumulated LCOTHER / LCOTHER ( + ) cells expressing LCGeneOrGeneProduct - LCGeneOrGeneProduct in metastatic areas was higher in WT than in LCGeneOrGeneProduct .	2
The LCGeneOrGeneProduct bone marrow ( BM ) ( LCOTHER - BM ) > WT showed suppressed formation of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature compared with WT - BM > WT .	1
The LCOTHER bone marrow ( BM ) ( LCGeneOrGeneProduct - BM ) > WT showed suppressed formation of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature compared with WT - BM > WT .	1
LCGeneOrGeneProduct LCGeneOrGeneProduct enhanced LCGeneOrGeneProduct - LCGeneOrGeneProduct expression in Kupffer cells .	2
Treatment of WT with LCChemicalEntity liposomes suppressed LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature by diminishing LCOTHER - LCOTHER ( + ) LCOTHER / LCOTHER ( + ) cells accumulation .	3
The formation of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature correlated with LCGeneOrGeneProduct deposition in the metastatic area , which was dependent on LCOTHER signaling .	1
The formation of LCOTHER LCOTHER correlated with LCGeneOrGeneProduct deposition in the metastatic area , which was dependent on LCGeneOrGeneProduct signaling .	1
These results suggested that resident hepatic macrophages induced LCOTHER LCOTHER formation by induction of LCGeneOrGeneProduct - LCGeneOrGeneProduct through LCGeneOrGeneProduct signaling . LCOTHER induces primary loss of LCOTHER in LCOTHER hearts : correlation with LCOTHER LCOTHER .	2
The mechanism of LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature is unknown , but a mismatch of LCOTHER supply vs .	2
Taking into account that the sarcolemmal integrity is stabilized by the LCGeneOrGeneProduct - LCGeneOrGeneProduct complex ( DGC ) that connects LCOTHER and LCOTHER in contractile machinery and extracellular matrix and by integrins , this study tests the hypothesis that LCOTHER affects sarcolemmal stability through changes in the DGC and integrins .	1
Taking into account that the sarcolemmal integrity is stabilized by the LCGeneOrGeneProduct - LCOTHER complex ( DGC ) that connects LCOTHER and LCGeneOrGeneProduct in contractile machinery and extracellular matrix and by integrins , this study tests the hypothesis that LCOTHER affects sarcolemmal stability through changes in the DGC and integrins .	2
In conclusion , administration of LCChemicalEntity to LCOTHER results in primary loss of LCGeneOrGeneProduct , the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte .	3
LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCOTHER ) are involved in the pathogenesis of LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCOTHER ) are involved in the pathogenesis of LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCOTHER ) are involved in the pathogenesis of LCOTHER and LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) are involved in the pathogenesis of LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) are involved in the pathogenesis of LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) are involved in the pathogenesis of LCOTHER and LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
LCGeneOrGeneProduct LCGeneOrGeneProduct are the main source of LCChemicalEntity in the vasculature .	1
LCGeneOrGeneProduct is a critical component of vascular LCGeneOrGeneProduct LCGeneOrGeneProduct and is encoded by the LCOTHER ( LCOTHER LCOTHER LCOTHER ) gene .	1
In conclusion the - 930A > G LCGeneOrGeneProduct polymorphism is associated with LCDiseaseOrPhenotypicFeature in the Polish population .	1
Mutations of the LCGeneOrGeneProduct / LCOTHER LCOTHER gene ( LCOTHER / LCOTHER ) account for both sporadic and familial forms of LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
Mutations of the LCGeneOrGeneProduct / LCOTHER LCOTHER gene ( LCOTHER / LCOTHER ) account for both sporadic and familial forms of LCOTHER ' LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
Mutations of the LCOTHER / LCGeneOrGeneProduct LCGeneOrGeneProduct gene ( LCOTHER / LCOTHER ) account for both sporadic and familial forms of LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
Mutations of the LCOTHER / LCGeneOrGeneProduct LCGeneOrGeneProduct gene ( LCOTHER / LCOTHER ) account for both sporadic and familial forms of LCOTHER ' LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
Mutations of the LCOTHER / LCOTHER LCOTHER gene ( LCGeneOrGeneProduct / LCOTHER ) account for both sporadic and familial forms of LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
Mutations of the LCOTHER / LCOTHER LCOTHER gene ( LCGeneOrGeneProduct / LCOTHER ) account for both sporadic and familial forms of LCOTHER ' LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
Mutations of the LCOTHER / LCOTHER LCOTHER gene ( LCOTHER / LCGeneOrGeneProduct ) account for both sporadic and familial forms of LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
Mutations of the LCOTHER / LCOTHER LCOTHER gene ( LCOTHER / LCGeneOrGeneProduct ) account for both sporadic and familial forms of LCOTHER ' LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
We originally described a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) of exon 8 , in the ubiquitin protein - binding domain of LCGeneOrGeneProduct / LCOTHER gene in an Italian LCDiseaseOrPhenotypicFeature LCOTHER .	1
We originally described a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) of exon 8 , in the ubiquitin protein - binding domain of LCOTHER / LCGeneOrGeneProduct gene in an Italian LCDiseaseOrPhenotypicFeature LCOTHER .	1
Of the five clinically ascertained affected members of the family , four possessed the LCSequenceVariant mutation and exhibited the polyostotic form of LCOTHER , except one LCOTHER with a single X - ray - assessed skeletal localization and one with a LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature who had died several years before the DNA analysis .	1
Taken together , these results support a genotype - phenotype correlation between the LCOTHER mutation in the LCGeneOrGeneProduct / LCOTHER gene and a polyostotic form of LCDiseaseOrPhenotypicFeature in this family .	1
Taken together , these results support a genotype - phenotype correlation between the LCOTHER mutation in the LCOTHER / LCGeneOrGeneProduct gene and a polyostotic form of LCDiseaseOrPhenotypicFeature in this family .	1
The high penetrance of the LCOTHER trait in this family together with the study of the asymptomatic gene carriers will allow us to confirm the proposed genotype - phenotype correlation and to evaluate the potential use of mutational analysis of the LCGeneOrGeneProduct / LCOTHER gene in the early detection of relatives at risk for LCDiseaseOrPhenotypicFeature . LCOTHER LCOTHER LCOTHER LCOTHER with LCOTHER LCOTHER and LCOTHER associated with mutations in exon 49 of LCOTHER .	1
The high penetrance of the LCOTHER trait in this family together with the study of the asymptomatic gene carriers will allow us to confirm the proposed genotype - phenotype correlation and to evaluate the potential use of mutational analysis of the LCOTHER / LCGeneOrGeneProduct gene in the early detection of relatives at risk for LCDiseaseOrPhenotypicFeature . LCOTHER LCOTHER LCOTHER LCOTHER with LCOTHER LCOTHER and LCOTHER associated with mutations in exon 49 of LCOTHER .	1
These observations suggest that mutations in this region of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct chain carry a high risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER . LCOTHER mutation - impaired T - cell activation in a family with LCOTHER LCOTHER LCOTHER .	1
These observations suggest that mutations in this region of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct chain carry a high risk of LCOTHER LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER mutation - impaired T - cell activation in a family with LCOTHER LCOTHER LCOTHER .	1
BACKGROUND : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is LCOTHER LCOTHER with an autosomal recessive inheritance and is caused by a mutation in the gene encoding LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER LCOTHER LCOTHER / LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ) .	1
BACKGROUND : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is LCOTHER LCOTHER with an autosomal recessive inheritance and is caused by a mutation in the gene encoding LCOTHER - LCOTHER ( LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct / LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ) .	1
BACKGROUND : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is LCOTHER LCOTHER with an autosomal recessive inheritance and is caused by a mutation in the gene encoding LCOTHER - LCOTHER ( LCOTHER LCOTHER LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ) .	1
BACKGROUND : LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is LCOTHER LCOTHER with an autosomal recessive inheritance and is caused by a mutation in the gene encoding LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER LCOTHER LCOTHER / LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ) .	1
BACKGROUND : LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is LCOTHER LCOTHER with an autosomal recessive inheritance and is caused by a mutation in the gene encoding LCOTHER - LCOTHER ( LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct / LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ) .	1
BACKGROUND : LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is LCOTHER LCOTHER with an autosomal recessive inheritance and is caused by a mutation in the gene encoding LCOTHER - LCOTHER ( LCOTHER LCOTHER LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ) .	1
LCGeneOrGeneProduct - LCGeneOrGeneProduct is an allosteric agonist to the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) and it regulates epidermal homeostasis .	2
LCGeneOrGeneProduct - LCGeneOrGeneProduct is an allosteric agonist to the LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) and it regulates epidermal homeostasis .	2
Among the family members , LCOTHER with the homozygous LCGeneOrGeneProduct ( previously known as ARS component B ) mutation are prone to LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER , which might link to defective T - cell function as well as a derangement of epidermal homeostasis .	1
Among the family members , LCOTHER with the homozygous LCGeneOrGeneProduct ( previously known as ARS component B ) mutation are prone to LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , which might link to defective T - cell function as well as a derangement of epidermal homeostasis .	1
METHODS : LCOTHER peripheral blood mononuclear cells ( PBMCs ) were isolated from a Taiwanese LCDiseaseOrPhenotypicFeature family bearing the LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant in the LCOTHER gene , corresponding to a LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) in the LCOTHER - LCOTHER protein .	2
METHODS : LCOTHER peripheral blood mononuclear cells ( PBMCs ) were isolated from a Taiwanese LCDiseaseOrPhenotypicFeature family bearing the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in the LCGeneOrGeneProduct gene , corresponding to a LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) in the LCOTHER - LCOTHER protein .	1
METHODS : LCOTHER peripheral blood mononuclear cells ( PBMCs ) were isolated from a Taiwanese LCDiseaseOrPhenotypicFeature family bearing the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in the LCOTHER gene , corresponding to a LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant ( LCOTHER ) in the LCOTHER - LCOTHER protein .	2
METHODS : LCOTHER peripheral blood mononuclear cells ( PBMCs ) were isolated from a Taiwanese LCDiseaseOrPhenotypicFeature family bearing the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in the LCOTHER gene , corresponding to a LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCSequenceVariant ) in the LCOTHER - LCOTHER protein .	2
METHODS : LCOTHER peripheral blood mononuclear cells ( PBMCs ) were isolated from a Taiwanese LCDiseaseOrPhenotypicFeature family bearing the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in the LCOTHER gene , corresponding to a LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) in the LCGeneOrGeneProduct - LCGeneOrGeneProduct protein .	1
CONCLUSIONS : LCOTHER with LCDiseaseOrPhenotypicFeature with the homozygous LCGeneOrGeneProduct - LCGeneOrGeneProduct LCOTHER mutation may have an impaired T - cell activation .	1
CONCLUSIONS : LCOTHER with LCDiseaseOrPhenotypicFeature with the homozygous LCOTHER - LCOTHER LCSequenceVariant mutation may have an impaired T - cell activation .	2
Another LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature harbored a heterozygous LCSequenceVariant . LCSequenceVariant missense mutation .	1
Also , it records a novel deletion in exon 1 of LCGeneOrGeneProduct gene in a LCOTHER with severe LCDiseaseOrPhenotypicFeature . People aged over 75 in LCOTHER LCOTHER on LCOTHER : the rate of major LCOTHER and LCOTHER in more than 500 LCOTHER - years of follow - up .	1
OBJECTIVES : To determine the incidence of major LCOTHER and LCDiseaseOrPhenotypicFeature in people aged 76 and older with LCOTHER LCOTHER on adjusted - dose LCChemicalEntity who had been recently been admitted to hospital .	3
OBJECTIVES : To determine the incidence of major LCOTHER and LCOTHER in people aged 76 and older with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature on adjusted - dose LCChemicalEntity who had been recently been admitted to hospital .	3
PARTICIPANTS : Two hundred thirty - five LCOTHER aged 76 and older admitted to a major healthcare network between July 1 , 2001 , and June 30 , 2002 , with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature on LCChemicalEntity were enrolled .	3
MEASUREMENTS : Information regarding major LCOTHER episodes , LCDiseaseOrPhenotypicFeature , and LCChemicalEntity use was obtained from LCOTHER , relatives , primary physicians , and medical records .	3
The annual LCDiseaseOrPhenotypicFeature rate after initiation of LCChemicalEntity was 2 . 6% .	3
CONCLUSION : The rate of major LCOTHER was high in this old , frail group , but excluding fatalities , resulted in no long - term sequelae , and the LCDiseaseOrPhenotypicFeature rate on LCChemicalEntity was low , demonstrating how effective LCOTHER treatment is . LCOTHER : an underutilized therapy for LCOTHER ' LCOTHER LCOTHER .	3
CONCLUSION : The rate of major LCOTHER was high in this old , frail group , but excluding fatalities , resulted in no long - term sequelae , and the LCDiseaseOrPhenotypicFeature rate on LCOTHER was low , demonstrating how effective LCChemicalEntity treatment is . LCOTHER : an underutilized therapy for LCOTHER ' LCOTHER LCOTHER .	3
LCChemicalEntity was the first LCOTHER LCOTHER ever used to treat symptoms of LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous LCChemicalEntity injections produce antiparkinsonian benefit close if not identical to that seen with LCChemicalEntity and that LCOTHER rescue injections can reliably revert off - periods even in LCOTHER with complex on - off motor swings .	3
In addition , there is convincing clinical evidence that monotherapy with continuous subcutaneous LCChemicalEntity infusions is associated with marked reductions of preexisting LCChemicalEntity - induced LCOTHER .	3
In addition , there is convincing clinical evidence that monotherapy with continuous subcutaneous LCChemicalEntity infusions is associated with marked reductions of preexisting LCOTHER - induced LCDiseaseOrPhenotypicFeature .	3
In addition , there is convincing clinical evidence that monotherapy with continuous subcutaneous LCOTHER infusions is associated with marked reductions of preexisting LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature .	2
Given the marked degree of efficacy of subcutaneous LCChemicalEntity treatment in fluctuating LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , this approach seems to deserve more widespread clinical use . LCOTHER - LCOTHER gene polymorphism in LCOTHER with LCOTHER LCOTHER LCOTHER .	3
We investigated the association between LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and the frequency of the single - nucleotide polymorphism LCSequenceVariant ( LCOTHER / LCOTHER ) , which causes a LCOTHER - LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER .	1
We investigated the association between LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and the frequency of the single - nucleotide polymorphism LCOTHER ( LCSequenceVariant / LCSequenceVariant ) , which causes a LCOTHER - LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER .	1
We investigated the association between LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and the frequency of the single - nucleotide polymorphism LCOTHER ( LCOTHER / LCOTHER ) , which causes a LCSequenceVariant - LCSequenceVariant - LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant .	1
RESULTS : Compared with the control group , LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature had a significantly lower frequency of the LCOTHER - LCOTHER LCSequenceVariant genotype ( 0% vs .	1
The number of LCGeneOrGeneProduct - LCGeneOrGeneProduct LCOTHER alleles among the LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature was also significantly lower than in the control group ( 8 . 7% vs .	1
Furthermore , LCOTHER with the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCOTHER genotype showed a severe LCDiseaseOrPhenotypicFeature state ( platelet count < 10 10 ( 9 ) / L ) at diagnosis than those with the LCOTHER - LCOTHER LCOTHER genotype ( 20 . 9% vs .	1
Furthermore , LCOTHER with the LCOTHER - LCOTHER LCSequenceVariant genotype showed a severe LCDiseaseOrPhenotypicFeature state ( platelet count < 10 10 ( 9 ) / L ) at diagnosis than those with the LCOTHER - LCOTHER LCOTHER genotype ( 20 . 9% vs .	1
CONCLUSION : These findings suggest that the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCOTHER LCOTHER allele is significantly associated with the development of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , suggesting a role for LCOTHER - LCOTHER in the pathogenesis of LCOTHER LCOTHER . Identification of the LCOTHER LCOTHER mutation in LCOTHER LCOTHER LCOTHER .	1
CONCLUSION : These findings suggest that the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCOTHER LCOTHER allele is significantly associated with the development of LCOTHER LCOTHER , suggesting a role for LCOTHER - LCOTHER in the pathogenesis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Identification of the LCOTHER LCOTHER mutation in LCOTHER LCOTHER LCOTHER .	1
CONCLUSION : These findings suggest that the LCOTHER - LCOTHER LCOTHER LCOTHER allele is significantly associated with the development of LCOTHER LCOTHER , suggesting a role for LCGeneOrGeneProduct - LCGeneOrGeneProduct in the pathogenesis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Identification of the LCOTHER LCOTHER mutation in LCOTHER LCOTHER LCOTHER .	1
Here , we performed whole exome sequencing of 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature from LCOTHER enrolled in a nonrandomized , open - labeled , single - center phase II study for LCChemicalEntity , and integrated our results with previously published results on pancreas ( n = 12 ) and small LCOTHER LCOTHER ( n = 50 ) .	3
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER .	1
Among 12 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCGeneOrGeneProduct .	1
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCDiseaseOrPhenotypicFeature - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	1
Three LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER with LCGeneOrGeneProduct mutations demonstrated a durable response and one small LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER with LCOTHER LCOTHER mutation showed progression after LCOTHER treatment .	1
Three LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER with LCOTHER mutations demonstrated a durable response and one small LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER with LCOTHER LCOTHER mutation showed progression after LCChemicalEntity treatment .	3
Three LCOTHER - LCOTHER LCOTHER with LCOTHER mutations demonstrated a durable response and one small LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER with LCGeneOrGeneProduct LCOTHER mutation showed progression after LCOTHER treatment .	1
Three LCOTHER - LCOTHER LCOTHER with LCOTHER mutations demonstrated a durable response and one small LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER with LCOTHER LCSequenceVariant mutation showed progression after LCOTHER treatment .	1
Three LCOTHER - LCOTHER LCOTHER with LCOTHER mutations demonstrated a durable response and one small LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER with LCOTHER LCOTHER mutation showed progression after LCChemicalEntity treatment .	3
Three LCOTHER - LCOTHER LCOTHER with LCOTHER mutations demonstrated a durable response and one small LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER with LCGeneOrGeneProduct LCOTHER mutation showed progression after LCChemicalEntity treatment .	3
Three LCOTHER - LCOTHER LCOTHER with LCOTHER mutations demonstrated a durable response and one small LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER with LCOTHER LCSequenceVariant mutation showed progression after LCChemicalEntity treatment .	3
We found LCGeneOrGeneProduct LCOTHER ( G1 LCDiseaseOrPhenotypicFeature from rectum and two G3 LCOTHER from colon ) and LCOTHER LCOTHER ( G2 LCOTHER from pancreas ) missense mutations ( 9 . 1% ) in an independent cohort of 44 LCOTHER - LCOTHER from the rectum ( n = 26 ) , colon ( n = 7 ) , pancreas ( n = 4 ) , small intestine ( n = 3 ) , stomach ( n = 3 ) and appendix ( n = 1 ) by Sanger sequencing .	1
We found LCGeneOrGeneProduct LCOTHER ( G1 LCOTHER from rectum and two G3 LCDiseaseOrPhenotypicFeature from colon ) and LCOTHER LCOTHER ( G2 LCOTHER from pancreas ) missense mutations ( 9 . 1% ) in an independent cohort of 44 LCOTHER - LCOTHER from the rectum ( n = 26 ) , colon ( n = 7 ) , pancreas ( n = 4 ) , small intestine ( n = 3 ) , stomach ( n = 3 ) and appendix ( n = 1 ) by Sanger sequencing .	1
We found LCGeneOrGeneProduct LCOTHER ( G1 LCOTHER from rectum and two G3 LCOTHER from colon ) and LCOTHER LCOTHER ( G2 LCDiseaseOrPhenotypicFeature from pancreas ) missense mutations ( 9 . 1% ) in an independent cohort of 44 LCOTHER - LCOTHER from the rectum ( n = 26 ) , colon ( n = 7 ) , pancreas ( n = 4 ) , small intestine ( n = 3 ) , stomach ( n = 3 ) and appendix ( n = 1 ) by Sanger sequencing .	1
We found LCGeneOrGeneProduct LCOTHER ( G1 LCOTHER from rectum and two G3 LCOTHER from colon ) and LCOTHER LCOTHER ( G2 LCOTHER from pancreas ) missense mutations ( 9 . 1% ) in an independent cohort of 44 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature from the rectum ( n = 26 ) , colon ( n = 7 ) , pancreas ( n = 4 ) , small intestine ( n = 3 ) , stomach ( n = 3 ) and appendix ( n = 1 ) by Sanger sequencing .	1
We found LCOTHER LCSequenceVariant ( G1 LCDiseaseOrPhenotypicFeature from rectum and two G3 LCOTHER from colon ) and LCOTHER LCOTHER ( G2 LCOTHER from pancreas ) missense mutations ( 9 . 1% ) in an independent cohort of 44 LCOTHER - LCOTHER from the rectum ( n = 26 ) , colon ( n = 7 ) , pancreas ( n = 4 ) , small intestine ( n = 3 ) , stomach ( n = 3 ) and appendix ( n = 1 ) by Sanger sequencing .	1
We found LCOTHER LCSequenceVariant ( G1 LCOTHER from rectum and two G3 LCDiseaseOrPhenotypicFeature from colon ) and LCOTHER LCOTHER ( G2 LCOTHER from pancreas ) missense mutations ( 9 . 1% ) in an independent cohort of 44 LCOTHER - LCOTHER from the rectum ( n = 26 ) , colon ( n = 7 ) , pancreas ( n = 4 ) , small intestine ( n = 3 ) , stomach ( n = 3 ) and appendix ( n = 1 ) by Sanger sequencing .	1
We found LCOTHER LCSequenceVariant ( G1 LCOTHER from rectum and two G3 LCOTHER from colon ) and LCOTHER LCOTHER ( G2 LCDiseaseOrPhenotypicFeature from pancreas ) missense mutations ( 9 . 1% ) in an independent cohort of 44 LCOTHER - LCOTHER from the rectum ( n = 26 ) , colon ( n = 7 ) , pancreas ( n = 4 ) , small intestine ( n = 3 ) , stomach ( n = 3 ) and appendix ( n = 1 ) by Sanger sequencing .	1
We found LCOTHER LCSequenceVariant ( G1 LCOTHER from rectum and two G3 LCOTHER from colon ) and LCOTHER LCOTHER ( G2 LCOTHER from pancreas ) missense mutations ( 9 . 1% ) in an independent cohort of 44 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature from the rectum ( n = 26 ) , colon ( n = 7 ) , pancreas ( n = 4 ) , small intestine ( n = 3 ) , stomach ( n = 3 ) and appendix ( n = 1 ) by Sanger sequencing .	1
We found LCOTHER LCOTHER ( G1 LCOTHER from rectum and two G3 LCOTHER from colon ) and LCGeneOrGeneProduct LCOTHER ( G2 LCDiseaseOrPhenotypicFeature from pancreas ) missense mutations ( 9 . 1% ) in an independent cohort of 44 LCOTHER - LCOTHER from the rectum ( n = 26 ) , colon ( n = 7 ) , pancreas ( n = 4 ) , small intestine ( n = 3 ) , stomach ( n = 3 ) and appendix ( n = 1 ) by Sanger sequencing .	1
We found LCOTHER LCOTHER ( G1 LCOTHER from rectum and two G3 LCOTHER from colon ) and LCGeneOrGeneProduct LCOTHER ( G2 LCOTHER from pancreas ) missense mutations ( 9 . 1% ) in an independent cohort of 44 LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature from the rectum ( n = 26 ) , colon ( n = 7 ) , pancreas ( n = 4 ) , small intestine ( n = 3 ) , stomach ( n = 3 ) and appendix ( n = 1 ) by Sanger sequencing .	1
We found LCOTHER LCOTHER ( G1 LCOTHER from rectum and two G3 LCOTHER from colon ) and LCOTHER LCSequenceVariant ( G2 LCDiseaseOrPhenotypicFeature from pancreas ) missense mutations ( 9 . 1% ) in an independent cohort of 44 LCOTHER - LCOTHER from the rectum ( n = 26 ) , colon ( n = 7 ) , pancreas ( n = 4 ) , small intestine ( n = 3 ) , stomach ( n = 3 ) and appendix ( n = 1 ) by Sanger sequencing .	1
In conclusion , LCGeneOrGeneProduct LCOTHER mutation is likely to result in resistance to LCChemicalEntity but may be a potentianally actionable mutation in metastatic LCOTHER - LCOTHER LCOTHER . A novel LCOTHER LCOTHER mutation , LCOTHER Osaka ( LCOTHER LCOTHER ) , in a LCOTHER LCOTHER with LCOTHER LCOTHER .	3
In conclusion , LCGeneOrGeneProduct LCOTHER mutation is likely to result in resistance to LCOTHER but may be a potentianally actionable mutation in metastatic LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER . A novel LCOTHER LCOTHER mutation , LCOTHER Osaka ( LCOTHER LCOTHER ) , in a LCOTHER LCOTHER with LCOTHER LCOTHER .	1
In conclusion , LCOTHER LCSequenceVariant mutation is likely to result in resistance to LCChemicalEntity but may be a potentianally actionable mutation in metastatic LCOTHER - LCOTHER LCOTHER . A novel LCOTHER LCOTHER mutation , LCOTHER Osaka ( LCOTHER LCOTHER ) , in a LCOTHER LCOTHER with LCOTHER LCOTHER .	3
In conclusion , LCOTHER LCSequenceVariant mutation is likely to result in resistance to LCOTHER but may be a potentianally actionable mutation in metastatic LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER . A novel LCOTHER LCOTHER mutation , LCOTHER Osaka ( LCOTHER LCOTHER ) , in a LCOTHER LCOTHER with LCOTHER LCOTHER .	1
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is a rare disease characterized by the presence of thrombuslike deposition in markedly dilated glomerular capillaries and is often accompanied by an increased serum LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) level .	2
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is a rare disease characterized by the presence of thrombuslike deposition in markedly dilated glomerular capillaries and is often accompanied by an increased serum LCOTHER LCOTHER ( LCGeneOrGeneProduct ) level .	2
LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is a rare disease characterized by the presence of thrombuslike deposition in markedly dilated glomerular capillaries and is often accompanied by an increased serum LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) level .	2
LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is a rare disease characterized by the presence of thrombuslike deposition in markedly dilated glomerular capillaries and is often accompanied by an increased serum LCOTHER LCOTHER ( LCGeneOrGeneProduct ) level .	2
In the current study , we report an LCDiseaseOrPhenotypicFeature LCOTHER with a novel LCGeneOrGeneProduct mutation , LCOTHER Osaka .	2
In the current study , we report an LCDiseaseOrPhenotypicFeature LCOTHER with a novel LCOTHER mutation , LCGeneOrGeneProduct Osaka .	2
His LCGeneOrGeneProduct phenotype was LCOTHER / LCOTHER and he had mild LCDiseaseOrPhenotypicFeature with a mid - band on LCOTHER gel electrophoresis .	1
His LCOTHER phenotype was LCGeneOrGeneProduct / LCGeneOrGeneProduct and he had mild LCDiseaseOrPhenotypicFeature with a mid - band on LCOTHER gel electrophoresis .	1
The precise mechanism of LCDiseaseOrPhenotypicFeature related with LCGeneOrGeneProduct Osaka , however , remains to be elucidated . Hemodynamic parameters and heart rate variability during a tilt test in relation to gene polymorphism of LCOTHER - LCOTHER and LCOTHER system .	2
RESULTS : AA genotype of LCSequenceVariant LCSequenceVariant polymorphism was associated with lower minimal systolic blood pressure ( SBP ) and diastolic blood pressure ( DBP ) during HUT compared with other genotypes ( minimal SBP : AA 59 . 6 + / - 21 , 8 , AC 79 . 9 + / - 22 . 7 , CC 65 . 4 + / - 22 . 7 mmHg , P = 0 . 007 ) , ( minimal DBP : AA 36 . 4 + / - 22 . 7 , AC 52 . 3 + / - 22 . 9 , CC 45 . 4 + / - 19 . 5 mmHg , P = 0 . 007 ) . AA genotype was also associated with higher SDNN compared to other genotypes in the early phase of HUT ( SDNN in 5 minutes of tilt : AA 59 . 7 + / - 24 . 6 , AC 50 . 6 + / - 20 . 6 , CC 46 . 0 + / - 13 . 2 , P = 0 . 01 ) and at LCOTHER occurrence ( SDNN : AA 71 . 0 + / - 20 . 9 , AC 58 . 2 + / - 17 . 9 , CC 58 + / - 10 , P = 0 . 04 ) CONCLUSION : AA genotype of LCOTHER LCOTHER polymorphism in the LCOTHER gene may be associated with LCDiseaseOrPhenotypicFeature and decline in sympathetic tone during HUT .	1
RESULTS : AA genotype of LCOTHER LCOTHER polymorphism was associated with lower minimal systolic blood pressure ( SBP ) and diastolic blood pressure ( DBP ) during HUT compared with other genotypes ( minimal SBP : AA 59 . 6 + / - 21 , 8 , AC 79 . 9 + / - 22 . 7 , CC 65 . 4 + / - 22 . 7 mmHg , P = 0 . 007 ) , ( minimal DBP : AA 36 . 4 + / - 22 . 7 , AC 52 . 3 + / - 22 . 9 , CC 45 . 4 + / - 19 . 5 mmHg , P = 0 . 007 ) . AA genotype was also associated with higher SDNN compared to other genotypes in the early phase of HUT ( SDNN in 5 minutes of tilt : AA 59 . 7 + / - 24 . 6 , AC 50 . 6 + / - 20 . 6 , CC 46 . 0 + / - 13 . 2 , P = 0 . 01 ) and at LCDiseaseOrPhenotypicFeature occurrence ( SDNN : AA 71 . 0 + / - 20 . 9 , AC 58 . 2 + / - 17 . 9 , CC 58 + / - 10 , P = 0 . 04 ) CONCLUSION : AA genotype of LCSequenceVariant LCSequenceVariant polymorphism in the LCOTHER gene may be associated with LCOTHER and decline in sympathetic tone during HUT .	1
RESULTS : AA genotype of LCOTHER LCOTHER polymorphism was associated with lower minimal systolic blood pressure ( SBP ) and diastolic blood pressure ( DBP ) during HUT compared with other genotypes ( minimal SBP : AA 59 . 6 + / - 21 , 8 , AC 79 . 9 + / - 22 . 7 , CC 65 . 4 + / - 22 . 7 mmHg , P = 0 . 007 ) , ( minimal DBP : AA 36 . 4 + / - 22 . 7 , AC 52 . 3 + / - 22 . 9 , CC 45 . 4 + / - 19 . 5 mmHg , P = 0 . 007 ) . AA genotype was also associated with higher SDNN compared to other genotypes in the early phase of HUT ( SDNN in 5 minutes of tilt : AA 59 . 7 + / - 24 . 6 , AC 50 . 6 + / - 20 . 6 , CC 46 . 0 + / - 13 . 2 , P = 0 . 01 ) and at LCDiseaseOrPhenotypicFeature occurrence ( SDNN : AA 71 . 0 + / - 20 . 9 , AC 58 . 2 + / - 17 . 9 , CC 58 + / - 10 , P = 0 . 04 ) CONCLUSION : AA genotype of LCOTHER LCOTHER polymorphism in the LCGeneOrGeneProduct gene may be associated with LCOTHER and decline in sympathetic tone during HUT .	1
RESULTS : AA genotype of LCOTHER LCOTHER polymorphism was associated with lower minimal systolic blood pressure ( SBP ) and diastolic blood pressure ( DBP ) during HUT compared with other genotypes ( minimal SBP : AA 59 . 6 + / - 21 , 8 , AC 79 . 9 + / - 22 . 7 , CC 65 . 4 + / - 22 . 7 mmHg , P = 0 . 007 ) , ( minimal DBP : AA 36 . 4 + / - 22 . 7 , AC 52 . 3 + / - 22 . 9 , CC 45 . 4 + / - 19 . 5 mmHg , P = 0 . 007 ) . AA genotype was also associated with higher SDNN compared to other genotypes in the early phase of HUT ( SDNN in 5 minutes of tilt : AA 59 . 7 + / - 24 . 6 , AC 50 . 6 + / - 20 . 6 , CC 46 . 0 + / - 13 . 2 , P = 0 . 01 ) and at LCOTHER occurrence ( SDNN : AA 71 . 0 + / - 20 . 9 , AC 58 . 2 + / - 17 . 9 , CC 58 + / - 10 , P = 0 . 04 ) CONCLUSION : AA genotype of LCSequenceVariant LCSequenceVariant polymorphism in the LCOTHER gene may be associated with LCDiseaseOrPhenotypicFeature and decline in sympathetic tone during HUT .	1
RESULTS : AA genotype of LCOTHER LCOTHER polymorphism was associated with lower minimal systolic blood pressure ( SBP ) and diastolic blood pressure ( DBP ) during HUT compared with other genotypes ( minimal SBP : AA 59 . 6 + / - 21 , 8 , AC 79 . 9 + / - 22 . 7 , CC 65 . 4 + / - 22 . 7 mmHg , P = 0 . 007 ) , ( minimal DBP : AA 36 . 4 + / - 22 . 7 , AC 52 . 3 + / - 22 . 9 , CC 45 . 4 + / - 19 . 5 mmHg , P = 0 . 007 ) . AA genotype was also associated with higher SDNN compared to other genotypes in the early phase of HUT ( SDNN in 5 minutes of tilt : AA 59 . 7 + / - 24 . 6 , AC 50 . 6 + / - 20 . 6 , CC 46 . 0 + / - 13 . 2 , P = 0 . 01 ) and at LCOTHER occurrence ( SDNN : AA 71 . 0 + / - 20 . 9 , AC 58 . 2 + / - 17 . 9 , CC 58 + / - 10 , P = 0 . 04 ) CONCLUSION : AA genotype of LCOTHER LCOTHER polymorphism in the LCGeneOrGeneProduct gene may be associated with LCDiseaseOrPhenotypicFeature and decline in sympathetic tone during HUT .	1
Three LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCSequenceVariant , LCOTHER , and LCOTHER - accounted for 51% , 20% , and 11% of the identified mutations , respectively . Allelic expression imbalance of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) caused by variant LCOTHER .	2
Three LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCOTHER , LCSequenceVariant , and LCOTHER - accounted for 51% , 20% , and 11% of the identified mutations , respectively . Allelic expression imbalance of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) caused by variant LCOTHER .	2
Three LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCOTHER , LCOTHER , and LCSequenceVariant - accounted for 51% , 20% , and 11% of the identified mutations , respectively . Allelic expression imbalance of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) caused by variant LCOTHER .	2
As a primary target for opioid drugs and peptides , the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) plays a key role in LCDiseaseOrPhenotypicFeature perception and addiction .	1
As a primary target for opioid drugs and peptides , the LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) plays a key role in LCDiseaseOrPhenotypicFeature perception and addiction .	1
Genetic variants of LCGeneOrGeneProduct have been implicated in predisposition to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , in particular the single nucleotide polymorphism LCOTHER , leading to an LCOTHER substitution , with an allele frequency of 10 - 32% , and uncertain functions .	1
Genetic variants of LCOTHER have been implicated in predisposition to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , in particular the single nucleotide polymorphism LCSequenceVariant , leading to an LCOTHER substitution , with an allele frequency of 10 - 32% , and uncertain functions .	1
Genetic variants of LCOTHER have been implicated in predisposition to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , in particular the single nucleotide polymorphism LCOTHER , leading to an LCSequenceVariant substitution , with an allele frequency of 10 - 32% , and uncertain functions .	1
CONCLUSION : Taken together with previous studies of LCOTHER LCGeneOrGeneProduct mutations , these findings suggest that LCOTHER - LCOTHER deficiency due either to haploinsufficiency or to substantial activity loss due to dominant negative interference of the normal allele product ' s function can each contribute to the LCDiseaseOrPhenotypicFeature phenotype . Cytostatic and anti - angiogenic effects of LCOTHER in refractory LCOTHER LCOTHER LCOTHER .	3
CONCLUSION : Taken together with previous studies of LCOTHER LCOTHER mutations , these findings suggest that LCGeneOrGeneProduct - LCGeneOrGeneProduct deficiency due either to haploinsufficiency or to substantial activity loss due to dominant negative interference of the normal allele product ' s function can each contribute to the LCDiseaseOrPhenotypicFeature phenotype . Cytostatic and anti - angiogenic effects of LCOTHER in refractory LCOTHER LCOTHER LCOTHER .	3
However , a 38% remission rate has been recently reported in refractory LCDiseaseOrPhenotypicFeature treated with LCChemicalEntity , a LCOTHER inhibitor . Here we had the opportunity to study a case of refractory LCOTHER who had LCOTHER regression two months after LCOTHER treatment , and a progression - free survival of 10 months .	3
However , a 38% remission rate has been recently reported in refractory LCDiseaseOrPhenotypicFeature treated with LCOTHER , a LCOTHER inhibitor . Here we had the opportunity to study a case of refractory LCOTHER who had LCOTHER regression two months after LCChemicalEntity treatment , and a progression - free survival of 10 months .	3
However , a 38% remission rate has been recently reported in refractory LCOTHER treated with LCChemicalEntity , a LCGeneOrGeneProduct inhibitor . Here we had the opportunity to study a case of refractory LCOTHER who had LCOTHER regression two months after LCOTHER treatment , and a progression - free survival of 10 months .	3
However , a 38% remission rate has been recently reported in refractory LCOTHER treated with LCChemicalEntity , a LCOTHER inhibitor . Here we had the opportunity to study a case of refractory LCOTHER who had LCDiseaseOrPhenotypicFeature regression two months after LCOTHER treatment , and a progression - free survival of 10 months .	3
However , a 38% remission rate has been recently reported in refractory LCOTHER treated with LCOTHER , a LCOTHER inhibitor . Here we had the opportunity to study a case of refractory LCDiseaseOrPhenotypicFeature who had LCOTHER regression two months after LCChemicalEntity treatment , and a progression - free survival of 10 months .	3
Comparison of the two biopsies showed that LCChemicalEntity inhibited LCDiseaseOrPhenotypicFeature cell proliferation through cell cycle arrest , but did not induce any change in the number of apoptotic LCOTHER cells .	3
Comparison of the two biopsies showed that LCChemicalEntity inhibited LCOTHER cell proliferation through cell cycle arrest , but did not induce any change in the number of apoptotic LCDiseaseOrPhenotypicFeature cells .	3
Apart from this cytostatic effect , LCChemicalEntity had an antiangiogenic effect with decrease of LCDiseaseOrPhenotypicFeature microvessel density and of LCOTHER expression .	3
Apart from this cytostatic effect , LCChemicalEntity had an antiangiogenic effect with decrease of LCOTHER microvessel density and of LCGeneOrGeneProduct expression .	3
Moreover , numerous patchy , well - limited fibrotic areas , compatible with post - LCDiseaseOrPhenotypicFeature tissue repair , were found after 6 - month LCChemicalEntity therapy .	3
Thus , LCChemicalEntity reduced LCDiseaseOrPhenotypicFeature burden through associated cytostatic and anti - angiogenic effects . This dual effect of LCOTHER on LCOTHER tissue could contribute to its recently reported efficiency in refractory LCOTHER resistant to conventional chemotherapy . Rapid reversal of anticoagulation reduces LCOTHER volume in a LCOTHER model of LCOTHER - associated LCOTHER LCOTHER .	3
Thus , LCChemicalEntity reduced LCOTHER burden through associated cytostatic and anti - angiogenic effects . This dual effect of LCOTHER on LCDiseaseOrPhenotypicFeature tissue could contribute to its recently reported efficiency in refractory LCOTHER resistant to conventional chemotherapy . Rapid reversal of anticoagulation reduces LCOTHER volume in a LCOTHER model of LCOTHER - associated LCOTHER LCOTHER .	3
Thus , LCOTHER reduced LCOTHER burden through associated cytostatic and anti - angiogenic effects . This dual effect of LCChemicalEntity on LCDiseaseOrPhenotypicFeature tissue could contribute to its recently reported efficiency in refractory LCOTHER resistant to conventional chemotherapy . Rapid reversal of anticoagulation reduces LCOTHER volume in a LCOTHER model of LCOTHER - associated LCOTHER LCOTHER .	3
LCChemicalEntity - associated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER - LCOTHER ) is a severe type of LCOTHER .	1
LCChemicalEntity - associated LCOTHER LCOTHER ( LCOTHER - LCDiseaseOrPhenotypicFeature ) is a severe type of LCOTHER .	1
LCOTHER - associated LCOTHER LCOTHER ( LCChemicalEntity - LCDiseaseOrPhenotypicFeature ) is a severe type of LCOTHER .	1
There is no consensus on the optimal treatment for LCChemicalEntity - LCDiseaseOrPhenotypicFeature .	1
Second , a stereotactic injection of LCChemicalEntity was administered to induce LCDiseaseOrPhenotypicFeature in the right striatum .	2
We provide experimental data suggesting LCChemicalEntity to be an effective acute treatment for LCChemicalEntity - LCOTHER in terms of reducing hemorrhagic blood volume .	3
We provide experimental data suggesting LCChemicalEntity to be an effective acute treatment for LCOTHER - LCDiseaseOrPhenotypicFeature in terms of reducing hemorrhagic blood volume .	3
We provide experimental data suggesting LCOTHER to be an effective acute treatment for LCChemicalEntity - LCDiseaseOrPhenotypicFeature in terms of reducing hemorrhagic blood volume .	1
Future studies are needed to assess the therapeutic potential emerging from our finding for LCOTHER LCChemicalEntity - LCDiseaseOrPhenotypicFeature . Role of stress - activated LCOTHER in the cell fate decisions of LCOTHER LCOTHER cells treated with LCOTHER .	1
Previously , we showed that following LCChemicalEntity ( LCOTHER ) treatment LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER - LCOTHER cells undergo a LCOTHER - dependent upregulation of LCOTHER and LCOTHER ( governing self - renewal and regulating cell cycle inhibition and senescence , respectively ) .	3
Previously , we showed that following LCChemicalEntity ( LCOTHER ) treatment LCOTHER LCOTHER LCOTHER - LCOTHER cells undergo a LCGeneOrGeneProduct - dependent upregulation of LCOTHER and LCOTHER ( governing self - renewal and regulating cell cycle inhibition and senescence , respectively ) .	1
Previously , we showed that following LCChemicalEntity ( LCOTHER ) treatment LCOTHER LCOTHER LCOTHER - LCOTHER cells undergo a LCOTHER - dependent upregulation of LCGeneOrGeneProduct and LCOTHER ( governing self - renewal and regulating cell cycle inhibition and senescence , respectively ) .	2
Previously , we showed that following LCChemicalEntity ( LCOTHER ) treatment LCOTHER LCOTHER LCOTHER - LCOTHER cells undergo a LCOTHER - dependent upregulation of LCOTHER and LCGeneOrGeneProduct ( governing self - renewal and regulating cell cycle inhibition and senescence , respectively ) .	2
Previously , we showed that following LCOTHER ( LCChemicalEntity ) treatment LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER - LCOTHER cells undergo a LCOTHER - dependent upregulation of LCOTHER and LCOTHER ( governing self - renewal and regulating cell cycle inhibition and senescence , respectively ) .	3
Previously , we showed that following LCOTHER ( LCChemicalEntity ) treatment LCOTHER LCOTHER LCOTHER - LCOTHER cells undergo a LCGeneOrGeneProduct - dependent upregulation of LCOTHER and LCOTHER ( governing self - renewal and regulating cell cycle inhibition and senescence , respectively ) .	1
Previously , we showed that following LCOTHER ( LCChemicalEntity ) treatment LCOTHER LCOTHER LCOTHER - LCOTHER cells undergo a LCOTHER - dependent upregulation of LCGeneOrGeneProduct and LCOTHER ( governing self - renewal and regulating cell cycle inhibition and senescence , respectively ) .	2
Previously , we showed that following LCOTHER ( LCChemicalEntity ) treatment LCOTHER LCOTHER LCOTHER - LCOTHER cells undergo a LCOTHER - dependent upregulation of LCOTHER and LCGeneOrGeneProduct ( governing self - renewal and regulating cell cycle inhibition and senescence , respectively ) .	2
Previously , we showed that following LCOTHER ( LCOTHER ) treatment LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER - LCOTHER cells undergo a LCGeneOrGeneProduct - dependent upregulation of LCOTHER and LCOTHER ( governing self - renewal and regulating cell cycle inhibition and senescence , respectively ) .	1
Previously , we showed that following LCOTHER ( LCOTHER ) treatment LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER - LCOTHER cells undergo a LCOTHER - dependent upregulation of LCGeneOrGeneProduct and LCOTHER ( governing self - renewal and regulating cell cycle inhibition and senescence , respectively ) .	1
Previously , we showed that following LCOTHER ( LCOTHER ) treatment LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER - LCOTHER cells undergo a LCOTHER - dependent upregulation of LCOTHER and LCGeneOrGeneProduct ( governing self - renewal and regulating cell cycle inhibition and senescence , respectively ) .	1
Previously , we showed that following LCOTHER ( LCOTHER ) treatment LCOTHER LCOTHER LCOTHER - LCOTHER cells undergo a LCGeneOrGeneProduct - dependent upregulation of LCGeneOrGeneProduct and LCOTHER ( governing self - renewal and regulating cell cycle inhibition and senescence , respectively ) .	2
Previously , we showed that following LCOTHER ( LCOTHER ) treatment LCOTHER LCOTHER LCOTHER - LCOTHER cells undergo a LCGeneOrGeneProduct - dependent upregulation of LCOTHER and LCGeneOrGeneProduct ( governing self - renewal and regulating cell cycle inhibition and senescence , respectively ) .	2
Previously , we showed that following LCOTHER ( LCOTHER ) treatment LCOTHER LCOTHER LCOTHER - LCOTHER cells undergo a LCOTHER - dependent upregulation of LCGeneOrGeneProduct and LCGeneOrGeneProduct ( governing self - renewal and regulating cell cycle inhibition and senescence , respectively ) .	2
LCOTHER - LCOTHER cells treated with LCChemicalEntity display highly heterogeneous increases in LCGeneOrGeneProduct and LCOTHER indicative of dis - adaptation catastrophe .	2
LCOTHER - LCOTHER cells treated with LCChemicalEntity display highly heterogeneous increases in LCOTHER and LCGeneOrGeneProduct indicative of dis - adaptation catastrophe .	2
LCOTHER - LCOTHER cells treated with LCOTHER display highly heterogeneous increases in LCGeneOrGeneProduct and LCGeneOrGeneProduct indicative of dis - adaptation catastrophe .	2
Silencing LCGeneOrGeneProduct suppresses LCGeneOrGeneProduct , changes cell cycle regulation and subsequently suppresses terminal senescence ; LCOTHER - silencing did not affect LCOTHER expression or cellular phenotype .	2
Silencing LCGeneOrGeneProduct suppresses LCOTHER , changes cell cycle regulation and subsequently suppresses terminal senescence ; LCGeneOrGeneProduct - silencing did not affect LCOTHER expression or cellular phenotype .	2
LCOTHER and LCOTHER expression did not change following LCChemicalEntity treatment suggesting a dissociation of LCGeneOrGeneProduct from its pluripotency function .	2
Instead , LCChemicalEntity - induced LCGeneOrGeneProduct was concomitant with activation of LCOTHER , a key component of metabolic stress and autophagy regulation .	2
Instead , LCChemicalEntity - induced LCOTHER was concomitant with activation of LCGeneOrGeneProduct , a key component of metabolic stress and autophagy regulation .	2
Instead , LCOTHER - induced LCGeneOrGeneProduct was concomitant with activation of LCGeneOrGeneProduct , a key component of metabolic stress and autophagy regulation .	2
LCGeneOrGeneProduct , the inducer of terminal senescence , underwent autophagic sequestration in the cytoplasm of LCChemicalEntity - treated cells , allowing alternative cell fates .	1
Together , these findings imply that LCGeneOrGeneProduct induction following DNA damage in LCOTHER - LCOTHER cells , performs a cell stress , rather than self - renewal , function by moderating the expression of LCGeneOrGeneProduct , which alongside LCOTHER helps to then regulate autophagy .	2
Together , these findings imply that LCGeneOrGeneProduct induction following DNA damage in LCOTHER - LCOTHER cells , performs a cell stress , rather than self - renewal , function by moderating the expression of LCOTHER , which alongside LCGeneOrGeneProduct helps to then regulate autophagy .	2
Together , these findings imply that LCOTHER induction following DNA damage in LCOTHER - LCOTHER cells , performs a cell stress , rather than self - renewal , function by moderating the expression of LCGeneOrGeneProduct , which alongside LCGeneOrGeneProduct helps to then regulate autophagy .	1
Although many advantageous roles of LCChemicalEntity ( LCOTHER - LCOTHER ( II ) , LCOTHER ) have been reported in LCDiseaseOrPhenotypicFeature therapy , the immunomodulatory roles of LCOTHER in the phenotypic and functional alterations of dendritic cells ( DCs ) are poorly understood .	3
Although many advantageous roles of LCOTHER ( LCChemicalEntity - LCChemicalEntity ( II ) , LCOTHER ) have been reported in LCDiseaseOrPhenotypicFeature therapy , the immunomodulatory roles of LCOTHER in the phenotypic and functional alterations of dendritic cells ( DCs ) are poorly understood .	3
Although many advantageous roles of LCOTHER ( LCOTHER - LCOTHER ( II ) , LCChemicalEntity ) have been reported in LCDiseaseOrPhenotypicFeature therapy , the immunomodulatory roles of LCOTHER in the phenotypic and functional alterations of dendritic cells ( DCs ) are poorly understood .	3
Here , we investigated the effect of LCChemicalEntity on the functionality of DCs and the changes in signaling pathways activated upon LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) stimulation .	2
Here , we investigated the effect of LCChemicalEntity on the functionality of DCs and the changes in signaling pathways activated upon LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) stimulation .	2
LCChemicalEntity - treated DCs down - regulated the expression of cell surface molecules ( LCGeneOrGeneProduct , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ) and up - regulated endocytic capacity in a dose - dependent manner .	3
LCChemicalEntity - treated DCs down - regulated the expression of cell surface molecules ( LCOTHER , LCGeneOrGeneProduct , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ) and up - regulated endocytic capacity in a dose - dependent manner .	3
Upon stimulation with various LCGeneOrGeneProduct agonists , LCOTHER - treated DCs showed markedly increased LCGeneOrGeneProduct - LCGeneOrGeneProduct production through activation of the LCOTHER LCOTHER and LCOTHER - LCOTHER signaling pathways without altering the levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , indicating the LCOTHER - mediated induction of tolerogenic DCs .	2
Upon stimulation with various LCGeneOrGeneProduct agonists , LCOTHER - treated DCs showed markedly increased LCOTHER - LCOTHER production through activation of the LCGeneOrGeneProduct LCGeneOrGeneProduct and LCOTHER - LCOTHER signaling pathways without altering the levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , indicating the LCOTHER - mediated induction of tolerogenic DCs .	2
Upon stimulation with various LCGeneOrGeneProduct agonists , LCOTHER - treated DCs showed markedly increased LCOTHER - LCOTHER production through activation of the LCOTHER LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct signaling pathways without altering the levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , indicating the LCOTHER - mediated induction of tolerogenic DCs .	2
Upon stimulation with various LCOTHER agonists , LCChemicalEntity - treated DCs showed markedly increased LCGeneOrGeneProduct - LCGeneOrGeneProduct production through activation of the LCOTHER LCOTHER and LCOTHER - LCOTHER signaling pathways without altering the levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , indicating the LCOTHER - mediated induction of tolerogenic DCs .	2
Upon stimulation with various LCOTHER agonists , LCChemicalEntity - treated DCs showed markedly increased LCOTHER - LCOTHER production through activation of the LCGeneOrGeneProduct LCGeneOrGeneProduct and LCOTHER - LCOTHER signaling pathways without altering the levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , indicating the LCOTHER - mediated induction of tolerogenic DCs .	2
Upon stimulation with various LCOTHER agonists , LCChemicalEntity - treated DCs showed markedly increased LCOTHER - LCOTHER production through activation of the LCOTHER LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct signaling pathways without altering the levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , indicating the LCOTHER - mediated induction of tolerogenic DCs .	2
Upon stimulation with various LCOTHER agonists , LCOTHER - treated DCs showed markedly increased LCGeneOrGeneProduct - LCGeneOrGeneProduct production through activation of the LCGeneOrGeneProduct LCGeneOrGeneProduct and LCOTHER - LCOTHER signaling pathways without altering the levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , indicating the LCOTHER - mediated induction of tolerogenic DCs .	2
Upon stimulation with various LCOTHER agonists , LCOTHER - treated DCs showed markedly increased LCGeneOrGeneProduct - LCGeneOrGeneProduct production through activation of the LCOTHER LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct signaling pathways without altering the levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , indicating the LCOTHER - mediated induction of tolerogenic DCs .	2
Interestingly , DCs that were co - treated with LCChemicalEntity and LCChemicalEntity ( LCOTHER ) exhibited a decreased immunostimulatory capacity for inducing the proliferation of Th1 - and Th17 - type T cells ; instead , these DCs contributed to Th2 - type T cell immunity .	5
Interestingly , DCs that were co - treated with LCChemicalEntity and LCOTHER ( LCChemicalEntity ) exhibited a decreased immunostimulatory capacity for inducing the proliferation of Th1 - and Th17 - type T cells ; instead , these DCs contributed to Th2 - type T cell immunity .	5
Taken together , our results suggest that LCChemicalEntity induces immune - suppressive tolerogenic DCs in LCOTHER LCOTHER - induced LCDiseaseOrPhenotypicFeature conditions via abundant LCOTHER - LCOTHER production , thereby skewing Th cell differentiation towards Th2 and Tr1 cells .	2
Taken together , our results suggest that LCChemicalEntity induces immune - suppressive tolerogenic DCs in LCOTHER LCOTHER - induced LCOTHER conditions via abundant LCGeneOrGeneProduct - LCGeneOrGeneProduct production , thereby skewing Th cell differentiation towards Th2 and Tr1 cells .	2
Neutralizing anti - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) IgG or control IgG was administered to a group of wild - type animals prior to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
Neutralizing anti - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) IgG or control IgG was administered to a group of wild - type animals prior to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
RESULTS AND DISCUSSION : LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER and LCOTHER cells release a network of cytokines , including newly identified LCOTHER - inducible cytokines LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) .	2
RESULTS AND DISCUSSION : LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER and LCOTHER cells release a network of cytokines , including newly identified LCOTHER - inducible cytokines LCOTHER , LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) .	2
RESULTS AND DISCUSSION : LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER and LCOTHER cells release a network of cytokines , including newly identified LCOTHER - inducible cytokines LCOTHER , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER , LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) .	2
RESULTS AND DISCUSSION : LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER and LCOTHER cells release a network of cytokines , including newly identified LCOTHER - inducible cytokines LCOTHER , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER , LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) .	2
RESULTS AND DISCUSSION : LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER and LCOTHER cells release a network of cytokines , including newly identified LCOTHER - inducible cytokines LCOTHER , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct , LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) .	2
RESULTS AND DISCUSSION : LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER and LCOTHER cells release a network of cytokines , including newly identified LCOTHER - inducible cytokines LCOTHER , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCGeneOrGeneProduct and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) .	2
RESULTS AND DISCUSSION : LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER and LCOTHER cells release a network of cytokines , including newly identified LCOTHER - inducible cytokines LCOTHER , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) .	2
RESULTS AND DISCUSSION : LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER and LCOTHER cells release a network of cytokines , including newly identified LCOTHER - inducible cytokines LCOTHER , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) .	2
In vivo induction of airway LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCGeneOrGeneProduct and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCGeneOrGeneProduct were dependent on LCGeneOrGeneProduct expression in LCOTHER .	1
Loss of LCGeneOrGeneProduct expression in LCOTHER altered the LCOTHER induction of LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER .	1
Loss of LCGeneOrGeneProduct expression in LCOTHER altered the LCOTHER induction of LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER .	1
Loss of LCGeneOrGeneProduct expression in LCOTHER altered the LCOTHER induction of LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER .	1
Loss of LCGeneOrGeneProduct expression in LCOTHER altered the LCOTHER induction of LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER - LCOTHER .	1
Loss of LCGeneOrGeneProduct expression in LCOTHER altered the LCOTHER induction of LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER - LCOTHER .	1
Loss of LCGeneOrGeneProduct expression in LCOTHER altered the LCOTHER induction of LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER - LCOTHER .	1
Loss of LCGeneOrGeneProduct expression in LCOTHER altered the LCOTHER induction of LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct .	1
To evaluate the role of LCGeneOrGeneProduct in the airways during LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , animals were treated with neutralizing anti - LCOTHER IgG , which enhanced LCOTHER pathology observed with increased airspace protein content , apoptosis and airway hyperresponsiveness compared to control IgG treatment .	1
CONCLUSIONS : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in the epithelium induces a network of immune factors to counter LCOTHER , primarily in a LCGeneOrGeneProduct - LCGeneOrGeneProduct dependent manner .	1
BACKGROUND : Electrocardiography has a very low sensitivity in detecting LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
OBJECTIVES : To assess the added diagnostic value of a new cardiac performance index ( dP / dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12 - lead ECG , for detecting LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , using Tc99m - Sestamibi single - photon emission computed tomography as the gold standard of comparison to assess the presence or absence of LCOTHER .	2
OBJECTIVES : To assess the added diagnostic value of a new cardiac performance index ( dP / dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12 - lead ECG , for detecting LCChemicalEntity - induced LCOTHER LCOTHER , using Tc99m - Sestamibi single - photon emission computed tomography as the gold standard of comparison to assess the presence or absence of LCDiseaseOrPhenotypicFeature .	1
The LCOTHER homozygous for both LCSequenceVariant and LCOTHER presented with a mild manifestation of LCDiseaseOrPhenotypicFeature at the age of 41 years .	1
The LCOTHER homozygous for both LCOTHER and LCSequenceVariant presented with a mild manifestation of LCDiseaseOrPhenotypicFeature at the age of 41 years .	1
His liver was LCDiseaseOrPhenotypicFeature with parenchymal LCChemicalEntity deposits and the result of a LCOTHER tolerance test was compatible with LCOTHER LCOTHER .	1
His liver was LCOTHER with parenchymal LCOTHER deposits and the result of a LCChemicalEntity tolerance test was compatible with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
The LCOTHER homozygous for LCSequenceVariant had severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with the triad of LCOTHER , LCOTHER LCOTHER and LCOTHER LCOTHER at the age of 58 years .	1
The LCOTHER homozygous for LCSequenceVariant had severe LCOTHER LCOTHER with the triad of LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER and LCOTHER LCOTHER at the age of 58 years .	1
The LCOTHER homozygous for LCSequenceVariant had severe LCOTHER LCOTHER with the triad of LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER at the age of 58 years .	1
The LCOTHER homozygous for LCSequenceVariant had severe LCOTHER LCOTHER with the triad of LCOTHER , LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature at the age of 58 years .	1
INTERPRETATION AND CONCLUSIONS : Taken together with the previous report , 5 of our 12 LCOTHER with LCDiseaseOrPhenotypicFeature manifesting in middle age had mutations in the LCGeneOrGeneProduct gene .	1
Of these , LCOTHER and LCOTHER have been reported to contribute to intravitreal neovascularization ( IVNV ) in LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature ( LCOTHER ) models .	2
Of these , LCOTHER and LCOTHER have been reported to contribute to intravitreal neovascularization ( IVNV ) in LCChemicalEntity - induced LCOTHER ( LCDiseaseOrPhenotypicFeature ) models .	2
Newborn LCOTHER pups and dams were placed into an LCOTHER model that cycled LCChemicalEntity concentration between 50% and 10% every 24 h for 14 days , and then were placed in room air ( RA ) for an additional 4 days ( LCOTHER LCDiseaseOrPhenotypicFeature model ) .	2
In hRMVECs transfected with LCGeneOrGeneProduct siRNA and treated with LCGeneOrGeneProduct or control , 1 ) LCOTHER generation was measured using the LCOTHER - ( LCOTHER - LCOTHER ) - LCOTHER - LCOTHER ' , LCOTHER ' - LCOTHER LCOTHER , LCOTHER LCOTHER fluorescence assay and 2 ) phosphorylated LCOTHER LCOTHER LCOTHER and LCOTHER , and total LCOTHER and LCOTHER were measured in western blot analyses .	1
In hRMVECs transfected with LCGeneOrGeneProduct siRNA and treated with LCOTHER or control , 1 ) LCChemicalEntity generation was measured using the LCOTHER - ( LCOTHER - LCOTHER ) - LCOTHER - LCOTHER ' , LCOTHER ' - LCOTHER LCOTHER , LCOTHER LCOTHER fluorescence assay and 2 ) phosphorylated LCOTHER LCOTHER LCOTHER and LCOTHER , and total LCOTHER and LCOTHER were measured in western blot analyses .	2
In hRMVECs transfected with LCGeneOrGeneProduct siRNA and treated with LCOTHER or control , 1 ) LCOTHER generation was measured using the LCOTHER - ( LCOTHER - LCOTHER ) - LCOTHER - LCOTHER ' , LCOTHER ' - LCOTHER LCOTHER , LCOTHER LCOTHER fluorescence assay and 2 ) phosphorylated LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct and LCOTHER , and total LCOTHER and LCOTHER were measured in western blot analyses .	2
In hRMVECs transfected with LCGeneOrGeneProduct siRNA and treated with LCOTHER or control , 1 ) LCOTHER generation was measured using the LCOTHER - ( LCOTHER - LCOTHER ) - LCOTHER - LCOTHER ' , LCOTHER ' - LCOTHER LCOTHER , LCOTHER LCOTHER fluorescence assay and 2 ) phosphorylated LCOTHER LCOTHER LCOTHER and LCGeneOrGeneProduct , and total LCOTHER and LCOTHER were measured in western blot analyses .	2
In hRMVECs transfected with LCGeneOrGeneProduct siRNA and treated with LCOTHER or control , 1 ) LCOTHER generation was measured using the LCOTHER - ( LCOTHER - LCOTHER ) - LCOTHER - LCOTHER ' , LCOTHER ' - LCOTHER LCOTHER , LCOTHER LCOTHER fluorescence assay and 2 ) phosphorylated LCOTHER LCOTHER LCOTHER and LCOTHER , and total LCGeneOrGeneProduct and LCOTHER were measured in western blot analyses .	2
In hRMVECs transfected with LCGeneOrGeneProduct siRNA and treated with LCOTHER or control , 1 ) LCOTHER generation was measured using the LCOTHER - ( LCOTHER - LCOTHER ) - LCOTHER - LCOTHER ' , LCOTHER ' - LCOTHER LCOTHER , LCOTHER LCOTHER fluorescence assay and 2 ) phosphorylated LCOTHER LCOTHER LCOTHER and LCOTHER , and total LCOTHER and LCGeneOrGeneProduct were measured in western blot analyses .	2
In hRMVECs transfected with LCOTHER siRNA and treated with LCGeneOrGeneProduct or control , 1 ) LCChemicalEntity generation was measured using the LCOTHER - ( LCOTHER - LCOTHER ) - LCOTHER - LCOTHER ' , LCOTHER ' - LCOTHER LCOTHER , LCOTHER LCOTHER fluorescence assay and 2 ) phosphorylated LCOTHER LCOTHER LCOTHER and LCOTHER , and total LCOTHER and LCOTHER were measured in western blot analyses .	2
In hRMVECs transfected with LCOTHER siRNA and treated with LCGeneOrGeneProduct or control , 1 ) LCOTHER generation was measured using the LCOTHER - ( LCOTHER - LCOTHER ) - LCOTHER - LCOTHER ' , LCOTHER ' - LCOTHER LCOTHER , LCOTHER LCOTHER fluorescence assay and 2 ) phosphorylated LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct and LCOTHER , and total LCOTHER and LCOTHER were measured in western blot analyses .	2
In hRMVECs transfected with LCOTHER siRNA and treated with LCGeneOrGeneProduct or control , 1 ) LCOTHER generation was measured using the LCOTHER - ( LCOTHER - LCOTHER ) - LCOTHER - LCOTHER ' , LCOTHER ' - LCOTHER LCOTHER , LCOTHER LCOTHER fluorescence assay and 2 ) phosphorylated LCOTHER LCOTHER LCOTHER and LCOTHER , and total LCGeneOrGeneProduct and LCOTHER were measured in western blot analyses .	2
LCOTHER - stimulated hRMVEC proliferation was measured following transfection with LCGeneOrGeneProduct siRNA or LCGeneOrGeneProduct siRNA , or respective controls .	2
In cultured hRMVECs , knockdown of LCGeneOrGeneProduct by siRNA transfection inhibited LCGeneOrGeneProduct - induced LCOTHER generation .	1
In cultured hRMVECs , knockdown of LCGeneOrGeneProduct by siRNA transfection inhibited LCOTHER - induced LCChemicalEntity generation .	2
In cultured hRMVECs , knockdown of LCOTHER by siRNA transfection inhibited LCGeneOrGeneProduct - induced LCChemicalEntity generation .	2
LCGeneOrGeneProduct induced a physical interaction of phosphorylated - LCGeneOrGeneProduct and LCOTHER .	2
Knockdown of LCGeneOrGeneProduct : 1 ) reduced LCGeneOrGeneProduct activation but did not abolish it and 2 ) abolished LCOTHER activation in response to LCOTHER .	2
Knockdown of LCGeneOrGeneProduct : 1 ) reduced LCOTHER activation but did not abolish it and 2 ) abolished LCGeneOrGeneProduct activation in response to LCOTHER .	2
Knockdown of LCGeneOrGeneProduct : 1 ) reduced LCOTHER activation but did not abolish it and 2 ) abolished LCOTHER activation in response to LCGeneOrGeneProduct .	1
Knockdown of LCOTHER : 1 ) reduced LCOTHER activation but did not abolish it and 2 ) abolished LCGeneOrGeneProduct activation in response to LCGeneOrGeneProduct .	1
Knockdown of either LCGeneOrGeneProduct or LCGeneOrGeneProduct inhibited LCOTHER - induced EC proliferation .	2
Knockdown of either LCGeneOrGeneProduct or LCOTHER inhibited LCGeneOrGeneProduct - induced EC proliferation .	1
Knockdown of either LCOTHER or LCGeneOrGeneProduct inhibited LCGeneOrGeneProduct - induced EC proliferation .	1
LCGeneOrGeneProduct - activated LCOTHER led to an interaction between LCOTHER - activated LCGeneOrGeneProduct and LCOTHER that mediated EC proliferation via activation of LCOTHER .	2
LCOTHER - activated LCGeneOrGeneProduct led to an interaction between LCGeneOrGeneProduct - activated LCOTHER and LCOTHER that mediated EC proliferation via activation of LCOTHER .	1
LCOTHER - activated LCGeneOrGeneProduct led to an interaction between LCOTHER - activated LCGeneOrGeneProduct and LCOTHER that mediated EC proliferation via activation of LCOTHER .	2
LCOTHER - activated LCGeneOrGeneProduct led to an interaction between LCOTHER - activated LCOTHER and LCOTHER that mediated EC proliferation via activation of LCGeneOrGeneProduct .	2
LCOTHER - activated LCOTHER led to an interaction between LCGeneOrGeneProduct - activated LCGeneOrGeneProduct and LCOTHER that mediated EC proliferation via activation of LCOTHER .	2
LCOTHER - activated LCOTHER led to an interaction between LCOTHER - activated LCOTHER and LCGeneOrGeneProduct that mediated EC proliferation via activation of LCGeneOrGeneProduct .	2
Altogether , our results suggest that LCGeneOrGeneProduct may regulate LCGeneOrGeneProduct - mediated IVNV through activated LCOTHER . LCOTHER polydrug users show process - specific central executive impairments coupled with LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER .	1
In recent years working LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature have been reported in users of LCChemicalEntity ( LCOTHER , LCOTHER - LCOTHER , LCOTHER ) .	2
In recent years working LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature have been reported in users of LCOTHER ( LCChemicalEntity , LCChemicalEntity - LCChemicalEntity , LCOTHER ) .	2
In recent years working LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature have been reported in users of LCOTHER ( LCOTHER , LCOTHER - LCOTHER , LCChemicalEntity ) .	2
However , successful anticoagulation was achieved by administration of direct LCGeneOrGeneProduct inhibitor , LCChemicalEntity .	3
Family studies of LCGeneOrGeneProduct activity revealed that she had LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
LCChemicalEntity administration would be effective in the treatment of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with LCOTHER LCOTHER . Mutational analysis of LCOTHER in LCOTHER LCOTHER using denaturing high performance liquid chromatography .	3
LCChemicalEntity administration would be effective in the treatment of LCOTHER LCOTHER LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Mutational analysis of LCOTHER in LCOTHER LCOTHER using denaturing high performance liquid chromatography .	3
LCChemicalEntity LCChemicalEntity metabolites such as LCOTHER LCOTHER and LCOTHER LCOTHER , produced may have a role in LCDiseaseOrPhenotypicFeature .	1
Genotypes and allelic frequencies of LCGeneOrGeneProduct between the healthy controls and LCOTHER with LCDiseaseOrPhenotypicFeature were compared .	1
A higher frequency of the LCSequenceVariant SNP was observed among LCDiseaseOrPhenotypicFeature LCOTHER than control subjects .	2
LCOTHER caused by the mutation in the gene coding for LCGeneOrGeneProduct are genetically protein aggregation LCDiseaseOrPhenotypicFeature .	1
Furthermore , we provide a LCOTHER model of LCOTHER for the investigation of LCGeneOrGeneProduct related LCDiseaseOrPhenotypicFeature . The cytogenetic action of LCOTHER , LCOTHER , and their combination on peripheral LCOTHER lymphocytes : an in vivo / in vitro cytogenetic study .	1
LCChemicalEntity ' s action , in conjunction with LCChemicalEntity reduces the frequency of SCEs , in comparison with the SCEs recordings obtained when LCOTHER is administered alone .	3
LCChemicalEntity ' s action , in conjunction with LCOTHER reduces the frequency of SCEs , in comparison with the SCEs recordings obtained when LCChemicalEntity is administered alone .	3
In addition to this , when high concentrations of LCChemicalEntity were administered alone significant reductions of the PRI were noted , than with LCChemicalEntity acting at the same concentration on the lymphocytes .	3
LCChemicalEntity significantly reduces LCChemicalEntity ' s LCOTHER , while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug . Two novel mutations of the LCOTHER gene causing different phenotype in a cohort of Chinese LCOTHER .	3
LCChemicalEntity significantly reduces LCOTHER ' s LCDiseaseOrPhenotypicFeature , while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug . Two novel mutations of the LCOTHER gene causing different phenotype in a cohort of Chinese LCOTHER .	3
LCOTHER significantly reduces LCChemicalEntity ' s LCDiseaseOrPhenotypicFeature , while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug . Two novel mutations of the LCOTHER gene causing different phenotype in a cohort of Chinese LCOTHER .	2
PURPOSE : LCDiseaseOrPhenotypicFeature ( LCOTHER ) is a rare LCOTHER LCOTHER LCOTHER caused by the mutations of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) gene .	1
PURPOSE : LCDiseaseOrPhenotypicFeature ( LCOTHER ) is a rare LCOTHER LCOTHER LCOTHER caused by the mutations of the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene .	1
PURPOSE : LCOTHER ( LCDiseaseOrPhenotypicFeature ) is a rare LCOTHER LCOTHER LCOTHER caused by the mutations of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) gene .	1
PURPOSE : LCOTHER ( LCDiseaseOrPhenotypicFeature ) is a rare LCOTHER LCOTHER LCOTHER caused by the mutations of the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene .	1
The LCGeneOrGeneProduct gene is also involved in other LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature including LCOTHER LCOTHER .	1
The LCGeneOrGeneProduct gene is also involved in other LCOTHER LCOTHER LCOTHER including LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
We studied the LCGeneOrGeneProduct gene mutations in a cohort of affected individuals with different clinical phenotype including LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , or LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
Sequencing of the LCOTHER gene , three intragenic mutations including a novel heterozygous splicing - site mutations LCSequenceVariant . LCSequenceVariant - LCSequenceVariant > LCSequenceVariant ( LCOTHER . LCOTHER ) were identified in the LCOTHER of the LCDiseaseOrPhenotypicFeature group .	2
Sequencing of the LCOTHER gene , three intragenic mutations including a novel heterozygous splicing - site mutations LCOTHER . LCOTHER - LCOTHER > LCOTHER ( LCSequenceVariant . LCSequenceVariant ) were identified in the LCOTHER of the LCDiseaseOrPhenotypicFeature group .	2
A novel missense mutation LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER . LCOTHER ) was detected in the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature group .	2
A novel missense mutation LCOTHER . LCOTHER > LCOTHER ( LCSequenceVariant . LCSequenceVariant ) was detected in the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature group .	2
The mutation LCSequenceVariant . LCSequenceVariant located in the homeodomain region of the LCOTHER caused the phenotype of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in family A6 with different expressing .	2
The mutation LCOTHER . LCOTHER located in the homeodomain region of the LCGeneOrGeneProduct caused the phenotype of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in family A6 with different expressing .	1
The importance of genetic variability of the components of LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) genes is well documented in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , but little is known about its role in LCOTHER LCOTHER .	1
The importance of genetic variability of the components of LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) genes is well documented in LCOTHER LCOTHER , but little is known about its role in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
The importance of genetic variability of the components of LCOTHER LCOTHER ( LCGeneOrGeneProduct ) genes is well documented in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , but little is known about its role in LCOTHER LCOTHER .	1
The importance of genetic variability of the components of LCOTHER LCOTHER ( LCGeneOrGeneProduct ) genes is well documented in LCOTHER LCOTHER , but little is known about its role in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
We performed a case - control study to test the association between two polymorphisms in the LCGeneOrGeneProduct gene : an LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER producing an LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCOTHER polymorphism ) and a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER resulting in a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCOTHER polymorphism ) and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk and LCOTHER progression .	1
We performed a case - control study to test the association between two polymorphisms in the LCGeneOrGeneProduct gene : an LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER producing an LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCOTHER polymorphism ) and a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER resulting in a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCOTHER polymorphism ) and LCOTHER LCOTHER risk and LCDiseaseOrPhenotypicFeature progression .	1
We performed a case - control study to test the association between two polymorphisms in the LCOTHER gene : an LCSequenceVariant - - > LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant producing an LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCOTHER polymorphism ) and a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER resulting in a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCOTHER polymorphism ) and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk and LCOTHER progression .	1
We performed a case - control study to test the association between two polymorphisms in the LCOTHER gene : an LCSequenceVariant - - > LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant producing an LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCOTHER polymorphism ) and a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER resulting in a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCOTHER polymorphism ) and LCOTHER LCOTHER risk and LCDiseaseOrPhenotypicFeature progression .	1
We performed a case - control study to test the association between two polymorphisms in the LCOTHER gene : an LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER producing an LCSequenceVariant - - > LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant ( the LCOTHER polymorphism ) and a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER resulting in a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCOTHER polymorphism ) and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk and LCOTHER progression .	1
We performed a case - control study to test the association between two polymorphisms in the LCOTHER gene : an LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER producing an LCSequenceVariant - - > LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant ( the LCOTHER polymorphism ) and a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER resulting in a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCOTHER polymorphism ) and LCOTHER LCOTHER risk and LCDiseaseOrPhenotypicFeature progression .	1
We performed a case - control study to test the association between two polymorphisms in the LCOTHER gene : an LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER producing an LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCSequenceVariant polymorphism ) and a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER resulting in a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCOTHER polymorphism ) and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk and LCOTHER progression .	1
We performed a case - control study to test the association between two polymorphisms in the LCOTHER gene : an LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER producing an LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCSequenceVariant polymorphism ) and a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER resulting in a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCOTHER polymorphism ) and LCOTHER LCOTHER risk and LCDiseaseOrPhenotypicFeature progression .	1
A strong association between LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature occurrence and the Gly / Gly phenotype of the LCSequenceVariant polymorphism ( odds ratio 8 . 39 ; 95% confidence interval 1 . 44 - 48 . 8 ) was found .	1
Therefore , LCGeneOrGeneProduct may play a role in the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and the LCOTHER polymorphism of the LCOTHER gene may be considered as a potential marker in LCOTHER LCOTHER . LCOTHER LCOTHER - LCOTHER LCOTHER gene polymorphism association with LCOTHER - LCOTHER autoantibodies in LCOTHER LCOTHER LCOTHER .	1
Therefore , LCGeneOrGeneProduct may play a role in the LCOTHER LCOTHER and the LCOTHER polymorphism of the LCOTHER gene may be considered as a potential marker in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER LCOTHER - LCOTHER LCOTHER gene polymorphism association with LCOTHER - LCOTHER autoantibodies in LCOTHER LCOTHER LCOTHER .	1
Therefore , LCOTHER may play a role in the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and the LCSequenceVariant polymorphism of the LCOTHER gene may be considered as a potential marker in LCOTHER LCOTHER . LCOTHER LCOTHER - LCOTHER LCOTHER gene polymorphism association with LCOTHER - LCOTHER autoantibodies in LCOTHER LCOTHER LCOTHER .	1
Therefore , LCOTHER may play a role in the LCOTHER LCOTHER and the LCOTHER polymorphism of the LCGeneOrGeneProduct gene may be considered as a potential marker in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER LCOTHER - LCOTHER LCOTHER gene polymorphism association with LCOTHER - LCOTHER autoantibodies in LCOTHER LCOTHER LCOTHER .	1
BACKGROUND : LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is the main systemic transporter of LCChemicalEntity . LCChemicalEntity ( LCChemicalEntity ) LCChemicalEntity and is essential for its cellular endocytosis .	1
BACKGROUND : LCOTHER LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is the main systemic transporter of LCChemicalEntity . LCChemicalEntity ( LCChemicalEntity ) LCChemicalEntity and is essential for its cellular endocytosis .	1
These LCGeneOrGeneProduct variants lead to differences in the affinity for LCChemicalEntity . LCChemicalEntity ( LCChemicalEntity ) LCChemicalEntity .	1
Correlations between LCGeneOrGeneProduct alleles and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature have been described in different populations .	1
Therefore , we investigated the polymorphism in codon 416 of the LCGeneOrGeneProduct gene for an association with autoimmune markers of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
These finding supports a role of the LCChemicalEntity LCChemicalEntity endocrine system in the autoimmune process of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Deletion of endothelial cell - specific LCOTHER LCOTHER LCOTHER increases angiogenesis and LCOTHER growth via LCOTHER LCOTHER LCOTHER LCOTHER .	1
Whether endothelial LCGeneOrGeneProduct regulates angiogenesis and LCDiseaseOrPhenotypicFeature growth is unknown .	3
Injection of LCGeneOrGeneProduct - neutralizing antibody but not the isotype - matched control antibody decreased endothelial - cell angiogenesis and LCDiseaseOrPhenotypicFeature growth in vivo .	1
Furthermore , LCGeneOrGeneProduct deletion enhanced LCOTHER retinal and cell angiogenesis , and knockdown of LCGeneOrGeneProduct by small - interfering RNA decreased endothelial cell proliferation and migration .	3
Re - expression of LCOTHER or knockdown of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct decreased the overproliferation and - migration observed in LCGeneOrGeneProduct ( endo - / - ) cells .	1
Mechanistically , LCGeneOrGeneProduct could bind to the LCGeneOrGeneProduct transcription factor , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , which then inhibited the binding of LCOTHER to the LCOTHER promoter to reduce LCOTHER expression .	3
Mechanistically , LCGeneOrGeneProduct could bind to the LCOTHER transcription factor , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , which then inhibited the binding of LCOTHER to the LCOTHER promoter to reduce LCOTHER expression .	4
Mechanistically , LCGeneOrGeneProduct could bind to the LCOTHER transcription factor , LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , which then inhibited the binding of LCOTHER to the LCOTHER promoter to reduce LCOTHER expression .	4
Mechanistically , LCGeneOrGeneProduct could bind to the LCOTHER transcription factor , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , which then inhibited the binding of LCGeneOrGeneProduct to the LCOTHER promoter to reduce LCOTHER expression .	4
Mechanistically , LCGeneOrGeneProduct could bind to the LCOTHER transcription factor , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , which then inhibited the binding of LCOTHER to the LCGeneOrGeneProduct promoter to reduce LCOTHER expression .	3
Mechanistically , LCGeneOrGeneProduct could bind to the LCOTHER transcription factor , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , which then inhibited the binding of LCOTHER to the LCOTHER promoter to reduce LCGeneOrGeneProduct expression .	3
Mechanistically , LCOTHER could bind to the LCGeneOrGeneProduct transcription factor , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , which then inhibited the binding of LCOTHER to the LCOTHER promoter to reduce LCOTHER expression .	1
Mechanistically , LCOTHER could bind to the LCGeneOrGeneProduct transcription factor , LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , which then inhibited the binding of LCOTHER to the LCOTHER promoter to reduce LCOTHER expression .	1
Mechanistically , LCOTHER could bind to the LCGeneOrGeneProduct transcription factor , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , which then inhibited the binding of LCGeneOrGeneProduct to the LCOTHER promoter to reduce LCOTHER expression .	1
Endothelial LCGeneOrGeneProduct may regulate endothelial angiogenesis and LCDiseaseOrPhenotypicFeature growth by modulating LCOTHER - mediated LCOTHER expression . LCOTHER LCOTHER LCOTHER in LCOTHER ' LCOTHER LCOTHER : risks and relation to LCOTHER .	3
Endothelial LCGeneOrGeneProduct may regulate endothelial angiogenesis and LCOTHER growth by modulating LCGeneOrGeneProduct - mediated LCOTHER expression . LCOTHER LCOTHER LCOTHER in LCOTHER ' LCOTHER LCOTHER : risks and relation to LCOTHER .	4
Endothelial LCGeneOrGeneProduct may regulate endothelial angiogenesis and LCOTHER growth by modulating LCOTHER - mediated LCGeneOrGeneProduct expression . LCOTHER LCOTHER LCOTHER in LCOTHER ' LCOTHER LCOTHER : risks and relation to LCOTHER .	3
Endothelial LCOTHER may regulate endothelial angiogenesis and LCDiseaseOrPhenotypicFeature growth by modulating LCGeneOrGeneProduct - mediated LCOTHER expression . LCOTHER LCOTHER LCOTHER in LCOTHER ' LCOTHER LCOTHER : risks and relation to LCOTHER .	1
OBJECTIVE : To assess and characterise the risk of LCOTHER LCOTHER , and its relation to LCChemicalEntity , in LCOTHER with LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
Nested within the cohort , a matched case - control study was performed to estimate the association between LCChemicalEntity and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature using odds ratios ( ORs ) as relative risk .	2
CONCLUSION : The results indicate a dose - response relationship between LCChemicalEntity and the risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before LCOTHER ' LCOTHER LCOTHER . Mutation analysis of LCOTHER in LCOTHER with LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) in combination with LCOTHER LCOTHER .	2
CONCLUSION : The results indicate a dose - response relationship between LCChemicalEntity and the risk of LCOTHER LCOTHER , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Mutation analysis of LCOTHER in LCOTHER with LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) in combination with LCOTHER LCOTHER .	1
In contrast to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature caused by lack of LCChemicalEntity production or inhibited LCOTHER action , defects affecting development of the bipotent genital anlagen have rarely been investigated in LCOTHER .	3
In contrast to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature caused by lack of LCOTHER production or inhibited LCChemicalEntity action , defects affecting development of the bipotent genital anlagen have rarely been investigated in LCOTHER .	3
Moreover , LCGeneOrGeneProduct knockout LCOTHER present with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in combination with LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER .	1
Moreover , LCGeneOrGeneProduct knockout LCOTHER present with LCOTHER LCOTHER in combination with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
We hypothesized that LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) in combination with LCOTHER LCOTHER could have mutations in the LCGeneOrGeneProduct gene .	1
We hypothesized that LCOTHER with LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) in combination with LCOTHER LCOTHER could have mutations in the LCGeneOrGeneProduct gene .	1
We hypothesized that LCOTHER with LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) in combination with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature could have mutations in the LCGeneOrGeneProduct gene .	1
The LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) modulates LCGeneOrGeneProduct signaling via effects on LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER ( LCOTHER ) .	2
The LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) modulates LCOTHER signaling via effects on LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	3
The LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) modulates LCOTHER signaling via effects on LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	3
The LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) modulates LCGeneOrGeneProduct signaling via effects on LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER ( LCOTHER ) .	2
The LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) modulates LCOTHER signaling via effects on LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	3
The LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) modulates LCOTHER signaling via effects on LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	3
The LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) modulates LCGeneOrGeneProduct signaling via effects on LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	1
The LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) modulates LCGeneOrGeneProduct signaling via effects on LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	1
The LCGeneOrGeneProduct agonist LCChemicalEntity - LCChemicalEntity dose - dependently inhibited LCOTHER activity in LCOTHER cells stably expressing the LCOTHER LCOTHER ; effects were reversed by LCOTHER LCOTHER antagonist .	2
The LCGeneOrGeneProduct agonist LCOTHER - LCOTHER dose - dependently inhibited LCGeneOrGeneProduct activity in LCOTHER cells stably expressing the LCOTHER LCOTHER ; effects were reversed by LCOTHER LCOTHER antagonist .	3
The LCGeneOrGeneProduct agonist LCOTHER - LCOTHER dose - dependently inhibited LCOTHER activity in LCOTHER cells stably expressing the LCOTHER LCGeneOrGeneProduct ; effects were reversed by LCOTHER LCOTHER antagonist .	4
The LCGeneOrGeneProduct agonist LCOTHER - LCOTHER dose - dependently inhibited LCOTHER activity in LCOTHER cells stably expressing the LCOTHER LCOTHER ; effects were reversed by LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist .	4
The LCOTHER agonist LCChemicalEntity - LCChemicalEntity dose - dependently inhibited LCGeneOrGeneProduct activity in LCOTHER cells stably expressing the LCOTHER LCOTHER ; effects were reversed by LCOTHER LCOTHER antagonist .	3
The LCOTHER agonist LCChemicalEntity - LCChemicalEntity dose - dependently inhibited LCOTHER activity in LCOTHER cells stably expressing the LCOTHER LCGeneOrGeneProduct ; effects were reversed by LCOTHER LCOTHER antagonist .	1
The LCOTHER agonist LCChemicalEntity - LCChemicalEntity dose - dependently inhibited LCOTHER activity in LCOTHER cells stably expressing the LCOTHER LCOTHER ; effects were reversed by LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist .	1
LCChemicalEntity - LCChemicalEntity time - and dose - dependently inhibited LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) phosphorylation , effects also reversed by a specific LCOTHER LCOTHER antagonist .	1
LCChemicalEntity - LCChemicalEntity time - and dose - dependently inhibited LCOTHER - LCOTHER ( LCSequenceVariant ) phosphorylation , effects also reversed by a specific LCOTHER LCOTHER antagonist .	1
LCChemicalEntity - LCChemicalEntity time - and dose - dependently inhibited LCOTHER - LCOTHER ( LCOTHER ) phosphorylation , effects also reversed by a specific LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist .	1
LCOTHER - LCOTHER time - and dose - dependently inhibited LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) phosphorylation , effects also reversed by a specific LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist .	1
LCChemicalEntity - LCChemicalEntity augmented LCGeneOrGeneProduct - stimulated LCOTHER phosphorylation in vitro .	1
LCChemicalEntity - LCChemicalEntity augmented LCOTHER - stimulated LCGeneOrGeneProduct phosphorylation in vitro .	1
LCOTHER - LCOTHER augmented LCGeneOrGeneProduct - stimulated LCGeneOrGeneProduct phosphorylation in vitro .	1
The LCGeneOrGeneProduct agonist LCChemicalEntity LCChemicalEntity increased LCOTHER - stimulated LCOTHER phosphorylation in the LCOTHER hypothalamus in vivo .	2
The LCGeneOrGeneProduct agonist LCOTHER LCOTHER increased LCGeneOrGeneProduct - stimulated LCOTHER phosphorylation in the LCOTHER hypothalamus in vivo .	1
The LCGeneOrGeneProduct agonist LCOTHER LCOTHER increased LCOTHER - stimulated LCGeneOrGeneProduct phosphorylation in the LCOTHER hypothalamus in vivo .	1
The LCOTHER agonist LCChemicalEntity LCChemicalEntity increased LCGeneOrGeneProduct - stimulated LCOTHER phosphorylation in the LCOTHER hypothalamus in vivo .	1
The LCOTHER agonist LCChemicalEntity LCChemicalEntity increased LCOTHER - stimulated LCGeneOrGeneProduct phosphorylation in the LCOTHER hypothalamus in vivo .	1
The LCOTHER agonist LCOTHER LCOTHER increased LCGeneOrGeneProduct - stimulated LCGeneOrGeneProduct phosphorylation in the LCOTHER hypothalamus in vivo .	1
LCChemicalEntity - LCChemicalEntity increased LCGeneOrGeneProduct - stimulated LCOTHER uptake in hypothalamic LCOTHER - LCOTHER cells .	1
LCChemicalEntity - LCChemicalEntity increased LCOTHER - stimulated LCChemicalEntity uptake in hypothalamic LCOTHER - LCOTHER cells .	2
Improvement and eventually full recovery only occurred after LCChemicalEntity was completely discontinued and successfully replaced by LCChemicalEntity . A Taiwanese boy with LCOTHER LCOTHER LCOTHER caused by homozygous LCOTHER mutation in the LCOTHER gene .	8
Mutations in the LCGeneOrGeneProduct gene are known to result in LCOTHER , a more severe phenotype than LCOTHER , with earlier onset , more extensive fat loss and biochemical changes , more severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and more severe LCOTHER .	1
Mutations in the LCGeneOrGeneProduct gene are known to result in LCOTHER , a more severe phenotype than LCOTHER , with earlier onset , more extensive fat loss and biochemical changes , more severe LCOTHER LCOTHER , and more severe LCDiseaseOrPhenotypicFeature .	1
We reviewed the genotype of LCDiseaseOrPhenotypicFeature cases from Japan , India , China and Taiwan , and found that LCGeneOrGeneProduct is a major causative gene for LCOTHER in Asian . LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER induces epithelial - mesenchymal transition via LCOTHER / LCOTHER - LCOTHER signaling pathway in LCOTHER LCOTHER LCOTHER .	1
Recent studies show that LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) could induce LCDiseaseOrPhenotypicFeature EMT and is an independent predictive factor associated with poor prognosis in LCOTHER .	1
Recent studies show that LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) could induce LCOTHER EMT and is an independent predictive factor associated with poor prognosis in LCDiseaseOrPhenotypicFeature .	1
Recent studies show that LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) could induce LCDiseaseOrPhenotypicFeature EMT and is an independent predictive factor associated with poor prognosis in LCOTHER .	1
Recent studies show that LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) could induce LCOTHER EMT and is an independent predictive factor associated with poor prognosis in LCDiseaseOrPhenotypicFeature .	1
In the present study , we confirmed the role of LCGeneOrGeneProduct in the prognosis of LCDiseaseOrPhenotypicFeature LCOTHER and provide molecular evidence of LCOTHER promoted EMT in LCOTHER cell line LCOTHER .	1
In the present study , we confirmed the role of LCGeneOrGeneProduct in the prognosis of LCOTHER LCOTHER and provide molecular evidence of LCOTHER promoted EMT in LCDiseaseOrPhenotypicFeature cell line LCOTHER .	1
In the present study , we confirmed the role of LCOTHER in the prognosis of LCOTHER LCOTHER and provide molecular evidence of LCGeneOrGeneProduct promoted EMT in LCDiseaseOrPhenotypicFeature cell line LCOTHER .	1
We found that LCGeneOrGeneProduct expression was upregulated in the LCChemicalEntity - embedded LCOTHER tissues compared to borderline or benign tissues .	1
We found that LCGeneOrGeneProduct expression was upregulated in the LCOTHER - embedded LCDiseaseOrPhenotypicFeature tissues compared to borderline or benign tissues .	1
We found that LCOTHER expression was upregulated in the LCChemicalEntity - embedded LCDiseaseOrPhenotypicFeature tissues compared to borderline or benign tissues .	1
Experimental EMT induced by LCGeneOrGeneProduct plasmid transfection proved LCOTHER protein overexpression could enhance the cell scratch wound - healing and transwell ability and significantly upregulated mesenchymal marker proteins , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER and concurrently downregulated epithelial marker of LCOTHER - LCOTHER .	2
Experimental EMT induced by LCGeneOrGeneProduct plasmid transfection proved LCOTHER protein overexpression could enhance the cell scratch wound - healing and transwell ability and significantly upregulated mesenchymal marker proteins , LCOTHER - LCOTHER and LCGeneOrGeneProduct and concurrently downregulated epithelial marker of LCOTHER - LCOTHER .	2
Experimental EMT induced by LCGeneOrGeneProduct plasmid transfection proved LCOTHER protein overexpression could enhance the cell scratch wound - healing and transwell ability and significantly upregulated mesenchymal marker proteins , LCOTHER - LCOTHER and LCOTHER and concurrently downregulated epithelial marker of LCGeneOrGeneProduct - LCGeneOrGeneProduct .	3
Experimental EMT induced by LCOTHER plasmid transfection proved LCGeneOrGeneProduct protein overexpression could enhance the cell scratch wound - healing and transwell ability and significantly upregulated mesenchymal marker proteins , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER and concurrently downregulated epithelial marker of LCOTHER - LCOTHER .	2
Experimental EMT induced by LCOTHER plasmid transfection proved LCGeneOrGeneProduct protein overexpression could enhance the cell scratch wound - healing and transwell ability and significantly upregulated mesenchymal marker proteins , LCOTHER - LCOTHER and LCGeneOrGeneProduct and concurrently downregulated epithelial marker of LCOTHER - LCOTHER .	2
Experimental EMT induced by LCOTHER plasmid transfection proved LCGeneOrGeneProduct protein overexpression could enhance the cell scratch wound - healing and transwell ability and significantly upregulated mesenchymal marker proteins , LCOTHER - LCOTHER and LCOTHER and concurrently downregulated epithelial marker of LCGeneOrGeneProduct - LCGeneOrGeneProduct .	3
Subsequently , through western blot assay , we found that LCGeneOrGeneProduct could activate the LCGeneOrGeneProduct - signaling component LCOTHER - LCOTHER in the nuclei .	1
Subsequently , through western blot assay , we found that LCGeneOrGeneProduct could activate the LCOTHER - signaling component LCGeneOrGeneProduct - LCGeneOrGeneProduct in the nuclei .	2
Subsequently , through western blot assay , we found that LCOTHER could activate the LCGeneOrGeneProduct - signaling component LCGeneOrGeneProduct - LCGeneOrGeneProduct in the nuclei .	1
Our findings indicated that LCGeneOrGeneProduct might be a very upstream key molecule regulating EMT involved in LCGeneOrGeneProduct / LCOTHER - LCOTHER signaling pathway . LCOTHER LCOTHER LCOTHER protects high LCOTHER - induced energy LCOTHER LCOTHER via blocking LCOTHER - ubiquitin proteasome pathway .	1
Our findings indicated that LCGeneOrGeneProduct might be a very upstream key molecule regulating EMT involved in LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct signaling pathway . LCOTHER LCOTHER LCOTHER protects high LCOTHER - induced energy LCOTHER LCOTHER via blocking LCOTHER - ubiquitin proteasome pathway .	2
Our findings indicated that LCOTHER might be a very upstream key molecule regulating EMT involved in LCGeneOrGeneProduct / LCGeneOrGeneProduct - LCGeneOrGeneProduct signaling pathway . LCOTHER LCOTHER LCOTHER protects high LCOTHER - induced energy LCOTHER LCOTHER via blocking LCOTHER - ubiquitin proteasome pathway .	1
The LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is a LCOTHER LCOTHER - LCOTHER LCOTHER , which is involved in maintaining LCChemicalEntity homeostasis , regulating cell proliferation and apoptosis , and so on .	1
The LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is a LCOTHER LCOTHER - LCOTHER LCOTHER , which is involved in maintaining LCChemicalEntity homeostasis , regulating cell proliferation and apoptosis , and so on .	1
The LCOTHER LCOTHER LCOTHER ( LCOTHER ) is a LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct , which is involved in maintaining LCChemicalEntity homeostasis , regulating cell proliferation and apoptosis , and so on .	1
In our previous study , we found that LCGeneOrGeneProduct expression , intracellular LCChemicalEntity levels and cardiac function were all significantly decreased in LCOTHER LCOTHER ; however , the exact mechanism are not clear yet .	1
In our previous study , we found that LCGeneOrGeneProduct expression , intracellular LCOTHER levels and cardiac function were all significantly decreased in LCDiseaseOrPhenotypicFeature LCOTHER ; however , the exact mechanism are not clear yet .	3
In our previous study , we found that LCOTHER expression , intracellular LCChemicalEntity levels and cardiac function were all significantly decreased in LCDiseaseOrPhenotypicFeature LCOTHER ; however , the exact mechanism are not clear yet .	3
The present study revealed the protective role of LCGeneOrGeneProduct in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature induced by high LCOTHER ( HG ) as well as the underlying mechanism .	1
The present study revealed the protective role of LCGeneOrGeneProduct in LCOTHER LCOTHER LCOTHER LCOTHER induced by high LCChemicalEntity ( HG ) as well as the underlying mechanism .	3
Here , we demonstrated that HG decreased the expression of LCGeneOrGeneProduct , mitochondrial fusion proteins ( LCGeneOrGeneProduct , LCOTHER ) , cell gap junction related proteins ( LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) , and intracellular LCOTHER concentration .	1
Here , we demonstrated that HG decreased the expression of LCGeneOrGeneProduct , mitochondrial fusion proteins ( LCOTHER , LCGeneOrGeneProduct ) , cell gap junction related proteins ( LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) , and intracellular LCOTHER concentration .	1
Here , we demonstrated that HG decreased the expression of LCGeneOrGeneProduct , mitochondrial fusion proteins ( LCOTHER , LCOTHER ) , cell gap junction related proteins ( LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) , and intracellular LCOTHER concentration .	1
Here , we demonstrated that HG decreased the expression of LCGeneOrGeneProduct , mitochondrial fusion proteins ( LCOTHER , LCOTHER ) , cell gap junction related proteins ( LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) , and intracellular LCChemicalEntity concentration .	1
In contrast , HG increased extracellular LCOTHER concentration , the expression of LCGeneOrGeneProduct , mitochondrial fission proteins ( LCGeneOrGeneProduct , LCOTHER ) , and the ubiquitination levels of LCOTHER , LCOTHER and LCOTHER .	1
In contrast , HG increased extracellular LCOTHER concentration , the expression of LCGeneOrGeneProduct , mitochondrial fission proteins ( LCOTHER , LCGeneOrGeneProduct ) , and the ubiquitination levels of LCOTHER , LCOTHER and LCOTHER .	1
In contrast , HG increased extracellular LCOTHER concentration , the expression of LCGeneOrGeneProduct , mitochondrial fission proteins ( LCOTHER , LCOTHER ) , and the ubiquitination levels of LCGeneOrGeneProduct , LCOTHER and LCOTHER .	1
In contrast , HG increased extracellular LCOTHER concentration , the expression of LCGeneOrGeneProduct , mitochondrial fission proteins ( LCOTHER , LCOTHER ) , and the ubiquitination levels of LCOTHER , LCGeneOrGeneProduct and LCOTHER .	1
In contrast , HG increased extracellular LCOTHER concentration , the expression of LCGeneOrGeneProduct , mitochondrial fission proteins ( LCOTHER , LCOTHER ) , and the ubiquitination levels of LCOTHER , LCOTHER and LCGeneOrGeneProduct .	1
Stimulation of LCGeneOrGeneProduct significantly attenuates HG - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , suggesting LCOTHER would be a promising potential therapeutic target for LCOTHER . Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in LCOTHER with LCOTHER LCOTHER LCOTHER .	1
Stimulation of LCGeneOrGeneProduct significantly attenuates HG - induced LCOTHER LCOTHER LCOTHER LCOTHER , suggesting LCOTHER would be a promising potential therapeutic target for LCDiseaseOrPhenotypicFeature . Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in LCOTHER with LCOTHER LCOTHER LCOTHER .	3
Stimulation of LCOTHER significantly attenuates HG - induced LCOTHER LCOTHER LCOTHER LCOTHER , suggesting LCGeneOrGeneProduct would be a promising potential therapeutic target for LCDiseaseOrPhenotypicFeature . Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in LCOTHER with LCOTHER LCOTHER LCOTHER .	3
The aim of this study was therefore to investigate the influence of mutations in these LCOTHER LCOTHER LCOTHER genes ( LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER , LCOTHER and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
The aim of this study was therefore to investigate the influence of mutations in these LCOTHER LCOTHER LCOTHER genes ( LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER , LCOTHER and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
The aim of this study was therefore to investigate the influence of mutations in these LCOTHER LCOTHER LCOTHER genes ( LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER / LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct , LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER , LCOTHER and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
The aim of this study was therefore to investigate the influence of mutations in these LCOTHER LCOTHER LCOTHER genes ( LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER / LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct , LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER , LCOTHER and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
The aim of this study was therefore to investigate the influence of mutations in these LCOTHER LCOTHER LCOTHER genes ( LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER / LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
The aim of this study was therefore to investigate the influence of mutations in these LCOTHER LCOTHER LCOTHER genes ( LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER / LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
The aim of this study was therefore to investigate the influence of mutations in these LCOTHER LCOTHER LCOTHER genes ( LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER / LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
The aim of this study was therefore to investigate the influence of mutations in these LCOTHER LCOTHER LCOTHER genes ( LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER / LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCOTHER ( 874 LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , 259 LCOTHER LCOTHER , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCGeneOrGeneProduct / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER / LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCOTHER ( 874 LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , 259 LCOTHER LCOTHER , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCGeneOrGeneProduct , LCOTHER / LCOTHER / LCOTHER , LCOTHER / LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCOTHER ( 874 LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , 259 LCOTHER LCOTHER , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCGeneOrGeneProduct / LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCOTHER ( 874 LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , 259 LCOTHER LCOTHER , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER / LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER and LCOTHER .	1
RESULTS : When compared with LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER without LCGeneOrGeneProduct mutations , the presence of at least one LCOTHER variant in LCOTHER ' LCOTHER LCOTHER LCOTHER more frequently led to gASCA positivity ( 66 . 1% versus 51 . 5% , p < 0 . 0001 ) and ALCA positivity ( 43 . 3% versus 34 . 9% , p = 0 . 018 ) and higher gASCA titers ( 85 . 7 versus 51 . 8 ELISA units , p < 0 . 0001 ) , independent of ileal involvement .	1
RESULTS : When compared with LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER without LCOTHER mutations , the presence of at least one LCGeneOrGeneProduct variant in LCOTHER ' LCOTHER LCOTHER LCOTHER more frequently led to gASCA positivity ( 66 . 1% versus 51 . 5% , p < 0 . 0001 ) and ALCA positivity ( 43 . 3% versus 34 . 9% , p = 0 . 018 ) and higher gASCA titers ( 85 . 7 versus 51 . 8 ELISA units , p < 0 . 0001 ) , independent of ileal involvement .	1
Similarly , LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER carrying LCGeneOrGeneProduct / LCOTHER indel had a higher prevalence of gASCA antibodies than wild - type LCOTHER ( 63 . 8% versus 55 . 2% , p = 0 . 014 ) , also with a gene dosage effect .	1
Similarly , LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER carrying LCOTHER / LCGeneOrGeneProduct indel had a higher prevalence of gASCA antibodies than wild - type LCOTHER ( 63 . 8% versus 55 . 2% , p = 0 . 014 ) , also with a gene dosage effect .	1
The LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) LCGeneOrGeneProduct is therapeutically targeted by several second generation LCChemicalEntity , such as LCOTHER and LCOTHER , and LCOTHER - LCOTHER - induced LCOTHER in LCOTHER is corrected with the use of a selective LCOTHER - LCOTHER LCOTHER LCOTHER .	1
The LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) LCGeneOrGeneProduct is therapeutically targeted by several second generation LCOTHER , such as LCChemicalEntity and LCOTHER , and LCOTHER - LCOTHER - induced LCOTHER in LCOTHER is corrected with the use of a selective LCOTHER - LCOTHER LCOTHER LCOTHER .	1
The LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) LCGeneOrGeneProduct is therapeutically targeted by several second generation LCOTHER , such as LCOTHER and LCChemicalEntity , and LCOTHER - LCOTHER - induced LCOTHER in LCOTHER is corrected with the use of a selective LCOTHER - LCOTHER LCOTHER LCOTHER .	1
The LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) LCGeneOrGeneProduct is therapeutically targeted by several second generation LCOTHER , such as LCOTHER and LCOTHER , and LCOTHER - LCOTHER - induced LCDiseaseOrPhenotypicFeature in LCOTHER is corrected with the use of a selective LCOTHER - LCOTHER LCOTHER LCOTHER .	1
The LCOTHER LCOTHER ( LCOTHER - LCOTHER ) LCOTHER is therapeutically targeted by several second generation LCOTHER , such as LCOTHER and LCOTHER , and LCChemicalEntity - LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature in LCOTHER is corrected with the use of a selective LCOTHER - LCOTHER LCOTHER LCOTHER .	2
The LCOTHER LCOTHER ( LCOTHER - LCOTHER ) LCOTHER is therapeutically targeted by several second generation LCOTHER , such as LCOTHER and LCOTHER , and LCChemicalEntity - LCChemicalEntity - induced LCOTHER in LCOTHER is corrected with the use of a selective LCChemicalEntity - LCChemicalEntity LCChemicalEntity LCChemicalEntity .	1
In addition , the disrupted prepulse inhibition induced by LCChemicalEntity - LCChemicalEntity or LCOTHER was restored by LCChemicalEntity - LCChemicalEntity LCChemicalEntity LCChemicalEntity in an animal study using LCOTHER .	1
In addition , the disrupted prepulse inhibition induced by LCOTHER - LCOTHER or LCChemicalEntity was restored by LCChemicalEntity - LCChemicalEntity LCChemicalEntity LCChemicalEntity in an animal study using LCOTHER .	1
These animal models were considered to reflect the positive symptoms of LCOTHER , and the above evidence suggests that altered LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct are involved in the pathophysiology of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
The symptoms of LCChemicalEntity ( LCOTHER ) - induced LCDiseaseOrPhenotypicFeature are similar to those of LCOTHER LCOTHER LCOTHER .	2
The symptoms of LCOTHER ( LCChemicalEntity ) - induced LCDiseaseOrPhenotypicFeature are similar to those of LCOTHER LCOTHER LCOTHER .	2
Therefore , we conducted an analysis of the association of the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene ( LCOTHER ) with LCChemicalEntity - induced LCOTHER .	1
Therefore , we conducted an analysis of the association of the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene ( LCOTHER ) with LCOTHER - induced LCDiseaseOrPhenotypicFeature .	1
Therefore , we conducted an analysis of the association of the LCOTHER - LCOTHER gene ( LCGeneOrGeneProduct ) with LCChemicalEntity - induced LCOTHER .	1
Therefore , we conducted an analysis of the association of the LCOTHER - LCOTHER gene ( LCGeneOrGeneProduct ) with LCOTHER - induced LCDiseaseOrPhenotypicFeature .	1
Therefore , we conducted an analysis of the association of the LCOTHER - LCOTHER gene ( LCOTHER ) with LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature .	2
METHOD : Using five tagging SNPs ( LCSequenceVariant , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) , we conducted a genetic association analysis of case - control samples ( 197 LCChemicalEntity - induced LCOTHER LCOTHER and 337 controls ) in the Japanese population .	1
METHOD : Using five tagging SNPs ( LCSequenceVariant , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) , we conducted a genetic association analysis of case - control samples ( 197 LCOTHER - induced LCDiseaseOrPhenotypicFeature LCOTHER and 337 controls ) in the Japanese population .	1
METHOD : Using five tagging SNPs ( LCOTHER , LCSequenceVariant , LCOTHER , LCOTHER and LCOTHER ) , we conducted a genetic association analysis of case - control samples ( 197 LCChemicalEntity - induced LCOTHER LCOTHER and 337 controls ) in the Japanese population .	1
METHOD : Using five tagging SNPs ( LCOTHER , LCSequenceVariant , LCOTHER , LCOTHER and LCOTHER ) , we conducted a genetic association analysis of case - control samples ( 197 LCOTHER - induced LCDiseaseOrPhenotypicFeature LCOTHER and 337 controls ) in the Japanese population .	1
METHOD : Using five tagging SNPs ( LCOTHER , LCOTHER , LCSequenceVariant , LCOTHER and LCOTHER ) , we conducted a genetic association analysis of case - control samples ( 197 LCChemicalEntity - induced LCOTHER LCOTHER and 337 controls ) in the Japanese population .	1
METHOD : Using five tagging SNPs ( LCOTHER , LCOTHER , LCSequenceVariant , LCOTHER and LCOTHER ) , we conducted a genetic association analysis of case - control samples ( 197 LCOTHER - induced LCDiseaseOrPhenotypicFeature LCOTHER and 337 controls ) in the Japanese population .	1
METHOD : Using five tagging SNPs ( LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) , we conducted a genetic association analysis of case - control samples ( 197 LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCOTHER and 337 controls ) in the Japanese population .	2
RESULTS : LCSequenceVariant was associated with LCChemicalEntity - induced LCOTHER LCOTHER in the allele / genotype - wise analysis .	1
RESULTS : LCSequenceVariant was associated with LCOTHER - induced LCDiseaseOrPhenotypicFeature LCOTHER in the allele / genotype - wise analysis .	1
RESULTS : LCOTHER was associated with LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCOTHER in the allele / genotype - wise analysis .	2
In the haplotype - wise analysis , we detected an association between two markers ( LCSequenceVariant and LCOTHER ) and three markers ( LCOTHER , LCOTHER and LCOTHER ) in LCOTHER and LCChemicalEntity - induced LCOTHER LCOTHER , respectively .	1
In the haplotype - wise analysis , we detected an association between two markers ( LCSequenceVariant and LCOTHER ) and three markers ( LCOTHER , LCOTHER and LCOTHER ) in LCOTHER and LCOTHER - induced LCDiseaseOrPhenotypicFeature LCOTHER , respectively .	1
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCSequenceVariant ) and three markers ( LCOTHER , LCOTHER and LCOTHER ) in LCOTHER and LCChemicalEntity - induced LCOTHER LCOTHER , respectively .	1
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCSequenceVariant ) and three markers ( LCOTHER , LCOTHER and LCOTHER ) in LCOTHER and LCOTHER - induced LCDiseaseOrPhenotypicFeature LCOTHER , respectively .	1
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCOTHER ) and three markers ( LCSequenceVariant , LCOTHER and LCOTHER ) in LCOTHER and LCChemicalEntity - induced LCOTHER LCOTHER , respectively .	1
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCOTHER ) and three markers ( LCSequenceVariant , LCOTHER and LCOTHER ) in LCOTHER and LCOTHER - induced LCDiseaseOrPhenotypicFeature LCOTHER , respectively .	1
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCOTHER ) and three markers ( LCOTHER , LCSequenceVariant and LCOTHER ) in LCOTHER and LCChemicalEntity - induced LCOTHER LCOTHER , respectively .	1
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCOTHER ) and three markers ( LCOTHER , LCSequenceVariant and LCOTHER ) in LCOTHER and LCOTHER - induced LCDiseaseOrPhenotypicFeature LCOTHER , respectively .	1
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCOTHER ) and three markers ( LCOTHER , LCOTHER and LCSequenceVariant ) in LCOTHER and LCChemicalEntity - induced LCOTHER LCOTHER , respectively .	1
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCOTHER ) and three markers ( LCOTHER , LCOTHER and LCSequenceVariant ) in LCOTHER and LCOTHER - induced LCDiseaseOrPhenotypicFeature LCOTHER , respectively .	1
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCOTHER ) and three markers ( LCOTHER , LCOTHER and LCOTHER ) in LCGeneOrGeneProduct and LCChemicalEntity - induced LCOTHER LCOTHER , respectively .	1
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCOTHER ) and three markers ( LCOTHER , LCOTHER and LCOTHER ) in LCGeneOrGeneProduct and LCOTHER - induced LCDiseaseOrPhenotypicFeature LCOTHER , respectively .	1
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCOTHER ) and three markers ( LCOTHER , LCOTHER and LCOTHER ) in LCOTHER and LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCOTHER , respectively .	2
CONCLUSION : LCGeneOrGeneProduct may play an important role in the pathophysiology of LCChemicalEntity - induced LCOTHER in the Japanese population . LCOTHER LCOTHER dose in LCOTHER LCOTHER - LCOTHER adults is not associated with LCOTHER - LCOTHER gene polymorphisms .	1
CONCLUSION : LCGeneOrGeneProduct may play an important role in the pathophysiology of LCOTHER - induced LCDiseaseOrPhenotypicFeature in the Japanese population . LCOTHER LCOTHER dose in LCOTHER LCOTHER - LCOTHER adults is not associated with LCOTHER - LCOTHER gene polymorphisms .	1
CONCLUSION : LCOTHER may play an important role in the pathophysiology of LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature in the Japanese population . LCOTHER LCOTHER dose in LCOTHER LCOTHER - LCOTHER adults is not associated with LCOTHER - LCOTHER gene polymorphisms .	2
Variance in LCGeneOrGeneProduct - LCGeneOrGeneProduct concentrations due to genetic variations may affect different response to LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) treatment , resulting in different individually required LCOTHER - doses in LCOTHER - LCOTHER LCOTHER .	1
Variance in LCGeneOrGeneProduct - LCGeneOrGeneProduct concentrations due to genetic variations may affect different response to LCOTHER LCOTHER ( LCGeneOrGeneProduct ) treatment , resulting in different individually required LCOTHER - doses in LCOTHER - LCOTHER LCOTHER .	1
Variance in LCGeneOrGeneProduct - LCGeneOrGeneProduct concentrations due to genetic variations may affect different response to LCOTHER LCOTHER ( LCOTHER ) treatment , resulting in different individually required LCGeneOrGeneProduct - doses in LCOTHER - LCOTHER LCOTHER .	1
Variance in LCOTHER - LCOTHER concentrations due to genetic variations may affect different response to LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) treatment , resulting in different individually required LCOTHER - doses in LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER .	3
Variance in LCOTHER - LCOTHER concentrations due to genetic variations may affect different response to LCOTHER LCOTHER ( LCGeneOrGeneProduct ) treatment , resulting in different individually required LCOTHER - doses in LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER .	3
Variance in LCOTHER - LCOTHER concentrations due to genetic variations may affect different response to LCOTHER LCOTHER ( LCOTHER ) treatment , resulting in different individually required LCGeneOrGeneProduct - doses in LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER .	3
The aim of this study was to test if the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene polymorphisms are associated with the LCGeneOrGeneProduct - dose of LCOTHER - LCOTHER adults .	1
The aim of this study was to test if the LCOTHER - LCOTHER gene polymorphisms are associated with the LCGeneOrGeneProduct - dose of LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature adults .	3
LCOTHER - dose after 1 year of treatment , LCGeneOrGeneProduct - LCGeneOrGeneProduct concentrations , LCOTHER - LCOTHER - standard deviation score ( SDS ) , the LCOTHER - LCOTHER : LCGeneOrGeneProduct ratio and anthropometric data were analyzed by genotype .	1
LCOTHER - dose after 1 year of treatment , LCOTHER - LCOTHER concentrations , LCGeneOrGeneProduct - LCGeneOrGeneProduct - standard deviation score ( SDS ) , the LCOTHER - LCOTHER : LCGeneOrGeneProduct ratio and anthropometric data were analyzed by genotype .	1
LCOTHER - dose after 1 year of treatment , LCOTHER - LCOTHER concentrations , LCOTHER - LCOTHER - standard deviation score ( SDS ) , the LCGeneOrGeneProduct - LCGeneOrGeneProduct : LCGeneOrGeneProduct ratio and anthropometric data were analyzed by genotype .	1
RESULTS : Except for LCOTHER , which showed a significant difference of LCGeneOrGeneProduct - LCGeneOrGeneProduct - SDS by genotypes ( p = 0 . 02 ) , all polymorphisms showed no associations with the LCGeneOrGeneProduct - doses , LCOTHER - LCOTHER concentrations , LCOTHER - LCOTHER - SDS and LCOTHER - LCOTHER : LCOTHER ratio after adjusting for the confounding variables gender , age and BMI .	1
RESULTS : Except for LCOTHER , which showed a significant difference of LCGeneOrGeneProduct - LCGeneOrGeneProduct - SDS by genotypes ( p = 0 . 02 ) , all polymorphisms showed no associations with the LCOTHER - doses , LCOTHER - LCOTHER concentrations , LCOTHER - LCOTHER - SDS and LCOTHER - LCOTHER : LCGeneOrGeneProduct ratio after adjusting for the confounding variables gender , age and BMI .	1
RESULTS : Except for LCOTHER , which showed a significant difference of LCOTHER - LCOTHER - SDS by genotypes ( p = 0 . 02 ) , all polymorphisms showed no associations with the LCOTHER - doses , LCGeneOrGeneProduct - LCGeneOrGeneProduct concentrations , LCOTHER - LCOTHER - SDS and LCOTHER - LCOTHER : LCGeneOrGeneProduct ratio after adjusting for the confounding variables gender , age and BMI .	1
RESULTS : Except for LCOTHER , which showed a significant difference of LCOTHER - LCOTHER - SDS by genotypes ( p = 0 . 02 ) , all polymorphisms showed no associations with the LCOTHER - doses , LCOTHER - LCOTHER concentrations , LCGeneOrGeneProduct - LCGeneOrGeneProduct - SDS and LCOTHER - LCOTHER : LCGeneOrGeneProduct ratio after adjusting for the confounding variables gender , age and BMI .	1
RESULTS : Except for LCOTHER , which showed a significant difference of LCOTHER - LCOTHER - SDS by genotypes ( p = 0 . 02 ) , all polymorphisms showed no associations with the LCOTHER - doses , LCOTHER - LCOTHER concentrations , LCOTHER - LCOTHER - SDS and LCGeneOrGeneProduct - LCGeneOrGeneProduct : LCGeneOrGeneProduct ratio after adjusting for the confounding variables gender , age and BMI .	1
CONCLUSION : LCGeneOrGeneProduct - LCGeneOrGeneProduct gene polymorphisms were not associated with the responsiveness to exogenous LCGeneOrGeneProduct in LCOTHER .	1
CONCLUSION : LCOTHER - LCOTHER gene polymorphisms were not associated with the responsiveness to exogenous LCGeneOrGeneProduct in LCDiseaseOrPhenotypicFeature .	3
Therefore , genetic variations of the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene seem not to be major influencing factors of the LCGeneOrGeneProduct - LCOTHER - axis causing variable response to exogenous LCOTHER - treatment . Fine mapping and identification of a candidate gene LCOTHER in LCOTHER LCOTHER LCOTHER LCOTHER .	1
Therefore , genetic variations of the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene seem not to be major influencing factors of the LCOTHER - LCOTHER - axis causing variable response to exogenous LCGeneOrGeneProduct - treatment . Fine mapping and identification of a candidate gene LCOTHER in LCOTHER LCOTHER LCOTHER LCOTHER .	1
Therefore , genetic variations of the LCOTHER - LCOTHER gene seem not to be major influencing factors of the LCOTHER - LCGeneOrGeneProduct - axis causing variable response to exogenous LCGeneOrGeneProduct - treatment . Fine mapping and identification of a candidate gene LCOTHER in LCOTHER LCOTHER LCOTHER LCOTHER .	1
Upon screening 30 candidate genes , we identified a missense mutation , LCSequenceVariant . LCSequenceVariant in LCOTHER in one family , a frameshift mutation , LCOTHER . LCOTHER in an alternative variant ( isoform f ) of LCOTHER in another family , and a frameshift mutation , LCOTHER . LCOTHER in the same alternative variant in one non - familial case with LCDiseaseOrPhenotypicFeature .	1
Upon screening 30 candidate genes , we identified a missense mutation , LCOTHER . LCOTHER in LCGeneOrGeneProduct in one family , a frameshift mutation , LCOTHER . LCOTHER in an alternative variant ( isoform f ) of LCOTHER in another family , and a frameshift mutation , LCOTHER . LCOTHER in the same alternative variant in one non - familial case with LCDiseaseOrPhenotypicFeature .	1
Upon screening 30 candidate genes , we identified a missense mutation , LCOTHER . LCOTHER in LCOTHER in one family , a frameshift mutation , LCSequenceVariant . LCSequenceVariant in an alternative variant ( isoform f ) of LCOTHER in another family , and a frameshift mutation , LCOTHER . LCOTHER in the same alternative variant in one non - familial case with LCDiseaseOrPhenotypicFeature .	1
Upon screening 30 candidate genes , we identified a missense mutation , LCOTHER . LCOTHER in LCOTHER in one family , a frameshift mutation , LCOTHER . LCOTHER in an alternative variant ( isoform f ) of LCGeneOrGeneProduct in another family , and a frameshift mutation , LCOTHER . LCOTHER in the same alternative variant in one non - familial case with LCDiseaseOrPhenotypicFeature .	1
Upon screening 30 candidate genes , we identified a missense mutation , LCOTHER . LCOTHER in LCOTHER in one family , a frameshift mutation , LCOTHER . LCOTHER in an alternative variant ( isoform f ) of LCOTHER in another family , and a frameshift mutation , LCSequenceVariant . LCSequenceVariant in the same alternative variant in one non - familial case with LCDiseaseOrPhenotypicFeature .	1
The present study aimed to investigate whether LCChemicalEntity protects against LCDiseaseOrPhenotypicFeature via anti - apoptotic effects by the upregulation of LCOTHER in vivo and in vitro .	3
The present study aimed to investigate whether LCChemicalEntity protects against LCOTHER via anti - apoptotic effects by the upregulation of LCGeneOrGeneProduct in vivo and in vitro .	2
To determine whether LCChemicalEntity attenuated LCDiseaseOrPhenotypicFeature , the LCOTHER response and apoptosis in vivo and in vitro , a LCOTHER model of LCOTHER - induced LCOTHER was used , and LCOTHER embryonic proximal tubule ( LCOTHER ) cell damage was assessed .	3
To determine whether LCChemicalEntity attenuated LCOTHER , the LCOTHER response and apoptosis in vivo and in vitro , a LCOTHER model of LCChemicalEntity - induced LCOTHER was used , and LCOTHER embryonic proximal tubule ( LCOTHER ) cell damage was assessed .	3
To determine whether LCChemicalEntity attenuated LCOTHER , the LCOTHER response and apoptosis in vivo and in vitro , a LCOTHER model of LCOTHER - induced LCDiseaseOrPhenotypicFeature was used , and LCOTHER embryonic proximal tubule ( LCOTHER ) cell damage was assessed .	3
To determine whether LCOTHER attenuated LCOTHER , the LCOTHER response and apoptosis in vivo and in vitro , a LCOTHER model of LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature was used , and LCOTHER embryonic proximal tubule ( LCOTHER ) cell damage was assessed .	2
The LCOTHER were assigned into four groups ( n = 10 per group ) , as follows : Control LCOTHER ; LCOTHER + LCChemicalEntity ; LCOTHER + LCChemicalEntity ; LCOTHER + LCOTHER + LCOTHER .	3
The LCOTHER were assigned into four groups ( n = 10 per group ) , as follows : Control LCOTHER ; LCOTHER + LCChemicalEntity ; LCOTHER + LCOTHER ; LCOTHER + LCChemicalEntity + LCOTHER .	3
In vitro , the LCOTHER cells were treated with LCChemicalEntity in the presence or absence of LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct small interfering ( si ) RNA or pcDNA3 . 1 - LCOTHER .	1
In vitro , the LCOTHER cells were treated with LCChemicalEntity in the presence or absence of LCOTHER , LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER small interfering ( si ) RNA or pcDNA3 . 1 - LCGeneOrGeneProduct .	1
The results showed that LCChemicalEntity ameliorated the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( P < 0 . 05 ) .	3
Furthermore , LCChemicalEntity reduced the LCChemicalEntity - induced activity of LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) / LCOTHER - LCOTHER and increased the expression of LCOTHER - LCOTHER in vivo and in vitro .	3
Furthermore , LCChemicalEntity reduced the LCOTHER - induced activity of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) / LCOTHER - LCOTHER and increased the expression of LCOTHER - LCOTHER in vivo and in vitro .	3
Furthermore , LCChemicalEntity reduced the LCOTHER - induced activity of LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) / LCOTHER - LCOTHER and increased the expression of LCOTHER - LCOTHER in vivo and in vitro .	3
Furthermore , LCChemicalEntity reduced the LCOTHER - induced activity of LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) / LCGeneOrGeneProduct - LCGeneOrGeneProduct and increased the expression of LCOTHER - LCOTHER in vivo and in vitro .	3
Furthermore , LCChemicalEntity reduced the LCOTHER - induced activity of LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) / LCOTHER - LCOTHER and increased the expression of LCGeneOrGeneProduct - LCGeneOrGeneProduct in vivo and in vitro .	2
Furthermore , LCOTHER reduced the LCChemicalEntity - induced activity of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) / LCOTHER - LCOTHER and increased the expression of LCOTHER - LCOTHER in vivo and in vitro .	2
Furthermore , LCOTHER reduced the LCChemicalEntity - induced activity of LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) / LCOTHER - LCOTHER and increased the expression of LCOTHER - LCOTHER in vivo and in vitro .	2
Furthermore , LCOTHER reduced the LCChemicalEntity - induced activity of LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) / LCGeneOrGeneProduct - LCGeneOrGeneProduct and increased the expression of LCOTHER - LCOTHER in vivo and in vitro .	2
Notably , following treatment with LCGeneOrGeneProduct siRNA or pcDNA3 . 1 - LCOTHER , it was found that LCOTHER enhanced or weakened the upregulation of LCGeneOrGeneProduct / LCOTHER - LCOTHER and downregulation of LCOTHER - LCOTHER in the LCOTHER cells , respectively .	1
Notably , following treatment with LCGeneOrGeneProduct siRNA or pcDNA3 . 1 - LCOTHER , it was found that LCOTHER enhanced or weakened the upregulation of LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct and downregulation of LCOTHER - LCOTHER in the LCOTHER cells , respectively .	1
Notably , following treatment with LCGeneOrGeneProduct siRNA or pcDNA3 . 1 - LCOTHER , it was found that LCOTHER enhanced or weakened the upregulation of LCOTHER / LCOTHER - LCOTHER and downregulation of LCGeneOrGeneProduct - LCGeneOrGeneProduct in the LCOTHER cells , respectively .	1
Notably , following treatment with LCOTHER siRNA or pcDNA3 . 1 - LCGeneOrGeneProduct , it was found that LCOTHER enhanced or weakened the upregulation of LCGeneOrGeneProduct / LCOTHER - LCOTHER and downregulation of LCOTHER - LCOTHER in the LCOTHER cells , respectively .	1
Notably , following treatment with LCOTHER siRNA or pcDNA3 . 1 - LCGeneOrGeneProduct , it was found that LCOTHER enhanced or weakened the upregulation of LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct and downregulation of LCOTHER - LCOTHER in the LCOTHER cells , respectively .	1
Notably , following treatment with LCOTHER siRNA or pcDNA3 . 1 - LCGeneOrGeneProduct , it was found that LCOTHER enhanced or weakened the upregulation of LCOTHER / LCOTHER - LCOTHER and downregulation of LCGeneOrGeneProduct - LCGeneOrGeneProduct in the LCOTHER cells , respectively .	1
Notably , following treatment with LCOTHER siRNA or pcDNA3 . 1 - LCOTHER , it was found that LCChemicalEntity enhanced or weakened the upregulation of LCGeneOrGeneProduct / LCOTHER - LCOTHER and downregulation of LCOTHER - LCOTHER in the LCOTHER cells , respectively .	1
Notably , following treatment with LCOTHER siRNA or pcDNA3 . 1 - LCOTHER , it was found that LCChemicalEntity enhanced or weakened the upregulation of LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct and downregulation of LCOTHER - LCOTHER in the LCOTHER cells , respectively .	1
Notably , following treatment with LCOTHER siRNA or pcDNA3 . 1 - LCOTHER , it was found that LCChemicalEntity enhanced or weakened the upregulation of LCOTHER / LCOTHER - LCOTHER and downregulation of LCGeneOrGeneProduct - LCGeneOrGeneProduct in the LCOTHER cells , respectively .	1
The results of the present study suggested that LCChemicalEntity protected against LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature through the upregulation of LCOTHER in vivo and in vitro . Possible LCOTHER LCOTHER LCOTHER related to concomitant treatment with LCOTHER and LCOTHER .	3
The results of the present study suggested that LCChemicalEntity protected against LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER through the upregulation of LCGeneOrGeneProduct in vivo and in vitro . Possible LCOTHER LCOTHER LCOTHER related to concomitant treatment with LCOTHER and LCOTHER .	2
Medical treatment was initiated at a daily dose of 20 mg LCChemicalEntity and 1 . 2 mg LCChemicalEntity .	7
On the 10th day of LCChemicalEntity and LCChemicalEntity treatment , the LCOTHER exhibited marked LCOTHER LCOTHER , disorientation , and severe LCOTHER LCOTHER with LCOTHER .	7
On the 10th day of LCChemicalEntity and LCOTHER treatment , the LCOTHER exhibited marked LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , disorientation , and severe LCOTHER LCOTHER with LCOTHER .	2
On the 10th day of LCChemicalEntity and LCOTHER treatment , the LCOTHER exhibited marked LCOTHER LCOTHER , disorientation , and severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with LCOTHER .	2
On the 10th day of LCChemicalEntity and LCOTHER treatment , the LCOTHER exhibited marked LCOTHER LCOTHER , disorientation , and severe LCOTHER LCOTHER with LCDiseaseOrPhenotypicFeature .	2
On the 10th day of LCOTHER and LCChemicalEntity treatment , the LCOTHER exhibited marked LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , disorientation , and severe LCOTHER LCOTHER with LCOTHER .	2
On the 10th day of LCOTHER and LCChemicalEntity treatment , the LCOTHER exhibited marked LCOTHER LCOTHER , disorientation , and severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with LCOTHER .	2
On the 10th day of LCOTHER and LCChemicalEntity treatment , the LCOTHER exhibited marked LCOTHER LCOTHER , disorientation , and severe LCOTHER LCOTHER with LCDiseaseOrPhenotypicFeature .	2
7 days later , the LCDiseaseOrPhenotypicFeature disappeared and the LCOTHER ' s serum LCChemicalEntity levels were normalized ( 175 IU / L ) .	2
This LCOTHER presented with symptoms of LCOTHER LCOTHER LCOTHER ( LCOTHER ) , thus demonstrating that LCOTHER - like symptoms can occur after combined LCChemicalEntity and LCChemicalEntity treatment .	7
elegans LCGeneOrGeneProduct - LCGeneOrGeneProduct , recently associated with autosomal - recessive LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , reveal that this small LCOTHER is exclusively expressed in ciliated neurons where it dynamically associates with IFT trains .	1
Whereas inactive LCChemicalEntity - bound LCGeneOrGeneProduct - LCGeneOrGeneProduct displays no IFT movement and diffuse localisation , LCOTHER - bound ( activated ) LCOTHER - LCOTHER concentrates at the periciliary membrane in a LCOTHER - dependent manner and undergoes bidirectional IFT .	4
Whereas inactive LCChemicalEntity - bound LCOTHER - LCOTHER displays no IFT movement and diffuse localisation , LCOTHER - bound ( activated ) LCGeneOrGeneProduct - LCGeneOrGeneProduct concentrates at the periciliary membrane in a LCOTHER - dependent manner and undergoes bidirectional IFT .	4
Whereas inactive LCOTHER - bound LCGeneOrGeneProduct - LCGeneOrGeneProduct displays no IFT movement and diffuse localisation , LCOTHER - bound ( activated ) LCOTHER - LCOTHER concentrates at the periciliary membrane in a LCGeneOrGeneProduct - dependent manner and undergoes bidirectional IFT .	1
Whereas inactive LCOTHER - bound LCOTHER - LCOTHER displays no IFT movement and diffuse localisation , LCChemicalEntity - bound ( activated ) LCGeneOrGeneProduct - LCGeneOrGeneProduct concentrates at the periciliary membrane in a LCOTHER - dependent manner and undergoes bidirectional IFT .	4
Whereas inactive LCOTHER - bound LCOTHER - LCOTHER displays no IFT movement and diffuse localisation , LCChemicalEntity - bound ( activated ) LCOTHER - LCOTHER concentrates at the periciliary membrane in a LCGeneOrGeneProduct - dependent manner and undergoes bidirectional IFT .	1
Whereas inactive LCOTHER - bound LCOTHER - LCOTHER displays no IFT movement and diffuse localisation , LCOTHER - bound ( activated ) LCGeneOrGeneProduct - LCGeneOrGeneProduct concentrates at the periciliary membrane in a LCGeneOrGeneProduct - dependent manner and undergoes bidirectional IFT .	1
Functional analyses reveal that whilst cilium structure , sensory function and IFT are seemingly normal in a LCOTHER - LCOTHER null allele , overexpression of predicted LCChemicalEntity or LCOTHER locked variants of LCGeneOrGeneProduct - LCGeneOrGeneProduct perturbs cilium and sensory pore morphogenesis and function .	4
Functional analyses reveal that whilst cilium structure , sensory function and IFT are seemingly normal in a LCOTHER - LCOTHER null allele , overexpression of predicted LCOTHER or LCChemicalEntity locked variants of LCGeneOrGeneProduct - LCGeneOrGeneProduct perturbs cilium and sensory pore morphogenesis and function .	4
Collectively , our findings present a new approach for identifying ciliary proteins , and unveil LCGeneOrGeneProduct , a LCOTHER most closely related to the LCDiseaseOrPhenotypicFeature protein LCOTHER / LCOTHER , as an IFT - associated cargo with LCOTHER - dependent cell autonomous and non - autonomous functions at the ciliary base . Compound heterozygous mutations in the LCOTHER gene exon 4 in a LCOTHER LCOTHER LCOTHER of Chinese origin .	1
Collectively , our findings present a new approach for identifying ciliary proteins , and unveil LCGeneOrGeneProduct , a LCOTHER most closely related to the LCOTHER protein LCGeneOrGeneProduct / LCOTHER , as an IFT - associated cargo with LCOTHER - dependent cell autonomous and non - autonomous functions at the ciliary base . Compound heterozygous mutations in the LCOTHER gene exon 4 in a LCOTHER LCOTHER LCOTHER of Chinese origin .	1
Collectively , our findings present a new approach for identifying ciliary proteins , and unveil LCGeneOrGeneProduct , a LCOTHER most closely related to the LCOTHER protein LCOTHER / LCGeneOrGeneProduct , as an IFT - associated cargo with LCOTHER - dependent cell autonomous and non - autonomous functions at the ciliary base . Compound heterozygous mutations in the LCOTHER gene exon 4 in a LCOTHER LCOTHER LCOTHER of Chinese origin .	1
Collectively , our findings present a new approach for identifying ciliary proteins , and unveil LCOTHER , a LCGeneOrGeneProduct most closely related to the LCDiseaseOrPhenotypicFeature protein LCOTHER / LCOTHER , as an IFT - associated cargo with LCOTHER - dependent cell autonomous and non - autonomous functions at the ciliary base . Compound heterozygous mutations in the LCOTHER gene exon 4 in a LCOTHER LCOTHER LCOTHER of Chinese origin .	1
Collectively , our findings present a new approach for identifying ciliary proteins , and unveil LCOTHER , a LCGeneOrGeneProduct most closely related to the LCOTHER protein LCGeneOrGeneProduct / LCOTHER , as an IFT - associated cargo with LCOTHER - dependent cell autonomous and non - autonomous functions at the ciliary base . Compound heterozygous mutations in the LCOTHER gene exon 4 in a LCOTHER LCOTHER LCOTHER of Chinese origin .	1
Collectively , our findings present a new approach for identifying ciliary proteins , and unveil LCOTHER , a LCGeneOrGeneProduct most closely related to the LCOTHER protein LCOTHER / LCGeneOrGeneProduct , as an IFT - associated cargo with LCOTHER - dependent cell autonomous and non - autonomous functions at the ciliary base . Compound heterozygous mutations in the LCOTHER gene exon 4 in a LCOTHER LCOTHER LCOTHER of Chinese origin .	1
Collectively , our findings present a new approach for identifying ciliary proteins , and unveil LCOTHER , a LCOTHER most closely related to the LCDiseaseOrPhenotypicFeature protein LCOTHER / LCOTHER , as an IFT - associated cargo with LCGeneOrGeneProduct - dependent cell autonomous and non - autonomous functions at the ciliary base . Compound heterozygous mutations in the LCOTHER gene exon 4 in a LCOTHER LCOTHER LCOTHER of Chinese origin .	1
The goal of this study was to perform LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene ( LCOTHER ) analysis in a LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) LCOTHER with normal LCOTHER ( LCOTHER ) production and normal LCOTHER LCOTHER ( LCOTHER ) gene coding sequences .	1
The goal of this study was to perform LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene ( LCOTHER ) analysis in a LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) LCOTHER with normal LCOTHER ( LCOTHER ) production and normal LCOTHER LCOTHER ( LCOTHER ) gene coding sequences .	1
The goal of this study was to perform LCOTHER - LCOTHER - LCOTHER LCOTHER LCOTHER gene ( LCGeneOrGeneProduct ) analysis in a LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) LCOTHER with normal LCOTHER ( LCOTHER ) production and normal LCOTHER LCOTHER ( LCOTHER ) gene coding sequences .	1
The goal of this study was to perform LCOTHER - LCOTHER - LCOTHER LCOTHER LCOTHER gene ( LCGeneOrGeneProduct ) analysis in a LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) LCOTHER with normal LCOTHER ( LCOTHER ) production and normal LCOTHER LCOTHER ( LCOTHER ) gene coding sequences .	1
A LCOTHER of Chinese origin with ambiguous genitalia at 14 months , a 46 , XY karyotype , and normal LCChemicalEntity secretion under LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCOTHER ) stimulation underwent a gonadectomy at 20 months .	1
A LCOTHER of Chinese origin with ambiguous genitalia at 14 months , a 46 , XY karyotype , and normal LCChemicalEntity secretion under LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) stimulation underwent a gonadectomy at 20 months .	1
The LCOTHER showed an LCSequenceVariant mutation that has been described in an Asian population and LCDiseaseOrPhenotypicFeature LCOTHER , along with a novel frameshift mutation , LCOTHER .	1
A recent addition to the list of widely confirmed LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk loci is the LCGeneOrGeneProduct gene encoding a LCOTHER - LCOTHER LCOTHER ( LCOTHER ) .	1
A recent addition to the list of widely confirmed LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk loci is the LCOTHER gene encoding a LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	1
A recent addition to the list of widely confirmed LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk loci is the LCOTHER gene encoding a LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	1
The LCSequenceVariant risk allele occurred on only a single haplotype that was strongly associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( P = 7 . 9 x 10 ( - 5 ) ) .	2
These results support the conclusion that the LCSequenceVariant / LCSequenceVariant allele is the major risk variant for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in the LCOTHER locus , but they suggest that additional infrequent coding variants at LCOTHER may also contribute to LCOTHER LCOTHER LCOTHER risk . LCOTHER - induced changes in LCOTHER LCOTHER LCOTHER and LCOTHER signaling via LCOTHER in skeletal muscle .	2
These results support the conclusion that the LCSequenceVariant / LCSequenceVariant allele is the major risk variant for LCOTHER LCOTHER LCOTHER in the LCOTHER locus , but they suggest that additional infrequent coding variants at LCOTHER may also contribute to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk . LCOTHER - induced changes in LCOTHER LCOTHER LCOTHER and LCOTHER signaling via LCOTHER in skeletal muscle .	2
These results support the conclusion that the LCOTHER / LCOTHER allele is the major risk variant for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in the LCGeneOrGeneProduct locus , but they suggest that additional infrequent coding variants at LCOTHER may also contribute to LCOTHER LCOTHER LCOTHER risk . LCOTHER - induced changes in LCOTHER LCOTHER LCOTHER and LCOTHER signaling via LCOTHER in skeletal muscle .	1
These results support the conclusion that the LCOTHER / LCOTHER allele is the major risk variant for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in the LCOTHER locus , but they suggest that additional infrequent coding variants at LCGeneOrGeneProduct may also contribute to LCOTHER LCOTHER LCOTHER risk . LCOTHER - induced changes in LCOTHER LCOTHER LCOTHER and LCOTHER signaling via LCOTHER in skeletal muscle .	1
The present study tested the hypothesis that LCDiseaseOrPhenotypicFeature - induced LCOTHER ( LCOTHER ) resistance in skeletal muscle is associated with a down - regulation of LCOTHER LCOTHER LCOTHER important in regulating LCOTHER flux or an impairment in the formation of the LCOTHER - sensitive LCGeneOrGeneProduct - LCOTHER LCOTHER .	3
The present study tested the hypothesis that LCOTHER - induced LCChemicalEntity ( LCOTHER ) resistance in skeletal muscle is associated with a down - regulation of LCOTHER LCOTHER LCOTHER important in regulating LCOTHER flux or an impairment in the formation of the LCOTHER - sensitive LCGeneOrGeneProduct - LCOTHER LCOTHER .	2
The present study tested the hypothesis that LCOTHER - induced LCOTHER ( LCChemicalEntity ) resistance in skeletal muscle is associated with a down - regulation of LCOTHER LCOTHER LCOTHER important in regulating LCOTHER flux or an impairment in the formation of the LCOTHER - sensitive LCGeneOrGeneProduct - LCOTHER LCOTHER .	2
The present study tested the hypothesis that LCOTHER - induced LCOTHER ( LCOTHER ) resistance in skeletal muscle is associated with a down - regulation of LCOTHER LCOTHER LCOTHER important in regulating LCChemicalEntity flux or an impairment in the formation of the LCOTHER - sensitive LCGeneOrGeneProduct - LCOTHER LCOTHER .	2
The present study tested the hypothesis that LCOTHER - induced LCOTHER ( LCOTHER ) resistance in skeletal muscle is associated with a down - regulation of LCOTHER LCOTHER LCOTHER important in regulating LCOTHER flux or an impairment in the formation of the LCChemicalEntity - sensitive LCGeneOrGeneProduct - LCOTHER LCOTHER .	2
LCDiseaseOrPhenotypicFeature in adult male LCOTHER decreased basal protein synthesis in gastrocnemius , associated with a reduction in LCGeneOrGeneProduct activation as indicated by decreased LCOTHER - LCOTHER and LCOTHER phosphorylation .	3
LCOTHER in adult male LCOTHER decreased basal protein synthesis in gastrocnemius , associated with a reduction in LCGeneOrGeneProduct activation as indicated by decreased LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER phosphorylation .	1
LCOTHER in adult male LCOTHER decreased basal protein synthesis in gastrocnemius , associated with a reduction in LCGeneOrGeneProduct activation as indicated by decreased LCOTHER - LCOTHER and LCGeneOrGeneProduct phosphorylation .	1
The ability of oral LCChemicalEntity to increase protein synthesis and LCGeneOrGeneProduct kinase after 1 h was largely prevented in LCOTHER .	2
The ability of oral LCChemicalEntity to increase protein synthesis and LCOTHER kinase after 1 h was largely prevented in LCDiseaseOrPhenotypicFeature .	1
LCDiseaseOrPhenotypicFeature increased LCGeneOrGeneProduct , LCOTHER and LCOTHER mRNA content two - to fourfold , but only the protein content for LCOTHER ( 20 % decrease ) differed significantly .	1
LCDiseaseOrPhenotypicFeature increased LCOTHER , LCGeneOrGeneProduct and LCOTHER mRNA content two - to fourfold , but only the protein content for LCOTHER ( 20 % decrease ) differed significantly .	1
LCDiseaseOrPhenotypicFeature increased LCOTHER , LCOTHER and LCGeneOrGeneProduct mRNA content two - to fourfold , but only the protein content for LCOTHER ( 20 % decrease ) differed significantly .	1
LCDiseaseOrPhenotypicFeature increased LCOTHER , LCOTHER and LCOTHER mRNA content two - to fourfold , but only the protein content for LCGeneOrGeneProduct ( 20 % decrease ) differed significantly .	1
There was no LCDiseaseOrPhenotypicFeature or LCOTHER effect on the protein content for LCOTHER - LCOTHER , LCOTHER - LCOTHER LCOTHER - LCOTHER , LCOTHER , LCOTHER or LCGeneOrGeneProduct in muscle .	3
There was no LCOTHER or LCChemicalEntity effect on the protein content for LCOTHER - LCOTHER , LCOTHER - LCOTHER LCOTHER - LCOTHER , LCGeneOrGeneProduct , LCOTHER or LCOTHER in muscle .	1
There was no LCOTHER or LCChemicalEntity effect on the protein content for LCOTHER - LCOTHER , LCOTHER - LCOTHER LCOTHER - LCOTHER , LCOTHER , LCOTHER or LCGeneOrGeneProduct in muscle .	2
The binding of LCGeneOrGeneProduct , LCOTHER and LCOTHER to LCGeneOrGeneProduct did not differ for control and septic muscle in the basal condition ; however , the LCOTHER - induced decrease in LCOTHER LCOTHER and increase in LCOTHER LCOTHER seen in control muscle was absent in LCOTHER .	4
The binding of LCGeneOrGeneProduct , LCOTHER and LCOTHER to LCOTHER did not differ for control and septic muscle in the basal condition ; however , the LCOTHER - induced decrease in LCOTHER LCGeneOrGeneProduct and increase in LCOTHER LCOTHER seen in control muscle was absent in LCOTHER .	4
The binding of LCGeneOrGeneProduct , LCOTHER and LCOTHER to LCOTHER did not differ for control and septic muscle in the basal condition ; however , the LCOTHER - induced decrease in LCOTHER LCOTHER and increase in LCOTHER LCGeneOrGeneProduct seen in control muscle was absent in LCOTHER .	4
The binding of LCOTHER , LCGeneOrGeneProduct and LCOTHER to LCGeneOrGeneProduct did not differ for control and septic muscle in the basal condition ; however , the LCOTHER - induced decrease in LCOTHER LCOTHER and increase in LCOTHER LCOTHER seen in control muscle was absent in LCOTHER .	4
The binding of LCOTHER , LCGeneOrGeneProduct and LCOTHER to LCOTHER did not differ for control and septic muscle in the basal condition ; however , the LCOTHER - induced decrease in LCOTHER LCGeneOrGeneProduct and increase in LCOTHER LCOTHER seen in control muscle was absent in LCOTHER .	4
The binding of LCOTHER , LCGeneOrGeneProduct and LCOTHER to LCOTHER did not differ for control and septic muscle in the basal condition ; however , the LCOTHER - induced decrease in LCOTHER LCOTHER and increase in LCOTHER LCGeneOrGeneProduct seen in control muscle was absent in LCOTHER .	4
The binding of LCOTHER , LCOTHER and LCOTHER to LCGeneOrGeneProduct did not differ for control and septic muscle in the basal condition ; however , the LCOTHER - induced decrease in LCOTHER LCOTHER and increase in LCGeneOrGeneProduct LCOTHER seen in control muscle was absent in LCOTHER .	4
The binding of LCOTHER , LCOTHER and LCOTHER to LCOTHER did not differ for control and septic muscle in the basal condition ; however , the LCChemicalEntity - induced decrease in LCGeneOrGeneProduct LCOTHER and increase in LCOTHER LCOTHER seen in control muscle was absent in LCOTHER .	3
The binding of LCOTHER , LCOTHER and LCOTHER to LCOTHER did not differ for control and septic muscle in the basal condition ; however , the LCChemicalEntity - induced decrease in LCOTHER LCGeneOrGeneProduct and increase in LCOTHER LCOTHER seen in control muscle was absent in LCOTHER .	1
The binding of LCOTHER , LCOTHER and LCOTHER to LCOTHER did not differ for control and septic muscle in the basal condition ; however , the LCChemicalEntity - induced decrease in LCOTHER LCOTHER and increase in LCGeneOrGeneProduct LCOTHER seen in control muscle was absent in LCOTHER .	2
The binding of LCOTHER , LCOTHER and LCOTHER to LCOTHER did not differ for control and septic muscle in the basal condition ; however , the LCChemicalEntity - induced decrease in LCOTHER LCOTHER and increase in LCOTHER LCGeneOrGeneProduct seen in control muscle was absent in LCOTHER .	1
The binding of LCOTHER , LCOTHER and LCOTHER to LCOTHER did not differ for control and septic muscle in the basal condition ; however , the LCChemicalEntity - induced decrease in LCOTHER LCOTHER and increase in LCOTHER LCOTHER seen in control muscle was absent in LCDiseaseOrPhenotypicFeature .	1
The binding of LCOTHER , LCOTHER and LCOTHER to LCOTHER did not differ for control and septic muscle in the basal condition ; however , the LCOTHER - induced decrease in LCGeneOrGeneProduct LCGeneOrGeneProduct and increase in LCOTHER LCOTHER seen in control muscle was absent in LCOTHER .	4
The binding of LCOTHER , LCOTHER and LCOTHER to LCOTHER did not differ for control and septic muscle in the basal condition ; however , the LCOTHER - induced decrease in LCGeneOrGeneProduct LCOTHER and increase in LCOTHER LCGeneOrGeneProduct seen in control muscle was absent in LCOTHER .	4
The binding of LCOTHER , LCOTHER and LCOTHER to LCOTHER did not differ for control and septic muscle in the basal condition ; however , the LCOTHER - induced decrease in LCOTHER LCGeneOrGeneProduct and increase in LCGeneOrGeneProduct LCOTHER seen in control muscle was absent in LCOTHER .	4
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCDiseaseOrPhenotypicFeature - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCGeneOrGeneProduct / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	3
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCDiseaseOrPhenotypicFeature - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCGeneOrGeneProduct and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	3
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCChemicalEntity resistance , the LCOTHER - stimulated binding of LCGeneOrGeneProduct with LCOTHER and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	1
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCChemicalEntity resistance , the LCOTHER - stimulated binding of LCOTHER with LCGeneOrGeneProduct and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	2
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCChemicalEntity resistance , the LCOTHER - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCGeneOrGeneProduct / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	2
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCChemicalEntity resistance , the LCOTHER - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCOTHER / LCGeneOrGeneProduct to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	1
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCChemicalEntity resistance , the LCOTHER - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCGeneOrGeneProduct and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	2
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCChemicalEntity - stimulated binding of LCGeneOrGeneProduct with LCOTHER and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	1
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCChemicalEntity - stimulated binding of LCOTHER with LCGeneOrGeneProduct and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	2
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCChemicalEntity - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCGeneOrGeneProduct / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	2
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCChemicalEntity - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCOTHER / LCGeneOrGeneProduct to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	1
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCChemicalEntity - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCGeneOrGeneProduct and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	2
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCGeneOrGeneProduct with LCGeneOrGeneProduct and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	4
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCGeneOrGeneProduct / LCGeneOrGeneProduct to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	4
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCChemicalEntity to fully activate LCGeneOrGeneProduct and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	2
PURPOSE : Mutations in the LCGeneOrGeneProduct and LCOTHER genes have been reported in LCOTHER with LCDiseaseOrPhenotypicFeature and / or LCOTHER .	1
PURPOSE : Mutations in the LCGeneOrGeneProduct and LCOTHER genes have been reported in LCOTHER with LCOTHER and / or LCDiseaseOrPhenotypicFeature .	1
PURPOSE : Mutations in the LCOTHER and LCGeneOrGeneProduct genes have been reported in LCOTHER with LCDiseaseOrPhenotypicFeature and / or LCOTHER .	1
PURPOSE : Mutations in the LCOTHER and LCGeneOrGeneProduct genes have been reported in LCOTHER with LCOTHER and / or LCDiseaseOrPhenotypicFeature .	1
Loss of LCGeneOrGeneProduct function results in severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
LCGeneOrGeneProduct was not implicated with LCDiseaseOrPhenotypicFeature / LCOTHER in our LCOTHER cohort . Combination of the LCOTHER LCOTHER inhibitor LCOTHER and LCOTHER - LCOTHER upregulates LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER and LCOTHER genes and activates LCOTHER - LCOTHER / LCOTHER in LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER cells .	1
LCGeneOrGeneProduct was not implicated with LCOTHER / LCDiseaseOrPhenotypicFeature in our LCOTHER cohort . Combination of the LCOTHER LCOTHER inhibitor LCOTHER and LCOTHER - LCOTHER upregulates LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER and LCOTHER genes and activates LCOTHER - LCOTHER / LCOTHER in LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER cells .	1
In the present study , we found that a very low concentration of LCChemicalEntity , an LCOTHER inhibitor , potentiated the antitumor activity of LCChemicalEntity - LCChemicalEntity ( LCOTHER - LCOTHER ) in a LCOTHER LCOTHER LCOTHER cell model using LCOTHER - LCOTHER , LCOTHER , and LCOTHER cells via the inhibition of colony formation ability or cellular viability .	5
In the present study , we found that a very low concentration of LCChemicalEntity , an LCOTHER inhibitor , potentiated the antitumor activity of LCOTHER - LCOTHER ( LCChemicalEntity - LCChemicalEntity ) in a LCOTHER LCOTHER LCOTHER cell model using LCOTHER - LCOTHER , LCOTHER , and LCOTHER cells via the inhibition of colony formation ability or cellular viability .	5
In the present study , we found that a very low concentration of LCChemicalEntity , an LCOTHER inhibitor , potentiated the antitumor activity of LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) in a LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell model using LCOTHER - LCOTHER , LCOTHER , and LCOTHER cells via the inhibition of colony formation ability or cellular viability .	3
In the present study , we found that a very low concentration of LCOTHER , an LCOTHER inhibitor , potentiated the antitumor activity of LCChemicalEntity - LCChemicalEntity ( LCOTHER - LCOTHER ) in a LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell model using LCOTHER - LCOTHER , LCOTHER , and LCOTHER cells via the inhibition of colony formation ability or cellular viability .	3
In the present study , we found that a very low concentration of LCOTHER , an LCOTHER inhibitor , potentiated the antitumor activity of LCOTHER - LCOTHER ( LCChemicalEntity - LCChemicalEntity ) in a LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell model using LCOTHER - LCOTHER , LCOTHER , and LCOTHER cells via the inhibition of colony formation ability or cellular viability .	3
Exposure to a combination of LCOTHER - LCOTHER ( 1 . 75 uM ) and 1 nM LCChemicalEntity for 24 and 48 h resulted in a 3 - to 4 - fold increase in activated LCOTHER - LCOTHER / LCOTHER , while LCChemicalEntity - LCChemicalEntity alone failed to activate LCOTHER - LCOTHER / LCOTHER .	5
Microarray and subsequent gene ontology analyses revealed that compared to LCOTHER - LCOTHER or LCChemicalEntity alone , the combination treatment of LCChemicalEntity - LCChemicalEntity and LCOTHER upregulated genes related to cell death and the apoptotic process consistent with the inhibition of colony formation and LCOTHER - LCOTHER / LCOTHER activation .	5
These analyses indicated marked upregulation of antigen processing and presentation of peptide or LCChemicalEntity antigen via LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct ( GO : 0002504 ) and LCOTHER LCOTHER LCOTHER ( GO : 0042611 ) .	1
These analyses indicated marked upregulation of antigen processing and presentation of peptide or LCChemicalEntity antigen via LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER ( GO : 0002504 ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( GO : 0042611 ) .	1
Furthermore , our global analysis of gene expression , which was focused on genes involved in the molecular regulation of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , showed enhancement of pro - apoptotic LCOTHER and LCOTHER after the combination of LCChemicalEntity - LCChemicalEntity and LCOTHER .	2
Furthermore , our global analysis of gene expression , which was focused on genes involved in the molecular regulation of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , showed enhancement of pro - apoptotic LCOTHER and LCOTHER after the combination of LCOTHER - LCOTHER and LCChemicalEntity .	2
These results may indicate a closer relationship between elevation of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct expression and cellular apoptosis induced by the combination of LCChemicalEntity and LCOTHER - LCOTHER .	2
These results may indicate a closer relationship between elevation of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct expression and cellular apoptosis induced by the combination of LCOTHER and LCChemicalEntity - LCChemicalEntity .	2
These results may indicate a closer relationship between elevation of LCOTHER LCOTHER LCOTHER expression and cellular apoptosis induced by the combination of LCChemicalEntity and LCChemicalEntity - LCChemicalEntity .	5
To the best of our knowledge , this is the first study to report that the combination of LCChemicalEntity - LCChemicalEntity and LCOTHER induces LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell apoptosis in a concerted manner with the induction of LCOTHER LCOTHER LCOTHER gene expression . LCOTHER is required for cambium homeostasis in LCOTHER .	3
To the best of our knowledge , this is the first study to report that the combination of LCOTHER - LCOTHER and LCChemicalEntity induces LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell apoptosis in a concerted manner with the induction of LCOTHER LCOTHER LCOTHER gene expression . LCOTHER is required for cambium homeostasis in LCOTHER .	3
By employing promoter reporter lines , we reveal that LCOTHER is active in a domain that is distinct from the domain of the positively acting LCGeneOrGeneProduct / LCGeneOrGeneProduct signaling module .	4
In particular , we show that LCOTHER acts in an opposing manner to the LCGeneOrGeneProduct / LCGeneOrGeneProduct module and that changing the domain or level of LCOTHER expression both result in disturbed cambium organization .	4
Furthermore , LCGeneOrGeneProduct but not LCOTHER is able to rescue LCGeneOrGeneProduct deficiency in the shoot apical meristem .	2
By identifying genes mis - expressed in LCGeneOrGeneProduct mutants , we demonstrate that LCOTHER represses genes associated with stress - related LCChemicalEntity and LCOTHER LCOTHER hormone signaling pathways which have known roles in coordinating lateral growth of the LCOTHER stem .	1
By identifying genes mis - expressed in LCGeneOrGeneProduct mutants , we demonstrate that LCOTHER represses genes associated with stress - related LCOTHER and LCChemicalEntity LCChemicalEntity hormone signaling pathways which have known roles in coordinating lateral growth of the LCOTHER stem .	1
By identifying genes mis - expressed in LCOTHER mutants , we demonstrate that LCGeneOrGeneProduct represses genes associated with stress - related LCChemicalEntity and LCOTHER LCOTHER hormone signaling pathways which have known roles in coordinating lateral growth of the LCOTHER stem .	1
By identifying genes mis - expressed in LCOTHER mutants , we demonstrate that LCGeneOrGeneProduct represses genes associated with stress - related LCOTHER and LCChemicalEntity LCChemicalEntity hormone signaling pathways which have known roles in coordinating lateral growth of the LCOTHER stem .	1
LCOTHER is a rare complication occurring during LCChemicalEntity - LCChemicalEntity ( LCOTHER - LCOTHER ) treatment for LCDiseaseOrPhenotypicFeature .	3
LCOTHER is a rare complication occurring during LCOTHER - LCOTHER ( LCChemicalEntity - LCChemicalEntity ) treatment for LCDiseaseOrPhenotypicFeature .	3
We herein report the case of a 70 - year - old LCOTHER with LCChemicalEntity - LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature , in whom a high serum level of LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCOTHER ) was observed .	2
We herein report the case of a 70 - year - old LCOTHER with LCChemicalEntity - LCChemicalEntity - induced LCOTHER , in whom a high serum level of LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity ( LCOTHER ) was observed .	2
We herein report the case of a 70 - year - old LCOTHER with LCChemicalEntity - LCChemicalEntity - induced LCOTHER , in whom a high serum level of LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCChemicalEntity ) was observed .	2
We herein report the case of a 70 - year - old LCOTHER with LCOTHER - LCOTHER - induced LCDiseaseOrPhenotypicFeature , in whom a high serum level of LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity ( LCOTHER ) was observed .	2
We herein report the case of a 70 - year - old LCOTHER with LCOTHER - LCOTHER - induced LCDiseaseOrPhenotypicFeature , in whom a high serum level of LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCChemicalEntity ) was observed .	2
After admission , the LCOTHER received a continuous intravenous infusion of LCChemicalEntity - LCChemicalEntity ( 1000 mg / day ) , during which LCOTHER LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature occurred concomitantly with a high serum LCOTHER concentration of 1955 ng / ml .	2
After admission , the LCOTHER received a continuous intravenous infusion of LCChemicalEntity - LCChemicalEntity ( 1000 mg / day ) , during which LCOTHER LCOTHER with LCOTHER LCOTHER LCOTHER LCOTHER occurred concomitantly with a high serum LCChemicalEntity concentration of 1955 ng / ml .	2
After admission , the LCOTHER received a continuous intravenous infusion of LCOTHER - LCOTHER ( 1000 mg / day ) , during which LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with LCOTHER LCOTHER LCOTHER LCOTHER occurred concomitantly with a high serum LCChemicalEntity concentration of 1955 ng / ml .	2
After admission , the LCOTHER received a continuous intravenous infusion of LCOTHER - LCOTHER ( 1000 mg / day ) , during which LCOTHER LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature occurred concomitantly with a high serum LCChemicalEntity concentration of 1955 ng / ml .	2
Both the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and the electrocardiographic changes disappeared spontaneously after the discontinuation of LCChemicalEntity - LCChemicalEntity .	2
As the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in this LCOTHER was considered to have been due to LCChemicalEntity - LCChemicalEntity - induced LCOTHER , the administration of LCOTHER - LCOTHER was abandoned .	2
As the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in this LCOTHER was considered to have been due to LCOTHER - LCOTHER - induced LCOTHER , the administration of LCChemicalEntity - LCChemicalEntity was abandoned .	2
As the LCOTHER LCOTHER in this LCOTHER was considered to have been due to LCChemicalEntity - LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature , the administration of LCOTHER - LCOTHER was abandoned .	2
Instead , oral administration of LCChemicalEntity - LCChemicalEntity ( a derivative of LCChemicalEntity - LCChemicalEntity ) , at 200 mg / day twice a week , was instituted , because LCOTHER - LCOTHER has a strong inhibitory effect on LCOTHER dehydrogenase , which catalyzes the degradative of LCOTHER - LCOTHER into LCOTHER .	6
Instead , oral administration of LCChemicalEntity - LCChemicalEntity ( a derivative of LCOTHER - LCOTHER ) , at 200 mg / day twice a week , was instituted , because LCOTHER - LCOTHER has a strong inhibitory effect on LCOTHER dehydrogenase , which catalyzes the degradative of LCChemicalEntity - LCChemicalEntity into LCOTHER .	6
Instead , oral administration of LCOTHER - LCOTHER ( a derivative of LCChemicalEntity - LCChemicalEntity ) , at 200 mg / day twice a week , was instituted , because LCOTHER - LCOTHER has a strong inhibitory effect on LCOTHER dehydrogenase , which catalyzes the degradative of LCOTHER - LCOTHER into LCChemicalEntity .	2
Instead , oral administration of LCOTHER - LCOTHER ( a derivative of LCOTHER - LCOTHER ) , at 200 mg / day twice a week , was instituted , because LCChemicalEntity - LCChemicalEntity has a strong inhibitory effect on LCOTHER dehydrogenase , which catalyzes the degradative of LCChemicalEntity - LCChemicalEntity into LCOTHER .	6
Instead , oral administration of LCOTHER - LCOTHER ( a derivative of LCOTHER - LCOTHER ) , at 200 mg / day twice a week , was instituted , because LCOTHER - LCOTHER has a strong inhibitory effect on LCOTHER dehydrogenase , which catalyzes the degradative of LCChemicalEntity - LCChemicalEntity into LCChemicalEntity .	2
The serum LCChemicalEntity concentration subsequently decreased to 352 ng / ml , the same as the value measured on the first day of LCChemicalEntity - LCChemicalEntity administration .	3
The experience of this case , together with a review of the literature , suggests that LCOTHER is related to LCChemicalEntity - LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature .	2
LCChemicalEntity - LCChemicalEntity may be administered safely to LCOTHER with LCChemicalEntity - LCChemicalEntity - induced LCOTHER . Hypoglycemic Effect of Combined LCOTHER and LCOTHER LCOTHER Blockade .	6
LCOTHER - LCOTHER may be administered safely to LCOTHER with LCChemicalEntity - LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature . Hypoglycemic Effect of Combined LCOTHER and LCOTHER LCOTHER Blockade .	2
LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) blockade has been proposed as an alternative to LCOTHER monotherapy for treating LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature since deletion or inhibition of LCOTHER corrects LCOTHER in models of LCOTHER .	1
LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) blockade has been proposed as an alternative to LCOTHER monotherapy for treating LCOTHER LCOTHER LCOTHER since deletion or inhibition of LCOTHER corrects LCDiseaseOrPhenotypicFeature in models of LCOTHER .	1
LCOTHER LCOTHER ( LCGeneOrGeneProduct ) blockade has been proposed as an alternative to LCOTHER monotherapy for treating LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature since deletion or inhibition of LCOTHER corrects LCOTHER in models of LCOTHER .	1
LCOTHER LCOTHER ( LCGeneOrGeneProduct ) blockade has been proposed as an alternative to LCOTHER monotherapy for treating LCOTHER LCOTHER LCOTHER since deletion or inhibition of LCOTHER corrects LCDiseaseOrPhenotypicFeature in models of LCOTHER .	1
LCOTHER LCOTHER ( LCOTHER ) blockade has been proposed as an alternative to LCGeneOrGeneProduct monotherapy for treating LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature since deletion or inhibition of LCOTHER corrects LCOTHER in models of LCOTHER .	3
LCOTHER LCOTHER ( LCOTHER ) blockade has been proposed as an alternative to LCOTHER monotherapy for treating LCOTHER LCOTHER LCOTHER since deletion or inhibition of LCGeneOrGeneProduct corrects LCDiseaseOrPhenotypicFeature in models of LCOTHER .	1
Not only is LCGeneOrGeneProduct release controlled by LCChemicalEntity but also LCOTHER has many actions that can raise or reduce falls in LCOTHER LCOTHER level .	1
Not only is LCGeneOrGeneProduct release controlled by LCOTHER but also LCOTHER has many actions that can raise or reduce falls in LCChemicalEntity LCChemicalEntity level .	1
Not only is LCOTHER release controlled by LCOTHER but also LCGeneOrGeneProduct has many actions that can raise or reduce falls in LCChemicalEntity LCChemicalEntity level .	1
Here , we tested the hypothesis that LCGeneOrGeneProduct rises to prevent LCDiseaseOrPhenotypicFeature in the absence of LCOTHER function .	3
Although treatment with the pancreatic b - cell toxin LCChemicalEntity induced LCDiseaseOrPhenotypicFeature and raised plasma LCOTHER levels in wild - type LCOTHER , LCOTHER was averted in similarly treated LCOTHER ( - / - ) LCOTHER and the plasma LCOTHER level was further increased .	2
Although treatment with the pancreatic b - cell toxin LCChemicalEntity induced LCOTHER and raised plasma LCGeneOrGeneProduct levels in wild - type LCOTHER , LCOTHER was averted in similarly treated LCOTHER ( - / - ) LCOTHER and the plasma LCOTHER level was further increased .	2
Although treatment with the pancreatic b - cell toxin LCChemicalEntity induced LCOTHER and raised plasma LCOTHER levels in wild - type LCOTHER , LCDiseaseOrPhenotypicFeature was averted in similarly treated LCOTHER ( - / - ) LCOTHER and the plasma LCOTHER level was further increased .	2
Although treatment with the pancreatic b - cell toxin LCChemicalEntity induced LCOTHER and raised plasma LCOTHER levels in wild - type LCOTHER , LCOTHER was averted in similarly treated LCOTHER ( - / - ) LCOTHER and the plasma LCGeneOrGeneProduct level was further increased .	2
Notably , administration of a LCOTHER LCOTHER antagonist further reduced LCChemicalEntity LCChemicalEntity levels into the markedly hypoglycemic range in overnight - fasted , LCChemicalEntity - treated LCOTHER ( - / - ) LCOTHER .	3
Notably , administration of a LCOTHER LCOTHER antagonist further reduced LCChemicalEntity LCChemicalEntity levels into the markedly hypoglycemic range in overnight - fasted , LCOTHER - treated LCGeneOrGeneProduct ( - / - ) LCOTHER .	3
A lowered LCChemicalEntity LCChemicalEntity level also was observed in overnight - fasted , LCChemicalEntity - treated LCOTHER LCOTHER - null LCOTHER that were administered LCOTHER monoclonal antibody .	3
A lowered LCChemicalEntity LCChemicalEntity level also was observed in overnight - fasted , LCOTHER - treated LCGeneOrGeneProduct LCGeneOrGeneProduct - null LCOTHER that were administered LCOTHER monoclonal antibody .	1
A lowered LCChemicalEntity LCChemicalEntity level also was observed in overnight - fasted , LCOTHER - treated LCOTHER LCOTHER - null LCOTHER that were administered LCGeneOrGeneProduct monoclonal antibody .	3
These data suggest that when LCGeneOrGeneProduct activity is blocked in the setting of LCOTHER LCOTHER LCOTHER , the plasma LCGeneOrGeneProduct level rises , preventing LCOTHER . LCOTHER - LCOTHER , a LCOTHER ( LCOTHER ) LCOTHER , functions as a LCOTHER suppressor in an orthotopic LCOTHER LCOTHER LCOTHER model .	3
These data suggest that when LCGeneOrGeneProduct activity is blocked in the setting of LCOTHER LCOTHER LCOTHER , the plasma LCOTHER level rises , preventing LCDiseaseOrPhenotypicFeature . LCOTHER - LCOTHER , a LCOTHER ( LCOTHER ) LCOTHER , functions as a LCOTHER suppressor in an orthotopic LCOTHER LCOTHER LCOTHER model .	1
These data suggest that when LCOTHER activity is blocked in the setting of LCOTHER LCOTHER LCOTHER , the plasma LCGeneOrGeneProduct level rises , preventing LCDiseaseOrPhenotypicFeature . LCOTHER - LCOTHER , a LCOTHER ( LCOTHER ) LCOTHER , functions as a LCOTHER suppressor in an orthotopic LCOTHER LCOTHER LCOTHER model .	3
However , the pathological role of LCGeneOrGeneProduct - LCGeneOrGeneProduct in LCDiseaseOrPhenotypicFeature largely remains unknown .	3
In this study , we observed decreased expression of LCGeneOrGeneProduct - LCGeneOrGeneProduct in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell lines and tissues .	1
Ectopic LCGeneOrGeneProduct - LCGeneOrGeneProduct expression inhibited proliferation as well as colony - forming ability of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cells .	1
Moreover , by regulating the expression of LCGeneOrGeneProduct ( LCOTHER - LCOTHER LCOTHER ) , LCGeneOrGeneProduct - LCGeneOrGeneProduct induced apoptosis of LCOTHER LCOTHER cells through the mitochondrial pathway .	1
Moreover , by regulating the expression of LCGeneOrGeneProduct ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER - LCOTHER induced apoptosis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cells through the mitochondrial pathway .	1
Moreover , by regulating the expression of LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ) , LCGeneOrGeneProduct - LCGeneOrGeneProduct induced apoptosis of LCOTHER LCOTHER cells through the mitochondrial pathway .	1
Moreover , by regulating the expression of LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ) , LCOTHER - LCOTHER induced apoptosis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cells through the mitochondrial pathway .	1
Moreover , by regulating the expression of LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCGeneOrGeneProduct - LCGeneOrGeneProduct induced apoptosis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cells through the mitochondrial pathway .	1
The growth of LCOTHER LCOTHER xenografts in NOD / LCOTHER LCOTHER was also inhibited by the LCChemicalEntity - induced LCGeneOrGeneProduct - LCGeneOrGeneProduct overexpression .	2
Furthermore , LCGeneOrGeneProduct - LCGeneOrGeneProduct sensitized LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cells to chemotherapy drugs both in vitro and in vivo .	1
These findings suggested that LCGeneOrGeneProduct - LCGeneOrGeneProduct possesses LCDiseaseOrPhenotypicFeature - suppressing activity and can be a valuable target for developing new LCOTHER therapeutic strategies . Chronic treatment with LCOTHER suppresses LCOTHER - LCOTHER LCOTHER LCOTHER signaling and attenuates LCOTHER LCOTHER LCOTHER following LCOTHER LCOTHER .	3
These findings suggested that LCGeneOrGeneProduct - LCGeneOrGeneProduct possesses LCOTHER - suppressing activity and can be a valuable target for developing new LCDiseaseOrPhenotypicFeature therapeutic strategies . Chronic treatment with LCOTHER suppresses LCOTHER - LCOTHER LCOTHER LCOTHER signaling and attenuates LCOTHER LCOTHER LCOTHER following LCOTHER LCOTHER .	3
Acute treatment with LCChemicalEntity has a protective effect in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature by suppression of LCOTHER responses due to activation of LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	3
Acute treatment with LCChemicalEntity has a protective effect in LCOTHER LCOTHER by suppression of LCDiseaseOrPhenotypicFeature responses due to activation of LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	3
Acute treatment with LCChemicalEntity has a protective effect in LCOTHER LCOTHER by suppression of LCOTHER responses due to activation of LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	2
Acute treatment with LCChemicalEntity has a protective effect in LCOTHER LCOTHER by suppression of LCOTHER responses due to activation of LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	2
In the present study , the effect of chronic pre - treatment with LCChemicalEntity on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) activities following LCOTHER LCOTHER and their relation with LCOTHER were assessed .	3
In the present study , the effect of chronic pre - treatment with LCChemicalEntity on LCOTHER LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) activities following LCOTHER LCOTHER and their relation with LCOTHER were assessed .	3
In the present study , the effect of chronic pre - treatment with LCChemicalEntity on LCOTHER LCOTHER and LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) activities following LCOTHER LCOTHER and their relation with LCOTHER were assessed .	3
In the present study , the effect of chronic pre - treatment with LCChemicalEntity on LCOTHER LCOTHER and LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) activities following LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and their relation with LCOTHER were assessed .	3
In the present study , the effect of chronic pre - treatment with LCChemicalEntity on LCOTHER LCOTHER and LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) activities following LCOTHER LCOTHER and their relation with LCGeneOrGeneProduct were assessed .	2
In the present study , the effect of chronic pre - treatment with LCOTHER on LCOTHER LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) activities following LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and their relation with LCOTHER were assessed .	1
In the present study , the effect of chronic pre - treatment with LCOTHER on LCOTHER LCOTHER and LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) activities following LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and their relation with LCOTHER were assessed .	1
LCChemicalEntity ( 100mg / kg ) was injected subcutaneously on the 13th and 14th days to induce LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
LCChemicalEntity markedly lowered LCChemicalEntity - induced elevation in the levels of LCOTHER mRNA , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) , and LCOTHER LCOTHER ( LCOTHER - LCOTHER ) in the heart tissues .	3
LCChemicalEntity markedly lowered LCOTHER - induced elevation in the levels of LCGeneOrGeneProduct mRNA , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) , and LCOTHER LCOTHER ( LCOTHER - LCOTHER ) in the heart tissues .	3
LCChemicalEntity markedly lowered LCOTHER - induced elevation in the levels of LCOTHER mRNA , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) , and LCOTHER LCOTHER ( LCOTHER - LCOTHER ) in the heart tissues .	3
LCChemicalEntity markedly lowered LCOTHER - induced elevation in the levels of LCOTHER mRNA , LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) , and LCOTHER LCOTHER ( LCOTHER - LCOTHER ) in the heart tissues .	3
LCChemicalEntity markedly lowered LCOTHER - induced elevation in the levels of LCOTHER mRNA , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) , and LCOTHER LCOTHER ( LCOTHER - LCOTHER ) in the heart tissues .	3
LCChemicalEntity markedly lowered LCOTHER - induced elevation in the levels of LCOTHER mRNA , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) , and LCOTHER LCOTHER ( LCOTHER - LCOTHER ) in the heart tissues .	3
LCChemicalEntity markedly lowered LCOTHER - induced elevation in the levels of LCOTHER mRNA , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) , and LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) in the heart tissues .	3
LCChemicalEntity markedly lowered LCOTHER - induced elevation in the levels of LCOTHER mRNA , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) , and LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) in the heart tissues .	3
LCOTHER markedly lowered LCChemicalEntity - induced elevation in the levels of LCGeneOrGeneProduct mRNA , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) , and LCOTHER LCOTHER ( LCOTHER - LCOTHER ) in the heart tissues .	2
LCOTHER markedly lowered LCChemicalEntity - induced elevation in the levels of LCOTHER mRNA , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) , and LCOTHER LCOTHER ( LCOTHER - LCOTHER ) in the heart tissues .	2
LCOTHER markedly lowered LCChemicalEntity - induced elevation in the levels of LCOTHER mRNA , LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) , and LCOTHER LCOTHER ( LCOTHER - LCOTHER ) in the heart tissues .	2
LCOTHER markedly lowered LCChemicalEntity - induced elevation in the levels of LCOTHER mRNA , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) , and LCOTHER LCOTHER ( LCOTHER - LCOTHER ) in the heart tissues .	2
LCOTHER markedly lowered LCChemicalEntity - induced elevation in the levels of LCOTHER mRNA , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) , and LCOTHER LCOTHER ( LCOTHER - LCOTHER ) in the heart tissues .	2
LCOTHER markedly lowered LCChemicalEntity - induced elevation in the levels of LCOTHER mRNA , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) , and LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) in the heart tissues .	2
LCOTHER markedly lowered LCChemicalEntity - induced elevation in the levels of LCOTHER mRNA , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) , and LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) in the heart tissues .	2
Chronic pre - treatment with LCChemicalEntity reduces post - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER LCOTHER and suppresses LCOTHER responses , possibly through inhibition of LCOTHER activities .	3
Chronic pre - treatment with LCChemicalEntity reduces post - LCOTHER LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and suppresses LCOTHER responses , possibly through inhibition of LCOTHER activities .	3
Chronic pre - treatment with LCChemicalEntity reduces post - LCOTHER LCOTHER LCOTHER LCOTHER and suppresses LCDiseaseOrPhenotypicFeature responses , possibly through inhibition of LCOTHER activities .	3
Chronic pre - treatment with LCChemicalEntity reduces post - LCOTHER LCOTHER LCOTHER LCOTHER and suppresses LCOTHER responses , possibly through inhibition of LCGeneOrGeneProduct activities .	3
Previous studies have shown that genetic disorders of LCGeneOrGeneProduct may contribute to the pathogenesis of LCDiseaseOrPhenotypicFeature , but LCOTHER may not be caused by LCOTHER gene mutations in Chinese LCOTHER .	1
Previous studies have shown that genetic disorders of LCGeneOrGeneProduct may contribute to the pathogenesis of LCOTHER , but LCDiseaseOrPhenotypicFeature may not be caused by LCOTHER gene mutations in Chinese LCOTHER .	1
This study investigated the association of a new variant of LCGeneOrGeneProduct with LCDiseaseOrPhenotypicFeature in a Chinese family .	1
METHODS : The LCGeneOrGeneProduct gene in a family with 4 LCDiseaseOrPhenotypicFeature LCOTHER was sequenced .	1
RESULTS : A novel point mutation in exon 4 of the LCGeneOrGeneProduct gene was identified in all 4 LCDiseaseOrPhenotypicFeature LCOTHER and 1 asymptomatic family member .	1
CONCLUSION : The results of this study suggest that LCGeneOrGeneProduct ( LCOTHER LCOTHER LCOTHER ) is a novel LCOTHER variant that etiologically related to LCDiseaseOrPhenotypicFeature .	1
CONCLUSION : The results of this study suggest that LCOTHER ( LCSequenceVariant LCSequenceVariant LCSequenceVariant ) is a novel LCOTHER variant that etiologically related to LCDiseaseOrPhenotypicFeature .	1
CONCLUSION : The results of this study suggest that LCOTHER ( LCOTHER LCOTHER LCOTHER ) is a novel LCGeneOrGeneProduct variant that etiologically related to LCDiseaseOrPhenotypicFeature .	1
This variant ( LCGeneOrGeneProduct Guangzhou ) may cause a marked molecular conformational change of the LCOTHER and thus impair its binding ability to LCChemicalEntity . A two base pair deletion in the LCOTHER gene is associated with LCOTHER , LCOTHER , and LCOTHER LCOTHER .	4
This variant ( LCOTHER Guangzhou ) may cause a marked molecular conformational change of the LCGeneOrGeneProduct and thus impair its binding ability to LCChemicalEntity . A two base pair deletion in the LCOTHER gene is associated with LCOTHER , LCOTHER , and LCOTHER LCOTHER .	4
LCOTHER - LCOTHER LCOTHER LCOTHER has been traditionally divided into syndromic ( S - LCOTHER ) and non - syndromic forms ( NS - LCOTHER ) , although the borderlines between these phenotypes begin to vanish and mutations in a single gene , for example LCGeneOrGeneProduct , can cause S - LCDiseaseOrPhenotypicFeature as well as NS - LCOTHER .	1
LCOTHER - LCOTHER LCOTHER LCOTHER has been traditionally divided into syndromic ( S - LCOTHER ) and non - syndromic forms ( NS - LCOTHER ) , although the borderlines between these phenotypes begin to vanish and mutations in a single gene , for example LCGeneOrGeneProduct , can cause S - LCOTHER as well as NS - LCDiseaseOrPhenotypicFeature .	1
A missense mutation in LCGeneOrGeneProduct was described in a family with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , a phenotype showing substantial overlapping features with that described in the two cousins .	1
In summary , our findings demonstrate for the first time that mutations in LCGeneOrGeneProduct are associated with an S - LCDiseaseOrPhenotypicFeature phenotype including LCOTHER , thereby further extending the clinical spectrum of phenotypes associated with LCOTHER mutations . Genetic investigation of the LCOTHER gene in LCOTHER LCOTHER LCOTHER LCOTHER .	1
In summary , our findings demonstrate for the first time that mutations in LCGeneOrGeneProduct are associated with an S - LCOTHER phenotype including LCDiseaseOrPhenotypicFeature , thereby further extending the clinical spectrum of phenotypes associated with LCOTHER mutations . Genetic investigation of the LCOTHER gene in LCOTHER LCOTHER LCOTHER LCOTHER .	1
Recently , a lethal phenotype characterized by LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) was identified to be caused by loss of function mutations in the LCGeneOrGeneProduct gene .	1
Recently , a lethal phenotype characterized by LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) was identified to be caused by loss of function mutations in the LCGeneOrGeneProduct gene .	1
Because LCDiseaseOrPhenotypicFeature is the result of homozygous LCGeneOrGeneProduct mutations , this heterozygous exchange cannot solely explain the LCOTHER LCOTHER in this child .	1
The reported mutation associated with LCDiseaseOrPhenotypicFeature ( LCSequenceVariant ) was not detectable in our cohort .	2
Often , chemotherapy by LCChemicalEntity ( LCOTHER ) is limited due to life threatening LCDiseaseOrPhenotypicFeature in patients during and posttherapy .	2
Often , chemotherapy by LCOTHER ( LCChemicalEntity ) is limited due to life threatening LCDiseaseOrPhenotypicFeature in patients during and posttherapy .	2
Recently , we have shown that moderate diet restriction remarkably protects against LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature .	2
This cardioprotection is accompanied by decreased cardiac oxidative stress and LCOTHER and increased cardiac LCOTHER - LCOTHER oxidation , LCOTHER synthesis , and upregulated LCGeneOrGeneProduct / LCGeneOrGeneProduct pathway .	1
In the current study , we investigated whether a physiological intervention by feeding 40% high LCChemicalEntity diet ( HFD ) , which induces LCDiseaseOrPhenotypicFeature in male Sprague - Dawley LCOTHER ( 250 - 275 g ) , sensitizes to LCOTHER - induced LCOTHER .	2
In the current study , we investigated whether a physiological intervention by feeding 40% high LCOTHER diet ( HFD ) , which induces LCDiseaseOrPhenotypicFeature in male Sprague - Dawley LCOTHER ( 250 - 275 g ) , sensitizes to LCChemicalEntity - induced LCOTHER .	2
In the current study , we investigated whether a physiological intervention by feeding 40% high LCOTHER diet ( HFD ) , which induces LCOTHER in male Sprague - Dawley LCOTHER ( 250 - 275 g ) , sensitizes to LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature .	2
A LD ( 10 ) dose ( 8 mg LCChemicalEntity / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER , LCOTHER peroxidation , and 80% mortality in the LCOTHER ( LCOTHER ) LCOTHER in the absence of any significant LCOTHER LCOTHER LCOTHER LCOTHER .	2
A LD ( 10 ) dose ( 8 mg LCChemicalEntity / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER peroxidation , and 80% mortality in the LCOTHER ( LCOTHER ) LCOTHER in the absence of any significant LCOTHER LCOTHER LCOTHER LCOTHER .	2
A LD ( 10 ) dose ( 8 mg LCChemicalEntity / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher LCOTHER , LCOTHER LCOTHER , LCChemicalEntity peroxidation , and 80% mortality in the LCOTHER ( LCOTHER ) LCOTHER in the absence of any significant LCOTHER LCOTHER LCOTHER LCOTHER .	1
Mechanistic studies revealed that LCDiseaseOrPhenotypicFeature LCOTHER are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct , ( 3 ) decreased plasma LCOTHER levels , ( 4 ) decreased cardiac LCOTHER - LCOTHER oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCOTHER ) , ( 5 ) decreased mitochondrial LCOTHER - LCOTHER LCOTHER LCOTHER , and ( 6 ) 86% drop in cardiac LCOTHER levels accompanied by decreased LCOTHER / LCOTHER ratio after LCOTHER administration .	1
Mechanistic studies revealed that LCDiseaseOrPhenotypicFeature LCOTHER are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER , ( 3 ) decreased plasma LCGeneOrGeneProduct levels , ( 4 ) decreased cardiac LCOTHER - LCOTHER oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCOTHER ) , ( 5 ) decreased mitochondrial LCOTHER - LCOTHER LCOTHER LCOTHER , and ( 6 ) 86% drop in cardiac LCOTHER levels accompanied by decreased LCOTHER / LCOTHER ratio after LCOTHER administration .	1
Mechanistic studies revealed that LCDiseaseOrPhenotypicFeature LCOTHER are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER , ( 3 ) decreased plasma LCOTHER levels , ( 4 ) decreased cardiac LCOTHER - LCOTHER oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCOTHER ) , ( 5 ) decreased mitochondrial LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , and ( 6 ) 86% drop in cardiac LCOTHER levels accompanied by decreased LCOTHER / LCOTHER ratio after LCOTHER administration .	1
Mechanistic studies revealed that LCDiseaseOrPhenotypicFeature LCOTHER are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER , ( 3 ) decreased plasma LCOTHER levels , ( 4 ) decreased cardiac LCOTHER - LCOTHER oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCOTHER ) , ( 5 ) decreased mitochondrial LCOTHER - LCOTHER LCOTHER LCOTHER , and ( 6 ) 86% drop in cardiac LCChemicalEntity levels accompanied by decreased LCOTHER / LCOTHER ratio after LCOTHER administration .	3
Mechanistic studies revealed that LCDiseaseOrPhenotypicFeature LCOTHER are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER , ( 3 ) decreased plasma LCOTHER levels , ( 4 ) decreased cardiac LCOTHER - LCOTHER oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCOTHER ) , ( 5 ) decreased mitochondrial LCOTHER - LCOTHER LCOTHER LCOTHER , and ( 6 ) 86% drop in cardiac LCOTHER levels accompanied by decreased LCChemicalEntity / LCOTHER ratio after LCOTHER administration .	3
Mechanistic studies revealed that LCDiseaseOrPhenotypicFeature LCOTHER are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER , ( 3 ) decreased plasma LCOTHER levels , ( 4 ) decreased cardiac LCOTHER - LCOTHER oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCOTHER ) , ( 5 ) decreased mitochondrial LCOTHER - LCOTHER LCOTHER LCOTHER , and ( 6 ) 86% drop in cardiac LCOTHER levels accompanied by decreased LCOTHER / LCOTHER ratio after LCChemicalEntity administration .	2
Mechanistic studies revealed that LCOTHER LCOTHER are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER , ( 3 ) decreased plasma LCOTHER levels , ( 4 ) decreased cardiac LCChemicalEntity - LCChemicalEntity oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCDiseaseOrPhenotypicFeature ) , ( 5 ) decreased mitochondrial LCOTHER - LCOTHER LCOTHER LCOTHER , and ( 6 ) 86% drop in cardiac LCOTHER levels accompanied by decreased LCOTHER / LCOTHER ratio after LCOTHER administration .	1
Mechanistic studies revealed that LCOTHER LCOTHER are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER , ( 3 ) decreased plasma LCOTHER levels , ( 4 ) decreased cardiac LCOTHER - LCOTHER oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCDiseaseOrPhenotypicFeature ) , ( 5 ) decreased mitochondrial LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , and ( 6 ) 86% drop in cardiac LCOTHER levels accompanied by decreased LCOTHER / LCOTHER ratio after LCOTHER administration .	1
Mechanistic studies revealed that LCOTHER LCOTHER are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER , ( 3 ) decreased plasma LCOTHER levels , ( 4 ) decreased cardiac LCOTHER - LCOTHER oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCDiseaseOrPhenotypicFeature ) , ( 5 ) decreased mitochondrial LCOTHER - LCOTHER LCOTHER LCOTHER , and ( 6 ) 86% drop in cardiac LCChemicalEntity levels accompanied by decreased LCOTHER / LCOTHER ratio after LCOTHER administration .	3
Mechanistic studies revealed that LCOTHER LCOTHER are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER , ( 3 ) decreased plasma LCOTHER levels , ( 4 ) decreased cardiac LCOTHER - LCOTHER oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCDiseaseOrPhenotypicFeature ) , ( 5 ) decreased mitochondrial LCOTHER - LCOTHER LCOTHER LCOTHER , and ( 6 ) 86% drop in cardiac LCOTHER levels accompanied by decreased LCChemicalEntity / LCOTHER ratio after LCOTHER administration .	3
Mechanistic studies revealed that LCOTHER LCOTHER are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER , ( 3 ) decreased plasma LCOTHER levels , ( 4 ) decreased cardiac LCOTHER - LCOTHER oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCDiseaseOrPhenotypicFeature ) , ( 5 ) decreased mitochondrial LCOTHER - LCOTHER LCOTHER LCOTHER , and ( 6 ) 86% drop in cardiac LCOTHER levels accompanied by decreased LCOTHER / LCOTHER ratio after LCChemicalEntity administration .	2
Decreased cardiac LCGeneOrGeneProduct and increased LCOTHER further downregulated the cardioprotective LCGeneOrGeneProduct / LCOTHER pathway .	2
Decreased cardiac LCGeneOrGeneProduct and increased LCOTHER further downregulated the cardioprotective LCOTHER / LCGeneOrGeneProduct pathway .	2
Decreased cardiac LCOTHER and increased LCGeneOrGeneProduct further downregulated the cardioprotective LCGeneOrGeneProduct / LCOTHER pathway .	3
Decreased cardiac LCOTHER and increased LCGeneOrGeneProduct further downregulated the cardioprotective LCOTHER / LCGeneOrGeneProduct pathway .	3
Decreased cardiac LCOTHER and increased LCOTHER further downregulated the cardioprotective LCGeneOrGeneProduct / LCGeneOrGeneProduct pathway .	1
In conclusion , HFD - induced LCDiseaseOrPhenotypicFeature LCOTHER are highly sensitized to LCChemicalEntity - induced LCOTHER by substantially downregulating cardiac mitochondrial LCOTHER generation , increasing oxidative stress and downregulating the LCOTHER / LCOTHER pathway . Risks and benefits of LCOTHER - LCOTHER LCOTHER vs non - selective LCOTHER : does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study .	2
In conclusion , HFD - induced LCDiseaseOrPhenotypicFeature LCOTHER are highly sensitized to LCOTHER - induced LCOTHER by substantially downregulating cardiac mitochondrial LCChemicalEntity generation , increasing oxidative stress and downregulating the LCOTHER / LCOTHER pathway . Risks and benefits of LCOTHER - LCOTHER LCOTHER vs non - selective LCOTHER : does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study .	3
In conclusion , HFD - induced LCOTHER LCOTHER are highly sensitized to LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature by substantially downregulating cardiac mitochondrial LCOTHER generation , increasing oxidative stress and downregulating the LCOTHER / LCOTHER pathway . Risks and benefits of LCOTHER - LCOTHER LCOTHER vs non - selective LCOTHER : does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study .	2
In conclusion , HFD - induced LCOTHER LCOTHER are highly sensitized to LCChemicalEntity - induced LCOTHER by substantially downregulating cardiac mitochondrial LCChemicalEntity generation , increasing oxidative stress and downregulating the LCOTHER / LCOTHER pathway . Risks and benefits of LCOTHER - LCOTHER LCOTHER vs non - selective LCOTHER : does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study .	3
In conclusion , HFD - induced LCOTHER LCOTHER are highly sensitized to LCOTHER - induced LCOTHER by substantially downregulating cardiac mitochondrial LCOTHER generation , increasing oxidative stress and downregulating the LCGeneOrGeneProduct / LCGeneOrGeneProduct pathway . Risks and benefits of LCOTHER - LCOTHER LCOTHER vs non - selective LCOTHER : does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study .	1
OBJECTIVES : The risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) with LCChemicalEntity - LCChemicalEntity LCChemicalEntity may offset their gastrointestinal ( GI ) benefit compared with non - selective ( NS ) LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER ( LCOTHER ) .	2
OBJECTIVES : The risk of LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) with LCChemicalEntity - LCChemicalEntity LCChemicalEntity may offset their gastrointestinal ( GI ) benefit compared with non - selective ( NS ) LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER ( LCOTHER ) .	2
OBJECTIVES : The risk of LCOTHER LCOTHER LCOTHER ( LCOTHER ) with LCChemicalEntity - LCChemicalEntity LCChemicalEntity may offset their gastrointestinal ( GI ) benefit compared with non - selective ( NS ) LCChemicalEntity - LCChemicalEntity LCChemicalEntity - LCChemicalEntity LCChemicalEntity ( LCOTHER ) .	6
OBJECTIVES : The risk of LCOTHER LCOTHER LCOTHER ( LCOTHER ) with LCChemicalEntity - LCChemicalEntity LCChemicalEntity may offset their gastrointestinal ( GI ) benefit compared with non - selective ( NS ) LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER ( LCChemicalEntity ) .	6
We aimed to compare the risks of hospitalization for LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER among elderly patients using LCChemicalEntity - LCChemicalEntity LCChemicalEntity , NS - LCOTHER and LCOTHER .	2
We aimed to compare the risks of hospitalization for LCOTHER and LCOTHER LCOTHER among elderly patients using LCChemicalEntity - LCChemicalEntity LCChemicalEntity , NS - LCChemicalEntity and LCOTHER .	6
We aimed to compare the risks of hospitalization for LCOTHER and LCOTHER LCOTHER among elderly patients using LCChemicalEntity - LCChemicalEntity LCChemicalEntity , NS - LCOTHER and LCChemicalEntity .	6
We aimed to compare the risks of hospitalization for LCOTHER and LCOTHER LCOTHER among elderly patients using LCOTHER - LCOTHER LCOTHER , NS - LCChemicalEntity and LCChemicalEntity .	6
METHODS : We conducted a retrospective cohort study using administrative data of patients > or = 65 years of age who filled a prescription for LCChemicalEntity or LCChemicalEntity during 1999 - 2002 .	6
RESULTS : Person - years of exposure among non - users of LCChemicalEntity were : 75 , 761 to LCChemicalEntity , 42 , 671 to LCOTHER 65 , 860 to LCOTHER , and 37 , 495 to NS - LCOTHER .	3
RESULTS : Person - years of exposure among non - users of LCChemicalEntity were : 75 , 761 to LCOTHER , 42 , 671 to LCChemicalEntity 65 , 860 to LCOTHER , and 37 , 495 to NS - LCOTHER .	3
RESULTS : Person - years of exposure among non - users of LCChemicalEntity were : 75 , 761 to LCOTHER , 42 , 671 to LCOTHER 65 , 860 to LCChemicalEntity , and 37 , 495 to NS - LCOTHER .	3
RESULTS : Person - years of exposure among non - users of LCChemicalEntity were : 75 , 761 to LCOTHER , 42 , 671 to LCOTHER 65 , 860 to LCOTHER , and 37 , 495 to NS - LCChemicalEntity .	3
Among users of LCChemicalEntity , they were : 14 , 671 to LCChemicalEntity , 22 , 875 to LCOTHER , 9 , 832 to NS - LCOTHER and 38 , 048 to LCOTHER .	3
Among users of LCChemicalEntity , they were : 14 , 671 to LCOTHER , 22 , 875 to LCChemicalEntity , 9 , 832 to NS - LCOTHER and 38 , 048 to LCOTHER .	3
Among users of LCChemicalEntity , they were : 14 , 671 to LCOTHER , 22 , 875 to LCOTHER , 9 , 832 to NS - LCChemicalEntity and 38 , 048 to LCOTHER .	3
Among users of LCChemicalEntity , they were : 14 , 671 to LCOTHER , 22 , 875 to LCOTHER , 9 , 832 to NS - LCOTHER and 38 , 048 to LCChemicalEntity .	3
Among users of LCOTHER , they were : 14 , 671 to LCOTHER , 22 , 875 to LCOTHER , 9 , 832 to NS - LCChemicalEntity and 38 , 048 to LCChemicalEntity .	6
Among non - users of LCChemicalEntity , the adjusted hazard ratios ( 95% confidence interval ) of hospitalization for LCOTHER / GI vs the LCChemicalEntity ( with no LCOTHER ) group were : LCOTHER 1 . 27 ( 1 . 13 , 1 . 42 ) , LCOTHER 0 . 93 ( 0 . 83 , 1 . 03 ) , LCOTHER 1 . 59 ( 1 . 31 , 1 . 93 ) , LCOTHER 1 . 17 ( 0 . 99 , 1 . 38 ) and LCOTHER 1 . 05 ( 0 . 74 , 1 . 51 ) .	3
Among non - users of LCChemicalEntity , the adjusted hazard ratios ( 95% confidence interval ) of hospitalization for LCOTHER / GI vs the LCOTHER ( with no LCOTHER ) group were : LCChemicalEntity 1 . 27 ( 1 . 13 , 1 . 42 ) , LCOTHER 0 . 93 ( 0 . 83 , 1 . 03 ) , LCOTHER 1 . 59 ( 1 . 31 , 1 . 93 ) , LCOTHER 1 . 17 ( 0 . 99 , 1 . 38 ) and LCOTHER 1 . 05 ( 0 . 74 , 1 . 51 ) .	3
Among non - users of LCChemicalEntity , the adjusted hazard ratios ( 95% confidence interval ) of hospitalization for LCOTHER / GI vs the LCOTHER ( with no LCOTHER ) group were : LCOTHER 1 . 27 ( 1 . 13 , 1 . 42 ) , LCChemicalEntity 0 . 93 ( 0 . 83 , 1 . 03 ) , LCOTHER 1 . 59 ( 1 . 31 , 1 . 93 ) , LCOTHER 1 . 17 ( 0 . 99 , 1 . 38 ) and LCOTHER 1 . 05 ( 0 . 74 , 1 . 51 ) .	3
Among non - users of LCOTHER , the adjusted hazard ratios ( 95% confidence interval ) of hospitalization for LCOTHER / GI vs the LCOTHER ( with no LCChemicalEntity ) group were : LCChemicalEntity 1 . 27 ( 1 . 13 , 1 . 42 ) , LCOTHER 0 . 93 ( 0 . 83 , 1 . 03 ) , LCOTHER 1 . 59 ( 1 . 31 , 1 . 93 ) , LCOTHER 1 . 17 ( 0 . 99 , 1 . 38 ) and LCOTHER 1 . 05 ( 0 . 74 , 1 . 51 ) .	3
Among non - users of LCOTHER , the adjusted hazard ratios ( 95% confidence interval ) of hospitalization for LCOTHER / GI vs the LCOTHER ( with no LCChemicalEntity ) group were : LCOTHER 1 . 27 ( 1 . 13 , 1 . 42 ) , LCChemicalEntity 0 . 93 ( 0 . 83 , 1 . 03 ) , LCOTHER 1 . 59 ( 1 . 31 , 1 . 93 ) , LCOTHER 1 . 17 ( 0 . 99 , 1 . 38 ) and LCOTHER 1 . 05 ( 0 . 74 , 1 . 51 ) .	3
Among users of LCChemicalEntity , they were : LCChemicalEntity 1 . 73 ( 1 . 52 , 1 . 98 ) , LCOTHER 1 . 34 ( 1 . 19 , 1 . 52 ) , LCOTHER 1 . 51 ( 0 . 95 , 2 . 41 ) , LCOTHER 1 . 69 ( 1 . 35 , 2 . 10 ) , LCOTHER 1 . 35 ( 0 . 97 , 1 . 88 ) and LCOTHER 1 . 29 ( 1 . 17 , 1 . 42 ) .	3
Among users of LCChemicalEntity , they were : LCOTHER 1 . 73 ( 1 . 52 , 1 . 98 ) , LCChemicalEntity 1 . 34 ( 1 . 19 , 1 . 52 ) , LCOTHER 1 . 51 ( 0 . 95 , 2 . 41 ) , LCOTHER 1 . 69 ( 1 . 35 , 2 . 10 ) , LCOTHER 1 . 35 ( 0 . 97 , 1 . 88 ) and LCOTHER 1 . 29 ( 1 . 17 , 1 . 42 ) .	3
Among users of LCChemicalEntity , they were : LCOTHER 1 . 73 ( 1 . 52 , 1 . 98 ) , LCOTHER 1 . 34 ( 1 . 19 , 1 . 52 ) , LCOTHER 1 . 51 ( 0 . 95 , 2 . 41 ) , LCOTHER 1 . 69 ( 1 . 35 , 2 . 10 ) , LCOTHER 1 . 35 ( 0 . 97 , 1 . 88 ) and LCChemicalEntity 1 . 29 ( 1 . 17 , 1 . 42 ) .	3
CONCLUSION : Among non - users of LCOTHER , LCChemicalEntity seemed to carry the highest risk for LCDiseaseOrPhenotypicFeature / LCOTHER LCOTHER .	2
CONCLUSION : Among non - users of LCOTHER , LCChemicalEntity seemed to carry the highest risk for LCOTHER / LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
The LCOTHER / LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature of LCChemicalEntity was similar to that of LCOTHER and seemed to be better than those of LCOTHER and NS - LCOTHER .	1
The LCOTHER / LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature of LCOTHER was similar to that of LCChemicalEntity and seemed to be better than those of LCOTHER and NS - LCOTHER .	1
The LCOTHER / LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature of LCOTHER was similar to that of LCOTHER and seemed to be better than those of LCChemicalEntity and NS - LCOTHER .	1
The LCOTHER / LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature of LCOTHER was similar to that of LCOTHER and seemed to be better than those of LCOTHER and NS - LCChemicalEntity .	1
Among users of LCChemicalEntity , both LCChemicalEntity and LCOTHER seemed to be the least toxic . In vivo characterization of a dual LCOTHER LCOTHER / LCOTHER LCOTHER LCOTHER in animal models of LCOTHER ' LCOTHER LCOTHER .	3
The in vivo characterization of a dual LCChemicalEntity LCChemicalEntity ( LCChemicalEntity ) / LCChemicalEntity ( LCChemicalEntity ) LCChemicalEntity LCChemicalEntity in several animal models of LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature is described .	1
Compound 1 is a potent LCChemicalEntity ( LCChemicalEntity ) / LCChemicalEntity ( LCChemicalEntity ) LCChemicalEntity LCChemicalEntity in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature including LCOTHER and LCOTHER models of LCOTHER - induced LCOTHER , LCOTHER model of LCOTHER - induced LCOTHER , LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) lesion model of drug - induced rotation , and LCOTHER - treated non - LCOTHER primate model . Coincidence of mutations in different connexin genes in Hungarian LCOTHER .	1
Compound 1 is a potent LCOTHER ( LCOTHER ) / LCOTHER ( LCOTHER ) LCOTHER LCOTHER in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature including LCOTHER and LCOTHER models of LCChemicalEntity - induced LCOTHER , LCOTHER model of LCOTHER - induced LCOTHER , LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) lesion model of drug - induced rotation , and LCOTHER - treated non - LCOTHER primate model . Coincidence of mutations in different connexin genes in Hungarian LCOTHER .	1
Compound 1 is a potent LCOTHER ( LCOTHER ) / LCOTHER ( LCOTHER ) LCOTHER LCOTHER in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature including LCOTHER and LCOTHER models of LCOTHER - induced LCOTHER , LCOTHER model of LCChemicalEntity - induced LCOTHER , LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) lesion model of drug - induced rotation , and LCOTHER - treated non - LCOTHER primate model . Coincidence of mutations in different connexin genes in Hungarian LCOTHER .	1
Compound 1 is a potent LCOTHER ( LCOTHER ) / LCOTHER ( LCOTHER ) LCOTHER LCOTHER in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature including LCOTHER and LCOTHER models of LCOTHER - induced LCOTHER , LCOTHER model of LCOTHER - induced LCOTHER , LCOTHER LCChemicalEntity - LCChemicalEntity ( LCOTHER - LCOTHER ) lesion model of drug - induced rotation , and LCOTHER - treated non - LCOTHER primate model . Coincidence of mutations in different connexin genes in Hungarian LCOTHER .	1
Compound 1 is a potent LCOTHER ( LCOTHER ) / LCOTHER ( LCOTHER ) LCOTHER LCOTHER in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature including LCOTHER and LCOTHER models of LCOTHER - induced LCOTHER , LCOTHER model of LCOTHER - induced LCOTHER , LCOTHER LCOTHER - LCOTHER ( LCChemicalEntity - LCChemicalEntity ) lesion model of drug - induced rotation , and LCOTHER - treated non - LCOTHER primate model . Coincidence of mutations in different connexin genes in Hungarian LCOTHER .	1
Compound 1 is a potent LCOTHER ( LCOTHER ) / LCOTHER ( LCOTHER ) LCOTHER LCOTHER in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature including LCOTHER and LCOTHER models of LCOTHER - induced LCOTHER , LCOTHER model of LCOTHER - induced LCOTHER , LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) lesion model of drug - induced rotation , and LCChemicalEntity - treated non - LCOTHER primate model . Coincidence of mutations in different connexin genes in Hungarian LCOTHER .	1
Compound 1 is a potent LCOTHER ( LCOTHER ) / LCOTHER ( LCOTHER ) LCOTHER LCOTHER in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of LCOTHER ' LCOTHER LCOTHER including LCOTHER and LCOTHER models of LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature , LCOTHER model of LCOTHER - induced LCOTHER , LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) lesion model of drug - induced rotation , and LCOTHER - treated non - LCOTHER primate model . Coincidence of mutations in different connexin genes in Hungarian LCOTHER .	2
Compound 1 is a potent LCOTHER ( LCOTHER ) / LCOTHER ( LCOTHER ) LCOTHER LCOTHER in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of LCOTHER ' LCOTHER LCOTHER including LCOTHER and LCOTHER models of LCOTHER - induced LCOTHER , LCOTHER model of LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) lesion model of drug - induced rotation , and LCOTHER - treated non - LCOTHER primate model . Coincidence of mutations in different connexin genes in Hungarian LCOTHER .	2
Mutations in the LCGeneOrGeneProduct gene are the most common cause of hereditary prelingual LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in Europe .	1
Therefore , we screened 47 Hungarian LCGeneOrGeneProduct - heterozygous ( one mutation in coding exon of the LCOTHER gene ) LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature for DNA changes in two further connexin genes ( LCOTHER and LCOTHER ) and in the 5 ' non - coding region of LCOTHER including the splice sites .	1
Therefore , we screened 47 Hungarian LCOTHER - heterozygous ( one mutation in coding exon of the LCGeneOrGeneProduct gene ) LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature for DNA changes in two further connexin genes ( LCOTHER and LCOTHER ) and in the 5 ' non - coding region of LCOTHER including the splice sites .	1
Our results suggest the importance of routine screening for the rather frequent - 3170G > A mutation ( in addition to LCSequenceVariant . LCSequenceVariant ) in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER LCOTHER LCOTHER LCOTHER genotype as a prognostic factor in LCOTHER LCOTHER LCOTHER receiving LCOTHER - based adjuvant treatment .	2
PURPOSE : The purpose of this study was to analyze the value of germline and LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) genotyping as a prognostic marker in a series of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER receiving adjuvant LCOTHER ( LCOTHER ) - based treatment .	1
PURPOSE : The purpose of this study was to analyze the value of germline and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) genotyping as a prognostic marker in a series of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER receiving adjuvant LCOTHER ( LCOTHER ) - based treatment .	1
PURPOSE : The purpose of this study was to analyze the value of germline and LCOTHER LCOTHER LCOTHER ( LCOTHER ) genotyping as a prognostic marker in a series of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER receiving adjuvant LCChemicalEntity ( LCOTHER ) - based treatment .	3
PURPOSE : The purpose of this study was to analyze the value of germline and LCOTHER LCOTHER LCOTHER ( LCOTHER ) genotyping as a prognostic marker in a series of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER receiving adjuvant LCOTHER ( LCChemicalEntity ) - based treatment .	3
LCOTHER AND METHODS : One hundred twenty - nine LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER homogeneously treated with LCChemicalEntity plus LCOTHER or LCOTHER in the adjuvant setting were included .	3
LCOTHER AND METHODS : One hundred twenty - nine LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER homogeneously treated with LCOTHER plus LCChemicalEntity or LCOTHER in the adjuvant setting were included .	3
LCOTHER AND METHODS : One hundred twenty - nine LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER homogeneously treated with LCOTHER plus LCOTHER or LCChemicalEntity in the adjuvant setting were included .	3
LCOTHER AND METHODS : One hundred twenty - nine LCOTHER LCOTHER LCOTHER homogeneously treated with LCChemicalEntity plus LCChemicalEntity or LCOTHER in the adjuvant setting were included .	5
LCOTHER AND METHODS : One hundred twenty - nine LCOTHER LCOTHER LCOTHER homogeneously treated with LCChemicalEntity plus LCOTHER or LCChemicalEntity in the adjuvant setting were included .	5
LCGeneOrGeneProduct enhancer region , 3R LCOTHER > LCOTHER single nucleotide polymorphism ( SNP ) , and LCOTHER LCOTHER polymorphisms were assessed in both fresh - frozen normal mucosa and LCDiseaseOrPhenotypicFeature .	1
LCOTHER enhancer region , 3R LCOTHER > LCOTHER single nucleotide polymorphism ( SNP ) , and LCGeneOrGeneProduct LCOTHER polymorphisms were assessed in both fresh - frozen normal mucosa and LCDiseaseOrPhenotypicFeature .	1
LCOTHER enhancer region , 3R LCOTHER > LCOTHER single nucleotide polymorphism ( SNP ) , and LCOTHER LCSequenceVariant polymorphisms were assessed in both fresh - frozen normal mucosa and LCDiseaseOrPhenotypicFeature .	1
Mutational analyses of LCGeneOrGeneProduct and allelic imbalances were studied in all primary LCDiseaseOrPhenotypicFeature and in 18 additional metachronic LCOTHER .	1
Mutational analyses of LCGeneOrGeneProduct and allelic imbalances were studied in all primary LCOTHER and in 18 additional metachronic LCDiseaseOrPhenotypicFeature .	1
LCGeneOrGeneProduct protein immunostaining was assessed in an expanded series of 214 LCDiseaseOrPhenotypicFeature .	1
No LCGeneOrGeneProduct point mutation was detected in primary LCDiseaseOrPhenotypicFeature or LCOTHER .	1
No LCGeneOrGeneProduct point mutation was detected in primary LCOTHER or LCDiseaseOrPhenotypicFeature .	1
CONCLUSION : LCOTHER LCGeneOrGeneProduct LCOTHER genotype may be a prognostic factor in LCOTHER - based adjuvant treatment of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER . Permeability , ultrastructural changes , and distribution of novel proteins in the glomerular barrier in early LCOTHER LCOTHER LCOTHER .	1
CONCLUSION : LCOTHER LCOTHER LCSequenceVariant genotype may be a prognostic factor in LCOTHER - based adjuvant treatment of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER . Permeability , ultrastructural changes , and distribution of novel proteins in the glomerular barrier in early LCOTHER LCOTHER LCOTHER .	1
Using LCChemicalEntity LCChemicalEntity LCDiseaseOrPhenotypicFeature ( LCOTHER ) LCOTHER , we studied early ultrastructural and permeability changes in relation to the expression of the podocyte - associated molecules LCOTHER , LCOTHER - LCOTHER , LCOTHER , and LCOTHER , the last two of which were only recently discovered in podocytes .	2
Using LCChemicalEntity LCChemicalEntity LCOTHER ( LCDiseaseOrPhenotypicFeature ) LCOTHER , we studied early ultrastructural and permeability changes in relation to the expression of the podocyte - associated molecules LCOTHER , LCOTHER - LCOTHER , LCOTHER , and LCOTHER , the last two of which were only recently discovered in podocytes .	2
Using LCOTHER LCOTHER LCDiseaseOrPhenotypicFeature ( LCOTHER ) LCOTHER , we studied early ultrastructural and permeability changes in relation to the expression of the podocyte - associated molecules LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct , and LCOTHER , the last two of which were only recently discovered in podocytes .	1
Using LCOTHER LCOTHER LCDiseaseOrPhenotypicFeature ( LCOTHER ) LCOTHER , we studied early ultrastructural and permeability changes in relation to the expression of the podocyte - associated molecules LCOTHER , LCOTHER - LCOTHER , LCOTHER , and LCGeneOrGeneProduct , the last two of which were only recently discovered in podocytes .	1
Using LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) LCOTHER , we studied early ultrastructural and permeability changes in relation to the expression of the podocyte - associated molecules LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct , and LCOTHER , the last two of which were only recently discovered in podocytes .	1
Using LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) LCOTHER , we studied early ultrastructural and permeability changes in relation to the expression of the podocyte - associated molecules LCOTHER , LCOTHER - LCOTHER , LCOTHER , and LCGeneOrGeneProduct , the last two of which were only recently discovered in podocytes .	1
CONTEXT : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is a rare LCOTHER LCOTHER , characterized by LCOTHER and LCOTHER / LCOTHER with increased serum LCChemicalEntity , LCChemicalEntity - LCChemicalEntity LCChemicalEntity [ LCOTHER , LCOTHER - ( LCOTHER ) ( LCOTHER ) LCOTHER ] resulting in LCOTHER .	2
CONTEXT : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is a rare LCOTHER LCOTHER , characterized by LCOTHER and LCOTHER / LCOTHER with increased serum LCOTHER , LCOTHER - LCOTHER LCOTHER [ LCChemicalEntity , LCChemicalEntity - ( LCChemicalEntity ) ( LCChemicalEntity ) LCChemicalEntity ] resulting in LCOTHER .	2
CONTEXT : LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is a rare LCOTHER LCOTHER , characterized by LCOTHER and LCOTHER / LCOTHER with increased serum LCChemicalEntity , LCChemicalEntity - LCChemicalEntity LCChemicalEntity [ LCOTHER , LCOTHER - ( LCOTHER ) ( LCOTHER ) LCOTHER ] resulting in LCOTHER .	2
CONTEXT : LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is a rare LCOTHER LCOTHER , characterized by LCOTHER and LCOTHER / LCOTHER with increased serum LCOTHER , LCOTHER - LCOTHER LCOTHER [ LCChemicalEntity , LCChemicalEntity - ( LCChemicalEntity ) ( LCChemicalEntity ) LCChemicalEntity ] resulting in LCOTHER .	2
CONTEXT : LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) is a rare LCOTHER LCOTHER , characterized by LCOTHER and LCOTHER / LCOTHER with increased serum LCChemicalEntity , LCChemicalEntity - LCChemicalEntity LCChemicalEntity [ LCOTHER , LCOTHER - ( LCOTHER ) ( LCOTHER ) LCOTHER ] resulting in LCDiseaseOrPhenotypicFeature .	2
CONTEXT : LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) is a rare LCOTHER LCOTHER , characterized by LCOTHER and LCOTHER / LCOTHER with increased serum LCOTHER , LCOTHER - LCOTHER LCOTHER [ LCChemicalEntity , LCChemicalEntity - ( LCChemicalEntity ) ( LCChemicalEntity ) LCChemicalEntity ] resulting in LCDiseaseOrPhenotypicFeature .	2
OBJECTIVE : Our objective was to determine whether mutations in the LCGeneOrGeneProduct gene , which encodes LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER , are responsible for the occurrence of LCDiseaseOrPhenotypicFeature .	1
OBJECTIVE : Our objective was to determine whether mutations in the LCOTHER gene , which encodes LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , are responsible for the occurrence of LCDiseaseOrPhenotypicFeature .	1
An unrelated individual with LCDiseaseOrPhenotypicFeature was a compound heterozygote for an LCSequenceVariant - LCSequenceVariant LCSequenceVariant in intron 10 and a LCOTHER - LCOTHER - LCOTHER substitution at the last nucleotide in exon 7 .	2
An unrelated individual with LCDiseaseOrPhenotypicFeature was a compound heterozygote for an LCOTHER - LCOTHER LCOTHER in intron 10 and a LCSequenceVariant - LCSequenceVariant - LCSequenceVariant substitution at the last nucleotide in exon 7 .	1
When tested in a multivariate regression analysis , LCChemicalEntity LCChemicalEntity was a strong independent predictor of LCDiseaseOrPhenotypicFeature ( OR 14 . 3 , 95% CI 5 . 5 - 36 . 7 ; p < 0 . 001 ) .	1
As LCChemicalEntity LCChemicalEntity is the only modifiable factor , its administration , particularly in doses exceeding 80 mg . kg ( - 1 ) , should be weighed against the risk of postoperative LCDiseaseOrPhenotypicFeature . A LCOTHER ligand attenuates LCOTHER LCOTHER after LCOTHER LCOTHER .	1
LCGeneOrGeneProduct ligands have shown anti - LCDiseaseOrPhenotypicFeature and neuroprotective properties in models of LCOTHER LCOTHER .	1
LCGeneOrGeneProduct ligands have shown anti - LCOTHER and neuroprotective properties in models of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
In this study , we determined the impact of a LCGeneOrGeneProduct ligand , LCChemicalEntity , on LCOTHER LCOTHER and LCOTHER in 2 LCOTHER models of LCOTHER .	1
In this study , we determined the impact of a LCGeneOrGeneProduct ligand , LCOTHER , on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER in 2 LCOTHER models of LCOTHER .	1
In this study , we determined the impact of a LCGeneOrGeneProduct ligand , LCOTHER , on LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature in 2 LCOTHER models of LCOTHER .	1
In this study , we determined the impact of a LCGeneOrGeneProduct ligand , LCOTHER , on LCOTHER LCOTHER and LCOTHER in 2 LCOTHER models of LCDiseaseOrPhenotypicFeature .	1
In this study , we determined the impact of a LCOTHER ligand , LCChemicalEntity , on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER in 2 LCOTHER models of LCOTHER .	3
In this study , we determined the impact of a LCOTHER ligand , LCChemicalEntity , on LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature in 2 LCOTHER models of LCOTHER .	3
In this study , we determined the impact of a LCOTHER ligand , LCChemicalEntity , on LCOTHER LCOTHER and LCOTHER in 2 LCOTHER models of LCDiseaseOrPhenotypicFeature .	3
LCGeneOrGeneProduct was up - regulated in LCGeneOrGeneProduct ( + ) cells from brains of LCOTHER with LCOTHER and in LCOTHER ( + ) LCOTHER ( int ) cells from LCOTHER subjected to LCOTHER - induced LCOTHER .	2
LCGeneOrGeneProduct was up - regulated in LCOTHER ( + ) cells from brains of LCOTHER with LCDiseaseOrPhenotypicFeature and in LCOTHER ( + ) LCOTHER ( int ) cells from LCOTHER subjected to LCOTHER - induced LCOTHER .	1
LCGeneOrGeneProduct was up - regulated in LCOTHER ( + ) cells from brains of LCOTHER with LCOTHER and in LCOTHER ( + ) LCOTHER ( int ) cells from LCOTHER subjected to LCOTHER - induced LCDiseaseOrPhenotypicFeature .	1
LCOTHER was up - regulated in LCOTHER ( + ) cells from brains of LCOTHER with LCOTHER and in LCOTHER ( + ) LCOTHER ( int ) cells from LCOTHER subjected to LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature .	2
LCChemicalEntity significantly reduced LCDiseaseOrPhenotypicFeature and perihematomal LCOTHER LCOTHER after LCOTHER induction by injection of either autologous blood or LCOTHER .	3
LCChemicalEntity significantly reduced LCOTHER and perihematomal LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature after LCOTHER induction by injection of either autologous blood or LCOTHER .	3
LCChemicalEntity significantly reduced LCOTHER and perihematomal LCOTHER LCOTHER after LCDiseaseOrPhenotypicFeature induction by injection of either autologous blood or LCOTHER .	3
In LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature LCOTHER , the protection of LCOTHER was associated with reduced leukocyte infiltration into the brain and microglial production of LCOTHER - LCOTHER and LCOTHER - LCOTHER .	2
In LCOTHER - induced LCOTHER LCOTHER , the protection of LCChemicalEntity was associated with reduced leukocyte infiltration into the brain and microglial production of LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER .	2
In LCOTHER - induced LCOTHER LCOTHER , the protection of LCChemicalEntity was associated with reduced leukocyte infiltration into the brain and microglial production of LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct .	2
Notably , the protective effect of LCChemicalEntity was abolished in LCOTHER depleted of microglia by using a LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct inhibitor .	1
These results indicate that the LCGeneOrGeneProduct ligand LCChemicalEntity attenuates LCOTHER LCOTHER and LCOTHER after LCOTHER .	1
These results indicate that the LCGeneOrGeneProduct ligand LCOTHER attenuates LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER after LCOTHER .	1
These results indicate that the LCGeneOrGeneProduct ligand LCOTHER attenuates LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature after LCOTHER .	1
These results indicate that the LCGeneOrGeneProduct ligand LCOTHER attenuates LCOTHER LCOTHER and LCOTHER after LCDiseaseOrPhenotypicFeature .	1
These results indicate that the LCOTHER ligand LCChemicalEntity attenuates LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER after LCOTHER .	3
These results indicate that the LCOTHER ligand LCChemicalEntity attenuates LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature after LCOTHER .	3
These results indicate that the LCOTHER ligand LCChemicalEntity attenuates LCOTHER LCOTHER and LCOTHER after LCDiseaseOrPhenotypicFeature .	3
LCGeneOrGeneProduct may be a viable therapeutic target that requires further investigations in LCDiseaseOrPhenotypicFeature . - Li , M . , Ren , H . , Sheth , K .	1
A LCGeneOrGeneProduct ligand attenuates LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature after LCOTHER LCOTHER . Mechanisms of LCOTHER induced by LCOTHER LCOTHER ( LCOTHER ) deficiency : focus on venous function .	1
A LCGeneOrGeneProduct ligand attenuates LCOTHER LCOTHER after LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Mechanisms of LCOTHER induced by LCOTHER LCOTHER ( LCOTHER ) deficiency : focus on venous function .	1
Loss of endothelial cell - derived LCChemicalEntity LCChemicalEntity ( LCOTHER ) in LCOTHER is a hallmark of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
Loss of endothelial cell - derived LCOTHER LCOTHER ( LCChemicalEntity ) in LCOTHER is a hallmark of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
Experimental LCDiseaseOrPhenotypicFeature created by the removal of LCChemicalEntity , however , involves mechanisms in addition to decreased arterial vasodilator activity .	3
We hypothesized that increased venous smooth muscle ( venomotor ) tone plays a role in LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity ( LCOTHER ) LCDiseaseOrPhenotypicFeature through these mechanisms .	2
We hypothesized that increased venous smooth muscle ( venomotor ) tone plays a role in LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCChemicalEntity ) LCDiseaseOrPhenotypicFeature through these mechanisms .	2
LCOTHER were treated with the LCGeneOrGeneProduct LCGeneOrGeneProduct inhibitor LCChemicalEntity ( 0 . 5 g / L in drinking water ) for 2 weeks .	3
Maximal contraction to LCChemicalEntity was modestly reduced in arteries from LCChemicalEntity compared with control LCOTHER whereas the maximum contraction to LCOTHER - LCOTHER was significantly reduced ( 54% control ) .	3
Maximal contraction to LCOTHER was modestly reduced in arteries from LCChemicalEntity compared with control LCOTHER whereas the maximum contraction to LCGeneOrGeneProduct - LCGeneOrGeneProduct was significantly reduced ( 54% control ) .	3
Mean circulatory filling pressure , an in vivo measure of venomotor tone , was not elevated in LCChemicalEntity LCDiseaseOrPhenotypicFeature at 1 or 2 weeks after LCOTHER .	2
The LCChemicalEntity scavenger LCChemicalEntity ( 30 , 100 , and 300 micromol kg ( - 1 ) , IV ) did not change arterial pressure in control LCOTHER but caused a dose - dependent decrease in LCOTHER LCOTHER ( - 18 + / - 8 , - 26 + / - 15 , and - 54 + / - 11 mm Hg ) .	3
The LCOTHER scavenger LCChemicalEntity ( 30 , 100 , and 300 micromol kg ( - 1 ) , IV ) did not change arterial pressure in control LCOTHER but caused a dose - dependent decrease in LCChemicalEntity LCOTHER ( - 18 + / - 8 , - 26 + / - 15 , and - 54 + / - 11 mm Hg ) .	3
Similarly , ganglionic blockade with LCChemicalEntity caused a significantly greater fall in LCChemicalEntity LCOTHER LCOTHER ( 76 + / - 9 mm Hg ) compared with control LCOTHER ( 35 + / - 10 mm Hg ) .	1
Similarly , ganglionic blockade with LCChemicalEntity caused a significantly greater fall in LCOTHER LCDiseaseOrPhenotypicFeature LCOTHER ( 76 + / - 9 mm Hg ) compared with control LCOTHER ( 35 + / - 10 mm Hg ) .	1
Similarly , ganglionic blockade with LCOTHER caused a significantly greater fall in LCChemicalEntity LCDiseaseOrPhenotypicFeature LCOTHER ( 76 + / - 9 mm Hg ) compared with control LCOTHER ( 35 + / - 10 mm Hg ) .	2
Carotid arteries , vena cava , and sympathetic ganglia from LCChemicalEntity LCOTHER had higher basal levels of LCChemicalEntity compared with those from control LCOTHER .	2
LCChemicalEntity and high - dose LCChemicalEntity - containing regimens are considered to be generally tolerable with few severe LCOTHER LCOTHER in LCOTHER with B - cell LCOTHER .	5
LCChemicalEntity and high - dose LCOTHER - containing regimens are considered to be generally tolerable with few severe LCOTHER LCOTHER in LCOTHER with B - cell LCDiseaseOrPhenotypicFeature .	3
LCOTHER and high - dose LCChemicalEntity - containing regimens are considered to be generally tolerable with few severe LCOTHER LCOTHER in LCOTHER with B - cell LCDiseaseOrPhenotypicFeature .	3
We report a case of a 76 - year - old LCOTHER with LCOTHER LCOTHER who suffered LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature without LCOTHER after the combination treatment with LCChemicalEntity , high - dose LCOTHER and LCOTHER .	2
We report a case of a 76 - year - old LCOTHER with LCOTHER LCOTHER who suffered LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature without LCOTHER after the combination treatment with LCOTHER , high - dose LCChemicalEntity and LCOTHER .	2
We report a case of a 76 - year - old LCOTHER with LCOTHER LCOTHER who suffered LCOTHER LCOTHER without LCOTHER after the combination treatment with LCChemicalEntity , high - dose LCChemicalEntity and LCOTHER .	5
We report a case of a 76 - year - old LCOTHER with LCOTHER LCOTHER who suffered LCOTHER LCOTHER without LCOTHER after the combination treatment with LCChemicalEntity , high - dose LCOTHER and LCChemicalEntity .	5
We report a case of a 76 - year - old LCOTHER with LCOTHER LCOTHER who suffered LCOTHER LCOTHER without LCOTHER after the combination treatment with LCOTHER , high - dose LCChemicalEntity and LCChemicalEntity .	5
Physicians should recognise the possibility of fatal LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature related to LCChemicalEntity plus high - dose LCOTHER in elderly LCOTHER , and we believe this case warrants further investigation . The LCOTHER LCOTHER - LCOTHER inhibitor LCOTHER displays a selective and specific antipsychotic - like profile in normal and transgenic LCOTHER .	2
Physicians should recognise the possibility of fatal LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature related to LCOTHER plus high - dose LCChemicalEntity in elderly LCOTHER , and we believe this case warrants further investigation . The LCOTHER LCOTHER - LCOTHER inhibitor LCOTHER displays a selective and specific antipsychotic - like profile in normal and transgenic LCOTHER .	2
Physicians should recognise the possibility of fatal LCOTHER LCOTHER related to LCChemicalEntity plus high - dose LCChemicalEntity in elderly LCOTHER , and we believe this case warrants further investigation . The LCOTHER LCOTHER - LCOTHER inhibitor LCOTHER displays a selective and specific antipsychotic - like profile in normal and transgenic LCOTHER .	5
LCDiseaseOrPhenotypicFeature has been initially associated with dysfunction in LCChemicalEntity neurotransmission .	1
However , the observation that antagonists of the LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct produce LCDiseaseOrPhenotypicFeature - like symptoms in LCOTHER has led to the idea of a dysfunctioning of the glutamatergic system via its LCOTHER LCOTHER .	1
Among them are LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) inhibitors such as LCChemicalEntity , which indirectly enhance LCOTHER LCOTHER function by increasing the LCOTHER ( a co - agonist for the LCOTHER LCOTHER ) levels in the synapse .	3
Among them are LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) inhibitors such as LCChemicalEntity , which indirectly enhance LCOTHER LCOTHER function by increasing the LCOTHER ( a co - agonist for the LCOTHER LCOTHER ) levels in the synapse .	3
Among them are LCOTHER LCOTHER - LCOTHER ( LCOTHER ) inhibitors such as LCChemicalEntity , which indirectly enhance LCGeneOrGeneProduct LCGeneOrGeneProduct function by increasing the LCOTHER ( a co - agonist for the LCOTHER LCOTHER ) levels in the synapse .	2
Among them are LCOTHER LCOTHER - LCOTHER ( LCOTHER ) inhibitors such as LCChemicalEntity , which indirectly enhance LCOTHER LCOTHER function by increasing the LCChemicalEntity ( a co - agonist for the LCOTHER LCOTHER ) levels in the synapse .	2
Among them are LCOTHER LCOTHER - LCOTHER ( LCOTHER ) inhibitors such as LCChemicalEntity , which indirectly enhance LCOTHER LCOTHER function by increasing the LCOTHER ( a co - agonist for the LCGeneOrGeneProduct LCGeneOrGeneProduct ) levels in the synapse .	2
Among them are LCOTHER LCOTHER - LCOTHER ( LCOTHER ) inhibitors such as LCOTHER , which indirectly enhance LCOTHER LCOTHER function by increasing the LCChemicalEntity ( a co - agonist for the LCGeneOrGeneProduct LCGeneOrGeneProduct ) levels in the synapse .	2
This study aimed at investigating the potential antipsychotic - like properties of LCChemicalEntity , with a particular focus on models of LCDiseaseOrPhenotypicFeature , involving either drug challenge ( ie , LCOTHER and LCOTHER - LCOTHER ) or transgenic LCOTHER ( ie , LCOTHER LCOTHER ( neo - / - ) and LCOTHER ( - / - ) ) .	3
This study aimed at investigating the potential antipsychotic - like properties of LCChemicalEntity , with a particular focus on models of LCOTHER , involving either drug challenge ( ie , LCOTHER and LCOTHER - LCOTHER ) or transgenic LCOTHER ( ie , LCGeneOrGeneProduct LCGeneOrGeneProduct ( neo - / - ) and LCOTHER ( - / - ) ) .	2
This study aimed at investigating the potential antipsychotic - like properties of LCOTHER , with a particular focus on models of LCDiseaseOrPhenotypicFeature , involving either drug challenge ( ie , LCChemicalEntity and LCOTHER - LCOTHER ) or transgenic LCOTHER ( ie , LCOTHER LCOTHER ( neo - / - ) and LCOTHER ( - / - ) ) .	2
This study aimed at investigating the potential antipsychotic - like properties of LCOTHER , with a particular focus on models of LCDiseaseOrPhenotypicFeature , involving either drug challenge ( ie , LCOTHER and LCChemicalEntity - LCChemicalEntity ) or transgenic LCOTHER ( ie , LCOTHER LCOTHER ( neo - / - ) and LCOTHER ( - / - ) ) .	2
This study aimed at investigating the potential antipsychotic - like properties of LCOTHER , with a particular focus on models of LCDiseaseOrPhenotypicFeature , involving either drug challenge ( ie , LCOTHER and LCOTHER - LCOTHER ) or transgenic LCOTHER ( ie , LCGeneOrGeneProduct LCGeneOrGeneProduct ( neo - / - ) and LCOTHER ( - / - ) ) .	1
Results showed that LCChemicalEntity ( 10 - 30 mg / kg p . o . ) blocked LCDiseaseOrPhenotypicFeature induced by the non - competitive LCOTHER LCOTHER antagonist , LCOTHER - LCOTHER and partially reversed spontaneous LCOTHER of LCOTHER LCOTHER ( neo - / - ) LCOTHER .	3
Results showed that LCChemicalEntity ( 10 - 30 mg / kg p . o . ) blocked LCOTHER induced by the non - competitive LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist , LCOTHER - LCOTHER and partially reversed spontaneous LCOTHER of LCOTHER LCOTHER ( neo - / - ) LCOTHER .	2
Results showed that LCChemicalEntity ( 10 - 30 mg / kg p . o . ) blocked LCOTHER induced by the non - competitive LCOTHER LCOTHER antagonist , LCOTHER - LCOTHER and partially reversed spontaneous LCDiseaseOrPhenotypicFeature of LCOTHER LCOTHER ( neo - / - ) LCOTHER .	3
Results showed that LCChemicalEntity ( 10 - 30 mg / kg p . o . ) blocked LCOTHER induced by the non - competitive LCOTHER LCOTHER antagonist , LCOTHER - LCOTHER and partially reversed spontaneous LCOTHER of LCGeneOrGeneProduct LCGeneOrGeneProduct ( neo - / - ) LCOTHER .	2
Results showed that LCOTHER ( 10 - 30 mg / kg p . o . ) blocked LCDiseaseOrPhenotypicFeature induced by the non - competitive LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist , LCOTHER - LCOTHER and partially reversed spontaneous LCOTHER of LCOTHER LCOTHER ( neo - / - ) LCOTHER .	1
Results showed that LCOTHER ( 10 - 30 mg / kg p . o . ) blocked LCDiseaseOrPhenotypicFeature induced by the non - competitive LCOTHER LCOTHER antagonist , LCChemicalEntity - LCChemicalEntity and partially reversed spontaneous LCOTHER of LCOTHER LCOTHER ( neo - / - ) LCOTHER .	2
Results showed that LCOTHER ( 10 - 30 mg / kg p . o . ) blocked LCDiseaseOrPhenotypicFeature induced by the non - competitive LCOTHER LCOTHER antagonist , LCOTHER - LCOTHER and partially reversed spontaneous LCOTHER of LCGeneOrGeneProduct LCGeneOrGeneProduct ( neo - / - ) LCOTHER .	1
Results showed that LCOTHER ( 10 - 30 mg / kg p . o . ) blocked LCOTHER induced by the non - competitive LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist , LCChemicalEntity - LCChemicalEntity and partially reversed spontaneous LCOTHER of LCOTHER LCOTHER ( neo - / - ) LCOTHER .	3
Results showed that LCOTHER ( 10 - 30 mg / kg p . o . ) blocked LCOTHER induced by the non - competitive LCOTHER LCOTHER antagonist , LCOTHER - LCOTHER and partially reversed spontaneous LCDiseaseOrPhenotypicFeature of LCGeneOrGeneProduct LCGeneOrGeneProduct ( neo - / - ) LCOTHER .	1
In contrast , LCChemicalEntity failed to affect LCDiseaseOrPhenotypicFeature induced by LCOTHER or naturally observed in LCOTHER LCOTHER ( LCOTHER ( - / - ) ) knockout LCOTHER ( 10 - 30 mg / kg p . o . ) .	3
In contrast , LCOTHER failed to affect LCDiseaseOrPhenotypicFeature induced by LCChemicalEntity or naturally observed in LCOTHER LCOTHER ( LCOTHER ( - / - ) ) knockout LCOTHER ( 10 - 30 mg / kg p . o . ) .	2
Importantly , both classical ( LCChemicalEntity ) and atypical ( LCOTHER , LCOTHER and LCOTHER ) antipsychotics were effective in all these models of LCDiseaseOrPhenotypicFeature .	3
Importantly , both classical ( LCOTHER ) and atypical ( LCChemicalEntity , LCOTHER and LCOTHER ) antipsychotics were effective in all these models of LCDiseaseOrPhenotypicFeature .	3
Importantly , both classical ( LCOTHER ) and atypical ( LCOTHER , LCChemicalEntity and LCOTHER ) antipsychotics were effective in all these models of LCDiseaseOrPhenotypicFeature .	3
Importantly , both classical ( LCOTHER ) and atypical ( LCOTHER , LCOTHER and LCChemicalEntity ) antipsychotics were effective in all these models of LCDiseaseOrPhenotypicFeature .	3
Together these findings show that the LCGeneOrGeneProduct inhibitor , LCChemicalEntity , produces antipsychotic - like effects , which differ from those observed with compounds primarily targeting the LCOTHER system , and has a reduced side - effect potential as compared with these latter drugs . LCOTHER LCOTHER following chemotherapy for stage IIIE diffuse large B - cell LCOTHER LCOTHER in a LCOTHER with LCOTHER LCOTHER ( LCOTHER ' LCOTHER LCOTHER ) .	3
The authors describe the unusual association between diffuse B - cell LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER , the most common form of adult LCOTHER LCOTHER , and sudden LCOTHER LCOTHER following one cycle of LCChemicalEntity - based chemotherapy in the same LCOTHER .	3
The authors describe the unusual association between diffuse B - cell LCOTHER LCOTHER and LCOTHER LCOTHER , the most common form of adult LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and sudden LCOTHER LCOTHER following one cycle of LCChemicalEntity - based chemotherapy in the same LCOTHER .	2
The authors describe the unusual association between diffuse B - cell LCOTHER LCOTHER and LCOTHER LCOTHER , the most common form of adult LCOTHER LCOTHER , and sudden LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature following one cycle of LCChemicalEntity - based chemotherapy in the same LCOTHER .	2
EXPERIMENTAL DESIGN : To isolate CSC from LCDiseaseOrPhenotypicFeature and characterize them , we used LCGeneOrGeneProduct inhibitor - supplemented cell culture , immunomagnetic cell sorting , andin vitro / in vivoassays for CSC viability and tumorigenicity .	1
RESULTS : We identified in LCDiseaseOrPhenotypicFeature LCGeneOrGeneProduct - positive CSC that expressed LCOTHER and LCOTHER , formed spheroids , and initiated LCOTHER in nude LCOTHER .	1
RESULTS : We identified in LCOTHER LCGeneOrGeneProduct - positive CSC that expressed LCGeneOrGeneProduct and LCOTHER , formed spheroids , and initiated LCOTHER in nude LCOTHER .	1
RESULTS : We identified in LCOTHER LCGeneOrGeneProduct - positive CSC that expressed LCOTHER and LCGeneOrGeneProduct , formed spheroids , and initiated LCOTHER in nude LCOTHER .	2
RESULTS : We identified in LCOTHER LCOTHER - positive CSC that expressed LCGeneOrGeneProduct and LCOTHER , formed spheroids , and initiated LCDiseaseOrPhenotypicFeature in nude LCOTHER .	1
RESULTS : We identified in LCOTHER LCOTHER - positive CSC that expressed LCOTHER and LCGeneOrGeneProduct , formed spheroids , and initiated LCDiseaseOrPhenotypicFeature in nude LCOTHER .	1
LCGeneOrGeneProduct ( + ) LCOTHER cells produced activated LCGeneOrGeneProduct ( LCOTHER ) and generated LCOTHER ( - ) cells that expressed LCOTHER as well as neural differentiation factors LCOTHER , LCOTHER , and LCOTHER .	1
LCGeneOrGeneProduct ( + ) LCOTHER cells produced activated LCOTHER ( LCGeneOrGeneProduct ) and generated LCOTHER ( - ) cells that expressed LCOTHER as well as neural differentiation factors LCOTHER , LCOTHER , and LCOTHER .	1
LCOTHER ( + ) LCDiseaseOrPhenotypicFeature cells produced activated LCOTHER ( LCOTHER ) and generated LCGeneOrGeneProduct ( - ) cells that expressed LCOTHER as well as neural differentiation factors LCOTHER , LCOTHER , and LCOTHER .	1
LCOTHER ( + ) LCDiseaseOrPhenotypicFeature cells produced activated LCOTHER ( LCOTHER ) and generated LCOTHER ( - ) cells that expressed LCGeneOrGeneProduct as well as neural differentiation factors LCOTHER , LCOTHER , and LCOTHER .	1
LCOTHER ( + ) LCDiseaseOrPhenotypicFeature cells produced activated LCOTHER ( LCOTHER ) and generated LCOTHER ( - ) cells that expressed LCOTHER as well as neural differentiation factors LCGeneOrGeneProduct , LCOTHER , and LCOTHER .	1
LCOTHER ( + ) LCDiseaseOrPhenotypicFeature cells produced activated LCOTHER ( LCOTHER ) and generated LCOTHER ( - ) cells that expressed LCOTHER as well as neural differentiation factors LCOTHER , LCGeneOrGeneProduct , and LCOTHER .	1
LCOTHER ( + ) LCDiseaseOrPhenotypicFeature cells produced activated LCOTHER ( LCOTHER ) and generated LCOTHER ( - ) cells that expressed LCOTHER as well as neural differentiation factors LCOTHER , LCOTHER , and LCGeneOrGeneProduct .	1
Knockdowns of LCGeneOrGeneProduct , LCOTHER , and their common effector LCGeneOrGeneProduct had negative effects on each other , inhibited spheroidogenesis , and induced cell death pointing at their essential roles in CSC maintenance .	2
Knockdowns of LCOTHER , LCGeneOrGeneProduct , and their common effector LCGeneOrGeneProduct had negative effects on each other , inhibited spheroidogenesis , and induced cell death pointing at their essential roles in CSC maintenance .	2
Among proliferation - linked LCGeneOrGeneProduct / LCGeneOrGeneProduct targets , we identified LCOTHER and its substrate LCOTHER .	2
Among proliferation - linked LCOTHER / LCOTHER targets , we identified LCGeneOrGeneProduct and its substrate LCGeneOrGeneProduct .	1
A LCGeneOrGeneProduct - LCGeneOrGeneProduct inhibitor , LCChemicalEntity , selectively depleted LCOTHER ( + ) cells , suppressed LCOTHER and LCOTHER , induced LCOTHER , inhibited LCOTHER growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	3
A LCGeneOrGeneProduct - LCGeneOrGeneProduct inhibitor , LCOTHER , selectively depleted LCGeneOrGeneProduct ( + ) cells , suppressed LCOTHER and LCOTHER , induced LCOTHER , inhibited LCOTHER growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	1
A LCGeneOrGeneProduct - LCGeneOrGeneProduct inhibitor , LCOTHER , selectively depleted LCOTHER ( + ) cells , suppressed LCGeneOrGeneProduct and LCOTHER , induced LCOTHER , inhibited LCOTHER growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	2
A LCGeneOrGeneProduct - LCGeneOrGeneProduct inhibitor , LCOTHER , selectively depleted LCOTHER ( + ) cells , suppressed LCOTHER and LCGeneOrGeneProduct , induced LCOTHER , inhibited LCOTHER growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	2
A LCGeneOrGeneProduct - LCGeneOrGeneProduct inhibitor , LCOTHER , selectively depleted LCOTHER ( + ) cells , suppressed LCOTHER and LCOTHER , induced LCGeneOrGeneProduct , inhibited LCOTHER growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	3
A LCGeneOrGeneProduct - LCGeneOrGeneProduct inhibitor , LCOTHER , selectively depleted LCOTHER ( + ) cells , suppressed LCOTHER and LCOTHER , induced LCOTHER , inhibited LCDiseaseOrPhenotypicFeature growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	1
A LCGeneOrGeneProduct - LCGeneOrGeneProduct inhibitor , LCOTHER , selectively depleted LCOTHER ( + ) cells , suppressed LCOTHER and LCOTHER , induced LCOTHER , inhibited LCOTHER growthin vivo , and sensitized LCGeneOrGeneProduct ( + ) cells to radiation .	1
A LCOTHER - LCOTHER inhibitor , LCChemicalEntity , selectively depleted LCGeneOrGeneProduct ( + ) cells , suppressed LCOTHER and LCOTHER , induced LCOTHER , inhibited LCOTHER growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	1
A LCOTHER - LCOTHER inhibitor , LCChemicalEntity , selectively depleted LCOTHER ( + ) cells , suppressed LCOTHER and LCGeneOrGeneProduct , induced LCOTHER , inhibited LCOTHER growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	3
A LCOTHER - LCOTHER inhibitor , LCChemicalEntity , selectively depleted LCOTHER ( + ) cells , suppressed LCOTHER and LCOTHER , induced LCGeneOrGeneProduct , inhibited LCOTHER growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	2
A LCOTHER - LCOTHER inhibitor , LCChemicalEntity , selectively depleted LCOTHER ( + ) cells , suppressed LCOTHER and LCOTHER , induced LCOTHER , inhibited LCDiseaseOrPhenotypicFeature growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	3
A LCOTHER - LCOTHER inhibitor , LCChemicalEntity , selectively depleted LCOTHER ( + ) cells , suppressed LCOTHER and LCOTHER , induced LCOTHER , inhibited LCOTHER growthin vivo , and sensitized LCGeneOrGeneProduct ( + ) cells to radiation .	1
A LCOTHER - LCOTHER inhibitor , LCOTHER , selectively depleted LCGeneOrGeneProduct ( + ) cells , suppressed LCGeneOrGeneProduct and LCOTHER , induced LCOTHER , inhibited LCOTHER growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	1
A LCOTHER - LCOTHER inhibitor , LCOTHER , selectively depleted LCOTHER ( + ) cells , suppressed LCGeneOrGeneProduct and LCOTHER , induced LCOTHER , inhibited LCDiseaseOrPhenotypicFeature growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	1
A LCOTHER - LCOTHER inhibitor , LCOTHER , selectively depleted LCOTHER ( + ) cells , suppressed LCOTHER and LCGeneOrGeneProduct , induced LCGeneOrGeneProduct , inhibited LCOTHER growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	1
A LCOTHER - LCOTHER inhibitor , LCOTHER , selectively depleted LCOTHER ( + ) cells , suppressed LCOTHER and LCGeneOrGeneProduct , induced LCOTHER , inhibited LCDiseaseOrPhenotypicFeature growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	1
A LCOTHER - LCOTHER inhibitor , LCOTHER , selectively depleted LCOTHER ( + ) cells , suppressed LCOTHER and LCOTHER , induced LCOTHER , inhibited LCDiseaseOrPhenotypicFeature growthin vivo , and sensitized LCGeneOrGeneProduct ( + ) cells to radiation .	1
CONCLUSIONS : These results establish in the majority of LCDiseaseOrPhenotypicFeature the presence of a previously uncharacterized population of LCGeneOrGeneProduct ( + ) cells with neural stem properties , which are driven by LCOTHER , LCOTHER , and LCOTHER .	1
CONCLUSIONS : These results establish in the majority of LCOTHER the presence of a previously uncharacterized population of LCGeneOrGeneProduct ( + ) cells with neural stem properties , which are driven by LCGeneOrGeneProduct , LCOTHER , and LCOTHER .	2
CONCLUSIONS : These results establish in the majority of LCOTHER the presence of a previously uncharacterized population of LCGeneOrGeneProduct ( + ) cells with neural stem properties , which are driven by LCOTHER , LCGeneOrGeneProduct , and LCOTHER .	1
CONCLUSIONS : These results establish in the majority of LCOTHER the presence of a previously uncharacterized population of LCOTHER ( + ) cells with neural stem properties , which are driven by LCGeneOrGeneProduct , LCOTHER , and LCGeneOrGeneProduct .	2
CONCLUSIONS : These results establish in the majority of LCOTHER the presence of a previously uncharacterized population of LCOTHER ( + ) cells with neural stem properties , which are driven by LCOTHER , LCGeneOrGeneProduct , and LCGeneOrGeneProduct .	2
Sensitivity of these cells to LCGeneOrGeneProduct inhibition and their dependence on LCOTHER offer new opportunities for targeted LCDiseaseOrPhenotypicFeature therapies . The impact of LCOTHER activation on whole genome gene expression in LCOTHER precision cut liver slices .	1
Sensitivity of these cells to LCOTHER inhibition and their dependence on LCGeneOrGeneProduct offer new opportunities for targeted LCDiseaseOrPhenotypicFeature therapies . The impact of LCOTHER activation on whole genome gene expression in LCOTHER precision cut liver slices .	1
BACKGROUND : Studies in LCOTHER have shown that LCGeneOrGeneProduct is an important regulator of LCChemicalEntity metabolism in liver and key transcription factor involved in the adaptive response to fasting .	1
METHODS : Here we set out to study the function of LCGeneOrGeneProduct in LCOTHER liver via analysis of whole genome gene regulation in LCOTHER liver slices treated with the LCOTHER agonist LCChemicalEntity .	2
METHODS : Here we set out to study the function of LCOTHER in LCOTHER liver via analysis of whole genome gene regulation in LCOTHER liver slices treated with the LCGeneOrGeneProduct agonist LCChemicalEntity .	2
RESULTS : Quantitative PCR indicated that LCGeneOrGeneProduct is well expressed in LCOTHER liver and LCOTHER liver slices and that the classical LCOTHER targets LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER and LCOTHER are robustly induced by LCOTHER activation .	2
RESULTS : Quantitative PCR indicated that LCOTHER is well expressed in LCOTHER liver and LCOTHER liver slices and that the classical LCGeneOrGeneProduct targets LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER and LCOTHER are robustly induced by LCOTHER activation .	2
RESULTS : Quantitative PCR indicated that LCOTHER is well expressed in LCOTHER liver and LCOTHER liver slices and that the classical LCOTHER targets LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER are robustly induced by LCGeneOrGeneProduct activation .	2
RESULTS : Quantitative PCR indicated that LCOTHER is well expressed in LCOTHER liver and LCOTHER liver slices and that the classical LCOTHER targets LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER are robustly induced by LCGeneOrGeneProduct activation .	2
RESULTS : Quantitative PCR indicated that LCOTHER is well expressed in LCOTHER liver and LCOTHER liver slices and that the classical LCOTHER targets LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER are robustly induced by LCGeneOrGeneProduct activation .	2
RESULTS : Quantitative PCR indicated that LCOTHER is well expressed in LCOTHER liver and LCOTHER liver slices and that the classical LCOTHER targets LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct are robustly induced by LCGeneOrGeneProduct activation .	2
Many genes induced by LCGeneOrGeneProduct activation were involved in LCChemicalEntity metabolism ( LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , xenobiotic metabolism ( LCOTHER , LCOTHER , LCOTHER ) or the unfolded protein response , whereas most of the downregulated genes were involved in immune - related pathways .	1
Many genes induced by LCGeneOrGeneProduct activation were involved in LCOTHER metabolism ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER ) , xenobiotic metabolism ( LCOTHER , LCOTHER , LCOTHER ) or the unfolded protein response , whereas most of the downregulated genes were involved in immune - related pathways .	2
Many genes induced by LCGeneOrGeneProduct activation were involved in LCOTHER metabolism ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER ) , xenobiotic metabolism ( LCOTHER , LCOTHER , LCOTHER ) or the unfolded protein response , whereas most of the downregulated genes were involved in immune - related pathways .	2
Many genes induced by LCGeneOrGeneProduct activation were involved in LCOTHER metabolism ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER ) , xenobiotic metabolism ( LCOTHER , LCOTHER , LCOTHER ) or the unfolded protein response , whereas most of the downregulated genes were involved in immune - related pathways .	2
Many genes induced by LCGeneOrGeneProduct activation were involved in LCOTHER metabolism ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct ) , xenobiotic metabolism ( LCOTHER , LCOTHER , LCOTHER ) or the unfolded protein response , whereas most of the downregulated genes were involved in immune - related pathways .	2
Many genes induced by LCGeneOrGeneProduct activation were involved in LCOTHER metabolism ( LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , xenobiotic metabolism ( LCGeneOrGeneProduct , LCOTHER , LCOTHER ) or the unfolded protein response , whereas most of the downregulated genes were involved in immune - related pathways .	2
Many genes induced by LCGeneOrGeneProduct activation were involved in LCOTHER metabolism ( LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , xenobiotic metabolism ( LCOTHER , LCGeneOrGeneProduct , LCOTHER ) or the unfolded protein response , whereas most of the downregulated genes were involved in immune - related pathways .	2
Many genes induced by LCGeneOrGeneProduct activation were involved in LCOTHER metabolism ( LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , xenobiotic metabolism ( LCOTHER , LCOTHER , LCGeneOrGeneProduct ) or the unfolded protein response , whereas most of the downregulated genes were involved in immune - related pathways .	2
Many genes induced by LCOTHER activation were involved in LCChemicalEntity metabolism ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER ) , xenobiotic metabolism ( LCOTHER , LCOTHER , LCOTHER ) or the unfolded protein response , whereas most of the downregulated genes were involved in immune - related pathways .	1
Many genes induced by LCOTHER activation were involved in LCChemicalEntity metabolism ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER ) , xenobiotic metabolism ( LCOTHER , LCOTHER , LCOTHER ) or the unfolded protein response , whereas most of the downregulated genes were involved in immune - related pathways .	1
Many genes induced by LCOTHER activation were involved in LCChemicalEntity metabolism ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER ) , xenobiotic metabolism ( LCOTHER , LCOTHER , LCOTHER ) or the unfolded protein response , whereas most of the downregulated genes were involved in immune - related pathways .	1
Many genes induced by LCOTHER activation were involved in LCChemicalEntity metabolism ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct ) , xenobiotic metabolism ( LCOTHER , LCOTHER , LCOTHER ) or the unfolded protein response , whereas most of the downregulated genes were involved in immune - related pathways .	1
In particular , LCGeneOrGeneProduct activation markedly suppressed immunity / LCDiseaseOrPhenotypicFeature - related genes in LCOTHER liver slices but not in primary hepatocytes .	1
Finally , several putative new target genes of LCGeneOrGeneProduct were identified that were commonly induced by LCOTHER activation in the two LCOTHER liver model systems , including LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER .	2
Finally , several putative new target genes of LCGeneOrGeneProduct were identified that were commonly induced by LCOTHER activation in the two LCOTHER liver model systems , including LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER .	2
Finally , several putative new target genes of LCGeneOrGeneProduct were identified that were commonly induced by LCOTHER activation in the two LCOTHER liver model systems , including LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER .	2
Finally , several putative new target genes of LCGeneOrGeneProduct were identified that were commonly induced by LCOTHER activation in the two LCOTHER liver model systems , including LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct .	2
Finally , several putative new target genes of LCOTHER were identified that were commonly induced by LCGeneOrGeneProduct activation in the two LCOTHER liver model systems , including LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER .	2
Finally , several putative new target genes of LCOTHER were identified that were commonly induced by LCGeneOrGeneProduct activation in the two LCOTHER liver model systems , including LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER .	2
Finally , several putative new target genes of LCOTHER were identified that were commonly induced by LCGeneOrGeneProduct activation in the two LCOTHER liver model systems , including LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER .	2
Finally , several putative new target genes of LCOTHER were identified that were commonly induced by LCGeneOrGeneProduct activation in the two LCOTHER liver model systems , including LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct .	2
Our data underscore the major role of LCGeneOrGeneProduct in regulation of hepatic LCChemicalEntity and xenobiotic metabolism in LCOTHER liver and reveal a marked immuno - suppressive / anti - LCOTHER effect of LCOTHER in LCOTHER liver slices that may be therapeutically relevant for LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER decreases LCOTHER LCOTHER expression in LCOTHER LCOTHER cells .	1
Our data underscore the major role of LCGeneOrGeneProduct in regulation of hepatic LCOTHER and xenobiotic metabolism in LCOTHER liver and reveal a marked immuno - suppressive / anti - LCDiseaseOrPhenotypicFeature effect of LCOTHER in LCOTHER liver slices that may be therapeutically relevant for LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER decreases LCOTHER LCOTHER expression in LCOTHER LCOTHER cells .	1
In this study , 10 to 25 micromol / L LCChemicalEntity inhibited LCOTHER - LCOTHER and LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCOTHER LCOTHER LCOTHER and the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	3
In this study , 10 to 25 micromol / L LCChemicalEntity inhibited LCOTHER - LCOTHER and LCOTHER LCOTHER LCOTHER cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCOTHER and the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	3
In this study , 10 to 25 micromol / L LCChemicalEntity inhibited LCOTHER - LCOTHER and LCOTHER LCOTHER LCOTHER cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCOTHER LCOTHER LCGeneOrGeneProduct and the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	3
In this study , 10 to 25 micromol / L LCChemicalEntity inhibited LCOTHER - LCOTHER and LCOTHER LCOTHER LCOTHER cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCOTHER LCOTHER LCOTHER and the LCOTHER LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	3
In this study , 10 to 25 micromol / L LCChemicalEntity inhibited LCOTHER - LCOTHER and LCOTHER LCOTHER LCOTHER cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCOTHER LCOTHER LCOTHER and the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	3
In this study , 10 to 25 micromol / L LCChemicalEntity inhibited LCOTHER - LCOTHER and LCOTHER LCOTHER LCOTHER cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCOTHER LCOTHER LCOTHER and the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	3
In this study , 10 to 25 micromol / L LCChemicalEntity inhibited LCOTHER - LCOTHER and LCOTHER LCOTHER LCOTHER cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCOTHER LCOTHER LCOTHER and the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	3
In this study , 10 to 25 micromol / L LCOTHER inhibited LCOTHER - LCOTHER and LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCOTHER and the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
In this study , 10 to 25 micromol / L LCOTHER inhibited LCOTHER - LCOTHER and LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCOTHER LCOTHER LCGeneOrGeneProduct and the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
In this study , 10 to 25 micromol / L LCOTHER inhibited LCOTHER - LCOTHER and LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCOTHER LCOTHER LCOTHER and the LCOTHER LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
In this study , 10 to 25 micromol / L LCOTHER inhibited LCOTHER - LCOTHER and LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCOTHER LCOTHER LCOTHER and the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	1
In this study , 10 to 25 micromol / L LCOTHER inhibited LCOTHER - LCOTHER and LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCOTHER LCOTHER LCOTHER and the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	1
In this study , 10 to 25 micromol / L LCOTHER inhibited LCOTHER - LCOTHER and LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCOTHER LCOTHER LCOTHER and the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	1
The results show that LCChemicalEntity induced LCGeneOrGeneProduct - dependent down - regulation of LCOTHER , LCOTHER , and LCOTHER in LCOTHER - LCOTHER and LCOTHER cells .	1
The results show that LCChemicalEntity induced LCOTHER - dependent down - regulation of LCGeneOrGeneProduct , LCOTHER , and LCOTHER in LCOTHER - LCOTHER and LCOTHER cells .	3
The results show that LCChemicalEntity induced LCOTHER - dependent down - regulation of LCOTHER , LCGeneOrGeneProduct , and LCOTHER in LCOTHER - LCOTHER and LCOTHER cells .	3
The results show that LCChemicalEntity induced LCOTHER - dependent down - regulation of LCOTHER , LCOTHER , and LCGeneOrGeneProduct in LCOTHER - LCOTHER and LCOTHER cells .	3
The results show that LCOTHER induced LCGeneOrGeneProduct - dependent down - regulation of LCGeneOrGeneProduct , LCOTHER , and LCOTHER in LCOTHER - LCOTHER and LCOTHER cells .	1
The results show that LCOTHER induced LCGeneOrGeneProduct - dependent down - regulation of LCOTHER , LCGeneOrGeneProduct , and LCOTHER in LCOTHER - LCOTHER and LCOTHER cells .	1
The results show that LCOTHER induced LCGeneOrGeneProduct - dependent down - regulation of LCOTHER , LCOTHER , and LCGeneOrGeneProduct in LCOTHER - LCOTHER and LCOTHER cells .	1
Moreover , using RNA interference with small inhibitory RNAs for LCGeneOrGeneProduct , LCOTHER , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCGeneOrGeneProduct , LCOTHER , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCGeneOrGeneProduct , LCOTHER , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - dependent genes , such as LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCGeneOrGeneProduct , LCOTHER , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCGeneOrGeneProduct , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCGeneOrGeneProduct , LCOTHER , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCGeneOrGeneProduct LCGeneOrGeneProduct , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCGeneOrGeneProduct , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCGeneOrGeneProduct , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCGeneOrGeneProduct , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - dependent genes , such as LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCGeneOrGeneProduct , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCGeneOrGeneProduct , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCGeneOrGeneProduct , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCGeneOrGeneProduct LCGeneOrGeneProduct , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCGeneOrGeneProduct , we observed that LCOTHER - dependent inhibition of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCGeneOrGeneProduct , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCGeneOrGeneProduct , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - dependent genes , such as LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCGeneOrGeneProduct , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCGeneOrGeneProduct , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCGeneOrGeneProduct , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCGeneOrGeneProduct LCGeneOrGeneProduct , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCOTHER , we observed that LCChemicalEntity - dependent inhibition of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCOTHER , we observed that LCChemicalEntity - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCOTHER , we observed that LCChemicalEntity - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - dependent genes , such as LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	3
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCOTHER , we observed that LCChemicalEntity - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCGeneOrGeneProduct , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	3
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCOTHER , we observed that LCChemicalEntity - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCGeneOrGeneProduct LCGeneOrGeneProduct , was also due , in part , to loss of LCOTHER proteins .	3
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) - dependent genes , such as LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCGeneOrGeneProduct , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCGeneOrGeneProduct LCGeneOrGeneProduct , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) - dependent genes , such as LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) - dependent genes , such as LCOTHER - LCOTHER , LCGeneOrGeneProduct , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	1
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCOTHER , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCGeneOrGeneProduct LCGeneOrGeneProduct , was also due , in part , to loss of LCOTHER proteins .	1
LCChemicalEntity also decreased LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature growth in athymic nude LCOTHER bearing LCOTHER cells as xenografts and this was accompanied by decreased LCOTHER , LCOTHER , and LCOTHER protein levels in LCOTHER .	3
LCChemicalEntity also decreased LCOTHER LCOTHER growth in athymic nude LCOTHER bearing LCOTHER cells as xenografts and this was accompanied by decreased LCGeneOrGeneProduct , LCOTHER , and LCOTHER protein levels in LCOTHER .	3
LCChemicalEntity also decreased LCOTHER LCOTHER growth in athymic nude LCOTHER bearing LCOTHER cells as xenografts and this was accompanied by decreased LCOTHER , LCGeneOrGeneProduct , and LCOTHER protein levels in LCOTHER .	3
LCChemicalEntity also decreased LCOTHER LCOTHER growth in athymic nude LCOTHER bearing LCOTHER cells as xenografts and this was accompanied by decreased LCOTHER , LCOTHER , and LCGeneOrGeneProduct protein levels in LCOTHER .	3
LCOTHER also decreased LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature growth in athymic nude LCOTHER bearing LCOTHER cells as xenografts and this was accompanied by decreased LCGeneOrGeneProduct , LCOTHER , and LCOTHER protein levels in LCOTHER .	1
LCOTHER also decreased LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature growth in athymic nude LCOTHER bearing LCOTHER cells as xenografts and this was accompanied by decreased LCOTHER , LCGeneOrGeneProduct , and LCOTHER protein levels in LCOTHER .	1
LCOTHER also decreased LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature growth in athymic nude LCOTHER bearing LCOTHER cells as xenografts and this was accompanied by decreased LCOTHER , LCOTHER , and LCGeneOrGeneProduct protein levels in LCOTHER .	1
LCOTHER also decreased LCOTHER LCOTHER growth in athymic nude LCOTHER bearing LCOTHER cells as xenografts and this was accompanied by decreased LCGeneOrGeneProduct , LCOTHER , and LCOTHER protein levels in LCDiseaseOrPhenotypicFeature .	1
LCOTHER also decreased LCOTHER LCOTHER growth in athymic nude LCOTHER bearing LCOTHER cells as xenografts and this was accompanied by decreased LCOTHER , LCGeneOrGeneProduct , and LCOTHER protein levels in LCDiseaseOrPhenotypicFeature .	1
LCOTHER also decreased LCOTHER LCOTHER growth in athymic nude LCOTHER bearing LCOTHER cells as xenografts and this was accompanied by decreased LCOTHER , LCOTHER , and LCGeneOrGeneProduct protein levels in LCDiseaseOrPhenotypicFeature .	1
These results show for the first time that one of the underlying mechanisms of action of LCChemicalEntity as a LCOTHER chemotherapeutic agent is due , in part , to decreased expression of LCOTHER LCOTHER LCOTHER in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cells . Study of a Taiwanese family with LCOTHER LCOTHER LCOTHER .	3
LCDiseaseOrPhenotypicFeature is caused by a short trinucleotide repeat expansion encoding an expanded LCChemicalEntity tract in the LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) gene .	1
LCOTHER is caused by a short trinucleotide repeat expansion encoding an expanded LCChemicalEntity tract in the LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) gene .	1
LCOTHER is caused by a short trinucleotide repeat expansion encoding an expanded LCChemicalEntity tract in the LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene .	1
We identified and characterized a LCGeneOrGeneProduct mutation in a Taiwanese family with LCDiseaseOrPhenotypicFeature .	1
CONCLUSIONS : In contrast to a single GCG expansion in most of LCDiseaseOrPhenotypicFeature LCOTHER in the literature , an LCSequenceVariant LCSequenceVariant ( LCSequenceVariant ) LCSequenceVariant in the LCOTHER gene was found in the Taiwanese LCOTHER subjects .	2
CONCLUSIONS : In contrast to a single GCG expansion in most of LCOTHER LCOTHER in the literature , an LCOTHER LCOTHER ( LCOTHER ) LCOTHER in the LCGeneOrGeneProduct gene was found in the Taiwanese LCDiseaseOrPhenotypicFeature subjects .	1
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is an inherited syndrome characterized by elevated serum LCChemicalEntity LCChemicalEntity ( LCOTHER ) , failure to suppress pituitary LCOTHER LCOTHER LCOTHER ( LCOTHER ) secretion , and variable peripheral tissue responsiveness to LCOTHER .	2
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is an inherited syndrome characterized by elevated serum LCOTHER LCOTHER ( LCChemicalEntity ) , failure to suppress pituitary LCOTHER LCOTHER LCOTHER ( LCOTHER ) secretion , and variable peripheral tissue responsiveness to LCOTHER .	2
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is an inherited syndrome characterized by elevated serum LCOTHER LCOTHER ( LCOTHER ) , failure to suppress pituitary LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) secretion , and variable peripheral tissue responsiveness to LCOTHER .	1
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is an inherited syndrome characterized by elevated serum LCOTHER LCOTHER ( LCOTHER ) , failure to suppress pituitary LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) secretion , and variable peripheral tissue responsiveness to LCOTHER .	1
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is an inherited syndrome characterized by elevated serum LCOTHER LCOTHER ( LCOTHER ) , failure to suppress pituitary LCOTHER LCOTHER LCOTHER ( LCOTHER ) secretion , and variable peripheral tissue responsiveness to LCChemicalEntity .	2
LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is an inherited syndrome characterized by elevated serum LCChemicalEntity LCChemicalEntity ( LCOTHER ) , failure to suppress pituitary LCOTHER LCOTHER LCOTHER ( LCOTHER ) secretion , and variable peripheral tissue responsiveness to LCOTHER .	2
LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is an inherited syndrome characterized by elevated serum LCOTHER LCOTHER ( LCChemicalEntity ) , failure to suppress pituitary LCOTHER LCOTHER LCOTHER ( LCOTHER ) secretion , and variable peripheral tissue responsiveness to LCOTHER .	2
LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is an inherited syndrome characterized by elevated serum LCOTHER LCOTHER ( LCOTHER ) , failure to suppress pituitary LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) secretion , and variable peripheral tissue responsiveness to LCOTHER .	1
LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is an inherited syndrome characterized by elevated serum LCOTHER LCOTHER ( LCOTHER ) , failure to suppress pituitary LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) secretion , and variable peripheral tissue responsiveness to LCOTHER .	1
LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is an inherited syndrome characterized by elevated serum LCOTHER LCOTHER ( LCOTHER ) , failure to suppress pituitary LCOTHER LCOTHER LCOTHER ( LCOTHER ) secretion , and variable peripheral tissue responsiveness to LCChemicalEntity .	2
However , in transient transfection assays , the LCSequenceVariant LCOTHER mutant exhibited impaired transcriptional regulation on two distinct positively regulated thyroid response elements ( F2 - and DR4 - TREs ) as well as on the negatively regulated LCOTHER LCGeneOrGeneProduct promoter .	2
These results strongly suggest that the LCSequenceVariant LCOTHER mutation is responsible for the LCDiseaseOrPhenotypicFeature phenotype in the proposita ' s family . Cloning of LCOTHER LCOTHER - LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER and molecular characterization of its deficiency in two LCOTHER .	2
These results strongly suggest that the LCOTHER LCGeneOrGeneProduct mutation is responsible for the LCDiseaseOrPhenotypicFeature phenotype in the proposita ' s family . Cloning of LCOTHER LCOTHER - LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER and molecular characterization of its deficiency in two LCOTHER .	1
Quantitative cDNA expression of normal LCOTHER LCOTHER was performed in the LCOTHER fibroblasts , using vaccinia viral system , which demonstrated that the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature causes impaired LCChemicalEntity - LCChemicalEntity LCChemicalEntity LCChemicalEntity beta - oxidation activity in the LCOTHER fibroblasts .	3
In LCOTHER fibroblasts , raising LCGeneOrGeneProduct activity to approximately 20% of normal control fibroblast activity raised LCChemicalEntity LCChemicalEntity beta - oxidation flux to the level found in control fibroblasts , which may offer important information for the rational design of future somatic gene therapy for LCOTHER LCOTHER . Haplotype structure of the LCOTHER LCOTHER LCOTHER genes in US Caucasians and African Americans .	2
In LCOTHER fibroblasts , raising LCOTHER activity to approximately 20% of normal control fibroblast activity raised LCChemicalEntity LCChemicalEntity beta - oxidation flux to the level found in control fibroblasts , which may offer important information for the rational design of future somatic gene therapy for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Haplotype structure of the LCOTHER LCOTHER LCOTHER genes in US Caucasians and African Americans .	1
The aim of this study was to investigate the association of DNA polymorphisms within LCOTHER LCOTHER LCOTHER ( LCOTHER , LCGeneOrGeneProduct ) and the postoperative resolution of LCDiseaseOrPhenotypicFeature in Chinese LCOTHER undergoing adrenalectomy for LCOTHER - LCOTHER LCOTHER ( LCOTHER ) .	1
The associations between LCOTHER / LCGeneOrGeneProduct polymorphisms and persistent postoperative LCDiseaseOrPhenotypicFeature were assessed by multivariate analysis .	1
RESULTS : LCOTHER - LCGeneOrGeneProduct haplotype was associated with persistent postoperative LCDiseaseOrPhenotypicFeature in Chinese LCOTHER undergoing adrenalectomy with LCOTHER ( P = . 006 ) .	1
We detected 24 LCGeneOrGeneProduct mutations in 15 / 25 ( 60% ) LCDiseaseOrPhenotypicFeature , 1 deletion and 23 base substitutions , the majority ( 78% ) being UV - specific LCOTHER LCOTHER LCOTHER transitions at bipyrimidine sites .	1
Importantly , 35% ( 6 / 17 ) are tandem mutations , including 4 UV signature LCSequenceVariant LCSequenceVariant LCSequenceVariant transitions possibly linked to modulated DNA repair caused by the immunosuppressive drug LCChemicalEntity LCChemicalEntity ( LCOTHER ) .	1
Importantly , 35% ( 6 / 17 ) are tandem mutations , including 4 UV signature LCSequenceVariant LCSequenceVariant LCSequenceVariant transitions possibly linked to modulated DNA repair caused by the immunosuppressive drug LCOTHER LCOTHER ( LCChemicalEntity ) .	1
We found 8 LCGeneOrGeneProduct mutations in 7 / 17 ( 41% ) LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) , suggesting that LCOTHER mutations are early events in RTR LCOTHER LCOTHER .	1
We found 8 LCGeneOrGeneProduct mutations in 7 / 17 ( 41% ) LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , suggesting that LCOTHER mutations are early events in RTR LCOTHER LCOTHER .	1
We found 8 LCGeneOrGeneProduct mutations in 7 / 17 ( 41% ) LCOTHER LCOTHER LCOTHER ( LCOTHER ) , suggesting that LCOTHER mutations are early events in RTR LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
We found 8 LCOTHER mutations in 7 / 17 ( 41% ) LCOTHER LCOTHER LCOTHER ( LCOTHER ) , suggesting that LCGeneOrGeneProduct mutations are early events in RTR LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
The LCGeneOrGeneProduct mutation spectrum , presenting a high level of LCOTHER LCOTHER LCOTHER mutations , shows that the UV component of sunlight is the major risk factor and modulated DNA repair by immunosuppressive drug treatment may be significant in the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature of RTRs . LCOTHER associated antigen recognition by autologous serum in LCOTHER with LCOTHER LCOTHER .	1
The LCOTHER mutation spectrum , presenting a high level of LCSequenceVariant LCSequenceVariant LCSequenceVariant mutations , shows that the UV component of sunlight is the major risk factor and modulated DNA repair by immunosuppressive drug treatment may be significant in the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature of RTRs . LCOTHER associated antigen recognition by autologous serum in LCOTHER with LCOTHER LCOTHER .	2
The objective of the present study was to examine the association of the LCOTHER polymorphism of exon 2 of the LCGeneOrGeneProduct ( LCOTHER ) gene with LCDiseaseOrPhenotypicFeature in a South Indian population from Andhra Pradesh .	1
The objective of the present study was to examine the association of the LCOTHER polymorphism of exon 2 of the LCOTHER ( LCGeneOrGeneProduct ) gene with LCDiseaseOrPhenotypicFeature in a South Indian population from Andhra Pradesh .	1
CONCLUSION : Our results suggest that the T allele of the LCGeneOrGeneProduct gene is significantly associated with LCDiseaseOrPhenotypicFeature in a South Indian population from Andhra Pradesh .	1
We have shown that the LCGeneOrGeneProduct LCOTHER is critical for LCDiseaseOrPhenotypicFeature - induced LCOTHER in the colon .	1
We have shown that the LCGeneOrGeneProduct LCOTHER is critical for LCOTHER - induced LCDiseaseOrPhenotypicFeature in the colon .	1
We have shown that the LCOTHER LCGeneOrGeneProduct is critical for LCDiseaseOrPhenotypicFeature - induced LCOTHER in the colon .	1
We have shown that the LCOTHER LCGeneOrGeneProduct is critical for LCOTHER - induced LCDiseaseOrPhenotypicFeature in the colon .	1
We investigated the effect of LCGeneOrGeneProduct in the LCDiseaseOrPhenotypicFeature microenvironment of LCOTHER with liver parenchymal cell - specific LCOTHER ablation ( LCOTHER - Cre ; LCOTHER ( f / f ) ) and LCOTHER deletion both in liver parenchymal and non - parenchymal cells ( LCOTHER - Cre ; LCOTHER ( f / f ) ) .	1
LCGeneOrGeneProduct upregulates LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct expression in LCOTHER cells .	2
LCGeneOrGeneProduct binds to LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) , mainly expressed in liver non - parenchymal cells , resulting in phosphorylation and activation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	4
LCGeneOrGeneProduct binds to LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) , mainly expressed in liver non - parenchymal cells , resulting in phosphorylation and activation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	4
LCGeneOrGeneProduct binds to LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) , mainly expressed in liver non - parenchymal cells , resulting in phosphorylation and activation of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	2
LCGeneOrGeneProduct binds to LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) , mainly expressed in liver non - parenchymal cells , resulting in phosphorylation and activation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	2
LCGeneOrGeneProduct deficiency in non - parenchymal cells , but not in parenchymal cells , reduced LCGeneOrGeneProduct activity , LCOTHER ( LCOTHER ) - LCOTHER production , and LCOTHER stem cell marker ( LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER [ LCOTHER ] ) expression , leading to attenuated LCOTHER potential .	2
LCGeneOrGeneProduct deficiency in non - parenchymal cells , but not in parenchymal cells , reduced LCOTHER activity , LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct production , and LCOTHER stem cell marker ( LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER [ LCOTHER ] ) expression , leading to attenuated LCOTHER potential .	2
LCGeneOrGeneProduct deficiency in non - parenchymal cells , but not in parenchymal cells , reduced LCOTHER activity , LCOTHER ( LCOTHER ) - LCOTHER production , and LCDiseaseOrPhenotypicFeature stem cell marker ( LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER [ LCOTHER ] ) expression , leading to attenuated LCOTHER potential .	1
LCGeneOrGeneProduct deficiency in non - parenchymal cells , but not in parenchymal cells , reduced LCOTHER activity , LCOTHER ( LCOTHER ) - LCOTHER production , and LCOTHER stem cell marker ( LCGeneOrGeneProduct and LCOTHER LCOTHER LCOTHER LCOTHER [ LCOTHER ] ) expression , leading to attenuated LCOTHER potential .	2
LCGeneOrGeneProduct deficiency in non - parenchymal cells , but not in parenchymal cells , reduced LCOTHER activity , LCOTHER ( LCOTHER ) - LCOTHER production , and LCOTHER stem cell marker ( LCOTHER and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct [ LCOTHER ] ) expression , leading to attenuated LCOTHER potential .	2
LCGeneOrGeneProduct deficiency in non - parenchymal cells , but not in parenchymal cells , reduced LCOTHER activity , LCOTHER ( LCOTHER ) - LCOTHER production , and LCOTHER stem cell marker ( LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER [ LCGeneOrGeneProduct ] ) expression , leading to attenuated LCOTHER potential .	2
LCGeneOrGeneProduct deficiency in non - parenchymal cells , but not in parenchymal cells , reduced LCOTHER activity , LCOTHER ( LCOTHER ) - LCOTHER production , and LCOTHER stem cell marker ( LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER [ LCOTHER ] ) expression , leading to attenuated LCDiseaseOrPhenotypicFeature potential .	1
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature enhances LCGeneOrGeneProduct expression in the LCOTHER liver .	2
LCOTHER expression in the LCOTHER microenvironment is negatively correlated with progression - free survival in LCOTHER undergoing LCChemicalEntity treatment for LCDiseaseOrPhenotypicFeature .	3
Thus , LCGeneOrGeneProduct appears to play a critical oncogenic function in LCDiseaseOrPhenotypicFeature microenvironment and may be a potential target for developing therapeutic and preventive strategies against LCOTHER . Effects of the LCOTHER - LCOTHER specific inhibitor LCOTHER versus LCOTHER LCOTHER LCOTHER and placebo on cardiovascular LCOTHER events in LCOTHER with LCOTHER .	1
Thus , LCGeneOrGeneProduct appears to play a critical oncogenic function in LCOTHER microenvironment and may be a potential target for developing therapeutic and preventive strategies against LCDiseaseOrPhenotypicFeature . Effects of the LCOTHER - LCOTHER specific inhibitor LCOTHER versus LCOTHER LCOTHER LCOTHER and placebo on cardiovascular LCOTHER events in LCOTHER with LCOTHER .	1
We evaluated cardiovascular event data for LCChemicalEntity , a new LCOTHER - LCOTHER - specific inhibitor in approximately 8000 LCOTHER with LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER treated with this agent in randomized clinical trials .	3
We evaluated cardiovascular event data for LCChemicalEntity , a new LCOTHER - LCOTHER - specific inhibitor in approximately 8000 LCOTHER with LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature treated with this agent in randomized clinical trials .	3
The incidence of cardiovascular LCOTHER events ( cardiac , cerebrovascular and peripheral vascular , or arterial LCOTHER ) was determined by analyzing pooled LCChemicalEntity ( 10 - 80 mg daily ) , nonselective LCChemicalEntity ( LCOTHER 75 mg bid , LCOTHER 800 mg tid , or LCOTHER 500 mg bid ) and placebo data from 10 randomized LCOTHER and LCOTHER LCOTHER trials that were 6 - 52 weeks in duration .	6
The incidence of cardiovascular LCOTHER events ( cardiac , cerebrovascular and peripheral vascular , or arterial LCOTHER ) was determined by analyzing pooled LCChemicalEntity ( 10 - 80 mg daily ) , nonselective LCOTHER ( LCOTHER 75 mg bid , LCOTHER 800 mg tid , or LCOTHER 500 mg bid ) and placebo data from 10 randomized LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER trials that were 6 - 52 weeks in duration .	3
The incidence of cardiovascular LCOTHER events ( cardiac , cerebrovascular and peripheral vascular , or arterial LCOTHER ) was determined by analyzing pooled LCChemicalEntity ( 10 - 80 mg daily ) , nonselective LCOTHER ( LCOTHER 75 mg bid , LCOTHER 800 mg tid , or LCOTHER 500 mg bid ) and placebo data from 10 randomized LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature trials that were 6 - 52 weeks in duration .	3
Crude and exposure - adjusted incidences of LCOTHER events were similar for LCChemicalEntity , LCChemicalEntity , and placebo .	6
LCDiseaseOrPhenotypicFeature risk was consistently higher for users of LCChemicalEntity users than nonusers of LCOTHER ( placebo , 1 . 4% vs .	2
LCDiseaseOrPhenotypicFeature risk was consistently higher for users of LCOTHER users than nonusers of LCChemicalEntity ( placebo , 1 . 4% vs .	2
Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) LCChemicalEntity doses was not associated with an increased incidence of LCOTHER events relative to nonselective LCChemicalEntity or placebo in LCOTHER and LCOTHER LCOTHER LCOTHER in controlled clinical trials . LCOTHER - LCOTHER as a biomarker of altered redox metabolism in LCOTHER LCOTHER cells exposed to LCOTHER .	6
Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) LCChemicalEntity doses was not associated with an increased incidence of LCOTHER events relative to nonselective LCOTHER or placebo in LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER in controlled clinical trials . LCOTHER - LCOTHER as a biomarker of altered redox metabolism in LCOTHER LCOTHER cells exposed to LCOTHER .	3
Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) LCChemicalEntity doses was not associated with an increased incidence of LCOTHER events relative to nonselective LCOTHER or placebo in LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER in controlled clinical trials . LCOTHER - LCOTHER as a biomarker of altered redox metabolism in LCOTHER LCOTHER cells exposed to LCOTHER .	3
BACKGROUND : LCChemicalEntity , a kinase inhibitor active against various solid LCDiseaseOrPhenotypicFeature , induces oxidative stress and ferroptosis , a new form of oxidative LCOTHER , in some LCOTHER cells .	3
BACKGROUND : LCChemicalEntity , a kinase inhibitor active against various solid LCOTHER , induces oxidative stress and ferroptosis , a new form of oxidative LCOTHER , in some LCDiseaseOrPhenotypicFeature cells .	3
Clinically - applicable biomarkers that reflect the impact of LCChemicalEntity on the redox metabolism of LCDiseaseOrPhenotypicFeature cells are lacking .	3
LCOTHER explants prepared from surgical LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) samples and serum samples obtained from LCOTHER LCOTHER receiving LCChemicalEntity were also used .	3
LCOTHER explants prepared from surgical LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) samples and serum samples obtained from LCOTHER LCOTHER receiving LCChemicalEntity were also used .	3
LCOTHER explants prepared from surgical LCOTHER LCOTHER ( LCOTHER ) samples and serum samples obtained from LCDiseaseOrPhenotypicFeature LCOTHER receiving LCChemicalEntity were also used .	3
RESULTS : We observed that genes of the LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) family are induced in the LCDiseaseOrPhenotypicFeature cell line LCOTHER exposed to LCOTHER .	1
RESULTS : We observed that genes of the LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) family are induced in the LCOTHER cell line LCOTHER exposed to LCChemicalEntity .	2
RESULTS : We observed that genes of the LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) family are induced in the LCDiseaseOrPhenotypicFeature cell line LCOTHER exposed to LCOTHER .	1
RESULTS : We observed that genes of the LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) family are induced in the LCOTHER cell line LCOTHER exposed to LCChemicalEntity .	2
RESULTS : We observed that genes of the LCOTHER - LCOTHER ( LCOTHER ) family are induced in the LCDiseaseOrPhenotypicFeature cell line LCOTHER exposed to LCChemicalEntity .	3
LCChemicalEntity increased the expression of LCOTHER mRNA in a panel of LCOTHER LCDiseaseOrPhenotypicFeature cells , an effect that was not observed with eight other clinically - approved kinase inhibitors .	3
LCOTHER increased the expression of LCGeneOrGeneProduct mRNA in a panel of LCOTHER LCDiseaseOrPhenotypicFeature cells , an effect that was not observed with eight other clinically - approved kinase inhibitors .	1
We identified the minimal region of the LCGeneOrGeneProduct promoter that confers inducibility by LCChemicalEntity to a 133 base pair region containing an Anti - oxidant Response Element ( ARE ) and showed the essential role of the transcription factor LCOTHER ( LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER ) .	2
We examined the clinical relevance of our findings by analysing the regulation of LCGeneOrGeneProduct in five LCDiseaseOrPhenotypicFeature explants prepared from surgical LCOTHER samples .	1
We examined the clinical relevance of our findings by analysing the regulation of LCGeneOrGeneProduct in five LCOTHER explants prepared from surgical LCDiseaseOrPhenotypicFeature samples .	1
Finally , we showed that the protein levels of LCGeneOrGeneProduct increase in the serum of some LCDiseaseOrPhenotypicFeature LCOTHER receiving LCOTHER , and found an association with reduced overall survival .	1
Finally , we showed that the protein levels of LCGeneOrGeneProduct increase in the serum of some LCOTHER LCOTHER receiving LCChemicalEntity , and found an association with reduced overall survival .	2
Finally , we showed that the protein levels of LCOTHER increase in the serum of some LCDiseaseOrPhenotypicFeature LCOTHER receiving LCChemicalEntity , and found an association with reduced overall survival .	3
CONCLUSION : These findings indicate that LCGeneOrGeneProduct constitute a biomarker adapted for exploring the impact of LCChemicalEntity on the redox metabolism of LCOTHER cells . Familial LCOTHER LCOTHER haploinsufficiency by non - sense mediated mRNA decay , LCOTHER LCOTHER and LCOTHER LCOTHER LCOTHER .	2
CONCLUSION : These findings indicate that LCGeneOrGeneProduct constitute a biomarker adapted for exploring the impact of LCOTHER on the redox metabolism of LCDiseaseOrPhenotypicFeature cells . Familial LCOTHER LCOTHER haploinsufficiency by non - sense mediated mRNA decay , LCOTHER LCOTHER and LCOTHER LCOTHER LCOTHER .	1
CONCLUSION : These findings indicate that LCOTHER constitute a biomarker adapted for exploring the impact of LCChemicalEntity on the redox metabolism of LCDiseaseOrPhenotypicFeature cells . Familial LCOTHER LCOTHER haploinsufficiency by non - sense mediated mRNA decay , LCOTHER LCOTHER and LCOTHER LCOTHER LCOTHER .	3
Primary LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER LCOTHER ) is a rare LCOTHER LCOTHER that causes a generalized partial insensitivity to LCChemicalEntity action , due to genetic alterations of the LCOTHER LCOTHER ( LCOTHER ) .	1
This reduced LCGeneOrGeneProduct expression leads to a significantly below - normal induction of LCChemicalEntity - induced target genes , LCOTHER in fibroblasts .	4
This reduced LCGeneOrGeneProduct expression leads to a significantly below - normal induction of LCOTHER - induced target genes , LCGeneOrGeneProduct in fibroblasts .	2
This reduced LCOTHER expression leads to a significantly below - normal induction of LCChemicalEntity - induced target genes , LCGeneOrGeneProduct in fibroblasts .	2
LCGeneOrGeneProduct haploinsufficiency leads to LCDiseaseOrPhenotypicFeature due to illicit occupation of renal LCOTHER LCOTHER by elevated LCOTHER rather than to increased LCOTHER production reported in primary LCOTHER LCOTHER .	1
LCGeneOrGeneProduct haploinsufficiency leads to LCOTHER due to illicit occupation of renal LCGeneOrGeneProduct LCGeneOrGeneProduct by elevated LCOTHER rather than to increased LCOTHER production reported in primary LCOTHER LCOTHER .	1
LCGeneOrGeneProduct haploinsufficiency leads to LCOTHER due to illicit occupation of renal LCOTHER LCOTHER by elevated LCOTHER rather than to increased LCOTHER production reported in primary LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
LCOTHER haploinsufficiency leads to LCDiseaseOrPhenotypicFeature due to illicit occupation of renal LCGeneOrGeneProduct LCGeneOrGeneProduct by elevated LCOTHER rather than to increased LCOTHER production reported in primary LCOTHER LCOTHER .	1
LCOTHER haploinsufficiency leads to LCDiseaseOrPhenotypicFeature due to illicit occupation of renal LCOTHER LCOTHER by elevated LCChemicalEntity rather than to increased LCOTHER production reported in primary LCOTHER LCOTHER .	1
LCOTHER haploinsufficiency leads to LCOTHER due to illicit occupation of renal LCGeneOrGeneProduct LCGeneOrGeneProduct by elevated LCChemicalEntity rather than to increased LCOTHER production reported in primary LCOTHER LCOTHER .	1
Indeed , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature was demonstrated by a decrease in urinary LCChemicalEntity - LCOTHER ratio in affected LCOTHER , revealing reduced LCOTHER degradation by renal activity of the LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER , a LCOTHER regulated gene .	1
Indeed , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature was demonstrated by a decrease in urinary LCOTHER - LCChemicalEntity ratio in affected LCOTHER , revealing reduced LCOTHER degradation by renal activity of the LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER , a LCOTHER regulated gene .	1
Indeed , LCOTHER LCOTHER LCOTHER was demonstrated by a decrease in urinary LCOTHER - LCOTHER ratio in affected LCOTHER , revealing reduced LCChemicalEntity degradation by renal activity of the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , a LCOTHER regulated gene .	2
Indeed , LCOTHER LCOTHER LCOTHER was demonstrated by a decrease in urinary LCOTHER - LCOTHER ratio in affected LCOTHER , revealing reduced LCOTHER degradation by renal activity of the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , a LCGeneOrGeneProduct regulated gene .	1
We propose thus that LCGeneOrGeneProduct haploinsufficiency compromises LCChemicalEntity sensitivity and may represent a novel genetic cause of subclinical LCOTHER , incidentally revealed LCOTHER LCOTHER LCOTHER and LCOTHER - independent LCOTHER . Genetic alterations in primary LCOTHER in Japan .	4
We propose thus that LCGeneOrGeneProduct haploinsufficiency compromises LCOTHER sensitivity and may represent a novel genetic cause of subclinical LCDiseaseOrPhenotypicFeature , incidentally revealed LCOTHER LCOTHER LCOTHER and LCOTHER - independent LCOTHER . Genetic alterations in primary LCOTHER in Japan .	1
We propose thus that LCGeneOrGeneProduct haploinsufficiency compromises LCOTHER sensitivity and may represent a novel genetic cause of subclinical LCOTHER , incidentally revealed LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER - independent LCOTHER . Genetic alterations in primary LCOTHER in Japan .	1
We propose thus that LCGeneOrGeneProduct haploinsufficiency compromises LCOTHER sensitivity and may represent a novel genetic cause of subclinical LCOTHER , incidentally revealed LCOTHER LCOTHER LCOTHER and LCOTHER - independent LCDiseaseOrPhenotypicFeature . Genetic alterations in primary LCOTHER in Japan .	1
We propose thus that LCOTHER haploinsufficiency compromises LCChemicalEntity sensitivity and may represent a novel genetic cause of subclinical LCDiseaseOrPhenotypicFeature , incidentally revealed LCOTHER LCOTHER LCOTHER and LCOTHER - independent LCOTHER . Genetic alterations in primary LCOTHER in Japan .	1
SSCP followed by DNA sequencing revealed LCGeneOrGeneProduct mutations in 16 of 73 ( 22% ) LCDiseaseOrPhenotypicFeature and LCOTHER mutations in 13 of 63 ( 21% ) cases analyzed .	1
Polymerase chain reaction ( PCR ) showed LCGeneOrGeneProduct amplification in 25 of 77 ( 32% ) cases and LCGeneOrGeneProduct homozygous deletion in 32 of 77 ( 42% ) cases .	3
As previously observed for LCDiseaseOrPhenotypicFeature in Europe , there was a positive association between LCGeneOrGeneProduct amplification and LCOTHER deletion ( p = 0 . 009 ) , whereas there was an inverse association between LCOTHER mutations and LCOTHER deletion ( p = 0 . 049 ) in LCOTHER in Japan .	1
As previously observed for LCDiseaseOrPhenotypicFeature in Europe , there was a positive association between LCOTHER amplification and LCGeneOrGeneProduct deletion ( p = 0 . 009 ) , whereas there was an inverse association between LCOTHER mutations and LCOTHER deletion ( p = 0 . 049 ) in LCOTHER in Japan .	1
As previously observed for LCDiseaseOrPhenotypicFeature in Europe , there was a positive association between LCOTHER amplification and LCOTHER deletion ( p = 0 . 009 ) , whereas there was an inverse association between LCOTHER mutations and LCGeneOrGeneProduct deletion ( p = 0 . 049 ) in LCOTHER in Japan .	1
As previously observed for LCOTHER in Europe , there was a positive association between LCGeneOrGeneProduct amplification and LCGeneOrGeneProduct deletion ( p = 0 . 009 ) , whereas there was an inverse association between LCOTHER mutations and LCOTHER deletion ( p = 0 . 049 ) in LCOTHER in Japan .	3
As previously observed for LCOTHER in Europe , there was a positive association between LCGeneOrGeneProduct amplification and LCOTHER deletion ( p = 0 . 009 ) , whereas there was an inverse association between LCOTHER mutations and LCGeneOrGeneProduct deletion ( p = 0 . 049 ) in LCOTHER in Japan .	3
As previously observed for LCOTHER in Europe , there was a positive association between LCOTHER amplification and LCOTHER deletion ( p = 0 . 009 ) , whereas there was an inverse association between LCGeneOrGeneProduct mutations and LCGeneOrGeneProduct deletion ( p = 0 . 049 ) in LCOTHER in Japan .	2
As previously observed for LCOTHER in Europe , there was a positive association between LCOTHER amplification and LCOTHER deletion ( p = 0 . 009 ) , whereas there was an inverse association between LCGeneOrGeneProduct mutations and LCOTHER deletion ( p = 0 . 049 ) in LCDiseaseOrPhenotypicFeature in Japan .	1
The allele frequencies of polymorphisms at LCSequenceVariant LCSequenceVariant LCSequenceVariant / LCSequenceVariant ( LCOTHER / LCOTHER ) in LCDiseaseOrPhenotypicFeature in Japan were G / G ( 82 . 4% ) , G / A ( 10 . 8% ) , A / A ( 6 . 8% ) , corresponding to G 0 . 878 versus A 0 . 122 , significantly different from those in LCOTHER in Switzerland : G / G ( 27 . 2% ) , G / A ( 28 . 4% ) , A / A ( 44 . 4% ) , corresponding to G 0 . 414 versus A 0 . 586 ( p < 0 . 0001 ) .	1
The allele frequencies of polymorphisms at LCSequenceVariant LCSequenceVariant LCSequenceVariant / LCSequenceVariant ( LCOTHER / LCOTHER ) in LCOTHER in Japan were G / G ( 82 . 4% ) , G / A ( 10 . 8% ) , A / A ( 6 . 8% ) , corresponding to G 0 . 878 versus A 0 . 122 , significantly different from those in LCDiseaseOrPhenotypicFeature in Switzerland : G / G ( 27 . 2% ) , G / A ( 28 . 4% ) , A / A ( 44 . 4% ) , corresponding to G 0 . 414 versus A 0 . 586 ( p < 0 . 0001 ) .	1
The allele frequencies of polymorphisms at LCOTHER LCOTHER LCOTHER / LCOTHER ( LCSequenceVariant / LCSequenceVariant ) in LCDiseaseOrPhenotypicFeature in Japan were G / G ( 82 . 4% ) , G / A ( 10 . 8% ) , A / A ( 6 . 8% ) , corresponding to G 0 . 878 versus A 0 . 122 , significantly different from those in LCOTHER in Switzerland : G / G ( 27 . 2% ) , G / A ( 28 . 4% ) , A / A ( 44 . 4% ) , corresponding to G 0 . 414 versus A 0 . 586 ( p < 0 . 0001 ) .	1
The allele frequencies of polymorphisms at LCOTHER LCOTHER LCOTHER / LCOTHER ( LCSequenceVariant / LCSequenceVariant ) in LCOTHER in Japan were G / G ( 82 . 4% ) , G / A ( 10 . 8% ) , A / A ( 6 . 8% ) , corresponding to G 0 . 878 versus A 0 . 122 , significantly different from those in LCDiseaseOrPhenotypicFeature in Switzerland : G / G ( 27 . 2% ) , G / A ( 28 . 4% ) , A / A ( 44 . 4% ) , corresponding to G 0 . 414 versus A 0 . 586 ( p < 0 . 0001 ) .	1
These results suggest that primary LCDiseaseOrPhenotypicFeature in Japan show genetic alterations similar to those in Switzerland , suggesting a similar molecular basis in caucasians and Asians , despite different genetic backgrounds , including different status of a polymorphism in the LCGeneOrGeneProduct gene . Large deletion involving exon 5 of the LCOTHER LCOTHER gene caused apparent homozygosity in a LCOTHER LCOTHER LCOTHER LCOTHER .	1
Most LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER are of Slavonic origin , and all of them known so far carry a founder homozygous LCSequenceVariant LCSequenceVariant LCSequenceVariant in the LCOTHER gene .	2
Most LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER are of Slavonic origin , and all of them known so far carry a founder homozygous LCOTHER LCOTHER LCOTHER in the LCGeneOrGeneProduct gene .	1
Here we report that two members of the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER ( LCOTHER LCOTHER ) LCOTHER ( LCOTHER LCOTHER ) components , LCGeneOrGeneProduct and LCGeneOrGeneProduct , are required during mammalian preimplantation development .	4
Expression of some lineage specific factors is markedly reduced in LCGeneOrGeneProduct knockdown embryos , including LCGeneOrGeneProduct , LCOTHER and LCOTHER , while others are inappropriately expressed ( LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) .	2
Expression of some lineage specific factors is markedly reduced in LCGeneOrGeneProduct knockdown embryos , including LCOTHER , LCGeneOrGeneProduct and LCOTHER , while others are inappropriately expressed ( LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) .	2
Expression of some lineage specific factors is markedly reduced in LCGeneOrGeneProduct knockdown embryos , including LCOTHER , LCOTHER and LCGeneOrGeneProduct , while others are inappropriately expressed ( LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) .	2
Expression of some lineage specific factors is markedly reduced in LCGeneOrGeneProduct knockdown embryos , including LCOTHER , LCOTHER and LCOTHER , while others are inappropriately expressed ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) .	3
Expression of some lineage specific factors is markedly reduced in LCGeneOrGeneProduct knockdown embryos , including LCOTHER , LCOTHER and LCOTHER , while others are inappropriately expressed ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER ) .	3
Expression of some lineage specific factors is markedly reduced in LCGeneOrGeneProduct knockdown embryos , including LCOTHER , LCOTHER and LCOTHER , while others are inappropriately expressed ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER ) .	1
Expression of some lineage specific factors is markedly reduced in LCGeneOrGeneProduct knockdown embryos , including LCOTHER , LCOTHER and LCOTHER , while others are inappropriately expressed ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER ) .	3
Expression of some lineage specific factors is markedly reduced in LCGeneOrGeneProduct knockdown embryos , including LCOTHER , LCOTHER and LCOTHER , while others are inappropriately expressed ( LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct ) .	3
We document a loss of LCOTHER LCOTHER LCOTHER LCOTHER trimethylation ( LCOTHER ) in LCGeneOrGeneProduct - deficient embryos and confirm that knockdown of either LCOTHER or LCGeneOrGeneProduct results in similar phenotypes .	4
LCChemicalEntity ( LCOTHER ) is an active ingredient that is isolated from LCOTHER LCOTHER , which has been reported to have anti - LCDiseaseOrPhenotypicFeature activities and a renal protective effect .	3
LCOTHER ( LCChemicalEntity ) is an active ingredient that is isolated from LCOTHER LCOTHER , which has been reported to have anti - LCDiseaseOrPhenotypicFeature activities and a renal protective effect .	3
However , the role of LCChemicalEntity on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature has not yet been elucidated .	3
Here , the purpose of the current study is to test the protective effects of LCChemicalEntity against LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) , and to explore the underlying mechanisms using both in vivo and in vitro models .	3
Here , the purpose of the current study is to test the protective effects of LCChemicalEntity against LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , and to explore the underlying mechanisms using both in vivo and in vitro models .	3
In this study , we establish the LCOTHER LCOTHER LCOTHER ( LCOTHER ) or LCChemicalEntity LCChemicalEntity ( LCOTHER ) - induced LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in vivo and the LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER - stimulated LCOTHER proximal tubular epithelial cell ( LCOTHER - LCOTHER ) model in vitro .	2
In this study , we establish the LCOTHER LCOTHER LCOTHER ( LCOTHER ) or LCOTHER LCOTHER ( LCChemicalEntity ) - induced LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in vivo and the LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER - stimulated LCOTHER proximal tubular epithelial cell ( LCOTHER - LCOTHER ) model in vitro .	2
Immunohistochemistry and western blotting are used to determine the mechanisms of LCChemicalEntity against LCDiseaseOrPhenotypicFeature .	3
Our results show that treatment with LCChemicalEntity can ameliorate LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and deposition of the extracellular matrix ( ECM ) components ( including LCOTHER LCOTHER and LCOTHER LCOTHER ) .	3
Additionally , LCChemicalEntity also reduces the levels of serum biochemical markers ( serum LCChemicalEntity , Scr ; blood LCOTHER LCOTHER , BUN ; and LCOTHER LCOTHER , LCOTHER ) and decreases the release of LCOTHER cytokines ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) .	3
Additionally , LCChemicalEntity also reduces the levels of serum biochemical markers ( serum LCOTHER , Scr ; blood LCOTHER LCOTHER , BUN ; and LCChemicalEntity LCChemicalEntity , LCOTHER ) and decreases the release of LCOTHER cytokines ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) .	3
Additionally , LCChemicalEntity also reduces the levels of serum biochemical markers ( serum LCOTHER , Scr ; blood LCOTHER LCOTHER , BUN ; and LCOTHER LCOTHER , LCChemicalEntity ) and decreases the release of LCOTHER cytokines ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) .	3
Additionally , LCChemicalEntity also reduces the levels of serum biochemical markers ( serum LCOTHER , Scr ; blood LCOTHER LCOTHER , BUN ; and LCOTHER LCOTHER , LCOTHER ) and decreases the release of LCDiseaseOrPhenotypicFeature cytokines ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) .	3
Further study revealed that the effect of LCChemicalEntity on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature is associated with the lower expression of LCOTHER , p - LCOTHER , p - LCOTHER - LCOTHER and LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , both in vivo and in vitro .	3
Furthermore , LCChemicalEntity treatment significantly decreases the release of LCDiseaseOrPhenotypicFeature cytokines and inhibits the LCOTHER / LCOTHER - LCOTHER and LCOTHER signaling pathways .	3
Collectively , these results suggest that the administration of LCChemicalEntity could be a novel therapeutic strategy in treating LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER - LCOTHER LCOTHER and LCOTHER - LCOTHER LCOTHER differentially affect the migration and invasion of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER cells .	3
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) are the most common LCOTHER associated with LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	1
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) are the most common LCOTHER associated with LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	1
LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) are the most common LCOTHER associated with LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	1
LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) are the most common LCOTHER associated with LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	1
We have shown that LCDiseaseOrPhenotypicFeature express LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) LCGeneOrGeneProduct isoforms , which promote Schwann cell migration during development , and LCOTHER - LCOTHER LCOTHER isoforms , whose effects on Schwann cells are poorly understood .	1
We have shown that LCDiseaseOrPhenotypicFeature express LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) LCOTHER isoforms , which promote Schwann cell migration during development , and LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct isoforms , whose effects on Schwann cells are poorly understood .	1
Hypothesizing that LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct and / or LCOTHER - LCOTHER LCOTHER promote LCOTHER invasion , we found that LCOTHER - LCOTHER LCOTHER promoted LCOTHER migration in a substrate - specific manner , markedly enhancing migration on LCGeneOrGeneProduct but not on LCOTHER LCOTHER LCOTHER or LCOTHER .	1
Hypothesizing that LCOTHER - LCOTHER LCOTHER and / or LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct promote LCOTHER invasion , we found that LCOTHER - LCOTHER LCOTHER promoted LCOTHER migration in a substrate - specific manner , markedly enhancing migration on LCGeneOrGeneProduct but not on LCOTHER LCOTHER LCOTHER or LCOTHER .	1
Hypothesizing that LCOTHER - LCOTHER LCOTHER and / or LCOTHER - LCOTHER LCOTHER promote LCDiseaseOrPhenotypicFeature invasion , we found that LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct promoted LCOTHER migration in a substrate - specific manner , markedly enhancing migration on LCOTHER but not on LCOTHER LCOTHER LCOTHER or LCOTHER .	1
Hypothesizing that LCOTHER - LCOTHER LCOTHER and / or LCOTHER - LCOTHER LCOTHER promote LCDiseaseOrPhenotypicFeature invasion , we found that LCOTHER - LCOTHER LCOTHER promoted LCOTHER migration in a substrate - specific manner , markedly enhancing migration on LCGeneOrGeneProduct but not on LCOTHER LCOTHER LCOTHER or LCOTHER .	1
Hypothesizing that LCOTHER - LCOTHER LCOTHER and / or LCOTHER - LCOTHER LCOTHER promote LCOTHER invasion , we found that LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct promoted LCOTHER migration in a substrate - specific manner , markedly enhancing migration on LCGeneOrGeneProduct but not on LCOTHER LCOTHER LCOTHER or LCOTHER .	1
Hypothesizing that LCOTHER - LCOTHER LCOTHER and / or LCOTHER - LCOTHER LCOTHER promote LCOTHER invasion , we found that LCOTHER - LCOTHER LCOTHER promoted LCDiseaseOrPhenotypicFeature migration in a substrate - specific manner , markedly enhancing migration on LCGeneOrGeneProduct but not on LCOTHER LCOTHER LCOTHER or LCOTHER .	1
The LCOTHER - LCOTHER receptors LCOTHER and LCOTHER were present in LCDiseaseOrPhenotypicFeature invadopodia ( processes mediating invasion ) , partially colocalized with LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct and the LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER and coimmunoprecipitated with LCOTHER ( LCOTHER ) - LCOTHER .	1
The LCOTHER - LCOTHER receptors LCOTHER and LCOTHER were present in LCDiseaseOrPhenotypicFeature invadopodia ( processes mediating invasion ) , partially colocalized with LCOTHER LCOTHER LCOTHER and the LCGeneOrGeneProduct LCGeneOrGeneProduct LCOTHER ( LCOTHER ) - LCOTHER and coimmunoprecipitated with LCOTHER ( LCOTHER ) - LCOTHER .	1
The LCOTHER - LCOTHER receptors LCOTHER and LCOTHER were present in LCDiseaseOrPhenotypicFeature invadopodia ( processes mediating invasion ) , partially colocalized with LCOTHER LCOTHER LCOTHER and the LCOTHER LCOTHER LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct and coimmunoprecipitated with LCOTHER ( LCOTHER ) - LCOTHER .	1
The LCOTHER - LCOTHER receptors LCOTHER and LCOTHER were present in LCDiseaseOrPhenotypicFeature invadopodia ( processes mediating invasion ) , partially colocalized with LCOTHER LCOTHER LCOTHER and the LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER and coimmunoprecipitated with LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct .	1
These findings suggest that LCOTHER - LCOTHER LCOTHER enhances LCDiseaseOrPhenotypicFeature migration and that LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct and LCOTHER - LCOTHER LCOTHER differentially modulate this process . Critical role of LCOTHER LCOTHER LCOTHER in mitochondria - mediated LCOTHER - LCOTHER LCOTHER LCOTHER .	1
These findings suggest that LCOTHER - LCOTHER LCOTHER enhances LCDiseaseOrPhenotypicFeature migration and that LCOTHER - LCOTHER LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct differentially modulate this process . Critical role of LCOTHER LCOTHER LCOTHER in mitochondria - mediated LCOTHER - LCOTHER LCOTHER LCOTHER .	1
Previously , we have reported induction of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , a novel neuronal protein of long - pentraxin family , following LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
Previously , we have reported induction of LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , a novel neuronal protein of long - pentraxin family , following LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
We used wild - type ( WT ) and LCGeneOrGeneProduct knockout ( LCOTHER - KO ) LCOTHER hippocampal cultures , modeled in vitro following exposure to LCOTHER LCOTHER deprivation ( OGD ) , and in vivo neonatal ( P9 - 10 ) LCOTHER model of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
We used wild - type ( WT ) and LCOTHER knockout ( LCGeneOrGeneProduct - KO ) LCOTHER hippocampal cultures , modeled in vitro following exposure to LCOTHER LCOTHER deprivation ( OGD ) , and in vivo neonatal ( P9 - 10 ) LCOTHER model of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
We also found increased LCGeneOrGeneProduct activity concurrent with OGD time - dependent ( 4 - 8 h ) dephosphorylation of LCGeneOrGeneProduct ( LCOTHER ) and LCOTHER - LCOTHER ( LCOTHER ) .	1
We also found increased LCGeneOrGeneProduct activity concurrent with OGD time - dependent ( 4 - 8 h ) dephosphorylation of LCOTHER ( LCOTHER ) and LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) .	1
Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of LCGeneOrGeneProduct and LCOTHER proteins from cytoplasm following OGD ( 4 h ) and simultaneously increased release of LCGeneOrGeneProduct LCGeneOrGeneProduct from mitochondria followed by activation of LCOTHER - LCOTHER .	1
Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of LCGeneOrGeneProduct and LCOTHER proteins from cytoplasm following OGD ( 4 h ) and simultaneously increased release of LCOTHER LCOTHER from mitochondria followed by activation of LCGeneOrGeneProduct - LCGeneOrGeneProduct .	1
Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of LCOTHER and LCGeneOrGeneProduct proteins from cytoplasm following OGD ( 4 h ) and simultaneously increased release of LCGeneOrGeneProduct LCGeneOrGeneProduct from mitochondria followed by activation of LCOTHER - LCOTHER .	1
Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of LCOTHER and LCGeneOrGeneProduct proteins from cytoplasm following OGD ( 4 h ) and simultaneously increased release of LCOTHER LCOTHER from mitochondria followed by activation of LCGeneOrGeneProduct - LCGeneOrGeneProduct .	1
LCGeneOrGeneProduct protein was immunoprecipitated with LCGeneOrGeneProduct and LCOTHER proteins ; OGD caused increased interactions of LCOTHER with LCOTHER and LCOTHER , thereby , facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential ( D ( m ) ) .	1
LCGeneOrGeneProduct protein was immunoprecipitated with LCOTHER and LCGeneOrGeneProduct proteins ; OGD caused increased interactions of LCOTHER with LCOTHER and LCOTHER , thereby , facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential ( D ( m ) ) .	1
LCGeneOrGeneProduct protein was immunoprecipitated with LCOTHER and LCOTHER proteins ; OGD caused increased interactions of LCOTHER with LCGeneOrGeneProduct and LCOTHER , thereby , facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential ( D ( m ) ) .	1
LCGeneOrGeneProduct protein was immunoprecipitated with LCOTHER and LCOTHER proteins ; OGD caused increased interactions of LCOTHER with LCOTHER and LCGeneOrGeneProduct , thereby , facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential ( D ( m ) ) .	1
LCOTHER protein was immunoprecipitated with LCOTHER and LCOTHER proteins ; OGD caused increased interactions of LCGeneOrGeneProduct with LCGeneOrGeneProduct and LCOTHER , thereby , facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential ( D ( m ) ) .	1
LCOTHER protein was immunoprecipitated with LCOTHER and LCOTHER proteins ; OGD caused increased interactions of LCGeneOrGeneProduct with LCOTHER and LCGeneOrGeneProduct , thereby , facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential ( D ( m ) ) .	1
In contrast , in LCGeneOrGeneProduct - KO neurons there was no translocation of LCGeneOrGeneProduct and LCOTHER from cytosol to the mitochondria , and no evidence of D ( m ) loss , increased LCOTHER LCOTHER release and LCOTHER - LCOTHER activation following OGD ; which resulted in significantly reduced LCOTHER LCOTHER .	1
In contrast , in LCGeneOrGeneProduct - KO neurons there was no translocation of LCOTHER and LCGeneOrGeneProduct from cytosol to the mitochondria , and no evidence of D ( m ) loss , increased LCOTHER LCOTHER release and LCOTHER - LCOTHER activation following OGD ; which resulted in significantly reduced LCOTHER LCOTHER .	1
In contrast , in LCGeneOrGeneProduct - KO neurons there was no translocation of LCOTHER and LCOTHER from cytosol to the mitochondria , and no evidence of D ( m ) loss , increased LCOTHER LCOTHER release and LCOTHER - LCOTHER activation following OGD ; which resulted in significantly reduced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
In contrast , in LCOTHER - KO neurons there was no translocation of LCGeneOrGeneProduct and LCOTHER from cytosol to the mitochondria , and no evidence of D ( m ) loss , increased LCGeneOrGeneProduct LCGeneOrGeneProduct release and LCOTHER - LCOTHER activation following OGD ; which resulted in significantly reduced LCOTHER LCOTHER .	1
In contrast , in LCOTHER - KO neurons there was no translocation of LCGeneOrGeneProduct and LCOTHER from cytosol to the mitochondria , and no evidence of D ( m ) loss , increased LCOTHER LCOTHER release and LCGeneOrGeneProduct - LCGeneOrGeneProduct activation following OGD ; which resulted in significantly reduced LCOTHER LCOTHER .	1
In contrast , in LCOTHER - KO neurons there was no translocation of LCGeneOrGeneProduct and LCOTHER from cytosol to the mitochondria , and no evidence of D ( m ) loss , increased LCOTHER LCOTHER release and LCOTHER - LCOTHER activation following OGD ; which resulted in significantly reduced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
In contrast , in LCOTHER - KO neurons there was no translocation of LCOTHER and LCGeneOrGeneProduct from cytosol to the mitochondria , and no evidence of D ( m ) loss , increased LCGeneOrGeneProduct LCGeneOrGeneProduct release and LCOTHER - LCOTHER activation following OGD ; which resulted in significantly reduced LCOTHER LCOTHER .	1
In contrast , in LCOTHER - KO neurons there was no translocation of LCOTHER and LCGeneOrGeneProduct from cytosol to the mitochondria , and no evidence of D ( m ) loss , increased LCOTHER LCOTHER release and LCGeneOrGeneProduct - LCGeneOrGeneProduct activation following OGD ; which resulted in significantly reduced LCOTHER LCOTHER .	1
In contrast , in LCOTHER - KO neurons there was no translocation of LCOTHER and LCGeneOrGeneProduct from cytosol to the mitochondria , and no evidence of D ( m ) loss , increased LCOTHER LCOTHER release and LCOTHER - LCOTHER activation following OGD ; which resulted in significantly reduced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
In contrast , in LCOTHER - KO neurons there was no translocation of LCOTHER and LCOTHER from cytosol to the mitochondria , and no evidence of D ( m ) loss , increased LCGeneOrGeneProduct LCGeneOrGeneProduct release and LCOTHER - LCOTHER activation following OGD ; which resulted in significantly reduced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
In contrast , in LCOTHER - KO neurons there was no translocation of LCOTHER and LCOTHER from cytosol to the mitochondria , and no evidence of D ( m ) loss , increased LCOTHER LCOTHER release and LCGeneOrGeneProduct - LCGeneOrGeneProduct activation following OGD ; which resulted in significantly reduced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
Our results indicate a regulatory role of LCGeneOrGeneProduct in LCGeneOrGeneProduct / LCOTHER - dependent mitochondrial release of LCOTHER LCOTHER and LCOTHER - LCOTHER activation .	1
Our results indicate a regulatory role of LCGeneOrGeneProduct in LCOTHER / LCGeneOrGeneProduct - dependent mitochondrial release of LCOTHER LCOTHER and LCOTHER - LCOTHER activation .	1
Our results indicate a regulatory role of LCOTHER in LCGeneOrGeneProduct / LCOTHER - dependent mitochondrial release of LCGeneOrGeneProduct LCGeneOrGeneProduct and LCOTHER - LCOTHER activation .	1
Our results indicate a regulatory role of LCOTHER in LCGeneOrGeneProduct / LCOTHER - dependent mitochondrial release of LCOTHER LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct activation .	1
Our results indicate a regulatory role of LCOTHER in LCOTHER / LCGeneOrGeneProduct - dependent mitochondrial release of LCGeneOrGeneProduct LCGeneOrGeneProduct and LCOTHER - LCOTHER activation .	1
Our results indicate a regulatory role of LCOTHER in LCOTHER / LCGeneOrGeneProduct - dependent mitochondrial release of LCOTHER LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct activation .	1
Together our findings demonstrate a novel mechanism by which LCGeneOrGeneProduct regulates mitochondria - driven hippocampal cell death ; suggesting LCOTHER as a potential therapeutic target against LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in neonates . Repeated LCOTHER LCOTHER administration prevents LCOTHER changes in colon of LCOTHER underwent to wrap restraint stress .	1
Together our findings demonstrate a novel mechanism by which LCOTHER regulates mitochondria - driven hippocampal cell death ; suggesting LCGeneOrGeneProduct as a potential therapeutic target against LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in neonates . Repeated LCOTHER LCOTHER administration prevents LCOTHER changes in colon of LCOTHER underwent to wrap restraint stress .	1
LCChemicalEntity LCChemicalEntity ( LCOTHER ) is a spasmolytic drug successfully used for the treatment of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	3
LCChemicalEntity LCChemicalEntity ( LCOTHER ) is a spasmolytic drug successfully used for the treatment of LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	3
LCOTHER LCOTHER ( LCChemicalEntity ) is a spasmolytic drug successfully used for the treatment of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	3
LCOTHER LCOTHER ( LCChemicalEntity ) is a spasmolytic drug successfully used for the treatment of LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	3
Furthermore , in healthy LCOTHER , repeated LCChemicalEntity administration modified LCChemicalEntity expression and function suggesting other mechanisms of action .	1
On this basis , we investigated whether repeated LCChemicalEntity treatment prevented the functional and neurochemical changes observed in the colon of LCOTHER underwent to wrap restrain stress ( WRS ) a psychosocial stressor considered suitable to reproduce the main LCDiseaseOrPhenotypicFeature signs and symptoms .	3
The results showed that LCChemicalEntity counteracts most of the LCChemicalEntity changes caused by WRS .	1
Finally , LCChemicalEntity per se increases the LCGeneOrGeneProduct expression in the muscle wall and decreases the number of the myenteric LCOTHER - IR neurons .	2
Finally , LCChemicalEntity per se increases the LCOTHER expression in the muscle wall and decreases the number of the myenteric LCGeneOrGeneProduct - IR neurons .	3
The ability of LCOTHER to block LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct + ) LCGeneOrGeneProduct , also expressed by enteric neurons , might represent a possible mechanism through which LCChemicalEntity exerts its actions . Lack of association of LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER status with LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER , and disease severity .	3
OBJECTIVE : LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) plays an important role in LCDiseaseOrPhenotypicFeature .	1
OBJECTIVE : LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) plays an important role in LCDiseaseOrPhenotypicFeature .	1
Therefore LCGeneOrGeneProduct activity , oxidative stress , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) activity , spatial learning and memory as well as the effect of LCOTHER , a previously proposed therapy for LCOTHER LCOTHER , were evaluated in an experimental model of LCOTHER administration in LCOTHER .	3
Therefore LCGeneOrGeneProduct activity , oxidative stress , LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) activity , spatial learning and memory as well as the effect of LCOTHER , a previously proposed therapy for LCOTHER LCOTHER , were evaluated in an experimental model of LCOTHER administration in LCOTHER .	3
Therefore LCGeneOrGeneProduct activity , oxidative stress , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) activity , spatial learning and memory as well as the effect of LCOTHER , a previously proposed therapy for LCOTHER LCOTHER , were evaluated in an experimental model of LCChemicalEntity administration in LCOTHER .	3
Therefore LCOTHER activity , oxidative stress , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) activity , spatial learning and memory as well as the effect of LCOTHER , a previously proposed therapy for LCOTHER LCOTHER , were evaluated in an experimental model of LCChemicalEntity administration in LCOTHER .	2
Therefore LCOTHER activity , oxidative stress , LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) activity , spatial learning and memory as well as the effect of LCOTHER , a previously proposed therapy for LCOTHER LCOTHER , were evaluated in an experimental model of LCChemicalEntity administration in LCOTHER .	2
Therefore LCOTHER activity , oxidative stress , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) activity , spatial learning and memory as well as the effect of LCChemicalEntity , a previously proposed therapy for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , were evaluated in an experimental model of LCOTHER administration in LCOTHER .	3
LCGeneOrGeneProduct activity was decreased in the frontal cortex of LCChemicalEntity treated LCOTHER , as well as LCOTHER concentration and LCOTHER peroxidase activity in the hippocampus , whereas LCOTHER activity in the hippocampus was increased .	3
LCGeneOrGeneProduct activity was decreased in the frontal cortex of LCOTHER treated LCOTHER , as well as LCOTHER concentration and LCOTHER peroxidase activity in the hippocampus , whereas LCGeneOrGeneProduct activity in the hippocampus was increased .	3
LCOTHER activity was decreased in the frontal cortex of LCChemicalEntity treated LCOTHER , as well as LCChemicalEntity concentration and LCOTHER peroxidase activity in the hippocampus , whereas LCOTHER activity in the hippocampus was increased .	1
LCOTHER activity was decreased in the frontal cortex of LCChemicalEntity treated LCOTHER , as well as LCOTHER concentration and LCChemicalEntity peroxidase activity in the hippocampus , whereas LCOTHER activity in the hippocampus was increased .	1
In contrast , learning of new tasks was enhanced and correlated with the increase of LCGeneOrGeneProduct activity and the decrease of LCChemicalEntity peroxidase .	1
These results provide evidence for a possible mechanistic role of oxidative and nitrosative stress and LCGeneOrGeneProduct in the alterations induced by LCChemicalEntity .	3
More than 100 different heterozygous mutations in LCGeneOrGeneProduct / LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) have been found in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) , a fatal LCOTHER LCOTHER .	1
More than 100 different heterozygous mutations in LCGeneOrGeneProduct / LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) have been found in LCOTHER with LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , a fatal LCOTHER LCOTHER .	1
More than 100 different heterozygous mutations in LCOTHER / LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) have been found in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) , a fatal LCOTHER LCOTHER .	1
More than 100 different heterozygous mutations in LCOTHER / LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) have been found in LCOTHER with LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , a fatal LCOTHER LCOTHER .	1
The frequency of LCSequenceVariant - LCOTHER is 50 times higher in Scandinavia ( 2 . 5% ) than elsewhere , though LCDiseaseOrPhenotypicFeature prevalence is not raised there .	3
The frequency of LCOTHER - LCGeneOrGeneProduct is 50 times higher in Scandinavia ( 2 . 5% ) than elsewhere , though LCDiseaseOrPhenotypicFeature prevalence is not raised there .	1
We propose that a cis - acting regulatory polymorphism has arisen close to LCSequenceVariant - LCOTHER in the recessive founder , which decreases LCDiseaseOrPhenotypicFeature susceptibility in heterozygotes and slows disease progression . LCOTHER LCOTHER inhibit LCOTHER growth in a LCOTHER - LCOTHER LCOTHER LCOTHER - dependent manner by altering the cytokine milieu from LCOTHER - LCOTHER / LCOTHER - LCOTHER to LCOTHER - LCOTHER .	3
We propose that a cis - acting regulatory polymorphism has arisen close to LCOTHER - LCGeneOrGeneProduct in the recessive founder , which decreases LCDiseaseOrPhenotypicFeature susceptibility in heterozygotes and slows disease progression . LCOTHER LCOTHER inhibit LCOTHER growth in a LCOTHER - LCOTHER LCOTHER LCOTHER - dependent manner by altering the cytokine milieu from LCOTHER - LCOTHER / LCOTHER - LCOTHER to LCOTHER - LCOTHER .	1
Administration of LCOTHER LCChemicalEntity suppressed LCDiseaseOrPhenotypicFeature growth in C3H / HeN LCOTHER , but not in LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , while increasing LCOTHER ( LCOTHER ) - LCOTHER levels .	3
Administration of LCOTHER LCChemicalEntity suppressed LCOTHER growth in C3H / HeN LCOTHER , but not in LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , while increasing LCOTHER ( LCOTHER ) - LCOTHER levels .	1
Administration of LCOTHER LCChemicalEntity suppressed LCOTHER growth in C3H / HeN LCOTHER , but not in LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , while increasing LCOTHER ( LCOTHER ) - LCOTHER levels .	1
Administration of LCOTHER LCChemicalEntity suppressed LCOTHER growth in C3H / HeN LCOTHER , but not in LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER , while increasing LCOTHER ( LCOTHER ) - LCOTHER levels .	3
Administration of LCOTHER LCChemicalEntity suppressed LCOTHER growth in C3H / HeN LCOTHER , but not in LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , while increasing LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct levels .	2
Administration of LCOTHER LCOTHER suppressed LCDiseaseOrPhenotypicFeature growth in C3H / HeN LCOTHER , but not in LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER , while increasing LCOTHER ( LCOTHER ) - LCOTHER levels .	1
Administration of LCOTHER LCOTHER suppressed LCDiseaseOrPhenotypicFeature growth in C3H / HeN LCOTHER , but not in LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct , while increasing LCOTHER ( LCOTHER ) - LCOTHER levels .	1
Administration of LCOTHER LCOTHER suppressed LCDiseaseOrPhenotypicFeature growth in C3H / HeN LCOTHER , but not in LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , while increasing LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct levels .	1
Administration of LCOTHER LCOTHER suppressed LCOTHER growth in C3H / HeN LCOTHER , but not in LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER , while increasing LCOTHER ( LCOTHER ) - LCOTHER levels .	1
Administration of LCOTHER LCOTHER suppressed LCOTHER growth in C3H / HeN LCOTHER , but not in LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct , while increasing LCOTHER ( LCOTHER ) - LCOTHER levels .	1
Administration of LCOTHER LCOTHER suppressed LCOTHER growth in C3H / HeN LCOTHER , but not in LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , while increasing LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct levels .	1
Administration of LCOTHER LCOTHER suppressed LCOTHER growth in C3H / HeN LCOTHER , but not in LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER , while increasing LCOTHER ( LCOTHER ) - LCOTHER levels .	1
Administration of LCOTHER LCOTHER suppressed LCOTHER growth in C3H / HeN LCOTHER , but not in LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct , while increasing LCOTHER ( LCOTHER ) - LCOTHER levels .	1
Administration of LCOTHER LCOTHER suppressed LCOTHER growth in C3H / HeN LCOTHER , but not in LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , while increasing LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct levels .	1
Moreover , in vitro experiments showed that LCOTHER LCChemicalEntity impaired the antigen - presenting function that supports the generation of LCGeneOrGeneProduct - LCGeneOrGeneProduct - producing cells in a LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER - dependent manner .	3
Moreover , in vitro experiments showed that LCOTHER LCChemicalEntity impaired the antigen - presenting function that supports the generation of LCOTHER - LCOTHER - producing cells in a LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct - dependent manner .	1
Of note , injection of anti - LCOTHER - LCOTHER antibody in LCDiseaseOrPhenotypicFeature - bearing C3H / HeN LCOTHER in the absence of LCOTHER LCOTHER markedly suppressed LCOTHER growth and augmented LCGeneOrGeneProduct - LCGeneOrGeneProduct responses .	1
Of note , injection of anti - LCOTHER - LCOTHER antibody in LCOTHER - bearing C3H / HeN LCOTHER in the absence of LCOTHER LCChemicalEntity markedly suppressed LCDiseaseOrPhenotypicFeature growth and augmented LCOTHER - LCOTHER responses .	3
Of note , injection of anti - LCOTHER - LCOTHER antibody in LCOTHER - bearing C3H / HeN LCOTHER in the absence of LCOTHER LCChemicalEntity markedly suppressed LCOTHER growth and augmented LCGeneOrGeneProduct - LCGeneOrGeneProduct responses .	2
Of note , injection of anti - LCOTHER - LCOTHER antibody in LCOTHER - bearing C3H / HeN LCOTHER in the absence of LCOTHER LCOTHER markedly suppressed LCDiseaseOrPhenotypicFeature growth and augmented LCGeneOrGeneProduct - LCGeneOrGeneProduct responses .	1
Thus , our results support the notion that LCOTHER - LCOTHER and LCOTHER - LCOTHER / LCOTHER - LCOTHER mutually regulate Th17 and Th1 responses in LCDiseaseOrPhenotypicFeature - bearing hosts , and LCOTHER LCOTHER modulates the balance of the LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCOTHER - LCOTHER / LCOTHER - LCOTHER axis towards LCOTHER - LCOTHER production , which leads to LCOTHER inhibition .	1
Thus , our results support the notion that LCOTHER - LCOTHER and LCOTHER - LCOTHER / LCOTHER - LCOTHER mutually regulate Th17 and Th1 responses in LCDiseaseOrPhenotypicFeature - bearing hosts , and LCOTHER LCOTHER modulates the balance of the LCOTHER - LCOTHER - LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCOTHER - LCOTHER axis towards LCOTHER - LCOTHER production , which leads to LCOTHER inhibition .	1
Thus , our results support the notion that LCOTHER - LCOTHER and LCOTHER - LCOTHER / LCOTHER - LCOTHER mutually regulate Th17 and Th1 responses in LCDiseaseOrPhenotypicFeature - bearing hosts , and LCOTHER LCOTHER modulates the balance of the LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct axis towards LCOTHER - LCOTHER production , which leads to LCOTHER inhibition .	1
Thus , our results support the notion that LCOTHER - LCOTHER and LCOTHER - LCOTHER / LCOTHER - LCOTHER mutually regulate Th17 and Th1 responses in LCDiseaseOrPhenotypicFeature - bearing hosts , and LCOTHER LCOTHER modulates the balance of the LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER - LCOTHER axis towards LCGeneOrGeneProduct - LCGeneOrGeneProduct production , which leads to LCOTHER inhibition .	1
Thus , our results support the notion that LCOTHER - LCOTHER and LCOTHER - LCOTHER / LCOTHER - LCOTHER mutually regulate Th17 and Th1 responses in LCOTHER - bearing hosts , and LCOTHER LCChemicalEntity modulates the balance of the LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCOTHER - LCOTHER / LCOTHER - LCOTHER axis towards LCOTHER - LCOTHER production , which leads to LCOTHER inhibition .	2
Thus , our results support the notion that LCOTHER - LCOTHER and LCOTHER - LCOTHER / LCOTHER - LCOTHER mutually regulate Th17 and Th1 responses in LCOTHER - bearing hosts , and LCOTHER LCChemicalEntity modulates the balance of the LCOTHER - LCOTHER - LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCOTHER - LCOTHER axis towards LCOTHER - LCOTHER production , which leads to LCOTHER inhibition .	3
Thus , our results support the notion that LCOTHER - LCOTHER and LCOTHER - LCOTHER / LCOTHER - LCOTHER mutually regulate Th17 and Th1 responses in LCOTHER - bearing hosts , and LCOTHER LCChemicalEntity modulates the balance of the LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER - LCOTHER axis towards LCGeneOrGeneProduct - LCGeneOrGeneProduct production , which leads to LCOTHER inhibition .	2
Thus , our results support the notion that LCOTHER - LCOTHER and LCOTHER - LCOTHER / LCOTHER - LCOTHER mutually regulate Th17 and Th1 responses in LCOTHER - bearing hosts , and LCOTHER LCChemicalEntity modulates the balance of the LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER - LCOTHER axis towards LCOTHER - LCOTHER production , which leads to LCDiseaseOrPhenotypicFeature inhibition .	3
Furthermore , LCOTHER LCChemicalEntity effectively inhibited the spontaneous development of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
This study has important implications for the exploitation of LCGeneOrGeneProduct - based immunomodulators for LCDiseaseOrPhenotypicFeature immunotherapy . LCOTHER LCOTHER LCOTHER LCOTHER is involved in the modulation of the LCOTHER + homeostasis in skeletal muscle cells .	1
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) , the most prevalent LCOTHER LCOTHER in adults , is caused by ( CTG ) n - repeat expansion in a gene encoding a protein kinase ( LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ; LCOTHER ) and involves changes in cytoarchitecture and ion homeostasis .	1
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) , the most prevalent LCOTHER LCOTHER in adults , is caused by ( CTG ) n - repeat expansion in a gene encoding a protein kinase ( LCOTHER LCOTHER LCOTHER ; LCGeneOrGeneProduct ) and involves changes in cytoarchitecture and ion homeostasis .	1
LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , the most prevalent LCOTHER LCOTHER in adults , is caused by ( CTG ) n - repeat expansion in a gene encoding a protein kinase ( LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ; LCOTHER ) and involves changes in cytoarchitecture and ion homeostasis .	1
LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , the most prevalent LCOTHER LCOTHER in adults , is caused by ( CTG ) n - repeat expansion in a gene encoding a protein kinase ( LCOTHER LCOTHER LCOTHER ; LCGeneOrGeneProduct ) and involves changes in cytoarchitecture and ion homeostasis .	1
To obtain clues to the normal biological role of LCOTHER in cellular ion homeostasis , we have compared the resting [ LCChemicalEntity + ] i , the amplitude and shape of depolarization - induced LCOTHER + transients , and the content of LCOTHER - driven ion pumps in cultured skeletal muscle cells of wild - type and LCGeneOrGeneProduct [ - / - ] knockout LCOTHER .	3
To obtain clues to the normal biological role of LCOTHER in cellular ion homeostasis , we have compared the resting [ LCOTHER + ] i , the amplitude and shape of depolarization - induced LCChemicalEntity + transients , and the content of LCOTHER - driven ion pumps in cultured skeletal muscle cells of wild - type and LCGeneOrGeneProduct [ - / - ] knockout LCOTHER .	3
We have identified 14 families with LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature ( LCOTHER - LCOTHER ) in which mutation of the LCGeneOrGeneProduct gene is associated with a less severe clinical and cellular phenotype ( approximately 10% - 15% of LCOTHER - LCOTHER families identified in the United Kingdom ) .	1
We have identified 14 families with LCOTHER - LCOTHER ( LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature ) in which mutation of the LCGeneOrGeneProduct gene is associated with a less severe clinical and cellular phenotype ( approximately 10% - 15% of LCOTHER - LCOTHER families identified in the United Kingdom ) .	1
Patients were randomly allocated to either receive or not receive 1 1 LCChemicalEntity , while a third group received LCChemicalEntity in addition to LCOTHER .	5
RESULTS : Omission of LCChemicalEntity did not reduce the overall incidence of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , but did reduce the incidence of LCOTHER and / or moderate to severe LCOTHER prior to discharge from 20% and 17% with LCOTHER and LCOTHER - LCOTHER , respectively , to 5% ( P = 0 . 013 ) .	2
RESULTS : Omission of LCChemicalEntity did not reduce the overall incidence of LCOTHER LCOTHER LCOTHER LCOTHER , but did reduce the incidence of LCDiseaseOrPhenotypicFeature and / or moderate to severe LCOTHER prior to discharge from 20% and 17% with LCOTHER and LCOTHER - LCOTHER , respectively , to 5% ( P = 0 . 013 ) .	2
RESULTS : Omission of LCChemicalEntity did not reduce the overall incidence of LCOTHER LCOTHER LCOTHER LCOTHER , but did reduce the incidence of LCOTHER and / or moderate to severe LCDiseaseOrPhenotypicFeature prior to discharge from 20% and 17% with LCOTHER and LCOTHER - LCOTHER , respectively , to 5% ( P = 0 . 013 ) .	2
RESULTS : Omission of LCChemicalEntity did not reduce the overall incidence of LCOTHER LCOTHER LCOTHER LCOTHER , but did reduce the incidence of LCOTHER and / or moderate to severe LCOTHER prior to discharge from 20% and 17% with LCOTHER and LCOTHER - LCChemicalEntity , respectively , to 5% ( P = 0 . 013 ) .	5
RESULTS : Omission of LCOTHER did not reduce the overall incidence of LCOTHER LCOTHER LCOTHER LCOTHER , but did reduce the incidence of LCOTHER and / or moderate to severe LCOTHER prior to discharge from 20% and 17% with LCChemicalEntity and LCOTHER - LCChemicalEntity , respectively , to 5% ( P = 0 . 013 ) .	5
RESULTS : Omission of LCOTHER did not reduce the overall incidence of LCOTHER LCOTHER LCOTHER LCOTHER , but did reduce the incidence of LCOTHER and / or moderate to severe LCOTHER prior to discharge from 20% and 17% with LCOTHER and LCChemicalEntity - LCChemicalEntity , respectively , to 5% ( P = 0 . 013 ) .	5
Combining the two LCChemicalEntity groups revealed further significant benefits from the avoidance of opioids , reducing LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER prior to discharge from 35% and 33% to 22% and 19% ( P = 0 . 049 and P = 0 . 035 ) , respectively , while LCOTHER in the first 24 h was decreased from 42% to 27% ( P = 0 . 034 ) .	2
Combining the two LCChemicalEntity groups revealed further significant benefits from the avoidance of opioids , reducing LCOTHER LCOTHER LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature prior to discharge from 35% and 33% to 22% and 19% ( P = 0 . 049 and P = 0 . 035 ) , respectively , while LCOTHER in the first 24 h was decreased from 42% to 27% ( P = 0 . 034 ) .	2
Combining the two LCChemicalEntity groups revealed further significant benefits from the avoidance of opioids , reducing LCOTHER LCOTHER LCOTHER LCOTHER and LCOTHER prior to discharge from 35% and 33% to 22% and 19% ( P = 0 . 049 and P = 0 . 035 ) , respectively , while LCDiseaseOrPhenotypicFeature in the first 24 h was decreased from 42% to 27% ( P = 0 . 034 ) .	2
LCChemicalEntity did reduce minor intraoperative movement but had no LCChemicalEntity - sparing effect and increased LCOTHER LCOTHER , LCOTHER and LCOTHER .	5
LCChemicalEntity did reduce minor intraoperative movement but had no LCOTHER - sparing effect and increased LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER and LCOTHER .	2
LCChemicalEntity did reduce minor intraoperative movement but had no LCOTHER - sparing effect and increased LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature and LCOTHER .	2
LCChemicalEntity did reduce minor intraoperative movement but had no LCOTHER - sparing effect and increased LCOTHER LCOTHER , LCOTHER and LCDiseaseOrPhenotypicFeature .	2
CONCLUSION : As LCChemicalEntity exacerbated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature without an improvement in LCOTHER LCOTHER and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to LCOTHER in day surgery . LCOTHER - induced LCOTHER + overload causes LCOTHER and triggers apoptosis through LCOTHER LCOTHER signaling pathway in LCOTHER .	2
CONCLUSION : As LCChemicalEntity exacerbated LCOTHER LCOTHER LCOTHER LCOTHER without an improvement in LCOTHER LCOTHER and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to LCChemicalEntity in day surgery . LCOTHER - induced LCOTHER + overload causes LCOTHER and triggers apoptosis through LCOTHER LCOTHER signaling pathway in LCOTHER .	5
CONCLUSION : As LCOTHER exacerbated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature without an improvement in LCOTHER LCOTHER and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to LCChemicalEntity in day surgery . LCOTHER - induced LCOTHER + overload causes LCOTHER and triggers apoptosis through LCOTHER LCOTHER signaling pathway in LCOTHER .	2
CONCLUSION : As LCOTHER exacerbated LCOTHER LCOTHER LCOTHER LCOTHER without an improvement in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to LCChemicalEntity in day surgery . LCOTHER - induced LCOTHER + overload causes LCOTHER and triggers apoptosis through LCOTHER LCOTHER signaling pathway in LCOTHER .	2
Emerging evidence indicates that voltage - dependent LCChemicalEntity ( + ) channels have pivotal roles in the LCDiseaseOrPhenotypicFeature of LCOTHER .	1
We found that LCChemicalEntity ( LCChemicalEntity + ) overload lead to accelerated beating rhythm in adult LCOTHER ventricular myocytes and caused LCDiseaseOrPhenotypicFeature in conscious freely moving LCOTHER .	2
To investigate effects of LCChemicalEntity on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , we performed LCOTHER assay in neonatal LCOTHER ventricular myocytes ( NRVMs ) , as well as measured LCOTHER LCOTHER level in the culture medium of NRVMs and activities of serum cardiac enzymes in LCOTHER .	2
The results showed that LCChemicalEntity resulted in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and reduced NRVMs viability dose - dependently .	2
The expression analysis of LCOTHER ( LCOTHER + ) handling proteins demonstrated that LCChemicalEntity promoted LCChemicalEntity ( LCChemicalEntity + ) overload through the expression regulation of LCOTHER ( LCOTHER + ) handling proteins .	2
The expression analysis of LCOTHER ( LCOTHER + ) handling proteins demonstrated that LCChemicalEntity promoted LCOTHER ( LCOTHER + ) overload through the expression regulation of LCChemicalEntity ( LCChemicalEntity + ) handling proteins .	2
Hence , our results suggest that LCChemicalEntity significantly aggravates LCChemicalEntity ( LCChemicalEntity + ) overload and causes LCOTHER and finally promotes apoptotic development via phosphorylation of LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER . LCOTHER LCOTHER treatment ameliorates acute LCOTHER LCOTHER in LCOTHER .	2
Hence , our results suggest that LCChemicalEntity significantly aggravates LCOTHER ( LCOTHER + ) overload and causes LCDiseaseOrPhenotypicFeature and finally promotes apoptotic development via phosphorylation of LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER . LCOTHER LCOTHER treatment ameliorates acute LCOTHER LCOTHER in LCOTHER .	2
Hence , our results suggest that LCChemicalEntity significantly aggravates LCOTHER ( LCOTHER + ) overload and causes LCOTHER and finally promotes apoptotic development via phosphorylation of LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct . LCOTHER LCOTHER treatment ameliorates acute LCOTHER LCOTHER in LCOTHER .	1
Hence , our results suggest that LCOTHER significantly aggravates LCChemicalEntity ( LCChemicalEntity + ) overload and causes LCDiseaseOrPhenotypicFeature and finally promotes apoptotic development via phosphorylation of LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER . LCOTHER LCOTHER treatment ameliorates acute LCOTHER LCOTHER in LCOTHER .	2
Hence , our results suggest that LCOTHER significantly aggravates LCOTHER ( LCOTHER + ) overload and causes LCDiseaseOrPhenotypicFeature and finally promotes apoptotic development via phosphorylation of LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct . LCOTHER LCOTHER treatment ameliorates acute LCOTHER LCOTHER in LCOTHER .	1
LCChemicalEntity LCChemicalEntity treatment ( 10 mg / kg / day , i . p . ) was applied for 6 consecutive days , starting 1 day before LCChemicalEntity administration .	3
LCChemicalEntity LCChemicalEntity significantly reduced LCChemicalEntity LCChemicalEntity LCChemicalEntity and serum LCOTHER levels which were increased by LCOTHER .	3
LCChemicalEntity LCChemicalEntity significantly reduced LCOTHER LCOTHER LCOTHER and serum LCChemicalEntity levels which were increased by LCOTHER .	3
LCChemicalEntity LCChemicalEntity significantly reduced LCOTHER LCOTHER LCOTHER and serum LCOTHER levels which were increased by LCChemicalEntity .	3
LCChemicalEntity LCChemicalEntity significantly compensated deficits in the antioxidant defense mechanisms ( reduced LCChemicalEntity level and LCOTHER LCOTHER activity ) , suppressed LCOTHER peroxidation , decreased the elevations of LCOTHER LCOTHER LCOTHER - LCOTHER , LCOTHER LCOTHER and LCOTHER ion concentration , and attenuated the reductions of LCOTHER and LCOTHER ions in renal tissue resulted from LCOTHER administration .	3
LCChemicalEntity LCChemicalEntity significantly compensated deficits in the antioxidant defense mechanisms ( reduced LCOTHER level and LCGeneOrGeneProduct LCGeneOrGeneProduct activity ) , suppressed LCOTHER peroxidation , decreased the elevations of LCOTHER LCOTHER LCOTHER - LCOTHER , LCOTHER LCOTHER and LCOTHER ion concentration , and attenuated the reductions of LCOTHER and LCOTHER ions in renal tissue resulted from LCOTHER administration .	3
LCChemicalEntity LCChemicalEntity significantly compensated deficits in the antioxidant defense mechanisms ( reduced LCOTHER level and LCOTHER LCOTHER activity ) , suppressed LCChemicalEntity peroxidation , decreased the elevations of LCOTHER LCOTHER LCOTHER - LCOTHER , LCOTHER LCOTHER and LCOTHER ion concentration , and attenuated the reductions of LCOTHER and LCOTHER ions in renal tissue resulted from LCOTHER administration .	3
LCChemicalEntity LCChemicalEntity significantly compensated deficits in the antioxidant defense mechanisms ( reduced LCOTHER level and LCOTHER LCOTHER activity ) , suppressed LCOTHER peroxidation , decreased the elevations of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER LCOTHER and LCOTHER ion concentration , and attenuated the reductions of LCOTHER and LCOTHER ions in renal tissue resulted from LCOTHER administration .	3
LCChemicalEntity LCChemicalEntity significantly compensated deficits in the antioxidant defense mechanisms ( reduced LCOTHER level and LCOTHER LCOTHER activity ) , suppressed LCOTHER peroxidation , decreased the elevations of LCOTHER LCOTHER LCOTHER - LCOTHER , LCChemicalEntity LCChemicalEntity and LCOTHER ion concentration , and attenuated the reductions of LCOTHER and LCOTHER ions in renal tissue resulted from LCOTHER administration .	3
LCChemicalEntity LCChemicalEntity significantly compensated deficits in the antioxidant defense mechanisms ( reduced LCOTHER level and LCOTHER LCOTHER activity ) , suppressed LCOTHER peroxidation , decreased the elevations of LCOTHER LCOTHER LCOTHER - LCOTHER , LCOTHER LCOTHER and LCChemicalEntity ion concentration , and attenuated the reductions of LCOTHER and LCOTHER ions in renal tissue resulted from LCOTHER administration .	3
LCChemicalEntity LCChemicalEntity significantly compensated deficits in the antioxidant defense mechanisms ( reduced LCOTHER level and LCOTHER LCOTHER activity ) , suppressed LCOTHER peroxidation , decreased the elevations of LCOTHER LCOTHER LCOTHER - LCOTHER , LCOTHER LCOTHER and LCOTHER ion concentration , and attenuated the reductions of LCChemicalEntity and LCOTHER ions in renal tissue resulted from LCOTHER administration .	2
LCChemicalEntity LCChemicalEntity significantly compensated deficits in the antioxidant defense mechanisms ( reduced LCOTHER level and LCOTHER LCOTHER activity ) , suppressed LCOTHER peroxidation , decreased the elevations of LCOTHER LCOTHER LCOTHER - LCOTHER , LCOTHER LCOTHER and LCOTHER ion concentration , and attenuated the reductions of LCOTHER and LCChemicalEntity ions in renal tissue resulted from LCOTHER administration .	2
LCChemicalEntity LCChemicalEntity significantly compensated deficits in the antioxidant defense mechanisms ( reduced LCOTHER level and LCOTHER LCOTHER activity ) , suppressed LCOTHER peroxidation , decreased the elevations of LCOTHER LCOTHER LCOTHER - LCOTHER , LCOTHER LCOTHER and LCOTHER ion concentration , and attenuated the reductions of LCOTHER and LCOTHER ions in renal tissue resulted from LCChemicalEntity administration .	3
LCOTHER LCOTHER significantly compensated deficits in the antioxidant defense mechanisms ( reduced LCOTHER level and LCOTHER LCOTHER activity ) , suppressed LCOTHER peroxidation , decreased the elevations of LCOTHER LCOTHER LCOTHER - LCOTHER , LCOTHER LCOTHER and LCOTHER ion concentration , and attenuated the reductions of LCChemicalEntity and LCOTHER ions in renal tissue resulted from LCChemicalEntity administration .	3
LCOTHER LCOTHER significantly compensated deficits in the antioxidant defense mechanisms ( reduced LCOTHER level and LCOTHER LCOTHER activity ) , suppressed LCOTHER peroxidation , decreased the elevations of LCOTHER LCOTHER LCOTHER - LCOTHER , LCOTHER LCOTHER and LCOTHER ion concentration , and attenuated the reductions of LCOTHER and LCChemicalEntity ions in renal tissue resulted from LCChemicalEntity administration .	3
Immunohistochemical analysis revealed that LCChemicalEntity LCChemicalEntity significantly decreased the LCChemicalEntity - induced overexpression of inducible LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER in renal tissue .	3
Immunohistochemical analysis revealed that LCChemicalEntity LCChemicalEntity significantly decreased the LCOTHER - induced overexpression of inducible LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER in renal tissue .	3
Immunohistochemical analysis revealed that LCChemicalEntity LCChemicalEntity significantly decreased the LCOTHER - induced overexpression of inducible LCOTHER LCOTHER LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER and LCOTHER in renal tissue .	3
Immunohistochemical analysis revealed that LCChemicalEntity LCChemicalEntity significantly decreased the LCOTHER - induced overexpression of inducible LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER in renal tissue .	3
Immunohistochemical analysis revealed that LCChemicalEntity LCChemicalEntity significantly decreased the LCOTHER - induced overexpression of inducible LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCGeneOrGeneProduct in renal tissue .	3
Immunohistochemical analysis revealed that LCOTHER LCOTHER significantly decreased the LCChemicalEntity - induced overexpression of inducible LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER in renal tissue .	2
Immunohistochemical analysis revealed that LCOTHER LCOTHER significantly decreased the LCChemicalEntity - induced overexpression of inducible LCOTHER LCOTHER LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER and LCOTHER in renal tissue .	2
Immunohistochemical analysis revealed that LCOTHER LCOTHER significantly decreased the LCChemicalEntity - induced overexpression of inducible LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER in renal tissue .	2
Immunohistochemical analysis revealed that LCOTHER LCOTHER significantly decreased the LCChemicalEntity - induced overexpression of inducible LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCGeneOrGeneProduct in renal tissue .	2
It was concluded that LCChemicalEntity LCChemicalEntity represents a potential therapeutic option to protect against acute LCChemicalEntity LCOTHER commonly encountered in clinical practice . LCOTHER decoded : the genomic sequence of a cytogenetically aberrant LCOTHER LCOTHER cell line .	3
It was concluded that LCChemicalEntity LCChemicalEntity represents a potential therapeutic option to protect against acute LCOTHER LCDiseaseOrPhenotypicFeature commonly encountered in clinical practice . LCOTHER decoded : the genomic sequence of a cytogenetically aberrant LCOTHER LCOTHER cell line .	3
It was concluded that LCOTHER LCOTHER represents a potential therapeutic option to protect against acute LCChemicalEntity LCDiseaseOrPhenotypicFeature commonly encountered in clinical practice . LCOTHER decoded : the genomic sequence of a cytogenetically aberrant LCOTHER LCOTHER cell line .	2
A missense mutation in the LCOTHER LCGeneOrGeneProduct gene has previously been linked to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
A missense mutation in the LCOTHER LCGeneOrGeneProduct gene has previously been linked to LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
The LCGeneOrGeneProduct LCOTHER allele associates with morning preference and is a potential candidate allele for LCDiseaseOrPhenotypicFeature . LCOTHER and LCOTHER - inhibitor variation and LCOTHER LCOTHER risk in Afro - Caribbeans .	1
The LCOTHER LCSequenceVariant allele associates with morning preference and is a potential candidate allele for LCDiseaseOrPhenotypicFeature . LCOTHER and LCOTHER - inhibitor variation and LCOTHER LCOTHER risk in Afro - Caribbeans .	2
Variation in the LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) gene has recently been reported to be associated with an increased risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
Variation in the LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene has recently been reported to be associated with an increased risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
However , whether LCGeneOrGeneProduct variation contributes to the increased risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature observed in populations of African ancestry remains unclear .	1
METHODS : We resequenced the positional candidate gene LCGeneOrGeneProduct in 48 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cases and genotyped the previously reported LCOTHER and LCOTHER polymorphisms in 230 LCOTHER LCOTHER cases and 458 controls .	1
METHODS : We resequenced the positional candidate gene LCGeneOrGeneProduct in 48 LCOTHER LCOTHER cases and genotyped the previously reported LCOTHER and LCOTHER polymorphisms in 230 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cases and 458 controls .	1
METHODS : We resequenced the positional candidate gene LCOTHER in 48 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cases and genotyped the previously reported LCSequenceVariant and LCOTHER polymorphisms in 230 LCOTHER LCOTHER cases and 458 controls .	1
METHODS : We resequenced the positional candidate gene LCOTHER in 48 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cases and genotyped the previously reported LCOTHER and LCSequenceVariant polymorphisms in 230 LCOTHER LCOTHER cases and 458 controls .	1
We also examined the inhibitor of LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) for variation associated with LCOTHER LCOTHER risk .	3
We also examined the inhibitor of LCGeneOrGeneProduct ( LCOTHER ) for variation associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk .	1
A novel variant ( LCSequenceVariant ) was identified in a single heterozygous individual with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
CONCLUSIONS : Our results suggest that common variation in the putative LCOTHER LCOTHER susceptibility gene , LCGeneOrGeneProduct , or its inhibitor does not contribute significantly to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk in this Afro - Caribbean population . Hepatic but not brain LCOTHER is rapidly chelated by LCOTHER in LCOTHER due to a novel gene mutation .	1
BACKGROUND _ # 38 ; AIMS : LCDiseaseOrPhenotypicFeature is a rare LCOTHER LCOTHER LCOTHER LCOTHER associated with brain and liver LCChemicalEntity accumulation which typically presents with LCOTHER LCOTHER , LCOTHER LCOTHER , and LCOTHER LCOTHER .	2
BACKGROUND _ # 38 ; AIMS : LCOTHER is a rare LCOTHER LCOTHER LCOTHER LCOTHER associated with brain and liver LCChemicalEntity accumulation which typically presents with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER , and LCOTHER LCOTHER .	2
BACKGROUND _ # 38 ; AIMS : LCOTHER is a rare LCOTHER LCOTHER LCOTHER LCOTHER associated with brain and liver LCChemicalEntity accumulation which typically presents with LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and LCOTHER LCOTHER .	2
BACKGROUND _ # 38 ; AIMS : LCOTHER is a rare LCOTHER LCOTHER LCOTHER LCOTHER associated with brain and liver LCChemicalEntity accumulation which typically presents with LCOTHER LCOTHER , LCOTHER LCOTHER , and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
LCGeneOrGeneProduct is a multi - copper LCOTHER that is secreted into plasma and facilitates cellular LCChemicalEntity export and LCOTHER binding to LCOTHER .	1
LCGeneOrGeneProduct is a multi - copper LCOTHER that is secreted into plasma and facilitates cellular LCOTHER export and LCChemicalEntity binding to LCOTHER .	1
LCOTHER is a multi - copper LCOTHER that is secreted into plasma and facilitates cellular LCChemicalEntity export and LCOTHER binding to LCGeneOrGeneProduct .	4
LCOTHER is a multi - copper LCOTHER that is secreted into plasma and facilitates cellular LCOTHER export and LCChemicalEntity binding to LCGeneOrGeneProduct .	4
RESULTS : A novel homozygous LCGeneOrGeneProduct gene mutation , LCOTHER . LCOTHER + LCOTHER > LCOTHER , was identified as the cause of LCDiseaseOrPhenotypicFeature in three affected siblings .	1
RESULTS : A novel homozygous LCOTHER gene mutation , LCSequenceVariant . LCSequenceVariant + LCSequenceVariant > LCSequenceVariant , was identified as the cause of LCDiseaseOrPhenotypicFeature in three affected siblings .	2
LCDiseaseOrPhenotypicFeature was associated with severe brain and liver LCOTHER LCOTHER , where hepatic mRNA expression of the LCChemicalEntity hormone LCOTHER was increased , corresponding to the degree of LCOTHER LCOTHER .	2
LCDiseaseOrPhenotypicFeature was associated with severe brain and liver LCOTHER LCOTHER , where hepatic mRNA expression of the LCOTHER hormone LCGeneOrGeneProduct was increased , corresponding to the degree of LCOTHER LCOTHER .	1
LCOTHER was associated with severe brain and liver LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , where hepatic mRNA expression of the LCChemicalEntity hormone LCOTHER was increased , corresponding to the degree of LCOTHER LCOTHER .	2
LCOTHER was associated with severe brain and liver LCOTHER LCOTHER , where hepatic mRNA expression of the LCOTHER hormone LCGeneOrGeneProduct was increased , corresponding to the degree of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
Hepatic LCChemicalEntity concentration normalized after 3 and 5months of LCOTHER chelation therapy with LCChemicalEntity , which was also associated with reduced LCOTHER demands .	4
Hepatic LCOTHER concentration normalized after 3 and 5months of LCChemicalEntity chelation therapy with LCChemicalEntity , which was also associated with reduced LCOTHER demands .	4
Hepatic LCOTHER concentration normalized after 3 and 5months of LCOTHER chelation therapy with LCChemicalEntity , which was also associated with reduced LCGeneOrGeneProduct demands .	3
CONCLUSIONS : LCDiseaseOrPhenotypicFeature can show an incomplete clinical penetrance but is invariably associated with LCChemicalEntity accumulation in the liver and in the brain .	2
LCOTHER accumulation in LCDiseaseOrPhenotypicFeature is a result of defective cellular LCChemicalEntity export , where LCOTHER regulation is appropriate for the degree of LCOTHER LCOTHER .	2
LCOTHER accumulation in LCDiseaseOrPhenotypicFeature is a result of defective cellular LCOTHER export , where LCGeneOrGeneProduct regulation is appropriate for the degree of LCOTHER LCOTHER .	1
LCOTHER accumulation in LCOTHER is a result of defective cellular LCOTHER export , where LCGeneOrGeneProduct regulation is appropriate for the degree of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
LCChemicalEntity chelation with LCChemicalEntity was effective in mobilizing hepatic LCOTHER but has no effect on brain LCOTHER . Aberrant LCOTHER - LCOTHER - mediated LCOTHER signaling and proliferation identified by analysis of LCOTHER LCOTHER LCOTHER mutation ( LCOTHER . LCOTHER ) in LCOTHER fibroblasts : a new perspective on the mechanism of LCOTHER LCOTHER .	4
A heterozygous LCGeneOrGeneProduct - LCGeneOrGeneProduct LCOTHER . LCOTHER mutation has been identified in a family with heritable LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
A heterozygous LCGeneOrGeneProduct - LCGeneOrGeneProduct LCOTHER . LCOTHER mutation has been identified in a family with heritable LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
A heterozygous LCOTHER - LCOTHER LCSequenceVariant . LCSequenceVariant mutation has been identified in a family with heritable LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
A heterozygous LCOTHER - LCOTHER LCSequenceVariant . LCSequenceVariant mutation has been identified in a family with heritable LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
These results demonstrate the critical role of the final 20 amino acids of LCGeneOrGeneProduct - LCGeneOrGeneProduct in modulating fibroblast proliferation by dampening LCOTHER signaling and suggest that augmented LCOTHER signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of LCDiseaseOrPhenotypicFeature in LCOTHER with LCOTHER - LCOTHER LCOTHER . LCOTHER mutation . Mutations in LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) LCOTHER in LCOTHER with LCOTHER - LCOTHER LCOTHER LCOTHER .	1
Accordingly , altered levels of protein LCGeneOrGeneProduct - LCGeneOrGeneProduct have been associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER .	1
Accordingly , altered levels of protein LCGeneOrGeneProduct - LCGeneOrGeneProduct have been associated with LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature .	1
Here , we report on two hemizygous mutations in LCGeneOrGeneProduct in individuals with LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) and dysmorphic features : one missense mutation ( LCOTHER . LCOTHER ) and one mutation leading to a splicing defect ( LCOTHER . LCOTHER - LCOTHER > LCOTHER ) .	1
Here , we report on two hemizygous mutations in LCGeneOrGeneProduct in individuals with LCOTHER - LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) and dysmorphic features : one missense mutation ( LCOTHER . LCOTHER ) and one mutation leading to a splicing defect ( LCOTHER . LCOTHER - LCOTHER > LCOTHER ) .	1
Recombinant LCGeneOrGeneProduct bearing the LCOTHER . LCOTHER mutation was prone to unfolding and exhibited reduced glycosylation activity against a complex array of glycosylation substrates and proteolytic processing of the transcription factor LCOTHER LCOTHER LCOTHER LCOTHER , which is also encoded by an LCDiseaseOrPhenotypicFeature - associated gene .	1
Recombinant LCOTHER bearing the LCSequenceVariant . LCSequenceVariant mutation was prone to unfolding and exhibited reduced glycosylation activity against a complex array of glycosylation substrates and proteolytic processing of the transcription factor LCOTHER LCOTHER LCOTHER LCOTHER , which is also encoded by an LCDiseaseOrPhenotypicFeature - associated gene .	1
Recombinant LCOTHER bearing the LCOTHER . LCOTHER mutation was prone to unfolding and exhibited reduced glycosylation activity against a complex array of glycosylation substrates and proteolytic processing of the transcription factor LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , which is also encoded by an LCDiseaseOrPhenotypicFeature - associated gene .	1
We conclude that defects in LCGeneOrGeneProduct - LCGeneOrGeneProduct homeostasis and LCOTHER LCOTHER LCOTHER LCOTHER proteolysis may play roles in mediation of LCDiseaseOrPhenotypicFeature in individuals with LCOTHER mutations . LCOTHER LCOTHER associated with LCOTHER treatment for LCOTHER LCOTHER .	1
We conclude that defects in LCOTHER - LCOTHER homeostasis and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct proteolysis may play roles in mediation of LCDiseaseOrPhenotypicFeature in individuals with LCOTHER mutations . LCOTHER LCOTHER associated with LCOTHER treatment for LCOTHER LCOTHER .	1
Severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature occurred in eight of 160 LCOTHER treated with LCChemicalEntity for LCOTHER LCOTHER .	1
Severe LCOTHER LCOTHER occurred in eight of 160 LCOTHER treated with LCChemicalEntity for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
Basic and clinical research has demonstrated that LCDiseaseOrPhenotypicFeature of sporadic LCOTHER ' LCOTHER LCOTHER ( LCOTHER ) type is associated with dysfunction of the LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) system followed by decreased LCOTHER transport via LCOTHER transporter LCOTHER and decreased LCOTHER metabolism in brain cells .	1
Basic and clinical research has demonstrated that LCDiseaseOrPhenotypicFeature of sporadic LCOTHER ' LCOTHER LCOTHER ( LCOTHER ) type is associated with dysfunction of the LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) system followed by decreased LCOTHER transport via LCOTHER transporter LCOTHER and decreased LCOTHER metabolism in brain cells .	1
Basic and clinical research has demonstrated that LCOTHER of sporadic LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) type is associated with dysfunction of the LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) system followed by decreased LCOTHER transport via LCOTHER transporter LCOTHER and decreased LCOTHER metabolism in brain cells .	1
Basic and clinical research has demonstrated that LCOTHER of sporadic LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) type is associated with dysfunction of the LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) system followed by decreased LCOTHER transport via LCOTHER transporter LCOTHER and decreased LCOTHER metabolism in brain cells .	1
Basic and clinical research has demonstrated that LCOTHER of sporadic LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) type is associated with dysfunction of the LCOTHER - LCOTHER ( LCOTHER ) system followed by decreased LCChemicalEntity transport via LCOTHER transporter LCOTHER and decreased LCOTHER metabolism in brain cells .	3
Basic and clinical research has demonstrated that LCOTHER of sporadic LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) type is associated with dysfunction of the LCOTHER - LCOTHER ( LCOTHER ) system followed by decreased LCOTHER transport via LCChemicalEntity transporter LCOTHER and decreased LCOTHER metabolism in brain cells .	3
Basic and clinical research has demonstrated that LCOTHER of sporadic LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) type is associated with dysfunction of the LCOTHER - LCOTHER ( LCOTHER ) system followed by decreased LCOTHER transport via LCOTHER transporter LCOTHER and decreased LCChemicalEntity metabolism in brain cells .	3
Basic and clinical research has demonstrated that LCOTHER of sporadic LCOTHER ' LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) type is associated with dysfunction of the LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) system followed by decreased LCOTHER transport via LCOTHER transporter LCOTHER and decreased LCOTHER metabolism in brain cells .	1
Basic and clinical research has demonstrated that LCOTHER of sporadic LCOTHER ' LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) type is associated with dysfunction of the LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) system followed by decreased LCOTHER transport via LCOTHER transporter LCOTHER and decreased LCOTHER metabolism in brain cells .	1
Basic and clinical research has demonstrated that LCOTHER of sporadic LCOTHER ' LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) type is associated with dysfunction of the LCOTHER - LCOTHER ( LCOTHER ) system followed by decreased LCChemicalEntity transport via LCOTHER transporter LCOTHER and decreased LCOTHER metabolism in brain cells .	3
Basic and clinical research has demonstrated that LCOTHER of sporadic LCOTHER ' LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) type is associated with dysfunction of the LCOTHER - LCOTHER ( LCOTHER ) system followed by decreased LCOTHER transport via LCChemicalEntity transporter LCOTHER and decreased LCOTHER metabolism in brain cells .	3
Basic and clinical research has demonstrated that LCOTHER of sporadic LCOTHER ' LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) type is associated with dysfunction of the LCOTHER - LCOTHER ( LCOTHER ) system followed by decreased LCOTHER transport via LCOTHER transporter LCOTHER and decreased LCChemicalEntity metabolism in brain cells .	3
Basic and clinical research has demonstrated that LCOTHER of sporadic LCOTHER ' LCOTHER LCOTHER ( LCOTHER ) type is associated with dysfunction of the LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) system followed by decreased LCChemicalEntity transport via LCOTHER transporter LCOTHER and decreased LCOTHER metabolism in brain cells .	3
Basic and clinical research has demonstrated that LCOTHER of sporadic LCOTHER ' LCOTHER LCOTHER ( LCOTHER ) type is associated with dysfunction of the LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) system followed by decreased LCOTHER transport via LCChemicalEntity transporter LCOTHER and decreased LCOTHER metabolism in brain cells .	3
Basic and clinical research has demonstrated that LCOTHER of sporadic LCOTHER ' LCOTHER LCOTHER ( LCOTHER ) type is associated with dysfunction of the LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) system followed by decreased LCOTHER transport via LCOTHER transporter LCOTHER and decreased LCChemicalEntity metabolism in brain cells .	3
Basic and clinical research has demonstrated that LCOTHER of sporadic LCOTHER ' LCOTHER LCOTHER ( LCOTHER ) type is associated with dysfunction of the LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) system followed by decreased LCChemicalEntity transport via LCOTHER transporter LCOTHER and decreased LCOTHER metabolism in brain cells .	3
Basic and clinical research has demonstrated that LCOTHER of sporadic LCOTHER ' LCOTHER LCOTHER ( LCOTHER ) type is associated with dysfunction of the LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) system followed by decreased LCOTHER transport via LCChemicalEntity transporter LCOTHER and decreased LCOTHER metabolism in brain cells .	3
Basic and clinical research has demonstrated that LCOTHER of sporadic LCOTHER ' LCOTHER LCOTHER ( LCOTHER ) type is associated with dysfunction of the LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) system followed by decreased LCOTHER transport via LCOTHER transporter LCOTHER and decreased LCChemicalEntity metabolism in brain cells .	3
Basic and clinical research has demonstrated that LCOTHER of sporadic LCOTHER ' LCOTHER LCOTHER ( LCOTHER ) type is associated with dysfunction of the LCOTHER - LCOTHER ( LCOTHER ) system followed by decreased LCOTHER transport via LCOTHER transporter LCGeneOrGeneProduct and decreased LCChemicalEntity metabolism in brain cells .	1
An alternative source of energy is LCChemicalEntity - LCChemicalEntity ( the C - 4 - epimer of LCOTHER - LCOTHER ) which is transported into the brain by LCOTHER - independent LCGeneOrGeneProduct transporter where it might be metabolized to LCOTHER via the Leloir pathway .	1
Exclusively parenteral daily injections of LCChemicalEntity induce LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in rodents and are used to generate animal aging model , but the effects of oral LCOTHER treatment on cognitive functions have never been tested .	2
We have investigated the effects of continuous daily oral LCChemicalEntity ( 200 mg / kg / day ) treatment on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER - induced ( LCOTHER - icv ) LCOTHER model of LCOTHER , tested by Morris Water Maze and Passive Avoidance test , respectively .	3
We have investigated the effects of continuous daily oral LCChemicalEntity ( 200 mg / kg / day ) treatment on LCOTHER LCOTHER in LCOTHER - induced ( LCOTHER - icv ) LCOTHER model of LCDiseaseOrPhenotypicFeature , tested by Morris Water Maze and Passive Avoidance test , respectively .	1
We have investigated the effects of continuous daily oral LCOTHER ( 200 mg / kg / day ) treatment on LCOTHER LCOTHER in LCChemicalEntity - induced ( LCOTHER - icv ) LCOTHER model of LCDiseaseOrPhenotypicFeature , tested by Morris Water Maze and Passive Avoidance test , respectively .	2
We have investigated the effects of continuous daily oral LCOTHER ( 200 mg / kg / day ) treatment on LCOTHER LCOTHER in LCOTHER - induced ( LCChemicalEntity - icv ) LCOTHER model of LCDiseaseOrPhenotypicFeature , tested by Morris Water Maze and Passive Avoidance test , respectively .	2
One month of oral LCChemicalEntity treatment initiated immediately after the LCOTHER - icv administration , successfully prevented development of the LCOTHER - icv - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
One month of oral LCOTHER treatment initiated immediately after the LCChemicalEntity - icv administration , successfully prevented development of the LCOTHER - icv - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
One month of oral LCOTHER treatment initiated immediately after the LCOTHER - icv administration , successfully prevented development of the LCChemicalEntity - icv - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	2
Oral LCChemicalEntity exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature associated with LCOTHER LCOTHER in LCOTHER . Biophysical and functional characterization of LCOTHER mutants responsible for LCOTHER LCOTHER .	3
Oral LCChemicalEntity exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of LCOTHER LCOTHER associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER . Biophysical and functional characterization of LCOTHER mutants responsible for LCOTHER LCOTHER .	1
Oral LCChemicalEntity exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of LCOTHER LCOTHER associated with LCOTHER LCOTHER in LCDiseaseOrPhenotypicFeature . Biophysical and functional characterization of LCOTHER mutants responsible for LCOTHER LCOTHER .	1
With the advent of next - generation sequencing technologies , the homozygous mutations LCOTHER and LCOTHER in the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) LCOTHER were identified as the genetic cause of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER LCOTHER ) .	1
With the advent of next - generation sequencing technologies , the homozygous mutations LCOTHER and LCOTHER in the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) LCOTHER were identified as the genetic cause of LCOTHER LCOTHER LCOTHER ( LCOTHER LCDiseaseOrPhenotypicFeature ) .	1
With the advent of next - generation sequencing technologies , the homozygous mutations LCOTHER and LCOTHER in the LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) LCOTHER were identified as the genetic cause of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER LCOTHER ) .	1
With the advent of next - generation sequencing technologies , the homozygous mutations LCOTHER and LCOTHER in the LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) LCOTHER were identified as the genetic cause of LCOTHER LCOTHER LCOTHER ( LCOTHER LCDiseaseOrPhenotypicFeature ) .	1
With the advent of next - generation sequencing technologies , the homozygous mutations LCOTHER and LCOTHER in the LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCGeneOrGeneProduct were identified as the genetic cause of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER LCOTHER ) .	1
With the advent of next - generation sequencing technologies , the homozygous mutations LCOTHER and LCOTHER in the LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCGeneOrGeneProduct were identified as the genetic cause of LCOTHER LCOTHER LCOTHER ( LCOTHER LCDiseaseOrPhenotypicFeature ) .	1
With the advent of next - generation sequencing technologies , the homozygous mutations LCOTHER and LCOTHER in the LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER were identified as the genetic cause of LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct LCDiseaseOrPhenotypicFeature ) .	1
Using a multidisciplinary approach , we demonstrated that LCGeneOrGeneProduct oligomerises in a LCChemicalEntity - dependent manner and binds to LCOTHER - LCOTHER LCOTHER LCOTHER .	2
Using a multidisciplinary approach , we demonstrated that LCGeneOrGeneProduct oligomerises in a LCOTHER - dependent manner and binds to LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct .	4
Mutations LCOTHER and LCOTHER in LCGeneOrGeneProduct did not affect stability , LCChemicalEntity - binding affinity or translocation to cellular membranes ( LCOTHER + / myristoyl switch ) .	2
In addition , we observed an increased LCChemicalEntity influx in LCChemicalEntity - depolarised cells expressing mutated LCOTHER , mostly driven by LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER .	1
In addition , we observed an increased LCOTHER influx in LCChemicalEntity - depolarised cells expressing mutated LCOTHER , mostly driven by LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct .	1
In addition , we observed an increased LCOTHER influx in LCOTHER - depolarised cells expressing mutated LCGeneOrGeneProduct , mostly driven by LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct .	1
Our data demonstrate that the LCOTHER - causing mutations strongly affect LCGeneOrGeneProduct cellular functions which suggest a central role for perturbed LCChemicalEntity signalling in LCOTHER LCOTHER . LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER : frequent abnormalities and inactivation of LCOTHER LCOTHER suppressor gene .	2
Our data demonstrate that the LCOTHER - causing mutations strongly affect LCGeneOrGeneProduct cellular functions which suggest a central role for perturbed LCOTHER signalling in LCOTHER LCDiseaseOrPhenotypicFeature . LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER : frequent abnormalities and inactivation of LCOTHER LCOTHER suppressor gene .	1
Our data demonstrate that the LCOTHER - causing mutations strongly affect LCOTHER cellular functions which suggest a central role for perturbed LCChemicalEntity signalling in LCOTHER LCDiseaseOrPhenotypicFeature . LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER : frequent abnormalities and inactivation of LCOTHER LCOTHER suppressor gene .	1
Our data demonstrate that the LCOTHER - causing mutations strongly affect LCOTHER cellular functions which suggest a central role for perturbed LCOTHER signalling in LCGeneOrGeneProduct LCDiseaseOrPhenotypicFeature . LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER : frequent abnormalities and inactivation of LCOTHER LCOTHER suppressor gene .	1
Ten LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER , LCOTHER LCOTHER ) were examined for LCGeneOrGeneProduct gene exon 1beta deletion , mutation and methylation by Southern blot analysis , nucleotide analysis of polymerase chain reaction clones and Southern blot - based methylation assay .	1
Ten LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER ) were examined for LCGeneOrGeneProduct gene exon 1beta deletion , mutation and methylation by Southern blot analysis , nucleotide analysis of polymerase chain reaction clones and Southern blot - based methylation assay .	1
Ten LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) were examined for LCGeneOrGeneProduct gene exon 1beta deletion , mutation and methylation by Southern blot analysis , nucleotide analysis of polymerase chain reaction clones and Southern blot - based methylation assay .	1
Our observation of frequent LCGeneOrGeneProduct gene abnormalities ( 90% ) and inactivation ( 40 - 60% ) was in striking contrast to the same pathological subtype of LCOTHER LCOTHER in which LCOTHER gene abnormalities and inactivation were infrequent , suggesting a difference in LCDiseaseOrPhenotypicFeature between LCOTHER and LCOTHER LCOTHER . LCOTHER LCOTHER LCOTHER LCOTHER in LCOTHER users and their neural correlates during a face - learning task .	1
Our observation of frequent LCOTHER gene abnormalities ( 90% ) and inactivation ( 40 - 60% ) was in striking contrast to the same pathological subtype of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in which LCGeneOrGeneProduct gene abnormalities and inactivation were infrequent , suggesting a difference in LCOTHER between LCOTHER and LCOTHER LCOTHER . LCOTHER LCOTHER LCOTHER LCOTHER in LCOTHER users and their neural correlates during a face - learning task .	1
Our observation of frequent LCOTHER gene abnormalities ( 90% ) and inactivation ( 40 - 60% ) was in striking contrast to the same pathological subtype of LCOTHER LCOTHER in which LCGeneOrGeneProduct gene abnormalities and inactivation were infrequent , suggesting a difference in LCDiseaseOrPhenotypicFeature between LCOTHER and LCOTHER LCOTHER . LCOTHER LCOTHER LCOTHER LCOTHER in LCOTHER users and their neural correlates during a face - learning task .	1
To address the potential confounding effects of the LCOTHER use of the LCChemicalEntity using group , a second analysis included 14 previously tested LCChemicalEntity users ( Nestor , L . , Roberts , G . , Garavan , H . , Hester , R . , 2008 .	1
LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER : parahippocampal LCDiseaseOrPhenotypicFeature and frontocortical hypoactivity in LCChemicalEntity users .	2
LCChemicalEntity users performed significantly worse in learning and memory compared to controls and LCChemicalEntity users .	1
A conjunction analysis of the encode and recall phases of the task revealed LCChemicalEntity - specific LCDiseaseOrPhenotypicFeature in bilateral frontal regions , left temporal , right parietal , bilateral temporal , and bilateral occipital brain regions .	2
In both LCChemicalEntity and LCChemicalEntity groups brain activation was decreased in the right medial frontal gyrus , left parahippocampal gyrus , left dorsal cingulate gyrus , and left caudate .	1
These results elucidated LCChemicalEntity - related deficits , only some of which might be attributed to LCChemicalEntity use .	1
These LCOTHER - specific effects may be related to the vulnerability of isocortical and allocortical regions to the LCDiseaseOrPhenotypicFeature effects of LCChemicalEntity . Variation in the LCOTHER gene ( LCOTHER ) is not associated with susceptibility to LCOTHER LCOTHER .	2
BACKGROUND : The LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( or LCOTHER - LCOTHER ) is a specific receptor for the LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) , which is chemoattractant for neutrophils and has an important role in the LCOTHER response .	4
BACKGROUND : The LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( or LCOTHER - LCOTHER ) is a specific receptor for the LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) , which is chemoattractant for neutrophils and has an important role in the LCOTHER response .	4
BACKGROUND : The LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( or LCOTHER - LCOTHER ) is a specific receptor for the LCOTHER LCOTHER ( LCOTHER - LCOTHER ) , which is chemoattractant for neutrophils and has an important role in the LCDiseaseOrPhenotypicFeature response .	1
BACKGROUND : The LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ( or LCGeneOrGeneProduct - LCGeneOrGeneProduct ) is a specific receptor for the LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) , which is chemoattractant for neutrophils and has an important role in the LCOTHER response .	4
BACKGROUND : The LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ( or LCGeneOrGeneProduct - LCGeneOrGeneProduct ) is a specific receptor for the LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) , which is chemoattractant for neutrophils and has an important role in the LCOTHER response .	4
BACKGROUND : The LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ( or LCGeneOrGeneProduct - LCGeneOrGeneProduct ) is a specific receptor for the LCOTHER LCOTHER ( LCOTHER - LCOTHER ) , which is chemoattractant for neutrophils and has an important role in the LCDiseaseOrPhenotypicFeature response .	1
BACKGROUND : The LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ( or LCOTHER - LCOTHER ) is a specific receptor for the LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) , which is chemoattractant for neutrophils and has an important role in the LCDiseaseOrPhenotypicFeature response .	1
BACKGROUND : The LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ( or LCOTHER - LCOTHER ) is a specific receptor for the LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) , which is chemoattractant for neutrophils and has an important role in the LCDiseaseOrPhenotypicFeature response .	1
Previous studies of our group found association of haplotypes in the LCGeneOrGeneProduct and in the LCOTHER genes with the multifactorial disease LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
Previous studies of our group found association of haplotypes in the LCOTHER and in the LCGeneOrGeneProduct genes with the multifactorial disease LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) joins LCGeneOrGeneProduct with LCOTHER into a ternary complex ( termed LCOTHER ) capable of processive movement .	4
LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) joins LCOTHER with LCGeneOrGeneProduct into a ternary complex ( termed LCOTHER ) capable of processive movement .	4
LCOTHER LCOTHER ( LCGeneOrGeneProduct ) joins LCGeneOrGeneProduct with LCOTHER into a ternary complex ( termed LCOTHER ) capable of processive movement .	4
LCOTHER LCOTHER ( LCGeneOrGeneProduct ) joins LCOTHER with LCGeneOrGeneProduct into a ternary complex ( termed LCOTHER ) capable of processive movement .	4
LCOTHER LCOTHER ( LCOTHER ) joins LCGeneOrGeneProduct with LCGeneOrGeneProduct into a ternary complex ( termed LCOTHER ) capable of processive movement .	4
Point mutations in the LCGeneOrGeneProduct gene have been identified in LCOTHER with a dominant form of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , but how these mutations cause disease is unknown .	1
LCGeneOrGeneProduct - LCGeneOrGeneProduct , either in solution or bound to artificial liposomes , released LCGeneOrGeneProduct from an autoinhibited state and promoted robust LCOTHER - LCOTHER transport .	2
LCGeneOrGeneProduct - LCGeneOrGeneProduct , either in solution or bound to artificial liposomes , released LCOTHER from an autoinhibited state and promoted robust LCGeneOrGeneProduct - LCOTHER transport .	2
LCGeneOrGeneProduct - LCGeneOrGeneProduct , either in solution or bound to artificial liposomes , released LCOTHER from an autoinhibited state and promoted robust LCOTHER - LCGeneOrGeneProduct transport .	2
LCOTHER - LCOTHER , either in solution or bound to artificial liposomes , released LCGeneOrGeneProduct from an autoinhibited state and promoted robust LCGeneOrGeneProduct - LCOTHER transport .	1
LCOTHER - LCOTHER , either in solution or bound to artificial liposomes , released LCGeneOrGeneProduct from an autoinhibited state and promoted robust LCOTHER - LCGeneOrGeneProduct transport .	1
LCOTHER - LCOTHER , either in solution or bound to artificial liposomes , released LCOTHER from an autoinhibited state and promoted robust LCGeneOrGeneProduct - LCGeneOrGeneProduct transport .	4
Our results reveal that dominant mutations in LCGeneOrGeneProduct hyperactivate LCOTHER motility and suggest that an imbalance of minus versus plus end - directed microtubule motility in neurons may underlie LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER metabolism in patients with LCOTHER treated with atypical LCOTHER LCOTHER : a frequently sampled intravenous LCOTHER tolerance test and minimal model analysis .	1
BACKGROUND : While the incidence of new - onset LCOTHER LCOTHER may be increasing in patients with LCDiseaseOrPhenotypicFeature treated with certain atypical LCChemicalEntity LCChemicalEntity , it remains unclear whether atypical agents are directly affecting LCOTHER metabolism or simply increasing known risk factors for LCOTHER .	3
BACKGROUND : While the incidence of new - onset LCOTHER LCOTHER may be increasing in patients with LCOTHER treated with certain atypical LCChemicalEntity LCChemicalEntity , it remains unclear whether atypical agents are directly affecting LCOTHER metabolism or simply increasing known risk factors for LCDiseaseOrPhenotypicFeature .	2
OBJECTIVE : To study the 2 drugs most clearly implicated ( LCChemicalEntity and LCChemicalEntity ) and LCOTHER using a frequently sampled intravenous LCOTHER tolerance test .	6
OBJECTIVE : To study the 2 drugs most clearly implicated ( LCChemicalEntity and LCOTHER ) and LCChemicalEntity using a frequently sampled intravenous LCOTHER tolerance test .	6
OBJECTIVE : To study the 2 drugs most clearly implicated ( LCChemicalEntity and LCOTHER ) and LCOTHER using a frequently sampled intravenous LCChemicalEntity tolerance test .	1
OBJECTIVE : To study the 2 drugs most clearly implicated ( LCOTHER and LCChemicalEntity ) and LCChemicalEntity using a frequently sampled intravenous LCOTHER tolerance test .	6
OBJECTIVE : To study the 2 drugs most clearly implicated ( LCOTHER and LCChemicalEntity ) and LCOTHER using a frequently sampled intravenous LCChemicalEntity tolerance test .	1
OBJECTIVE : To study the 2 drugs most clearly implicated ( LCOTHER and LCOTHER ) and LCChemicalEntity using a frequently sampled intravenous LCChemicalEntity tolerance test .	1
Thirty - six nonobese subjects with LCDiseaseOrPhenotypicFeature or LCOTHER LCOTHER , matched by body mass index and treated with either LCChemicalEntity , LCOTHER , or LCOTHER , were included in the analysis .	3
Thirty - six nonobese subjects with LCDiseaseOrPhenotypicFeature or LCOTHER LCOTHER , matched by body mass index and treated with either LCOTHER , LCChemicalEntity , or LCOTHER , were included in the analysis .	3
Thirty - six nonobese subjects with LCDiseaseOrPhenotypicFeature or LCOTHER LCOTHER , matched by body mass index and treated with either LCOTHER , LCOTHER , or LCChemicalEntity , were included in the analysis .	3
Thirty - six nonobese subjects with LCOTHER or LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , matched by body mass index and treated with either LCChemicalEntity , LCOTHER , or LCOTHER , were included in the analysis .	3
Thirty - six nonobese subjects with LCOTHER or LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , matched by body mass index and treated with either LCOTHER , LCChemicalEntity , or LCOTHER , were included in the analysis .	3
Thirty - six nonobese subjects with LCOTHER or LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , matched by body mass index and treated with either LCOTHER , LCOTHER , or LCChemicalEntity , were included in the analysis .	3
Thirty - six nonobese subjects with LCOTHER or LCOTHER LCOTHER , matched by body mass index and treated with either LCChemicalEntity , LCChemicalEntity , or LCOTHER , were included in the analysis .	6
Thirty - six nonobese subjects with LCOTHER or LCOTHER LCOTHER , matched by body mass index and treated with either LCChemicalEntity , LCOTHER , or LCChemicalEntity , were included in the analysis .	6
Thirty - six nonobese subjects with LCOTHER or LCOTHER LCOTHER , matched by body mass index and treated with either LCOTHER , LCChemicalEntity , or LCChemicalEntity , were included in the analysis .	6
RESULTS : The mean + / - SD duration of treatment with the identified atypical LCOTHER LCOTHER was 68 . 3 + / - 28 . 9 months ( LCChemicalEntity ) , 29 . 5 + / - 17 . 5 months ( LCChemicalEntity ) , and 40 . 9 + / - 33 . 7 ( LCOTHER ) .	6
RESULTS : The mean + / - SD duration of treatment with the identified atypical LCOTHER LCOTHER was 68 . 3 + / - 28 . 9 months ( LCChemicalEntity ) , 29 . 5 + / - 17 . 5 months ( LCOTHER ) , and 40 . 9 + / - 33 . 7 ( LCChemicalEntity ) .	6
RESULTS : The mean + / - SD duration of treatment with the identified atypical LCOTHER LCOTHER was 68 . 3 + / - 28 . 9 months ( LCOTHER ) , 29 . 5 + / - 17 . 5 months ( LCChemicalEntity ) , and 40 . 9 + / - 33 . 7 ( LCChemicalEntity ) .	6
Fasting serum LCOTHER concentrations differed among groups ( F ( 33 ) = 3 . 35 ; P = . 047 ) ( LCChemicalEntity > LCChemicalEntity > LCOTHER ) with significant differences between LCOTHER and LCOTHER ( t ( 33 ) = 2 . 32 ; P = . 03 ) and LCOTHER and LCOTHER ( t ( 33 ) = 2 . 15 ; P = . 04 ) .	6
Fasting serum LCOTHER concentrations differed among groups ( F ( 33 ) = 3 . 35 ; P = . 047 ) ( LCChemicalEntity > LCOTHER > LCChemicalEntity ) with significant differences between LCOTHER and LCOTHER ( t ( 33 ) = 2 . 32 ; P = . 03 ) and LCOTHER and LCOTHER ( t ( 33 ) = 2 . 15 ; P = . 04 ) .	6
Fasting serum LCOTHER concentrations differed among groups ( F ( 33 ) = 3 . 35 ; P = . 047 ) ( LCChemicalEntity > LCOTHER > LCOTHER ) with significant differences between LCOTHER and LCChemicalEntity ( t ( 33 ) = 2 . 32 ; P = . 03 ) and LCOTHER and LCOTHER ( t ( 33 ) = 2 . 15 ; P = . 04 ) .	6
Fasting serum LCOTHER concentrations differed among groups ( F ( 33 ) = 3 . 35 ; P = . 047 ) ( LCChemicalEntity > LCOTHER > LCOTHER ) with significant differences between LCOTHER and LCOTHER ( t ( 33 ) = 2 . 32 ; P = . 03 ) and LCChemicalEntity and LCOTHER ( t ( 33 ) = 2 . 15 ; P = . 04 ) .	6
Fasting serum LCOTHER concentrations differed among groups ( F ( 33 ) = 3 . 35 ; P = . 047 ) ( LCChemicalEntity > LCOTHER > LCOTHER ) with significant differences between LCOTHER and LCOTHER ( t ( 33 ) = 2 . 32 ; P = . 03 ) and LCOTHER and LCChemicalEntity ( t ( 33 ) = 2 . 15 ; P = . 04 ) .	6
Fasting serum LCOTHER concentrations differed among groups ( F ( 33 ) = 3 . 35 ; P = . 047 ) ( LCOTHER > LCChemicalEntity > LCChemicalEntity ) with significant differences between LCOTHER and LCOTHER ( t ( 33 ) = 2 . 32 ; P = . 03 ) and LCOTHER and LCOTHER ( t ( 33 ) = 2 . 15 ; P = . 04 ) .	6
Fasting serum LCOTHER concentrations differed among groups ( F ( 33 ) = 3 . 35 ; P = . 047 ) ( LCOTHER > LCChemicalEntity > LCOTHER ) with significant differences between LCOTHER and LCChemicalEntity ( t ( 33 ) = 2 . 32 ; P = . 03 ) and LCOTHER and LCOTHER ( t ( 33 ) = 2 . 15 ; P = . 04 ) .	6
Fasting serum LCOTHER concentrations differed among groups ( F ( 33 ) = 3 . 35 ; P = . 047 ) ( LCOTHER > LCChemicalEntity > LCOTHER ) with significant differences between LCOTHER and LCOTHER ( t ( 33 ) = 2 . 32 ; P = . 03 ) and LCOTHER and LCChemicalEntity ( t ( 33 ) = 2 . 15 ; P = . 04 ) .	6
Fasting serum LCOTHER concentrations differed among groups ( F ( 33 ) = 3 . 35 ; P = . 047 ) ( LCOTHER > LCOTHER > LCOTHER ) with significant differences between LCChemicalEntity and LCChemicalEntity ( t ( 33 ) = 2 . 32 ; P = . 03 ) and LCOTHER and LCOTHER ( t ( 33 ) = 2 . 15 ; P = . 04 ) .	6
Fasting serum LCOTHER concentrations differed among groups ( F ( 33 ) = 3 . 35 ; P = . 047 ) ( LCOTHER > LCOTHER > LCOTHER ) with significant differences between LCChemicalEntity and LCOTHER ( t ( 33 ) = 2 . 32 ; P = . 03 ) and LCChemicalEntity and LCOTHER ( t ( 33 ) = 2 . 15 ; P = . 04 ) .	6
Fasting serum LCOTHER concentrations differed among groups ( F ( 33 ) = 3 . 35 ; P = . 047 ) ( LCOTHER > LCOTHER > LCOTHER ) with significant differences between LCChemicalEntity and LCOTHER ( t ( 33 ) = 2 . 32 ; P = . 03 ) and LCOTHER and LCChemicalEntity ( t ( 33 ) = 2 . 15 ; P = . 04 ) .	6
Fasting serum LCOTHER concentrations differed among groups ( F ( 33 ) = 3 . 35 ; P = . 047 ) ( LCOTHER > LCOTHER > LCOTHER ) with significant differences between LCOTHER and LCOTHER ( t ( 33 ) = 2 . 32 ; P = . 03 ) and LCChemicalEntity and LCChemicalEntity ( t ( 33 ) = 2 . 15 ; P = . 04 ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCChemicalEntity < LCChemicalEntity < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCChemicalEntity < LCOTHER < LCChemicalEntity ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCChemicalEntity < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCChemicalEntity exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCChemicalEntity < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	2
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCChemicalEntity < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCChemicalEntity ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCChemicalEntity < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCChemicalEntity , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCChemicalEntity < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCChemicalEntity vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCChemicalEntity < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCChemicalEntity , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCChemicalEntity < LCChemicalEntity ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCChemicalEntity < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	2
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCChemicalEntity < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCChemicalEntity ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCChemicalEntity < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCChemicalEntity , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCChemicalEntity < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCChemicalEntity , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCOTHER ) , with subjects who received LCChemicalEntity and LCChemicalEntity exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCOTHER ) , with subjects who received LCChemicalEntity and LCOTHER exhibiting significant LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	2
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCOTHER ) , with subjects who received LCChemicalEntity and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCChemicalEntity ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCOTHER ) , with subjects who received LCChemicalEntity and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCChemicalEntity , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCOTHER ) , with subjects who received LCChemicalEntity and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCChemicalEntity vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCOTHER ) , with subjects who received LCChemicalEntity and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCChemicalEntity , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCChemicalEntity exhibiting significant LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	2
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCChemicalEntity exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCChemicalEntity ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCChemicalEntity exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCChemicalEntity , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCChemicalEntity exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCChemicalEntity , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCChemicalEntity vs LCChemicalEntity , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCChemicalEntity vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCChemicalEntity vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCChemicalEntity vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCChemicalEntity , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCChemicalEntity vs LCChemicalEntity , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	6
The homeostasis model assessment of LCOTHER LCOTHER also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( LCChemicalEntity > LCChemicalEntity > LCOTHER ) ( LCOTHER vs LCOTHER , t ( 33 ) = 2 . 94 ; P = . 006 ; LCOTHER vs LCOTHER , t ( 33 ) = 2 . 42 ; P = . 02 ) .	6
The homeostasis model assessment of LCOTHER LCOTHER also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( LCChemicalEntity > LCOTHER > LCChemicalEntity ) ( LCOTHER vs LCOTHER , t ( 33 ) = 2 . 94 ; P = . 006 ; LCOTHER vs LCOTHER , t ( 33 ) = 2 . 42 ; P = . 02 ) .	6
The homeostasis model assessment of LCOTHER LCOTHER also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( LCChemicalEntity > LCOTHER > LCOTHER ) ( LCOTHER vs LCChemicalEntity , t ( 33 ) = 2 . 94 ; P = . 006 ; LCOTHER vs LCOTHER , t ( 33 ) = 2 . 42 ; P = . 02 ) .	6
The homeostasis model assessment of LCOTHER LCOTHER also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( LCChemicalEntity > LCOTHER > LCOTHER ) ( LCOTHER vs LCOTHER , t ( 33 ) = 2 . 94 ; P = . 006 ; LCChemicalEntity vs LCOTHER , t ( 33 ) = 2 . 42 ; P = . 02 ) .	6
The homeostasis model assessment of LCOTHER LCOTHER also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( LCChemicalEntity > LCOTHER > LCOTHER ) ( LCOTHER vs LCOTHER , t ( 33 ) = 2 . 94 ; P = . 006 ; LCOTHER vs LCChemicalEntity , t ( 33 ) = 2 . 42 ; P = . 02 ) .	6
The homeostasis model assessment of LCOTHER LCOTHER also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( LCOTHER > LCChemicalEntity > LCChemicalEntity ) ( LCOTHER vs LCOTHER , t ( 33 ) = 2 . 94 ; P = . 006 ; LCOTHER vs LCOTHER , t ( 33 ) = 2 . 42 ; P = . 02 ) .	6
The homeostasis model assessment of LCOTHER LCOTHER also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( LCOTHER > LCChemicalEntity > LCOTHER ) ( LCOTHER vs LCChemicalEntity , t ( 33 ) = 2 . 94 ; P = . 006 ; LCOTHER vs LCOTHER , t ( 33 ) = 2 . 42 ; P = . 02 ) .	6
The homeostasis model assessment of LCOTHER LCOTHER also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( LCOTHER > LCChemicalEntity > LCOTHER ) ( LCOTHER vs LCOTHER , t ( 33 ) = 2 . 94 ; P = . 006 ; LCOTHER vs LCChemicalEntity , t ( 33 ) = 2 . 42 ; P = . 02 ) .	6
The homeostasis model assessment of LCOTHER LCOTHER also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( LCOTHER > LCOTHER > LCOTHER ) ( LCChemicalEntity vs LCChemicalEntity , t ( 33 ) = 2 . 94 ; P = . 006 ; LCOTHER vs LCOTHER , t ( 33 ) = 2 . 42 ; P = . 02 ) .	6
The homeostasis model assessment of LCOTHER LCOTHER also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( LCOTHER > LCOTHER > LCOTHER ) ( LCChemicalEntity vs LCOTHER , t ( 33 ) = 2 . 94 ; P = . 006 ; LCChemicalEntity vs LCOTHER , t ( 33 ) = 2 . 42 ; P = . 02 ) .	6
The homeostasis model assessment of LCOTHER LCOTHER also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( LCOTHER > LCOTHER > LCOTHER ) ( LCChemicalEntity vs LCOTHER , t ( 33 ) = 2 . 94 ; P = . 006 ; LCOTHER vs LCChemicalEntity , t ( 33 ) = 2 . 42 ; P = . 02 ) .	6
The homeostasis model assessment of LCOTHER LCOTHER also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( LCOTHER > LCOTHER > LCOTHER ) ( LCOTHER vs LCOTHER , t ( 33 ) = 2 . 94 ; P = . 006 ; LCChemicalEntity vs LCChemicalEntity , t ( 33 ) = 2 . 42 ; P = . 02 ) .	6
There was a significant difference among groups in LCOTHER effectiveness ( F ( 30 ) = 4 . 18 ; P = . 02 ) ( LCChemicalEntity < LCChemicalEntity < LCOTHER ) with significant differences between LCOTHER and LCOTHER ( t ( 30 ) = - 2 . 59 ; P = . 02 ) and LCOTHER and LCOTHER ( t ( 30 ) = - 2 . 34 , P = . 03 ) .	6
There was a significant difference among groups in LCOTHER effectiveness ( F ( 30 ) = 4 . 18 ; P = . 02 ) ( LCChemicalEntity < LCOTHER < LCChemicalEntity ) with significant differences between LCOTHER and LCOTHER ( t ( 30 ) = - 2 . 59 ; P = . 02 ) and LCOTHER and LCOTHER ( t ( 30 ) = - 2 . 34 , P = . 03 ) .	6
There was a significant difference among groups in LCOTHER effectiveness ( F ( 30 ) = 4 . 18 ; P = . 02 ) ( LCChemicalEntity < LCOTHER < LCOTHER ) with significant differences between LCOTHER and LCChemicalEntity ( t ( 30 ) = - 2 . 59 ; P = . 02 ) and LCOTHER and LCOTHER ( t ( 30 ) = - 2 . 34 , P = . 03 ) .	6
There was a significant difference among groups in LCOTHER effectiveness ( F ( 30 ) = 4 . 18 ; P = . 02 ) ( LCChemicalEntity < LCOTHER < LCOTHER ) with significant differences between LCOTHER and LCOTHER ( t ( 30 ) = - 2 . 59 ; P = . 02 ) and LCChemicalEntity and LCOTHER ( t ( 30 ) = - 2 . 34 , P = . 03 ) .	6
There was a significant difference among groups in LCOTHER effectiveness ( F ( 30 ) = 4 . 18 ; P = . 02 ) ( LCChemicalEntity < LCOTHER < LCOTHER ) with significant differences between LCOTHER and LCOTHER ( t ( 30 ) = - 2 . 59 ; P = . 02 ) and LCOTHER and LCChemicalEntity ( t ( 30 ) = - 2 . 34 , P = . 03 ) .	6
There was a significant difference among groups in LCOTHER effectiveness ( F ( 30 ) = 4 . 18 ; P = . 02 ) ( LCOTHER < LCChemicalEntity < LCChemicalEntity ) with significant differences between LCOTHER and LCOTHER ( t ( 30 ) = - 2 . 59 ; P = . 02 ) and LCOTHER and LCOTHER ( t ( 30 ) = - 2 . 34 , P = . 03 ) .	6
There was a significant difference among groups in LCOTHER effectiveness ( F ( 30 ) = 4 . 18 ; P = . 02 ) ( LCOTHER < LCChemicalEntity < LCOTHER ) with significant differences between LCOTHER and LCChemicalEntity ( t ( 30 ) = - 2 . 59 ; P = . 02 ) and LCOTHER and LCOTHER ( t ( 30 ) = - 2 . 34 , P = . 03 ) .	6
There was a significant difference among groups in LCOTHER effectiveness ( F ( 30 ) = 4 . 18 ; P = . 02 ) ( LCOTHER < LCChemicalEntity < LCOTHER ) with significant differences between LCOTHER and LCOTHER ( t ( 30 ) = - 2 . 59 ; P = . 02 ) and LCOTHER and LCChemicalEntity ( t ( 30 ) = - 2 . 34 , P = . 03 ) .	6
There was a significant difference among groups in LCOTHER effectiveness ( F ( 30 ) = 4 . 18 ; P = . 02 ) ( LCOTHER < LCOTHER < LCOTHER ) with significant differences between LCChemicalEntity and LCChemicalEntity ( t ( 30 ) = - 2 . 59 ; P = . 02 ) and LCOTHER and LCOTHER ( t ( 30 ) = - 2 . 34 , P = . 03 ) .	6
There was a significant difference among groups in LCOTHER effectiveness ( F ( 30 ) = 4 . 18 ; P = . 02 ) ( LCOTHER < LCOTHER < LCOTHER ) with significant differences between LCChemicalEntity and LCOTHER ( t ( 30 ) = - 2 . 59 ; P = . 02 ) and LCChemicalEntity and LCOTHER ( t ( 30 ) = - 2 . 34 , P = . 03 ) .	6
There was a significant difference among groups in LCOTHER effectiveness ( F ( 30 ) = 4 . 18 ; P = . 02 ) ( LCOTHER < LCOTHER < LCOTHER ) with significant differences between LCChemicalEntity and LCOTHER ( t ( 30 ) = - 2 . 59 ; P = . 02 ) and LCOTHER and LCChemicalEntity ( t ( 30 ) = - 2 . 34 , P = . 03 ) .	6
There was a significant difference among groups in LCOTHER effectiveness ( F ( 30 ) = 4 . 18 ; P = . 02 ) ( LCOTHER < LCOTHER < LCOTHER ) with significant differences between LCOTHER and LCOTHER ( t ( 30 ) = - 2 . 59 ; P = . 02 ) and LCChemicalEntity and LCChemicalEntity ( t ( 30 ) = - 2 . 34 , P = . 03 ) .	6
CONCLUSIONS : Both nonobese LCChemicalEntity - and LCChemicalEntity - treated groups displayed significant LCOTHER LCOTHER and impairment of LCOTHER effectiveness compared with LCOTHER - treated subjects .	6
CONCLUSIONS : Both nonobese LCChemicalEntity - and LCOTHER - treated groups displayed significant LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and impairment of LCOTHER effectiveness compared with LCOTHER - treated subjects .	2
CONCLUSIONS : Both nonobese LCChemicalEntity - and LCOTHER - treated groups displayed significant LCOTHER LCOTHER and impairment of LCChemicalEntity effectiveness compared with LCOTHER - treated subjects .	1
CONCLUSIONS : Both nonobese LCChemicalEntity - and LCOTHER - treated groups displayed significant LCOTHER LCOTHER and impairment of LCOTHER effectiveness compared with LCChemicalEntity - treated subjects .	6
CONCLUSIONS : Both nonobese LCOTHER - and LCChemicalEntity - treated groups displayed significant LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and impairment of LCOTHER effectiveness compared with LCOTHER - treated subjects .	2
CONCLUSIONS : Both nonobese LCOTHER - and LCChemicalEntity - treated groups displayed significant LCOTHER LCOTHER and impairment of LCChemicalEntity effectiveness compared with LCOTHER - treated subjects .	1
CONCLUSIONS : Both nonobese LCOTHER - and LCChemicalEntity - treated groups displayed significant LCOTHER LCOTHER and impairment of LCOTHER effectiveness compared with LCChemicalEntity - treated subjects .	6
Patients taking LCChemicalEntity and LCChemicalEntity must be examined for LCOTHER LCOTHER and its consequences . LCOTHER phenotype and the pharmacokinetics and LCOTHER - LCOTHER LCOTHER pharmacodynamics of LCOTHER and its enantiomers .	6
Patients taking LCChemicalEntity and LCOTHER must be examined for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and its consequences . LCOTHER phenotype and the pharmacokinetics and LCOTHER - LCOTHER LCOTHER pharmacodynamics of LCOTHER and its enantiomers .	2
Patients taking LCOTHER and LCChemicalEntity must be examined for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and its consequences . LCOTHER phenotype and the pharmacokinetics and LCOTHER - LCOTHER LCOTHER pharmacodynamics of LCOTHER and its enantiomers .	2
The metabolism of the cardioselective beta - blocker LCChemicalEntity is under genetic control of the LCChemicalEntity / LCOTHER type .	1
The metabolism of the cardioselective beta - blocker LCChemicalEntity is under genetic control of the LCOTHER / LCChemicalEntity type .	1
The two metabolic phenotypes , extensive ( EM ) and poor metabolizers ( PM ) , show different stereoselective metabolism , resulting in apparently higher LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct antagonistic potency of racemic LCChemicalEntity in EMs .	3
The drug effect studied was the antagonism by LCChemicalEntity of LCChemicalEntity - induced LCOTHER .	2
The drug effect studied was the antagonism by LCChemicalEntity of LCOTHER - induced LCDiseaseOrPhenotypicFeature .	3
The drug effect studied was the antagonism by LCOTHER of LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature .	2
In PMs , LCChemicalEntity increased the LCChemicalEntity area under the plasma concentration vs .	2
PURPOSE : The LCChemicalEntity LCOTHER and LCOTHER and the LCOTHER LCOTHER are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER limit their use .	2
PURPOSE : The LCChemicalEntity LCOTHER and LCOTHER and the LCOTHER LCOTHER are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature limit their use .	2
PURPOSE : The LCOTHER LCChemicalEntity and LCChemicalEntity and the LCOTHER LCOTHER are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , LCOTHER and LCOTHER LCOTHER limit their use .	6
PURPOSE : The LCOTHER LCChemicalEntity and LCOTHER and the LCOTHER LCOTHER are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature limit their use .	2
PURPOSE : The LCOTHER LCOTHER and LCChemicalEntity and the LCOTHER LCOTHER are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER limit their use .	2
PURPOSE : The LCOTHER LCOTHER and LCChemicalEntity and the LCOTHER LCOTHER are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature limit their use .	2
PURPOSE : The LCOTHER LCOTHER and LCOTHER and the LCChemicalEntity LCOTHER are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER limit their use .	2
PURPOSE : The LCOTHER LCOTHER and LCOTHER and the LCChemicalEntity LCOTHER are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature limit their use .	2
PURPOSE : The LCOTHER LCOTHER and LCOTHER and the LCOTHER LCChemicalEntity are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature limit their use .	2
LCChemicalEntity ( LCOTHER - LCOTHER ) is recommended for protection against LCChemicalEntity - induced LCOTHER .	3
LCChemicalEntity ( LCOTHER - LCOTHER ) is recommended for protection against LCOTHER - induced LCDiseaseOrPhenotypicFeature .	3
LCOTHER ( LCChemicalEntity - LCChemicalEntity ) is recommended for protection against LCChemicalEntity - induced LCOTHER .	3
LCOTHER ( LCChemicalEntity - LCChemicalEntity ) is recommended for protection against LCOTHER - induced LCDiseaseOrPhenotypicFeature .	3
LCOTHER ( LCOTHER - LCOTHER ) is recommended for protection against LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature .	2
EXPERIMENTAL DESIGN : Because of their widespread use , the LCOTHER LCOTHER following coadministration of LCChemicalEntity and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of LCOTHER and LCOTHER blood progenitor cells to LCChemicalEntity , LCOTHER , and LCOTHER + / - LCOTHER was determined in granulocyte - macrophage colony forming assays .	3
EXPERIMENTAL DESIGN : Because of their widespread use , the LCOTHER LCOTHER following coadministration of LCChemicalEntity and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of LCOTHER and LCOTHER blood progenitor cells to LCOTHER , LCChemicalEntity , and LCOTHER + / - LCOTHER was determined in granulocyte - macrophage colony forming assays .	3
EXPERIMENTAL DESIGN : Because of their widespread use , the LCOTHER LCOTHER following coadministration of LCOTHER and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of LCOTHER and LCOTHER blood progenitor cells to LCChemicalEntity , LCOTHER , and LCChemicalEntity + / - LCOTHER was determined in granulocyte - macrophage colony forming assays .	6
EXPERIMENTAL DESIGN : Because of their widespread use , the LCOTHER LCOTHER following coadministration of LCOTHER and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of LCOTHER and LCOTHER blood progenitor cells to LCOTHER , LCChemicalEntity , and LCChemicalEntity + / - LCOTHER was determined in granulocyte - macrophage colony forming assays .	6
Likewise , in vivo , B6D2F1 LCOTHER were treated with LCChemicalEntity , LCOTHER , and LCChemicalEntity , with or without LCOTHER over a wide range of doses : posttreatment , a full hematologic evaluation was done .	6
Likewise , in vivo , B6D2F1 LCOTHER were treated with LCOTHER , LCChemicalEntity , and LCChemicalEntity , with or without LCOTHER over a wide range of doses : posttreatment , a full hematologic evaluation was done .	6
RESULTS : Nontoxic doses of LCChemicalEntity reduced LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER from LCOTHER and LCOTHER in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCOTHER , LCOTHER LCOTHER , nor the in vitro LCOTHER from LCOTHER .	3
RESULTS : Nontoxic doses of LCChemicalEntity reduced LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature from LCOTHER and LCOTHER in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCOTHER , LCOTHER LCOTHER , nor the in vitro LCOTHER from LCOTHER .	3
RESULTS : Nontoxic doses of LCChemicalEntity reduced LCOTHER and LCOTHER LCOTHER from LCChemicalEntity and LCOTHER in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCOTHER , LCOTHER LCOTHER , nor the in vitro LCOTHER from LCOTHER .	3
RESULTS : Nontoxic doses of LCChemicalEntity reduced LCOTHER and LCOTHER LCOTHER from LCOTHER and LCChemicalEntity in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCOTHER , LCOTHER LCOTHER , nor the in vitro LCOTHER from LCOTHER .	3
RESULTS : Nontoxic doses of LCChemicalEntity reduced LCOTHER and LCOTHER LCOTHER from LCOTHER and LCOTHER in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER , nor the in vitro LCOTHER from LCOTHER .	3
RESULTS : Nontoxic doses of LCChemicalEntity reduced LCOTHER and LCOTHER LCOTHER from LCOTHER and LCOTHER in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , nor the in vitro LCOTHER from LCOTHER .	3
RESULTS : Nontoxic doses of LCOTHER reduced LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER from LCChemicalEntity and LCOTHER in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCOTHER , LCOTHER LCOTHER , nor the in vitro LCOTHER from LCOTHER .	2
RESULTS : Nontoxic doses of LCOTHER reduced LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER from LCOTHER and LCChemicalEntity in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCOTHER , LCOTHER LCOTHER , nor the in vitro LCOTHER from LCOTHER .	2
RESULTS : Nontoxic doses of LCOTHER reduced LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature from LCChemicalEntity and LCOTHER in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCOTHER , LCOTHER LCOTHER , nor the in vitro LCOTHER from LCOTHER .	2
RESULTS : Nontoxic doses of LCOTHER reduced LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature from LCOTHER and LCChemicalEntity in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCOTHER , LCOTHER LCOTHER , nor the in vitro LCOTHER from LCOTHER .	2
RESULTS : Nontoxic doses of LCOTHER reduced LCOTHER and LCOTHER LCOTHER from LCChemicalEntity and LCOTHER in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCOTHER , LCOTHER LCOTHER , nor the in vitro LCOTHER from LCChemicalEntity .	6
RESULTS : Nontoxic doses of LCOTHER reduced LCOTHER and LCOTHER LCOTHER from LCOTHER and LCChemicalEntity in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCOTHER , LCOTHER LCOTHER , nor the in vitro LCOTHER from LCChemicalEntity .	6
RESULTS : Nontoxic doses of LCOTHER reduced LCOTHER and LCOTHER LCOTHER from LCOTHER and LCOTHER in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCChemicalEntity neither reduced LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER , nor the in vitro LCOTHER from LCOTHER .	3
RESULTS : Nontoxic doses of LCOTHER reduced LCOTHER and LCOTHER LCOTHER from LCOTHER and LCOTHER in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCChemicalEntity neither reduced LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , nor the in vitro LCOTHER from LCOTHER .	3
CONCLUSION : Although our findings support the observation that LCChemicalEntity reduces neither hematologic activity nor antitumor activity from LCOTHER clinically , the potent antagonism of LCChemicalEntity activity raises concern ; a possible interference with anticancer efficacy certainly would call for renewed attention .	3
Clinical trials in patients with brain LCOTHER combining LCChemicalEntity and high doses of LCChemicalEntity is ongoing with the aim of improving efficacy without aggravating LCOTHER LCOTHER .	3
Clinical trials in patients with brain LCOTHER combining LCChemicalEntity and high doses of LCOTHER is ongoing with the aim of improving efficacy without aggravating LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	3
Recent studies have reported germline mutations in LCGeneOrGeneProduct gene in some types of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
Recent studies have reported germline mutations in LCGeneOrGeneProduct gene in some types of LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
However , the prevalence of LCGeneOrGeneProduct mutations in LCDiseaseOrPhenotypicFeature and the correlation between the LCOTHER genotype and LCOTHER phenotype have not been extensively studied .	1
However , the prevalence of LCGeneOrGeneProduct mutations in LCOTHER and the correlation between the LCOTHER genotype and LCDiseaseOrPhenotypicFeature phenotype have not been extensively studied .	1
However , the prevalence of LCOTHER mutations in LCOTHER and the correlation between the LCGeneOrGeneProduct genotype and LCDiseaseOrPhenotypicFeature phenotype have not been extensively studied .	1
We screened germline mutations in the coding exons and the flanking intron sequences of the LCGeneOrGeneProduct gene in 486 LCDiseaseOrPhenotypicFeature LCOTHER by denaturing high - performance liquid chromatography ( DHPLC ) , and confirmed the mutations by sequencing .	1
Nine distinct mutations including one small deletion mutation ( LCSequenceVariant ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , two with LCOTHER LCOTHER LCOTHER , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCSequenceVariant ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCSequenceVariant ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCOTHER LCOTHER LCOTHER , and one with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCSequenceVariant - LCSequenceVariant and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , two with LCOTHER LCOTHER LCOTHER , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCSequenceVariant - LCSequenceVariant and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCSequenceVariant - LCSequenceVariant and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCOTHER LCOTHER LCOTHER , and one with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCSequenceVariant - LCSequenceVariant ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , two with LCOTHER LCOTHER LCOTHER , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCSequenceVariant - LCSequenceVariant ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCSequenceVariant - LCSequenceVariant ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCOTHER LCOTHER LCOTHER , and one with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCSequenceVariant , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , two with LCOTHER LCOTHER LCOTHER , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCSequenceVariant , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCSequenceVariant , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCOTHER LCOTHER LCOTHER , and one with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCSequenceVariant , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , two with LCOTHER LCOTHER LCOTHER , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCSequenceVariant , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCSequenceVariant , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCOTHER LCOTHER LCOTHER , and one with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCSequenceVariant , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , two with LCOTHER LCOTHER LCOTHER , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCSequenceVariant , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCSequenceVariant , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCOTHER LCOTHER LCOTHER , and one with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCSequenceVariant , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , two with LCOTHER LCOTHER LCOTHER , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCSequenceVariant , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCSequenceVariant , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCOTHER LCOTHER LCOTHER , and one with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCSequenceVariant and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , two with LCOTHER LCOTHER LCOTHER , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCSequenceVariant and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCSequenceVariant and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCOTHER LCOTHER LCOTHER , and one with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCSequenceVariant ) were identified in 12 of the 486 LCOTHER ( nine with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , two with LCOTHER LCOTHER LCOTHER , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCSequenceVariant ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and one with LCOTHER LCOTHER LCOTHER ) .	1
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCSequenceVariant ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCOTHER LCOTHER LCOTHER , and one with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	1
Of them , two LCOTHER carrying LCSequenceVariant mutation were from two generations in one family with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	1
Of them , two LCOTHER carrying LCSequenceVariant mutation were from two generations in one family with LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	1
Interestingly , a nucleotide insertion of LCSequenceVariant . LCSequenceVariant + LCSequenceVariant in exon 6 was detected in five LCDiseaseOrPhenotypicFeature LCOTHER , but not in 486 normal healthy controls .	1
Our findings are useful in understanding the prevalence of LCGeneOrGeneProduct mutations and the correlation between the LCOTHER genotype and the LCDiseaseOrPhenotypicFeature phenotype in Chinese LCOTHER . Two novel mutations of the LCOTHER - LCOTHER subunit gene underlying LCOTHER LCOTHER LCOTHER undetectable in neonatal LCOTHER screening .	1
Our findings are useful in understanding the prevalence of LCOTHER mutations and the correlation between the LCGeneOrGeneProduct genotype and the LCDiseaseOrPhenotypicFeature phenotype in Chinese LCOTHER . Two novel mutations of the LCOTHER - LCOTHER subunit gene underlying LCOTHER LCOTHER LCOTHER undetectable in neonatal LCOTHER screening .	1
CONTEXT : LCOTHER with LCGeneOrGeneProduct - LCGeneOrGeneProduct subunit defects and LCOTHER LCOTHER are missed by LCGeneOrGeneProduct - based neonatal screening .	1
CONTEXT : LCOTHER with LCOTHER - LCOTHER subunit defects and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature are missed by LCGeneOrGeneProduct - based neonatal screening .	1
OBJECTIVE : Our objective was to report the molecular consequences of a novel splice - junction mutation and a novel missense mutation in the LCGeneOrGeneProduct - LCGeneOrGeneProduct subunit gene found in two LCOTHER with LCOTHER LCOTHER LCOTHER and conventional treatment - resistant LCDiseaseOrPhenotypicFeature .	1
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature is characterized by prolonged LCOTHER after the use of LCOTHER LCOTHER ( LCChemicalEntity or LCOTHER ) in LCOTHER who have mutations in the LCOTHER gene .	2
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature is characterized by prolonged LCOTHER after the use of LCOTHER LCOTHER ( LCOTHER or LCChemicalEntity ) in LCOTHER who have mutations in the LCOTHER gene .	2
LCOTHER LCOTHER is characterized by prolonged LCDiseaseOrPhenotypicFeature after the use of LCOTHER LCOTHER ( LCOTHER or LCChemicalEntity ) in LCOTHER who have mutations in the LCOTHER gene .	2
Here , we report a case of prolonged LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature after administration of LCChemicalEntity leading to the discovery of a novel LCOTHER variant ( LCOTHER . LCOTHER > LCOTHER , LCOTHER . LCOTHER ) .	2
Here , we report a case of prolonged LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature after administration of LCOTHER leading to the discovery of a novel LCOTHER variant ( LCSequenceVariant . LCSequenceVariant > LCSequenceVariant , LCOTHER . LCOTHER ) .	2
Here , we report a case of prolonged LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature after administration of LCOTHER leading to the discovery of a novel LCOTHER variant ( LCOTHER . LCOTHER > LCOTHER , LCSequenceVariant . LCSequenceVariant ) .	2
Here , we report a case of prolonged LCOTHER LCOTHER after administration of LCChemicalEntity leading to the discovery of a novel LCOTHER variant ( LCSequenceVariant . LCSequenceVariant > LCSequenceVariant , LCOTHER . LCOTHER ) .	1
Low activity of LCOTHER plasma LCGeneOrGeneProduct with LCChemicalEntity ( LCOTHER ) and LCOTHER , and values of LCOTHER and LCOTHER numbers fit with heterozygous atypical silent genotype .	1
Low activity of LCOTHER plasma LCGeneOrGeneProduct with LCOTHER ( LCChemicalEntity ) and LCOTHER , and values of LCOTHER and LCOTHER numbers fit with heterozygous atypical silent genotype .	1
Kinetic analysis showed that the LCSequenceVariant . LCSequenceVariant / LCSequenceVariant . LCSequenceVariant - LCOTHER . LCOTHER LCOTHER displays a pure Michaelian behavior with LCOTHER as the substrate .	1
Kinetic analysis showed that the LCSequenceVariant . LCSequenceVariant / LCOTHER . LCOTHER - LCSequenceVariant . LCSequenceVariant LCOTHER displays a pure Michaelian behavior with LCOTHER as the substrate .	1
Kinetic analysis showed that the LCSequenceVariant . LCSequenceVariant / LCOTHER . LCOTHER - LCOTHER . LCOTHER LCOTHER displays a pure Michaelian behavior with LCChemicalEntity as the substrate .	1
Kinetic analysis showed that the LCOTHER . LCOTHER / LCSequenceVariant . LCSequenceVariant - LCSequenceVariant . LCSequenceVariant LCOTHER displays a pure Michaelian behavior with LCOTHER as the substrate .	1
Kinetic analysis showed that the LCOTHER . LCOTHER / LCSequenceVariant . LCSequenceVariant - LCOTHER . LCOTHER LCOTHER displays a pure Michaelian behavior with LCChemicalEntity as the substrate .	1
Kinetic analysis showed that the LCOTHER . LCOTHER / LCOTHER . LCOTHER - LCSequenceVariant . LCSequenceVariant LCOTHER displays a pure Michaelian behavior with LCChemicalEntity as the substrate .	1
Kinetic analysis showed that the LCOTHER . LCOTHER / LCOTHER . LCOTHER - LCOTHER . LCOTHER LCGeneOrGeneProduct displays a pure Michaelian behavior with LCChemicalEntity as the substrate .	1
This fits with the reduced concentration of LCOTHER . LCOTHER / LCSequenceVariant . LCSequenceVariant - LCSequenceVariant . LCSequenceVariant tetrameric enzyme in the plasma and non - detectable fast moving - bands on electrophoresis gels . The promoter of inducible LCOTHER LCOTHER LCOTHER implicated in LCOTHER based on genetic analysis and nuclear factor binding .	1
PURPOSE : LCChemicalEntity LCChemicalEntity has many beneficial functions in the LCOTHER body at the right amounts , but it can also be hazardous if it is produced in amounts more than needed and has therefore been studied in relation to several LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	1
In vitro and in vivo studies demonstrate a connection between the inducible form of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER , and the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , one of the major causes of LCOTHER in the world .	1
In vitro and in vivo studies demonstrate a connection between the inducible form of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER , and the LCOTHER LCOTHER LCOTHER , one of the major causes of LCDiseaseOrPhenotypicFeature in the world .	1
In vitro and in vivo studies demonstrate a connection between the inducible form of LCOTHER LCOTHER LCOTHER , LCGeneOrGeneProduct , and the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , one of the major causes of LCOTHER in the world .	1
In vitro and in vivo studies demonstrate a connection between the inducible form of LCOTHER LCOTHER LCOTHER , LCGeneOrGeneProduct , and the LCOTHER LCOTHER LCOTHER , one of the major causes of LCDiseaseOrPhenotypicFeature in the world .	1
In this study , we sought to establish the genetic association between LCGeneOrGeneProduct and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER , and to find the functional element ( s ) connected with the pathogenesis of the disease .	1
In this study , we sought to establish the genetic association between LCGeneOrGeneProduct and LCOTHER LCOTHER LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature , and to find the functional element ( s ) connected with the pathogenesis of the disease .	1
METHODS : Two microsatellites , 1 insertion / deletion , and 8 single nucleotide polymorphisms ( SNPs ) in the regulatory region of LCGeneOrGeneProduct were genotyped in 200 LCDiseaseOrPhenotypicFeature LCOTHER and 200 age - matched controls .	1
CONCLUSIONS : These results , together with other studies on this gene and the CCTTT - microsatellite , establish , for the first time , a genetic association of LCGeneOrGeneProduct with LCDiseaseOrPhenotypicFeature and suggest a regulatory function for the microsatellite . Severe form of LCOTHER LCOTHER LCOTHER in a LCOTHER with homozygous / hemizygous mutation of LCOTHER LCOTHER gene .	1
We present a LCOTHER with LCDiseaseOrPhenotypicFeature found to be homo - / hemizygous for a mutation in the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene .	1
The severe phenotype with seriously LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER behaviour , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER is probably due to the dominant negative effect of the LCSequenceVariant mutant protein and the absence of any functional LCOTHER - LCOTHER . The LCOTHER LCOTHER confers protection against diet - induced LCOTHER , LCOTHER , and LCOTHER in female LCOTHER .	2
The severe phenotype with seriously LCOTHER LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature behaviour , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER is probably due to the dominant negative effect of the LCSequenceVariant mutant protein and the absence of any functional LCOTHER - LCOTHER . The LCOTHER LCOTHER confers protection against diet - induced LCOTHER , LCOTHER , and LCOTHER in female LCOTHER .	2
The severe phenotype with seriously LCOTHER LCOTHER LCOTHER , LCOTHER behaviour , LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER LCOTHER LCOTHER is probably due to the dominant negative effect of the LCSequenceVariant mutant protein and the absence of any functional LCOTHER - LCOTHER . The LCOTHER LCOTHER confers protection against diet - induced LCOTHER , LCOTHER , and LCOTHER in female LCOTHER .	2
To determine the physiologic LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - dependent actions of LCChemicalEntity on LCOTHER in female LCOTHER , we generated female LCOTHER - knockout ( LCOTHER ) LCOTHER on an LCOTHER - prone LCOTHER LCOTHER ( LCOTHER ) - deficient background .	4
To determine the physiologic LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - dependent actions of LCOTHER on LCDiseaseOrPhenotypicFeature in female LCOTHER , we generated female LCOTHER - knockout ( LCOTHER ) LCOTHER on an LCOTHER - prone LCOTHER LCOTHER ( LCOTHER ) - deficient background .	3
To determine the physiologic LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - dependent actions of LCOTHER on LCOTHER in female LCOTHER , we generated female LCOTHER - knockout ( LCOTHER ) LCOTHER on an LCDiseaseOrPhenotypicFeature - prone LCOTHER LCOTHER ( LCOTHER ) - deficient background .	3
To determine the physiologic LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - dependent actions of LCChemicalEntity on LCOTHER in female LCOTHER , we generated female LCOTHER - knockout ( LCOTHER ) LCOTHER on an LCOTHER - prone LCOTHER LCOTHER ( LCOTHER ) - deficient background .	4
To determine the physiologic LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - dependent actions of LCOTHER on LCDiseaseOrPhenotypicFeature in female LCOTHER , we generated female LCOTHER - knockout ( LCOTHER ) LCOTHER on an LCOTHER - prone LCOTHER LCOTHER ( LCOTHER ) - deficient background .	3
To determine the physiologic LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - dependent actions of LCOTHER on LCOTHER in female LCOTHER , we generated female LCOTHER - knockout ( LCOTHER ) LCOTHER on an LCDiseaseOrPhenotypicFeature - prone LCOTHER LCOTHER ( LCOTHER ) - deficient background .	3
To determine the physiologic LCOTHER LCOTHER ( LCOTHER ) - dependent actions of LCOTHER on LCOTHER in female LCOTHER , we generated female LCGeneOrGeneProduct - knockout ( LCOTHER ) LCOTHER on an LCDiseaseOrPhenotypicFeature - prone LCOTHER LCOTHER ( LCOTHER ) - deficient background .	3
To determine the physiologic LCOTHER LCOTHER ( LCOTHER ) - dependent actions of LCOTHER on LCOTHER in female LCOTHER , we generated female LCOTHER - knockout ( LCGeneOrGeneProduct ) LCOTHER on an LCDiseaseOrPhenotypicFeature - prone LCOTHER LCOTHER ( LCOTHER ) - deficient background .	3
They also displayed increased body weight ( + 18% ) , body fat percentage ( + 62% ) , and hepatic LCOTHER levels , reduced LCOTHER sensitivity , and a marked LCDiseaseOrPhenotypicFeature LCOTHER ( serum LCChemicalEntity , + 52% ) .	2
They also displayed increased body weight ( + 18% ) , body fat percentage ( + 62% ) , and hepatic LCOTHER levels , reduced LCOTHER sensitivity , and a marked LCOTHER LCDiseaseOrPhenotypicFeature ( serum LCChemicalEntity , + 52% ) .	2
Differences in LCDiseaseOrPhenotypicFeature , body weight , and LCChemicalEntity levels between LCOTHER and control LCOTHER were abolished in LCOTHER that were ovariectomized before puberty , consistent with a protective action of ovarian LCOTHER mediated via the LCOTHER .	1
Differences in LCOTHER , body weight , and LCOTHER levels between LCGeneOrGeneProduct and control LCOTHER were abolished in LCOTHER that were ovariectomized before puberty , consistent with a protective action of ovarian LCChemicalEntity mediated via the LCOTHER .	4
Furthermore , the LCGeneOrGeneProduct agonist LCChemicalEntity reduced LCOTHER ( - 41% ; thoracic aorta ) , subcutaneous fat mass ( - 44% ) , and LCOTHER levels ( - 35% ) in ovariectomized LCOTHER , reduced hepatocyte LCOTHER accumulation in LCOTHER cells in vitro , and regulated mRNA expression of hepatic genes pivotal for LCOTHER homeostasis .	2
Furthermore , the LCGeneOrGeneProduct agonist LCOTHER reduced LCDiseaseOrPhenotypicFeature ( - 41% ; thoracic aorta ) , subcutaneous fat mass ( - 44% ) , and LCOTHER levels ( - 35% ) in ovariectomized LCOTHER , reduced hepatocyte LCOTHER accumulation in LCOTHER cells in vitro , and regulated mRNA expression of hepatic genes pivotal for LCOTHER homeostasis .	3
Furthermore , the LCOTHER agonist LCChemicalEntity reduced LCDiseaseOrPhenotypicFeature ( - 41% ; thoracic aorta ) , subcutaneous fat mass ( - 44% ) , and LCOTHER levels ( - 35% ) in ovariectomized LCOTHER , reduced hepatocyte LCOTHER accumulation in LCOTHER cells in vitro , and regulated mRNA expression of hepatic genes pivotal for LCOTHER homeostasis .	3
Furthermore , the LCOTHER agonist LCChemicalEntity reduced LCOTHER ( - 41% ; thoracic aorta ) , subcutaneous fat mass ( - 44% ) , and LCChemicalEntity levels ( - 35% ) in ovariectomized LCOTHER , reduced hepatocyte LCOTHER accumulation in LCOTHER cells in vitro , and regulated mRNA expression of hepatic genes pivotal for LCOTHER homeostasis .	3
Furthermore , the LCOTHER agonist LCChemicalEntity reduced LCOTHER ( - 41% ; thoracic aorta ) , subcutaneous fat mass ( - 44% ) , and LCOTHER levels ( - 35% ) in ovariectomized LCOTHER , reduced hepatocyte LCChemicalEntity accumulation in LCOTHER cells in vitro , and regulated mRNA expression of hepatic genes pivotal for LCOTHER homeostasis .	3
Furthermore , the LCOTHER agonist LCChemicalEntity reduced LCOTHER ( - 41% ; thoracic aorta ) , subcutaneous fat mass ( - 44% ) , and LCOTHER levels ( - 35% ) in ovariectomized LCOTHER , reduced hepatocyte LCOTHER accumulation in LCOTHER cells in vitro , and regulated mRNA expression of hepatic genes pivotal for LCChemicalEntity homeostasis .	3
Furthermore , the LCOTHER agonist LCOTHER reduced LCDiseaseOrPhenotypicFeature ( - 41% ; thoracic aorta ) , subcutaneous fat mass ( - 44% ) , and LCChemicalEntity levels ( - 35% ) in ovariectomized LCOTHER , reduced hepatocyte LCOTHER accumulation in LCOTHER cells in vitro , and regulated mRNA expression of hepatic genes pivotal for LCOTHER homeostasis .	2
Furthermore , the LCOTHER agonist LCOTHER reduced LCDiseaseOrPhenotypicFeature ( - 41% ; thoracic aorta ) , subcutaneous fat mass ( - 44% ) , and LCOTHER levels ( - 35% ) in ovariectomized LCOTHER , reduced hepatocyte LCChemicalEntity accumulation in LCOTHER cells in vitro , and regulated mRNA expression of hepatic genes pivotal for LCOTHER homeostasis .	1
Furthermore , the LCOTHER agonist LCOTHER reduced LCDiseaseOrPhenotypicFeature ( - 41% ; thoracic aorta ) , subcutaneous fat mass ( - 44% ) , and LCOTHER levels ( - 35% ) in ovariectomized LCOTHER , reduced hepatocyte LCOTHER accumulation in LCOTHER cells in vitro , and regulated mRNA expression of hepatic genes pivotal for LCChemicalEntity homeostasis .	1
In conclusion , we demonstrate that the LCGeneOrGeneProduct protects against diet - induced LCDiseaseOrPhenotypicFeature in female LCOTHER and propose that this is mediated by modulation of body composition and LCOTHER metabolism . LCOTHER LCOTHER LCOTHER in a Chinese family related with novel mutations of LCOTHER .	3
In conclusion , we demonstrate that the LCOTHER protects against diet - induced LCDiseaseOrPhenotypicFeature in female LCOTHER and propose that this is mediated by modulation of body composition and LCChemicalEntity metabolism . LCOTHER LCOTHER LCOTHER in a Chinese family related with novel mutations of LCOTHER .	1
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOrganismTaxon with healthy pregnancies .	0
LCOTHER , like LCOTHER , is a LCChemicalEntity LCChemicalEntity that has anti - LCOTHER property , although it also pro - LCDiseaseOrPhenotypicFeature that can cause various LCOTHER , including severe LCOTHER such as multiple LCOTHER .	0
Screening of LCOTHER identified two synonymous sequence variants , LCSequenceVariant . LCSequenceVariant LCSequenceVariant > LCSequenceVariant ( LCOTHER . LCOTHER , LCOTHER ) and LCSequenceVariant . LCSequenceVariant LCSequenceVariant > LCSequenceVariant ( LCOTHER .	0
METHODS : 133 LCOrganismTaxon who developed LCOTHER following chemotherapy and / or radiotherapy ( n = 133 ) , 420 LCOrganismTaxon diagnosed with de novo LCOTHER LCOTHER , 242 LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER , and 1177 healthy controls were genotyped for the LCOTHER - 93 polymorphism by allelic discrimination polymerase chain reaction ( PCR ) and restriction fragment length polymorphism assay .	0
Treatment of WT with LCChemicalEntity liposomes suppressed LCOTHER LCOTHER by diminishing LCGeneOrGeneProduct - LCGeneOrGeneProduct ( + ) LCOTHER / LCOTHER ( + ) cells accumulation .	0
Loss - of - function experiments demonstrate that LCGeneOrGeneProduct serves as a LCOTHER antagonist with functions that overlap and are redundant with those of LCOTHER in forming the dorsoventral axis . Polymorphic forms of LCOTHER LCOTHER LCOTHER and their interaction with LCGeneOrGeneProduct LCGeneOrGeneProduct trinucleotide repeats in LCOTHER LCOTHER .	0
This study aimed at investigating the potential antipsychotic - like properties of LCOTHER , with a particular focus on models of LCDiseaseOrPhenotypicFeature , involving either drug challenge ( ie , LCOTHER and LCOTHER - LCOTHER ) or transgenic LCOTHER ( ie , LCOTHER LCOTHER ( neo - / - ) and LCGeneOrGeneProduct ( - / - ) ) .	0
In LCDiseaseOrPhenotypicFeature FLSs , the level of LCOTHER was up - regulated by stimulation with LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCGeneOrGeneProduct , LCOTHER [ LCOTHER , LCGeneOrGeneProduct ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
LCOrganismTaxon developing LCDiseaseOrPhenotypicFeature had a 6 - year survival after onset of LCOTHER of 27% for the LCOTHER receiving hemodialysis versus 71 . 4% for the LCOTHER developing LCOTHER who subsequently received kidney transplants .	0
In this study we investigated the polymorphism LCSequenceVariant in 395 Brazilian subjects with and without LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
n = 15 ) after methylating chemotherapy for LCOTHER LCOTHER compared to LCOrganismTaxon without previous methylating exposure ( t - LCOTHER , 30 . 4% , n = 69 ; LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER , 27 . 2% , n = 22 ) .	0
BACKGROUND : The LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( or LCGeneOrGeneProduct - LCGeneOrGeneProduct ) is a specific receptor for the LCOTHER LCOTHER ( LCOTHER - LCOTHER ) , which is chemoattractant for neutrophils and has an important role in the LCOTHER response .	0
LCOTHER consists of three pairs of non - identical polypeptide chains , encoded by different genes ( LCOTHER LCOTHER [ LCOTHER ] , LCGeneOrGeneProduct LCGeneOrGeneProduct [ LCOTHER ] and LCOTHER LCOTHER [ LCGeneOrGeneProduct ] ) .	0
Our results thus indicates that LCOTHER LCSequenceVariant homozygosity is associated with increased mortality in LCOrganismTaxon in the second half of life and that this increased mortality is possibly related to LCOTHER severity and survival after LCOTHER rather than susceptibility to development of LCOTHER . The antiarrhythmic effect and possible ionic mechanisms of LCOTHER on animal models .	0
LCOTHER AND METHODS : We examined associations between 54 polymorphisms that tag the known common variants ( minor allele frequency > 0 . 05 ) in 10 genes involved in oxidative damage repair ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER ) and survival in 4 , 470 LCOTHER with LCOTHER LCOTHER .	0
BACKGROUND : LCOTHER LCOTHER LCOTHER ( LCOTHER ) is LCOTHER LCOTHER with an autosomal recessive inheritance and is caused by a mutation in the gene encoding LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct / LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ) .	0
RESULTS : Two single nucleotide polymorphisms ( SNPs ) in LCGeneOrGeneProduct ( LCOTHER and LCSequenceVariant ) were associated with all - cause mortality even after adjusting for multiple hypothesis testing ( adjusted P = . 0041 and P = . 0035 ) .	0
Independent predictors of postoperative LCOTHER included age , female sex , redo cardiac surgery , LCOTHER LCOTHER LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , deep LCDiseaseOrPhenotypicFeature circulatory arrest , duration of aortic cross - clamp and LCOTHER LCOTHER .	0
METHODS : Isoforms of LCGeneOrGeneProduct LCGeneOrGeneProduct MRNA were measured in several types of cultured vascular ecs : LCOTHER retinal microvascular ECs ( hRMVECs ) , choroidal ECs ( CECs ) , and LCOrganismTaxon umbilical vascular ECs ( HUVECs ) using real - time PCR .	0
We reviewed the genotype of LCDiseaseOrPhenotypicFeature cases from Japan , India , China and Taiwan , and found that LCOTHER is a major causative gene for LCOTHER in Asian . LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct induces epithelial - mesenchymal transition via LCOTHER / LCOTHER - LCOTHER signaling pathway in LCOTHER LCOTHER LCOTHER .	0
Despite the absence of functional LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) protein in LCOTHER cells , LCOTHER knockdown reduced LCOTHER phosphorylation at LCOTHER LCOTHER and concomitantly inhibited phosphorylation of the LCOTHER target , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) .	0
DISCUSSION : Epigenetic reprogramming that imparts functional changes in gene expression , the development of LCDiseaseOrPhenotypicFeature stem cells , and immunomodulation are plausible underlying mechanisms by which early - life LCChemicalEntity exposure elicits latent LCOTHER effects .	0
Our data show that ablation of LCGeneOrGeneProduct preserves LCOTHER and LCOTHER - LCOTHER protein expression and localization in LCOTHER - induced LCOTHER , and prevents the development of the severe LCOTHER associated with LCOTHER therapy . LCOTHER LCOTHER LCOTHER - mediated activation of LCOTHER LCOTHER LCOTHER inhibits the growth of LCDiseaseOrPhenotypicFeature in vitro and in vivo .	0
LCOTHER - LCOTHER LCOTHER LCOTHER has been traditionally divided into syndromic ( S - LCDiseaseOrPhenotypicFeature ) and non - syndromic forms ( NS - LCOTHER ) , although the borderlines between these phenotypes begin to vanish and mutations in a single gene , for example LCOTHER , can cause S - LCDiseaseOrPhenotypicFeature as well as NS - LCOTHER .	0
We reviewed the genotype of LCOTHER cases from Japan , India , China and Taiwan , and found that LCOTHER is a major causative gene for LCOTHER in Asian . LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct induces epithelial - mesenchymal transition via LCOTHER / LCOTHER - LCOTHER signaling pathway in LCOrganismTaxon LCOTHER LCOTHER .	0
Moreover , two polymorphisms were also found : one allele carried a LCOTHER polymorphism ( 1 / 39 LCDiseaseOrPhenotypicFeature ) , while a LCOTHER polymorphism ( LCSequenceVariant / LCSequenceVariant ) was found in 15 and 8 LCOTHER in hetero ( CT ) and homozygosity ( TT ) , respectively .	0
CONCLUSION : As LCChemicalEntity exacerbated LCOTHER LCOTHER LCOTHER LCOTHER without an improvement in LCOTHER LCOTHER and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to LCOTHER in day surgery . LCOTHER - induced LCChemicalEntity + overload causes LCOTHER and triggers apoptosis through LCOTHER LCOTHER signaling pathway in LCOTHER .	0
We reviewed the genotype of LCOTHER cases from Japan , India , China and Taiwan , and found that LCOTHER is a major causative gene for LCDiseaseOrPhenotypicFeature in Asian . LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER induces epithelial - mesenchymal transition via LCGeneOrGeneProduct / LCOTHER - LCOTHER signaling pathway in LCOTHER LCOTHER LCOTHER .	0
She had profound LCOTHER LCOTHER , LCOTHER , severe LCDiseaseOrPhenotypicFeature and relapsing LCDiseaseOrPhenotypicFeature , while her pre - pubescent daughter had normal fat distribution but elevated plasma LCOTHER and LCOTHER - LCOTHER and depressed LCOTHER - LCOTHER LCOTHER LCOTHER .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCGeneOrGeneProduct [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCGeneOrGeneProduct ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
LCOTHER LCOTHER ( LCOTHER ) is required to convert the LCOTHER LCOTHER used in supplements and for food fortification and the LCOTHER produced by LCGeneOrGeneProduct LCGeneOrGeneProduct during DNA synthesis to the reduced LCChemicalEntity forms used by the cell .	0
Knockdown and overexpression of LCOTHER in LCOTHER LCOTHER cells was performed using specifically constructed plasmids , which either had anti - LCGeneOrGeneProduct ribozyme transgene or the full length LCOrganismTaxon LCOTHER coding sequence .	0
Eleven subjects presented LCOTHER homozygous single - base mutations ( two first cousins and four unrelated LCOTHER with LCOTHER , two with LCOTHER , one with LCOTHER , one with LCOTHER , and one with LCSequenceVariant plus the LCOTHER variant in heterozygosis ) , whereas four were compound heterozygotes ( one with LCOTHER / LCOTHER + LCOTHER > LCOTHER , one with LCOTHER / LCOTHER , and two brothers with LCOTHER / LCSequenceVariant ) .	0
The fact that no truncation or frame shift mutations have been found in any of the LCOTHER LCOrganismTaxon , coupled with our recent finding that some breeding pairs of LCOTHER LCOTHER knockout LCOTHER yield litters that show not only LCOTHER , but also severe LCOTHER and LCOTHER LCOTHER , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOTHER . Midline B3 LCChemicalEntity nerves in LCOTHER medulla are involved in LCOTHER effect of LCOTHER .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCGeneOrGeneProduct LCGeneOrGeneProduct ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
A decrease of LCOTHER expression in addition to an up - regulation of LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , retinoid signaling , and LCChemicalEntity LCChemicalEntity response element signaling was selectively observed in WAT of LCOTHER fed a normal - LCOTHER LCOTHER , high - fat diet .	0
In addition , the substitution LCOTHER > LCOTHER ( LCSequenceVariant ) has also been found in excess among children with LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	0
There was no LCDiseaseOrPhenotypicFeature or LCOTHER effect on the protein content for LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , LCOTHER or LCOTHER in muscle .	0
LCOTHER AND METHODS : We examined associations between 54 polymorphisms that tag the known common variants ( minor allele frequency > 0 . 05 ) in 10 genes involved in oxidative damage repair ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) and survival in 4 , 470 LCOrganismTaxon with LCOTHER LCOTHER .	0
In a baby LCOTHER with early onset , severe LCOTHER , LCOTHER LCOTHER and profound , isolated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in skeletal muscle , we identified a disease - segregating homozygous mutation ( LCOTHER . LCOTHER > LCOTHER ) in LCGeneOrGeneProduct / LCOTHER , predicting a drastic change in a highly conserved amino - acid residue ( LCOTHER . LCOTHER ) .	0
METHODS : Here we set out to study the function of LCOTHER in LCOrganismTaxon liver via analysis of whole genome gene regulation in LCOTHER liver slices treated with the LCOTHER agonist LCChemicalEntity .	0
Also , the multichannel blockers LCChemicalEntity , LCChemicalEntity , LCOTHER and LCOTHER prolonged FPDc in a concentration dependent manner .	0
They also displayed increased body weight ( + 18% ) , body fat percentage ( + 62% ) , and hepatic LCOTHER levels , reduced LCGeneOrGeneProduct sensitivity , and a marked LCOTHER LCDiseaseOrPhenotypicFeature ( serum LCOTHER , + 52% ) .	0
In a multivariate logistic regression analysis including age , sex , smoking , LCOTHER , arterial LCOTHER and LCDiseaseOrPhenotypicFeature , the LCOTHER LCSequenceVariant LCSequenceVariant variant was not significantly associated with the presence of LCOTHER ( Odds ratio 1 . 07 , 95% confidence interval 0 . 84 - 1 . 37 ; p = 0 . 60 ) .	0
Also , LCGeneOrGeneProduct , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , and LCOTHER - LCOTHER ( LCOTHER ) expression levels were increased , whereas LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER levels were drastically reduced compared with those found in wild - type B cells .	0
Differences were found for serum FBG , FINS , HOMA - IR , and HOMA - beta , and placental LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER .	0
The aim of this study was therefore to investigate the influence of mutations in these LCOTHER LCOTHER LCOTHER genes ( LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER / LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct , LCOTHER / LCOTHER , LCGeneOrGeneProduct / LCOTHER / LCOTHER , LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER , LCOTHER and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
LCOTHER is likely to be an LCOTHER - susceptibility gene and LCOTHER mutations may increase the risk of developing a LCOTHER LCOTHER rather than being a direct causative mutation . The differential effects of LCOTHER and LCOTHER on LCGeneOrGeneProduct LCGeneOrGeneProduct release , LCOTHER gene expression and LCDiseaseOrPhenotypicFeature in a clinical LCOTHER model .	0
Recently , heterozygous LCOTHER mutations were shown to result in early - onset LCOTHER , LCOTHER , and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) .	0
All LCOTHER were genotyped for LCOTHER ( LCSequenceVariant - LCSequenceVariant LCSequenceVariant ) , intron 2 conversion , LCOTHER ( LCOTHER ) within LCOTHER and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER ( LCOTHER ) within LCGeneOrGeneProduct .	0
On the whole , our findings indicate that the absence of LCOTHER plays a cardioprotective role in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature by promoting changes in LCOTHER / LCOTHER signalling . Long - Lived LCOTHER + LCOTHER - LCOTHER + T Cells rather than Short - Lived LCGeneOrGeneProduct + LCOTHER - LCOTHER + LCOTHER - LCOTHER + T Cells Initiate Rapid LCOTHER - LCOTHER Production To Suppress Anamnestic T Cell Responses during Secondary LCOTHER LCOTHER .	0
CONCLUSION : Our results suggest that use of high - dose LCOTHER in older LCOTHER in conjunction with cardiopulmonary bypass and open - chamber cardiac surgery is associated with clinical LCDiseaseOrPhenotypicFeature in susceptible LCOTHER . Cardioprotective effect of LCOTHER LCOTHER LCOTHER on LCChemicalEntity - induced LCOTHER LCOTHER in LCOTHER .	0
Finally , several putative new target genes of LCOTHER were identified that were commonly induced by LCOTHER activation in the two LCOrganismTaxon liver model systems , including LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct .	0
LCOTHER was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCOTHER , LCOTHER ] , by secretagogues activating LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) [ LCOTHER , LCOTHER , LCChemicalEntity ] and by post - receptor stimulants activating LCOTHER [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	0
LCOTHER haploinsufficiency leads to LCDiseaseOrPhenotypicFeature due to illicit occupation of renal LCOTHER LCOTHER by elevated LCOTHER rather than to increased LCOTHER production reported in primary LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
The fact that no truncation or frame shift mutations have been found in any of the LCOTHER LCOrganismTaxon , coupled with our recent finding that some breeding pairs of LCOTHER LCOTHER knockout LCOrganismTaxon yield litters that show not only LCOTHER , but also severe LCOTHER and LCOTHER LCOTHER , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOTHER . Midline B3 LCOTHER nerves in LCOTHER medulla are involved in LCOTHER effect of LCOTHER .	0
METHODS : One hundred LCDiseaseOrPhenotypicFeature LCOrganismTaxon and an age matched cohort of 79 LCOTHER LCOTHER LCOTHER and 67 population controls were entered in this study .	0
LCOTHER ( LCOTHER ) LCOTHER displayed severe LCDiseaseOrPhenotypicFeature with runting , impaired formation of secondary centres of ossification , and LCOTHER LCOTHER including LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER .	0
Silencing of LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) expression in LCOTHER cells had a greater impact on LCOTHER - inducible cytokines than LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , and LCGeneOrGeneProduct expression .	0
Although uncommon , point mutations in the LCGeneOrGeneProduct gene may be a cause of LCOTHER and LCOTHER LCOTHER in Japanese LCOTHER . Homozygously deleted gene LCOTHER regulates LCDiseaseOrPhenotypicFeature - initiating activity of LCOTHER cells .	0
Using the two Asian cohorts , significant association of LCOTHER - LCOTHER / Thr with LCOTHER was observed only in the presence of LCOTHER - * 1 / * 1 genotype ( OR 4 . 63 , 95% CI 1 . 47 - 14 . 6 , P = 0 . 009 versus LCGeneOrGeneProduct - LCSequenceVariant / Ile plus LCOTHER - * 2 / * 2 ) .	0
The LCSequenceVariant mutation , predicted to result in the substitution of an LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) in the N - terminal subdomain , affected conserved residues in the LCGeneOrGeneProduct paired domain .	0
These results indicated that the presence of LCGeneOrGeneProduct - * 2 allele decreases risk for LCOTHER LCOTHER conferred by LCOTHER - LCOTHER , possibly by increasing the AS isoform of LCGeneOrGeneProduct . Vaccine candidates derived from a novel infectious cDNA clone of an American genotype LCOTHER LCOTHER LCOTHER LCOTHER .	0
All 24 LCOrganismTaxon with LCOTHER received high doses of LCChemicalEntity intraoperatively ranging from 61 to 259 mg / kg , had a mean age of 69 . 9 years , and 21 of 24 had undergone open chamber rather than coronary bypass procedures .	0
LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) is an inherited syndrome characterized by elevated serum LCOTHER LCOTHER ( LCChemicalEntity ) , failure to suppress pituitary LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) secretion , and variable peripheral tissue responsiveness to LCOTHER .	0
A total of 10 novel variants was recognized , among them four variants in the adjacent 5 ' - region of the LCOTHER coding exon 2 ( LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER ) , a 6 base - pair deletion ( LCOTHER . LCOTHER [ LCOTHER . LCOTHER ] ) , a variant leading to a stop codon ( LCSequenceVariant . LCSequenceVariant > LCSequenceVariant [ LCOTHER . LCOTHER ] ) , synonymous variants ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , and one non - synonymous variant ( LCOTHER . LCOTHER > LCOTHER [ LCSequenceVariant . LCSequenceVariant ] ) .	0
Continuous LCOTHER - LCOTHER remodelling by subunit turnover might facilitate shape adaptions to variable membrane geometries , with broad implications for diverse cellular processes . Acute effects of LCChemicalEntity - ( LCChemicalEntity - LCChemicalEntity ) LCChemicalEntity on hippocampal amino acid neurotransmitters in LCChemicalEntity - induced LCOTHER in LCOTHER .	0
Silencing of LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) expression in LCCellLine cells had a greater impact on LCOTHER - inducible cytokines than LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , and LCGeneOrGeneProduct expression .	0
Notably , LCGeneOrGeneProduct - LCGeneOrGeneProduct exerted quantitatively stronger regulatory effects on innate and LCGeneOrGeneProduct ( + ) T cell responses during primary and secondary infections , respectively .	0
The LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) on chromosome 6p21 is a key contributor to the genetic basis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	0
Urinary LCChemicalEntity , LCOTHER and LCOTHER were elevated in LCOTHER - fed WT but not in LCOTHER - fed LCGeneOrGeneProduct KO LCOTHER .	0
Three LCOTHER gene mutations , LCOTHER - LCOTHER > LCOTHER , LCOTHER - LCOTHER LCOTHER and LCOTHER , have been identified in two Chinese pedigree with LCOTHER LCOTHER LCOTHER , respectively . Gene therapy for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature airway disease - is clinical success imminent? LCOTHER LCOTHER ( LCOTHER ) was one of the first LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature for which gene therapy was seriously considered as a realistic option for treatment , and as such , it has long provided a paradigm for gene therapy of LCOTHER LCOTHER .	0
Our recent study showed that LCOTHER / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCGeneOrGeneProduct to promote LCOTHER LCOTHER by activating LCGeneOrGeneProduct and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCDiseaseOrPhenotypicFeature - related gene , including LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
We hypothesized that mutations in acetylcholine receptor - related genes might also result in a LCOTHER / LCOTHER LCOTHER phenotype and so we analyzed 15 cases of lethal LCOTHER / LCOTHER LCOTHER without LCOTHER mutations for mutations in the LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER ( LCGeneOrGeneProduct ) genes .	0
In conclusion , HFD - induced LCDiseaseOrPhenotypicFeature LCOrganismTaxon are highly sensitized to LCOTHER - induced LCOTHER by substantially downregulating cardiac mitochondrial LCOTHER generation , increasing oxidative stress and downregulating the LCOTHER / LCOTHER pathway . Risks and benefits of LCOTHER - LCOTHER LCOTHER vs non - selective LCOTHER : does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study .	0
LCOTHER elimination also decreased number and tightness of correlations between adaptive changes in lung function and LCDiseaseOrPhenotypicFeature parameters in LCOTHER / LCGeneOrGeneProduct - treated female LCOTHER .	0
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCChemicalEntity < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCChemicalEntity vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	0
We hypothesized that mutations in acetylcholine receptor - related genes might also result in a LCOTHER / LCOTHER LCOTHER phenotype and so we analyzed 15 cases of lethal LCOTHER / LCOTHER LCOTHER without LCGeneOrGeneProduct mutations for mutations in the LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER ( LCOTHER ) genes .	0
IMPORTANCE OF THE FIELD : LCOTHER , in particular LCChemicalEntity - LCChemicalEntity ( LCOTHER - LCOTHER ) , have been the mainstay of treatment for several solid LCOTHER , including LCDiseaseOrPhenotypicFeature , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , for > 40 years .	0
In the present study , we found that a very low concentration of LCChemicalEntity , an LCOTHER inhibitor , potentiated the antitumor activity of LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) in a LCOTHER LCOTHER LCOTHER cell model using LCOTHER - LCOTHER , LCCellLine , and LCOTHER cells via the inhibition of colony formation ability or cellular viability .	0
In a LCOTHER LCOrganismTaxon strain , the expression of a LCGeneOrGeneProduct ( LCOTHER ) mutant allele caused temperature - sensitive LCOTHER LCOTHER LCOTHER , decreased LCOTHER consumption , impaired maturation / stabilization of the LCOTHER LCOTHER - LCOTHER LCOTHER , and reduced LCOTHER LCOTHER activity and amount .	0
Serum concentrations of LCGeneOrGeneProduct , LCOTHER and LCOTHER - LCOTHER as markers of LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	0
Three similar associations of LCOTHER LCOTHER / LCOTHER with LCOTHER LCOTHER were found in the literature , suggesting that LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature may have a role in LCOTHER LCOTHER LCOTHER .	0
LCOTHER ( + ) LCOTHER cells produced activated LCOTHER ( LCOTHER ) and generated LCOTHER ( - ) cells that expressed LCOTHER as well as neural differentiation factors LCGeneOrGeneProduct , LCOTHER , and LCGeneOrGeneProduct .	0
When examining a worldwide cohort of 62 independent LCOTHER with LCOTHER and associated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature we identified altogether four novel mutations ( LCSequenceVariant . LCSequenceVariant , LCOTHER . LCOTHER , LCOTHER . LCOTHER , and LCOTHER . LCOTHER ) in five of them .	0
LCGeneOrGeneProduct - activated LCOTHER led to an interaction between LCOTHER - activated LCOTHER and LCGeneOrGeneProduct that mediated EC proliferation via activation of LCOTHER .	0
Our recent study showed that LCOTHER / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCGeneOrGeneProduct pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct .	0
These animal models were considered to reflect the positive symptoms of LCDiseaseOrPhenotypicFeature , and the above evidence suggests that altered LCOTHER - LCOTHER LCOTHER are involved in the pathophysiology of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Moreover , LCGeneOrGeneProduct codon 72 or frequencies of three LCGeneOrGeneProduct genotypes of RTRs are comparable with control populations .	0
Therefore , urinary acidification could be an option to prevent LCOTHER LCDiseaseOrPhenotypicFeature in LCOTHER . Absence of LCOTHER - LCOTHER attenuates LCChemicalEntity - induced LCOTHER LCOTHER LCOTHER .	0
Cells were pretreated with LCChemicalEntity LCChemicalEntity - LCChemicalEntity , before exposed to LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) , LCChemicalEntity or LCOTHER .	0
We investigated whether the LCOTHER LCOTHER is associated with disease susceptibility in a population of LCOTHER with LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) , and LCOTHER LCOTHER ( LCOTHER ) ; and whether it is associated with disease severity .	0
Our findings show that microinjection of LCOTHER into the CA1 region of the hippocampus improves the LCOTHER - induced LCOTHER . LCGeneOrGeneProduct : A LCOTHER LCOTHER LCOTHER LCOTHER candidate susceptibility gene? The chromosomal region 12q24 has been previously implicated by linkage studies of both LCOTHER LCOTHER and LCOTHER LCOTHER LCOTHER and we have reported two pedigrees segregating both LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER ' LCOTHER LCOTHER that show linkage across this region .	0
Modulation of LCOTHER by LCOTHER LCOTHER may be important in regulating LCOTHER growth . The LCOTHER LCOTHER LCOTHER LCOTHER polymorphism is associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER .	0
Mechanistic studies revealed that LCOTHER LCOTHER are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , ( 2 ) downregulation of cardiac LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct , ( 3 ) decreased plasma LCOTHER levels , ( 4 ) decreased cardiac LCOTHER - LCOTHER oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCOTHER ) , ( 5 ) decreased mitochondrial LCOTHER - LCOTHER LCOTHER LCOTHER , and ( 6 ) 86% drop in cardiac LCOTHER levels accompanied by decreased LCOTHER / LCOTHER ratio after LCOTHER administration .	0
Its role in genetic predisposition to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cannot be excluded . Founder mutations in the LCOTHER gene in Polish families with LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
RESULTS : Family - based TDT showed a significant association of LCOTHER with a LCSequenceVariant polymorphism in the LCOTHER - LCOTHER gene ( LCGeneOrGeneProduct ) ( P = 5 . 74 x 10 ( - 6 ) ) and a LCOTHER polymorphism in the LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER gene ( LCOTHER ) ( P = 9 . 58 x 10 ( - 6 ) ) .	0
In addition , the previously described variants LCOTHER . LCOTHER ( commonly designated LCOTHER or LCOTHER LCOTHER ) , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , and LCOTHER . LCOTHER > LCOTHER [ LCSequenceVariant . LCSequenceVariant ] were identified .	0
LCOTHER and high - dose LCOTHER - containing regimens are considered to be generally tolerable with few severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOrganismTaxon with B - cell LCOTHER .	0
METHODS : We examined five hotspot mutations in the LCOTHER gene ( LCOTHER , LCSequenceVariant , LCOTHER , LCOTHER , and LCOTHER ) in LCOTHER - fixed and LCChemicalEntity - embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 LCOTHER undergoing curative resection for LCOTHER between 2000 and 2011 using a Luminex technology - based multiplex gene mutation detection kit .	0
The LCSequenceVariant - LCSequenceVariant LCSequenceVariant in exon 13 introduced a premature termination code at LCOTHER LCOTHER and the substitution of LCOTHER LCOTHER LCOTHER in exon 23 lead to the missense mutation LCSequenceVariant .	0
LCOTHER was not independently associated with body mass index , family history of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER location ( colon versus rectum ) , stage , LCOTHER grade , signet ring cells , CIMP , MSI , LINE - 1 hypomethylation , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER , or LCOTHER - LCOTHER .	0
LCOTHER : LCOTHER LCOTHER ( LCOTHER LCOTHER ) of the mitochondrial respiratory chain can be fragmented in a LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , and LCOTHER LCOTHER ( LCGeneOrGeneProduct ) subfraction .	0
Our results reveal that dominant mutations in LCOTHER hyperactivate LCOTHER motility and suggest that an imbalance of minus versus plus end - directed microtubule motility in neurons may underlie LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCChemicalEntity metabolism in patients with LCOTHER treated with atypical LCOTHER LCOTHER : a frequently sampled intravenous LCOTHER tolerance test and minimal model analysis .	0
Here we investigated the role of LCOTHER / LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct in cellular senescence and immortalization of LCOrganismTaxon embryonic fibroblasts ( MEFs ) and report that LCOTHER is required for proper cell proliferation and LCOTHER ( LCOTHER ) - induced immortalization .	0
PURPOSE : This study was designed to establish a LCOTHER model of LCOTHER LCOTHER LCOTHER ( LCOTHER ) by LCOTHER LCOTHER ( LCOTHER ( LCOTHER ) ) - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and to explore the potential role of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER ( LCGeneOrGeneProduct ) and their endogenous inhibitors ( TIMPs ) in LCOTHER formation .	0
Chronic exposure to LCOTHER alone significantly decreased locomotor activity and increased LCDiseaseOrPhenotypicFeature but had no effect on sexual behavior , partner preference , or LCDiseaseOrPhenotypicFeature .	0
Among the family members , LCOTHER with the homozygous LCOTHER ( previously known as ARS component B ) mutation are prone to LCDiseaseOrPhenotypicFeature and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , which might link to defective T - cell function as well as a derangement of epidermal homeostasis .	0
On the pivotal role of LCOTHER in adaptation of the heart to LCOTHER and why fat in the diet increases LCOTHER injury . High - dose LCChemicalEntity LCChemicalEntity is associated with nonischemic clinical LCDiseaseOrPhenotypicFeature in cardiac surgical LCOTHER .	0
Mean arterial pressure of conscious LCOTHER was 119 + / - 2 mm Hg in control and 194 + / - 5 mm Hg in LCChemicalEntity LCOrganismTaxon ( P < 0 . 05 ) .	0
PURPOSE : This study was designed to establish a LCOrganismTaxon model of LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) by LCOTHER LCOTHER ( LCOTHER ( LCOTHER ) ) - induced LCOTHER LCOTHER and to explore the potential role of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER ( LCOTHER ) and their endogenous inhibitors ( TIMPs ) in LCOTHER formation .	0
Modulation of LCOTHER by LCOTHER LCOTHER may be important in regulating LCOTHER growth . The LCSequenceVariant LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct polymorphism is associated with LCOTHER LCOTHER in LCOTHER ' LCOTHER LCOTHER LCOTHER .	0
Here we describe the characterization of the LCOTHER ( + LCOTHER LCOTHER - > LCOTHER ) polymorphism of the LCOTHER - LCOTHER gene associated in LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOrganismTaxon with high LCOTHER in erythroid precursor cells . LCOTHER consumption and LCOTHER LCOTHER incidence and progression : A Mendelian randomisation study .	0
The aim of this study was to investigate the association of DNA polymorphisms within LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER , LCGeneOrGeneProduct ) and the postoperative resolution of LCOTHER in Chinese LCOTHER undergoing adrenalectomy for LCOTHER - LCOTHER LCOTHER ( LCOTHER ) .	0
The authors report here a LCOTHER LCOTHER comorbid with LCOTHER LCOTHER who developed LCOTHER after LCChemicalEntity had been added to his LCChemicalEntity therapy .	0
An alternative source of energy is LCOTHER - LCOTHER ( the C - 4 - epimer of LCOTHER - LCOTHER ) which is transported into the brain by LCGeneOrGeneProduct - independent LCGeneOrGeneProduct transporter where it might be metabolized to LCOTHER via the Leloir pathway .	0
important species differences in these effects , which could relate to differences in LCGeneOrGeneProduct LCGeneOrGeneProduct expression in gonadotrophs . Single nucleotide polymorphisms of the LCGeneOrGeneProduct gene are associated with the conversion to LCOTHER LCOTHER LCOTHER LCOTHER : the STOP - NIDDM trial .	0
The cumulative discontinuation rate due to LCOTHER LCOTHER was significantly lower with LCOTHER than LCChemicalEntity ( 5 . 2 vs 8 . 5 events per 100 LCOrganismTaxon - years , respectively ; hazard ratio 0 . 62 ( 95% CI : 0 . 47 , 0 . 81 ; p < or = 0 . 001 ) ) .	0
LCOTHER - LCOTHER reduced LCOTHER mRNA up - regulation in response to LCGeneOrGeneProduct ( + / - LCOTHER ) and decreased LCOTHER LCOTHER expression , which would favour LCOTHER , rather than LCGeneOrGeneProduct , synthesis and secretion .	0
Urinary LCOTHER , LCOTHER and LCOTHER were elevated in LCChemicalEntity - fed WT but not in LCOTHER - fed LCOTHER KO LCOrganismTaxon .	0
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCOTHER ( 874 LCOTHER ' LCOTHER LCOTHER , 259 LCOTHER LCOTHER , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER / LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCGeneOrGeneProduct .	0
Dysregulated expression of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is found in the cells of LCOTHER who have LCOTHER LCOTHER LCOTHER ( LCOTHER ) , a genetic disorder of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER and progressive LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Our data show that ablation of LCOTHER preserves LCOTHER and LCOTHER - LCOTHER protein expression and localization in LCOTHER - induced LCDiseaseOrPhenotypicFeature , and prevents the development of the severe LCOTHER associated with LCOTHER therapy . LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - mediated activation of LCOTHER LCOTHER LCOTHER inhibits the growth of LCOTHER in vitro and in vivo .	0
LCOTHER can be induced in LEW . 1WR1 weanling LCOrganismTaxon challenged with virus or with the viral mimetic LCChemicalEntity : LCChemicalEntity LCChemicalEntity ( LCOTHER LCOTHER : LCOTHER ) .	0
We propose thus that LCOTHER haploinsufficiency compromises LCOTHER sensitivity and may represent a novel genetic cause of subclinical LCOTHER , incidentally revealed LCOTHER LCOTHER LCOTHER and LCChemicalEntity - independent LCOTHER . Genetic alterations in primary LCDiseaseOrPhenotypicFeature in Japan .	0
RESULTS : LCOTHER with LCOTHER had higher serum LCOTHER and LCOTHER ( P < 0 . 001 for LCOTHER , LCOTHER , LCOTHER and LCOTHER ) and lower LCOTHER ( P = 0 . 008 ) levels than LCDiseaseOrPhenotypicFeature LCOrganismTaxon without LCOTHER .	0
LCOTHER were excised and evaluated for proliferation , apoptosis , and expression of LCGeneOrGeneProduct , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER LCOTHER LCOTHER , and LCOTHER LCOTHER LCOTHER .	0
Furthermore , LCOTHER with the LCOTHER - LCOTHER LCOTHER genotype showed a severe LCOTHER state ( platelet count < 10 10 ( 9 ) / L ) at diagnosis than those with the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCSequenceVariant genotype ( 20 . 9% vs .	0
LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is a sensor of oxidative stress and participates in memory formation that could be involved in drug LCDiseaseOrPhenotypicFeature and addiction mechanisms .	0
Using LCOTHER LCOTHER LCDiseaseOrPhenotypicFeature ( LCOTHER ) LCOrganismTaxon , we studied early ultrastructural and permeability changes in relation to the expression of the podocyte - associated molecules LCOTHER , LCOTHER - LCOTHER , LCOTHER , and LCOTHER , the last two of which were only recently discovered in podocytes .	0
The incidence of discontinuations for LCOTHER - related and LCOTHER - related AEs were significantly higher with LCOTHER ( 2 . 5% and 1 . 1% respectively ) compared with LCOTHER ( 1 . 5% and 0 . 4% respectively ; p < 0 . 001 for LCDiseaseOrPhenotypicFeature and p < 0 . 01 for LCDiseaseOrPhenotypicFeature ) .	0
Furthermore , we established a small amplicon genotyping ( SAG ) method for detecting three high frequency coding - region SNPs ( LCOTHER : LCOTHER > LCOTHER , LCOTHER : LCSequenceVariant > LCSequenceVariant , and LCSequenceVariant : LCOTHER > LCOTHER ) in LCOTHER to differentiate mutations before sequencing .	0
LCOTHER - LCOTHER null LCOrganismTaxon ( LCOTHER KO ) and strain - matched wild type ( WT ) controls were treated with LCChemicalEntity for 0 , 3 or 5 days .	0
To prepare a vaccine candidate , a previously described LCOTHER LCOTHER LCOTHER ( LCOTHER ) in the 3 ' untranslated region of LCOrganismTaxon - LCOrganismTaxon has been engineered into the LCOrganismTaxon - LCOrganismTaxon isolate .	0
These results illustrate that LCOTHER is a distinctive LCOTHER suppressor , which does not only suppress growth of LCDiseaseOrPhenotypicFeature cells but also regulates LCOTHER - mediated LCOTHER - initiating activity of LCOTHER cells . LCOTHER LCOTHER LCOTHER resulting from a new nonsense mutation , LCOTHER . LCOTHER , in the LCGeneOrGeneProduct gene .	0
These findings suggested that LCOTHER - LCOTHER possesses LCOTHER - suppressing activity and can be a valuable target for developing new LCOTHER therapeutic strategies . Chronic treatment with LCOTHER suppresses LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct signaling and attenuates LCOTHER LCOTHER LCOTHER following LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
These results strongly suggest that the LCOTHER LCOTHER mutation is responsible for the LCDiseaseOrPhenotypicFeature phenotype in the proposita ' s family . Cloning of LCOrganismTaxon LCOTHER - LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER and molecular characterization of its deficiency in two LCOTHER .	0
In line , recombinant LCGeneOrGeneProduct LCOTHER ( G allele ) synthesized 2 . 6 - fold more LCOTHER LCOTHER per unit of time than LCOTHER LCOTHER ( A allele ; LCOTHER LCSequenceVariant [ 8 . 26 + / - 3 . 57 nmol / hour . mg ] vs LCOTHER LCOTHER [ 3 . 22 + / - 0 . 67 nmol / hour . mg ] ; P = . 01 ) .	0
LCOTHER gene analysis revealed 2 consecutive mutations in exon 4 , each located in a different allele : 1 ) a LCSequenceVariant LCSequenceVariant LCSequenceVariant , LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant , and 2 ) a missense mutation at codon 227 , where the substitution of LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) predicts a LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant ( LCOTHER ) .	0
The present study aimed to evaluate the LCOTHER effects at doses of 25 , 50 or 75 mg / kg on LCOTHER parameters to determine their anticonvulsant activity and its effects on amino acid ( LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER and LCChemicalEntity ) levels as well as on LCOTHER ( LCOTHER ) activity in LCOrganismTaxon hippocampus after LCOTHER .	0
LCChemicalEntity and high - dose LCOTHER - containing regimens are considered to be generally tolerable with few severe LCOTHER LCOTHER in LCOrganismTaxon with B - cell LCOTHER .	0
On the test day ( day 10 ) , LCOrganismTaxon were subjected to the thermal sensitivity test and the LCChemicalEntity LCChemicalEntity - induced writhing test .	0
Also known as LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCDiseaseOrPhenotypicFeature presents with characteristic linear streaks of LCOTHER LCOTHER and variable abnormalities of bone , nails , hair , limbs , teeth and eyes .	0
A unique set of LCOTHER - regulated survival factors included LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct LCGeneOrGeneProduct .	0
Modulation of LCOTHER by LCOTHER LCOTHER may be important in regulating LCDiseaseOrPhenotypicFeature growth . The LCSequenceVariant LCOTHER LCOTHER LCOTHER polymorphism is associated with LCOTHER LCOTHER in LCOTHER ' LCOTHER LCOTHER LCOTHER .	0
Here , we show that a single LCSequenceVariant ( LCSequenceVariant ) LCSequenceVariant LCSequenceVariant ( LCSequenceVariant ) LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
The protein expressions of LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) in liver were analyzed with Western blotting .	0
We describe a 4 - year - old child with modest LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and normal serum concentrations of LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , but clinical evidence of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Differences in LCDiseaseOrPhenotypicFeature , body weight , and LCOTHER levels between LCOTHER and control LCOTHER were abolished in LCOTHER that were ovariectomized before puberty , consistent with a protective action of ovarian LCChemicalEntity mediated via the LCOTHER .	0
Nonetheless , LCGeneOrGeneProduct gene heterozygosity is not a major risk factor for LCOTHER LCOTHER in childhood and adolescence . LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct deficiency in B lymphocytes predisposes to LCOTHER LCOTHER LCOTHER / LCOTHER LCOTHER LCOTHER in LCOTHER .	0
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCChemicalEntity ) , with subjects who received LCOTHER and LCChemicalEntity exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCOTHER ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCOTHER vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	0
Accumulating evidence from epidemiologic studies , chemical carcinogen - induced rodent models and clinical trials indicate that LCGeneOrGeneProduct - LCGeneOrGeneProduct plays a role in LCOrganismTaxon LCOTHER and is overexpressed in LCOTHER LCOTHER tissue .	0
LCOTHER - LCOTHER , which prevents LCOTHER binding to LCOTHER - LCOTHER partially inhibited LCOTHER - activation , as well as reduced LCOTHER - induced LCGeneOrGeneProduct / LCGeneOrGeneProduct activation and LCOTHER release induced by LCGeneOrGeneProduct or LCOTHER .	0
Hence , our results suggest that LCChemicalEntity significantly aggravates LCOTHER ( LCOTHER + ) overload and causes LCOTHER and finally promotes apoptotic development via phosphorylation of LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER . LCOTHER LCOTHER treatment ameliorates acute LCOTHER LCDiseaseOrPhenotypicFeature in LCOTHER .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
In a prospective study involving 74 LCOTHER LCOrganismTaxon and 170 control subjects , we identified four LCOTHER harboring a heterozygous single nucleotide polymorphism in exon 6 of the LCOTHER gene , encoding LCSequenceVariant ( LCSequenceVariant ) - - > LCSequenceVariant substitution in its extracellular domain .	0
Many genes induced by LCOTHER activation were involved in LCOTHER metabolism ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER ) , xenobiotic metabolism ( LCGeneOrGeneProduct , LCOTHER , LCOTHER ) or the unfolded protein response , whereas most of the downregulated genes were involved in immune - related pathways .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct [ LCGeneOrGeneProduct ] , LCOTHER , LCOTHER , LCGeneOrGeneProduct [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
The HH genotype of the nonconservative amino acid substitution polymorphism LCOTHER in the LCGeneOrGeneProduct gene was reported to be associated with a 1 . 3 - to 1 . 5 - fold increase in risk of both LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
LCOTHER protein was immunoprecipitated with LCOTHER and LCOTHER proteins ; OGD caused increased interactions of LCOTHER with LCGeneOrGeneProduct and LCGeneOrGeneProduct , thereby , facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential ( D ( m ) ) .	0
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCSequenceVariant . LCSequenceVariant ] have been reported in Japanese LCOTHER , but not in LCOTHER LCOrganismTaxon from other ethnic groups .	0
LCOTHER signalling was markedly impaired in LCOTHER - deficient chondrocytes as evidenced by reduced expression of known LCOTHER target genes as well as reduced phosphorylation of LCOTHER / LCOTHER / LCOTHER and LCGeneOrGeneProduct / LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER .	0
LCOTHER LCOTHER significantly compensated deficits in the antioxidant defense mechanisms ( reduced LCOTHER level and LCGeneOrGeneProduct LCGeneOrGeneProduct activity ) , suppressed LCOTHER peroxidation , decreased the elevations of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER LCOTHER and LCOTHER ion concentration , and attenuated the reductions of LCOTHER and LCOTHER ions in renal tissue resulted from LCOTHER administration .	0
With the advent of next - generation sequencing technologies , the homozygous mutations LCOTHER and LCSequenceVariant in the LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER were identified as the genetic cause of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER LCOTHER ) .	0
LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER mRNA levels were increased in LCOTHER ( LCOTHER ) - treated segments ( all p < 0 . 01 ) , with trends of elevation in LCOTHER ( LCOTHER ) - untreated segments , as compared with LCOTHER - treated segments .	0
Both LCGeneOrGeneProduct knockout ( LCOTHER ( - / - ) ) LCOTHER and db / db LCOTHER that were administered LCOTHER monoclonal antibody displayed lower LCChemicalEntity LCChemicalEntity levels accompanied by elevated plasma LCOTHER levels .	0
LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) is an 11 - kDa small LCOTHER LCOTHER LCOTHER initially isolated from LCOTHER LCOTHER LCOTHER .	0
Administration of LCOTHER LCChemicalEntity suppressed LCOTHER growth in C3H / HeN LCOTHER , but not in LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct , while increasing LCOTHER ( LCOTHER ) - LCOTHER levels .	0
In line , recombinant LCOTHER LCOTHER ( G allele ) synthesized 2 . 6 - fold more LCOTHER LCOTHER per unit of time than LCGeneOrGeneProduct LCOTHER ( A allele ; LCOTHER LCOTHER [ 8 . 26 + / - 3 . 57 nmol / hour . mg ] vs LCOTHER LCSequenceVariant [ 3 . 22 + / - 0 . 67 nmol / hour . mg ] ; P = . 01 ) .	0
LCOTHER LCOTHER significantly compensated deficits in the antioxidant defense mechanisms ( reduced LCOTHER level and LCGeneOrGeneProduct LCGeneOrGeneProduct activity ) , suppressed LCOTHER peroxidation , decreased the elevations of LCOTHER LCOTHER LCOTHER - LCOTHER , LCOTHER LCOTHER and LCOTHER ion concentration , and attenuated the reductions of LCChemicalEntity and LCOTHER ions in renal tissue resulted from LCOTHER administration .	0
LCOTHER was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCOTHER , LCOTHER ] , by secretagogues activating LCOTHER - LCOTHER ( LCOTHER ) [ LCOTHER , LCOTHER , LCChemicalEntity ] and by post - receptor stimulants activating LCOTHER [ LCOTHER ] , but not agents only mobilizing cellular LCChemicalEntity or increasing LCOTHER LCOTHER .	0
RESULTS : HAT adipose tissue demonstrated increased LCOTHER related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCGeneOrGeneProduct , LCOTHER ) , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	0
A high - fat diet increased cardiac LCGeneOrGeneProduct expression , LCOTHER LCOTHER oxidation , and LCGeneOrGeneProduct levels with decreased glycolysis .	0
Our findings show that microinjection of LCOTHER into the CA1 region of the hippocampus improves the LCOTHER - induced LCOTHER . LCOTHER : A LCOTHER LCOTHER LCOTHER LCOTHER candidate susceptibility gene? The chromosomal region 12q24 has been previously implicated by linkage studies of both LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER and we have reported two pedigrees segregating both LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER ' LCOTHER LCOTHER that show linkage across this region .	0
We cloned the cDNA of three remaining LCOrganismTaxon LCOTHER : LCOTHER LCOTHER LCOTHER of this LCOTHER fraction : the LCGeneOrGeneProduct ( 49 kDa ) , LCOTHER ( 30 kDa ) , and LCOTHER ( 13 kDa ) subunits .	0
Nominal association with the disorder was observed for LCOTHER - CC , and phenotypic variability in LCDiseaseOrPhenotypicFeature symptoms was influenced by LCSequenceVariant , LCOTHER and LCOTHER .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCGeneOrGeneProduct ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCGeneOrGeneProduct [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
CONCLUSIONS : Our study shows that LCGeneOrGeneProduct is expressed locally in LCOTHER LCOTHER and that the gene polymorphism influences metastatic behavior . LCOTHER mutations associated with LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER .	0
We then examined them on genomic DNA in six LCGeneOrGeneProduct probands without mutations in the LCOTHER , LCOTHER and LCGeneOrGeneProduct genes and in 54 LCOTHER with late - onset LCOTHER LCOTHER LCOTHER by combined single strand conformational polymorphism - heteroduplex analysis followed by direct sequencing of identified variants .	0
In this study , 10 to 25 micromol / L LCOTHER inhibited LCOTHER - LCOTHER and LCOTHER LCOTHER LCOTHER cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct and the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
The goal of this study was to perform LCOTHER - LCOTHER - LCOTHER LCOTHER LCOTHER gene ( LCOTHER ) analysis in a LCOTHER LCOTHER ( LCOTHER ) LCOTHER with normal LCChemicalEntity ( LCChemicalEntity ) production and normal LCOTHER LCOTHER ( LCOTHER ) gene coding sequences .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
RESULTS : Except for LCOTHER , which showed a significant difference of LCOTHER - LCOTHER - SDS by genotypes ( p = 0 . 02 ) , all polymorphisms showed no associations with the LCOTHER - doses , LCGeneOrGeneProduct - LCGeneOrGeneProduct concentrations , LCGeneOrGeneProduct - LCGeneOrGeneProduct - SDS and LCOTHER - LCOTHER : LCOTHER ratio after adjusting for the confounding variables gender , age and BMI .	0
In summary , our findings demonstrate for the first time that mutations in LCOTHER are associated with an S - LCDiseaseOrPhenotypicFeature phenotype including LCOTHER , thereby further extending the clinical spectrum of phenotypes associated with LCOTHER mutations . Genetic investigation of the LCGeneOrGeneProduct gene in LCOTHER LCOTHER LCOTHER LCOTHER .	0
LCOTHER and LCOTHER expression was not increased by treatment of LCCellLine cells with LCOTHER and LCGeneOrGeneProduct inhibitors , suggesting that LCOTHER regulates LCOTHER expression independently of LCOTHER and LCOTHER .	0
Our observation of frequent LCGeneOrGeneProduct gene abnormalities ( 90% ) and inactivation ( 40 - 60% ) was in striking contrast to the same pathological subtype of LCOTHER LCOTHER in which LCOTHER gene abnormalities and inactivation were infrequent , suggesting a difference in LCOTHER between LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER LCOTHER LCOTHER LCOTHER in LCOTHER users and their neural correlates during a face - learning task .	0
CONCLUSIONS : The LCOTHER - LCOTHER polymorphism of the LCOrganismTaxon LCOTHER gene is associated with LCOTHER and may be a potential regulatory site . Protective effects of LCOTHER on LCChemicalEntity LCChemicalEntity LCOTHER in LCOTHER .	0
CONCLUSION : We corroborated the association of the promoter indel with LCDiseaseOrPhenotypicFeature in 5 different populations and revealed that LCOTHER is the main single - nucleotide polymorphism responsible for altered LCOTHER expression in PBMC . Tissue - Specific Ablation of the LCOTHER LCOTHER in the LCOrganismTaxon Uterine Epithelium Results in Implantation Failure .	0
Both LCGeneOrGeneProduct knockout ( LCOTHER ( - / - ) ) LCOrganismTaxon and db / db LCOTHER that were administered LCOTHER monoclonal antibody displayed lower LCOTHER LCOTHER levels accompanied by elevated plasma LCOTHER levels .	0
Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) LCOTHER doses was not associated with an increased incidence of LCOTHER events relative to nonselective LCOTHER or placebo in LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER in controlled clinical trials . LCOTHER - LCOTHER as a biomarker of altered redox metabolism in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cells exposed to LCOTHER .	0
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCOTHER ( 874 LCOTHER ' LCOTHER LCOTHER , 259 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER / LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER .	0
These data suggest that when LCOTHER activity is blocked in the setting of LCOTHER LCOTHER LCOTHER , the plasma LCOTHER level rises , preventing LCOTHER . LCOTHER - LCOTHER , a LCOTHER ( LCOTHER ) LCOTHER , functions as a LCDiseaseOrPhenotypicFeature suppressor in an orthotopic LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature model .	0
CONCLUSION : This study showed that SNPs LCOTHER ( P = 0 . 0276 ) , LCOTHER ( P = 0 . 0266 ) , LCOTHER ( P = 0 . 00514 ) , and LCOTHER ( P = 0 . 0089 ) , but not LCOTHER , LCSequenceVariant , or LCOTHER , in LCOTHER were significantly associated with wet LCDiseaseOrPhenotypicFeature in a mainland Han Chinese population .	0
LCChemicalEntity on either day induced LCOTHER LCOTHER ; LCOTHER LCOTHER at P45 resulted in LCOTHER cell loss and spontaneous LCOTHER , whereas P20 LCOrganismTaxon had no cell loss or spontaneous LCOTHER .	0
CONCLUSIONS : The LCOTHER and LCOrganismTaxon - LCSequenceVariant viruses can be considered for evaluation in LCOrganismTaxon and for inclusion in a tetravalent LCOTHER vaccine . The effects of short - term LCOTHER therapy on fibrinolysis markers : LCOTHER , LCOTHER , and LCOTHER - LCOTHER .	0
Eight Alu sequences ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER ) were analyzed in two samples from Navarre and Guipuzcoa provinces ( Basque Country , Spain ) .	0
RESULTS : A heterozygous germline LCOTHER LCOTHER LCOTHER transition in exon 10 of the LCOTHER gene ( LCSequenceVariant . LCSequenceVariant - - > LCSequenceVariant ) resulting in the substitution of LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER ( LCSequenceVariant . LCSequenceVariant ) was identified in the father and his two children .	0
Like LCOTHER LCOTHER , the truncated LCOTHER LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) , which lacks the C - terminal domain required for LCOTHER ( LCOTHER + ) - calmodulin binding , does not form constitutive active channels , whereas the LCOTHER LCGeneOrGeneProduct ( LCOTHER ) , carrying a point mutation in the presumed pore region , does not function as a channel .	0
We investigated whether the LCOTHER LCOTHER is associated with disease susceptibility in a population of LCOTHER with LCOTHER LCOTHER ( LCOTHER ) , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) , and LCOTHER LCOTHER ( LCOTHER ) ; and whether it is associated with disease severity .	0
RESULTS : Family - based TDT showed a significant association of LCOTHER with a LCOTHER polymorphism in the LCOTHER - LCOTHER gene ( LCOTHER ) ( P = 5 . 74 x 10 ( - 6 ) ) and a LCSequenceVariant polymorphism in the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene ( LCOTHER ) ( P = 9 . 58 x 10 ( - 6 ) ) .	0
Serum concentrations of LCOTHER , LCOTHER and LCOTHER - LCOTHER as markers of LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	0
LCOTHER - treated WT LCOrganismTaxon had 19 - fold increased urine output whereas treated LCGeneOrGeneProduct KO animals had a 4 - fold increase in output .	0
RESULTS : When compared with LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER without LCOTHER mutations , the presence of at least one LCOTHER variant in LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER more frequently led to gASCA positivity ( 66 . 1% versus 51 . 5% , p < 0 . 0001 ) and ALCA positivity ( 43 . 3% versus 34 . 9% , p = 0 . 018 ) and higher gASCA titers ( 85 . 7 versus 51 . 8 ELISA units , p < 0 . 0001 ) , independent of ileal involvement .	0
It was concluded that LCChemicalEntity LCChemicalEntity represents a potential therapeutic option to protect against acute LCOTHER LCOTHER commonly encountered in clinical practice . LCOTHER decoded : the genomic sequence of a cytogenetically aberrant LCOrganismTaxon LCOTHER cell line .	0
LCChemicalEntity - associated LCOTHER LCOTHER ( LCChemicalEntity - LCOTHER ) is a severe type of LCOTHER .	0
Our results thus indicates that LCGeneOrGeneProduct LCSequenceVariant homozygosity is associated with increased mortality in LCOTHER in the second half of life and that this increased mortality is possibly related to LCOTHER severity and survival after LCOTHER rather than susceptibility to development of LCOTHER . The antiarrhythmic effect and possible ionic mechanisms of LCOTHER on animal models .	0
Conditional haplotype analysis revealed three other SNPs , LCSequenceVariant ( OR = 1 . 86 , p = 1 . 2 10 ( - 4 ) ) , LCOTHER ( OR = 1 . 53 , p = 1 . 0 10 ( - 3 ) ) , and LCSequenceVariant ( OR = 1 . 43 , p = 1 . 3 10 ( - 3 ) ) , to be associated with LCOTHER independent of the LCOTHER SNP .	0
No association of LCOTHER polymorphisms and self - limited LCOTHER LCOTHER could be demonstrated . LCOTHER LCOTHER ( LCGeneOrGeneProduct ) defects are common in LCOTHER LCOTHER LCOTHER LCOTHER and co - occur with LCGeneOrGeneProduct mutations .	0
The homeostasis model assessment of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( LCOTHER > LCOTHER > LCOTHER ) ( LCOTHER vs LCChemicalEntity , t ( 33 ) = 2 . 94 ; P = . 006 ; LCOTHER vs LCOTHER , t ( 33 ) = 2 . 42 ; P = . 02 ) .	0
LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ) are two members of this group that have been described in LCOTHER , LCOTHER , and LCOrganismTaxon .	0
A LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct cDNA has been identified from a cerebral cortical cDNA library using sequences from the LCOrganismTaxon LCOTHER LCOTHER LCOTHER cDNA .	0
Thus , our results support the notion that LCOTHER - LCOTHER and LCOTHER - LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct mutually regulate Th17 and Th1 responses in LCOTHER - bearing hosts , and LCOTHER LCChemicalEntity modulates the balance of the LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER - LCOTHER axis towards LCOTHER - LCOTHER production , which leads to LCOTHER inhibition .	0
Next to the LCOTHER mutations we noted 2 cases of deletion in LCOTHER [ Delta ( LCOTHER - D13S1830 ) ] and 3 ( 2 new and 1 described ) base substitutions in LCOTHER [ LCOTHER . LCOTHER > LCOTHER , LCOTHER . LCOTHER > LCOTHER and LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCSequenceVariant . LCSequenceVariant ) ] which are unlikely disease - causing .	0
The LCOTHER were assigned into four groups ( n = 10 per group ) , as follows : Control LCOTHER ; LCOTHER + LCOTHER ; LCOTHER + LCOTHER ; LCOTHER + LCChemicalEntity + LCChemicalEntity .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
RESULTS : Omission of LCOTHER did not reduce the overall incidence of LCOTHER LCOTHER LCOTHER LCOTHER , but did reduce the incidence of LCOTHER and / or moderate to severe LCDiseaseOrPhenotypicFeature prior to discharge from 20% and 17% with LCOTHER and LCChemicalEntity - LCOTHER , respectively , to 5% ( P = 0 . 013 ) .	0
The genotype frequencies of LCOrganismTaxon did not differ significantly from controls ( LCOTHER / LCOTHER , LCOTHER / LCOTHER : LCOTHER 18 . 3% and 1 . 2% , respectively ; LCDiseaseOrPhenotypicFeature 17 . 5% and 2 . 1% ; LCOTHER 13 . 3% and 1 . 8% ; controls 20 . 0% and 2 . 8% ) .	0
Modulation of LCOTHER by LCOTHER LCOTHER may be important in regulating LCOTHER growth . The LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct polymorphism is associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER ' LCOTHER LCOTHER LCOTHER .	0
The present study was undertaken to identify susceptibility genes contributing to LCDiseaseOrPhenotypicFeature , using a novel candidate gene pathway microarray platform to investigate gene expression in LCOTHER with childhood - onset LCDiseaseOrPhenotypicFeature and both of their parents .	0
Because all heterozygous LCOTHER mutations that have been described are localized in the signal sequence , screening of the LCOTHER gene for LCOTHER with LCOTHER with LCOTHER and LCOTHER may best be focused on sequencing of exon 1 , which encodes the signal peptide . A Critical Role for the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct in Virus - Induced LCOTHER LCOTHER in LCOrganismTaxon .	0
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	0
Limited prospective data corroborate these findings , but larger prospective studies are urgently required . Efficacy of LCOTHER ( LCChemicalEntity ) in LCOTHER with advanced LCDiseaseOrPhenotypicFeature previously treated with chemotherapy alone or with chemotherapy and LCOTHER inhibitors .	0
Serum concentrations of LCOTHER , LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct as markers of LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	0
The isoforms LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct have profibrotic properties , whereas LCGeneOrGeneProduct - LCGeneOrGeneProduct may have antifibrotic functions .	0
LCOTHER - LCOTHER LCOTHER ( LCOTHER ) is a ligand of the LCGeneOrGeneProduct pathway family which has been widely studied in the context of LCOTHER angiogenesis , its blockade shown to result in non - productive angiogenesis and halted LCDiseaseOrPhenotypicFeature growth .	0
Thus , LCOTHER appears to play a critical oncogenic function in LCOTHER microenvironment and may be a potential target for developing therapeutic and preventive strategies against LCOTHER . Effects of the LCOTHER - LCOTHER specific inhibitor LCOTHER versus LCOTHER LCOTHER LCOTHER and placebo on cardiovascular LCDiseaseOrPhenotypicFeature events in LCOTHER with LCDiseaseOrPhenotypicFeature .	0
METHOD : Using five tagging SNPs ( LCSequenceVariant , LCOTHER , LCOTHER , LCSequenceVariant and LCOTHER ) , we conducted a genetic association analysis of case - control samples ( 197 LCOTHER - induced LCOTHER LCOTHER and 337 controls ) in the Japanese population .	0
CONCLUSIONS : The symptoms of LCOTHER observed in the LCOTHER homozygote mutation carrier and in both LCOrganismTaxon with a heterozygous substitution in exon 2 of the LCGeneOrGeneProduct gene provide indirect evidence of the role of genes involved in meiotic recombination in the regulation of ovarian function .	0
BACKGROUND AND PURPOSE : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) are potential risk factors for LCOTHER LCOTHER ( LCOTHER ) , but it is unclear if they are a contraindication to using LCChemicalEntity LCChemicalEntity .	0
LCOTHER increased the expression of LCOTHER mRNA in a panel of LCOrganismTaxon LCDiseaseOrPhenotypicFeature cells , an effect that was not observed with eight other clinically - approved kinase inhibitors .	0
This study also shows that this assay can help detect EAD for drugs with LCDiseaseOrPhenotypicFeature potential . A novel splicing mutation in LCOTHER associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER .	0
Here , we demonstrated that HG decreased the expression of LCOTHER , mitochondrial fusion proteins ( LCGeneOrGeneProduct , LCGeneOrGeneProduct ) , cell gap junction related proteins ( LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) , and intracellular LCOTHER concentration .	0
We report mutation analysis of the LCOTHER gene in 39 kindreds with LCOTHER and LCDiseaseOrPhenotypicFeature who previously tested negative for mutations in the LCOTHER ( LCOTHER ) and LCOTHER ( LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ) genes .	0
Mechanistic studies revealed that LCOTHER LCOTHER are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct , ( 3 ) decreased plasma LCOTHER levels , ( 4 ) decreased cardiac LCOTHER - LCOTHER oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCOTHER ) , ( 5 ) decreased mitochondrial LCOTHER - LCOTHER LCOTHER LCOTHER , and ( 6 ) 86% drop in cardiac LCOTHER levels accompanied by decreased LCOTHER / LCChemicalEntity ratio after LCOTHER administration .	0
Taking these in vitro and in vivo results together , our study suggests that LCChemicalEntity LCChemicalEntity - LCChemicalEntity is a potentially effective candidate against LCOTHER ' LCOTHER LCOTHER that is characterized by wide spread LCOTHER LCOTHER and progressive LCOTHER LCOTHER LCOTHER LCOTHER . Anticipation in familial LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER with LCOTHER mutation in the LCOTHER ( LCGeneOrGeneProduct ) gene .	0
LCOTHER was found to be under - expressed in LCCellLine / LCCellLine and LCCellLine - LCCellLine / LCCellLine ( a LCOTHER MDR LCOTHER LCOTHER cell line ) compared with their non - MDR parental cell lines .	0
These results unravel a hidden link between LCGeneOrGeneProduct and a functional putative LCOTHER risk SNP , whose allele alteration affects LCOTHER regulation of its host gene LCOTHER . LCOTHER LCOTHER LCOTHER LCOTHER protects liver sinusoidal endothelial cells in acute LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER .	0
LCOTHER chelation with LCChemicalEntity was effective in mobilizing hepatic LCOTHER but has no effect on brain LCOTHER . Aberrant LCGeneOrGeneProduct - LCGeneOrGeneProduct - mediated LCOTHER signaling and proliferation identified by analysis of LCOTHER LCOTHER LCOTHER mutation ( LCOTHER . LCOTHER ) in LCOTHER fibroblasts : a new perspective on the mechanism of LCOTHER LCOTHER .	0
A total of 10 novel variants was recognized , among them four variants in the adjacent 5 ' - region of the LCGeneOrGeneProduct coding exon 2 ( LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCSequenceVariant . LCSequenceVariant - LCSequenceVariant > LCSequenceVariant , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER ) , a 6 base - pair deletion ( LCOTHER . LCOTHER [ LCOTHER . LCOTHER ] ) , a variant leading to a stop codon ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , synonymous variants ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , and one non - synonymous variant ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) .	0
RESULTS : LCOTHER with LCOTHER had higher serum LCOTHER and LCGeneOrGeneProduct ( P < 0 . 001 for LCOTHER , LCOTHER , LCOTHER and LCOTHER ) and lower LCOTHER ( P = 0 . 008 ) levels than LCOTHER LCOrganismTaxon without LCOTHER .	0
Several risk factors for LCDiseaseOrPhenotypicFeature should be noted in elderly LCOTHER LCOTHER whose symptoms often include LCDiseaseOrPhenotypicFeature , LCOTHER , LCOTHER , and exhaustion .	0
CONCLUSION : Our results suggest that use of high - dose LCChemicalEntity in older LCOTHER in conjunction with cardiopulmonary bypass and open - chamber cardiac surgery is associated with clinical LCOTHER in susceptible LCOrganismTaxon . Cardioprotective effect of LCOTHER LCOTHER LCOTHER on LCOTHER - induced LCOTHER LCOTHER in LCOTHER .	0
Our results thus indicates that LCGeneOrGeneProduct LCOTHER homozygosity is associated with increased mortality in LCOTHER in the second half of life and that this increased mortality is possibly related to LCOTHER severity and survival after LCOTHER rather than susceptibility to development of LCOTHER . The antiarrhythmic effect and possible ionic mechanisms of LCChemicalEntity on animal models .	0
Extensive literature search revealed multiple cases of LCOTHER LCOTHER LCOTHER secondary to LCChemicalEntity , but none of the cases were associated with LCOTHER . Characterization of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER with LCOTHER mutations .	0
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	0
The aim of this study was therefore to investigate the influence of mutations in these LCOTHER LCOTHER LCOTHER genes ( LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER / LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	0
The LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) modulates LCOTHER signaling via effects on LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) .	0
Furthermore , we provide a LCOTHER model of LCDiseaseOrPhenotypicFeature for the investigation of LCOTHER related LCOTHER . The cytogenetic action of LCOTHER , LCChemicalEntity , and their combination on peripheral LCOTHER lymphocytes : an in vivo / in vitro cytogenetic study .	0
Adipocyte cell culture revealed that endogenous and synthetic LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER - and LCOTHER - selective agonists , as well as a synthetic LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct agonist , efficiently reduced LCOTHER expression , whereas LCGeneOrGeneProduct expression only increased with LCOTHER agonists .	0
The LCOTHER mutation LCOTHER on one allele was found in 3 of 270 LCOTHER with LCOTHER and 2 of 212 children and adolescents with LCDiseaseOrPhenotypicFeature ; no carrier was found among 63 LCOrganismTaxon with LCOTHER LCOTHER ( LCOTHER ) .	0
The LCOTHER homozygous for LCOTHER had severe LCOTHER LCOTHER with the triad of LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature at the age of 58 years .	0
Thus , LCGeneOrGeneProduct appears to play a critical oncogenic function in LCOTHER microenvironment and may be a potential target for developing therapeutic and preventive strategies against LCOTHER . Effects of the LCOTHER - LCOTHER specific inhibitor LCOTHER versus LCOTHER LCOTHER LCOTHER and placebo on cardiovascular LCOTHER events in LCOrganismTaxon with LCOTHER .	0
Genome - wide association studies have identified genomic loci , whose single - nucleotide polymorphisms ( SNPs ) predispose to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) .	0
RESULTS : LCGeneOrGeneProduct - LCOTHER haplotype was associated with persistent postoperative LCOTHER in Chinese LCOrganismTaxon undergoing adrenalectomy with LCOTHER ( P = . 006 ) .	0
LCGeneOrGeneProduct was not implicated with LCOTHER / LCOTHER in our LCOTHER cohort . Combination of the LCOTHER LCOTHER inhibitor LCChemicalEntity and LCOTHER - LCOTHER upregulates LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER and LCOTHER genes and activates LCOTHER - LCOTHER / LCOTHER in LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER cells .	0
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	0
Our results suggest that SNPs of LCOTHER and their haplotypes predispose to LCOTHER LCOTHER LCOTHER LCOTHER in female subjects of the STOP - NIDDM study population . Identification of three LCGeneOrGeneProduct gene mutations associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in two Chinese pedigrees .	0
Moreover , LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) antagonist LCOTHER - LCOTHER ( LCOTHER - LCOTHER - LCOTHER - LCOTHER - LCOTHER ) partially abolished the beneficial effects of LCChemicalEntity .	0
Because polymorphism of LCOTHER , another inhibitory receptor of B cells , was associated with LCOTHER LCDiseaseOrPhenotypicFeature , we identified LCOTHER LCOTHER polymorphisms , tested their association with LCOTHER and examined genetic interaction with LCOTHER in the Japanese ( 160 LCOTHER , 277 controls ) , Thais ( 87 LCOTHER , 187 controls ) and Caucasians ( 94 families containing LCDiseaseOrPhenotypicFeature members ) .	0
Severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature occurred in eight of 160 LCOrganismTaxon treated with LCOTHER for LCOTHER LCOTHER .	0
We investigated the effect of LCOTHER in the LCOTHER microenvironment of LCOTHER with liver parenchymal cell - specific LCOTHER ablation ( LCOTHER - Cre ; LCOTHER ( f / f ) ) and LCGeneOrGeneProduct deletion both in liver parenchymal and non - parenchymal cells ( LCGeneOrGeneProduct - Cre ; LCOTHER ( f / f ) ) .	0
METHODS : We performed a systematic review of published and unpublished data from cohorts with LCOTHER or LCOTHER to compare the presence of LCDiseaseOrPhenotypicFeature in : ( 1 ) antithrombotic users vs nonantithrombotic users with LCOTHER ; ( 2 ) antithrombotic users vs nonusers with LCOTHER / LCOTHER ; and ( 3 ) LCDiseaseOrPhenotypicFeature vs LCOTHER events stratified by antithrombotic use .	0
The present study revealed the protective role of LCOTHER in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature induced by high LCChemicalEntity ( HG ) as well as the underlying mechanism .	0
Five of them [ LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCOTHER . LCOTHER ] have been reported in Japanese LCOTHER , but not in LCOTHER LCOrganismTaxon from other ethnic groups .	0
Serum concentrations of LCOTHER , LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct as markers of LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	0
LCOTHER developing LCOTHER had a 6 - year survival after onset of LCOTHER of 27% for the LCOTHER receiving hemodialysis versus 71 . 4% for the LCOrganismTaxon developing LCDiseaseOrPhenotypicFeature who subsequently received kidney transplants .	0
Modulation of LCOTHER by LCOTHER LCOTHER may be important in regulating LCOTHER growth . The LCOTHER LCOTHER LCOTHER LCOTHER polymorphism is associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER ' LCOTHER LCOTHER LCOrganismTaxon .	0
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCOTHER ) and three markers ( LCSequenceVariant , LCOTHER and LCSequenceVariant ) in LCOTHER and LCOTHER - induced LCOTHER LCOTHER , respectively .	0
METHODS : LCOTHER , primary LCOTHER small airway epithelial ( LCOTHER ) cells and wild - type , LCOTHER - LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) and LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) knockout ( KO ) LCOrganismTaxon were infected with LCOTHER and cytokine responses were investigated by ELISA , multiplex analysis and qPCR .	0
In LCOTHER - LCOTHER - LCOTHER cells stimulated with ( LCOTHER ) - ( LCOTHER ) - ( - ) - LCOTHER LCOTHER ( LCOTHER ) , we measured ( a ) cell growth , ( b ) LCChemicalEntity ( LCChemicalEntity ) and LCChemicalEntity LCChemicalEntity levels , and ( c ) phosphorylation of LCOTHER and LCOTHER - LCOTHER LCOTHER LCOTHER isoforms .	0
Three SNPs in the P2 promoter region ( LCSequenceVariant , LCOTHER , and LCSequenceVariant ) were in almost complete association ( D ' > 0 . 97 , r ( 2 ) > 0 . 95 ) and , therefore , only LCOTHER was included in further analyses .	0
In addition , accumulated LCOTHER / LCOTHER ( + ) cells in the LCOTHER LCOTHER were not BM - derived LCOTHER / LCOTHER ( + ) cells , but mainly resident hepatic LCGeneOrGeneProduct / LCGeneOrGeneProduct ( + ) cells , and these resident hepatic LCOTHER / LCOTHER ( + ) cells were positive for LCGeneOrGeneProduct - LCGeneOrGeneProduct .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCGeneOrGeneProduct ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCGeneOrGeneProduct and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
CONCLUSION : LCGeneOrGeneProduct may play an important role in the pathophysiology of LCOTHER - induced LCOTHER in the Japanese population . LCOTHER LCOTHER dose in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature adults is not associated with LCOTHER - LCOTHER gene polymorphisms .	0
The authors report here a LCOTHER LCOrganismTaxon comorbid with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature who developed LCOTHER after LCOTHER had been added to his LCOTHER therapy .	0
CONCLUSIONS : Our results suggest that common variation in the putative LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature susceptibility gene , LCOTHER , or its inhibitor does not contribute significantly to LCOTHER LCOTHER risk in this Afro - Caribbean population . Hepatic but not brain LCChemicalEntity is rapidly chelated by LCOTHER in LCOTHER due to a novel gene mutation .	0
Our data suggest that dysregulated expression of LCOTHER and LCGeneOrGeneProduct genes is associated with an array of LCOTHER LCOTHER LCOTHER LCOTHER similar to the short ear LCOTHER and LCOTHER . The activation of spinal LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct may contribute to degeneration of spinal motor neurons induced by neuraxial LCOTHER after a noninjurious interval of LCOTHER LCOTHER LCOTHER .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCGeneOrGeneProduct ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
METHODS : We analyzed 186 individuals with spontaneous LCOrganismTaxon clearance , 501 chronically LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER , and 217 healthy controls .	0
LCOTHER was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCOTHER , LCOTHER ] , by secretagogues activating LCOTHER - LCOTHER ( LCOTHER ) [ LCOTHER , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCGeneOrGeneProduct [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCChemicalEntity LCChemicalEntity .	0
We report a case of a 76 - year - old LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature who suffered LCOTHER LCOTHER without LCOTHER after the combination treatment with LCOTHER , high - dose LCChemicalEntity and LCOTHER .	0
To clarify the role of LCOTHER host genetic background and disease progression on viral evolutionary patterns , we obtain LCOTHER envelope sequences from clonal LCOrganismTaxon - LCOrganismTaxon variants isolated at multiple time points in the course of LCOTHER from populations of LCOTHER - LCOTHER - LCOTHER individuals who only harbored LCGeneOrGeneProduct - using LCOTHER - LCOTHER variants at all time points .	0
These findings suggest that LCOTHER - LCOTHER can negatively affect both cell proliferation and hippocampal dependent working memory and that these deficits can be reversed by the simultaneous administration of the antidepressant LCChemicalEntity . LCOTHER deficiency confers enhanced myocardial protection in the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature by mediating the LCOTHER / LCOTHER signalling pathway .	0
Eleven subjects presented LCGeneOrGeneProduct homozygous single - base mutations ( two first cousins and four unrelated LCOTHER with LCOTHER , two with LCOTHER , one with LCOTHER , one with LCOTHER , and one with LCOTHER plus the LCOTHER variant in heterozygosis ) , whereas four were compound heterozygotes ( one with LCOTHER / LCOTHER + LCOTHER > LCOTHER , one with LCOTHER / LCOTHER , and two brothers with LCSequenceVariant / LCOTHER ) .	0
Modulation of LCOTHER by LCGeneOrGeneProduct LCGeneOrGeneProduct may be important in regulating LCOTHER growth . The LCSequenceVariant LCOTHER LCOTHER LCOTHER polymorphism is associated with LCOTHER LCOTHER in LCOTHER ' LCOTHER LCOTHER LCOTHER .	0
The precise mechanism of LCDiseaseOrPhenotypicFeature related with LCOTHER Osaka , however , remains to be elucidated . Hemodynamic parameters and heart rate variability during a tilt test in relation to gene polymorphism of LCOTHER - LCOTHER and LCChemicalEntity system .	0
We have analyzed LCOTHER LCOTHER from RTRs with aggressive LCDiseaseOrPhenotypicFeature for LCGeneOrGeneProduct gene modifications , the presence of LCOTHER LCOTHER LCOTHER ( LCOTHER ) DNA in relation to the LCOTHER codon 72 genotype and polymorphisms of the LCOTHER repair gene .	0
Therefore , our results indicate that LCOTHER B cells have already acquired enhanced survival and growth capabilities before transformation , and that elevated LCOTHER levels confer resistance to pharmacologic inhibitors of LCGeneOrGeneProduct signaling , which has significant implications for LCOTHER - LCOTHER treatment . Genetic investigation of four meiotic genes in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
LCGeneOrGeneProduct enhancer region , 3R LCOTHER > LCOTHER single nucleotide polymorphism ( SNP ) , and LCGeneOrGeneProduct LCOTHER polymorphisms were assessed in both fresh - frozen normal mucosa and LCOTHER .	0
METHODS : DNA samples from 405 LCDiseaseOrPhenotypicFeature LCOTHER , 97 LCOTHER LCOrganismTaxon , 113 LCOTHER LCOTHER , and 431 healthy controls were genotyped for the LCOTHER LCOTHER LCOTHER .	0
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCSequenceVariant ) and three markers ( LCOTHER , LCSequenceVariant and LCOTHER ) in LCOTHER and LCOTHER - induced LCOTHER LCOTHER , respectively .	0
We investigated the relationship between the degeneration of spinal motor neurons and activation of LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct after neuraxial LCChemicalEntity following a noninjurious interval of LCOTHER LCOTHER in LCOTHER .	0
The authors report here a LCOTHER LCOrganismTaxon comorbid with LCOTHER LCOTHER who developed LCDiseaseOrPhenotypicFeature after LCOTHER had been added to his LCOTHER therapy .	0
Although uncommon , point mutations in the LCOTHER gene may be a cause of LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER in Japanese LCOTHER . Homozygously deleted gene LCOTHER regulates LCDiseaseOrPhenotypicFeature - initiating activity of LCOTHER cells .	0
The ability of LCChemicalEntity to block LCOTHER - LCOTHER LCOTHER ( LCOTHER + ) LCOTHER , also expressed by enteric neurons , might represent a possible mechanism through which LCOTHER exerts its actions . Lack of association of LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER status with LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER , and disease severity .	0
RESULTS : LCChemicalEntity ( 0 . 05 - 0 . 25 mg / kg ) itself did not produce any significant effect in the EPM test , whereas LCOTHER ( 70 mg / kg ) and LCChemicalEntity ( 30 mg / kg ) produced an LCOTHER LCOTHER , apparent with decreases in open - arm time and entry .	0
One - hundred and fifty LCOTHER ( 90 LCOTHER LCOTHER LCOTHER [ LCOTHER ] and 60 LCOTHER LCOTHER LCOTHER [ LCOTHER ] ) LCOrganismTaxon and 165 age - and sex - matched normal healthy controls without known LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER were included in the study .	0
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCOTHER . LCOTHER ] have been reported in Japanese LCOTHER , but not in LCOTHER LCOrganismTaxon from other ethnic groups .	0
LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is an LCOTHER LCOTHER LCOTHER , which is characterized by periodic attacks of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature associated with a decrease in the serum LCOTHER level .	0
PURPOSE : The LCChemicalEntity LCOTHER and LCOTHER and the LCChemicalEntity LCOTHER are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , LCOTHER and LCOTHER LCOTHER limit their use .	0
These data suggest that LCOTHER produced antiarrhythmic actions on LCOTHER LCOTHER and LCOrganismTaxon LCOrganismTaxon models induced by LCOTHER or LCChemicalEntity via stimulating the cardiac LCOTHER ( LCOTHER ) - LCOTHER .	0
n = 15 ) after methylating chemotherapy for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature compared to LCOTHER without previous methylating exposure ( t - LCDiseaseOrPhenotypicFeature , 30 . 4% , n = 69 ; LCOTHER LCOTHER LCOTHER , 27 . 2% , n = 22 ) .	0
Further , LCOTHER , LCOTHER - LCOTHER lesion of LCChemicalEntity nerves travelling in the median forebrain bundle , one of the main ascending pathways from the B3 LCChemicalEntity cells , did not affect the fall in blood pressure associated with a midline B3 LCOTHER LCOTHER injection .	0
CONCLUSIONS LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCSequenceVariant / LCSequenceVariant SNP , hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER / LCOTHER - LCOTHER were associated with LCOTHER in LCOTHER from Inner Mongolia , as was serious LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER . LCChemicalEntity prevents LCOTHER LCOTHER accumulation in macrophages induced by the LCOTHER LCOTHER inhibitor LCOTHER .	0
Therefore LCOTHER activity , oxidative stress , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) activity , spatial learning and memory as well as the effect of LCOTHER , a previously proposed therapy for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , were evaluated in an experimental model of LCOTHER administration in LCOrganismTaxon .	0
Sequencing analysis detected 17 different LCOTHER gene mutations , and 7 of these were identified as novel : 3 missense mutations , including LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 3 , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER . LCOTHER ) in exon 3 and LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 7 ; 2 deletion mutations , including LCOTHER . LCOTHER ( LCOTHER . LCOTHER ) in exon 5 and LCOTHER . LCOTHER ( LCSequenceVariant . LCSequenceVariant ) in exon 11 ; and 2 alternative splicing mutations , including LCOTHER . LCOTHER + LCOTHER in intron 4 at splicing donor sites and LCOTHER . LCOTHER - LCOTHER > LCOTHER in intron 13 at splicing acceptor sites .	0
Genetic analysis of LCOTHER seems to be of limited significance in the differential diagnosis of LCOTHER without LCOTHER LCOTHER LCOTHER LCOTHER . High LCOTHER diet - fed LCDiseaseOrPhenotypicFeature LCOrganismTaxon are highly sensitive to LCOTHER - induced LCOTHER .	0
In the present study , we found that a very low concentration of LCOTHER , an LCGeneOrGeneProduct inhibitor , potentiated the antitumor activity of LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) in a LCOTHER LCOTHER LCOTHER cell model using LCOTHER - LCOTHER , LCOTHER , and LCCellLine cells via the inhibition of colony formation ability or cellular viability .	0
We report a case of a 76 - year - old LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature who suffered LCOTHER LCOTHER without LCOTHER after the combination treatment with LCChemicalEntity , high - dose LCOTHER and LCOTHER .	0
Our data show that ablation of LCOTHER preserves LCOTHER and LCOTHER - LCOTHER protein expression and localization in LCOTHER - induced LCOTHER , and prevents the development of the severe LCOTHER associated with LCOTHER therapy . LCOTHER LCOTHER LCOTHER - mediated activation of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct inhibits the growth of LCDiseaseOrPhenotypicFeature in vitro and in vivo .	0
Male Wistar LCOTHER were randomly assigned to one of 5 groups ( n = 6 ) : normal control and groups were injected LCChemicalEntity after chronic pre - treatment with 0 , 25 , 50 , or 100mg / kg of LCChemicalEntity twice daily for 14 days .	0
Lipolytic enzymes ( LCOTHER and LCGeneOrGeneProduct phosphorylation ) were increased and lipogenic regulators ( LCOTHER and LCOTHER / LCOTHER ) were decreased in eWAT by LCChemicalEntity .	0
LCOTHER LCOTHER is characterized by prolonged LCOTHER after the use of LCOTHER LCOTHER ( LCOTHER or LCChemicalEntity ) in LCOrganismTaxon who have mutations in the LCOTHER gene .	0
A total of 10 novel variants was recognized , among them four variants in the adjacent 5 ' - region of the LCOTHER coding exon 2 ( LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCSequenceVariant . LCSequenceVariant - LCSequenceVariant > LCSequenceVariant ) , a 6 base - pair deletion ( LCOTHER . LCOTHER [ LCOTHER . LCOTHER ] ) , a variant leading to a stop codon ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , synonymous variants ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , and one non - synonymous variant ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) .	0
Serum concentrations of LCOTHER , LCOTHER and LCOTHER - LCOTHER as markers of LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	0
LCOTHER , like LCOTHER , is a LCOTHER LCOTHER that has anti - LCOTHER property , although it also pro - LCDiseaseOrPhenotypicFeature that can cause various LCOTHER , including severe LCDiseaseOrPhenotypicFeature such as multiple LCOTHER .	0
LCGeneOrGeneProduct deficiency significantly delayed the onset and frequency of LCOTHER and greatly reduced the intensity of LCOTHER after LCChemicalEntity LCChemicalEntity : LCChemicalEntity treatment .	0
CONCLUSIONS LCOTHER - LCOTHER - LCOTHER / LCOTHER SNP , hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER / LCOTHER - LCOTHER were associated with LCOTHER in LCOTHER from Inner Mongolia , as was serious LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER . LCChemicalEntity prevents LCChemicalEntity LCChemicalEntity accumulation in macrophages induced by the LCOTHER LCOTHER inhibitor LCOTHER .	0
LCOTHER ( LCOTHER ) - LCOTHER ( LCOTHER ) is an effective therapy for relapsed / refractory ( R / R ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) .	0
LCDiseaseOrPhenotypicFeature LCOrganismTaxon are with LCOTHER and LCOTHER LCOTHER .	0
LCOTHER also decreased LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature growth in athymic nude LCOTHER bearing LCCellLine cells as xenografts and this was accompanied by decreased LCOTHER , LCOTHER , and LCOTHER protein levels in LCOTHER .	0
CONCLUSIONS : As a potential explanation of our findings , we hypothesize that in LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature the LCOTHER - LCOTHER - XmnI / LCOTHER - LCOTHER - ( LCOTHER - > LCOTHER ) genotype is frequently under genetic linkage with LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) - LCDiseaseOrPhenotypicFeature mutations , but not with the LCOTHER ( + ) - LCOTHER mutation here studied ( i . e .	0
RESULTS : Except for LCSequenceVariant , which showed a significant difference of LCOTHER - LCOTHER - SDS by genotypes ( p = 0 . 02 ) , all polymorphisms showed no associations with the LCGeneOrGeneProduct - doses , LCOTHER - LCOTHER concentrations , LCOTHER - LCOTHER - SDS and LCOTHER - LCOTHER : LCOTHER ratio after adjusting for the confounding variables gender , age and BMI .	0
LCOTHER risk was consistently higher for users of LCChemicalEntity users than nonusers of LCChemicalEntity ( placebo , 1 . 4% vs .	0
Histological analyses of apoptosis , proliferation , angiogenesis and LCDiseaseOrPhenotypicFeature zone assessments were performed using LCGeneOrGeneProduct LCGeneOrGeneProduct - mediated LCOTHER nick - end labelling ( TUNEL ) staining , BrdU immunostaining , LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) / LCOTHER immunostaining and Masson ' s trichrome staining , respectively .	0
Compound 1 is a potent LCOTHER ( LCOTHER ) / LCOTHER ( LCOTHER ) LCOTHER LCOTHER in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of LCOTHER ' LCOTHER LCOTHER including LCOrganismTaxon and LCOTHER models of LCOTHER - induced LCOTHER , LCOTHER model of LCOTHER - induced LCOTHER , LCOTHER LCOTHER - LCOTHER ( LCChemicalEntity - LCChemicalEntity ) lesion model of drug - induced rotation , and LCOTHER - treated non - LCOTHER primate model . Coincidence of mutations in different connexin genes in Hungarian LCOTHER .	0
Eleven subjects presented LCOTHER homozygous single - base mutations ( two first cousins and four unrelated LCOTHER with LCOTHER , two with LCOTHER , one with LCOTHER , one with LCSequenceVariant , and one with LCOTHER plus the LCSequenceVariant variant in heterozygosis ) , whereas four were compound heterozygotes ( one with LCOTHER / LCOTHER + LCOTHER > LCOTHER , one with LCOTHER / LCOTHER , and two brothers with LCOTHER / LCOTHER ) .	0
A unique set of LCOTHER - regulated survival factors included LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER LCOTHER .	0
Using LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) LCOTHER , we studied early ultrastructural and permeability changes in relation to the expression of the podocyte - associated molecules LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER , and LCOTHER , the last two of which were only recently discovered in podocytes .	0
LCOTHER consists of three pairs of non - identical polypeptide chains , encoded by different genes ( LCOTHER LCOTHER [ LCGeneOrGeneProduct ] , LCOTHER LCOTHER [ LCOTHER ] and LCGeneOrGeneProduct LCGeneOrGeneProduct [ LCOTHER ] ) .	0
LCGeneOrGeneProduct and LCOTHER - LCOTHER expression was lowered in 6 week LCOTHER - treated WT animals whereas in treated LCOTHER KO LCOTHER , LCGeneOrGeneProduct was only reduced by 2 - fold and LCOTHER - LCOTHER expression was unaffected .	0
CONCLUSION : Taken together with previous studies of LCOTHER LCOTHER mutations , these findings suggest that LCGeneOrGeneProduct - LCGeneOrGeneProduct deficiency due either to haploinsufficiency or to substantial activity loss due to dominant negative interference of the normal allele product ' s function can each contribute to the LCOTHER phenotype . Cytostatic and anti - angiogenic effects of LCChemicalEntity in refractory LCOTHER LCOTHER LCOTHER .	0
CONTEXT : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is a rare LCOTHER LCOTHER , characterized by LCOTHER and LCOTHER / LCOTHER with increased serum LCOTHER , LCOTHER - LCOTHER LCOTHER [ LCOTHER , LCOTHER - ( LCOTHER ) ( LCOTHER ) LCOTHER ] resulting in LCDiseaseOrPhenotypicFeature .	0
Our results confirmed a previous study on the relationship between LCOTHER and LCOTHER in Caucasians . Does LCChemicalEntity potentiate LCOTHER - associated LCOTHER LCOTHER LCOTHER There is now evidence to suggest a central role for the dopaminergic system in LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	0
CONCLUSIONS : The excess of LCOTHER in LCChemicalEntity users with LCOTHER compared to other groups suggests that LCOTHER increase the risk of LCChemicalEntity - associated LCOTHER .	0
In LCDiseaseOrPhenotypicFeature FLSs , the level of LCOTHER was up - regulated by stimulation with LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct .	0
PURPOSE : We present a case of a LCOrganismTaxon who developed LCOTHER shortly after initiating treatment with LCOTHER and to discuss the potential drug - drug interactions related to the inhibition of LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct in this case , as well as in other cases , of LCOTHER - induced LCOTHER .	0
Because expression of LCOTHER , LCGeneOrGeneProduct , and LCOTHER are dependent on LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER , we also investigated the effects of LCChemicalEntity on LCOTHER protein expression as an underlying mechanism for the apoptotic and antiangiogenic activity of this compound .	0
LCOTHER administration to control LCOTHER significantly increased renal LCOTHER ( LCOTHER ) and urinary LCOTHER - LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCGeneOrGeneProduct , a marker of LCOTHER LCOTHER LCOTHER ) excretion but decreased LCOTHER LCOTHER ( LCOTHER ) and LCOTHER ( LCGeneOrGeneProduct ) activities .	0
B cells overexpressing LCOTHER displayed constitutively higher levels of activated LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct and LCOTHER / LCOTHER .	0
Three LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER with LCOTHER mutations demonstrated a durable response and one small LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER with LCOTHER LCSequenceVariant mutation showed progression after LCOTHER treatment .	0
Also , LCOTHER , LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER , and LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) expression levels were increased , whereas LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct levels were drastically reduced compared with those found in wild - type B cells .	0
LCOTHER LCOTHER LCOTHER ( LCOTHER ) is a LCOrganismTaxon LCOTHER LCOTHER LCOTHER characterized by genomic instability and enhanced LCOTHER predisposition , in particular to LCOTHER and LCDiseaseOrPhenotypicFeature .	0
Here we describe three LCOTHER , a boy ( aged 15 years ) and two girls ( aged 17 and 7 years ) with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature who suffered LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and in addition had LCOTHER and LCOTHER LCOTHER .	0
BACKGROUND : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER [ LCOTHER ] LCOTHER ) results from heterozygous mutations in LCOTHER encoding LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct .	0
METHODS : We performed a systematic review of published and unpublished data from cohorts with LCDiseaseOrPhenotypicFeature or LCOTHER to compare the presence of LCDiseaseOrPhenotypicFeature in : ( 1 ) antithrombotic users vs nonantithrombotic users with LCOTHER ; ( 2 ) antithrombotic users vs nonusers with LCOTHER / LCOTHER ; and ( 3 ) LCOTHER vs LCOTHER events stratified by antithrombotic use .	0
Our observation of frequent LCGeneOrGeneProduct gene abnormalities ( 90% ) and inactivation ( 40 - 60% ) was in striking contrast to the same pathological subtype of LCOTHER LCOTHER in which LCOTHER gene abnormalities and inactivation were infrequent , suggesting a difference in LCOTHER between LCOTHER and LCOTHER LCOTHER . LCOTHER LCOTHER LCOTHER LCOTHER in LCChemicalEntity users and their neural correlates during a face - learning task .	0
METHODS : We identified seven SNP ( single nucleotide polymorphism ) ( - 141Cins > del , TaqIB , TaqID , LCSequenceVariant , LCOTHER , LCSequenceVariant and TaqIA ) in the LCOTHER gene in 146 LCOTHER LCOTHER ( 59 with LCOTHER and 87 without LCOTHER according to the Simpson - Angus Scale ) treated with LCOTHER after 8 weeks .	0
These results demonstrate the critical role of the final 20 amino acids of LCGeneOrGeneProduct - LCGeneOrGeneProduct in modulating fibroblast proliferation by dampening LCOTHER signaling and suggest that augmented LCOTHER signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of LCOTHER in LCOTHER with LCOTHER - LCOTHER LCOTHER . LCOTHER mutation . Mutations in LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) LCOTHER in LCOTHER with LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
A high - fat diet increased cardiac LCOTHER expression , LCChemicalEntity LCChemicalEntity oxidation , and LCGeneOrGeneProduct levels with decreased glycolysis .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
CONCLUSIONS : This study identified novel mutations in the LCGeneOrGeneProduct gene as a cause of LCDiseaseOrPhenotypicFeature .	0
A LCOTHER - LCOTHER inhibitor , LCOTHER , selectively depleted LCOTHER ( + ) cells , suppressed LCGeneOrGeneProduct and LCOTHER , induced LCGeneOrGeneProduct , inhibited LCOTHER growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	0
These results indicated that the presence of LCOTHER - * 2 allele decreases risk for LCOTHER LCDiseaseOrPhenotypicFeature conferred by LCOTHER - LCOTHER , possibly by increasing the AS isoform of LCOTHER . Vaccine candidates derived from a novel infectious cDNA clone of an American genotype LCOrganismTaxon LCOrganismTaxon LCOrganismTaxon LCOrganismTaxon .	0
These results suggest that primary LCDiseaseOrPhenotypicFeature in Japan show genetic alterations similar to those in Switzerland , suggesting a similar molecular basis in caucasians and Asians , despite different genetic backgrounds , including different status of a polymorphism in the LCOTHER gene . Large deletion involving exon 5 of the LCOTHER LCOTHER gene caused apparent homozygosity in a LCOTHER LCOTHER LCOTHER LCOrganismTaxon .	0
Finally , we found that LCOTHER deletion inactivates LCOTHER ( LCSequenceVariant ) activity and block the LCOTHER signaling pathway , together with accumulated LCGeneOrGeneProduct , to induce senescence .	0
The LCChemicalEntity peroxidation indicators including antisuperoxideanion ( ASAFR ) , LCChemicalEntity LCChemicalEntity LCChemicalEntity ( . LCChemicalEntity ) , LCOTHER LCOTHER ( LCOTHER ) , LCOTHER and LCOTHER LCOTHER - LCOTHER ( LCOTHER ) were determined with kits , and LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER / LCOTHER ) activities in liver were analyzed with gelatin zymography and in situ fluorescent zymography respectively .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCGeneOrGeneProduct ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCGeneOrGeneProduct - specific LCOTHER .	0
Further , LCChemicalEntity , LCChemicalEntity - LCChemicalEntity lesion of LCOTHER nerves travelling in the median forebrain bundle , one of the main ascending pathways from the B3 LCChemicalEntity cells , did not affect the fall in blood pressure associated with a midline B3 LCOTHER LCOTHER injection .	0
CONCLUSION : This study establishes a LCOTHER model by periarterial LCOTHER ( LCOTHER ) exposure in LCOrganismTaxon , and demonstrates a significant elevation of expression of LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER and LCOTHER in the pathogenesis of vascular remodeling . Expanding clinical spectrum of LCOTHER - LCOTHER LCOTHER due to an activating germline mutation , LCOTHER . LCOTHER , in the LCOTHER LCOTHER gene .	0
LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is an uncommon autosomal dominant chronic LCOTHER LCOTHER , characterized by multiple superficial LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature surrounded by a slightly raised keratotic border .	0
In LCChemicalEntity - induced LCOTHER LCOTHER , the protection of LCOTHER was associated with reduced leukocyte infiltration into the brain and microglial production of LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct .	0
Further study revealed that the effect of LCOTHER on LCOTHER LCOTHER LCOTHER is associated with the lower expression of LCOTHER , p - LCGeneOrGeneProduct , p - LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , both in vivo and in vitro .	0
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCGeneOrGeneProduct with LCOTHER and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCGeneOrGeneProduct genes in LCOTHER with LCOTHER / LCOTHER .	0
Moreover , LCOrganismTaxon with aberrant LCGeneOrGeneProduct protein expression showed tendencies to receive neoadjuvant chemotherapy ( P < 0 . 001 ) and cytoreductive surgery ( P = 0 . 020 ) .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
RESULTS AND DISCUSSION : LCOTHER - LCOTHER LCOTHER and LCCellLine cells release a network of cytokines , including newly identified LCOTHER - inducible cytokines LCOTHER , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) .	0
We sought to define a functional role for the LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) isoform , LCOTHER , in an established cell model of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
In five LCOTHER LCSequenceVariant . LCSequenceVariant missense mutation was detected , of which four were homozygous and one was compound heterozygous : LCOTHER . LCOTHER LCOTHER ( LCOTHER . LCOTHER ) and LCSequenceVariant . LCSequenceVariant .	0
These results support the conclusion that the LCSequenceVariant / LCSequenceVariant allele is the major risk variant for LCOTHER LCOTHER LCOTHER in the LCOTHER locus , but they suggest that additional infrequent coding variants at LCOTHER may also contribute to LCOTHER LCOTHER LCOTHER risk . LCOTHER - induced changes in LCOTHER LCOTHER LCOTHER and LCChemicalEntity signaling via LCOTHER in skeletal muscle .	0
LCOTHER was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCGeneOrGeneProduct , LCOTHER ] , by secretagogues activating LCOTHER - LCOTHER ( LCOTHER ) [ LCOTHER , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCGeneOrGeneProduct [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	0
We report a case of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) in a dizygotic twin who presented at 12 years of age with LCOTHER LCOTHER , LCOTHER LCOTHER , LCOTHER and LCOTHER with inappropriate kaliuresis , and LCOTHER LCOTHER LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER LCOTHER ) .	0
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCGeneOrGeneProduct / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCChemicalEntity to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	0
The LCGeneOrGeneProduct LCOTHER allele associates with morning preference and is a potential candidate allele for LCOTHER . LCGeneOrGeneProduct and LCOTHER - inhibitor variation and LCOTHER LCOTHER risk in Afro - Caribbeans .	0
We report on a new allele at the LCOTHER LCOTHER ( LCOTHER ) locus causing late - onset LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) .	0
By contrast , no significant correlation was detected between the protein levels and LCOTHER age , histological type , or serum LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER - LCOTHER levels .	0
Furthermore , in vitro and in vivo investigations revealed a unique T cell population , LCOTHER - LCOTHER - producing LCOTHER + LCGeneOrGeneProduct + LCOTHER - LCOTHER + LCOTHER + LCOTHER - LCGeneOrGeneProduct - Tr1 cells , that was significantly increased without altering the LCOTHER + regulatory T cell population .	0
To determine the physiologic LCOTHER LCOTHER ( LCOTHER ) - dependent actions of LCChemicalEntity on LCOTHER in female LCOTHER , we generated female LCOTHER - knockout ( LCOTHER ) LCOTHER on an LCOTHER - prone LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - deficient background .	0
We studied the LCGeneOrGeneProduct gene mutations in a cohort of affected individuals with different clinical phenotype including LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , or LCOTHER LCOTHER LCOTHER .	0
Sequencing analysis detected 17 different LCGeneOrGeneProduct gene mutations , and 7 of these were identified as novel : 3 missense mutations , including LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 3 , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER . LCOTHER ) in exon 3 and LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 7 ; 2 deletion mutations , including LCOTHER . LCOTHER ( LCOTHER . LCOTHER ) in exon 5 and LCOTHER . LCOTHER ( LCOTHER . LCOTHER ) in exon 11 ; and 2 alternative splicing mutations , including LCOTHER . LCOTHER + LCOTHER in intron 4 at splicing donor sites and LCOTHER . LCOTHER - LCOTHER > LCOTHER in intron 13 at splicing acceptor sites .	0
CONCLUSION : Taken together , the profile of LCOTHER receptor , LCOTHER gene expression and metabolic factors in adipose tissue from morbidly LCOTHER HAT subjects suggests a compensatory response associated with the increased plasma LCOTHER and LCChemicalEntity . LCGeneOrGeneProduct region and risk of LCOTHER LCOTHER LCOTHER in African American LCOTHER .	0
Furthermore , we provide a LCOTHER model of LCOTHER for the investigation of LCOTHER related LCDiseaseOrPhenotypicFeature . The cytogenetic action of LCOTHER , LCChemicalEntity , and their combination on peripheral LCOTHER lymphocytes : an in vivo / in vitro cytogenetic study .	0
BACKGROUND : LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is an LCOTHER LCOTHER LCOTHER resulting from inactivating mutations in the LCOTHER - sensitive LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) gene .	0
LCOTHER was found to be under - expressed in LCCellLine / LCCellLine and LCOTHER - LCOTHER / LCOTHER ( a LCOTHER MDR LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cell line ) compared with their non - MDR parental cell lines .	0
Our result expands the mutation spectrum of LCOTHER and contributes to the study of the molecular pathogenesis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCGeneOrGeneProduct polymorphisms associated with alternative splicing modify susceptibility to LCOTHER LCOTHER LCOTHER LCOTHER through epistatic interaction with LCOTHER .	0
In a prospective study involving 74 LCOTHER LCOrganismTaxon and 170 control subjects , we identified four LCOTHER harboring a heterozygous single nucleotide polymorphism in exon 6 of the LCGeneOrGeneProduct gene , encoding LCOTHER ( LCOTHER ) - - > LCOTHER substitution in its extracellular domain .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCGeneOrGeneProduct ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature study .	0
CONCLUSIONS : High serum levels of LCOTHER LCGeneOrGeneProduct such as LCOTHER and LCGeneOrGeneProduct in the serum of LCOTHER LCOTHER indicate the presence of LCOTHER . Over - expression of LCOTHER and LCOTHER in a child with LCOTHER LCOTHER LCOTHER and LCOTHER LCOTHER : a new syndrome .	0
The remaining four mutations [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCSequenceVariant . LCSequenceVariant + LCSequenceVariant , LCOTHER . LCOTHER and LCSequenceVariant + LCSequenceVariant > LCSequenceVariant ] were novel .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCGeneOrGeneProduct expression in LCOrganismTaxon .	0
We investigated whether single nucleotide polymorphisms ( SNPs ) of LCGeneOrGeneProduct , encoding LCOTHER , influenced the conversion from LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) to LCOTHER LCOTHER LCOTHER LCOTHER in subjects of the STOP - NIDDM trial .	0
Our findings indicated that LCOTHER might be a very upstream key molecule regulating EMT involved in LCOTHER / LCOTHER - LCOTHER signaling pathway . LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct protects high LCChemicalEntity - induced energy LCOTHER LCOTHER via blocking LCOTHER - ubiquitin proteasome pathway .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
Most carrier females have mild LCOTHER LCOTHER and subtle facial changes . Serum levels of LCOTHER LCOTHER and LCOTHER in LCDiseaseOrPhenotypicFeature LCOrganismTaxon indicate the presence of LCOTHER LCOTHER .	0
LCChemicalEntity dose , presence of LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER , LCChemicalEntity level , and liver function contribute to LCOTHER LCOTHER .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
Additionally , LCOTHER also reduces the levels of serum biochemical markers ( serum LCOTHER , Scr ; blood LCOTHER LCOTHER , BUN ; and LCOTHER LCOTHER , LCOTHER ) and decreases the release of LCDiseaseOrPhenotypicFeature cytokines ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct ) .	0
The LCOTHER LCOTHER - suppressor gene was mutated in all LCOTHER with documented LCGeneOrGeneProduct mutation , suggesting that the pathways regulated by these two LCOTHER - suppressor proteins often cooperate in the development of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with serous differentiation . Drug - induced LCOTHER LCOTHER LCOTHER in injection drug users receiving LCOTHER : high frequency in hospitalized LCOTHER and risk factors .	0
RATIONALE : LCChemicalEntity and LCOTHER are widely consumed licit LCChemicalEntity LCChemicalEntity worldwide .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER ) .	0
All LCOTHER were genotyped for LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , intron 2 conversion , LCOTHER ( LCOTHER ) within LCOTHER and LCSequenceVariant ( LCOTHER LCOTHER ) , LCOTHER ( LCOTHER ) within LCGeneOrGeneProduct .	0
METHODS : We identified seven SNP ( single nucleotide polymorphism ) ( - 141Cins > del , TaqIB , TaqID , LCOTHER , LCOTHER , LCSequenceVariant and TaqIA ) in the LCOTHER gene in 146 LCOTHER LCOTHER ( 59 with LCOTHER and 87 without LCDiseaseOrPhenotypicFeature according to the Simpson - Angus Scale ) treated with LCOTHER after 8 weeks .	0
Further , LCChemicalEntity , LCChemicalEntity - LCChemicalEntity lesion of LCOTHER nerves travelling in the median forebrain bundle , one of the main ascending pathways from the B3 LCOTHER cells , did not affect the fall in blood pressure associated with a midline B3 LCChemicalEntity LCOTHER injection .	0
The ability of LCOTHER to block LCOTHER - LCOTHER LCOTHER ( LCOTHER + ) LCOTHER , also expressed by enteric neurons , might represent a possible mechanism through which LCOTHER exerts its actions . Lack of association of LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCOTHER LCOTHER status with LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER , and disease severity .	0
To determine the physiologic LCOTHER LCOTHER ( LCOTHER ) - dependent actions of LCOTHER on LCDiseaseOrPhenotypicFeature in female LCOTHER , we generated female LCOTHER - knockout ( LCOTHER ) LCOTHER on an LCOTHER - prone LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - deficient background .	0
Our results demonstrate the utility of the SEREX approach for the identification of potential LCOTHER associated antigens in LCOTHER LCOTHER LCOTHER . The LCOTHER polymorphism of the LCOTHER gene in South Indian LCOrganismTaxon of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
METHODS : Allele frequencies of LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , and LCOTHER - LCOTHER were determined by polymerase chain reaction in 303 LCOTHER with microbiologically proven LCOTHER LCOTHER , including 18 LCOrganismTaxon who LCOTHER , and 222 healthy control subjects .	0
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCGeneOrGeneProduct LCGeneOrGeneProduct ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ) , LCOTHER and LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
On the whole , our findings indicate that the absence of LCOTHER plays a cardioprotective role in LCOTHER LCOTHER LCOTHER by promoting changes in LCOTHER / LCOTHER signalling . Long - Lived LCGeneOrGeneProduct + LCOTHER - LCOTHER + T Cells rather than Short - Lived LCOTHER + LCOTHER - LCOTHER + LCOTHER - LCOTHER + T Cells Initiate Rapid LCGeneOrGeneProduct - LCGeneOrGeneProduct Production To Suppress Anamnestic T Cell Responses during Secondary LCOTHER LCOTHER .	0
Silencing of LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) expression in LCOTHER cells had a greater impact on LCOTHER - inducible cytokines than LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , and LCGeneOrGeneProduct expression .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCGeneOrGeneProduct LCGeneOrGeneProduct ) , LCOTHER , LCGeneOrGeneProduct and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
METHODS : Following induction of anesthesia by LCChemicalEntity ( 0 . 15 mg kg ( - 1 ) ) and LCChemicalEntity ( 2 . 0 mg kg ( - 1 ) ) , 13 LCOTHER received LCOTHER ( 0 . 1 mg iv ) and 12 LCOTHER received LCOTHER ( 10 mg iv ) to restore mean arterial pressure ( MAP ) .	0
Eight Alu sequences ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER and LCOTHER ) were analyzed in two samples from Navarre and Guipuzcoa provinces ( Basque Country , Spain ) .	0
The LCOTHER showed an LCOTHER mutation that has been described in an Asian population and LCOTHER LCOrganismTaxon , along with a novel frameshift mutation , LCSequenceVariant .	0
It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a LCOTHER - induced LCDiseaseOrPhenotypicFeature via descending projections , the midline LCOTHER B3 cells in the medulla contribute to the LCOTHER action of LCChemicalEntity , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem . A novel mutation screening system for LCOTHER - LCOTHER LCOTHER , LCOTHER LCOTHER by high - resolution melting curve analysis in combination with small amplicon genotyping using genomic DNA .	0
In some families LCOTHER LCOTHER LCOTHER also forms a component of the complex and as such has been described as LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature : LCOTHER LCOTHER ) .	0
The prognostic value of serum LCOTHER markers LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) and LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) is limited .	0
Chronic administration of LCGeneOrGeneProduct strongly reduced the blood pressure and production of LCOTHER and improved antioxidant capacity in LCOTHER - induced LCOTHER , suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LCOTHER . Role of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct in LCOTHER and migration of fibroblast - like synoviocytes in LCOTHER LCOTHER .	0
Twenty - five LCOrganismTaxon were given LCOTHER LCOTHER ( 60 mg / day ) plus LCChemicalEntity ( 500 mg / day ) .	0
In line , recombinant LCGeneOrGeneProduct LCSequenceVariant ( G allele ) synthesized 2 . 6 - fold more LCOTHER LCOTHER per unit of time than LCOTHER LCOTHER ( A allele ; LCOTHER LCOTHER [ 8 . 26 + / - 3 . 57 nmol / hour . mg ] vs LCOTHER LCOTHER [ 3 . 22 + / - 0 . 67 nmol / hour . mg ] ; P = . 01 ) .	0
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCChemicalEntity to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOrganismTaxon with LCOTHER / LCOTHER .	0
Loss of LCOTHER expression in LCOTHER altered the LCOTHER induction of LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER - LCOTHER .	0
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCSequenceVariant , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOrganismTaxon ( nine with LCOTHER LCOTHER LCOTHER , two with LCOTHER LCOTHER LCOTHER , and one with LCOTHER LCOTHER LCOTHER ) .	0
CONCLUSIONS : LCOTHER treatment is effective in controlling the LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature , LCOTHER , and LCOTHER in this child case , wherein LCOTHER LCOTHER plays a key role in the proper formation of the ligand - binding pocket and the AF - 2 surface of the LCOTHER LCOTHER LBD . Inactivation of LCOTHER / LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER LCOTHER triggers senescence and inhibits LCOTHER - induced immortalization .	0
LCChemicalEntity administration would be effective in the treatment of LCOTHER LCOTHER LCOTHER with LCOTHER LCOTHER . Mutational analysis of LCOTHER in LCDiseaseOrPhenotypicFeature LCOTHER using denaturing high performance liquid chromatography .	0
We found LCOTHER LCOTHER ( G1 LCOTHER from rectum and two G3 LCDiseaseOrPhenotypicFeature from colon ) and LCOTHER LCSequenceVariant ( G2 LCOTHER from pancreas ) missense mutations ( 9 . 1% ) in an independent cohort of 44 LCOTHER - LCOTHER from the rectum ( n = 26 ) , colon ( n = 7 ) , pancreas ( n = 4 ) , small intestine ( n = 3 ) , stomach ( n = 3 ) and appendix ( n = 1 ) by Sanger sequencing .	0
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature from LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) are a clinically significant problem .	0
In contrast , LCGeneOrGeneProduct ( + ) YFP ( + ) GFP ( - ) T cell - derived cells expanded rapidly and upregulated LCOTHER - LCOTHER expression during secondary LCDiseaseOrPhenotypicFeature .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
Common > or = grade 3 events were LCOTHER , LCDiseaseOrPhenotypicFeature , LCOTHER , LCDiseaseOrPhenotypicFeature , and LCOTHER .	0
Hence , while alterations in select LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct are not associated with development of LCOTHER - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOrganismTaxon with LCOTHER / LCOTHER .	0
Compared to that in the normal control , more severe LCOTHER LCOTHER and hepatocyte apoptosis , worse hepatic LCOTHER peroxidation demonstrated by the increased ASAFR , . LCOTHER and LCChemicalEntity , but decreased LCOTHER and LCGeneOrGeneProduct , increased LCOTHER - LCOTHER / LCOTHER activities and LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER expressions , which revealed obvious LCOTHER LCOTHER and scaffold structure broken , were shown in the model control .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCGeneOrGeneProduct and LCOTHER were dependent on LCOTHER expression in LCOrganismTaxon .	0
CONCLUSIONS : LCOTHER treatment is effective in controlling the LCOTHER LCOTHER , LCOTHER , LCOTHER , and LCOTHER in this child case , wherein LCSequenceVariant LCSequenceVariant plays a key role in the proper formation of the ligand - binding pocket and the AF - 2 surface of the LCOTHER LCOTHER LBD . Inactivation of LCOTHER / LCOTHER / LCGeneOrGeneProduct LCOTHER LCOTHER LCOTHER triggers senescence and inhibits LCOTHER - induced immortalization .	0
We investigated the effects of LCChemicalEntity , a plasma inhibitor of coagulation factors , in LCOTHER with LCOTHER LCOTHER - induced LCOTHER , which is an experimental model of LCOrganismTaxon LCOTHER LCOTHER .	0
Elevated levels of LCOTHER and LCGeneOrGeneProduct mRNA and protein were detected in the LCOTHER ' s cells while levels of LCGeneOrGeneProduct mRNA were unchanged .	0
Most LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) develop as a result of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
These findings suggest that LCOTHER - mediated mechanisms in the neural circuits at the IC level influence LCOTHER - induced LCOTHER and participate in the regulation of motor activity . LCOTHER effects of LCOTHER LCOTHER on LCOTHER - induced LCDiseaseOrPhenotypicFeature in LCOrganismTaxon .	0
CONCLUSION : We suggest that the increased risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature due to LCOTHER treatment may be related to increased LCOTHER levels , but not LCGeneOrGeneProduct levels . LCOTHER serves as a prognostic biomarker for LCOTHER LCOTHER .	0
Both baseline and LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - induced migration were LCOTHER - dependent and required the action of LCOTHER LCOTHER / LCOTHER , LCOTHER / LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER LCOTHER LCOTHER and LCOTHER - LCOTHER / LCOTHER .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
Meanwhile apoptosis related proteins LCOTHER and LCOTHER were involved in LCDiseaseOrPhenotypicFeature LCOTHER and LCOTHER LCOTHER model , but not LCOTHER - LCOTHER , LCOTHER - LCOTHER or LCOTHER . LCOTHER and LCOTHER are closely relevant in the tissue splices of deminopathies LCOTHER and LCOrganismTaxon with LCOTHER at protein lever .	0
LCOTHER deficiency in non - parenchymal cells , but not in parenchymal cells , reduced LCOTHER activity , LCOTHER ( LCOTHER ) - LCOTHER production , and LCOTHER stem cell marker ( LCGeneOrGeneProduct and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct [ LCOTHER ] ) expression , leading to attenuated LCOTHER potential .	0
LCOrganismTaxon AND METHODS : We examined associations between 54 polymorphisms that tag the known common variants ( minor allele frequency > 0 . 05 ) in 10 genes involved in oxidative damage repair ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER ) and survival in 4 , 470 LCOTHER with LCOTHER LCOTHER .	0
In a baby LCOTHER with early onset , severe LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER and profound , isolated LCOTHER LCOTHER in skeletal muscle , we identified a disease - segregating homozygous mutation ( LCOTHER . LCOTHER > LCOTHER ) in LCOTHER / LCGeneOrGeneProduct , predicting a drastic change in a highly conserved amino - acid residue ( LCOTHER . LCOTHER ) .	0
These results strongly suggest that the LCSequenceVariant LCOTHER mutation is responsible for the LCOTHER phenotype in the proposita ' s family . Cloning of LCOTHER LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct and molecular characterization of its deficiency in two LCOTHER .	0
LCOTHER was up - regulated in LCGeneOrGeneProduct ( + ) cells from brains of LCOTHER with LCOTHER and in LCOTHER ( + ) LCOTHER ( int ) cells from LCOrganismTaxon subjected to LCOTHER - induced LCOTHER .	0
The LCOTHER contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site and the LCOTHER subunit contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site which make them strong candidates for future mutation detection studies in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER . The LCOTHER mutation database : an online database of LCOTHER LCOTHER mutations involved in the LCDiseaseOrPhenotypicFeature ( LCOTHER ) LCOTHER LCOTHER and congenital LCOTHER LCOTHER .	0
These findings suggest that LCChemicalEntity - LCChemicalEntity can negatively affect both cell proliferation and hippocampal dependent working memory and that these deficits can be reversed by the simultaneous administration of the antidepressant LCOTHER . LCOTHER deficiency confers enhanced myocardial protection in the LCOTHER LCOTHER by mediating the LCOTHER / LCGeneOrGeneProduct signalling pathway .	0
In spontaneously LCDiseaseOrPhenotypicFeature , LCOTHER - prone LCOTHER , microinjection of LCOTHER into the area of the midline B3 LCOTHER cell group in the ventral medulla caused a potent LCOTHER of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the LCChemicalEntity neurotoxin LCOTHER , LCOTHER - LCOTHER ( LCOTHER , LCOTHER - LCOTHER ) injected intracerebroventricularly .	0
The binding of LCOTHER , LCGeneOrGeneProduct and LCOTHER to LCOTHER did not differ for control and septic muscle in the basal condition ; however , the LCOTHER - induced decrease in LCOTHER LCOTHER and increase in LCOTHER LCOTHER seen in control muscle was absent in LCDiseaseOrPhenotypicFeature .	0
A total of 10 novel variants was recognized , among them four variants in the adjacent 5 ' - region of the LCGeneOrGeneProduct coding exon 2 ( LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER ) , a 6 base - pair deletion ( LCSequenceVariant . LCSequenceVariant [ LCOTHER . LCOTHER ] ) , a variant leading to a stop codon ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , synonymous variants ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , and one non - synonymous variant ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) .	0
The incidence of cardiovascular LCDiseaseOrPhenotypicFeature events ( cardiac , cerebrovascular and peripheral vascular , or arterial LCOTHER ) was determined by analyzing pooled LCOTHER ( 10 - 80 mg daily ) , nonselective LCOTHER ( LCOTHER 75 mg bid , LCOTHER 800 mg tid , or LCChemicalEntity 500 mg bid ) and placebo data from 10 randomized LCOTHER and LCOTHER LCOTHER trials that were 6 - 52 weeks in duration .	0
Three LCOTHER LCOTHER - LCOTHER , LCOTHER , and LCOTHER - accounted for 51% , 20% , and 11% of the identified mutations , respectively . Allelic expression imbalance of LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) caused by variant LCOTHER .	0
Biochemical tests showed elevated free LCOTHER ( LCChemicalEntity : 20 . 8 pg / ml ( normal , 8 . 5 - 18 ) ) and LCChemicalEntity ( LCOTHER : 5 . 7 pg / ml ( normal , 1 . 4 - 4 ) ) in the serum , together with an inappropriately nonsuppressed LCOTHER level of 4 . 7 mU / ml ( normal , 0 . 4 - 4 ) .	0
The LCChemicalEntity peroxidation indicators including antisuperoxideanion ( ASAFR ) , LCOTHER LCOTHER LCOTHER ( . LCOTHER ) , LCOTHER LCOTHER ( LCOTHER ) , LCOTHER and LCOTHER LCOTHER - LCOTHER ( LCOTHER ) were determined with kits , and LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER / LCOTHER ) activities in liver were analyzed with gelatin zymography and in situ fluorescent zymography respectively .	0
LCOTHER significantly reduces LCChemicalEntity ' s LCOTHER , while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug . Two novel mutations of the LCGeneOrGeneProduct gene causing different phenotype in a cohort of Chinese LCOTHER .	0
Mutations of the LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) gene in 46 , XY subjects cause masculinization defects of varying degrees , due to reduced or impaired enzymatic activity .	0
The binding of LCOTHER , LCOTHER and LCOTHER to LCOTHER did not differ for control and septic muscle in the basal condition ; however , the LCOTHER - induced decrease in LCOTHER LCOTHER and increase in LCGeneOrGeneProduct LCGeneOrGeneProduct seen in control muscle was absent in LCOTHER .	0
The LCOTHER LCOTHER intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the LCOTHER in the predisposed myocardium of this LCOTHER . LCOTHER and LCGeneOrGeneProduct are Essential for Proliferation and Radiation Resistance of LCDiseaseOrPhenotypicFeature Stem - Like Cells in LCOTHER LCOTHER LCOTHER .	0
In contrast , HG increased extracellular LCChemicalEntity concentration , the expression of LCOTHER , mitochondrial fission proteins ( LCOTHER , LCOTHER ) , and the ubiquitination levels of LCOTHER , LCGeneOrGeneProduct and LCOTHER .	0
RESULTS : HAT adipose tissue demonstrated increased LCOTHER related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	0
Such a temporal relationship between the use of LCOTHER and the symptoms of LCDiseaseOrPhenotypicFeature in our LCOTHER did not support a potentiating effect of LCOTHER on LCChemicalEntity - associated LCOTHER .	0
Carriage of alleles encoding LCOTHER LCOTHER LCOTHER LCOTHER was found in 61% of LCOrganismTaxon who LCDiseaseOrPhenotypicFeature , compared with 35% of those who survived ( OR adjusted for age , 2 . 9 ; 95% CI , 1 . 1 - 7 . 7 ) .	0
A total of 10 novel variants was recognized , among them four variants in the adjacent 5 ' - region of the LCOTHER coding exon 2 ( LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER ) , a 6 base - pair deletion ( LCSequenceVariant . LCSequenceVariant [ LCOTHER . LCOTHER ] ) , a variant leading to a stop codon ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , synonymous variants ( LCSequenceVariant . LCSequenceVariant > LCSequenceVariant [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , and one non - synonymous variant ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
The fact that no truncation or frame shift mutations have been found in any of the LCOTHER LCOTHER , coupled with our recent finding that some breeding pairs of LCOTHER LCOTHER knockout LCOrganismTaxon yield litters that show not only LCOTHER , but also severe LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOTHER . Midline B3 LCOTHER nerves in LCOTHER medulla are involved in LCOTHER effect of LCOTHER .	0
The LCOTHER LCOTHER ( LCOTHER - LCOTHER ) LCOTHER is therapeutically targeted by several second generation LCOTHER , such as LCOTHER and LCChemicalEntity , and LCOTHER - LCOTHER - induced LCDiseaseOrPhenotypicFeature in LCOTHER is corrected with the use of a selective LCOTHER - LCOTHER LCOTHER LCOTHER .	0
In a multivariate logistic regression analysis including age , sex , smoking , LCOTHER , arterial LCDiseaseOrPhenotypicFeature and LCOTHER , the LCOTHER LCOTHER LCOTHER variant was not significantly associated with the presence of LCDiseaseOrPhenotypicFeature ( Odds ratio 1 . 07 , 95% confidence interval 0 . 84 - 1 . 37 ; p = 0 . 60 ) .	0
Compared with WT LCOrganismTaxon , the liver weight and LCOTHER LCOTHER rate were significantly lower in LCGeneOrGeneProduct .	0
Together these findings show that the LCGeneOrGeneProduct inhibitor , LCOTHER , produces antipsychotic - like effects , which differ from those observed with compounds primarily targeting the LCOTHER system , and has a reduced side - effect potential as compared with these latter drugs . LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature following chemotherapy for stage IIIE diffuse large B - cell LCOTHER LCOTHER in a LCOTHER with LCOTHER LCOTHER ( LCOTHER ' LCOTHER LCOTHER ) .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCGeneOrGeneProduct ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
Changes included increases in LCOTHER , LCGeneOrGeneProduct , LCOTHER / LCOTHER , and LCGeneOrGeneProduct and decreases in LCOTHER , LCOTHER , and LCOTHER .	0
All LCOTHER were genotyped for LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , intron 2 conversion , LCOTHER ( LCOTHER ) within LCOTHER and LCOTHER ( LCSequenceVariant LCSequenceVariant ) , LCOTHER ( LCOTHER ) within LCGeneOrGeneProduct .	0
BACKGROUND : LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER LCOTHER LCOTHER [ LCOTHER ] LCOTHER ) results from heterozygous mutations in LCOTHER encoding LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct .	0
Further study revealed that the effect of LCOTHER on LCOTHER LCOTHER LCOTHER is associated with the lower expression of LCGeneOrGeneProduct , p - LCOTHER , p - LCOTHER - LCOTHER and LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , both in vivo and in vitro .	0
The LCOTHER - LCOTHER receptors LCOTHER and LCGeneOrGeneProduct were present in LCOTHER invadopodia ( processes mediating invasion ) , partially colocalized with LCOTHER LCOTHER LCOTHER and the LCGeneOrGeneProduct LCGeneOrGeneProduct LCOTHER ( LCOTHER ) - LCOTHER and coimmunoprecipitated with LCOTHER ( LCOTHER ) - LCOTHER .	0
RESULTS AND DISCUSSION : LCOTHER - LCOTHER LCOTHER and LCCellLine cells release a network of cytokines , including newly identified LCOrganismTaxon - inducible cytokines LCOTHER , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) .	0
LCChemicalEntity prevented all the alterations observed , showing novel neuroprotective properties . LCOTHER - LCOTHER mediated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature : a single founder for all cases with evidence for a Cis - acting disease modifier in the recessive haplotype .	0
PURPOSE : This study was designed to establish a LCOrganismTaxon model of LCOTHER LCOTHER LCOTHER ( LCOTHER ) by LCOTHER LCOTHER ( LCChemicalEntity ( LCChemicalEntity ) ) - induced LCOTHER LCOTHER and to explore the potential role of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER ( LCOTHER ) and their endogenous inhibitors ( TIMPs ) in LCOTHER formation .	0
METHODS : We performed a systematic review of published and unpublished data from cohorts with LCOTHER or LCDiseaseOrPhenotypicFeature to compare the presence of LCOTHER in : ( 1 ) antithrombotic users vs nonantithrombotic users with LCOTHER ; ( 2 ) antithrombotic users vs nonusers with LCOTHER / LCDiseaseOrPhenotypicFeature ; and ( 3 ) LCOTHER vs LCOTHER events stratified by antithrombotic use .	0
The LCOTHER peroxidation indicators including antisuperoxideanion ( ASAFR ) , LCChemicalEntity LCChemicalEntity LCChemicalEntity ( . LCChemicalEntity ) , LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER and LCOTHER LCOTHER - LCOTHER ( LCOTHER ) were determined with kits , and LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER / LCOTHER ) activities in liver were analyzed with gelatin zymography and in situ fluorescent zymography respectively .	0
Re - expression of LCGeneOrGeneProduct or knockdown of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct decreased the overproliferation and - migration observed in LCOTHER ( endo - / - ) cells .	0
LCOTHER and LCOTHER expression was not increased by treatment of LCOTHER cells with LCOTHER and LCOTHER inhibitors , suggesting that LCOTHER regulates LCOTHER expression independently of LCGeneOrGeneProduct and LCGeneOrGeneProduct .	0
Our results confirmed a previous study on the relationship between LCGeneOrGeneProduct and LCOTHER in Caucasians . Does LCOTHER potentiate LCChemicalEntity - associated LCOTHER LCOTHER LCOTHER There is now evidence to suggest a central role for the dopaminergic system in LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
CONCLUSIONS : Our study shows that LCOTHER is expressed locally in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and that the gene polymorphism influences metastatic behavior . LCOTHER mutations associated with LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER .	0
CONCLUSIONS : The LCOTHER - LCOTHER polymorphism of the LCOTHER LCOTHER gene is associated with LCOTHER and may be a potential regulatory site . Protective effects of LCOTHER on LCOTHER LCOTHER LCDiseaseOrPhenotypicFeature in LCOrganismTaxon .	0
Sequence analysis confirmed a nucleotide LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant ( LCSequenceVariant LCSequenceVariant ) of the LCGeneOrGeneProduct gene in all LCOTHER and the asymptomatic family member .	0
METHODS : Allele frequencies of LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , and LCGeneOrGeneProduct - LCGeneOrGeneProduct were determined by polymerase chain reaction in 303 LCOTHER with microbiologically proven LCOTHER LCOTHER , including 18 LCOTHER who LCOTHER , and 222 healthy control subjects .	0
METHODS : We performed a systematic review of published and unpublished data from cohorts with LCOTHER or LCOTHER to compare the presence of LCOTHER in : ( 1 ) antithrombotic users vs nonantithrombotic users with LCOTHER ; ( 2 ) antithrombotic users vs nonusers with LCDiseaseOrPhenotypicFeature / LCDiseaseOrPhenotypicFeature ; and ( 3 ) LCOTHER vs LCOTHER events stratified by antithrombotic use .	0
In addition to these new mutations , this investigation reveals the prevalence of LCOTHER substitution among a subset of African - Brazilian LCOTHER and presents evidences of the recurrence of already known mutations . Effects of LCChemicalEntity on LCChemicalEntity - induced LCOTHER in LCOTHER .	0
METHODS : DNA samples from 405 LCOTHER LCOTHER , 97 LCDiseaseOrPhenotypicFeature LCOrganismTaxon , 113 LCOTHER LCOTHER , and 431 healthy controls were genotyped for the LCOTHER LCOTHER LCOTHER .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCGeneOrGeneProduct ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature study .	0
These results show for the first time that one of the underlying mechanisms of action of LCOTHER as a LCOTHER chemotherapeutic agent is due , in part , to decreased expression of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cells . Study of a Taiwanese family with LCOTHER LCOTHER LCOTHER .	0
Electrophoretic analysis of plasma LCGeneOrGeneProduct of the proband and his mother showed that LCOrganismTaxon has a reduced amount of tetrameric enzyme in plasma and that minor fast - moving LCOTHER components : monomer , dimer , and monomer - albumin conjugate are missing .	0
LCOTHER LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) was widely used for a variety of diseases including LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , the current study aims to investigate the protective effects of LCOTHER on liver sinusoidal endothelial cells ( LSECs ) in acute LCOTHER LCOTHER and related action mechanisms .	0
We conducted a screening of the LCGeneOrGeneProduct region for 1 , 536 single nucleotide polymorphisms ( SNPs ) and the deletion of the LCGeneOrGeneProduct gene in a LCOTHER case - control study ( 380 cases , 765 age - matched controls ) nested within the prospective Black LCOTHER ' s Health Study .	0
RESULTS : Nontoxic doses of LCOTHER reduced LCOTHER and LCOTHER LCOTHER from LCOTHER and LCOTHER in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCOTHER , LCOTHER LCOTHER , nor the in vitro LCDiseaseOrPhenotypicFeature from LCChemicalEntity .	0
Subsequently , after lysis of myofilaments , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , and LCOTHER LCOTHER - LCOTHER expressions were reduced followed by their breakdown , as epiphenomena of the myocytolytic process .	0
Collectively , our findings present a new approach for identifying ciliary proteins , and unveil LCOTHER , a LCGeneOrGeneProduct most closely related to the LCOTHER protein LCOTHER / LCOTHER , as an IFT - associated cargo with LCOTHER - dependent cell autonomous and non - autonomous functions at the ciliary base . Compound heterozygous mutations in the LCOTHER gene exon 4 in a LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER of Chinese origin .	0
The present study aimed to evaluate the LCOTHER effects at doses of 25 , 50 or 75 mg / kg on LCOTHER parameters to determine their anticonvulsant activity and its effects on amino acid ( LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCChemicalEntity , LCOTHER and LCOTHER ) levels as well as on LCOTHER ( LCOTHER ) activity in LCOTHER hippocampus after LCDiseaseOrPhenotypicFeature .	0
A LD ( 10 ) dose ( 8 mg LCOTHER / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher LCOTHER , LCOTHER LCOTHER , LCChemicalEntity peroxidation , and 80% mortality in the LCOTHER ( LCDiseaseOrPhenotypicFeature ) LCOTHER in the absence of any significant LCOTHER LCOTHER LCOTHER LCOTHER .	0
In vitro , the LCGeneOrGeneProduct / LCOTHER subunits of LCGeneOrGeneProduct - LCGeneOrGeneProduct formed side - by - side filaments with LCOTHER and inhibited further polymerization , but the growth inhibition was alleviated by the addition of LCOTHER and LCOTHER .	0
This study was designed to evaluate the effects of LCOTHER and explore the underlying ionic mechanism , using both LCChemicalEntity - induced LCOrganismTaxon and LCOTHER - induced LCOTHER LCOTHER LCOTHER models .	0
The aim of this study was therefore to investigate the influence of mutations in these LCOTHER LCOTHER LCOTHER genes ( LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
Compared to that in the normal control , more severe LCOTHER LCOTHER and hepatocyte apoptosis , worse hepatic LCOTHER peroxidation demonstrated by the increased ASAFR , . LCOTHER and LCOTHER , but decreased LCOTHER and LCGeneOrGeneProduct , increased LCOTHER - LCOTHER / LCOTHER activities and LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCGeneOrGeneProduct expressions , which revealed obvious LCOTHER LCOTHER and scaffold structure broken , were shown in the model control .	0
CONCLUSION : This study showed that SNPs LCOTHER ( P = 0 . 0276 ) , LCOTHER ( P = 0 . 0266 ) , LCSequenceVariant ( P = 0 . 00514 ) , and LCOTHER ( P = 0 . 0089 ) , but not LCOTHER , LCOTHER , or LCOTHER , in LCGeneOrGeneProduct were significantly associated with wet LCOTHER in a mainland Han Chinese population .	0
Administration of parenteral LCOTHER must be done carefully and with good observation because of its pro - LCOTHER effect , especially in older patients who have LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature or patients with LCOTHER LCOTHER ( LCOTHER ) which frequently occurs due to LCOTHER and or LCOTHER in LCOTHER cases . Low frequency of LCOTHER - associated LCGeneOrGeneProduct variants in Kenya and Sudan and novel LCOTHER variants .	0
PURPOSE : The aim of the study was to evaluate the LCOTHER - LCGeneOrGeneProduct system and LCGeneOrGeneProduct LCGeneOrGeneProduct gene polymorphisms in relation to hemodynamic parameters and heart rate variability during a head - up tilt test ( HUT ) in LCOTHER with LCOTHER LCOTHER .	0
Our data suggested that the LCOTHER LCOTHER , but not LCChemicalEntity or LCOTHER , may contribute toward reversal of LCOTHER . Association study of LCOTHER LCOTHER LCOTHER , LCOTHER , LCOTHER , and LCGeneOrGeneProduct and LCOTHER - LCOTHER LCOTHER LCOTHER in a Han Chinese population .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCSequenceVariant variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
The results suggest a novel role for the LCOTHER - LCOTHER axis in vascular EC protection that is critical for improvement of pathological states associated with increased vascular leakage and LCDiseaseOrPhenotypicFeature . Genetic polymorphisms in the LCOTHER LCOTHER LCOTHER gene LCGeneOrGeneProduct and the LCOTHER ( LCOTHER ) LCOTHER : LCOTHER LCOTHER LCOTHER gene LCOTHER in LCOTHER who developed LCOTHER - related LCOTHER LCOTHER LCOTHER after childhood LCOTHER .	0
The metrics from DNA damage and repair study were correlated with the genotypes of common polymorphisms of the LCOTHER and LCOTHER genes : a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER of the LCOTHER gene producing a LCSequenceVariant - - > LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant ( the LCOTHER polymorphism ) and a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( 5 ' - untranslated region ) of the LCGeneOrGeneProduct gene ( the LCOTHER polymorphism ) .	0
This study showed that LCOTHER was more likely to be LCOTHER susceptibility gene at Chr . 1q31 based on the finding that the LCOTHER and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCOTHER in a white population in LCOTHER , LCOTHER , and LCOTHER genes showed a significant association with LCOTHER . Seven novel and six de novo LCGeneOrGeneProduct gene mutations in LCOrganismTaxon with LCOTHER LCOTHER .	0
The genotype frequencies of LCOTHER did not differ significantly from controls ( LCGeneOrGeneProduct / LCOTHER , LCOTHER / LCSequenceVariant : LCOTHER 18 . 3% and 1 . 2% , respectively ; LCOTHER 17 . 5% and 2 . 1% ; LCOTHER 13 . 3% and 1 . 8% ; controls 20 . 0% and 2 . 8% ) .	0
LCDiseaseOrPhenotypicFeature implanted in LCOTHER ( endo - / - ) LCOrganismTaxon but not macrophage - specific LCOTHER - knockout LCOTHER grew faster and showed enhanced vascular permeability and increased angiogenesis as compared with those implanted in wild - type LCOTHER .	0
Knockdowns of LCGeneOrGeneProduct , LCGeneOrGeneProduct , and their common effector LCOTHER had negative effects on each other , inhibited spheroidogenesis , and induced cell death pointing at their essential roles in CSC maintenance .	0
Eighteen children with LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature were identified in the L beck LCDiseaseOrPhenotypicFeature database ( about 1 , 500 entries ) .	0
Hypothesizing that LCOTHER - LCOTHER LCOTHER and / or LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct promote LCOTHER invasion , we found that LCOTHER - LCOTHER LCOTHER promoted LCDiseaseOrPhenotypicFeature migration in a substrate - specific manner , markedly enhancing migration on LCOTHER but not on LCOTHER LCOTHER LCOTHER or LCOTHER .	0
LCOTHER was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCOTHER , LCOTHER ] , by secretagogues activating LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) [ LCOTHER , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCOTHER [ LCChemicalEntity ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	0
CONCLUSION : This study showed that SNPs LCOTHER ( P = 0 . 0276 ) , LCSequenceVariant ( P = 0 . 0266 ) , LCOTHER ( P = 0 . 00514 ) , and LCOTHER ( P = 0 . 0089 ) , but not LCSequenceVariant , LCOTHER , or LCOTHER , in LCOTHER were significantly associated with wet LCOTHER in a mainland Han Chinese population .	0
This study also shows that this assay can help detect EAD for drugs with LCDiseaseOrPhenotypicFeature potential . A novel splicing mutation in LCGeneOrGeneProduct associated with LCOTHER LCOTHER and LCOTHER LCOTHER LCOTHER .	0
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is a common LCOTHER where LCDiseaseOrPhenotypicFeature is directly linked to LCOTHER survival .	0
LCOTHER , an agonist of LCGeneOrGeneProduct , enhances the sensitivity of parental LCOTHER cells , but not LCGeneOrGeneProduct - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	0
Three LCOTHER - LCOTHER LCOTHER with LCGeneOrGeneProduct mutations demonstrated a durable response and one small LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER with LCOTHER LCSequenceVariant mutation showed progression after LCOTHER treatment .	0
Sequencing analysis detected 17 different LCOTHER gene mutations , and 7 of these were identified as novel : 3 missense mutations , including LCOTHER . LCOTHER > LCOTHER ( LCSequenceVariant . LCSequenceVariant ) in exon 3 , LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 3 and LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 7 ; 2 deletion mutations , including LCOTHER . LCOTHER ( LCOTHER . LCOTHER ) in exon 5 and LCSequenceVariant . LCSequenceVariant ( LCOTHER . LCOTHER ) in exon 11 ; and 2 alternative splicing mutations , including LCOTHER . LCOTHER + LCOTHER in intron 4 at splicing donor sites and LCOTHER . LCOTHER - LCOTHER > LCOTHER in intron 13 at splicing acceptor sites .	0
The identification of three independent deletions in introns 9 and 10 suggests that the LCOTHER gene may be susceptible to unequal crossing over because of sequence misalignment during meiosis . The association between LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature after cardiac surgery : a multivariate analysis in 11 529 LCOrganismTaxon .	0
LCOTHER LCOTHER LCOTHER is one of the most common causes of LCOTHER LCOTHER in males , and LCOrganismTaxon with LCOTHER LCOTHER LCOTHER occasionally develop LCDiseaseOrPhenotypicFeature .	0
Our data underscore the major role of LCGeneOrGeneProduct in regulation of hepatic LCOTHER and xenobiotic metabolism in LCOTHER liver and reveal a marked immuno - suppressive / anti - LCOTHER effect of LCOTHER in LCOrganismTaxon liver slices that may be therapeutically relevant for LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER decreases LCOTHER LCOTHER expression in LCOTHER LCOTHER cells .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCGeneOrGeneProduct .	0
The metrics from DNA damage and repair study were correlated with the genotypes of common polymorphisms of the LCOTHER and LCOTHER genes : a LCSequenceVariant - - > LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant of the LCOTHER gene producing a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCOTHER polymorphism ) and a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( 5 ' - untranslated region ) of the LCOTHER gene ( the LCSequenceVariant polymorphism ) .	0
Decreased sensitivity to LCOTHER coincided with the appearance of amino acid substitution LCSequenceVariant in DNA polymerase , whereas cross - resistance to LCOTHER and LCChemicalEntity was due to the LCOTHER substitution .	0
These findings firmly establish that alterations in innate immunity influence the course of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and support the use of targeted strategies to limit or prevent the development of LCOTHER LCOTHER LCOTHER . Anticonvulsant effect of LCOTHER LCOTHER ( LCOTHER LCOTHER - LCOTHER ) on LCOTHER induced by microperfusion of LCOTHER in the hippocampus of freely moving LCOrganismTaxon .	0
These data suggest that LCOTHER produced antiarrhythmic actions on LCOTHER LCOTHER and LCOrganismTaxon LCOrganismTaxon models induced by LCOTHER or LCOTHER via stimulating the cardiac LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct .	0
This study showed that LCOTHER was more likely to be LCOTHER susceptibility gene at Chr . 1q31 based on the finding that the LCGeneOrGeneProduct and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCDiseaseOrPhenotypicFeature in a white population in LCOTHER , LCOTHER , and LCOTHER genes showed a significant association with LCOTHER . Seven novel and six de novo LCOTHER gene mutations in LCOTHER with LCOTHER LCOTHER .	0
These results identify a new mutation in LCGeneOrGeneProduct and expand the spectrum of LCOTHER mutations associated with LCDiseaseOrPhenotypicFeature . Elevation of LCOTHER , LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCOTHER expression with media degeneration features LCOTHER - induced LCOTHER LCOTHER LCOTHER in a LCOTHER model .	0
DNA analysis revealed compound heterozygosity for mutations of LCGeneOrGeneProduct , including a previously reported LCOTHER mutation and a novel duplication of a nucleotide in exon 9 ( LCSequenceVariant ) , the latter resulting in a frameshift and a premature stop codon .	0
We hypothesized that LCGeneOrGeneProduct and / or LCOTHER pathways may be modulated by LCOTHER - LCOTHER , but neither the LCGeneOrGeneProduct - stimulated phosphorylation of LCOTHER / LCOTHER nor the LCOTHER - induced LCOTHER / LCOTHER or LCOTHER LCOTHER LCOTHER - LCOTHER phosphorylation were modified .	0
The homeostasis model assessment of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( LCOTHER > LCOTHER > LCOTHER ) ( LCOTHER vs LCOTHER , t ( 33 ) = 2 . 94 ; P = . 006 ; LCOTHER vs LCChemicalEntity , t ( 33 ) = 2 . 42 ; P = . 02 ) .	0
To elucidate the pathogenic mechanism producing LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature caused by this mutation , we analyzed the binding of wild - type and mutant LCGeneOrGeneProduct paired domain protein to double - stranded DNA targets .	0
The LCGeneOrGeneProduct mutation spectrum , presenting a high level of LCOTHER LCOTHER LCOTHER mutations , shows that the UV component of sunlight is the major risk factor and modulated DNA repair by immunosuppressive drug treatment may be significant in the LCOTHER LCOTHER of RTRs . LCOTHER associated antigen recognition by autologous serum in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
RESULTS : LCOrganismTaxon with a deletion allele had a significantly greater risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature [ adjusted odds ratio ( AOR ) : 3 . 0 ; 95% CI : 1 . 0 , 8 . 8 ; P < 0 . 05 ] than did those without a deletion allele .	0
The goal of this study was to perform LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene ( LCOTHER ) analysis in a LCOTHER LCOTHER ( LCOTHER ) LCOTHER with normal LCOTHER ( LCOTHER ) production and normal LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene coding sequences .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCGeneOrGeneProduct ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
Our findings indicated that LCOTHER might be a very upstream key molecule regulating EMT involved in LCOTHER / LCOTHER - LCOTHER signaling pathway . LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct protects high LCOTHER - induced energy LCOTHER LCOTHER via blocking LCGeneOrGeneProduct - ubiquitin proteasome pathway .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
Silencing of LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) expression in LCOTHER cells had a greater impact on LCOTHER - inducible cytokines than LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , and LCOTHER expression .	0
MAIN OUTCOME MEASURES : Fasting plasma LCOTHER and fasting serum LCOTHER levels , insulin sensitivity index , homeostasis model assessment of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and LCChemicalEntity effectiveness .	0
PURPOSE : We present a case of a LCOTHER who developed LCDiseaseOrPhenotypicFeature shortly after initiating treatment with LCOTHER and to discuss the potential drug - drug interactions related to the inhibition of LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct in this case , as well as in other cases , of LCOTHER - induced LCOTHER .	0
These findings firmly establish that alterations in innate immunity influence the course of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and support the use of targeted strategies to limit or prevent the development of LCOTHER LCOTHER LCOTHER . Anticonvulsant effect of LCOTHER LCOTHER ( LCOTHER LCOTHER - LCOTHER ) on LCOTHER induced by microperfusion of LCChemicalEntity in the hippocampus of freely moving LCOTHER .	0
RESULTS : In a pooled analysis of 1460 LCOTHER and 3817 LCDiseaseOrPhenotypicFeature / LCDiseaseOrPhenotypicFeature , LCOTHER were more frequent in LCOTHER vs LCOTHER / LCOTHER in all treatment groups , but the excess increased from 2 . 8 ( odds ratio ; range , 2 . 3 - 3 . 5 ) in nonantithrombotic users to 5 . 7 ( range , 3 . 4 - 9 . 7 ) in antiplatelet users and 8 . 0 ( range , 3 . 5 - 17 . 8 ) in LCOTHER users ( P difference = 0 . 01 ) .	0
We used wild - type ( WT ) and LCOTHER knockout ( LCOTHER - KO ) LCOrganismTaxon hippocampal cultures , modeled in vitro following exposure to LCChemicalEntity LCOTHER deprivation ( OGD ) , and in vivo neonatal ( P9 - 10 ) LCOTHER model of LCOTHER LCOTHER LCOTHER .	0
IMPORTANCE OF THE FIELD : LCChemicalEntity , in particular LCOTHER - LCOTHER ( LCChemicalEntity - LCChemicalEntity ) , have been the mainstay of treatment for several solid LCOTHER , including LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , for > 40 years .	0
LCDiseaseOrPhenotypicFeature is a rare complication occurring during LCOTHER - LCOTHER ( LCChemicalEntity - LCChemicalEntity ) treatment for LCOTHER .	0
On the pivotal role of LCOTHER in adaptation of the heart to LCDiseaseOrPhenotypicFeature and why fat in the diet increases LCDiseaseOrPhenotypicFeature injury . High - dose LCOTHER LCOTHER is associated with nonischemic clinical LCOTHER in cardiac surgical LCOTHER .	0
Insights could be gained by pooling data on LCOTHER frequency stratified by antithrombotic use in cohorts with LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) / LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
RESULTS : The mean + / - SD duration of treatment with the identified atypical LCChemicalEntity LCChemicalEntity was 68 . 3 + / - 28 . 9 months ( LCOTHER ) , 29 . 5 + / - 17 . 5 months ( LCChemicalEntity ) , and 40 . 9 + / - 33 . 7 ( LCOTHER ) .	0
Our observation of frequent LCOTHER gene abnormalities ( 90% ) and inactivation ( 40 - 60% ) was in striking contrast to the same pathological subtype of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in which LCOTHER gene abnormalities and inactivation were infrequent , suggesting a difference in LCOTHER between LCOTHER and LCOTHER LCOTHER . LCOTHER LCOTHER LCOTHER LCOTHER in LCChemicalEntity users and their neural correlates during a face - learning task .	0
Notably , LCGeneOrGeneProduct - overexpressing B cells maintained elevated LCOTHER signaling despite treatment with LCOTHER , a LCGeneOrGeneProduct ' LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct inhibitor .	0
Furthermore , in vitro and in vivo investigations revealed a unique T cell population , LCGeneOrGeneProduct - LCGeneOrGeneProduct - producing LCOTHER + LCGeneOrGeneProduct + LCOTHER - LCOTHER + LCOTHER + LCOTHER - LCOTHER - Tr1 cells , that was significantly increased without altering the LCOTHER + regulatory T cell population .	0
METHODS : 133 LCOTHER who developed LCOTHER following chemotherapy and / or radiotherapy ( n = 133 ) , 420 LCOrganismTaxon diagnosed with de novo LCOTHER LCOTHER , 242 LCOrganismTaxon diagnosed with LCOTHER LCOTHER LCOTHER , and 1177 healthy controls were genotyped for the LCOTHER - 93 polymorphism by allelic discrimination polymerase chain reaction ( PCR ) and restriction fragment length polymorphism assay .	0
Changes included increases in LCOTHER , LCOTHER , LCOTHER / LCOTHER , and LCOTHER and decreases in LCGeneOrGeneProduct , LCGeneOrGeneProduct , and LCOTHER .	0
LCOTHER - treated LCOrganismTaxon ( 4 microg / 0 . 5 microl / side ) showed a significant decrease in the mentioned parameters as compared to LCChemicalEntity - treated group .	0
The severe phenotype with seriously LCOTHER LCOTHER LCOTHER , LCOTHER behaviour , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER is probably due to the dominant negative effect of the LCOTHER mutant protein and the absence of any functional LCOTHER - LCOTHER . The LCGeneOrGeneProduct LCGeneOrGeneProduct confers protection against diet - induced LCDiseaseOrPhenotypicFeature , LCOTHER , and LCOTHER in female LCOTHER .	0
The data suggest that in LCOTHER ( - / - ) LCOrganismTaxon with LCOTHER LCOTHER , LCOTHER mediators are increased above that observed in WT with LCChemicalEntity .	0
This LCOTHER presented with symptoms of LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , thus demonstrating that LCOTHER - like symptoms can occur after combined LCChemicalEntity and LCOTHER treatment .	0
Of these , LCOTHER : LCSequenceVariant > LCSequenceVariant in an intron of the LCOTHER gene ( LCOTHER ) was within a novel putative auxiliary LCOTHER - binding motif , which is enriched in the neighborhood of canonical LCChemicalEntity - responsive elements .	0
The LCOTHER were injected intraperitoneally with LCOTHER ( LCChemicalEntity ) and LCChemicalEntity - LCChemicalEntity ( LCOTHER - LCOTHER ) .	0
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCDiseaseOrPhenotypicFeature cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCChemicalEntity - LCChemicalEntity and LCOTHER , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	0
Based on recent papers describing the prognostic roles of the polymorphisms and the LCGeneOrGeneProduct functions on LCOTHER development , we sought to determine if Japanese LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER were affected by the LCOTHER - 31 / - 511 and LCOTHER - 670 polymorphisms .	0
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	0
LCOTHER markedly lowered LCOTHER - induced elevation in the levels of LCOTHER mRNA , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) , and LCOTHER LCOTHER ( LCOTHER - LCOTHER ) in the heart tissues .	0
A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous LCChemicalEntity injections produce antiparkinsonian benefit close if not identical to that seen with LCOTHER and that LCOTHER rescue injections can reliably revert off - periods even in LCOrganismTaxon with complex on - off motor swings .	0
The study was designed as case - control study including 891 LCOrganismTaxon with documented LCDiseaseOrPhenotypicFeature and 777 control subjects .	0
Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) LCOTHER doses was not associated with an increased incidence of LCOTHER events relative to nonselective LCOTHER or placebo in LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER in controlled clinical trials . LCGeneOrGeneProduct - LCGeneOrGeneProduct as a biomarker of altered redox metabolism in LCOTHER LCOTHER cells exposed to LCOTHER .	0
Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) LCOTHER doses was not associated with an increased incidence of LCOTHER events relative to nonselective LCChemicalEntity or placebo in LCOTHER and LCOTHER LCOTHER LCOTHER in controlled clinical trials . LCGeneOrGeneProduct - LCGeneOrGeneProduct as a biomarker of altered redox metabolism in LCOTHER LCOTHER cells exposed to LCOTHER .	0
Compared to that in the normal control , more severe LCOTHER LCOTHER and hepatocyte apoptosis , worse hepatic LCOTHER peroxidation demonstrated by the increased ASAFR , . LCOTHER and LCOTHER , but decreased LCOTHER and LCGeneOrGeneProduct , increased LCOTHER - LCOTHER / LCOTHER activities and LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER expressions , which revealed obvious LCOTHER LCOTHER and scaffold structure broken , were shown in the model control .	0
We propose that a cis - acting regulatory polymorphism has arisen close to LCOTHER - LCOTHER in the recessive founder , which decreases LCOTHER susceptibility in heterozygotes and slows disease progression . LCOrganismTaxon LCOTHER inhibit LCDiseaseOrPhenotypicFeature growth in a LCOTHER - LCOTHER LCOTHER LCOTHER - dependent manner by altering the cytokine milieu from LCOTHER - LCOTHER / LCOTHER - LCOTHER to LCOTHER - LCOTHER .	0
This is the first known constitutional rearrangement of LCOTHER , and further systematic genetic analysis and clinical studies of DGAP128 may offer unique insights into the role of LCGeneOrGeneProduct in neurodevelopment . LCChemicalEntity prevented and reversed LCOTHER - induced LCOTHER in the LCOTHER .	0
LCOTHER was not independently associated with body mass index , family history of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER location ( colon versus rectum ) , stage , LCOTHER grade , signet ring cells , CIMP , MSI , LINE - 1 hypomethylation , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , or LCOTHER - LCOTHER .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCGeneOrGeneProduct [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
Our findings reveal a novel role of LCOTHER in regulating meiotic G2 / M transition by acting via the LCGeneOrGeneProduct / LCGeneOrGeneProduct ( LCOTHER ) - LCOTHER LCOTHER pathway . The LCGeneOrGeneProduct LCGeneOrGeneProduct LCOTHER > LCOTHER polymorphism is not associated with LCOTHER LCOTHER LCOTHER .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCGeneOrGeneProduct LCGeneOrGeneProduct ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCGeneOrGeneProduct .	0
It was reported that there was a case of LCOTHER LCOTHER patient with LCDiseaseOrPhenotypicFeature who presented with LCOTHER ( LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) while getting LCOTHER infusion was reported .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
Urinary LCOTHER , LCOTHER and LCChemicalEntity were elevated in LCOTHER - fed WT but not in LCOTHER - fed LCGeneOrGeneProduct KO LCOTHER .	0
CONCLUSIONS LCOTHER - LCOTHER - LCOTHER / LCOTHER SNP , hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCGeneOrGeneProduct - LCGeneOrGeneProduct were associated with LCOTHER in LCOTHER from Inner Mongolia , as was serious LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER prevents LCOTHER LCOTHER accumulation in macrophages induced by the LCOTHER LCOTHER inhibitor LCOTHER .	0
This study aimed at investigating the potential antipsychotic - like properties of LCChemicalEntity , with a particular focus on models of LCOTHER , involving either drug challenge ( ie , LCOTHER and LCOTHER - LCOTHER ) or transgenic LCOrganismTaxon ( ie , LCOTHER LCOTHER ( neo - / - ) and LCOTHER ( - / - ) ) .	0
LCOTHER and LCOTHER mutations may be one explanation for LCDiseaseOrPhenotypicFeature , albeit uncommon . LCOTHER antagonizes LCOTHER - but not LCOTHER - induced LCOTHER LCOTHER in LCOrganismTaxon .	0
These findings show that the LCGeneOrGeneProduct LCGeneOrGeneProduct is required for mammalian development , likely through regulation of LCOTHER , and indicate functional conservation of the LCOTHER LCOTHER from LCOTHER to mammals in vivo . LCOTHER Ameliorates LCOTHER LCOTHER LCOTHER by Inhibiting the LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER Signaling Pathways .	0
Furthermore , in vitro and in vivo investigations revealed a unique T cell population , LCOTHER - LCOTHER - producing LCGeneOrGeneProduct + LCOTHER + LCOTHER - LCOTHER + LCOTHER + LCOTHER - LCGeneOrGeneProduct - Tr1 cells , that was significantly increased without altering the LCOTHER + regulatory T cell population .	0
Maximal contraction to LCOTHER was modestly reduced in arteries from LCOTHER compared with control LCOrganismTaxon whereas the maximum contraction to LCGeneOrGeneProduct - LCGeneOrGeneProduct was significantly reduced ( 54% control ) .	0
Serum concentrations of LCGeneOrGeneProduct , LCOTHER and LCOTHER - LCOTHER as markers of LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct ) were measured .	0
There is currently no known LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature linked to LCOTHER ( LCOTHER ) or its receptor ( LCGeneOrGeneProduct ) in LCOTHER .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
All LCOrganismTaxon were genotyped for LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , intron 2 conversion , LCOTHER ( LCSequenceVariant ) within LCOTHER and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER ( LCOTHER ) within LCOTHER .	0
Our recent study showed that LCOTHER / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCGeneOrGeneProduct , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct .	0
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	0
Eight Alu sequences ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER ) were analyzed in two samples from Navarre and Guipuzcoa provinces ( Basque Country , Spain ) .	0
Taken together , our results demonstrated that LCOTHER is a LCOTHER ( LCOTHER ) - cooperating oncogene required for LCOTHER ( LCSequenceVariant ) - induced immortalization and transformation , and targeting LCOTHER - LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct may , therefore , have therapeutic value for senescence - based LCOTHER treatment . In vivo evidences suggesting the role of oxidative stress in pathogenesis of LCOTHER - induced LCOTHER : protection by LCOTHER .	0
These findings suggest that LCOTHER - LCOTHER LCOTHER enhances LCDiseaseOrPhenotypicFeature migration and that LCOTHER - LCOTHER LCOTHER and LCOTHER - LCOTHER LCOTHER differentially modulate this process . Critical role of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct in mitochondria - mediated LCOTHER - LCOTHER LCOTHER LCOTHER .	0
METHODS : DNA samples from 405 LCOTHER LCOTHER , 97 LCOTHER LCOrganismTaxon , 113 LCDiseaseOrPhenotypicFeature LCOTHER , and 431 healthy controls were genotyped for the LCOTHER LCOTHER LCOTHER .	0
RESULTS : LCDiseaseOrPhenotypicFeature was present in 49% of 83 boys ( n = 41 ) treated with LCChemicalEntity for a mean of 2 . 9 years .	0
Our data underscore the major role of LCGeneOrGeneProduct in regulation of hepatic LCOTHER and xenobiotic metabolism in LCOTHER liver and reveal a marked immuno - suppressive / anti - LCOTHER effect of LCOTHER in LCOTHER liver slices that may be therapeutically relevant for LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER . LCChemicalEntity decreases LCOTHER LCOTHER expression in LCOTHER LCOTHER cells .	0
Sequencing of the LCOTHER gene , three intragenic mutations including a novel heterozygous splicing - site mutations LCOTHER . LCOTHER - LCOTHER > LCOTHER ( LCSequenceVariant . LCSequenceVariant ) were identified in the LCOrganismTaxon of the LCOTHER group .	0
This study showed that LCOTHER was more likely to be LCDiseaseOrPhenotypicFeature susceptibility gene at Chr . 1q31 based on the finding that the LCGeneOrGeneProduct and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCOTHER in a white population in LCOTHER , LCOTHER , and LCOTHER genes showed a significant association with LCOTHER . Seven novel and six de novo LCOTHER gene mutations in LCOTHER with LCOTHER LCOTHER .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCGeneOrGeneProduct , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCGeneOrGeneProduct ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
No significant effect of the LCSequenceVariant LCSequenceVariant on disease severity was demonstrated . LCOTHER causes LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER : involvement of LCOTHER LCOTHER LCOTHER LCOTHER and oxidative stress , and prevention by LCOTHER .	0
A total of 10 novel variants was recognized , among them four variants in the adjacent 5 ' - region of the LCOTHER coding exon 2 ( LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER ) , a 6 base - pair deletion ( LCOTHER . LCOTHER [ LCOTHER . LCOTHER ] ) , a variant leading to a stop codon ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , synonymous variants ( LCSequenceVariant . LCSequenceVariant > LCSequenceVariant [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , and one non - synonymous variant ( LCOTHER . LCOTHER > LCOTHER [ LCSequenceVariant . LCSequenceVariant ] ) .	0
In some families LCOTHER LCOTHER LCOTHER also forms a component of the complex and as such has been described as LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	0
LCOTHER ( + ) T cells that produce LCGeneOrGeneProduct - LCGeneOrGeneProduct are the source of host - protective LCGeneOrGeneProduct - LCGeneOrGeneProduct during primary LCOTHER with a number of different pathogens , including Plasmodium spp .	0
Four binary comparisons were made : WT control versus LCOTHER treatment ( 48 h ) , LCOTHER ( - / - ) control versus LCChemicalEntity treatment ( 48 h ) , WT control versus LCOTHER ( - / - ) control , and WT with LCOTHER treatment ( 48 h ) versus LCOTHER ( - / - ) with LCChemicalEntity treatment ( 48 h ) .	0
The LCOTHER LCOTHER - suppressor gene was mutated in all LCOTHER with documented LCOTHER mutation , suggesting that the pathways regulated by these two LCOTHER - suppressor proteins often cooperate in the development of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with serous differentiation . Drug - induced LCOTHER LCOTHER LCOTHER in injection drug users receiving LCOTHER : high frequency in hospitalized LCOrganismTaxon and risk factors .	0
Although LCDiseaseOrPhenotypicFeature affects African Americans disproportionately compared to European Americans , there has been no comprehensive analysis of the LCOTHER region in relationship to LCDiseaseOrPhenotypicFeature in African Americans .	0
We originally described a LCSequenceVariant - - > LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant ( LCSequenceVariant ) of exon 8 , in the ubiquitin protein - binding domain of LCOTHER / LCOTHER gene in an Italian LCOTHER LCOTHER .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
LCOTHER did reduce minor intraoperative movement but had no LCChemicalEntity - sparing effect and increased LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature and LCOTHER .	0
This retrospective study examines the incidence and treatment of LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) in OLTX LCOTHER .	0
The remaining four mutations [ LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER ) , LCOTHER . LCOTHER + LCOTHER , LCSequenceVariant . LCSequenceVariant and LCOTHER + LCOTHER > LCOTHER ] were novel .	0
Conversion of LCGeneOrGeneProduct to LCGeneOrGeneProduct plays an essential role in hemostasis and results in stabilization of the LCOTHER clot .	0
METHODS : To begin to determine whether mutations in LCOTHER genes might play a role in LCOrganismTaxon LCDiseaseOrPhenotypicFeature , we genotyped all four LCOTHER genes in 76 LCOTHER with radiologically proven primary LCOTHER by polymerase chain reaction ( PCR ) amplification and sequencing of all their exons plus 50 to 150 bp of flanking intronic sequences .	0
The LCOTHER contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site and the LCOTHER subunit contains a highly conserved LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct phosphorylation site which make them strong candidates for future mutation detection studies in LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER . The LCOTHER mutation database : an online database of LCOTHER LCOTHER mutations involved in the LCOTHER ( LCDiseaseOrPhenotypicFeature ) LCOTHER LCOTHER and congenital LCOTHER LCOTHER .	0
CONCLUSION : The results indicate a dose - response relationship between LCOTHER and the risk of LCOTHER LCOTHER , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Mutation analysis of LCOTHER in LCOrganismTaxon with LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) in combination with LCOTHER LCOTHER .	0
We investigated whether the LCOTHER LCOTHER is associated with disease susceptibility in a population of LCOTHER with LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) ; and whether it is associated with disease severity .	0
In contrast , in LCOrganismTaxon LCOTHER gonadotrophs , others have shown a stimulatory effect of LCOTHER on basal or LCGeneOrGeneProduct - stimulated LCOTHER promoter - driven transcription .	0
CONCLUSIONS : The functional LCOTHER LCSequenceVariant polymorphism may have an impact on the risk of LCOTHER - related LCOTHER among childhood LCOTHER survivors by modulating the intracardiac formation of LCDiseaseOrPhenotypicFeature LCOTHER LCOTHER metabolites .	0
There are differential effects of age , gender and smoking status on the association of the LCOTHER - LCOTHER polymorphism with LCDiseaseOrPhenotypicFeature ; the LCOTHER - LCOTHER polymorphism is significantly associated with LCDiseaseOrPhenotypicFeature in subjects over 60years old , in females and in nonsmokers .	0
One week later , they received repeatedly vehicles ( saline , LCOTHER , saline + LCOTHER ) , LCOTHER ( 2 microg / 0 . 5 microl saline / side ; 30 min before training ) , LCOTHER ( 2 , 4 and 8 microg / 0 . 5 microl LCOTHER / side ; 20 min before training ) and LCOTHER ( 2 microg / 0 . 5 microl ; 30 min before LCChemicalEntity injection ) + LCOTHER ( 4 microg / 0 . 5 microl LCChemicalEntity ) through cannulae each day .	0
LCOTHER LCOTHER significantly compensated deficits in the antioxidant defense mechanisms ( reduced LCOTHER level and LCGeneOrGeneProduct LCGeneOrGeneProduct activity ) , suppressed LCOTHER peroxidation , decreased the elevations of LCOTHER LCOTHER LCOTHER - LCOTHER , LCOTHER LCOTHER and LCChemicalEntity ion concentration , and attenuated the reductions of LCOTHER and LCOTHER ions in renal tissue resulted from LCOTHER administration .	0
Genotypes and allelic frequencies of LCGeneOrGeneProduct between the healthy controls and LCOrganismTaxon with LCOTHER were compared .	0
We will discuss the history of LCOTHER gene therapy with specific reference to these and other issues that pre - occupy the field at present : namely , the question of what vectors appear to be suitable for airway gene delivery in LCOTHER , what cells must be targeted , how airway epithelium defences can be overcome or eluded to allow efficient gene delivery , how to ensure safe and long - term transgene expression and the need to identify relevant surrogate success measures that can be used to assess the outcome of gene therapy in LCDiseaseOrPhenotypicFeature LCOTHER . LCChemicalEntity related LCOTHER - LCOTHER LCOTHER in an adolescent LCOTHER .	0
Although uncommon , point mutations in the LCOTHER gene may be a cause of LCOTHER and LCOTHER LCOTHER in Japanese LCOrganismTaxon . Homozygously deleted gene LCOTHER regulates LCOTHER - initiating activity of LCDiseaseOrPhenotypicFeature cells .	0
Collectively , these results suggest that the administration of LCOTHER could be a novel therapeutic strategy in treating LCOTHER LCOTHER . LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct and LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct differentially affect the migration and invasion of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER cells .	0
CONCLUSIONS : Clinicians are exhorted to pay close attention when initiating LCOTHER therapy in LCOTHER taking medications with epileptogenic properties that are LCGeneOrGeneProduct substrates . LCOTHER LCOTHER ( or LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) secondary to LCOTHER .	0
In conclusion , our data suggest that LCOTHER may influence in epileptogenesis and promote anticonvulsant actions in LCOTHER model by modulating the LCChemicalEntity and LCOTHER contents and of LCOTHER activity in seized LCOrganismTaxon hippocampus .	0
Here we describe the characterization of the LCOTHER ( + LCOTHER LCOTHER - > LCOTHER ) polymorphism of the LCOTHER - LCOTHER gene associated in LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOrganismTaxon with high LCOTHER in erythroid precursor cells . LCChemicalEntity consumption and LCOTHER LCOTHER incidence and progression : A Mendelian randomisation study .	0
OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of LCChemicalEntity and LCOTHER in LCOrganismTaxon with LCOTHER LCOTHER ( LCOTHER ) .	0
These results suggested that resident hepatic macrophages induced LCOTHER LCOTHER formation by induction of LCGeneOrGeneProduct - LCGeneOrGeneProduct through LCOTHER signaling . LCChemicalEntity induces primary loss of LCOTHER in LCOTHER hearts : correlation with LCOTHER LCOTHER .	0
LCOTHER / LCGeneOrGeneProduct is a novel disease gene , causing LCOTHER - LCOTHER , early onset , severe LCOTHER LCOTHER . cDNA sequence and chromosomal localization of the remaining three LCOrganismTaxon LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER : the LCOTHER LCOTHER fraction is completed .	0
CONCLUSIONS : The present study demonstrates a sex - differential effect of LCOTHER on IMT , plaque index and LCOTHER , which highlights its influence on various aspects of LCOTHER . Reduced LCGeneOrGeneProduct expression after high - fat diet is associated with selective up - regulation of LCGeneOrGeneProduct and further LCOTHER LCOTHER LCOTHER signaling in adipose tissue .	0
METHODS : LCOrganismTaxon peripheral blood mononuclear cells ( PBMCs ) were isolated from a Taiwanese LCOTHER family bearing the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in the LCOTHER gene , corresponding to a LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) in the LCGeneOrGeneProduct - LCGeneOrGeneProduct protein .	0
Moreover , our study suggests that the distribution of mutations in the LCOTHER gene in Japanese LCDiseaseOrPhenotypicFeature LCOTHER potentially differs from that in other populations . Autosomal dominant mutation in the signal peptide of LCOTHER in a kindred with LCOTHER , LCDiseaseOrPhenotypicFeature , and LCOTHER .	0
No adverse effects of LCOTHER LCOTHER were observed in the behavioral / EEG patterns studied , including sleep / wakefulness cycle , at the doses studied . Hypomorphic mutations in LCOTHER ( LCGeneOrGeneProduct / LCOTHER ) cause LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	0
In this study , we generated endothelial cell - specific LCGeneOrGeneProduct - knockout ( LCOTHER ( endo - / - ) ) LCOrganismTaxon by crossbreeding LCOTHER LCOTHER - LCOTHER - Cre LCOTHER with LCOTHER ( flox / flox ) LCOTHER .	0
PURPOSE : This study was designed to establish a LCOTHER model of LCOTHER LCOTHER LCOTHER ( LCOTHER ) by LCOTHER LCOTHER ( LCOTHER ( LCOTHER ) ) - induced LCOTHER LCOTHER and to explore the potential role of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER LCOTHER ( LCOTHER ) and their endogenous inhibitors ( TIMPs ) in LCDiseaseOrPhenotypicFeature formation .	0
Depletion of LCOTHER was sufficient to confer an aggressive invasive phenotype on minimally invasive LCCellLine and LCCellLine - LCCellLine cell lines .	0
In the present study , we found that a very low concentration of LCOTHER , an LCGeneOrGeneProduct inhibitor , potentiated the antitumor activity of LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) in a LCOTHER LCOTHER LCOTHER cell model using LCCellLine - LCCellLine , LCOTHER , and LCOTHER cells via the inhibition of colony formation ability or cellular viability .	0
RESULTS : Multivariate analyses adjusted for sex and primary disease recurrence were used to test for associations between the candidate genetic polymorphisms ( LCGeneOrGeneProduct * 2 and LCOTHER LCSequenceVariant ) and the risk of LCOTHER .	0
Serum concentrations of LCOTHER , LCOTHER and LCOTHER - LCOTHER as markers of LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER - LCOTHER ) were measured .	0
There have been concerns that the risk of cardiovascular LCDiseaseOrPhenotypicFeature events may be higher with LCOTHER ( LCOTHER ) - LCOTHER - specific inhibitors than nonselective LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCOTHER ) .	0
SNPs within LCOTHER associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature mortality were LCOTHER ( fixed effects hazard ratio , HRfixed = 0 . 78 ; 95% confidence interval ( 95%CI ) : 0 . 66 , 0 . 91 ; p values = 0 . 002 ) ; LCOTHER , HRfixed = 0 . 76 ; 95%CI : 0 . 64 , 0 . 91 ; p values = 0 . 003 ) ; and LCSequenceVariant ( HRfixed = 0 . 76 ; 95%CI : 0 . 64 , 0 . 91 ; p values = 0 . 002 ) .	0
In this study , utilizing LCOTHER - LCOTHER - yellow fluorescent protein ( YFP ) and LCOTHER - LCOTHER - GFP dual reporter LCOrganismTaxon , we show that primary LCOTHER LCOTHER - induced LCOTHER ( + ) YFP ( + ) GFP ( + ) T cells have limited memory potential , do not stably express LCOTHER - LCOTHER , and are disproportionately lost from the Ag - experienced LCGeneOrGeneProduct ( + ) T cell memory population during the maintenance phase postinfection .	0
Compared with the model group , LCOTHER and LCOTHER , LCOTHER - LCOTHER significantly improved serum LCOTHER / LCGeneOrGeneProduct , attenuated LCOTHER LCOTHER and improved peroxidative LCOTHER LCOTHER LCOTHER , decreased LCOTHER - LCOTHER / LCOTHER activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER .	0
Our results thus indicates that LCGeneOrGeneProduct LCOTHER homozygosity is associated with increased mortality in LCOrganismTaxon in the second half of life and that this increased mortality is possibly related to LCOTHER severity and survival after LCOTHER rather than susceptibility to development of LCOTHER . The antiarrhythmic effect and possible ionic mechanisms of LCOTHER on animal models .	0
In conclusion , HFD - induced LCOTHER LCOTHER are highly sensitized to LCOTHER - induced LCOTHER by substantially downregulating cardiac mitochondrial LCChemicalEntity generation , increasing oxidative stress and downregulating the LCOTHER / LCOTHER pathway . Risks and benefits of LCChemicalEntity - LCChemicalEntity LCChemicalEntity vs non - selective LCOTHER : does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study .	0
Therefore , our result suggest that the LCOTHER polymorphism of the LCGeneOrGeneProduct gene may be linked with LCOTHER LCOTHER by the modulation of the cellular response to oxidative stress and this polymorphism may be a useful additional marker in this disease along with the genetic or / and environmental indicators of oxidative stress . LCChemicalEntity + dependence of the LCOTHER + - selective LCOTHER channel .	0
We report cytogenetic and molecular studies of a de novo , apparently balanced t ( 1 ; 3 ) ( q32 . 1 ; q25 . 1 ) identified in a 12 - year - old female ( designated DGAP128 ) with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCDiseaseOrPhenotypicFeature LCOTHER , and LCOTHER LCOTHER .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCGeneOrGeneProduct .	0
The expression of LCGeneOrGeneProduct in LCOTHER LCOTHER was investigated by immunohistochemistry in 100 of 113 LCOrganismTaxon .	0
Our data suggest that dysregulated expression of LCOTHER and LCGeneOrGeneProduct genes is associated with an array of LCOTHER LCOTHER LCOTHER LCOTHER similar to the short ear LCOrganismTaxon and LCOTHER . The activation of spinal LCOTHER - LCOTHER - LCOTHER - LCOTHER LCOTHER may contribute to degeneration of spinal motor neurons induced by neuraxial LCOTHER after a noninjurious interval of LCOTHER LCOTHER LCOTHER .	0
Also , it records a novel deletion in exon 1 of LCOTHER gene in a LCOTHER with severe LCDiseaseOrPhenotypicFeature . People aged over 75 in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature on LCOTHER : the rate of major LCOTHER and LCOTHER in more than 500 LCOTHER - years of follow - up .	0
LCOTHER biomarkers in serum ( hs - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOrganismTaxon with healthy pregnancies .	0
Three LCOTHER were heterozygous for LCSequenceVariant , LCSequenceVariant , and LCOTHER substitutions .	0
LCOTHER LCOTHER ( LCOTHER LCOTHER - LCOTHER , LCOTHER - ( - ) - LCOTHER - LCOTHER - LCOTHER , LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER , LCOTHER / LCOTHER - LCOTHER - LCOTHER ) is a novel LCChemicalEntity LCChemicalEntity , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs LCChemicalEntity ( LCOTHER ) and LCOTHER ( LCOTHER ) .	0
The severe phenotype with seriously LCOTHER LCOTHER LCOTHER , LCOTHER behaviour , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER is probably due to the dominant negative effect of the LCOTHER mutant protein and the absence of any functional LCGeneOrGeneProduct - LCGeneOrGeneProduct . The LCOTHER LCOTHER confers protection against diet - induced LCOTHER , LCDiseaseOrPhenotypicFeature , and LCOTHER in female LCOTHER .	0
Also , it records a novel deletion in exon 1 of LCOTHER gene in a LCOrganismTaxon with severe LCOTHER . People aged over 75 in LCOTHER LCOTHER on LCOTHER : the rate of major LCDiseaseOrPhenotypicFeature and LCOTHER in more than 500 LCOTHER - years of follow - up .	0
We found that the LCSequenceVariant mutation neither significantly affected the affinity of the receptor for LCOTHER nor modified heterodimer formation with LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) when bound to DNA .	0
Independent predictors of postoperative LCDiseaseOrPhenotypicFeature included age , female sex , redo cardiac surgery , LCOTHER LCOTHER LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , deep LCOTHER circulatory arrest , duration of aortic cross - clamp and LCOTHER LCOTHER .	0
Also , it records a novel deletion in exon 1 of LCOTHER gene in a LCOrganismTaxon with severe LCOTHER . People aged over 75 in LCOTHER LCOTHER on LCChemicalEntity : the rate of major LCOTHER and LCOTHER in more than 500 LCOTHER - years of follow - up .	0
In the present study , we confirmed the role of LCGeneOrGeneProduct in the prognosis of LCOTHER LCOTHER and provide molecular evidence of LCOTHER promoted EMT in LCOTHER cell line LCCellLine .	0
These results reveal that uterine expression of the LCGeneOrGeneProduct is essential for embryo implantation and further define the components of the LCOTHER signaling pathway necessary for effective implantation . LCGeneOrGeneProduct promotes invasion , aggregation and survival of LCOTHER LCOTHER cells ; association with disease progression .	0
CONCLUSION : LCGeneOrGeneProduct may play an important role in the pathophysiology of LCOTHER - induced LCOTHER in the Japanese population . LCOTHER LCOTHER dose in LCOTHER LCOTHER - LCOTHER adults is not associated with LCGeneOrGeneProduct - LCGeneOrGeneProduct gene polymorphisms .	0
As LCChemicalEntity LCChemicalEntity is the only modifiable factor , its administration , particularly in doses exceeding 80 mg . kg ( - 1 ) , should be weighed against the risk of postoperative LCOTHER . A LCGeneOrGeneProduct ligand attenuates LCOTHER LCOTHER after LCOTHER LCOTHER .	0
This study showed that LCOTHER was more likely to be LCOTHER susceptibility gene at Chr . 1q31 based on the finding that the LCOTHER and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCDiseaseOrPhenotypicFeature in a white population in LCOTHER , LCOTHER , and LCOTHER genes showed a significant association with LCOTHER . Seven novel and six de novo LCOTHER gene mutations in LCOrganismTaxon with LCOTHER LCOTHER .	0
Cilium formation , maintenance and function depend on intracellular transport systems such as intraflagellar transport ( IFT ) , which is driven by LCGeneOrGeneProduct - LCGeneOrGeneProduct and IFT - LCOTHER motors and regulated by the LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER - LCOTHER LCOTHER LCOTHER , or LCGeneOrGeneProduct .	0
In addition , the disrupted prepulse inhibition induced by LCOTHER - LCOTHER or LCChemicalEntity was restored by LCOTHER - LCOTHER LCOTHER LCOTHER in an animal study using LCOrganismTaxon .	0
Recent studies indicate that genetic ablation of LCOrganismTaxon LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct gene , which encodes a 47 kD urothelial - specific integral membrane protein forming urothelial plaques , causes LCOTHER and LCOTHER .	0
Thus , LCOTHER reduced LCOTHER burden through associated cytostatic and anti - angiogenic effects . This dual effect of LCChemicalEntity on LCOTHER tissue could contribute to its recently reported efficiency in refractory LCOTHER resistant to conventional chemotherapy . Rapid reversal of anticoagulation reduces LCOTHER volume in a LCOTHER model of LCOTHER - associated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Sequencing analysis detected 17 different LCOTHER gene mutations , and 7 of these were identified as novel : 3 missense mutations , including LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 3 , LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 3 and LCOTHER . LCOTHER > LCOTHER ( LCSequenceVariant . LCSequenceVariant ) in exon 7 ; 2 deletion mutations , including LCOTHER . LCOTHER ( LCOTHER . LCOTHER ) in exon 5 and LCSequenceVariant . LCSequenceVariant ( LCOTHER . LCOTHER ) in exon 11 ; and 2 alternative splicing mutations , including LCOTHER . LCOTHER + LCOTHER in intron 4 at splicing donor sites and LCOTHER . LCOTHER - LCOTHER > LCOTHER in intron 13 at splicing acceptor sites .	0
Our recent study showed that LCOTHER / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCGeneOrGeneProduct , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCOTHER and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER .	0
We propose here a possible pathological tie between chronic tubulointerstitial LCOTHER and progressive LCOTHER LCOTHER . LCDiseaseOrPhenotypicFeature potential of LCOTHER and LCChemicalEntity in LCOTHER .	0
CONTEXT : LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) is a rare LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , characterized by LCOTHER and LCOTHER / LCDiseaseOrPhenotypicFeature with increased serum LCOTHER , LCOTHER - LCOTHER LCOTHER [ LCOTHER , LCOTHER - ( LCOTHER ) ( LCOTHER ) LCOTHER ] resulting in LCOTHER .	0
Discontinuations from renovascular AEs , although less common than discontinuations from LCOTHER LCOTHER , were significantly higher with LCOTHER . Putative LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature Risk SNP in an LCOTHER LCOTHER - Binding Site of the LCOTHER Gene Illustrates Enrichment of Risk SNPs in LCGeneOrGeneProduct LCGeneOrGeneProduct Target Sites .	0
Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental LCDiseaseOrPhenotypicFeature . Exaggerated expression of LCOTHER mediators in LCOTHER LCOTHER LCOTHER knockout ( LCOTHER - / - ) LCOTHER with LCOTHER ( LCOTHER ) - induced LCDiseaseOrPhenotypicFeature .	0
Three LCOTHER LCOTHER - LCSequenceVariant , LCSequenceVariant , and LCOTHER - accounted for 51% , 20% , and 11% of the identified mutations , respectively . Allelic expression imbalance of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) caused by variant LCOTHER .	0
In the present study , we found that a very low concentration of LCOTHER , an LCGeneOrGeneProduct inhibitor , potentiated the antitumor activity of LCChemicalEntity - LCChemicalEntity ( LCOTHER - LCOTHER ) in a LCOTHER LCOTHER LCOTHER cell model using LCOTHER - LCOTHER , LCOTHER , and LCOTHER cells via the inhibition of colony formation ability or cellular viability .	0
METHODS : DNA samples from 405 LCOTHER LCOTHER , 97 LCOTHER LCOTHER , 113 LCDiseaseOrPhenotypicFeature LCOrganismTaxon , and 431 healthy controls were genotyped for the LCOTHER LCOTHER LCOTHER .	0
Meanwhile apoptosis related proteins LCOTHER and LCOTHER were involved in LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature LCOTHER model , but not LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER or LCOTHER . LCOTHER and LCOTHER are closely relevant in the tissue splices of deminopathies LCOTHER and LCOTHER with LCOTHER at protein lever .	0
We propose that a cis - acting regulatory polymorphism has arisen close to LCSequenceVariant - LCOTHER in the recessive founder , which decreases LCOTHER susceptibility in heterozygotes and slows disease progression . LCOTHER LCOTHER inhibit LCOTHER growth in a LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - dependent manner by altering the cytokine milieu from LCOTHER - LCOTHER / LCOTHER - LCOTHER to LCOTHER - LCOTHER .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCGeneOrGeneProduct signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
These findings firmly establish that alterations in innate immunity influence the course of LCOTHER LCOTHER and support the use of targeted strategies to limit or prevent the development of LCOTHER LCOTHER LCOTHER . Anticonvulsant effect of LCOTHER LCOTHER ( LCChemicalEntity LCChemicalEntity - LCChemicalEntity ) on LCDiseaseOrPhenotypicFeature induced by microperfusion of LCOTHER in the hippocampus of freely moving LCOTHER .	0
Moreover , we confirm previous results that a short LCOTHER LCOTHER in conjunction with GG genotype significantly increases the risk of LCOTHER LCOTHER . A homozygous mutation in LCOTHER / LCOTHER associated with early onset LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature activity .	0
These findings suggested that LCOTHER - LCOTHER possesses LCDiseaseOrPhenotypicFeature - suppressing activity and can be a valuable target for developing new LCOTHER therapeutic strategies . Chronic treatment with LCOTHER suppresses LCOTHER - LCOTHER LCOTHER LCOTHER signaling and attenuates LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature following LCOTHER LCOTHER .	0
The liver levels of beta - oxidation metabolites of LCChemicalEntity were decreased by day 14 , while the levels of LCChemicalEntity - LCChemicalEntity - LCChemicalEntity and ( E ) - LCOTHER , LCOTHER - LCOTHER - LCOTHER were not elevated throughout the study .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
These findings reveal the differential impact of immune escape variants on the replication and drug susceptibility of complex LCOrganismTaxon mutants , supporting the need of close surveillance and treatment adjustment in response to the selection of distinct mutational patterns . Bilateral LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER after LCChemicalEntity and LCOTHER intoxication .	0
Also , histopathological LCOTHER LCOTHER LCOTHER mediated by LCChemicalEntity was ameliorated by LCChemicalEntity LCChemicalEntity treatment .	0
The LCOrganismTaxon showed an LCSequenceVariant mutation that has been described in an Asian population and LCOTHER LCOTHER , along with a novel frameshift mutation , LCOTHER .	0
RESULTS AND DISCUSSION : LCOTHER - LCOTHER LCOTHER and LCOTHER cells release a network of cytokines , including newly identified LCOrganismTaxon - inducible cytokines LCOTHER , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) .	0
The Serum liver function parameters including LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) and LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) levels were assayed with the commercial kit .	0
CONCLUSION : Our findings suggest that the genetic variants of the LCOTHER - LCOTHER but not the LCOTHER - LCOTHER gene contribute to LCDiseaseOrPhenotypicFeature susceptibility in this African - American population . Identification of a gain - of - function mutation of the LCOTHER LCOTHER in LCOrganismTaxon with LCOTHER LCOTHER LCOTHER .	0
This shift in balance may contribute to increased LCOTHER LCOTHER in LCGeneOrGeneProduct ( - / - ) LCOTHER with LCOTHER LCOTHER and altered neurochemical expression in micturition pathways . LCDiseaseOrPhenotypicFeature associated with LCOTHER : case presentation and literature review .	0
Three LCOTHER LCOTHER - LCSequenceVariant , LCOTHER , and LCOTHER - accounted for 51% , 20% , and 11% of the identified mutations , respectively . Allelic expression imbalance of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) caused by variant LCSequenceVariant .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCGeneOrGeneProduct - specific LCOTHER .	0
These observations suggest that LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCSequenceVariant are associated with disease progression . On the pivotal role of LCOTHER in adaptation of the heart to LCDiseaseOrPhenotypicFeature and why fat in the diet increases LCOTHER injury .	0
This is the first known constitutional rearrangement of LCOTHER , and further systematic genetic analysis and clinical studies of DGAP128 may offer unique insights into the role of LCOTHER in neurodevelopment . LCChemicalEntity prevented and reversed LCChemicalEntity - induced LCOTHER in the LCOTHER .	0
The loss of LCOTHER results in both the failure for LCGeneOrGeneProduct to translocate to the LE nuclei and a reduction in the expression of the LCOTHER regulated gene LCGeneOrGeneProduct that regulates uterine receptivity .	0
Silencing LCOTHER suppresses LCOTHER , changes cell cycle regulation and subsequently suppresses terminal senescence ; LCGeneOrGeneProduct - silencing did not affect LCGeneOrGeneProduct expression or cellular phenotype .	0
Thus , LCOTHER reduced LCOTHER burden through associated cytostatic and anti - angiogenic effects . This dual effect of LCOTHER on LCOTHER tissue could contribute to its recently reported efficiency in refractory LCOTHER resistant to conventional chemotherapy . Rapid reversal of anticoagulation reduces LCDiseaseOrPhenotypicFeature volume in a LCOrganismTaxon model of LCOTHER - associated LCOTHER LCOTHER .	0
We hypothesized that mutations in acetylcholine receptor - related genes might also result in a LCOTHER / LCOTHER LCOTHER phenotype and so we analyzed 15 cases of lethal LCOTHER / LCOTHER LCOTHER without LCOTHER mutations for mutations in the LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER ( LCGeneOrGeneProduct ) genes .	0
Of note , injection of anti - LCGeneOrGeneProduct - LCGeneOrGeneProduct antibody in LCOTHER - bearing C3H / HeN LCOTHER in the absence of LCOTHER LCOTHER markedly suppressed LCOTHER growth and augmented LCGeneOrGeneProduct - LCGeneOrGeneProduct responses .	0
The LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) LCGeneOrGeneProduct is therapeutically targeted by several second generation LCOTHER , such as LCOTHER and LCOTHER , and LCOTHER - LCOTHER - induced LCOTHER in LCOrganismTaxon is corrected with the use of a selective LCOTHER - LCOTHER LCOTHER LCOTHER .	0
LCOTHER was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCOTHER , LCGeneOrGeneProduct ] , by secretagogues activating LCOTHER - LCOTHER ( LCOTHER ) [ LCOTHER , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCOTHER [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCChemicalEntity LCChemicalEntity .	0
However , we did not find significant association of this polymorphism with LCOTHER . LCOTHER induces LCOTHER activation in LCDiseaseOrPhenotypicFeature microenvironment and LCChemicalEntity resistance in LCOTHER LCOTHER .	0
RESULTS : Person - years of exposure among non - users of LCOTHER were : 75 , 761 to LCChemicalEntity , 42 , 671 to LCOTHER 65 , 860 to LCOTHER , and 37 , 495 to NS - LCChemicalEntity .	0
Dysregulated expression of LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is found in the cells of LCOrganismTaxon who have LCOTHER LCOTHER LCOTHER ( LCOTHER ) , a genetic disorder of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER and progressive LCOTHER LCOTHER .	0
LCChemicalEntity administration with LCOTHER injections caused significantly decreased renal LCOTHER and urinary LCOTHER excretion , and increased LCChemicalEntity activity , but not LCOTHER activity in renal tissue when compared with LCOTHER alone .	0
This sole substitution was sufficient to confer constitutive activity to the receptor variant ( LCOTHER ( LCOTHER ) ) , as assessed in three reconstituted cell models ( LCOTHER / LCOTHER , LCCellLine and LCOTHER - LCOTHER cells ) by LCOTHER - independent ( i ) LCGeneOrGeneProduct tyrosine phosphorylation , ( ii ) activation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) signaling , ( iii ) transcriptional activity toward a LCOTHER - responsive reporter gene , and ( iv ) cell proliferation and protection from cell death .	0
Expression of some lineage specific factors is markedly reduced in LCOTHER knockdown embryos , including LCOTHER , LCOTHER and LCGeneOrGeneProduct , while others are inappropriately expressed ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER ) .	0
A unique set of LCOTHER - regulated survival factors included LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER LCOTHER .	0
Inactivating mutations in LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) have been identified as a cause of LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ; LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	0
BACKGROUND : Markers of fibrinolysis , LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) , and LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) levels were studied for the evaluation of short - term effects of LCOTHER administration in postmenopausal LCOTHER .	0
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCGeneOrGeneProduct transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	0
Because polymorphism of LCOTHER , another inhibitory receptor of B cells , was associated with LCOTHER LCOTHER , we identified LCOTHER LCOTHER polymorphisms , tested their association with LCDiseaseOrPhenotypicFeature and examined genetic interaction with LCOTHER in the Japanese ( 160 LCDiseaseOrPhenotypicFeature , 277 controls ) , Thais ( 87 LCOTHER , 187 controls ) and Caucasians ( 94 families containing LCOTHER members ) .	0
Here we report that two members of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , LCGeneOrGeneProduct ( LCGeneOrGeneProduct LCGeneOrGeneProduct ) LCGeneOrGeneProduct ( LCOTHER LCOTHER ) components , LCOTHER and LCGeneOrGeneProduct , are required during mammalian preimplantation development .	0
LCGeneOrGeneProduct and LCOTHER expression was not increased by treatment of LCOTHER cells with LCOTHER and LCOTHER inhibitors , suggesting that LCOTHER regulates LCGeneOrGeneProduct expression independently of LCOTHER and LCOTHER .	0
LCOTHER ( LCOTHER ) is an active ingredient that is isolated from LCOrganismTaxon LCOrganismTaxon , which has been reported to have anti - LCDiseaseOrPhenotypicFeature activities and a renal protective effect .	0
METHODS : Following induction of anesthesia by LCOTHER ( 0 . 15 mg kg ( - 1 ) ) and LCOTHER ( 2 . 0 mg kg ( - 1 ) ) , 13 LCOrganismTaxon received LCOTHER ( 0 . 1 mg iv ) and 12 LCOrganismTaxon received LCOTHER ( 10 mg iv ) to restore mean arterial pressure ( MAP ) .	0
This LCOTHER ( + LCOTHER LCOTHER - > LCOTHER ) polymorphism is associated with the LCOTHER - LCOTHER - XmnI polymorphism and both are linked with the LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct - LCGeneOrGeneProduct gene , but not with the LCGeneOrGeneProduct ( + ) LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct gene .	0
The signal transduction target upon LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) stimulation , the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) activation , supports LCOTHER development , signal transduction in which is mediated by LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) signaling .	0
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCOTHER ( 874 LCOTHER ' LCOTHER LCOTHER , 259 LCOTHER LCOTHER , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCGeneOrGeneProduct , LCGeneOrGeneProduct / LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER .	0
BACKGROUND : The LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) proteins and their genetic variants have been suggested to play a role in regulating LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
To determine the physiologic LCOTHER LCOTHER ( LCOTHER ) - dependent actions of LCOTHER on LCOTHER in female LCOTHER , we generated female LCGeneOrGeneProduct - knockout ( LCOTHER ) LCOTHER on an LCOTHER - prone LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - deficient background .	0
We document a loss of LCGeneOrGeneProduct LCGeneOrGeneProduct LCSequenceVariant LCSequenceVariant trimethylation ( LCOTHER ) in LCOTHER - deficient embryos and confirm that knockdown of either LCOTHER or LCOTHER results in similar phenotypes .	0
The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case , indicating a probable relationship between the LCOrganismTaxon ' s LCDiseaseOrPhenotypicFeature - like adverse symptoms and the combined treatment used in this case .	0
Expression of some lineage specific factors is markedly reduced in LCOTHER knockdown embryos , including LCOTHER , LCOTHER and LCGeneOrGeneProduct , while others are inappropriately expressed ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER ) .	0
A lowered LCChemicalEntity LCChemicalEntity level also was observed in overnight - fasted , LCOTHER - treated LCOTHER LCOTHER - null LCOrganismTaxon that were administered LCOTHER monoclonal antibody .	0
These findings firmly establish that alterations in innate immunity influence the course of LCOTHER LCOTHER and support the use of targeted strategies to limit or prevent the development of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Anticonvulsant effect of LCOTHER LCOTHER ( LCChemicalEntity LCChemicalEntity - LCChemicalEntity ) on LCOTHER induced by microperfusion of LCOTHER in the hippocampus of freely moving LCOTHER .	0
BACKGROUND : A LCOrganismTaxon LCOrganismTaxon LCOrganismTaxon LCOrganismTaxon ( LCOTHER - LCOTHER Tonga / 74 ) isolated from a 1974 epidemic was characterized by mild illness and belongs to the American genotype of LCOrganismTaxon - LCOrganismTaxon viruses .	0
Thus , LCOTHER appears to play a critical oncogenic function in LCOTHER microenvironment and may be a potential target for developing therapeutic and preventive strategies against LCDiseaseOrPhenotypicFeature . Effects of the LCOTHER - LCOTHER specific inhibitor LCOTHER versus LCOTHER LCOTHER LCOTHER and placebo on cardiovascular LCOTHER events in LCOrganismTaxon with LCOTHER .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCGeneOrGeneProduct [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
Functional studies were consistent with the hypothesis that whereas incomplete loss of LCOTHER function may cause LCOTHER LCOTHER , more severe loss of function can result in a lethal LCOTHER LCOTHER phenotype . Comparison of sequential LCOrganismTaxon isolates in a LCOrganismTaxon with LCOTHER and failing antiviral therapy .	0
RESULTS : HAT adipose tissue demonstrated increased LCOTHER related genes for storage ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	0
LCOTHER is likely to be an LCOTHER - susceptibility gene and LCOTHER mutations may increase the risk of developing a LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature rather than being a direct causative mutation . The differential effects of LCOTHER and LCOTHER on LCOTHER LCOTHER release , LCGeneOrGeneProduct gene expression and LCOTHER in a clinical LCOTHER model .	0
CONCLUSION : This study establishes a LCOTHER model by periarterial LCOTHER ( LCOTHER ) exposure in LCOTHER , and demonstrates a significant elevation of expression of LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER and LCOTHER in the pathogenesis of vascular remodeling . Expanding clinical spectrum of LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature due to an activating germline mutation , LCOTHER . LCOTHER , in the LCOTHER LCOTHER gene .	0
Like LCOTHER LCOTHER , the truncated LCOTHER LCOTHER ( LCSequenceVariant - LCSequenceVariant ) , which lacks the C - terminal domain required for LCOTHER ( LCOTHER + ) - calmodulin binding , does not form constitutive active channels , whereas the LCOTHER LCOTHER ( LCSequenceVariant ) , carrying a point mutation in the presumed pore region , does not function as a channel .	0
Fasting serum LCChemicalEntity concentrations differed among groups ( F ( 33 ) = 3 . 35 ; P = . 047 ) ( LCOTHER > LCOTHER > LCOTHER ) with significant differences between LCOTHER and LCOTHER ( t ( 33 ) = 2 . 32 ; P = . 03 ) and LCChemicalEntity and LCOTHER ( t ( 33 ) = 2 . 15 ; P = . 04 ) .	0
RESULTS : LCOrganismTaxon with LCOTHER had higher serum LCOTHER and LCOTHER ( P < 0 . 001 for LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER ) and lower LCOTHER ( P = 0 . 008 ) levels than LCOTHER LCOTHER without LCOTHER .	0
The fact that no truncation or frame shift mutations have been found in any of the LCDiseaseOrPhenotypicFeature LCOTHER , coupled with our recent finding that some breeding pairs of LCOTHER LCOTHER knockout LCOTHER yield litters that show not only LCOTHER , but also severe LCOTHER and LCOTHER LCOTHER , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOrganismTaxon . Midline B3 LCOTHER nerves in LCOTHER medulla are involved in LCOTHER effect of LCOTHER .	0
LCChemicalEntity also increased LCOTHER phosphorylation and decreased LCGeneOrGeneProduct phosphorylation consistent with increased translation elongation .	0
A 74 - year - old LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature was admitted to a LCOTHER hospital due to LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , exhaustion , and LCOTHER .	0
The nephroprotective effect of LCChemicalEntity LCChemicalEntity was investigated in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature induced by a single i . p .	0
Therefore , our results indicate that LCDiseaseOrPhenotypicFeature B cells have already acquired enhanced survival and growth capabilities before transformation , and that elevated LCOTHER levels confer resistance to pharmacologic inhibitors of LCOTHER signaling , which has significant implications for LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature treatment . Genetic investigation of four meiotic genes in LCOTHER with LCOTHER LCOTHER LCOTHER .	0
Both LCOTHER knockout ( LCOTHER ( - / - ) ) LCOrganismTaxon and db / db LCOTHER that were administered LCOTHER monoclonal antibody displayed lower LCChemicalEntity LCChemicalEntity levels accompanied by elevated plasma LCOTHER levels .	0
Oxidative stress was assessed by determining plasma and liver levels of LCOTHER - LCOTHER ( LCOTHER ) - LCOTHER , LCOTHER LCOTHER ( LCOTHER ) , and LCChemicalEntity LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCChemicalEntity ) .	0
Chronic administration of LCOTHER strongly reduced the blood pressure and production of LCChemicalEntity and improved antioxidant capacity in LCOTHER - induced LCDiseaseOrPhenotypicFeature , suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LCOTHER . Role of LCOTHER LCOTHER LCOTHER LCOTHER in LCOTHER and migration of fibroblast - like synoviocytes in LCOTHER LCOTHER .	0
As a species comparison with our previous results , we used LCCellLine cells to investigate the effects of LCOTHER - LCOTHER on LCOTHER mRNA and secretion modulated by LCGeneOrGeneProduct and LCOTHER .	0
In this study , 10 to 25 micromol / L LCOTHER inhibited LCOTHER - LCOTHER and LCCellLine LCOTHER LCOTHER cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCOTHER LCOTHER LCOTHER and the LCOTHER LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
The LCOTHER - LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER - LCOTHER ( LCChemicalEntity ( LCChemicalEntity ) ) / LCOTHER ( LCOTHER + ) / LCOTHER LCOTHER LCOTHER ( LCOTHER ) / LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct pathway regulates LCOTHER growth .	0
The search for LCOTHER - associated polymorphisms ( such as the XmnI , LCOTHER and LCGeneOrGeneProduct polymorphisms ) has recently gained great attention , in order to stratify LCOTHER - LCOTHER LCOTHER with respect to expectancy of the first transfusion , need for annual intake of blood , response to LCGeneOrGeneProduct inducers ( the most studied of which is hydroxyurea ) .	0
LCOTHER was not implicated with LCOTHER / LCOTHER in our LCOTHER cohort . Combination of the LCOTHER LCOTHER inhibitor LCOTHER and LCChemicalEntity - LCChemicalEntity upregulates LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER and LCOTHER genes and activates LCOTHER - LCOTHER / LCOTHER in LCOTHER LCOTHER LCOTHER LCCellLine - LCCellLine cells .	0
CONCLUSIONS LCOTHER - LCOTHER - LCOTHER / LCOTHER SNP , hs - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER / LCOTHER - LCOTHER were associated with LCOTHER in LCOTHER from Inner Mongolia , as was serious LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER . LCChemicalEntity prevents LCOTHER LCOTHER accumulation in macrophages induced by the LCOTHER LCOTHER inhibitor LCOTHER .	0
Following knockdown of LCOTHER , LCCellLine - LCCellLine - LCCellLine cells were stimulated with LCChemicalEntity before evaluating cell growth and LCOTHER LCOTHER - LCOTHER LCOTHER ( LCOTHER ) - LCOTHER / LCOTHER phosphorylation .	0
Serum concentrations of LCOTHER , LCOTHER and LCOTHER - LCOTHER as markers of LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct ) were measured .	0
RESULTS : Nontoxic doses of LCOTHER reduced LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER from LCOTHER and LCOTHER in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCOTHER , LCOTHER LCOTHER , nor the in vitro LCDiseaseOrPhenotypicFeature from LCOTHER .	0
We have shown previously that , in LCOTHER primary pituitary cells , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct inhibits LCOTHER mRNA expression and LCGeneOrGeneProduct release .	0
On the whole , our findings indicate that the absence of LCOTHER plays a cardioprotective role in LCOTHER LCOTHER LCOTHER by promoting changes in LCOTHER / LCOTHER signalling . Long - Lived LCOTHER + LCOTHER - LCOTHER + T Cells rather than Short - Lived LCGeneOrGeneProduct + LCGeneOrGeneProduct - LCGeneOrGeneProduct + LCOTHER - LCOTHER + T Cells Initiate Rapid LCOTHER - LCOTHER Production To Suppress Anamnestic T Cell Responses during Secondary LCOTHER LCOTHER .	0
Our results suggest that SNPs of LCGeneOrGeneProduct and their haplotypes predispose to LCOTHER LCOTHER LCOTHER LCOTHER in female subjects of the STOP - NIDDM study population . Identification of three LCGeneOrGeneProduct gene mutations associated with LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in two Chinese pedigrees .	0
Thus , LCGeneOrGeneProduct appears to play a critical oncogenic function in LCOTHER microenvironment and may be a potential target for developing therapeutic and preventive strategies against LCOTHER . Effects of the LCGeneOrGeneProduct - LCGeneOrGeneProduct specific inhibitor LCOTHER versus LCOTHER LCOTHER LCOTHER and placebo on cardiovascular LCOTHER events in LCOTHER with LCOTHER .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCGeneOrGeneProduct [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
Differences were found for serum FBG , FINS , HOMA - IR , and HOMA - beta , and placental LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER .	0
This study tested the hypothesis that the reduction in WAT mass in chronic LCOTHER - fed LCOrganismTaxon is associated with a decreased protein synthesis specifically related to impaired function of LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
Hence , our results suggest that LCOTHER significantly aggravates LCOTHER ( LCOTHER + ) overload and causes LCOTHER and finally promotes apoptotic development via phosphorylation of LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER . LCChemicalEntity LCChemicalEntity treatment ameliorates acute LCOTHER LCDiseaseOrPhenotypicFeature in LCOTHER .	0
CONCLUSIONS : These results suggest that LCChemicalEntity stimulates LCOTHER - LCOTHER gene expression after LCOTHER LCOTHER , which is associated with higher LCOTHER production and LCOTHER after the local anesthetic effect dissipates . LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER among LCOTHER treated with LCOTHER for LCOTHER LCOTHER in the city of Copenhagen .	0
PURPOSE : This study was designed to establish a LCOrganismTaxon model of LCOTHER LCOTHER LCOTHER ( LCOTHER ) by LCOTHER LCOTHER ( LCOTHER ( LCOTHER ) ) - induced LCOTHER LCOTHER and to explore the potential role of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER ( LCOTHER ) and their endogenous inhibitors ( TIMPs ) in LCDiseaseOrPhenotypicFeature formation .	0
A single dose of LCOTHER LCOTHER ( LCOTHER ) , which is a widely used LCOTHER LCOTHER , is associated with oxidative stress in LCOrganismTaxon , as recently demonstrated by elevated levels of LCOTHER - LCOTHER ( LCOTHER ) - LCOTHER ( LCChemicalEntity - LCChemicalEntity ( LCChemicalEntity ) - LCChemicalEntity ) .	0
It also shows the independent segregation of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER . Regulation of lung endothelial permeability and LCOTHER responses by LCOTHER LCOTHER : role of LCGeneOrGeneProduct LCGeneOrGeneProduct .	0
A derivative of LCOTHER , designated LCOTHER - LCOTHER , was generated by incorporation of a point mutation previously identified in the LCOTHER gene of LCOTHER - LCOTHER and was found to be more attenuated than LCOrganismTaxon in LCOTHER - LCOTHER - LCOTHER LCOrganismTaxon .	0
CONCLUSIONS : As a potential explanation of our findings , we hypothesize that in LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature the LCOTHER - LCOTHER - XmnI / LCGeneOrGeneProduct - LCGeneOrGeneProduct - ( LCOTHER - > LCOTHER ) genotype is frequently under genetic linkage with LCOTHER ( LCOTHER ) - LCOTHER mutations , but not with the LCOTHER ( + ) - LCOTHER mutation here studied ( i . e .	0
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER causes an age - dependent , long - term LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Recently , significantly higher frequencies of heterozygous carriers of the Slavic founder LCOTHER mutation , LCOTHER , were found in Russian children with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and in Polish adults with LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	0
EXPERIMENTAL DESIGN : Because of their widespread use , the LCOTHER LCOTHER following coadministration of LCOTHER and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of LCOrganismTaxon and LCOTHER blood progenitor cells to LCOTHER , LCOTHER , and LCChemicalEntity + / - LCOTHER was determined in granulocyte - macrophage colony forming assays .	0
The novel proteins LCGeneOrGeneProduct and LCOTHER were both reduced , suggesting roles in LCOTHER , whereas LCOTHER - LCOTHER was unchanged . Intronic deletions in the LCOTHER gene cause LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Elevated levels of LCGeneOrGeneProduct and LCOTHER mRNA and protein were detected in the LCOTHER ' s cells while levels of LCGeneOrGeneProduct mRNA were unchanged .	0
LCOTHER LCOTHER can be effectively treated by atypical LCChemicalEntity such as LCOTHER , LCChemicalEntity and LCOTHER .	0
CONCLUSIONS : Gene polymorphism resulting in the substitution of LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant in the LCOTHER recognition domain of LCOTHER - LCOTHER increases susceptibility to LCOTHER LCOTHER , as well as the risk of LCOTHER . Risk factors and predictors of LCChemicalEntity - induced LCOTHER among multiethnic Malaysians with LCOTHER ' LCOTHER LCOTHER .	0
Genomic profiles of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature ) are still insufficiently understood , and the genetic alterations associated with drug responses have not been studied .	0
Here , we show that a single LCSequenceVariant ( LCSequenceVariant ) LCSequenceVariant LCSequenceVariant ( LCSequenceVariant ) LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER ) .	0
Improved cardiac function and less scar formation were observed in LCOTHER KO LCOrganismTaxon , and we also observed the altered expression of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER and LCOTHER - LCOTHER / LCOTHER , as well as LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	0
Combining the two LCOTHER groups revealed further significant benefits from the avoidance of opioids , reducing LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER prior to discharge from 35% and 33% to 22% and 19% ( P = 0 . 049 and P = 0 . 035 ) , respectively , while LCDiseaseOrPhenotypicFeature in the first 24 h was decreased from 42% to 27% ( P = 0 . 034 ) .	0
The LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) enzymes synthesize the LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER ( LCOTHER ) LCOTHER ) , which has been detected at the Golgi complex and endosomal compartments and recruits LCGeneOrGeneProduct adaptors .	0
RESULTS : Family - based TDT showed a significant association of LCOTHER with a LCOTHER polymorphism in the LCOTHER - LCOTHER gene ( LCGeneOrGeneProduct ) ( P = 5 . 74 x 10 ( - 6 ) ) and a LCOTHER polymorphism in the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene ( LCOTHER ) ( P = 9 . 58 x 10 ( - 6 ) ) .	0
BACKGROUND / AIMS : LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) governs the Th1 - type immune response , affecting the spontaneous and treatment - induced recovery from LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature .	0
BACKGROUND : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER LCOTHER LCOTHER [ LCOTHER ] LCOTHER ) results from heterozygous mutations in LCOTHER encoding LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER .	0
LCOTHER has a well - established safety profile and can be given safely to LCOTHER with advanced age , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER improves the LCOTHER LCOTHER caused by the chemotherapy agent LCChemicalEntity - LCChemicalEntity .	0
LCOTHER can be associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER - LCOTHER LCOTHER ) , brainstem and LCOTHER LCOTHER ( LCOTHER LCOTHER ) , or LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
We will discuss the history of LCDiseaseOrPhenotypicFeature gene therapy with specific reference to these and other issues that pre - occupy the field at present : namely , the question of what vectors appear to be suitable for airway gene delivery in LCDiseaseOrPhenotypicFeature , what cells must be targeted , how airway epithelium defences can be overcome or eluded to allow efficient gene delivery , how to ensure safe and long - term transgene expression and the need to identify relevant surrogate success measures that can be used to assess the outcome of gene therapy in LCOTHER LCOTHER . LCOTHER related LCOTHER - LCOTHER LCOTHER in an adolescent LCOTHER .	0
In addition to these new mutations , this investigation reveals the prevalence of LCOTHER substitution among a subset of African - Brazilian LCOrganismTaxon and presents evidences of the recurrence of already known mutations . Effects of LCChemicalEntity on LCOTHER - induced LCOTHER in LCOTHER .	0
Molecular dynamic ( MD ) simulations showed that the overall effect of the mutation LCOTHER . LCOTHER is disruption of hydrogen bonding between LCSequenceVariant and LCSequenceVariant , leading LCOTHER and LCOTHER to move away from each other with subsequent disruption of the catalytic triad functionality regardless of the type of substrate .	0
Here we describe the characterization of the LCOTHER ( + LCOTHER LCOTHER - > LCOTHER ) polymorphism of the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene associated in LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER with high LCOTHER in erythroid precursor cells . LCOTHER consumption and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature incidence and progression : A Mendelian randomisation study .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
Recently , significantly higher frequencies of heterozygous carriers of the Slavic founder LCGeneOrGeneProduct mutation , LCSequenceVariant , were found in Russian children with LCOTHER LCOTHER LCOTHER , and in Polish adults with LCOTHER - LCOTHER LCOTHER ( LCOTHER ) .	0
However , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER with high baseline LCOTHER carrying the LCOTHER 3 ' - UTR LCSequenceVariant - LCSequenceVariant - allele showed significantly higher sustained virologic response ( SVR ) rates ( 25 . 3% vs .	0
CONCLUSIONS : The present study demonstrates a sex - differential effect of LCGeneOrGeneProduct on IMT , plaque index and LCOTHER , which highlights its influence on various aspects of LCOTHER . Reduced LCOTHER expression after high - fat diet is associated with selective up - regulation of LCGeneOrGeneProduct and further LCOTHER LCOTHER LCOTHER signaling in adipose tissue .	0
We investigated also the expression of angiocrine genes upon LCOTHER treatment in vivo , and demonstrate that LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct are upregulated , while LCOTHER and LCOTHER are reduced .	0
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature were identified in 68 and 32 LCOrganismTaxon , respectively .	0
"Moreover , diagnosis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature should be considered in the face of severe infant LCOTHER of uncertain etiology . Characterization of a novel LCGeneOrGeneProduct """""""" silent """""""" allele : point mutation ( LCOTHER . LCOTHER ) causes loss of activity and prolonged LCOTHER with LCOTHER ."	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER .	0
LCOTHER - LCOTHER was an effective salvage treatment for LCOTHER LCOTHER , particularly for those in first relapse . LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct gene ( LCOTHER ) variants may increase LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER in LCOTHER LCOTHER LCOTHER .	0
Enzyme activity assays with recombinant LCOTHER isoforms ( LCOTHER LCOTHER and LCOTHER LCOTHER ) and the LCChemicalEntity substrate LCChemicalEntity were used to investigate the functional impact of the LCOTHER LCOTHER polymorphism .	0
In this study , we generated endothelial cell - specific LCOTHER - knockout ( LCGeneOrGeneProduct ( endo - / - ) ) LCOTHER by crossbreeding LCOTHER LCOTHER - LCOTHER - Cre LCOTHER with LCOTHER ( flox / flox ) LCOrganismTaxon .	0
Careful therapeutic intervention is necessary in cases involving elderly LCOTHER who suffer from LCDiseaseOrPhenotypicFeature . Whole - Organism Developmental Expression Profiling Identifies LCGeneOrGeneProduct - LCGeneOrGeneProduct as a Novel Ciliary LCOTHER Associated with the LCOTHER and Intraflagellar Transport .	0
Histopathological examination revealed severe LCOTHER LCOTHER such as proteinaceous casts in tubuli and tubular expansion in the kidney of control LCOrganismTaxon , while an improvement of the damage was seen in LCOTHER - treated LCOrganismTaxon .	0
These results unravel a hidden link between LCOTHER and a functional putative LCDiseaseOrPhenotypicFeature risk SNP , whose allele alteration affects LCOTHER regulation of its host gene LCGeneOrGeneProduct . LCOTHER LCOTHER LCOTHER LCOTHER protects liver sinusoidal endothelial cells in acute LCOTHER LCOTHER LCOTHER .	0
We used wild - type ( WT ) and LCOTHER knockout ( LCGeneOrGeneProduct - KO ) LCOrganismTaxon hippocampal cultures , modeled in vitro following exposure to LCOTHER LCOTHER deprivation ( OGD ) , and in vivo neonatal ( P9 - 10 ) LCOTHER model of LCOTHER LCOTHER LCOTHER .	0
LCOTHER - LCOTHER LCOTHER ( LCOTHER ) is a ligand of the LCOTHER pathway family which has been widely studied in the context of LCDiseaseOrPhenotypicFeature angiogenesis , its blockade shown to result in non - productive angiogenesis and halted LCDiseaseOrPhenotypicFeature growth .	0
It is an autosomal recessive , developmental LCOTHER LCOTHER LCOTHER disorder characterized by deficiency in mitochondrial LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) catalytic activity , refractory LCOTHER , LCOTHER , and LCOTHER LCOTHER .	0
The LCOTHER peroxidation indicators including antisuperoxideanion ( ASAFR ) , LCChemicalEntity LCChemicalEntity LCChemicalEntity ( . LCChemicalEntity ) , LCOTHER LCOTHER ( LCOTHER ) , LCOTHER and LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) were determined with kits , and LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER / LCOTHER ) activities in liver were analyzed with gelatin zymography and in situ fluorescent zymography respectively .	0
METHODS : We resequenced the positional candidate gene LCOTHER in 48 LCOTHER LCOTHER cases and genotyped the previously reported LCOTHER and LCSequenceVariant polymorphisms in 230 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cases and 458 controls .	0
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCSequenceVariant , LCSequenceVariant , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCOTHER LCOTHER LCOTHER , and one with LCOTHER LCOTHER LCOTHER ) .	0
BACKGROUND : Millions of individuals worldwide , particularly those living in rural and developing areas , are exposed to harmful levels of LCChemicalEntity LCChemicalEntity ( LCChemicalEntity ) in their drinking water .	0
As these studies concerned sporadic LCOTHER cases , we investigated whether LCSequenceVariant and another common variant located in the 5 ' - untranslated region ( LCOTHER > LCOTHER ) of the LCOTHER gene modify LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk in LCOTHER mutation carriers .	0
A total of 10 novel variants was recognized , among them four variants in the adjacent 5 ' - region of the LCOTHER coding exon 2 ( LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER ) , a 6 base - pair deletion ( LCOTHER . LCOTHER [ LCOTHER . LCOTHER ] ) , a variant leading to a stop codon ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , synonymous variants ( LCOTHER . LCOTHER > LCOTHER [ LCSequenceVariant . LCSequenceVariant ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCSequenceVariant . LCSequenceVariant ] ) , and one non - synonymous variant ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) .	0
However , the prevalence of LCGeneOrGeneProduct mutations in LCOTHER and the correlation between the LCGeneOrGeneProduct genotype and LCOTHER phenotype have not been extensively studied .	0
LCDiseaseOrPhenotypicFeature is caused by a short trinucleotide repeat expansion encoding an expanded LCOTHER tract in the LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) gene .	0
RESULTS AND DISCUSSION : LCOTHER - LCOTHER LCCellLine and LCOTHER cells release a network of cytokines , including newly identified LCOTHER - inducible cytokines LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) .	0
This sole substitution was sufficient to confer constitutive activity to the receptor variant ( LCOTHER ( LCOTHER ) ) , as assessed in three reconstituted cell models ( LCOTHER / LCOTHER , LCOTHER and LCOTHER - LCOTHER cells ) by LCOTHER - independent ( i ) LCGeneOrGeneProduct tyrosine phosphorylation , ( ii ) activation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) signaling , ( iii ) transcriptional activity toward a LCGeneOrGeneProduct - responsive reporter gene , and ( iv ) cell proliferation and protection from cell death .	0
LCOTHER were excised and evaluated for proliferation , apoptosis , and expression of LCGeneOrGeneProduct , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER LCOTHER LCOTHER , and LCOTHER LCOTHER LCOTHER .	0
PURPOSE : This study was designed to establish a LCOTHER model of LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) by LCOTHER LCOTHER ( LCOTHER ( LCOTHER ) ) - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and to explore the potential role of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER ( LCOTHER ) and their endogenous inhibitors ( TIMPs ) in LCOTHER formation .	0
CONCLUSION : The present experimental findings substantiate the clinically observed LCDiseaseOrPhenotypicFeature potential of LCOTHER and LCOTHER . LCOTHER LCOTHER gene variants as susceptibility marker for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
CONCLUSION : The results indicate a dose - response relationship between LCOTHER and the risk of LCOTHER LCOTHER , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Mutation analysis of LCOTHER in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) in combination with LCOTHER LCOTHER .	0
LCOTHER was not implicated with LCOTHER / LCOTHER in our LCOrganismTaxon cohort . Combination of the LCOTHER LCOTHER inhibitor LCOTHER and LCOTHER - LCOTHER upregulates LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER and LCGeneOrGeneProduct genes and activates LCOTHER - LCOTHER / LCOTHER in LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER cells .	0
Knockdown and overexpression of LCOTHER in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature cells was performed using specifically constructed plasmids , which either had anti - LCOTHER ribozyme transgene or the full length LCOTHER LCGeneOrGeneProduct coding sequence .	0
CONCLUSIONS : The utilization of LCOTHER to correct LCDiseaseOrPhenotypicFeature induced by anesthesia has a negative impact on S ( c ) O ( 2 ) while LCOTHER maintains frontal lobe oxygenation potentially related to an increase in CO . LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) and LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) Single Nucleotide Polymorphisms ( SNPs ) , LCOTHER and Metabolism in LCOTHER LCOTHER LCOTHER in Inner Mongolia .	0
This study showed that LCGeneOrGeneProduct was more likely to be LCOTHER susceptibility gene at Chr . 1q31 based on the finding that the LCOTHER and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCOTHER in a white population in LCGeneOrGeneProduct , LCOTHER , and LCOTHER genes showed a significant association with LCOTHER . Seven novel and six de novo LCOTHER gene mutations in LCOTHER with LCOTHER LCOTHER .	0
Insights could be gained by pooling data on LCOTHER frequency stratified by antithrombotic use in cohorts with LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) / LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
Changes included increases in LCOTHER , LCGeneOrGeneProduct , LCOTHER / LCOTHER , and LCOTHER and decreases in LCOTHER , LCGeneOrGeneProduct , and LCOTHER .	0
BACKGROUND : Recent data has suggested that polymorphisms in the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) may increase LCOTHER LCOTHER ( LCOTHER ) risk .	0
The goal of this study was to perform LCOTHER - LCOTHER - LCOTHER LCOTHER LCOTHER gene ( LCOTHER ) analysis in a LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) LCOTHER with normal LCOTHER ( LCOTHER ) production and normal LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene coding sequences .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
A LD ( 10 ) dose ( 8 mg LCChemicalEntity / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher LCOTHER , LCOTHER LCOTHER , LCOTHER peroxidation , and 80% mortality in the LCOTHER ( LCDiseaseOrPhenotypicFeature ) LCOTHER in the absence of any significant LCOTHER LCOTHER LCOTHER LCOTHER .	0
CONCLUSIONS LCOTHER - LCOTHER - LCOTHER / LCOTHER SNP , hs - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER / LCOTHER - LCOTHER were associated with LCOTHER in LCOrganismTaxon from Inner Mongolia , as was serious LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER prevents LCOTHER LCOTHER accumulation in macrophages induced by the LCOTHER LCOTHER inhibitor LCOTHER .	0
A total of 10 novel variants was recognized , among them four variants in the adjacent 5 ' - region of the LCOTHER coding exon 2 ( LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCSequenceVariant . LCSequenceVariant - LCSequenceVariant > LCSequenceVariant ) , a 6 base - pair deletion ( LCOTHER . LCOTHER [ LCOTHER . LCOTHER ] ) , a variant leading to a stop codon ( LCOTHER . LCOTHER > LCOTHER [ LCSequenceVariant . LCSequenceVariant ] ) , synonymous variants ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , and one non - synonymous variant ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) .	0
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCSequenceVariant ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCOTHER . LCOTHER ] have been reported in Japanese LCOrganismTaxon , but not in LCOTHER LCOTHER from other ethnic groups .	0
A unique set of LCOTHER - regulated survival factors included LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCGeneOrGeneProduct LCGeneOrGeneProduct .	0
Moreover , using RNA interference with small inhibitory RNAs for LCOTHER , LCGeneOrGeneProduct , and LCOTHER , we observed that LCChemicalEntity - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCOTHER proteins .	0
To address the potential confounding effects of the LCChemicalEntity use of the LCOTHER using group , a second analysis included 14 previously tested LCChemicalEntity users ( Nestor , L . , Roberts , G . , Garavan , H . , Hester , R . , 2008 .	0
We believe that this knowledge will assist clinical geneticists and treating physicians when advising LCOrganismTaxon and their families , will provide a rapid and convenient resource for research scientists , and may eventually assist in gaining novel insights into LCOTHER and its related clinical syndromes . Mechanisms Underlying Latent Disease Risk Associated with Early - Life LCChemicalEntity Exposure : Current Research Trends and Scientific Gaps .	0
The present study tested the hypothesis that LCOTHER - induced LCOTHER ( LCOTHER ) resistance in skeletal muscle is associated with a down - regulation of LCOTHER LCOTHER LCOTHER important in regulating LCChemicalEntity flux or an impairment in the formation of the LCChemicalEntity - sensitive LCOTHER - LCOTHER LCOTHER .	0
LCOTHER AND METHODS : We examined 102 LCOrganismTaxon ( LCOTHER / LCOTHER , 40 / 62 ; median age , 42 ) diagnosed with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and 188 healthy controls ( LCOTHER / LCOTHER , 78 / 110 ; median age , 38 ) .	0
We aimed to compare the risks of hospitalization for LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature among elderly patients using LCOTHER - LCOTHER LCOTHER , NS - LCChemicalEntity and LCOTHER .	0
LCOTHER may also be utilized for effective treatment of LCOTHER - LCOTHER - resistant LCDiseaseOrPhenotypicFeature . Oncogene advance online publication , 26 June 2017 ; doi : 10 . 1038 / onc . 2017 . 211 . rTMS of supplementary motor area modulates therapy - induced LCOTHER in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Biochemical tests showed elevated free LCChemicalEntity ( LCOTHER : 20 . 8 pg / ml ( normal , 8 . 5 - 18 ) ) and LCOTHER ( LCOTHER : 5 . 7 pg / ml ( normal , 1 . 4 - 4 ) ) in the serum , together with an inappropriately nonsuppressed LCGeneOrGeneProduct level of 4 . 7 mU / ml ( normal , 0 . 4 - 4 ) .	0
However , it cannot be excluded that the 2 unique DNA sequence alterations could have affected LCGeneOrGeneProduct on the mRNA or protein level thus contributing to the observed disturbances in genital and palate development . LCOTHER - LCOTHER LCOTHER activation inhibits LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct activity and promotes LCOTHER signaling .	0
Alteration of LCOTHER protein levels may contribute to invasion and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , which may occur through activation of LCOTHER signaling and promotion of LCOTHER - LCOTHER expression . The number of LCOTHER LCOTHER LCOTHER in LCOTHER LCOTHER correlates with the LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct gene insertion / deletion polymorphism .	0
An alternative source of energy is LCChemicalEntity - LCChemicalEntity ( the C - 4 - epimer of LCOTHER - LCOTHER ) which is transported into the brain by LCOTHER - independent LCOTHER transporter where it might be metabolized to LCChemicalEntity via the Leloir pathway .	0
Expression of LCGeneOrGeneProduct protects the lung from LCOTHER LCOTHER and enhanced pathology during LCOTHER LCOTHER . Assessment of a new non - invasive index of cardiac performance for detection of LCChemicalEntity - induced LCOTHER LCOTHER .	0
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCOTHER ( 874 LCOTHER ' LCOTHER LCOTHER , 259 LCOTHER LCOTHER , 30 indeterminate LCDiseaseOrPhenotypicFeature ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCGeneOrGeneProduct , LCOTHER / LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER .	0
Altogether , our results suggest that LCOTHER deficiency cooperates with LCOTHER - LCOTHER in promoting LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature / LCOTHER LCOTHER LCOTHER in LCOrganismTaxon , possibly by specifically enforcing marginal zone B cell accumulation , increasing LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER expression , and rendering B cells independent of LCOTHER LCOTHER LCOTHER LCOTHER for survival . Association of adipocyte genes with LCOTHER expression : a microarray analysis of subcutaneous and omental adipose tissue in morbidly LCOTHER subjects .	0
An analysis of the multiple single - nucleotide polymorphisms in LCGeneOrGeneProduct - LCGeneOrGeneProduct demonstrated that homozygosity for alleles encoding LCOTHER ( LCOTHER LCOTHER ) LCOTHER LCOTHER LCOTHER ( LCOTHER LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the LCChemicalEntity recognition domain was associated with an increased risk of LCOTHER LCOTHER ( OR , 6 . 7 ; 95% CI , 1 . 4 - 31 . 5 ) .	0
Enzyme activity assays with recombinant LCOTHER isoforms ( LCOTHER LCOTHER and LCOTHER LCOTHER ) and the LCOTHER substrate LCChemicalEntity were used to investigate the functional impact of the LCGeneOrGeneProduct LCOTHER polymorphism .	0
Moreover , in vitro experiments showed that LCOrganismTaxon LCChemicalEntity impaired the antigen - presenting function that supports the generation of LCOTHER - LCOTHER - producing cells in a LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER - dependent manner .	0
Similar to B cells with targeted LCGeneOrGeneProduct deletion , LCOTHER - LCOTHER LCOrganismTaxon show expanded marginal zone B cell population and have constitutive LCOTHER LCOTHER - LCOTHER processing .	0
All 5 LCOrganismTaxon were heterozygous for a base substitution LCSequenceVariant . LCSequenceVariant > LCSequenceVariant changing the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER codon ( LCOTHER . LCOTHER ) in exon 4 .	0
There are two known polymorphisms in exon 11 of the LCOTHER gene resulting in amino acid variants : LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ; and LCSequenceVariant - - > LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant leads to an exchange of LCSequenceVariant LCSequenceVariant LCSequenceVariant .	0
These results demonstrate the critical role of the final 20 amino acids of LCOTHER - LCOTHER in modulating fibroblast proliferation by dampening LCOTHER signaling and suggest that augmented LCOTHER signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of LCOTHER in LCOrganismTaxon with LCOTHER - LCOTHER LCSequenceVariant . LCSequenceVariant mutation . Mutations in LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) LCOTHER in LCOTHER with LCOTHER - LCOTHER LCOTHER LCOTHER .	0
Most carrier females have mild LCOTHER LCOTHER and subtle facial changes . Serum levels of LCGeneOrGeneProduct LCOTHER and LCGeneOrGeneProduct in LCOTHER LCOTHER indicate the presence of LCOTHER LCOTHER .	0
LCOTHER chelation with LCOTHER was effective in mobilizing hepatic LCOTHER but has no effect on brain LCOTHER . Aberrant LCOTHER - LCOTHER - mediated LCOTHER signaling and proliferation identified by analysis of LCSequenceVariant LCSequenceVariant LCSequenceVariant mutation ( LCOTHER . LCOTHER ) in LCOrganismTaxon fibroblasts : a new perspective on the mechanism of LCOTHER LCOTHER .	0
METHODS : 133 LCOTHER who developed LCOTHER following chemotherapy and / or radiotherapy ( n = 133 ) , 420 LCOrganismTaxon diagnosed with de novo LCOTHER LCOTHER , 242 LCOTHER diagnosed with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and 1177 healthy controls were genotyped for the LCOTHER - 93 polymorphism by allelic discrimination polymerase chain reaction ( PCR ) and restriction fragment length polymorphism assay .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER .	0
The results in this study significantly improve our understanding of the durability of LCOTHER - LCOTHER - producing LCOTHER ( + ) T cells postinfection and provide information on how LCGeneOrGeneProduct - LCGeneOrGeneProduct may contribute to optimized parasite control and prevention of immune - mediated pathology during repeated LCOTHER LCOTHER . LCOTHER as a LCOTHER LCOTHER : the role of critical LCChemicalEntity groups in LCOTHER LCOTHER .	0
RESULTS : Despite similar external diameters among LCOTHER ( LCOTHER ) - treated , non - LCOTHER ( LCOTHER ) - treated and LCChemicalEntity - treated segments , aneurymal alteration ( n = 6 , 50% ) , media degeneration with regional disruption , fragmentation of elastic fiber , and increased collagen deposition ( n = 12 , 100% ) were demonstrated in LCChemicalEntity ( LCChemicalEntity ) - treated segments .	0
Functional studies were consistent with the hypothesis that whereas incomplete loss of LCGeneOrGeneProduct function may cause LCOTHER LCOTHER , more severe loss of function can result in a lethal LCOTHER LCOTHER phenotype . Comparison of sequential LCOTHER isolates in a LCOrganismTaxon with LCOTHER and failing antiviral therapy .	0
Differences were found for serum FBG , FINS , HOMA - IR , and HOMA - beta , and placental LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , and LCOTHER - LCOTHER .	0
LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) ( LCOTHER # LCOTHER ) is an LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature caused by LCOTHER LCOTHER LCOTHER gene ( LCOTHER ) mutations .	0
Materials and METHODS : A cohort of 1163 unrelated LCOrganismTaxon with LCOTHER ( 874 LCOTHER ' LCOTHER LCOTHER , 259 LCOTHER LCOTHER , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER / LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct .	0
Hence , while alterations in select LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct are not associated with development of LCOTHER - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCOTHER with LCGeneOrGeneProduct and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	0
Thus , LCOTHER prevented and reversed LCOTHER - induced LCDiseaseOrPhenotypicFeature in the LCOTHER . Comparison of unilateral pallidotomy and subthalamotomy findings in advanced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Interestingly , we found LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER in the bilateral pallidi in our LCOrganismTaxon .	0
Patients taking LCOTHER and LCOTHER must be examined for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and its consequences . LCOTHER phenotype and the pharmacokinetics and LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct pharmacodynamics of LCOTHER and its enantiomers .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
No association of LCOTHER polymorphisms and self - limited LCOTHER LCOTHER could be demonstrated . LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) defects are common in LCOTHER LCOTHER LCOTHER LCOTHER and co - occur with LCGeneOrGeneProduct mutations .	0
LCOTHER administration to control LCOTHER significantly increased renal LCOTHER ( LCOTHER ) and urinary LCOTHER - LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCOTHER , a marker of LCOTHER LCOTHER LCOTHER ) excretion but decreased LCChemicalEntity LCChemicalEntity ( LCChemicalEntity ) and LCOTHER ( LCOTHER ) activities .	0
Using a LCOrganismTaxon model , we tested whether the rapid reversal of anticoagulation using LCOrganismTaxon LCOTHER LCOTHER LCOTHER ( LCOTHER ) can reduce hemorrhagic blood volume .	0
LCChemicalEntity had no significant effect on the incidence or severity of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
On the whole , our findings indicate that the absence of LCGeneOrGeneProduct plays a cardioprotective role in LCOTHER LCOTHER LCOTHER by promoting changes in LCOTHER / LCOTHER signalling . Long - Lived LCGeneOrGeneProduct + LCOTHER - LCOTHER + T Cells rather than Short - Lived LCOTHER + LCOTHER - LCOTHER + LCOTHER - LCOTHER + T Cells Initiate Rapid LCOTHER - LCOTHER Production To Suppress Anamnestic T Cell Responses during Secondary LCOTHER LCOTHER .	0
One - hundred and fifty LCOTHER ( 90 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature [ LCOTHER ] and 60 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature [ LCOTHER ] ) LCOTHER and 165 age - and sex - matched normal healthy controls without known LCOTHER and LCOTHER LCOTHER LCOTHER were included in the study .	0
CONCLUSIONS : The LCOrganismTaxon and LCOTHER - LCOTHER viruses can be considered for evaluation in LCOTHER and for inclusion in a tetravalent LCOTHER vaccine . The effects of short - term LCOTHER therapy on fibrinolysis markers : LCGeneOrGeneProduct , LCOTHER , and LCOTHER - LCOTHER .	0
She had profound LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER , severe LCDiseaseOrPhenotypicFeature and relapsing LCOTHER , while her pre - pubescent daughter had normal fat distribution but elevated plasma LCOTHER and LCOTHER - LCOTHER and depressed LCOTHER - LCOTHER LCOTHER LCOTHER .	0
All LCOTHER were genotyped for LCSequenceVariant ( LCOTHER - LCOTHER LCOTHER ) , intron 2 conversion , LCOTHER ( LCOTHER ) within LCOTHER and LCOTHER ( LCOTHER LCOTHER ) , LCSequenceVariant ( LCOTHER ) within LCOTHER .	0
METHODS : 133 LCOTHER who developed LCOTHER following chemotherapy and / or radiotherapy ( n = 133 ) , 420 LCOTHER diagnosed with de novo LCOTHER LCOTHER , 242 LCOrganismTaxon diagnosed with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and 1177 healthy controls were genotyped for the LCOTHER - 93 polymorphism by allelic discrimination polymerase chain reaction ( PCR ) and restriction fragment length polymorphism assay .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCGeneOrGeneProduct , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCGeneOrGeneProduct ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
LCOTHER , an agonist of LCGeneOrGeneProduct , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCGeneOrGeneProduct is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	0
This sole substitution was sufficient to confer constitutive activity to the receptor variant ( LCOTHER ( LCOTHER ) ) , as assessed in three reconstituted cell models ( LCOTHER / LCOTHER , LCOTHER and LCOTHER - LCOTHER cells ) by LCOTHER - independent ( i ) LCOTHER tyrosine phosphorylation , ( ii ) activation of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) signaling , ( iii ) transcriptional activity toward a LCGeneOrGeneProduct - responsive reporter gene , and ( iv ) cell proliferation and protection from cell death .	0
Genetic analysis of LCOTHER seems to be of limited significance in the differential diagnosis of LCDiseaseOrPhenotypicFeature without LCOTHER LCOTHER LCOTHER LCOTHER . High LCOTHER diet - fed LCDiseaseOrPhenotypicFeature LCOTHER are highly sensitive to LCOTHER - induced LCOTHER .	0
A positive LCOTHER result in plasma DNA has a high predictive value for LCOTHER LCOTHER status and for favorable clinical course on LCOTHER - targeted therapy and could therefore be useful in guiding clinical decisions in LCOrganismTaxon with insufficient or unavailable LCOTHER specimens . Dynamic subunit turnover in LCOTHER - LCOTHER assemblies is regulated by LCGeneOrGeneProduct to mediate membrane remodelling during cytokinesis .	0
RESULTS : The results show that the LCOTHER polymorphism is present in LCOTHER - LCOTHER LCOTHER in the 5 ' UTR sequence ( + 25 ) of the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene , known to affect the LCOTHER ( LCOTHER homologue of LCOrganismTaxon LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ) binding site 5 ' - GGTTAT - 3 ' .	0
Here we show that LCOTHER blockade with monoclonal antibodies perturbs the BM vascular niche of sub - lethally irradiated LCOTHER , resulting in increased LCGeneOrGeneProduct ( + ) , LCOTHER - LCOTHER ( + ) and LCOTHER - LCOTHER ( + ) vessel density , and also increased megakaryocytes , whereas LCOTHER ( + ) , LCOTHER ( + ) , LCOTHER ( + ) and LCGeneOrGeneProduct ( + ) vessel density remained unaltered .	0
LCOTHER AND METHODS : We examined associations between 54 polymorphisms that tag the known common variants ( minor allele frequency > 0 . 05 ) in 10 genes involved in oxidative damage repair ( LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) and survival in 4 , 470 LCOTHER with LCOTHER LCOTHER .	0
Given LCOTHER ' s role as an anti - LCDiseaseOrPhenotypicFeature mediator , we hypothesized that LCOTHER ( - / - ) LCOTHER would exhibit enhanced LCDiseaseOrPhenotypicFeature mediator expression after LCOTHER .	0
Exogenous LCOTHER rescues spheroid - forming activity and tumorigenicity of the LCCellLine - LCGeneOrGeneProduct - high cells , suggesting that loss of LCOTHER increases the number of LCOTHER - initiating cells through transcriptional activation of LCOTHER .	0
LCOTHER administration to control LCOTHER significantly increased renal LCOTHER ( LCChemicalEntity ) and urinary LCOTHER - LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCOTHER , a marker of LCOTHER LCOTHER LCOTHER ) excretion but decreased LCOTHER LCOTHER ( LCChemicalEntity ) and LCOTHER ( LCOTHER ) activities .	0
Pre - treatment of the LCOTHER LCOTHER antagonist LCOTHER - LCOTHER , LCOTHER ( 10ug , i . c . v ) reversed the effects of LCChemicalEntity - LCChemicalEntity , but the LCOTHER LCOTHER antagonist LCChemicalEntity - LCChemicalEntity , LCChemicalEntity ( 10ug , i . c . v ) did not .	0
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCOTHER ) and three markers ( LCSequenceVariant , LCOTHER and LCOTHER ) in LCGeneOrGeneProduct and LCOTHER - induced LCOTHER LCOTHER , respectively .	0
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCDiseaseOrPhenotypicFeature cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCGeneOrGeneProduct - mediated apoptotic pathway .	0
We screened one family with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature for mutations in LCGeneOrGeneProduct and LCOTHER .	0
Apparent homozygosity for the mutation LCOTHER . LCOTHER present on exon 5 of the LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene in a LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER was solved in this study by further testing for a second mutation .	0
Loss - of - function experiments demonstrate that LCOTHER serves as a LCGeneOrGeneProduct antagonist with functions that overlap and are redundant with those of LCGeneOrGeneProduct in forming the dorsoventral axis . Polymorphic forms of LCOTHER LCOTHER LCOTHER and their interaction with LCOTHER LCOTHER trinucleotide repeats in LCOTHER LCOTHER .	0
We investigated whether the LCOTHER LCOTHER is associated with disease susceptibility in a population of LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) , LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , and LCOTHER LCOTHER ( LCOTHER ) ; and whether it is associated with disease severity .	0
Taken together , our results demonstrated that LCOTHER is a LCOTHER ( LCOTHER ) - cooperating oncogene required for LCOTHER ( LCOTHER ) - induced immortalization and transformation , and targeting LCOTHER - LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct may , therefore , have therapeutic value for senescence - based LCOTHER treatment . In vivo evidences suggesting the role of oxidative stress in pathogenesis of LCChemicalEntity - induced LCOTHER : protection by LCOTHER .	0
RESULTS AND DISCUSSION : LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER and LCCellLine cells release a network of cytokines , including newly identified LCOTHER - inducible cytokines LCOTHER , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) .	0
Patients taking LCChemicalEntity and LCOTHER must be examined for LCOTHER LCOTHER and its consequences . LCOTHER phenotype and the pharmacokinetics and LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct pharmacodynamics of LCOTHER and its enantiomers .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCGeneOrGeneProduct and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
The following gene polymorphisms were determined in genomic DNA : LCOTHER - LCOTHER LCOTHER insertion / deletion polymorphism ( I / D LCOTHER ) , LCGeneOrGeneProduct gene polymorphism ( LCSequenceVariant LCSequenceVariant ) , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) polymorphism ( LCOTHER LCOTHER ) , and polymorphism of LCOTHER LCOTHER gene ( LCOTHER ) . Heart rate variability during HUT was assessed in 5 - minute intervals by low frequency , high frequency , standard deviation of the normal - to - normal ( SDNN ) , and root mean square successive difference parameters .	0
We then examined them on genomic DNA in six LCOTHER probands without mutations in the LCGeneOrGeneProduct , LCOTHER and LCOTHER genes and in 54 LCOrganismTaxon with late - onset LCOTHER LCOTHER LCOTHER by combined single strand conformational polymorphism - heteroduplex analysis followed by direct sequencing of identified variants .	0
The LCOTHER LCOTHER - suppressor gene was mutated in all LCOTHER with documented LCGeneOrGeneProduct mutation , suggesting that the pathways regulated by these two LCOTHER - suppressor proteins often cooperate in the development of LCOTHER LCOTHER with serous differentiation . Drug - induced LCOTHER LCOTHER LCOTHER in injection drug users receiving LCOTHER : high frequency in hospitalized LCOrganismTaxon and risk factors .	0
CONCLUSION : LCOTHER and LCGeneOrGeneProduct were identified as novel LCOTHER - associated genes with a high degree of significance , suggesting new directions in understanding the pathogenesis of LCDiseaseOrPhenotypicFeature .	0
Moreover , apoptotic proteins are also involved in the LCOTHER , like LCGeneOrGeneProduct , LCOTHER , but not LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct or LCOTHER .	0
Therefore , our results indicate that LCOTHER B cells have already acquired enhanced survival and growth capabilities before transformation , and that elevated LCOTHER levels confer resistance to pharmacologic inhibitors of LCOTHER signaling , which has significant implications for LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature treatment . Genetic investigation of four meiotic genes in LCOrganismTaxon with LCOTHER LCOTHER LCOTHER .	0
In our LCOTHER , transient LCOTHER LCOTHER or LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature related to LCOTHER and / or LCOTHER use were the most likely causes of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Detailed spectral profile analysis of LCOTHER - induced LCOTHER LCOTHER in anesthetized LCOTHER .	0
Given LCOTHER ' s role as an anti - LCOTHER mediator , we hypothesized that LCOTHER ( - / - ) LCOrganismTaxon would exhibit enhanced LCOTHER mediator expression after LCDiseaseOrPhenotypicFeature .	0
Quantitative cDNA expression of normal LCOTHER LCGeneOrGeneProduct was performed in the LCOTHER fibroblasts , using vaccinia viral system , which demonstrated that the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER causes impaired LCChemicalEntity - LCChemicalEntity LCChemicalEntity LCChemicalEntity beta - oxidation activity in the LCOTHER fibroblasts .	0
Serum concentrations of LCOTHER , LCOTHER and LCOTHER - LCOTHER as markers of LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	0
Moreover , we confirm previous results that a short LCSequenceVariant LCSequenceVariant in conjunction with GG genotype significantly increases the risk of LCOTHER LCOTHER . A homozygous mutation in LCGeneOrGeneProduct / LCOTHER associated with early onset LCOTHER , LCOTHER LCOTHER , and severe LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER activity .	0
Through linkage with the Swedish LCDiseaseOrPhenotypicFeature Register , all subjects in this cohort diagnosed with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature were identified .	0
Eight Alu sequences ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct ) were analyzed in two samples from Navarre and Guipuzcoa provinces ( Basque Country , Spain ) .	0
LCOTHER treatment significantly ( p < or = 0 . 001 ) increased expression of LCGeneOrGeneProduct and LCOTHER - LCOTHER in the urinary bladder of WT and LCOTHER ( - / - ) LCOTHER , but expression in LCOTHER ( - / - ) LCOrganismTaxon with LCOTHER treatment was significantly ( p < or = 0 . 001 ) greater ( 4 . 2 - to 13 - fold increase ) than that observed in WT urinary bladder ( 3 . 6 - to 5 - fold increase ) .	0
"Moreover , diagnosis of LCOTHER LCOTHER should be considered in the face of severe infant LCDiseaseOrPhenotypicFeature of uncertain etiology . Characterization of a novel LCGeneOrGeneProduct """""""" silent """""""" allele : point mutation ( LCOTHER . LCOTHER ) causes loss of activity and prolonged LCOTHER with LCOTHER ."	0
Previously , we and others reported that recessive mutations in the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) can cause both lethal and nonlethal LCOTHER , thus demonstrating that pterygia resulted from LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Here , we report two maternal cousins with an apparently LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER , LCOTHER LCOTHER , and LCOTHER LCOTHER .	0
CONCLUSIONS : Clinicians are exhorted to pay close attention when initiating LCChemicalEntity therapy in LCOTHER taking medications with epileptogenic properties that are LCOTHER substrates . LCOTHER LCOTHER ( or LCOTHER LCOTHER LCOTHER ) secondary to LCChemicalEntity .	0
Administration of LCOTHER LCOTHER suppressed LCOTHER growth in C3H / HeN LCOrganismTaxon , but not in LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct , while increasing LCOTHER ( LCOTHER ) - LCOTHER levels .	0
The fact that no truncation or frame shift mutations have been found in any of the LCOTHER LCOTHER , coupled with our recent finding that some breeding pairs of LCOTHER LCOTHER knockout LCOrganismTaxon yield litters that show not only LCOTHER , but also severe LCOTHER and LCOTHER LCOTHER , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOTHER . Midline B3 LCChemicalEntity nerves in LCOTHER medulla are involved in LCOTHER effect of LCOTHER .	0
Additionally , when LCOTHER genotype was cross classified with LCSequenceVariant LCSequenceVariant , significantly more cases than both LCDiseaseOrPhenotypicFeature and population controls were observed to have a short ( < 22 ) CAG / GG genotype ( P = 0 . 006 ) .	0
Our data support potential interactions between the LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCGeneOrGeneProduct pathways , and possible influence by LCOTHER or LCOTHER mutation on therapy or chemoprevention targeting LCGeneOrGeneProduct . Identification of novel type LCOTHER LCOTHER gene mutations resulting in severe LCOTHER LCOTHER LCOTHER LCOTHER .	0
Alteration of LCOTHER protein levels may contribute to invasion and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , which may occur through activation of LCOTHER signaling and promotion of LCOTHER - LCOTHER expression . The number of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER LCOTHER correlates with the LCOTHER LCOTHER - LCOTHER LCOTHER gene insertion / deletion polymorphism .	0
In the present study , we found that a very low concentration of LCOTHER , an LCOTHER inhibitor , potentiated the antitumor activity of LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) in a LCOrganismTaxon LCOTHER LCOTHER cell model using LCOTHER - LCOTHER , LCOTHER , and LCCellLine cells via the inhibition of colony formation ability or cellular viability .	0
LCGeneOrGeneProduct was not implicated with LCOTHER / LCOTHER in our LCOTHER cohort . Combination of the LCOTHER LCOTHER inhibitor LCOTHER and LCOTHER - LCOTHER upregulates LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER and LCOTHER genes and activates LCOTHER - LCOTHER / LCOTHER in LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER - LCOTHER cells .	0
Base pair changes in LCGeneOrGeneProduct and LCGeneOrGeneProduct were confirmed by sequencing bidirectionally in LCOTHER samples .	0
The mechanism may be related to the improvement of LCOTHER ( LCOTHER + ) handling . LCOTHER LCOTHER deletion in myeloid cells affects the LCDiseaseOrPhenotypicFeature response in allergic LCDiseaseOrPhenotypicFeature , but not lung mechanics , in female LCOTHER .	0
Mutations of the LCOTHER / LCOTHER LCOTHER gene ( LCGeneOrGeneProduct / LCGeneOrGeneProduct ) account for both sporadic and familial forms of LCOTHER ' LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct [ LCGeneOrGeneProduct ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCGeneOrGeneProduct ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
Chronic overexpression influences steady - state levels of mRNAs for metastasis - related genes . LCChemicalEntity LCChemicalEntity reduces LCOTHER LCOTHER in individuals with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and the LCOTHER 2 - 2 genotype .	0
Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental LCOTHER . Exaggerated expression of LCDiseaseOrPhenotypicFeature mediators in LCOTHER LCOTHER LCOTHER knockout ( LCOTHER - / - ) LCOrganismTaxon with LCOTHER ( LCOTHER ) - induced LCOTHER .	0
Findings point toward a possible mediating role of LCOTHER variants on phenotypic expression in LCOTHER that need to be replicated in a larger sample . LCDiseaseOrPhenotypicFeature in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with LCOTHER and / or glomerular LCOTHER .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
After 30 hours of LCOTHER infusion the patient felt LCOTHER and electrocardiography ( ECG ) recording showed LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) > 5 x / minute , trigemini , constant type - - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , positive U wave .	0
The results in this study significantly improve our understanding of the durability of LCOTHER - LCOTHER - producing LCGeneOrGeneProduct ( + ) T cells postinfection and provide information on how LCOTHER - LCOTHER may contribute to optimized parasite control and prevention of immune - mediated pathology during repeated LCOTHER LCOTHER . LCOTHER as a LCOTHER LCOTHER : the role of critical LCChemicalEntity groups in LCOTHER LCOTHER .	0
CONCLUSIONS : The LCOTHER and LCOTHER - LCOTHER viruses can be considered for evaluation in LCOTHER and for inclusion in a tetravalent LCOTHER vaccine . The effects of short - term LCChemicalEntity therapy on fibrinolysis markers : LCOTHER , LCOTHER , and LCGeneOrGeneProduct - LCGeneOrGeneProduct .	0
CONCLUSIONS : These results suggest that LCOTHER stimulates LCOTHER - LCOTHER gene expression after LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , which is associated with higher LCOTHER production and LCOTHER after the local anesthetic effect dissipates . LCOTHER and LCOTHER LCOTHER among LCOTHER treated with LCOTHER for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in the city of Copenhagen .	0
LCOTHER - induced LCDiseaseOrPhenotypicFeature was challenged with prior intracollicular microinjections of LCOTHER LCOTHER LCOTHER antagonists , LCOTHER - LCOTHER ( 15 or 30 mmol / 0 . 5 microl ) and LCOTHER ( 10 or 20 nmol / 0 . 5 microl ) , or of the LCOTHER LCOTHER agonist LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity ( LCOTHER , 20 or 30 nmol / 0 . 5 microl ) .	0
With the advent of next - generation sequencing technologies , the homozygous mutations LCOTHER and LCSequenceVariant in the LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCGeneOrGeneProduct were identified as the genetic cause of LCOTHER LCOTHER LCOTHER ( LCOTHER LCOTHER ) .	0
Insights could be gained by pooling data on LCDiseaseOrPhenotypicFeature frequency stratified by antithrombotic use in cohorts with LCOTHER and LCOTHER LCOTHER ( LCOTHER ) / LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
We report a case of LCOTHER LCOTHER ( LCOTHER ) in a dizygotic twin who presented at 12 years of age with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER , LCOTHER and LCOTHER with inappropriate kaliuresis , and LCOTHER LCOTHER LCOTHER with LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	0
Therefore , urinary acidification could be an option to prevent LCOTHER LCDiseaseOrPhenotypicFeature in LCOTHER . Absence of LCOTHER - LCOTHER attenuates LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
Overall , these findings indicate that LCOTHER treatment results in oxidative stress , as measured by levels of LCOTHER - LCOTHER ( LCOTHER ) - LCOTHER , which precedes the onset of LCDiseaseOrPhenotypicFeature , LCOTHER , and elevated levels of serum LCGeneOrGeneProduct - LCGeneOrGeneProduct . Delineation of the clinical phenotype associated with LCOTHER mutations based on the clinical and neuropsychological evaluation of three families .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCGeneOrGeneProduct were dependent on LCOTHER expression in LCOTHER .	0
LCOTHER AND METHODS : We examined associations between 54 polymorphisms that tag the known common variants ( minor allele frequency > 0 . 05 ) in 10 genes involved in oxidative damage repair ( LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) and survival in 4 , 470 LCOTHER with LCOTHER LCOTHER .	0
CONCLUSION : Among non - users of LCChemicalEntity , LCOTHER seemed to carry the highest risk for LCOTHER / LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
The Turkish LCOTHER and her affected relatives all had a heterozygous LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant ( LCSequenceVariant - - > LCSequenceVariant ) of exon 10 of LCOTHER that results in a replacement of LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant .	0
Here , we show that a single LCSequenceVariant ( LCSequenceVariant ) LCSequenceVariant LCSequenceVariant ( LCSequenceVariant ) LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
Findings point toward a possible mediating role of LCOTHER variants on phenotypic expression in LCOTHER that need to be replicated in a larger sample . LCDiseaseOrPhenotypicFeature in LCOTHER LCOTHER with LCDiseaseOrPhenotypicFeature and / or glomerular LCOTHER .	0
The aim of this study was therefore to investigate the influence of mutations in these LCOTHER LCOTHER LCOTHER genes ( LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER / LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct , LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
This is the first known constitutional rearrangement of LCOTHER , and further systematic genetic analysis and clinical studies of DGAP128 may offer unique insights into the role of LCOTHER in neurodevelopment . LCChemicalEntity prevented and reversed LCOTHER - induced LCDiseaseOrPhenotypicFeature in the LCOTHER .	0
LCOTHER ( + ) LCOTHER cells produced activated LCOTHER ( LCOTHER ) and generated LCOTHER ( - ) cells that expressed LCOTHER as well as neural differentiation factors LCOTHER , LCGeneOrGeneProduct , and LCGeneOrGeneProduct .	0
The following gene polymorphisms were determined in genomic DNA : LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct insertion / deletion polymorphism ( I / D LCOTHER ) , LCGeneOrGeneProduct gene polymorphism ( LCOTHER LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) polymorphism ( LCOTHER LCOTHER ) , and polymorphism of LCOTHER LCOTHER gene ( LCOTHER ) . Heart rate variability during HUT was assessed in 5 - minute intervals by low frequency , high frequency , standard deviation of the normal - to - normal ( SDNN ) , and root mean square successive difference parameters .	0
By contrast , oxidation related genes were decreased ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCGeneOrGeneProduct ) .	0
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCOTHER ) and three markers ( LCOTHER , LCOTHER and LCSequenceVariant ) in LCGeneOrGeneProduct and LCOTHER - induced LCOTHER LCOTHER , respectively .	0
LCChemicalEntity LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCOTHER ) was widely used for a variety of diseases including LCOTHER LCOTHER , the current study aims to investigate the protective effects of LCChemicalEntity on liver sinusoidal endothelial cells ( LSECs ) in acute LCOTHER LCOTHER and related action mechanisms .	0
The pathogenesis of LCOrganismTaxon LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , characterized by immune - mediated damage of LCOTHER - producing b - cells of pancreatic islets , may involve LCOTHER LCOTHER .	0
There was a difference in LCChemicalEntity potency with higher racemic LCOTHER IC50 values in PMs ( 72 + / - 7 ng . ml - 1 ) than EMs ( 42 + / - 8 ng . ml - 1 , P less than . 001 ) . ( ABSTRACT TRUNCATED AT 250 WORDS ) LCOTHER protects against LCOTHER from the DNA cleavage - enhancing drugs LCOTHER and LCChemicalEntity but not LCOTHER .	0
All LCOTHER were genotyped for LCOTHER ( LCSequenceVariant - LCSequenceVariant LCSequenceVariant ) , intron 2 conversion , LCOTHER ( LCOTHER ) within LCOTHER and LCOTHER ( LCOTHER LCOTHER ) , LCSequenceVariant ( LCOTHER ) within LCOTHER .	0
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCSequenceVariant . LCSequenceVariant ] have been reported in Japanese LCOTHER , but not in LCOTHER LCOTHER from other ethnic groups .	0
To determine whether LCOTHER attenuated LCOTHER , the LCOTHER response and apoptosis in vivo and in vitro , a LCOTHER model of LCOTHER - induced LCDiseaseOrPhenotypicFeature was used , and LCOrganismTaxon embryonic proximal tubule ( LCOTHER ) cell damage was assessed .	0
LCOTHER AND METHODS : We examined associations between 54 polymorphisms that tag the known common variants ( minor allele frequency > 0 . 05 ) in 10 genes involved in oxidative damage repair ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER ) and survival in 4 , 470 LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Oxidative stress was assessed by determining plasma and liver levels of LCOTHER - LCOTHER ( LCOTHER ) - LCOTHER , LCOTHER LCOTHER ( LCChemicalEntity ) , and LCOTHER LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) .	0
RESULTS : Nontoxic doses of LCOTHER reduced LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature from LCOTHER and LCOTHER in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCChemicalEntity neither reduced LCOTHER , LCOTHER LCOTHER , nor the in vitro LCOTHER from LCOTHER .	0
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOrganismTaxon with LCOTHER and LCOrganismTaxon with healthy pregnancies .	0
This is the first known constitutional rearrangement of LCGeneOrGeneProduct , and further systematic genetic analysis and clinical studies of DGAP128 may offer unique insights into the role of LCGeneOrGeneProduct in neurodevelopment . LCOTHER prevented and reversed LCOTHER - induced LCOTHER in the LCOTHER .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER .	0
CONCLUSION : These data provide strong support for the hypothesis that common variation in LCOTHER is associated with prognosis after a diagnosis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . A novel LCGeneOrGeneProduct nonsense mutation ( LCOTHER ) in a German family with LCOTHER LCOTHER LCOTHER LCOTHER .	0
OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of LCOTHER and LCChemicalEntity in LCOrganismTaxon with LCOTHER LCOTHER ( LCOTHER ) .	0
The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters ( LCChemicalEntity , LCOTHER , LCOTHER and LCOTHER ) of LCOTHER - ( LCOTHER - LCOTHER ) LCOTHER ( LCOTHER ) in comparison to its parent compound , LCChemicalEntity LCChemicalEntity ( LCOTHER ) .	0
Thus , LCOTHER reduced LCDiseaseOrPhenotypicFeature burden through associated cytostatic and anti - angiogenic effects . This dual effect of LCOTHER on LCDiseaseOrPhenotypicFeature tissue could contribute to its recently reported efficiency in refractory LCOTHER resistant to conventional chemotherapy . Rapid reversal of anticoagulation reduces LCOTHER volume in a LCOTHER model of LCOTHER - associated LCOTHER LCOTHER .	0
LCOTHER deficiency in non - parenchymal cells , but not in parenchymal cells , reduced LCOTHER activity , LCOTHER ( LCOTHER ) - LCOTHER production , and LCDiseaseOrPhenotypicFeature stem cell marker ( LCGeneOrGeneProduct and LCOTHER LCOTHER LCOTHER LCOTHER [ LCOTHER ] ) expression , leading to attenuated LCOTHER potential .	0
In five LCOrganismTaxon LCOTHER . LCOTHER missense mutation was detected , of which four were homozygous and one was compound heterozygous : LCOTHER . LCOTHER LCOTHER ( LCSequenceVariant . LCSequenceVariant ) and LCOTHER . LCOTHER .	0
RESULTS : The rare allele of the tagging single nucleotide polymorphism ( SNP ) LCSequenceVariant is associated with an increased risk of LCOTHER ( hazard ratio = 1 . 26 per rare allele carried , 95% confidence interval : 1 . 12 to 1 . 42 ; P = 0 . 0001 ) , which was not attenuated after adjusting for LCDiseaseOrPhenotypicFeature stage , grade , and treatment .	0
Stimulation of LCOTHER significantly attenuates HG - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , suggesting LCOTHER would be a promising potential therapeutic target for LCOTHER . Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
The LCOTHER homozygous for LCOTHER had severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with the triad of LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER at the age of 58 years .	0
In this study , utilizing LCOTHER - LCOTHER - yellow fluorescent protein ( YFP ) and LCGeneOrGeneProduct - LCGeneOrGeneProduct - GFP dual reporter LCOTHER , we show that primary LCOTHER LCOTHER - induced LCOTHER ( + ) YFP ( + ) GFP ( + ) T cells have limited memory potential , do not stably express LCOTHER - LCOTHER , and are disproportionately lost from the Ag - experienced LCGeneOrGeneProduct ( + ) T cell memory population during the maintenance phase postinfection .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCGeneOrGeneProduct .	0
The metrics from DNA damage and repair study were correlated with the genotypes of common polymorphisms of the LCOTHER and LCOTHER genes : a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER of the LCOTHER gene producing a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCSequenceVariant polymorphism ) and a LCSequenceVariant - - > LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant ( 5 ' - untranslated region ) of the LCOTHER gene ( the LCOTHER polymorphism ) .	0
LCOTHER LCOTHER is located near the LCChemicalEntity insertion sequence element in the LCOTHER 3 ' untranslated region , and the rare allele of this SNP is associated with an increased risk of LCDiseaseOrPhenotypicFeature , with a hazard ratio of 1 . 27 per rare allele carried ( 95% CI , 1 . 13 to 11 . 43 ) .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCGeneOrGeneProduct [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
CONCLUSION : As LCChemicalEntity exacerbated LCOTHER LCOTHER LCOTHER LCOTHER without an improvement in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to LCOTHER in day surgery . LCOTHER - induced LCOTHER + overload causes LCOTHER and triggers apoptosis through LCOTHER LCOTHER signaling pathway in LCOTHER .	0
LCOTHER consists of three pairs of non - identical polypeptide chains , encoded by different genes ( LCGeneOrGeneProduct LCGeneOrGeneProduct [ LCOTHER ] , LCOTHER LCOTHER [ LCOTHER ] and LCGeneOrGeneProduct LCGeneOrGeneProduct [ LCOTHER ] ) .	0
There have been concerns that the risk of cardiovascular LCOTHER events may be higher with LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct - specific inhibitors than nonselective LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) .	0
RESULTS : The results show that the LCOTHER polymorphism is present in LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER in the 5 ' UTR sequence ( + 25 ) of the LCOTHER - LCOTHER gene , known to affect the LCGeneOrGeneProduct ( LCOTHER homologue of LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ) binding site 5 ' - GGTTAT - 3 ' .	0
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCOTHER . LCOTHER ] have been reported in Japanese LCOrganismTaxon , but not in LCOTHER LCOTHER from other ethnic groups .	0
The LCOTHER - LCOTHER receptors LCOTHER and LCGeneOrGeneProduct were present in LCDiseaseOrPhenotypicFeature invadopodia ( processes mediating invasion ) , partially colocalized with LCOTHER LCOTHER LCOTHER and the LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER and coimmunoprecipitated with LCOTHER ( LCOTHER ) - LCOTHER .	0
Altogether , our results suggest that LCOTHER deficiency cooperates with LCGeneOrGeneProduct - LCGeneOrGeneProduct in promoting LCOTHER LCOTHER LCOTHER / LCOTHER LCOTHER LCOTHER in LCOrganismTaxon , possibly by specifically enforcing marginal zone B cell accumulation , increasing LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER expression , and rendering B cells independent of LCOTHER LCOTHER LCOTHER LCOTHER for survival . Association of adipocyte genes with LCOTHER expression : a microarray analysis of subcutaneous and omental adipose tissue in morbidly LCOTHER subjects .	0
The fact that no truncation or frame shift mutations have been found in any of the LCOTHER LCOTHER , coupled with our recent finding that some breeding pairs of LCOTHER LCOTHER knockout LCOTHER yield litters that show not only LCOTHER , but also severe LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOTHER . Midline B3 LCOTHER nerves in LCOrganismTaxon medulla are involved in LCOTHER effect of LCOTHER .	0
The LCOrganismTaxon showed an LCOTHER mutation that has been described in an Asian population and LCOTHER LCOrganismTaxon , along with a novel frameshift mutation , LCOTHER .	0
An MspI polymorphism , producing a 3 . 7 kb band , may prove useful in assessing this gene ' s involvement in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature involving opiatergic systems . An LCOTHER - LCOTHER LCSequenceVariant - > LCSequenceVariant gene polymorphism associated with LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER gene and high LCOTHER LCOTHER production .	0
Three LCOTHER - LCOTHER LCOTHER with LCOTHER mutations demonstrated a durable response and one small LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOrganismTaxon with LCOTHER LCOTHER mutation showed progression after LCOTHER treatment .	0
The LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) enzymes synthesize the LCOTHER LCOTHER LCOTHER - LCOTHER ( LCChemicalEntity ( LCChemicalEntity ) LCChemicalEntity ) , which has been detected at the Golgi complex and endosomal compartments and recruits LCOTHER adaptors .	0
In the present study , the effect of chronic pre - treatment with LCOTHER on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) activities following LCOTHER LCOTHER and their relation with LCGeneOrGeneProduct were assessed .	0
BACKGROUND : LCOTHER , a kinase inhibitor active against various solid LCDiseaseOrPhenotypicFeature , induces oxidative stress and ferroptosis , a new form of oxidative LCDiseaseOrPhenotypicFeature , in some LCOTHER cells .	0
In vivo induction of airway LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
Certain concepts concerning LCGeneOrGeneProduct / LCOTHER action modes have been challenged by in vivo studies : LCGeneOrGeneProduct - LCGeneOrGeneProduct levels are elevated in maturing erythroblasts , but not in their progenitors ; truncated LCOTHER alleles that lack a major LCOTHER / LCOTHER recruitment site nonetheless promote LCOTHER ; and LCOTHER disruption unexpectedly bolsters erythropoiesis .	0
Compound 1 is a potent LCOTHER ( LCOTHER ) / LCOTHER ( LCOTHER ) LCOTHER LCOTHER in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of LCOTHER ' LCOTHER LCOTHER including LCOTHER and LCOTHER models of LCOTHER - induced LCDiseaseOrPhenotypicFeature , LCOTHER model of LCOTHER - induced LCOTHER , LCOTHER LCOTHER - LCOTHER ( LCChemicalEntity - LCChemicalEntity ) lesion model of drug - induced rotation , and LCOTHER - treated non - LCOTHER primate model . Coincidence of mutations in different connexin genes in Hungarian LCOTHER .	0
Patients taking LCOTHER and LCChemicalEntity must be examined for LCOTHER LCOTHER and its consequences . LCOTHER phenotype and the pharmacokinetics and LCOTHER - LCOTHER LCOTHER pharmacodynamics of LCChemicalEntity and its enantiomers .	0
The aim of this study was therefore to investigate the influence of mutations in these LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct genes ( LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER / LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
LCOTHER and other LCOTHER - LCOTHER / LCOTHER / growth - factors activate LCOTHER via LCOTHER LCOTHER ( LCGeneOrGeneProduct / LCGeneOrGeneProduct ) , LCOTHER and LCOTHER but not cytosolic LCOTHER or LCOTHER .	0
Our study suggests that Alu is a promoting factor for the genomic recombinations in both LCGeneOrGeneProduct and LCOTHER , and the local Alu density may be involved in shaping the deletion pattern . LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct expression is associated with LCOTHER and LCOTHER mutations in LCOTHER LCOTHER .	0
Therefore , our results indicate that LCOTHER B cells have already acquired enhanced survival and growth capabilities before transformation , and that elevated LCOTHER levels confer resistance to pharmacologic inhibitors of LCOTHER signaling , which has significant implications for LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature treatment . Genetic investigation of four meiotic genes in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Dysregulated expression of LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is found in the cells of LCOTHER who have LCOTHER LCOTHER LCOTHER ( LCOTHER ) , a genetic disorder of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER and progressive LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
BACKGROUND : Increase of the expression of LCGeneOrGeneProduct - LCGeneOrGeneProduct gene and high production of LCOTHER LCOTHER ( LCOTHER ) in LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER is widely accepted as associated with a milder or even asymptomatic disease .	0
Differences were found for serum FBG , FINS , HOMA - IR , and HOMA - beta , and placental LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER .	0
In summary , no constitutive open LCGeneOrGeneProduct channels were detected in patch - clamp experiments from transfected LCCellLine cells .	0
A positive LCOTHER result in plasma DNA has a high predictive value for LCOTHER LCGeneOrGeneProduct status and for favorable clinical course on LCOTHER - targeted therapy and could therefore be useful in guiding clinical decisions in LCOTHER with insufficient or unavailable LCOTHER specimens . Dynamic subunit turnover in LCGeneOrGeneProduct - LCGeneOrGeneProduct assemblies is regulated by LCOTHER to mediate membrane remodelling during cytokinesis .	0
CONCLUSION : Our results suggest that use of high - dose LCOTHER in older LCOrganismTaxon in conjunction with cardiopulmonary bypass and open - chamber cardiac surgery is associated with clinical LCOTHER in susceptible LCOrganismTaxon . Cardioprotective effect of LCOTHER LCOTHER LCOTHER on LCOTHER - induced LCOTHER LCOTHER in LCOTHER .	0
It is concluded that oxidative tubular damage plays an important role in the LCOTHER - induced LCDiseaseOrPhenotypicFeature and the modulation of oxidative stress with LCOTHER reduces the LCOTHER - induced LCOTHER LCOTHER both at the biochemical and histological levels . LCOTHER LCOTHER LCOTHER - LCOTHER interacts with LCOTHER and LCOTHER to modulate LCGeneOrGeneProduct secretion in LCOTHER gonadotrophs .	0
To assess the LCChemicalEntity effects of LCChemicalEntity ( LCOTHER ) on LCOTHER ( LCOTHER ) - induced LCOTHER , 60 male Sprague - Dawley LCOTHER were treated with LCOTHER 30 mg / kg / day or tap water for 15 days .	0
Crossing LCOTHER - Cre LCOTHER with LCGeneOrGeneProduct flx / flx LCOTHER generated LCOTHER flx / D : LCGeneOrGeneProduct Cre / + females that were overtly normal but infertile .	0
Our recent study showed that LCOTHER / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCGeneOrGeneProduct and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct .	0
LCOTHER AND METHODS : We examined associations between 54 polymorphisms that tag the known common variants ( minor allele frequency > 0 . 05 ) in 10 genes involved in oxidative damage repair ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct , and LCOTHER ) and survival in 4 , 470 LCOTHER with LCOTHER LCOTHER .	0
Increased LCGeneOrGeneProduct was discovered in STs and FLSs from LCOrganismTaxon with LCOTHER .	0
Although LCDiseaseOrPhenotypicFeature affects African Americans disproportionately compared to European Americans , there has been no comprehensive analysis of the LCGeneOrGeneProduct region in relationship to LCOTHER in African Americans .	0
Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental LCOTHER . Exaggerated expression of LCOTHER mediators in LCOTHER LCOTHER LCOTHER knockout ( LCGeneOrGeneProduct - / - ) LCOTHER with LCOTHER ( LCOTHER ) - induced LCDiseaseOrPhenotypicFeature .	0
RESULTS : We identified in LCOTHER LCOTHER - positive CSC that expressed LCOTHER and LCOTHER , formed spheroids , and initiated LCDiseaseOrPhenotypicFeature in nude LCOrganismTaxon .	0
Decreased sensitivity to LCChemicalEntity coincided with the appearance of amino acid substitution LCOTHER in DNA polymerase , whereas cross - resistance to LCOTHER and LCOTHER was due to the LCSequenceVariant substitution .	0
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCDiseaseOrPhenotypicFeature - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCChemicalEntity to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	0
Eleven subjects presented LCOTHER homozygous single - base mutations ( two first cousins and four unrelated LCOTHER with LCSequenceVariant , two with LCSequenceVariant , one with LCOTHER , one with LCOTHER , and one with LCOTHER plus the LCOTHER variant in heterozygosis ) , whereas four were compound heterozygotes ( one with LCOTHER / LCOTHER + LCOTHER > LCOTHER , one with LCOTHER / LCOTHER , and two brothers with LCOTHER / LCOTHER ) .	0
Low activity of LCOTHER plasma LCOTHER with LCOTHER ( LCChemicalEntity ) and LCOTHER , and values of LCOTHER and LCChemicalEntity numbers fit with heterozygous atypical silent genotype .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCGeneOrGeneProduct - specific LCGeneOrGeneProduct .	0
On the contrary , LCOTHER does not affect the increase in LCGeneOrGeneProduct - IR neurons observed in WRS LCOrganismTaxon and does not interfere with the mild LCOTHER LCOTHER due to WRS .	0
WHAT IS KNOWN AND OBJECTIVE : LCGeneOrGeneProduct is involved in the LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct pathway .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCGeneOrGeneProduct and LCOTHER ( LCOTHER ) , LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
Epigenetic anticancer drugs such as LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) inhibitors have been combined with existing anticancer drugs for synergistic or additive effects .	0
Additionally , when LCGeneOrGeneProduct genotype was cross classified with LCOTHER LCOTHER , significantly more cases than both LCDiseaseOrPhenotypicFeature and population controls were observed to have a short ( < 22 ) CAG / GG genotype ( P = 0 . 006 ) .	0
We propose here a possible pathological tie between chronic tubulointerstitial LCOTHER and progressive LCOTHER LCOTHER . LCOTHER potential of LCChemicalEntity and LCChemicalEntity in LCOTHER .	0
Low activity of LCOTHER plasma LCOTHER with LCOTHER ( LCOTHER ) and LCChemicalEntity , and values of LCChemicalEntity and LCOTHER numbers fit with heterozygous atypical silent genotype .	0
The LCOTHER were assigned into four groups ( n = 10 per group ) , as follows : Control LCOTHER ; LCOTHER + LCOTHER ; LCOTHER + LCChemicalEntity ; LCOTHER + LCOTHER + LCChemicalEntity .	0
PURPOSE : LCChemicalEntity LCChemicalEntity has many beneficial functions in the LCOrganismTaxon body at the right amounts , but it can also be hazardous if it is produced in amounts more than needed and has therefore been studied in relation to several LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER .	0
These results indicated that the presence of LCOTHER - * 2 allele decreases risk for LCOrganismTaxon LCDiseaseOrPhenotypicFeature conferred by LCOTHER - LCOTHER , possibly by increasing the AS isoform of LCOTHER . Vaccine candidates derived from a novel infectious cDNA clone of an American genotype LCOTHER LCOTHER LCOTHER LCOTHER .	0
This fits with the reduced concentration of LCOTHER . LCOTHER / LCSequenceVariant . LCSequenceVariant - LCOTHER . LCOTHER tetrameric enzyme in the plasma and non - detectable fast moving - bands on electrophoresis gels . The promoter of inducible LCOTHER LCOTHER LCOTHER implicated in LCDiseaseOrPhenotypicFeature based on genetic analysis and nuclear factor binding .	0
LCOTHER LCOTHER gene polymorphisms have been demonstrated to associate with LCOTHER LCOTHER risk , of which LCGeneOrGeneProduct - LCSequenceVariant / LCSequenceVariant and - LCSequenceVariant / LCSequenceVariant changes have been well investigated due to the possibility that they may alter the LCGeneOrGeneProduct transcription .	0
CONCLUSIONS : The functional LCOTHER LCOTHER polymorphism may have an impact on the risk of LCChemicalEntity - related LCOTHER among childhood LCOTHER survivors by modulating the intracardiac formation of LCOTHER LCChemicalEntity LCChemicalEntity metabolites .	0
Nominal association with the disorder was observed for LCOTHER - CC , and phenotypic variability in LCOTHER symptoms was influenced by LCOTHER , LCSequenceVariant and LCSequenceVariant .	0
The association between LCChemicalEntity dose and QT , and LCChemicalEntity dose and reporting of LCOTHER was assessed using multivariate linear regression and logistic regression , respectively .	0
Administration of LCOTHER LCOTHER suppressed LCOTHER growth in C3H / HeN LCOTHER , but not in LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) - mutant C3H / HeJ LCOTHER , by reducing serum levels of LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCGeneOrGeneProduct - LCGeneOrGeneProduct , while increasing LCOTHER ( LCOTHER ) - LCOTHER levels .	0
RESULTS : HAT adipose tissue demonstrated increased LCOTHER related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCGeneOrGeneProduct ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCGeneOrGeneProduct ) .	0
Transfection into LCOTHER LCOTHER ovary cells of a cDNA representing only the coding region of LCGeneOrGeneProduct , carrying LCSequenceVariant , LCSequenceVariant , LCSequenceVariant , LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant , resulted in 1 . 5 - fold lower mRNA levels only for LCOTHER - LCOTHER , and more than 10 - fold lower LCOTHER protein levels , measured by Western blotting and receptor binding assay .	0
However , physicians should be aware of the possibility that LCChemicalEntity can be associated with LCOTHER in some individuals , especially those receiving concomitant LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) after orthotopic liver transplantation ( OLTX ) using LCGeneOrGeneProduct - based immunotherapy : risk of development and treatment .	0
There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( LCOTHER < LCOTHER < LCOTHER ) , with subjects who received LCOTHER and LCOTHER exhibiting significant LCOTHER LCOTHER compared with subjects who were treated with LCChemicalEntity ( LCOTHER vs LCOTHER , t ( 33 ) = - 4 . 29 ; P < . 001 ; LCChemicalEntity vs LCOTHER , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .	0
The search for LCOTHER - associated polymorphisms ( such as the XmnI , LCOTHER and LCGeneOrGeneProduct polymorphisms ) has recently gained great attention , in order to stratify LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCOTHER with respect to expectancy of the first transfusion , need for annual intake of blood , response to LCOTHER inducers ( the most studied of which is hydroxyurea ) .	0
Here we show that LCOTHER blockade with monoclonal antibodies perturbs the BM vascular niche of sub - lethally irradiated LCOTHER , resulting in increased LCOTHER ( + ) , LCGeneOrGeneProduct - LCGeneOrGeneProduct ( + ) and LCOTHER - LCOTHER ( + ) vessel density , and also increased megakaryocytes , whereas LCGeneOrGeneProduct ( + ) , LCOTHER ( + ) , LCOTHER ( + ) and LCOTHER ( + ) vessel density remained unaltered .	0
RESULTS : HAT adipose tissue demonstrated increased LCOTHER related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCGeneOrGeneProduct , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	0
The LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature resolved completely after we reduced the dose of LCChemicalEntity down to 800 mg per day .	0
RESULTS : LCOTHER with LCOTHER had higher serum LCGeneOrGeneProduct and LCOTHER ( P < 0 . 001 for LCOTHER , LCOTHER , LCOTHER and LCOTHER ) and lower LCGeneOrGeneProduct ( P = 0 . 008 ) levels than LCOTHER LCOTHER without LCOTHER .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCGeneOrGeneProduct ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCGeneOrGeneProduct [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
EXPERIMENTAL DESIGN : Because of their widespread use , the LCOTHER LCOTHER following coadministration of LCChemicalEntity and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of LCOTHER and LCOTHER blood progenitor cells to LCOTHER , LCOTHER , and LCOTHER + / - LCChemicalEntity was determined in granulocyte - macrophage colony forming assays .	0
One week later , they received repeatedly vehicles ( saline , LCOTHER , saline + LCOTHER ) , LCChemicalEntity ( 2 microg / 0 . 5 microl saline / side ; 30 min before training ) , LCOTHER ( 2 , 4 and 8 microg / 0 . 5 microl LCChemicalEntity / side ; 20 min before training ) and LCOTHER ( 2 microg / 0 . 5 microl ; 30 min before LCOTHER injection ) + LCOTHER ( 4 microg / 0 . 5 microl LCOTHER ) through cannulae each day .	0
METHODS : DNA was collected from 191 LCOTHER ( mean age 44 + / - 18 years , 61 LCOrganismTaxon , 130 LCOrganismTaxon ) .	0
These findings suggested that LCOTHER - LCOTHER possesses LCDiseaseOrPhenotypicFeature - suppressing activity and can be a valuable target for developing new LCDiseaseOrPhenotypicFeature therapeutic strategies . Chronic treatment with LCOTHER suppresses LCOTHER - LCOTHER LCOTHER LCOTHER signaling and attenuates LCOTHER LCOTHER LCOTHER following LCOTHER LCOTHER .	0
Loss of LCOTHER expression in LCOrganismTaxon altered the LCOTHER induction of LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct .	0
Our results indicate a regulatory role of LCGeneOrGeneProduct in LCOTHER / LCOTHER - dependent mitochondrial release of LCOTHER LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct activation .	0
Urinary LCOTHER , LCOTHER and LCChemicalEntity were elevated in LCOTHER - fed WT but not in LCOTHER - fed LCOTHER KO LCOrganismTaxon .	0
Taken together , our results demonstrated that LCOTHER is a LCOTHER ( LCSequenceVariant ) - cooperating oncogene required for LCOTHER ( LCOTHER ) - induced immortalization and transformation , and targeting LCOTHER - LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct may , therefore , have therapeutic value for senescence - based LCOTHER treatment . In vivo evidences suggesting the role of oxidative stress in pathogenesis of LCOTHER - induced LCOTHER : protection by LCOTHER .	0
The high penetrance of the LCOTHER trait in this family together with the study of the asymptomatic gene carriers will allow us to confirm the proposed genotype - phenotype correlation and to evaluate the potential use of mutational analysis of the LCOTHER / LCGeneOrGeneProduct gene in the early detection of relatives at risk for LCOTHER . LCOTHER LCOTHER LCOTHER LCOTHER with LCOTHER LCOTHER and LCOTHER associated with mutations in exon 49 of LCGeneOrGeneProduct .	0
Some other mechanism than those being reported herein should be further investigated . Carrier frequency of mutation LCSequenceVariant in the LCOTHER gene in a population of Polish pediatric LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
There was also an excess of LCOTHER in LCChemicalEntity users vs nonusers with LCDiseaseOrPhenotypicFeature ( OR , 2 . 7 ; 95% CI , 1 . 6 - 4 . 4 ; P < 0 . 001 ) but none in LCOTHER users with LCOTHER / LCOTHER ( OR , 1 . 3 ; 95% CI , 0 . 9 - 1 . 7 ; P = 0 . 33 ; P difference = 0 . 01 ) .	0
These studies have produced intriguing but inconsistent results , potentially because the known functional variants : LCGeneOrGeneProduct LCOTHER and LCSequenceVariant , LCOTHER LCOTHER and LCOTHER , and LCOTHER LCOTHER provided an incomplete picture of the total functional diversity at these genes .	0
CONCLUSIONS : The utilization of LCOTHER to correct LCOTHER induced by anesthesia has a negative impact on S ( c ) O ( 2 ) while LCOTHER maintains frontal lobe oxygenation potentially related to an increase in CO . LCOTHER LCOTHER ( LCOTHER - LCOTHER ) and LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) Single Nucleotide Polymorphisms ( SNPs ) , LCOTHER and Metabolism in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in Inner Mongolia .	0
LCOTHER - LCOTHER , which prevents LCOTHER binding to LCGeneOrGeneProduct - LCGeneOrGeneProduct partially inhibited LCOTHER - activation , as well as reduced LCOTHER - induced LCGeneOrGeneProduct / LCGeneOrGeneProduct activation and LCOTHER release induced by LCOTHER or LCOTHER .	0
As the LCOTHER LCOTHER in this LCOrganismTaxon was considered to have been due to LCChemicalEntity - LCChemicalEntity - induced LCOTHER , the administration of LCOTHER - LCOTHER was abandoned .	0
LCGeneOrGeneProduct - LCGeneOrGeneProduct turnover depended on the LCOTHER LCGeneOrGeneProduct , which accumulated at the midbody simultaneously with LCOTHER - LCOTHER subunits , and was required for assembly of functional LCOTHER - LCOTHER structures .	0
In the present work we determined the level of basal and oxidative DNA damage and the kinetics of removal of DNA damage induced by LCOTHER LCOTHER in peripheral blood lymphocytes of 30 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOrganismTaxon and 30 healthy individuals .	0
The mechanism may be related to the improvement of LCOTHER ( LCOTHER + ) handling . LCGeneOrGeneProduct LCGeneOrGeneProduct deletion in myeloid cells affects the LCOTHER response in allergic LCOTHER , but not lung mechanics , in female LCOrganismTaxon .	0
In vivo , LCOTHER was protective in two distinct models of LCOTHER LCOTHER LCOTHER ( LCOTHER ) : LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and two - hit LCDiseaseOrPhenotypicFeature caused by suboptimal mechanical ventilation and injection of LCOTHER LCOTHER - activating peptide .	0
On the whole , our findings indicate that the absence of LCGeneOrGeneProduct plays a cardioprotective role in LCOTHER LCOTHER LCOTHER by promoting changes in LCOTHER / LCOTHER signalling . Long - Lived LCOTHER + LCGeneOrGeneProduct - LCGeneOrGeneProduct + T Cells rather than Short - Lived LCOTHER + LCOTHER - LCOTHER + LCOTHER - LCOTHER + T Cells Initiate Rapid LCOTHER - LCOTHER Production To Suppress Anamnestic T Cell Responses during Secondary LCOTHER LCOTHER .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCGeneOrGeneProduct - specific LCOTHER .	0
Meanwhile apoptosis related proteins LCOTHER and LCOTHER were involved in LCOTHER LCOTHER and LCOTHER LCOTHER model , but not LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER or LCOTHER . LCOTHER and LCOTHER are closely relevant in the tissue splices of deminopathies LCOTHER and LCOTHER with LCDiseaseOrPhenotypicFeature at protein lever .	0
The fact that no truncation or frame shift mutations have been found in any of the LCOTHER LCOTHER , coupled with our recent finding that some breeding pairs of LCOTHER LCOTHER knockout LCOTHER yield litters that show not only LCDiseaseOrPhenotypicFeature , but also severe LCOTHER and LCOTHER LCOTHER , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOTHER . Midline B3 LCOTHER nerves in LCOrganismTaxon medulla are involved in LCOTHER effect of LCOTHER .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
RESULTS : LCOTHER ablation had no influence on the development of LCGeneOrGeneProduct - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCGeneOrGeneProduct - specific LCOTHER .	0
As such , the proposed implications of LCGeneOrGeneProduct in invasion , disease progression and as a potential therapeutic target warrant further investigation . Influence of LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) polymorphisms on spontaneous and treatment - induced recovery from LCOTHER LCOTHER LCOTHER LCOTHER .	0
CONCLUSION : Taken together with previous studies of LCOTHER LCOTHER mutations , these findings suggest that LCGeneOrGeneProduct - LCGeneOrGeneProduct deficiency due either to haploinsufficiency or to substantial activity loss due to dominant negative interference of the normal allele product ' s function can each contribute to the LCOTHER phenotype . Cytostatic and anti - angiogenic effects of LCOTHER in refractory LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Thus , LCOTHER plays a role in the pathogenesis of LCOTHER in Japan . Endothelial LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct mediates LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - induced intravitreal neovascularization in a LCOTHER model of LCOTHER LCOTHER LCOTHER .	0
Our findings show that microinjection of LCOTHER into the CA1 region of the hippocampus improves the LCOTHER - induced LCDiseaseOrPhenotypicFeature . LCGeneOrGeneProduct : A LCOTHER LCOTHER LCOTHER LCOTHER candidate susceptibility gene? The chromosomal region 12q24 has been previously implicated by linkage studies of both LCOTHER LCOTHER and LCOTHER LCOTHER LCOTHER and we have reported two pedigrees segregating both LCOTHER LCOTHER and LCOTHER ' LCOTHER LCOTHER that show linkage across this region .	0
RESULTS : Quantitative PCR indicated that LCOTHER is well expressed in LCOrganismTaxon liver and LCOTHER liver slices and that the classical LCOTHER targets LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct are robustly induced by LCOTHER activation .	0
We suggest that LCOTHER may be LCOTHER in the setting of LCOTHER LCOTHER LCOTHER via LCGeneOrGeneProduct LCGeneOrGeneProduct activation . Association of LCOTHER polymorphisms and LCChemicalEntity - induced LCOTHER LCOTHER in Chinese LCOTHER LCOTHER .	0
RESULTS : Nontoxic doses of LCOTHER reduced LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature from LCOTHER and LCOTHER in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCOTHER , LCOTHER LCOTHER , nor the in vitro LCOTHER from LCChemicalEntity .	0
The severe phenotype with seriously LCOTHER LCOTHER LCOTHER , LCOTHER behaviour , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER is probably due to the dominant negative effect of the LCOTHER mutant protein and the absence of any functional LCGeneOrGeneProduct - LCGeneOrGeneProduct . The LCOTHER LCOTHER confers protection against diet - induced LCOTHER , LCOTHER , and LCDiseaseOrPhenotypicFeature in female LCOTHER .	0
An opposite effect was observed for the LCOTHER LCSequenceVariant and LCGeneOrGeneProduct LCOTHER variants , with a lower prevalence of ACCA antibodies ( 23 . 4% versus 35% , p = 0 . 013 ) and Omp antibodies ( 20 . 5% versus 34 . 6% , p = 0 . 009 ) , respectively .	0
Our data support potential interactions between the LCOTHER , LCGeneOrGeneProduct - LCOTHER and LCGeneOrGeneProduct - LCOTHER pathways , and possible influence by LCOTHER or LCOTHER mutation on therapy or chemoprevention targeting LCOTHER . Identification of novel type LCOTHER LCOTHER gene mutations resulting in severe LCOTHER LCOTHER LCOTHER LCOTHER .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
Our findings offer new opportunities to understand the molecular mechanisms accounting for the B - cell growth - promoting activity of vp17s . Mutation analysis of LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER genes in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature / LCOTHER LCOTHER LCOTHER .	0
These findings extend the body of evidence for compound heterozygous mutations leading to LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature and provide the basis for prenatal diagnosis in this family . Detection of LCOTHER mutations in plasma DNA from LCOTHER LCOTHER LCOTHER by mass spectrometry genotyping is predictive of LCDiseaseOrPhenotypicFeature LCOTHER status and response to LCOTHER inhibitors .	0
We suggest that LCChemicalEntity may be LCOTHER in the setting of LCOTHER LCOTHER LCOTHER via LCOTHER LCOTHER activation . Association of LCOTHER polymorphisms and LCOTHER - induced LCOTHER LCOTHER in Chinese LCDiseaseOrPhenotypicFeature LCOTHER .	0
In particular , the drug prevents the decrease in LCOTHER - , LCOTHER - , LCOTHER - , LCOTHER - , and LCGeneOrGeneProduct - immunoreactivity ( IR ) and the increase in LCGeneOrGeneProduct - , and LCOTHER - IR .	0
Of these , LCGeneOrGeneProduct and LCGeneOrGeneProduct have been reported to contribute to intravitreal neovascularization ( IVNV ) in LCOTHER - induced LCOTHER ( LCOTHER ) models .	0
Our results show that treatment with LCOTHER can ameliorate LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and deposition of the extracellular matrix ( ECM ) components ( including LCGeneOrGeneProduct LCGeneOrGeneProduct and LCOTHER LCOTHER ) .	0
These findings suggested that LCOTHER - LCOTHER possesses LCOTHER - suppressing activity and can be a valuable target for developing new LCOTHER therapeutic strategies . Chronic treatment with LCOTHER suppresses LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct signaling and attenuates LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature following LCOTHER LCOTHER .	0
The effect of LCOTHER ( LCOTHER - LCOTHER antagonist ) on LCOTHER ( LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist ) - induced LCDiseaseOrPhenotypicFeature in Morris water maze ( MWM ) was investigated .	0
METHODS : LCOrganismTaxon peripheral blood mononuclear cells ( PBMCs ) were isolated from a Taiwanese LCDiseaseOrPhenotypicFeature family bearing the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in the LCOTHER gene , corresponding to a LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) in the LCOTHER - LCOTHER protein .	0
We conclude that defects in LCOTHER - LCOTHER homeostasis and LCOTHER LCOTHER LCOTHER LCOTHER proteolysis may play roles in mediation of LCOTHER in individuals with LCOTHER mutations . LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature associated with LCChemicalEntity treatment for LCOTHER LCOTHER .	0
LCGeneOrGeneProduct activates environmental procarcinogens and catalyzes oxidative metabolism of estrogens and is likely to play an important role in the etiology of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Genetic analysis of LCGeneOrGeneProduct seems to be of limited significance in the differential diagnosis of LCOTHER without LCOTHER LCOTHER LCOTHER LCOTHER . High LCOTHER diet - fed LCOTHER LCOTHER are highly sensitive to LCChemicalEntity - induced LCOTHER .	0
Mutations in the coding region of the LCOTHER - LCOTHER gene are not associated with LCOTHER LCOTHER LCOTHER or with changes in LCGeneOrGeneProduct responses to LCChemicalEntity among the Caucasians examined . LCOTHER - associated LCOTHER in a healthy adolescent receiving LCOTHER for LCOTHER LCOTHER control .	0
Thus , LCGeneOrGeneProduct plays a role in the pathogenesis of LCOTHER in Japan . Endothelial LCOTHER LCOTHER LCOTHER mediates LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER - induced intravitreal neovascularization in a LCOrganismTaxon model of LCOTHER LCOTHER LCOTHER .	0
PURPOSE : This study was designed to establish a LCOrganismTaxon model of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) by LCOTHER LCOTHER ( LCOTHER ( LCOTHER ) ) - induced LCOTHER LCOTHER and to explore the potential role of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER ( LCOTHER ) and their endogenous inhibitors ( TIMPs ) in LCOTHER formation .	0
LCGeneOrGeneProduct is likely to be an LCOTHER - susceptibility gene and LCOTHER mutations may increase the risk of developing a LCOTHER LCOTHER rather than being a direct causative mutation . The differential effects of LCChemicalEntity and LCOTHER on LCOTHER LCOTHER release , LCOTHER gene expression and LCOTHER in a clinical LCOTHER model .	0
Notably , administration of a LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist further reduced LCChemicalEntity LCChemicalEntity levels into the markedly hypoglycemic range in overnight - fasted , LCOTHER - treated LCOTHER ( - / - ) LCOTHER .	0
Four binary comparisons were made : WT control versus LCChemicalEntity treatment ( 48 h ) , LCOTHER ( - / - ) control versus LCOTHER treatment ( 48 h ) , WT control versus LCOTHER ( - / - ) control , and WT with LCChemicalEntity treatment ( 48 h ) versus LCOTHER ( - / - ) with LCOTHER treatment ( 48 h ) .	0
Given the marked degree of efficacy of subcutaneous LCOTHER treatment in fluctuating LCOTHER ' LCOTHER LCOTHER , this approach seems to deserve more widespread clinical use . LCGeneOrGeneProduct - LCGeneOrGeneProduct gene polymorphism in LCOrganismTaxon with LCOTHER LCOTHER LCOTHER .	0
The LCOTHER - LCOTHER receptors LCOTHER and LCOTHER were present in LCOTHER invadopodia ( processes mediating invasion ) , partially colocalized with LCOTHER LCOTHER LCOTHER and the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct and coimmunoprecipitated with LCOTHER ( LCOTHER ) - LCOTHER .	0
CONCLUSIONS : If ECG alone is used for specificity , the combination with dP / dtejc improved the sensitivity of the test and could be a cost - savings alternative to cardiac imaging or perfusion studies to detect LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , especially in LCOrganismTaxon unable to exercise . Two novel mutations , LCOTHER and LCOTHER , of the LCOTHER LCOTHER LCOTHER gene in Japanese LCOTHER with LCOTHER .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct ( LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
Immunohistochemical analysis revealed that LCOTHER LCOTHER significantly decreased the LCOTHER - induced overexpression of inducible LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCGeneOrGeneProduct in renal tissue .	0
Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher LCOTHER rate ensues . Behavioral and neurochemical studies in LCOTHER pretreated with LCOTHER LCOTHER in LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature .	0
transplanted LCOTHER in LCOTHER are reduced in LCOTHER - LCOTHER cells with LCGeneOrGeneProduct expression ( LCOTHER - LCOTHER - high ) , compared with LCOTHER - nonexpressing LCOTHER - LCOTHER cells ( LCOTHER - LCGeneOrGeneProduct - low ) .	0
In this study , we establish the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) or LCOTHER LCOTHER ( LCOTHER ) - induced LCOTHER LCOTHER LCOTHER LCOTHER in vivo and the LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER - stimulated LCOTHER proximal tubular epithelial cell ( LCOTHER - LCOTHER ) model in vitro .	0
This study showed that LCOTHER was more likely to be LCOTHER susceptibility gene at Chr . 1q31 based on the finding that the LCGeneOrGeneProduct and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCOTHER in a white population in LCOTHER , LCGeneOrGeneProduct , and LCOTHER genes showed a significant association with LCOTHER . Seven novel and six de novo LCOTHER gene mutations in LCOTHER with LCOTHER LCOTHER .	0
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCGeneOrGeneProduct / LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCGeneOrGeneProduct were dependent on LCOTHER expression in LCOTHER .	0
By contrast , no significant correlation was detected between the protein levels and LCOTHER age , histological type , or serum LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCGeneOrGeneProduct - LCGeneOrGeneProduct levels .	0
Chronic administration of LCGeneOrGeneProduct strongly reduced the blood pressure and production of LCOTHER and improved antioxidant capacity in LCOTHER - induced LCOTHER , suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LCOTHER . Role of LCOTHER LCOTHER LCOTHER LCOTHER in LCDiseaseOrPhenotypicFeature and migration of fibroblast - like synoviocytes in LCOTHER LCOTHER .	0
We report a case of LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) in a dizygotic twin who presented at 12 years of age with LCOTHER LCOTHER , LCOTHER LCOTHER , LCOTHER and LCOTHER with inappropriate kaliuresis , and LCOTHER LCOTHER LCOTHER with LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	0
LCGeneOrGeneProduct signalling was markedly impaired in LCOTHER - deficient chondrocytes as evidenced by reduced expression of known LCOTHER target genes as well as reduced phosphorylation of LCOTHER / LCOTHER / LCOTHER and LCOTHER / LCOTHER / LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct .	0
One possibility might be that individuals who are compound heterozygotes for LCOTHER mutations are more common than we realize . Omitting LCOTHER reduces LCDiseaseOrPhenotypicFeature and LCDiseaseOrPhenotypicFeature , without increasing LCOTHER , after LCOTHER for day surgery .	0
Mechanistic studies revealed that LCOTHER LCOrganismTaxon are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct , ( 3 ) decreased plasma LCOTHER levels , ( 4 ) decreased cardiac LCOTHER - LCOTHER oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCOTHER ) , ( 5 ) decreased mitochondrial LCOTHER - LCOTHER LCOTHER LCOTHER , and ( 6 ) 86% drop in cardiac LCOTHER levels accompanied by decreased LCOTHER / LCOTHER ratio after LCOTHER administration .	0
These findings suggest that LCOTHER - LCOTHER can negatively affect both cell proliferation and hippocampal dependent working memory and that these deficits can be reversed by the simultaneous administration of the antidepressant LCOTHER . LCOTHER deficiency confers enhanced myocardial protection in the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature by mediating the LCGeneOrGeneProduct / LCOTHER signalling pathway .	0
METHODS : We performed a systematic review of published and unpublished data from cohorts with LCDiseaseOrPhenotypicFeature or LCOTHER to compare the presence of LCOTHER in : ( 1 ) antithrombotic users vs nonantithrombotic users with LCOTHER ; ( 2 ) antithrombotic users vs nonusers with LCOTHER / LCDiseaseOrPhenotypicFeature ; and ( 3 ) LCOTHER vs LCOTHER events stratified by antithrombotic use .	0
We identified the minimal region of the LCOTHER promoter that confers inducibility by LCOTHER to a 133 base pair region containing an Anti - oxidant Response Element ( ARE ) and showed the essential role of the transcription factor LCGeneOrGeneProduct ( LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ) .	0
LCOTHER , like LCChemicalEntity , is a LCOTHER LCOTHER that has anti - LCOTHER property , although it also pro - LCDiseaseOrPhenotypicFeature that can cause various LCOTHER , including severe LCOTHER such as multiple LCOTHER .	0
BACKGROUND : LCDiseaseOrPhenotypicFeature ( LCOTHER ) , a rare recessive LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , is the most frequent genetic cause of LCOTHER LCOTHER LCOTHER in children and young adults .	0
PURPOSE : The purpose of this study was to analyze the value of germline and LCDiseaseOrPhenotypicFeature LCOTHER LCOTHER ( LCGeneOrGeneProduct ) genotyping as a prognostic marker in a series of LCOTHER LCOTHER LCOTHER receiving adjuvant LCOTHER ( LCOTHER ) - based treatment .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
METHOD : DNAs were extracted from 31 plasma samples from 31 LCOrganismTaxon and analyzed by both methods for LCOTHER Exon 19 deletion and LCGeneOrGeneProduct LCOTHER mutation .	0
The growth of LCOTHER LCOTHER xenografts in NOD / LCOTHER LCOrganismTaxon was also inhibited by the LCChemicalEntity - induced LCOTHER - LCOTHER overexpression .	0
Hepatic LCChemicalEntity concentration normalized after 3 and 5months of LCOTHER chelation therapy with LCOTHER , which was also associated with reduced LCGeneOrGeneProduct demands .	0
Notably , following treatment with LCOTHER siRNA or pcDNA3 . 1 - LCGeneOrGeneProduct , it was found that LCOTHER enhanced or weakened the upregulation of LCOTHER / LCOTHER - LCOTHER and downregulation of LCOTHER - LCOTHER in the LCCellLine cells , respectively .	0
The results suggest a novel role for the LCOTHER - LCOTHER axis in vascular EC protection that is critical for improvement of pathological states associated with increased vascular leakage and LCDiseaseOrPhenotypicFeature . Genetic polymorphisms in the LCOTHER LCOTHER LCOTHER gene LCOTHER and the LCOTHER ( LCOTHER ) LCOTHER : LCOTHER LCOTHER LCOTHER gene LCOTHER in LCOTHER who developed LCOTHER - related LCOTHER LCOTHER LCOTHER after childhood LCDiseaseOrPhenotypicFeature .	0
Decreased cardiac LCGeneOrGeneProduct and increased LCGeneOrGeneProduct further downregulated the cardioprotective LCOTHER / LCOTHER pathway .	0
This shift in balance may contribute to increased LCOTHER LCOTHER in LCOTHER ( - / - ) LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and altered neurochemical expression in micturition pathways . LCDiseaseOrPhenotypicFeature associated with LCOTHER : case presentation and literature review .	0
LCChemicalEntity treatment significantly ( p < or = 0 . 001 ) increased expression of LCOTHER and LCOTHER - LCOTHER in the urinary bladder of WT and LCOTHER ( - / - ) LCOTHER , but expression in LCOTHER ( - / - ) LCOrganismTaxon with LCOTHER treatment was significantly ( p < or = 0 . 001 ) greater ( 4 . 2 - to 13 - fold increase ) than that observed in WT urinary bladder ( 3 . 6 - to 5 - fold increase ) .	0
In a baby LCOTHER with early onset , severe LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and profound , isolated LCOTHER LCOTHER in skeletal muscle , we identified a disease - segregating homozygous mutation ( LCOTHER . LCOTHER > LCOTHER ) in LCGeneOrGeneProduct / LCOTHER , predicting a drastic change in a highly conserved amino - acid residue ( LCOTHER . LCOTHER ) .	0
The decreased capacity to concentrate urine is likely due to LCOTHER acutely disrupting the LCOTHER pathway and chronically reducing LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) and water channel ( LCOTHER ) expression in the inner medulla .	0
This SNP is part of a large linkage disequilibrium block , which contains LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER .	0
LCOTHER - activated LCOTHER led to an interaction between LCGeneOrGeneProduct - activated LCOTHER and LCGeneOrGeneProduct that mediated EC proliferation via activation of LCOTHER .	0
Our findings show that microinjection of LCOTHER into the CA1 region of the hippocampus improves the LCOTHER - induced LCDiseaseOrPhenotypicFeature . LCOTHER : A LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature candidate susceptibility gene? The chromosomal region 12q24 has been previously implicated by linkage studies of both LCOTHER LCOTHER and LCOTHER LCOTHER LCOTHER and we have reported two pedigrees segregating both LCOTHER LCOTHER and LCOTHER ' LCOTHER LCOTHER that show linkage across this region .	0
Its action mechanism was associated with the down - regulation of LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCGeneOrGeneProduct activities and inhibition of peroxidation in LCOTHER LCOTHER . Defining an LCOTHER - regulated transcriptome for primary progenitors , including LCGeneOrGeneProduct - LCGeneOrGeneProduct as a novel mediator of LCOTHER - dependent erythroblast formation .	0
Sequencing analysis detected 17 different LCOTHER gene mutations , and 7 of these were identified as novel : 3 missense mutations , including LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 3 , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER . LCOTHER ) in exon 3 and LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 7 ; 2 deletion mutations , including LCSequenceVariant . LCSequenceVariant ( LCOTHER . LCOTHER ) in exon 5 and LCOTHER . LCOTHER ( LCOTHER . LCOTHER ) in exon 11 ; and 2 alternative splicing mutations , including LCOTHER . LCOTHER + LCOTHER in intron 4 at splicing donor sites and LCOTHER . LCOTHER - LCOTHER > LCOTHER in intron 13 at splicing acceptor sites .	0
CONCLUSIONS : LCOTHER is associated with LCOTHER LCOTHER and higher reporting of LCOTHER in a population of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Clusters of multidrug - resistant LCOrganismTaxon LCOrganismTaxon cases , Europe .	0
In two unrelated pedigrees of LCOTHER ' LCOTHER , each affected child was found to carry a homozygous mutation in exon 17 of the LCGeneOrGeneProduct locus that led to a LCSequenceVariant mutation just upstream of the polymerase domain of the protein .	0
LCDiseaseOrPhenotypicFeature explants prepared from surgical LCOTHER LCOTHER ( LCOTHER ) samples and serum samples obtained from LCOTHER LCOrganismTaxon receiving LCOTHER were also used .	0
BACKGROUND : While the incidence of new - onset LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature may be increasing in patients with LCOTHER treated with certain atypical LCOTHER LCOTHER , it remains unclear whether atypical agents are directly affecting LCChemicalEntity metabolism or simply increasing known risk factors for LCOTHER .	0
As these studies concerned sporadic LCDiseaseOrPhenotypicFeature cases , we investigated whether LCOTHER and another common variant located in the 5 ' - untranslated region ( LCOTHER > LCOTHER ) of the LCOTHER gene modify LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk in LCOTHER mutation carriers .	0
RESULTS : A novel heterozygous LCSequenceVariant . LCSequenceVariant > LCSequenceVariant change in exon 29 of LCGeneOrGeneProduct was detected in the proband , which resulted in the substitution of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER . LCOTHER ) .	0
While LCOTHER - LCOTHER LCOTHER potently and persistently activated LCOTHER LCOTHER / LCOTHER , LCOTHER / LCOTHER , LCGeneOrGeneProduct and LCOTHER LCOTHER LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct did not activate LCOTHER and activated these other kinases with kinetics distinct from those evident in LCOTHER - LCOTHER LCOTHER - stimulated cells .	0
Inability to identify a separate LCOrganismTaxon gene corresponding to the mammalian LCOTHER gene suggests that LCOTHER may serve roles in LCOTHER distributed between LCGeneOrGeneProduct and LCOTHER in other species .	0
RESULTS : The results show that the LCSequenceVariant polymorphism is present in LCOTHER - LCOTHER LCOTHER in the 5 ' UTR sequence ( + 25 ) of the LCOTHER - LCOTHER gene , known to affect the LCOTHER ( LCOrganismTaxon homologue of LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ) binding site 5 ' - GGTTAT - 3 ' .	0
These data lend further support to the proposal that cognitive processes mediated by the prefrontal cortex may be impaired by recreational LCChemicalEntity use . Successful therapy with LCOTHER for superior mesenteric LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in a LCOTHER with LCOTHER LCOTHER LCOTHER .	0
Discontinuations from renovascular AEs , although less common than discontinuations from LCOTHER LCOTHER , were significantly higher with LCChemicalEntity . Putative LCOTHER LCOTHER Risk SNP in an LCOTHER LCOTHER - Binding Site of the LCGeneOrGeneProduct Gene Illustrates Enrichment of Risk SNPs in LCOTHER LCOTHER Target Sites .	0
This effect was dependent on the production of LCOTHER - LCOTHER from DCs , as neither DCs isolated from LCGeneOrGeneProduct - LCGeneOrGeneProduct - / - LCOTHER nor LCGeneOrGeneProduct - LCGeneOrGeneProduct - neutralized DCs generated tolerogenic DCs .	0
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCOTHER ( 874 LCOTHER ' LCOTHER LCOTHER , 259 LCOTHER LCOTHER , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCGeneOrGeneProduct / LCOTHER , LCGeneOrGeneProduct / LCOTHER / LCOTHER , LCOTHER / LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER .	0
We suggest that LCOTHER may be LCDiseaseOrPhenotypicFeature in the setting of LCOTHER LCOTHER LCOTHER via LCOTHER LCOTHER activation . Association of LCOTHER polymorphisms and LCChemicalEntity - induced LCOTHER LCOTHER in Chinese LCOTHER LCOTHER .	0
Furthermore , we established a small amplicon genotyping ( SAG ) method for detecting three high frequency coding - region SNPs ( LCOTHER : LCOTHER > LCOTHER , LCSequenceVariant : LCOTHER > LCOTHER , and LCOTHER : LCOTHER > LCOTHER ) in LCGeneOrGeneProduct to differentiate mutations before sequencing .	0
METHODS : LCOTHER , primary LCOTHER small airway epithelial ( LCCellLine ) cells and wild - type , LCOTHER - LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) and LCOTHER LCOTHER - LCOTHER LCOTHER ( LCOTHER ) knockout ( KO ) LCOrganismTaxon were infected with LCOTHER and cytokine responses were investigated by ELISA , multiplex analysis and qPCR .	0
LCOTHER - LCOTHER , which prevents LCGeneOrGeneProduct binding to LCGeneOrGeneProduct - LCGeneOrGeneProduct partially inhibited LCOTHER - activation , as well as reduced LCOTHER - induced LCOTHER / LCOTHER activation and LCOTHER release induced by LCOTHER or LCOTHER .	0
On the whole , our findings indicate that the absence of LCOTHER plays a cardioprotective role in LCOTHER LCOTHER LCOTHER by promoting changes in LCGeneOrGeneProduct / LCOTHER signalling . Long - Lived LCOTHER + LCOTHER - LCOTHER + T Cells rather than Short - Lived LCOTHER + LCOTHER - LCOTHER + LCGeneOrGeneProduct - LCGeneOrGeneProduct + T Cells Initiate Rapid LCOTHER - LCOTHER Production To Suppress Anamnestic T Cell Responses during Secondary LCOTHER LCOTHER .	0
RESULTS : LCOTHER LCOTHER significantly increased the levels of LCOTHER , LCGeneOrGeneProduct , phosphorylated ( p ) - LCGeneOrGeneProduct , p - LCOTHER , and p - LCOTHER ; triggered LCOTHER mRNA splicing ; and enhanced ER chaperone gene expression in WT embryos .	0
Indeed , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature was demonstrated by a decrease in urinary LCOTHER - LCOTHER ratio in affected LCOrganismTaxon , revealing reduced LCOTHER degradation by renal activity of the LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER , a LCOTHER regulated gene .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCGeneOrGeneProduct , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOrganismTaxon diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
In conclusion , we report a new LCOTHER splice site mutation that provide insight into a critical protein domain ( LCGeneOrGeneProduct kinase domain ) and the first founder mutation in a North - African population . Atypical LCOTHER LCOTHER LCOTHER and severe LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature resulting from compound heterozygous mutations of the LCOTHER LCOTHER , including a novel frameshift mutation affecting the intracellular domain .	0
The adaptive metabolic changes caused by LCOTHER in control LCOrganismTaxon hearts were found to have occurred already in LCOTHER - deficient ( LCOTHER ( - / - ) ) LCOrganismTaxon hearts and sustained function in LCOTHER despite an inability for further metabolic remodeling .	0
In contrast , LCOTHER failed to affect LCOTHER induced by LCOTHER or naturally observed in LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ( - / - ) ) knockout LCOrganismTaxon ( 10 - 30 mg / kg p . o . ) .	0
When examining a worldwide cohort of 62 independent LCOrganismTaxon with LCOTHER and associated LCOTHER LCOTHER we identified altogether four novel mutations ( LCOTHER . LCOTHER , LCSequenceVariant . LCSequenceVariant , LCOTHER . LCOTHER , and LCOTHER . LCOTHER ) in five of them .	0
LCOTHER was not independently associated with body mass index , family history of LCOTHER LCOTHER , LCOTHER location ( colon versus rectum ) , stage , LCOTHER grade , signet ring cells , CIMP , MSI , LINE - 1 hypomethylation , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER , or LCGeneOrGeneProduct - LCGeneOrGeneProduct .	0
The current study shows that the melanocortinergic system interacts with LCOTHER signaling via novel effects on LCGeneOrGeneProduct activity . Recovery of LCOTHER - associated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature after conversion to LCOTHER in a pediatric renal transplant recipient - - case report and review of the literature .	0
In contrast , LCOTHER deficiency had no effect on LCGeneOrGeneProduct - mediated LCOTHER LCOTHER activation but significantly reduced LCGeneOrGeneProduct - mediated LCOTHER activation .	0
Using the two Asian cohorts , significant association of LCGeneOrGeneProduct - LCOTHER / Thr with LCOTHER was observed only in the presence of LCOTHER - * 1 / * 1 genotype ( OR 4 . 63 , 95% CI 1 . 47 - 14 . 6 , P = 0 . 009 versus LCGeneOrGeneProduct - LCOTHER / Ile plus LCOTHER - * 2 / * 2 ) .	0
Meanwhile apoptosis related proteins LCOTHER and LCOTHER were involved in LCDiseaseOrPhenotypicFeature LCOrganismTaxon and LCOTHER LCOTHER model , but not LCOTHER - LCOTHER , LCOTHER - LCOTHER or LCOTHER . LCOTHER and LCOTHER are closely relevant in the tissue splices of deminopathies LCOTHER and LCOTHER with LCOTHER at protein lever .	0
Exon 4 of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) was screened for the most frequent mutation , LCOTHER , in the proband by sequencing .	0
Improving the understanding of LCOTHER - LCOTHER in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature could lead to the development of clinically useful therapeutic modalities for treatment of LCOTHER LCOTHER or even allow identification of preventive strategies . LCGeneOrGeneProduct is an essential regulator of LCOTHER signalling in cartilage .	0
After DNA extraction from LCChemicalEntity - embedded tissues , we amplified by PCR and sequenced the exons 2 - 10 of the LCGeneOrGeneProduct gene .	0
Blood samples for the analysis of plasma LCChemicalEntity , LCChemicalEntity , LCOTHER ( racemic , R - and S - isomer ) , and LCOTHER - LCOTHER concentrations were taken at regular time intervals , during 8 hr after LCOTHER .	0
Differences were found for serum FBG , FINS , HOMA - IR , and HOMA - beta , and placental LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER .	0
Hypothesizing that LCOTHER - LCOTHER LCOTHER and / or LCOTHER - LCOTHER LCOTHER promote LCDiseaseOrPhenotypicFeature invasion , we found that LCOTHER - LCOTHER LCOTHER promoted LCOTHER migration in a substrate - specific manner , markedly enhancing migration on LCOTHER but not on LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct or LCOTHER .	0
This study showed that LCOTHER was more likely to be LCOTHER susceptibility gene at Chr . 1q31 based on the finding that the LCOTHER and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCDiseaseOrPhenotypicFeature in a white population in LCOTHER , LCOTHER , and LCOTHER genes showed a significant association with LCOTHER . Seven novel and six de novo LCOTHER gene mutations in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
The identification of this mutation appears to support the molecular mechanism of unequal cross - over of two LCGeneOrGeneProduct alleles . A novel mutation ( LCOTHER ) in the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct causing LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER .	0
We investigated also the expression of angiocrine genes upon LCOTHER treatment in vivo , and demonstrate that LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER are upregulated , while LCOTHER and LCGeneOrGeneProduct are reduced .	0
Enzyme activity assays with recombinant LCOTHER isoforms ( LCOTHER LCOTHER and LCOTHER LCOTHER ) and the LCChemicalEntity substrate LCOTHER were used to investigate the functional impact of the LCGeneOrGeneProduct LCOTHER polymorphism .	0
LCDiseaseOrPhenotypicFeature in adult male LCOTHER decreased basal protein synthesis in gastrocnemius , associated with a reduction in LCOTHER activation as indicated by decreased LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER phosphorylation .	0
LCOTHER may also be utilized for effective treatment of LCChemicalEntity - LCChemicalEntity - resistant LCOTHER . Oncogene advance online publication , 26 June 2017 ; doi : 10 . 1038 / onc . 2017 . 211 . rTMS of supplementary motor area modulates therapy - induced LCOTHER in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCSequenceVariant ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCOTHER . LCOTHER ] have been reported in Japanese LCOTHER , but not in LCOTHER LCOrganismTaxon from other ethnic groups .	0
Here we describe three LCOTHER , a boy ( aged 15 years ) and two girls ( aged 17 and 7 years ) with LCOTHER LCOTHER LCOTHER who suffered LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and in addition had LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
In particular , the drug prevents the decrease in LCOTHER - , LCOTHER - , LCOTHER - , LCGeneOrGeneProduct - , and LCGeneOrGeneProduct - immunoreactivity ( IR ) and the increase in LCOTHER - , and LCOTHER - IR .	0
By mass spectrometry genotyping , the plasma samples contained mutant DNA corresponding to 5 / 14 LCGeneOrGeneProduct Exon 19 deletions and 3 / 4 LCOTHER LCSequenceVariant mutations previously diagnosed in the matched LCOTHER .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
CONCLUSIONS : These results suggest that LCOTHER stimulates LCOTHER - LCOTHER gene expression after LCOTHER LCOTHER , which is associated with higher LCGeneOrGeneProduct production and LCOTHER after the local anesthetic effect dissipates . LCOTHER and LCOTHER LCOTHER among LCOTHER treated with LCOTHER for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in the city of Copenhagen .	0
Here we describe the characterization of the LCOTHER ( + LCOTHER LCOTHER - > LCOTHER ) polymorphism of the LCOTHER - LCOTHER gene associated in LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER with high LCOTHER in erythroid precursor cells . LCChemicalEntity consumption and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature incidence and progression : A Mendelian randomisation study .	0
Of them , two LCOTHER carrying LCOTHER mutation were from two generations in one family with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) .	0
There was a difference in LCOTHER potency with higher racemic LCOTHER IC50 values in PMs ( 72 + / - 7 ng . ml - 1 ) than EMs ( 42 + / - 8 ng . ml - 1 , P less than . 001 ) . ( ABSTRACT TRUNCATED AT 250 WORDS ) LCChemicalEntity protects against LCOTHER from the DNA cleavage - enhancing drugs LCOTHER and LCChemicalEntity but not LCOTHER .	0
LCOTHER is a multi - copper LCChemicalEntity that is secreted into plasma and facilitates cellular LCOTHER export and LCOTHER binding to LCGeneOrGeneProduct .	0
BACKGROUND : Markers of fibrinolysis , LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , and LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) levels were studied for the evaluation of short - term effects of LCOTHER administration in postmenopausal LCOTHER .	0
RESULTS : LCOTHER with LCOTHER had higher serum LCOTHER and LCOTHER ( P < 0 . 001 for LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER and LCOTHER ) and lower LCOTHER ( P = 0 . 008 ) levels than LCOTHER LCOTHER without LCOTHER .	0
LCOTHER ( LCOTHER ) LCOrganismTaxon displayed severe LCOTHER with runting , impaired formation of secondary centres of ossification , and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature including LCOTHER LCOTHER and LCOTHER LCOTHER .	0
The fact that no truncation or frame shift mutations have been found in any of the LCOTHER LCOTHER , coupled with our recent finding that some breeding pairs of LCGeneOrGeneProduct LCGeneOrGeneProduct knockout LCOTHER yield litters that show not only LCOTHER , but also severe LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOTHER . Midline B3 LCOTHER nerves in LCOTHER medulla are involved in LCOTHER effect of LCOTHER .	0
CONCLUSIONS LCOTHER - LCOTHER - LCOTHER / LCOTHER SNP , hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER / LCOTHER - LCOTHER were associated with LCOTHER in LCOrganismTaxon from Inner Mongolia , as was serious LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER prevents LCOTHER LCOTHER accumulation in macrophages induced by the LCOTHER LCOTHER inhibitor LCOTHER .	0
Laboratory tests showed an elevation of LCChemicalEntity LCChemicalEntity ( 2218 IU / L ) , LCChemicalEntity LCChemicalEntity ( 134 IU / L ) , LCOTHER LCOTHER ( 78 IU / L ) , and BUN ( 27 . 9 mg / ml ) levels .	0
Mechanistically , LCOTHER could bind to the LCOTHER transcription factor , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , which then inhibited the binding of LCGeneOrGeneProduct to the LCOTHER promoter to reduce LCOTHER expression .	0
CONCLUSIONS : The LCOTHER - LCOTHER polymorphism of the LCOTHER LCOTHER gene is associated with LCDiseaseOrPhenotypicFeature and may be a potential regulatory site . Protective effects of LCChemicalEntity on LCOTHER LCOTHER LCOTHER in LCOTHER .	0
Reduced LCOTHER expression after high - fat diet is associated with selective up - regulation of LCOTHER and further LCOTHER LCOTHER LCOTHER signaling in adipose tissue . Effect of the abrogation of LCGeneOrGeneProduct - LCGeneOrGeneProduct by antisense LCChemicalEntity on the expression of LCOTHER - LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in isolated fibroblasts from LCOTHER LCOTHER .	0
We performed RNA - seq of the LCDiseaseOrPhenotypicFeature cell line LCOTHER - LCOTHER and the normal liver cell line LCCellLine - LCCellLine using the Ion Proton System .	0
It was partially reduced by LCOTHER - or LCOTHER - inhibition , but not with LCOTHER - inhibitors ( LCChemicalEntity , LCOTHER ) or LCChemicalEntity .	0
After transfection and inhibition of transcription with LCOTHER LCOTHER , analysis of mRNA turnover failed to reveal differences in mRNA stability between LCSequenceVariant and LCSequenceVariant alleles , indicating a defect in transcription or mRNA maturation .	0
LCOTHER also suppressed LCOTHER - induced LCOTHER signaling by inhibiting the LCGeneOrGeneProduct pathway and expression of LCOTHER LCOTHER LCOTHER LCOTHER and LCGeneOrGeneProduct .	0
BACKGROUND AND PURPOSE : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) are potential risk factors for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) , but it is unclear if they are a contraindication to using LCOTHER LCOTHER .	0
LCOTHER and other LCOTHER - LCOTHER / LCOTHER / growth - factors activate LCOTHER via LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct / LCOTHER ) , LCOTHER and LCOTHER but not cytosolic LCOTHER or LCOTHER .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
A model of LCOTHER LCOTHER was developed by intrasplenic injection of LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) into LCGeneOrGeneProduct knockout LCOTHER ( LCGeneOrGeneProduct ) and wild - type ( LCOTHER / LCOTHER ) LCOTHER ( WT ) .	0
Therefore , genetic variations of the LCOTHER - LCOTHER gene seem not to be major influencing factors of the LCGeneOrGeneProduct - LCOTHER - axis causing variable response to exogenous LCGeneOrGeneProduct - treatment . Fine mapping and identification of a candidate gene LCOTHER in LCOTHER LCOTHER LCOTHER LCOTHER .	0
Our data demonstrate that the LCDiseaseOrPhenotypicFeature - causing mutations strongly affect LCOTHER cellular functions which suggest a central role for perturbed LCOTHER signalling in LCOTHER LCOTHER . LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature : frequent abnormalities and inactivation of LCOTHER LCOTHER suppressor gene .	0
Among them are LCOTHER LCOTHER - LCOTHER ( LCOTHER ) inhibitors such as LCOTHER , which indirectly enhance LCGeneOrGeneProduct LCGeneOrGeneProduct function by increasing the LCChemicalEntity ( a co - agonist for the LCOTHER LCOTHER ) levels in the synapse .	0
LCOTHER could protect LCOTHER LCOTHER LCOTHER and maintain the microvasculature integration in acute LCOTHER LCOTHER of LCOTHER induced by LCChemicalEntity / LCChemicalEntity - LCChemicalEntity .	0
As LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature sometimes faint while using illicit drugs , doctors might attribute too many episodes of LCDiseaseOrPhenotypicFeature to illicit drug use and thereby underestimate the incidence of LCOTHER in this special population , and the high mortality in this population may , in part , be caused by the proarrhythmic effect of LCOTHER .	0
Mechanistically , LCOTHER could bind to the LCOTHER transcription factor , LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , which then inhibited the binding of LCGeneOrGeneProduct to the LCOTHER promoter to reduce LCOTHER expression .	0
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCGeneOrGeneProduct / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCDiseaseOrPhenotypicFeature .	0
The aim of this study was to investigate the association of DNA polymorphisms within LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct , LCOTHER ) and the postoperative resolution of LCOTHER in Chinese LCOTHER undergoing adrenalectomy for LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	0
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is a common LCOTHER LCOTHER that in more than 95% of cases is sporadic and only in some cases is caused by LCOTHER LCOTHER , isolated or as part of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER LCOTHER LCOTHER ) .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
We also show that several imprinted genes ( LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct and LCOTHER ) are aberrantly expressed although allele specific DNA methylation is not altered .	0
In vivo induction of airway LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
LCChemicalEntity administration would be effective in the treatment of LCOTHER LCOTHER LCOTHER with LCOTHER LCOTHER . Mutational analysis of LCOTHER in LCOTHER LCOrganismTaxon using denaturing high performance liquid chromatography .	0
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) messenger RNA ( mRNA ) splicing .	0
CONCLUSION : This study showed that SNPs LCOTHER ( P = 0 . 0276 ) , LCSequenceVariant ( P = 0 . 0266 ) , LCSequenceVariant ( P = 0 . 00514 ) , and LCOTHER ( P = 0 . 0089 ) , but not LCOTHER , LCOTHER , or LCOTHER , in LCOTHER were significantly associated with wet LCOTHER in a mainland Han Chinese population .	0
RESULTS : LCOTHER with LCOTHER had higher serum LCOTHER and LCOTHER ( P < 0 . 001 for LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct and LCOTHER ) and lower LCOTHER ( P = 0 . 008 ) levels than LCOTHER LCOTHER without LCOTHER .	0
Our findings show that microinjection of LCOTHER into the CA1 region of the hippocampus improves the LCOTHER - induced LCOTHER . LCGeneOrGeneProduct : A LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature candidate susceptibility gene? The chromosomal region 12q24 has been previously implicated by linkage studies of both LCOTHER LCOTHER and LCOTHER LCOTHER LCOTHER and we have reported two pedigrees segregating both LCOTHER LCOTHER and LCOTHER ' LCOTHER LCOTHER that show linkage across this region .	0
OGD also caused a time - dependent decrease in the phosphorylation of LCGeneOrGeneProduct ( LCOTHER ) , and LCGeneOrGeneProduct protein levels .	0
Mutations in the coding region of the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene are not associated with LCOTHER LCOTHER LCOTHER or with changes in LCOTHER responses to LCOTHER among the Caucasians examined . LCOTHER - associated LCOTHER in a healthy adolescent receiving LCOTHER for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature control .	0
We found that depletion of LCGeneOrGeneProduct and LCGeneOrGeneProduct using small interfering RNA led to LCOTHER remodeling .	0
A LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct cDNA has been identified from a cerebral cortical cDNA library using sequences from the LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct cDNA .	0
LCOrganismTaxon AND METHODS : We examined associations between 54 polymorphisms that tag the known common variants ( minor allele frequency > 0 . 05 ) in 10 genes involved in oxidative damage repair ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) and survival in 4 , 470 LCOTHER with LCOTHER LCOTHER .	0
RESULTS : HAT adipose tissue demonstrated increased LCOTHER related genes for storage ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCGeneOrGeneProduct , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	0
Microarray and subsequent gene ontology analyses revealed that compared to LCChemicalEntity - LCChemicalEntity or LCOTHER alone , the combination treatment of LCOTHER - LCOTHER and LCOTHER upregulated genes related to cell death and the apoptotic process consistent with the inhibition of colony formation and LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCGeneOrGeneProduct activation .	0
The LCOTHER LCGeneOrGeneProduct is a low - affinity receptor relative to most rodents , but some reports suggest that there may be individuals with polymorphic high - affinity receptors , thereby possibly increasing the sensitivity to LCChemicalEntity in such people .	0
Increased LCGeneOrGeneProduct was discovered in STs and FLSs from LCOTHER with LCDiseaseOrPhenotypicFeature .	0
Our data support potential interactions between the LCOTHER , LCOTHER - LCGeneOrGeneProduct and LCOTHER - LCOTHER pathways , and possible influence by LCOTHER or LCOTHER mutation on therapy or chemoprevention targeting LCOTHER . Identification of novel type LCGeneOrGeneProduct LCGeneOrGeneProduct gene mutations resulting in severe LCOTHER LCOTHER LCOTHER LCOTHER .	0
These findings show that the LCGeneOrGeneProduct LCGeneOrGeneProduct is required for mammalian development , likely through regulation of LCOTHER , and indicate functional conservation of the LCOTHER LCOTHER from LCOTHER to mammals in vivo . LCChemicalEntity Ameliorates LCOTHER LCOTHER LCOTHER by Inhibiting the LCOTHER / LCOTHER - LCOTHER and LCOTHER Signaling Pathways .	0
In our LCOTHER , transient LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature or LCOTHER LCOTHER related to LCOTHER and / or LCOTHER use were the most likely causes of LCOTHER LCOTHER . Detailed spectral profile analysis of LCOTHER - induced LCOTHER LCOTHER in anesthetized LCOrganismTaxon .	0
This finding points to the urgent need for evidence - based public health initiatives targeted at people who smoke LCChemicalEntity LCChemicalEntity . Common LCOTHER LCOTHER LCSequenceVariant - LCSequenceVariant LCSequenceVariant LCSequenceVariant allele : a novel risk factor for LCOTHER LCOTHER .	0
The fact that no truncation or frame shift mutations have been found in any of the LCOTHER LCOTHER , coupled with our recent finding that some breeding pairs of LCOTHER LCOTHER knockout LCOTHER yield litters that show not only LCOTHER , but also severe LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOrganismTaxon . Midline B3 LCOTHER nerves in LCOTHER medulla are involved in LCOTHER effect of LCOTHER .	0
LCOTHER administration with LCChemicalEntity injections caused significantly decreased renal LCOTHER and urinary LCOTHER excretion , and increased LCOTHER activity , but not LCOTHER activity in renal tissue when compared with LCChemicalEntity alone .	0
Meanwhile apoptosis related proteins LCOTHER and LCOTHER were involved in LCOTHER LCOTHER and LCOTHER LCOTHER model , but not LCOTHER - LCOTHER , LCOTHER - LCOTHER or LCOTHER . LCOTHER and LCGeneOrGeneProduct are closely relevant in the tissue splices of deminopathies LCOTHER and LCOrganismTaxon with LCOTHER at protein lever .	0
Nominal association with the disorder was observed for LCOTHER - CC , and phenotypic variability in LCDiseaseOrPhenotypicFeature symptoms was influenced by LCOTHER , LCSequenceVariant and LCOTHER .	0
To investigate effects of LCOTHER on LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , we performed LCOTHER assay in neonatal LCOTHER ventricular myocytes ( NRVMs ) , as well as measured LCOTHER LCOTHER level in the culture medium of NRVMs and activities of serum cardiac enzymes in LCOrganismTaxon .	0
In the current study , we investigated whether a physiological intervention by feeding 40% high LCChemicalEntity diet ( HFD ) , which induces LCOTHER in male Sprague - Dawley LCOTHER ( 250 - 275 g ) , sensitizes to LCChemicalEntity - induced LCOTHER .	0
Differences were found for serum FBG , FINS , HOMA - IR , and HOMA - beta , and placental LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , and LCOTHER - LCOTHER .	0
Nominal association with the disorder was observed for LCSequenceVariant - CC , and phenotypic variability in LCDiseaseOrPhenotypicFeature symptoms was influenced by LCOTHER , LCOTHER and LCOTHER .	0
CONCLUSION : The results indicate a dose - response relationship between LCOTHER and the risk of LCOTHER LCOTHER , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Mutation analysis of LCGeneOrGeneProduct in LCOTHER with LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) in combination with LCOTHER LCOTHER .	0
METHODS : LCGeneOrGeneProduct - LCGeneOrGeneProduct gene sequencing was performed on genomic DNA isolated from a total of 75 LCOTHER - LCOTHER LCOrganismTaxon , including 31 b ( 0 ) 39 / b ( 0 ) 39 , 33 b ( 0 ) 39 / b ( + ) IVSI - 110 , 9 b ( + ) IVSI - 110 / b ( + ) IVSI - 110 , one b ( 0 ) IVSI - 1 / b ( + ) IVSI - 6 and one b ( 0 ) 39 / b ( + ) IVSI - 6 .	0
CONCLUSIONS : If ECG alone is used for specificity , the combination with dP / dtejc improved the sensitivity of the test and could be a cost - savings alternative to cardiac imaging or perfusion studies to detect LCOTHER LCOTHER , especially in LCOrganismTaxon unable to exercise . Two novel mutations , LCOTHER and LCSequenceVariant , of the LCOTHER LCOTHER LCOTHER gene in Japanese LCOTHER with LCOTHER .	0
Given the absence of clear d ( N ) / d ( S ) differences between LCOTHER groups , delayed onset of LCDiseaseOrPhenotypicFeature symptoms appears to be solely associated with lower viral replication rates rather than with differences in selection on amino acid fixation . LCChemicalEntity but not LCOTHER reduces frontal lobe oxygenation following anesthesia - induced LCOTHER .	0
Also , LCGeneOrGeneProduct , LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER , and LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) expression levels were increased , whereas LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER levels were drastically reduced compared with those found in wild - type B cells .	0
In vitro , the LCCellLine cells were treated with LCOTHER in the presence or absence of LCOTHER , LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER small interfering ( si ) RNA or pcDNA3 . 1 - LCGeneOrGeneProduct .	0
LCOTHER administration to control LCOrganismTaxon significantly increased renal LCOTHER ( LCOTHER ) and urinary LCOTHER - LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCOTHER , a marker of LCOTHER LCOTHER LCOTHER ) excretion but decreased LCOTHER LCOTHER ( LCOTHER ) and LCOTHER ( LCGeneOrGeneProduct ) activities .	0
Taking these in vitro and in vivo results together , our study suggests that LCChemicalEntity LCChemicalEntity - LCChemicalEntity is a potentially effective candidate against LCOTHER ' LCOTHER LCOTHER that is characterized by wide spread LCOTHER LCOTHER and progressive LCOTHER LCOTHER LCOTHER LCOTHER . Anticipation in familial LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with LCOTHER mutation in the LCOTHER ( LCOTHER ) gene .	0
OBJECTIVE : The goal of this study was to determine whether mutations of meiotic genes , such as disrupted meiotic cDNA ( LCOTHER ) , LCOTHER homolog ( LCGeneOrGeneProduct ) , LCGeneOrGeneProduct , and LCOTHER .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOrganismTaxon .	0
LCOTHER toxicokinetics studies revealed no change in accumulation of LCOTHER and LCChemicalEntity ( toxic metabolite ) in the normal diet - fed ( ND ) and LCDiseaseOrPhenotypicFeature hearts .	0
METHODS : We identified seven SNP ( single nucleotide polymorphism ) ( - 141Cins > del , TaqIB , TaqID , LCOTHER , LCSequenceVariant , LCSequenceVariant and TaqIA ) in the LCOTHER gene in 146 LCOTHER LCOTHER ( 59 with LCOTHER and 87 without LCOTHER according to the Simpson - Angus Scale ) treated with LCOTHER after 8 weeks .	0
The loss of LCGeneOrGeneProduct results in both the failure for LCGeneOrGeneProduct to translocate to the LE nuclei and a reduction in the expression of the LCOTHER regulated gene LCOTHER that regulates uterine receptivity .	0
LCDiseaseOrPhenotypicFeature LCOTHER are with LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
DNA was isolated from peripheral leukocytes and the region of interest in the LCOTHER gene bearing a missense mutation LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant ( LCSequenceVariant ) of exon 2 , was amplified by polymerase chain reaction ( PCR ) .	0
Hence , our results suggest that LCOTHER significantly aggravates LCOTHER ( LCOTHER + ) overload and causes LCOTHER and finally promotes apoptotic development via phosphorylation of LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER . LCChemicalEntity LCChemicalEntity treatment ameliorates acute LCChemicalEntity LCOTHER in LCOTHER .	0
The severe phenotype with seriously LCOTHER LCOTHER LCOTHER , LCOTHER behaviour , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER is probably due to the dominant negative effect of the LCSequenceVariant mutant protein and the absence of any functional LCOTHER - LCOTHER . The LCOTHER LCOTHER confers protection against diet - induced LCDiseaseOrPhenotypicFeature , LCOTHER , and LCOTHER in female LCOTHER .	0
Therefore LCOTHER activity , oxidative stress , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) activity , spatial learning and memory as well as the effect of LCChemicalEntity , a previously proposed therapy for LCOTHER LCOTHER , were evaluated in an experimental model of LCOTHER administration in LCOrganismTaxon .	0
Notably , this and other converging lines of evidence underline the importance of LCGeneOrGeneProduct - related functional pathways in the etiology of LCOTHER . LCOTHER regulates meiotic G2 / M transition by modulating the LCGeneOrGeneProduct / LCGeneOrGeneProduct - LCOTHER LCOTHER pathway in oocytes .	0
A total of 10 novel variants was recognized , among them four variants in the adjacent 5 ' - region of the LCOTHER coding exon 2 ( LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCSequenceVariant . LCSequenceVariant - LCSequenceVariant > LCSequenceVariant , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER ) , a 6 base - pair deletion ( LCOTHER . LCOTHER [ LCOTHER . LCOTHER ] ) , a variant leading to a stop codon ( LCSequenceVariant . LCSequenceVariant > LCSequenceVariant [ LCOTHER . LCOTHER ] ) , synonymous variants ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , and one non - synonymous variant ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) .	0
Meanwhile apoptosis related proteins LCOTHER and LCOTHER were involved in LCDiseaseOrPhenotypicFeature LCOTHER and LCOTHER LCOrganismTaxon model , but not LCOTHER - LCOTHER , LCOTHER - LCOTHER or LCOTHER . LCOTHER and LCOTHER are closely relevant in the tissue splices of deminopathies LCOTHER and LCOTHER with LCOTHER at protein lever .	0
By unbiased genome - wide RNAi screening , we found that among 10 resistant LCOTHER clones , six hits were for LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , two hits were for LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) and another two hits were for LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) .	0
Together our findings demonstrate a novel mechanism by which LCGeneOrGeneProduct regulates mitochondria - driven hippocampal cell death ; suggesting LCGeneOrGeneProduct as a potential therapeutic target against LCOTHER LCOTHER LCOTHER in neonates . Repeated LCOTHER LCOTHER administration prevents LCOTHER changes in colon of LCOTHER underwent to wrap restraint stress .	0
Functional findings show a significantly reduction in the number of spontaneous abdominal contraction in LCChemicalEntity treated LCOrganismTaxon .	0
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCDiseaseOrPhenotypicFeature ( 874 LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , 259 LCOTHER LCOTHER , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER / LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER .	0
PURPOSE : Mutations of the LCGeneOrGeneProduct gene , a novel family member of the LCOTHER LCOTHER genes on chromosome 4q35 , have recently been identified in LCOrganismTaxon with LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
Semiquantitative assessment of the density of LCGeneOrGeneProduct colabeling with LCOTHER - stained retinal ECs was determined by immunolabeling of retinal cryosections from P18 pups in LCDiseaseOrPhenotypicFeature or in RA .	0
Expression of some lineage specific factors is markedly reduced in LCOTHER knockdown embryos , including LCOTHER , LCOTHER and LCOTHER , while others are inappropriately expressed ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct ) .	0
These data lend further support to the proposal that cognitive processes mediated by the prefrontal cortex may be impaired by recreational LCOTHER use . Successful therapy with LCOTHER for superior mesenteric LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in a LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
On admission , laboratory examination showed LCOTHER LCOTHER ( + + + + ) , total LCOTHER 8 . 25 mg / dL , conjugated LCChemicalEntity 4 . 36 mg / dL , unconjugated LCOTHER 3 . 89 mg / dL , LCOTHER 3 . 52 meq / L Patient was diagnosed as LCOTHER LCOTHER with LCOTHER and got LCChemicalEntity infusion in LCOTHER 5% 500 mg / 8 hour .	0
We investigated the relationship between the degeneration of spinal motor neurons and activation of LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCOTHER ) LCOTHER after neuraxial LCOTHER following a noninjurious interval of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOrganismTaxon .	0
RESULTS AND DISCUSSION : LCOTHER - LCOTHER LCOTHER and LCOTHER cells release a network of cytokines , including newly identified LCOTHER - inducible cytokines LCGeneOrGeneProduct , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) .	0
Further analysis of the expression of LCOTHER and TRAF2DN in purified B cells demonstrated that expression of both endogenous LCGeneOrGeneProduct and tg TRAF2DN was negligible in LCOTHER - LCOTHER LCOTHER cells compared with wild - type LCOrganismTaxon .	0
It was concluded that LCOTHER LCOTHER represents a potential therapeutic option to protect against acute LCOTHER LCDiseaseOrPhenotypicFeature commonly encountered in clinical practice . LCOTHER decoded : the genomic sequence of a cytogenetically aberrant LCOTHER LCDiseaseOrPhenotypicFeature cell line .	0
These data suggest that LCOTHER produced antiarrhythmic actions on LCOTHER LCOrganismTaxon and LCOTHER LCOTHER models induced by LCChemicalEntity or LCOTHER via stimulating the cardiac LCOTHER ( LCOTHER ) - LCOTHER .	0
The degree of LCDiseaseOrPhenotypicFeature showed a positive correlation with microscopic LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in both models .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
Its associated LCDiseaseOrPhenotypicFeature is an important cause of LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in children and adults .	0
Because LCOTHER - LCOTHER transporters play a key element in the regulation of synaptic LCOTHER - LCOTHER transmission it may be important to control for the potential covariance effect of a polymorphism in the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) when studying the effects of LCOTHER as well as cognitive functioning .	0
We report mutation analysis of the LCGeneOrGeneProduct gene in 39 kindreds with LCOTHER and LCOTHER who previously tested negative for mutations in the LCOTHER ( LCGeneOrGeneProduct ) and LCOTHER ( LCOTHER LCOTHER LCOTHER LCOTHER ) genes .	0
The ability of LCOTHER to block LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct + ) LCGeneOrGeneProduct , also expressed by enteric neurons , might represent a possible mechanism through which LCOTHER exerts its actions . Lack of association of LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCOTHER LCOTHER status with LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER , and disease severity .	0
Alteration of LCOTHER protein levels may contribute to invasion and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , which may occur through activation of LCOTHER signaling and promotion of LCGeneOrGeneProduct - LCGeneOrGeneProduct expression . The number of LCOTHER LCOTHER LCOTHER in LCOTHER LCOTHER correlates with the LCOTHER LCOTHER - LCOTHER LCOTHER gene insertion / deletion polymorphism .	0
"Moreover , diagnosis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature should be considered in the face of severe infant LCOTHER of uncertain etiology . Characterization of a novel LCOTHER """""""" silent """""""" allele : point mutation ( LCOTHER . LCOTHER ) causes loss of activity and prolonged LCDiseaseOrPhenotypicFeature with LCOTHER ."	0
Thus , LCOTHER reduced LCOTHER burden through associated cytostatic and anti - angiogenic effects . This dual effect of LCOTHER on LCOTHER tissue could contribute to its recently reported efficiency in refractory LCOTHER resistant to conventional chemotherapy . Rapid reversal of anticoagulation reduces LCOTHER volume in a LCOrganismTaxon model of LCOTHER - associated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Thus , targeting LCOTHER may provide novel therapeutic options in LCOTHER LCOTHER . Common LCGeneOrGeneProduct variants and modification of LCOTHER LCOTHER LCOTHER LCOTHER risk in LCGeneOrGeneProduct mutation carriers .	0
Future research should include animal studies that address mechanistic hypotheses and studies of LCOrganismTaxon populations that integrate early - life exposure , molecular alterations , and latent disease outcomes . Two novel mutations in LCGeneOrGeneProduct gene form Chinese LCOTHER LCOTHER LCOTHER females .	0
CONCLUSION : Our results did not lend strong support to the view that the genetic variation of the LCOTHER gene plays a major role in the individually variable adverse effect induced by LCOTHER , at least in Chinese LCOrganismTaxon with LCDiseaseOrPhenotypicFeature .	0
Our data show that ablation of LCOTHER preserves LCOTHER and LCOTHER - LCOTHER protein expression and localization in LCOTHER - induced LCOTHER , and prevents the development of the severe LCOTHER associated with LCChemicalEntity therapy . LCOTHER LCOTHER LCOTHER - mediated activation of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct inhibits the growth of LCOTHER in vitro and in vivo .	0
CONTEXT : LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) is a rare LCOTHER LCOTHER , characterized by LCOTHER and LCDiseaseOrPhenotypicFeature / LCOTHER with increased serum LCChemicalEntity , LCChemicalEntity - LCChemicalEntity LCChemicalEntity [ LCOTHER , LCOTHER - ( LCOTHER ) ( LCOTHER ) LCOTHER ] resulting in LCOTHER .	0
The results in this study significantly improve our understanding of the durability of LCOTHER - LCOTHER - producing LCOTHER ( + ) T cells postinfection and provide information on how LCGeneOrGeneProduct - LCGeneOrGeneProduct may contribute to optimized parasite control and prevention of immune - mediated pathology during repeated LCOTHER LCOTHER . LCChemicalEntity as a LCOTHER LCOTHER : the role of critical LCOTHER groups in LCOTHER LCOTHER .	0
LCOTHER consists of three pairs of non - identical polypeptide chains , encoded by different genes ( LCOTHER LCOTHER [ LCOTHER ] , LCGeneOrGeneProduct LCGeneOrGeneProduct [ LCOTHER ] and LCGeneOrGeneProduct LCGeneOrGeneProduct [ LCOTHER ] ) .	0
METHODS : We identified seven SNP ( single nucleotide polymorphism ) ( - 141Cins > del , TaqIB , TaqID , LCOTHER , LCOTHER , LCOTHER and TaqIA ) in the LCGeneOrGeneProduct gene in 146 LCOTHER LCOTHER ( 59 with LCDiseaseOrPhenotypicFeature and 87 without LCOTHER according to the Simpson - Angus Scale ) treated with LCOTHER after 8 weeks .	0
Similarly , LCOTHER ' LCOTHER LCOTHER LCOTHER carrying LCGeneOrGeneProduct / LCOTHER indel had a higher prevalence of gASCA antibodies than wild - type LCOrganismTaxon ( 63 . 8% versus 55 . 2% , p = 0 . 014 ) , also with a gene dosage effect .	0
First , we showed that an intravenous administration of LCOrganismTaxon LCOTHER rapidly reversed anticoagulation in LCOrganismTaxon .	0
Findings point toward a possible mediating role of LCGeneOrGeneProduct variants on phenotypic expression in LCOTHER that need to be replicated in a larger sample . LCDiseaseOrPhenotypicFeature in LCOTHER LCOTHER with LCOTHER and / or glomerular LCOTHER .	0
In contrast , HG increased extracellular LCChemicalEntity concentration , the expression of LCOTHER , mitochondrial fission proteins ( LCGeneOrGeneProduct , LCOTHER ) , and the ubiquitination levels of LCOTHER , LCOTHER and LCOTHER .	0
Dysregulated expression of LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) is found in the cells of LCOTHER who have LCOTHER LCOTHER LCOTHER ( LCOTHER ) , a genetic disorder of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and progressive LCOTHER LCOTHER .	0
A missense mutation in the LCOTHER LCOTHER gene has previously been linked to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) .	0
Thus , in this study , the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of LCOTHER ( in particular , the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct : LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene LCOTHER and the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene LCOTHER ) had an impact on the risk of LCOTHER - related LCOTHER .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCGeneOrGeneProduct , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCGeneOrGeneProduct [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
CONCLUSIONS LCOTHER - LCOTHER - LCOTHER / LCOTHER SNP , hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER / LCOTHER - LCOTHER were associated with LCOTHER in LCOTHER from Inner Mongolia , as was serious LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER . LCChemicalEntity prevents LCOTHER LCOTHER accumulation in macrophages induced by the LCGeneOrGeneProduct LCGeneOrGeneProduct inhibitor LCOTHER .	0
Fifteen polydrug LCChemicalEntity users and 15 polydrug non - LCChemicalEntity user controls completed a general drug use questionnaire , the Brixton Spatial Anticipation task ( set shifting ) , Backward Digit Span procedure ( memory updating ) , Inhibition of Return ( inhibition ) , an emotional intelligence scale , the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire ( DEX ) .	0
RESULTS : The results show that the LCOTHER polymorphism is present in LCOTHER - LCOTHER LCOrganismTaxon in the 5 ' UTR sequence ( + 25 ) of the LCOTHER - LCOTHER gene , known to affect the LCOTHER ( LCOTHER homologue of LCOrganismTaxon LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ) binding site 5 ' - GGTTAT - 3 ' .	0
After transfection and inhibition of transcription with LCChemicalEntity LCChemicalEntity , analysis of mRNA turnover failed to reveal differences in mRNA stability between LCSequenceVariant and LCOTHER alleles , indicating a defect in transcription or mRNA maturation .	0
METHODS : DNA samples from 405 LCOTHER LCOTHER , 97 LCOTHER LCOrganismTaxon , 113 LCOTHER LCOTHER , and 431 healthy controls were genotyped for the LCOTHER LCSequenceVariant LCSequenceVariant .	0
RESULTS : LCOTHER - LCOTHER haplotype was associated with persistent postoperative LCDiseaseOrPhenotypicFeature in Chinese LCOTHER undergoing adrenalectomy with LCDiseaseOrPhenotypicFeature ( P = . 006 ) .	0
Administration of parenteral LCOTHER must be done carefully and with good observation because of its pro - LCDiseaseOrPhenotypicFeature effect , especially in older patients who have LCOTHER LCOTHER or patients with LCOTHER LCOTHER ( LCOTHER ) which frequently occurs due to LCOTHER and or LCOTHER in LCDiseaseOrPhenotypicFeature cases . Low frequency of LCOTHER - associated LCOTHER variants in Kenya and Sudan and novel LCOTHER variants .	0
Future studies are needed to assess the therapeutic potential emerging from our finding for LCOTHER LCOTHER - LCDiseaseOrPhenotypicFeature . Role of stress - activated LCGeneOrGeneProduct in the cell fate decisions of LCOTHER LCOTHER cells treated with LCOTHER .	0
"Moreover , diagnosis of LCOTHER LCOTHER should be considered in the face of severe infant LCOTHER of uncertain etiology . Characterization of a novel LCOTHER """""""" silent """""""" allele : point mutation ( LCOTHER . LCOTHER ) causes loss of activity and prolonged LCDiseaseOrPhenotypicFeature with LCChemicalEntity ."	0
In a LCGeneOrGeneProduct LCOTHER strain , the expression of a LCOTHER ( LCSequenceVariant ) mutant allele caused temperature - sensitive LCOTHER LCOTHER LCOTHER , decreased LCOTHER consumption , impaired maturation / stabilization of the LCOTHER LCOTHER - LCOTHER LCOTHER , and reduced LCOTHER LCOTHER activity and amount .	0
BACKGROUND : LCOTHER ( LCDiseaseOrPhenotypicFeature ) , a rare recessive LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , is the most frequent genetic cause of LCOTHER LCOTHER LCOTHER in children and young adults .	0
In this study , 10 to 25 micromol / L LCOTHER inhibited LCCellLine - LCCellLine and LCOTHER LCOTHER LCOTHER cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCOTHER LCOTHER LCGeneOrGeneProduct and the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
LCOTHER enhancer region , 3R LCSequenceVariant > LCSequenceVariant single nucleotide polymorphism ( SNP ) , and LCOTHER LCOTHER polymorphisms were assessed in both fresh - frozen normal mucosa and LCDiseaseOrPhenotypicFeature .	0
These results support the conclusion that the LCOTHER / LCOTHER allele is the major risk variant for LCOTHER LCOTHER LCOTHER in the LCOTHER locus , but they suggest that additional infrequent coding variants at LCGeneOrGeneProduct may also contribute to LCOTHER LCOTHER LCOTHER risk . LCOTHER - induced changes in LCOTHER LCOTHER LCOTHER and LCChemicalEntity signaling via LCOTHER in skeletal muscle .	0
We analyzed for LCGeneOrGeneProduct and LCOTHER mutations and LINE - 1 methylation by Pyrosequencing , microsatellite instability ( MSI ) , and DNA methylation ( epigenetic changes ) in eight CpG island methylator phenotype ( CIMP ) - specific promoters [ LCOTHER , LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER ] by MethyLight ( real - time PCR ) .	0
LCOTHER increased LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER LCOTHER - LCOTHER , and LCGeneOrGeneProduct LCOTHER phosphorylation , suggesting increased autophagy , while markers of apoptosis ( cleaved LCOTHER - LCOTHER LCOTHER - LCOTHER , and LCOTHER ) were unchanged .	0
LCChemicalEntity toxicokinetics studies revealed no change in accumulation of LCOTHER and LCOTHER ( toxic metabolite ) in the normal diet - fed ( ND ) and LCDiseaseOrPhenotypicFeature hearts .	0
In the animals treated with threshold doses of LCOTHER , the average number of LCDiseaseOrPhenotypicFeature was 2 . 3 + / - 1 . 2 , and average LCDiseaseOrPhenotypicFeature duration was 39 . 5 + / - 8 . 4s .	0
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is a common LCDiseaseOrPhenotypicFeature where LCOTHER is directly linked to LCOTHER survival .	0
Compound 1 is a potent LCOTHER ( LCOTHER ) / LCOTHER ( LCOTHER ) LCOTHER LCOTHER in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of LCOTHER ' LCOTHER LCOTHER including LCOTHER and LCOTHER models of LCOTHER - induced LCOTHER , LCOTHER model of LCOTHER - induced LCOTHER , LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) lesion model of drug - induced rotation , and LCOTHER - treated non - LCOrganismTaxon primate model . Coincidence of mutations in different connexin genes in Hungarian LCOrganismTaxon .	0
RESULTS : Quantitative PCR indicated that LCOTHER is well expressed in LCOTHER liver and LCOTHER liver slices and that the classical LCGeneOrGeneProduct targets LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER are robustly induced by LCOTHER activation .	0
Our results suggest the importance of routine screening for the rather frequent - 3170G > A mutation ( in addition to LCOTHER . LCOTHER ) in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER LCOTHER LCOTHER LCOTHER genotype as a prognostic factor in LCOTHER LCOTHER LCOTHER receiving LCChemicalEntity - based adjuvant treatment .	0
In line , recombinant LCOTHER LCOTHER ( G allele ) synthesized 2 . 6 - fold more LCOTHER LCOTHER per unit of time than LCOTHER LCSequenceVariant ( A allele ; LCOTHER LCSequenceVariant [ 8 . 26 + / - 3 . 57 nmol / hour . mg ] vs LCOTHER LCOTHER [ 3 . 22 + / - 0 . 67 nmol / hour . mg ] ; P = . 01 ) .	0
To assess the LCOTHER effects of LCOTHER ( LCOTHER ) on LCOTHER ( LCChemicalEntity ) - induced LCOTHER , 60 male Sprague - Dawley LCOrganismTaxon were treated with LCOTHER 30 mg / kg / day or tap water for 15 days .	0
CONCLUSIONS : Clinicians are exhorted to pay close attention when initiating LCOTHER therapy in LCOrganismTaxon taking medications with epileptogenic properties that are LCOTHER substrates . LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( or LCOTHER LCOTHER LCOTHER ) secondary to LCOTHER .	0
Because all heterozygous LCOTHER mutations that have been described are localized in the signal sequence , screening of the LCOTHER gene for LCOTHER with LCDiseaseOrPhenotypicFeature with LCOTHER and LCOTHER may best be focused on sequencing of exon 1 , which encodes the signal peptide . A Critical Role for the LCOTHER LCOTHER LCOTHER LCOTHER in Virus - Induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER .	0
Pulmonary LCGeneOrGeneProduct - LCGeneOrGeneProduct protein content increased , but LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER and LCOTHER content , and lung histopathology , were not affected .	0
OBJECTIVES : To assess the added diagnostic value of a new cardiac performance index ( dP / dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12 - lead ECG , for detecting LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , using Tc99m - Sestamibi single - photon emission computed tomography as the gold standard of comparison to assess the presence or absence of LCDiseaseOrPhenotypicFeature .	0
These studies have produced intriguing but inconsistent results , potentially because the known functional variants : LCOTHER LCOTHER and LCOTHER , LCOTHER LCSequenceVariant and LCSequenceVariant , and LCOTHER LCOTHER provided an incomplete picture of the total functional diversity at these genes .	0
In addition to these new mutations , this investigation reveals the prevalence of LCOTHER substitution among a subset of African - Brazilian LCOTHER and presents evidences of the recurrence of already known mutations . Effects of LCChemicalEntity on LCOTHER - induced LCOTHER in LCOrganismTaxon .	0
Moreover , apoptotic proteins are also involved in the LCDiseaseOrPhenotypicFeature , like LCOTHER , LCOTHER , but not LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER or LCOTHER .	0
The results of the present study suggested that LCChemicalEntity protected against LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER through the upregulation of LCOTHER in vivo and in vitro . Possible LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature related to concomitant treatment with LCOTHER and LCOTHER .	0
In addition , the previously described variants LCOTHER . LCOTHER ( commonly designated LCSequenceVariant or LCOTHER LCOTHER ) , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , and LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] were identified .	0
These findings reveal the differential impact of immune escape variants on the replication and drug susceptibility of complex LCOrganismTaxon mutants , supporting the need of close surveillance and treatment adjustment in response to the selection of distinct mutational patterns . Bilateral LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER after LCOTHER and LCChemicalEntity intoxication .	0
In vivo induction of airway LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
DNA polymorphisms at LCOTHER / LCOTHER locus may confer susceptibility to postoperative LCOTHER of LCOTHER with LCOTHER . Analysis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk factors in immunosuppressed renal transplant LCOTHER shows high levels of UV - specific tandem LCOTHER LCOTHER LCOTHER mutations of the LCGeneOrGeneProduct gene .	0
Thus the present study indicates that individuals with the variant w1 / m1 genotype exhibit an increased risk while those with w2 / m2 genotype exhibit a decreased risk for LCOTHER LCOTHER . Four novel mutations in the LCOTHER - sensitive LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct gene in Japanese LCOTHER with LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Differences were found for serum FBG , FINS , HOMA - IR , and HOMA - beta , and placental LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
The metrics from DNA damage and repair study were correlated with the genotypes of common polymorphisms of the LCOTHER and LCOTHER genes : a LCSequenceVariant - - > LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant of the LCOTHER gene producing a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCOTHER polymorphism ) and a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( 5 ' - untranslated region ) of the LCGeneOrGeneProduct gene ( the LCOTHER polymorphism ) .	0
Together these findings show that the LCOTHER inhibitor , LCOTHER , produces antipsychotic - like effects , which differ from those observed with compounds primarily targeting the LCChemicalEntity system , and has a reduced side - effect potential as compared with these latter drugs . LCOTHER LCOTHER following chemotherapy for stage IIIE diffuse large B - cell LCOTHER LCOTHER in a LCOrganismTaxon with LCOTHER LCOTHER ( LCOTHER ' LCOTHER LCOTHER ) .	0
Results showed that LCOTHER ( 10 - 30 mg / kg p . o . ) blocked LCOTHER induced by the non - competitive LCOTHER LCOTHER antagonist , LCOTHER - LCOTHER and partially reversed spontaneous LCDiseaseOrPhenotypicFeature of LCOTHER LCOTHER ( neo - / - ) LCOrganismTaxon .	0
LCOTHER AND METHODS : We examined associations between 54 polymorphisms that tag the known common variants ( minor allele frequency > 0 . 05 ) in 10 genes involved in oxidative damage repair ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) and survival in 4 , 470 LCOrganismTaxon with LCOTHER LCOTHER .	0
Limited prospective data corroborate these findings , but larger prospective studies are urgently required . Efficacy of LCChemicalEntity ( LCChemicalEntity ) in LCOTHER with advanced LCOTHER previously treated with chemotherapy alone or with chemotherapy and LCOTHER inhibitors .	0
Alteration of LCOTHER protein levels may contribute to invasion and LCOTHER LCOTHER LCOTHER , which may occur through activation of LCOTHER signaling and promotion of LCOTHER - LCOTHER expression . The number of LCOTHER LCOTHER LCOTHER in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature correlates with the LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct gene insertion / deletion polymorphism .	0
Compared to that in the normal control , more severe LCOTHER LCOTHER and hepatocyte apoptosis , worse hepatic LCOTHER peroxidation demonstrated by the increased ASAFR , . LCOTHER and LCOTHER , but decreased LCOTHER and LCOTHER , increased LCOTHER - LCOTHER / LCOTHER activities and LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCGeneOrGeneProduct expressions , which revealed obvious LCOTHER LCOTHER and scaffold structure broken , were shown in the model control .	0
CONCLUSIONS : Our results indicate that the LCOTHER / ARE GG genotype confers an increased risk of LCDiseaseOrPhenotypicFeature especially among younger LCOrganismTaxon .	0
The ability of LCOTHER to block LCOTHER - LCOTHER LCOTHER ( LCOTHER + ) LCOTHER , also expressed by enteric neurons , might represent a possible mechanism through which LCOTHER exerts its actions . Lack of association of LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCSequenceVariant LCSequenceVariant status with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER , and disease severity .	0
METHODS : Isogenic LCDiseaseOrPhenotypicFeature cell lines that differ in LCGeneOrGeneProduct expression were characterized using in vitro assays of growth and invasiveness and a LCOTHER tail vein assay of experimental metastasis .	0
Compared with a normoxic , chow - fed control LCOTHER heart , LCOTHER decreased LCGeneOrGeneProduct expression , LCOTHER LCOTHER oxidation , and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) levels , while increasing glycolysis , all of which served to maintain normal LCOTHER concentrations ( [ LCOTHER ] ) and thereby , ejection fractions .	0
These results identify a new mutation in LCOTHER and expand the spectrum of LCOTHER mutations associated with LCDiseaseOrPhenotypicFeature . Elevation of LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCOTHER expression with media degeneration features LCOTHER - induced LCOTHER LCOTHER LCOTHER in a LCOTHER model .	0
As such , the proposed implications of LCGeneOrGeneProduct in invasion , disease progression and as a potential therapeutic target warrant further investigation . Influence of LCOTHER LCOTHER ( LCGeneOrGeneProduct ) polymorphisms on spontaneous and treatment - induced recovery from LCOTHER LCOTHER LCOTHER LCOTHER .	0
Our findings suggest that the LCSequenceVariant LCGeneOrGeneProduct polymorphism is associated with a faster rate of LCOTHER LCOTHER in LCOTHER LCOTHER , highlighting the important role of purine metabolism in the progression of this LCOTHER LCOTHER . LCOTHER LCOTHER use , LCOTHER LCOTHER , and LCOTHER LCOTHER : a systematic review of published and unpublished studies .	0
Histological analyses of apoptosis , proliferation , angiogenesis and LCDiseaseOrPhenotypicFeature zone assessments were performed using LCOTHER LCOTHER - mediated LCOTHER nick - end labelling ( TUNEL ) staining , BrdU immunostaining , LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) / LCOTHER immunostaining and Masson ' s trichrome staining , respectively .	0
The fact that no truncation or frame shift mutations have been found in any of the LCOTHER LCOTHER , coupled with our recent finding that some breeding pairs of LCOTHER LCOTHER knockout LCOTHER yield litters that show not only LCOTHER , but also severe LCOTHER and LCOTHER LCOTHER , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOTHER . Midline B3 LCOTHER nerves in LCOrganismTaxon medulla are involved in LCOTHER effect of LCChemicalEntity .	0
These data suggest that when LCOTHER activity is blocked in the setting of LCOTHER LCOTHER LCOTHER , the plasma LCGeneOrGeneProduct level rises , preventing LCOTHER . LCOTHER - LCOTHER , a LCOTHER ( LCOTHER ) LCOTHER , functions as a LCDiseaseOrPhenotypicFeature suppressor in an orthotopic LCOTHER LCOTHER LCOTHER model .	0
Our findings provide evidence that common regulatory mechanisms in different plant stem cell niches are adapted to specific niche anatomies and emphasize the importance of a complex spatial organization of intercellular signaling cascades for a strictly bidirectional tissue production . LCSequenceVariant mutation in the LCOTHER gene in a family with LCDiseaseOrPhenotypicFeature in the UAE .	0
Physicians should recognise the possibility of fatal LCOTHER LCOTHER related to LCChemicalEntity plus high - dose LCOTHER in elderly LCOTHER , and we believe this case warrants further investigation . The LCOTHER LCOTHER - LCOTHER inhibitor LCChemicalEntity displays a selective and specific antipsychotic - like profile in normal and transgenic LCOTHER .	0
Beneficial effect of oral LCOTHER was independent of the LCOrganismTaxon age and of the LCChemicalEntity dose ranging from 100 to 300 mg / kg / day .	0
LCOTHER administration would be effective in the treatment of LCOTHER LCOTHER LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Mutational analysis of LCOTHER in LCOTHER LCOrganismTaxon using denaturing high performance liquid chromatography .	0
Furthermore , LCOTHER ( LCSequenceVariant ) - induced immortalization can also be abrogated by LCOTHER deletion via senescence induction , which is again rescued by simultaneous deletion of LCGeneOrGeneProduct .	0
A total of 10 novel variants was recognized , among them four variants in the adjacent 5 ' - region of the LCOTHER coding exon 2 ( LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCSequenceVariant . LCSequenceVariant - LCSequenceVariant > LCSequenceVariant ) , a 6 base - pair deletion ( LCOTHER . LCOTHER [ LCOTHER . LCOTHER ] ) , a variant leading to a stop codon ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , synonymous variants ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , and one non - synonymous variant ( LCOTHER . LCOTHER > LCOTHER [ LCSequenceVariant . LCSequenceVariant ] ) .	0
CONCLUSIONS LCOTHER - LCOTHER - LCOTHER / LCOTHER SNP , hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct were associated with LCOTHER in LCOTHER from Inner Mongolia , as was serious LCOTHER and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER prevents LCOTHER LCOTHER accumulation in macrophages induced by the LCGeneOrGeneProduct LCGeneOrGeneProduct inhibitor LCOTHER .	0
By contrast , oxidation related genes were decreased ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct ) .	0
In this study , 10 to 25 micromol / L LCChemicalEntity inhibited LCCellLine - LCCellLine and LCOTHER LCOTHER LCOTHER cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCOTHER LCOTHER LCOTHER and the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
Two heterozygous DNA sequence variations were solely present in one single LCOrganismTaxon each but in none of the 20 normal controls : a LCOTHER LCOTHER LCOTHER ( LCSequenceVariant . LCSequenceVariant [ LCSequenceVariant ] + [ LCSequenceVariant ] ) resulting in an extra alanine within exon 1 and a LCOTHER * LCOTHER > LCOTHER substitution in the 3 ' - untranslated region .	0
Screening of LCOTHER identified two synonymous sequence variants , LCOTHER . LCOTHER LCOTHER > LCOTHER ( LCOTHER . LCOTHER , LCOTHER ) and LCSequenceVariant . LCSequenceVariant LCSequenceVariant > LCSequenceVariant ( LCSequenceVariant .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCGeneOrGeneProduct , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
Of 13 documented LCOTHER , 3 occurred after LCOTHER and LCOTHER were started , and none occurred in LCOrganismTaxon with LCDiseaseOrPhenotypicFeature .	0
These results identify a new mutation in LCOTHER and expand the spectrum of LCGeneOrGeneProduct mutations associated with LCOTHER . Elevation of LCOTHER , LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCOTHER expression with media degeneration features LCOTHER - induced LCOTHER LCOTHER LCOTHER in a LCOrganismTaxon model .	0
We investigated also the expression of angiocrine genes upon LCOTHER treatment in vivo , and demonstrate that LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER - LCOTHER are upregulated , while LCOTHER and LCOTHER are reduced .	0
There was no significant association between the LCOTHER status and disease severity in LCDiseaseOrPhenotypicFeature , LCOTHER , or LCDiseaseOrPhenotypicFeature .	0
Our data support potential interactions between the LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCOTHER pathways , and possible influence by LCOTHER or LCGeneOrGeneProduct mutation on therapy or chemoprevention targeting LCOTHER . Identification of novel type LCOTHER LCOTHER gene mutations resulting in severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
CONCLUSION : Our results suggest that use of high - dose LCOTHER in older LCOTHER in conjunction with cardiopulmonary bypass and open - chamber cardiac surgery is associated with clinical LCOTHER in susceptible LCOrganismTaxon . Cardioprotective effect of LCOTHER LCOTHER LCOTHER on LCOTHER - induced LCOTHER LCOTHER in LCOrganismTaxon .	0
He had a homozygous insertion of a nucleotide , LCSequenceVariant ( LCSequenceVariant mutation ) , in exon 7 of the LCOTHER gene .	0
Our data provide evidence that LCOTHER LCOTHER LCOTHER mediates severity of weight regulation disturbances in females with LCDiseaseOrPhenotypicFeature , and the gene - dose effect - like differences suggest a direct functional role of LCOTHER LCOTHER LCOTHER in the behavioral regulation of body weight . LCGeneOrGeneProduct , a new member of the LCOTHER gene family , is involved in drug resistance in LCOTHER / LCOTHER cells .	0
Expression of some lineage specific factors is markedly reduced in LCOTHER knockdown embryos , including LCGeneOrGeneProduct , LCOTHER and LCOTHER , while others are inappropriately expressed ( LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct ) .	0
No LCGeneOrGeneProduct , LCOTHER , or LCOTHER mutations were detected , but a homozygous LCOTHER frameshift mutation , LCSequenceVariant . LCSequenceVariant - LCSequenceVariant , was identified in a family with three children affected with lethal LCOTHER LCOTHER LCOTHER .	0
Serum concentrations of LCGeneOrGeneProduct , LCChemicalEntity and LCOTHER - LCOTHER as markers of LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	0
LCOTHER was not independently associated with body mass index , family history of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER location ( colon versus rectum ) , stage , LCOTHER grade , signet ring cells , CIMP , MSI , LINE - 1 hypomethylation , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER , or LCOTHER - LCOTHER .	0
These results demonstrate the critical role of the final 20 amino acids of LCOTHER - LCOTHER in modulating fibroblast proliferation by dampening LCOTHER signaling and suggest that augmented LCGeneOrGeneProduct signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of LCOTHER in LCOTHER with LCOTHER - LCOTHER LCSequenceVariant . LCSequenceVariant mutation . Mutations in LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) LCOTHER in LCOTHER with LCOTHER - LCOTHER LCOTHER LCOTHER .	0
Our data support potential interactions between the LCOTHER , LCOTHER - LCOTHER and LCOTHER - LCOTHER pathways , and possible influence by LCOTHER or LCOTHER mutation on therapy or chemoprevention targeting LCOTHER . Identification of novel type LCGeneOrGeneProduct LCGeneOrGeneProduct gene mutations resulting in severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
In the current study , the haplotype structure of the LCGeneOrGeneProduct region was determined , and individual haplotypes were tested for association with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in family - based tests .	0
Serum concentrations of LCOTHER , LCOTHER and LCOTHER - LCOTHER as markers of LCOTHER and LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	0
These results strongly suggest that the LCOTHER LCOTHER mutation is responsible for the LCDiseaseOrPhenotypicFeature phenotype in the proposita ' s family . Cloning of LCOTHER LCOTHER - LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER and molecular characterization of its deficiency in two LCOrganismTaxon .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER ) .	0
LCChemicalEntity LCChemicalEntity ( LCChemicalEntity ) isolated from hexanic fraction seed extract of species LCOTHER LCOTHER LCOTHER .	0
The LCOTHER contains a highly conserved LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct phosphorylation site and the LCOTHER subunit contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site which make them strong candidates for future mutation detection studies in LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER . The LCOTHER mutation database : an online database of LCOTHER LCOTHER mutations involved in the LCDiseaseOrPhenotypicFeature ( LCOTHER ) LCOTHER LCOTHER and congenital LCOTHER LCOTHER .	0
Our result expands the mutation spectrum of LCOTHER and contributes to the study of the molecular pathogenesis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER polymorphisms associated with alternative splicing modify susceptibility to LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature through epistatic interaction with LCOTHER .	0
LCOTHER - induced LCOTHER was challenged with prior intracollicular microinjections of LCOTHER LCOTHER LCOTHER antagonists , LCChemicalEntity - LCChemicalEntity ( 15 or 30 mmol / 0 . 5 microl ) and LCOTHER ( 10 or 20 nmol / 0 . 5 microl ) , or of the LCOTHER LCOTHER agonist LCChemicalEntity - LCChemicalEntity - LCChemicalEntity - LCChemicalEntity ( LCOTHER , 20 or 30 nmol / 0 . 5 microl ) .	0
Sequencing analysis detected 17 different LCGeneOrGeneProduct gene mutations , and 7 of these were identified as novel : 3 missense mutations , including LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 3 , LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 3 and LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 7 ; 2 deletion mutations , including LCOTHER . LCOTHER ( LCOTHER . LCOTHER ) in exon 5 and LCSequenceVariant . LCSequenceVariant ( LCOTHER . LCOTHER ) in exon 11 ; and 2 alternative splicing mutations , including LCOTHER . LCOTHER + LCOTHER in intron 4 at splicing donor sites and LCOTHER . LCOTHER - LCOTHER > LCOTHER in intron 13 at splicing acceptor sites .	0
Moreover , we confirm previous results that a short LCOTHER LCOTHER in conjunction with GG genotype significantly increases the risk of LCOTHER LCOTHER . A homozygous mutation in LCOTHER / LCGeneOrGeneProduct associated with early onset LCOTHER , LCOTHER LCOTHER , and severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature activity .	0
Thus LCOTHER , LCOTHER , and LCOTHER represent LCOTHER LCOTHER . Genetic variants of the LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER but not the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene are associated with LCDiseaseOrPhenotypicFeature in an African American population .	0
Sequencing analysis detected 17 different LCOTHER gene mutations , and 7 of these were identified as novel : 3 missense mutations , including LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER . LCOTHER ) in exon 3 , LCOTHER . LCOTHER > LCOTHER ( LCSequenceVariant . LCSequenceVariant ) in exon 3 and LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 7 ; 2 deletion mutations , including LCOTHER . LCOTHER ( LCOTHER . LCOTHER ) in exon 5 and LCOTHER . LCOTHER ( LCOTHER . LCOTHER ) in exon 11 ; and 2 alternative splicing mutations , including LCOTHER . LCOTHER + LCOTHER in intron 4 at splicing donor sites and LCOTHER . LCOTHER - LCOTHER > LCOTHER in intron 13 at splicing acceptor sites .	0
Loss of LCOTHER expression in LCOTHER altered the LCOTHER induction of LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER - LCOTHER .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCOTHER [ LCOTHER , LCGeneOrGeneProduct ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCGeneOrGeneProduct [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
In the haplotype - wise analysis , we detected an association between two markers ( LCOTHER and LCOTHER ) and three markers ( LCOTHER , LCSequenceVariant and LCSequenceVariant ) in LCOTHER and LCOTHER - induced LCOTHER LCOTHER , respectively .	0
Histological analyses of apoptosis , proliferation , angiogenesis and LCOTHER zone assessments were performed using LCOTHER LCOTHER - mediated LCOTHER nick - end labelling ( TUNEL ) staining , BrdU immunostaining , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) / LCGeneOrGeneProduct immunostaining and Masson ' s trichrome staining , respectively .	0
To the best of our knowledge , this is the first study to report that the combination of LCChemicalEntity - LCChemicalEntity and LCChemicalEntity induces LCOTHER LCOTHER LCOTHER cell apoptosis in a concerted manner with the induction of LCOTHER LCOTHER LCOTHER gene expression . LCOTHER is required for cambium homeostasis in LCOTHER .	0
Thus , immunosuppression has increased the risk of LCOTHER by LCOrganismTaxon , predominantly LCOTHER LCOTHER , speculated to play a role in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature development .	0
This sole substitution was sufficient to confer constitutive activity to the receptor variant ( LCGeneOrGeneProduct ( LCOTHER ) ) , as assessed in three reconstituted cell models ( LCOTHER / LCOTHER , LCOTHER and LCOTHER - LCOTHER cells ) by LCOTHER - independent ( i ) LCGeneOrGeneProduct tyrosine phosphorylation , ( ii ) activation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) signaling , ( iii ) transcriptional activity toward a LCOTHER - responsive reporter gene , and ( iv ) cell proliferation and protection from cell death .	0
CONCLUSIONS : High serum levels of LCOTHER LCGeneOrGeneProduct such as LCOTHER and LCOTHER in the serum of LCOTHER LCOTHER indicate the presence of LCOTHER . Over - expression of LCOTHER and LCGeneOrGeneProduct in a child with LCOTHER LCOTHER LCOTHER and LCOTHER LCOTHER : a new syndrome .	0
The genotype frequencies of LCOTHER did not differ significantly from controls ( LCGeneOrGeneProduct / LCOTHER , LCOTHER / LCOTHER : LCOTHER 18 . 3% and 1 . 2% , respectively ; LCDiseaseOrPhenotypicFeature 17 . 5% and 2 . 1% ; LCOTHER 13 . 3% and 1 . 8% ; controls 20 . 0% and 2 . 8% ) .	0
Serum concentrations of LCOTHER , LCOTHER and LCOTHER - LCOTHER as markers of LCOTHER and LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER - LCOTHER ) were measured .	0
Altogether , our results suggest that LCOTHER deficiency cooperates with LCOTHER - LCOTHER in promoting LCOTHER LCOTHER LCOTHER / LCOTHER LCOTHER LCOTHER in LCOrganismTaxon , possibly by specifically enforcing marginal zone B cell accumulation , increasing LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct expression , and rendering B cells independent of LCOTHER LCOTHER LCOTHER LCOTHER for survival . Association of adipocyte genes with LCOTHER expression : a microarray analysis of subcutaneous and omental adipose tissue in morbidly LCOTHER subjects .	0
Apparent homozygosity for the mutation LCSequenceVariant . LCSequenceVariant present on exon 5 of the LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) gene in a LCOTHER LCOTHER LCOTHER LCOTHER was solved in this study by further testing for a second mutation .	0
An MspI polymorphism , producing a 3 . 7 kb band , may prove useful in assessing this gene ' s involvement in LCOTHER LCOTHER involving opiatergic systems . An LCOTHER - LCOTHER LCSequenceVariant - > LCSequenceVariant gene polymorphism associated with LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene and high LCOTHER LCOTHER production .	0
By contrast , no significant correlation was detected between the protein levels and LCOTHER age , histological type , or serum LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER - LCOTHER levels .	0
This LCOrganismTaxon presented with symptoms of LCOTHER LCOTHER LCOTHER ( LCOTHER ) , thus demonstrating that LCOTHER - like symptoms can occur after combined LCOTHER and LCChemicalEntity treatment .	0
LCOTHER and LCOTHER - LCOTHER expression was lowered in 6 week LCChemicalEntity - treated WT animals whereas in treated LCGeneOrGeneProduct KO LCOTHER , LCOTHER was only reduced by 2 - fold and LCOTHER - LCOTHER expression was unaffected .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
METHODS : We identified seven SNP ( single nucleotide polymorphism ) ( - 141Cins > del , TaqIB , TaqID , LCOTHER , LCSequenceVariant , LCOTHER and TaqIA ) in the LCOTHER gene in 146 LCOTHER LCOTHER ( 59 with LCOTHER and 87 without LCDiseaseOrPhenotypicFeature according to the Simpson - Angus Scale ) treated with LCOTHER after 8 weeks .	0
Taken together , our results demonstrated that LCOTHER is a LCOTHER ( LCOTHER ) - cooperating oncogene required for LCOTHER ( LCSequenceVariant ) - induced immortalization and transformation , and targeting LCGeneOrGeneProduct - LCOTHER LCOTHER LCOTHER may , therefore , have therapeutic value for senescence - based LCOTHER treatment . In vivo evidences suggesting the role of oxidative stress in pathogenesis of LCOTHER - induced LCOTHER : protection by LCOTHER .	0
Common > or = grade 3 events were LCOTHER , LCOTHER , LCDiseaseOrPhenotypicFeature , LCOTHER , and LCDiseaseOrPhenotypicFeature .	0
LCOTHER was up - regulated in LCGeneOrGeneProduct ( + ) cells from brains of LCOTHER with LCDiseaseOrPhenotypicFeature and in LCOTHER ( + ) LCOTHER ( int ) cells from LCOTHER subjected to LCOTHER - induced LCOTHER .	0
No association of LCOTHER polymorphisms and self - limited LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature could be demonstrated . LCOTHER LCOTHER ( LCGeneOrGeneProduct ) defects are common in LCOTHER LCOTHER LCOTHER LCOTHER and co - occur with LCOTHER mutations .	0
Additional predictors of persistent postoperative LCOTHER included duration of LCDiseaseOrPhenotypicFeature ( P < . 0005 ) , family history of LCDiseaseOrPhenotypicFeature ( P = . 001 ) , and elevated systolic blood pressure ( P = . 015 ) .	0
It is an autosomal recessive , developmental LCOTHER LCOTHER LCOTHER disorder characterized by deficiency in mitochondrial LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) catalytic activity , refractory LCOTHER , LCDiseaseOrPhenotypicFeature , and LCOTHER LCOTHER .	0
The aim of this study was therefore to investigate the influence of mutations in these LCOTHER LCOTHER LCOTHER genes ( LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER / LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER , LCOTHER and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) .	0
The goal of this study was to perform LCOTHER - LCOTHER - LCOTHER LCOTHER LCOTHER gene ( LCOTHER ) analysis in a LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) LCOTHER with normal LCChemicalEntity ( LCOTHER ) production and normal LCOTHER LCOTHER ( LCOTHER ) gene coding sequences .	0
Although many advantageous roles of LCOTHER ( LCOTHER - LCOTHER ( II ) , LCOTHER ) have been reported in LCDiseaseOrPhenotypicFeature therapy , the immunomodulatory roles of LCChemicalEntity in the phenotypic and functional alterations of dendritic cells ( DCs ) are poorly understood .	0
In vivo induction of airway LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
To investigate effects of LCOTHER on LCOTHER LCOTHER , we performed LCOTHER assay in neonatal LCOrganismTaxon ventricular myocytes ( NRVMs ) , as well as measured LCOTHER LCOTHER level in the culture medium of NRVMs and activities of serum cardiac enzymes in LCOrganismTaxon .	0
Thus , our results support the notion that LCOTHER - LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCOTHER - LCOTHER mutually regulate Th17 and Th1 responses in LCOTHER - bearing hosts , and LCOTHER LCOTHER modulates the balance of the LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER - LCOTHER axis towards LCOTHER - LCOTHER production , which leads to LCDiseaseOrPhenotypicFeature inhibition .	0
We report a case of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) in a dizygotic twin who presented at 12 years of age with LCOTHER LCOTHER , LCOTHER LCOTHER , LCOTHER and LCOTHER with inappropriate kaliuresis , and LCOTHER LCOTHER LCOTHER with LCOTHER LCOTHER ( LCOTHER LCOTHER ) .	0
The fact that no truncation or frame shift mutations have been found in any of the LCDiseaseOrPhenotypicFeature LCOTHER , coupled with our recent finding that some breeding pairs of LCOTHER LCOTHER knockout LCOTHER yield litters that show not only LCOTHER , but also severe LCOTHER and LCOTHER LCOTHER , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOTHER . Midline B3 LCOTHER nerves in LCOTHER medulla are involved in LCOTHER effect of LCChemicalEntity .	0
BACKGROUND : LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) is an LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature resulting from inactivating mutations in the LCOTHER - sensitive LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) gene .	0
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCOTHER ( 874 LCOTHER ' LCOTHER LCOTHER , 259 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER / LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER .	0
LCOTHER was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCGeneOrGeneProduct , LCOTHER ] , by secretagogues activating LCOTHER - LCOTHER ( LCOTHER ) [ LCOTHER , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCOTHER [ LCOTHER ] , but not agents only mobilizing cellular LCChemicalEntity or increasing LCOTHER LCOTHER .	0
Fifteen moderate LCOTHER users ( < 55 lifetime tablets ) , 22 heavy LCChemicalEntity + users ( > 55 lifetime tablets ) , 16 ex - LCChemicalEntity + users ( last tablet > 1 year ago ) and 13 controls were compared on a battery of neuropsychological tests .	0
METHODS : We performed a systematic review of published and unpublished data from cohorts with LCOTHER or LCOTHER to compare the presence of LCOTHER in : ( 1 ) antithrombotic users vs nonantithrombotic users with LCOTHER ; ( 2 ) antithrombotic users vs nonusers with LCDiseaseOrPhenotypicFeature / LCOTHER ; and ( 3 ) LCDiseaseOrPhenotypicFeature vs LCOTHER events stratified by antithrombotic use .	0
CONCLUSIONS LCOTHER - LCOTHER - LCOTHER / LCOTHER SNP , hs - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER / LCOTHER - LCOTHER were associated with LCOTHER in LCOTHER from Inner Mongolia , as was serious LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER prevents LCOTHER LCOTHER accumulation in macrophages induced by the LCOTHER LCOTHER inhibitor LCOTHER .	0
LCOrganismTaxon received LCOTHER - treatment for 12 months with finished dose - titration of LCGeneOrGeneProduct and centralized LCOTHER - LCOTHER measurements .	0
We have previously shown that transgenic ( tg ) LCOTHER expressing in B lymphocytes both LCGeneOrGeneProduct - LCGeneOrGeneProduct and a LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) mutant lacking the really interesting new gene and zinc finger domains ( TRAF2DN ) develop LCOTHER LCOTHER LCOTHER and LCOTHER LCOTHER LCOTHER with high incidence ( Zapata et al .	0
Consistent with this premise , LCOTHER LCOTHER cells with relatively high levels of LCOTHER are more sensitive to LCChemicalEntity - LCChemicalEntity treatment compared to LCOTHER - depleted LCOTHER cells , further indicating that LCOTHER loss has a crucial role in LCChemicalEntity - LCChemicalEntity resistance in LCOTHER LCOTHER .	0
We report a case of LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) in a dizygotic twin who presented at 12 years of age with LCOTHER LCOTHER , LCOTHER LCOTHER , LCOTHER and LCOTHER with inappropriate kaliuresis , and LCOTHER LCOTHER LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER LCOTHER ) .	0
Our findings offer new opportunities to understand the molecular mechanisms accounting for the B - cell growth - promoting activity of vp17s . Mutation analysis of LCGeneOrGeneProduct , LCGeneOrGeneProduct , LCOTHER , and LCOTHER genes in LCOTHER LCOTHER LCOTHER / LCOTHER LCOTHER LCOTHER .	0
Additionally , when LCGeneOrGeneProduct genotype was cross classified with LCSequenceVariant LCSequenceVariant , significantly more cases than both LCOTHER and population controls were observed to have a short ( < 22 ) CAG / GG genotype ( P = 0 . 006 ) .	0
We investigated the effect of LCOTHER in the LCOTHER microenvironment of LCOTHER with liver parenchymal cell - specific LCGeneOrGeneProduct ablation ( LCOTHER - Cre ; LCOTHER ( f / f ) ) and LCGeneOrGeneProduct deletion both in liver parenchymal and non - parenchymal cells ( LCOTHER - Cre ; LCOTHER ( f / f ) ) .	0
LCOTHER mediated barrier - protective effects of LCChemicalEntity by activating LCOTHER / LCOTHER LCOTHER and LCOTHER LCOTHER LCOTHER targets at cell adhesions and cytoskeleton : LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , and LCOTHER .	0
Eleven subjects presented LCOTHER homozygous single - base mutations ( two first cousins and four unrelated LCOTHER with LCOTHER , two with LCOTHER , one with LCOTHER , one with LCOTHER , and one with LCOTHER plus the LCOTHER variant in heterozygosis ) , whereas four were compound heterozygotes ( one with LCOTHER / LCSequenceVariant + LCSequenceVariant > LCSequenceVariant , one with LCSequenceVariant / LCOTHER , and two brothers with LCOTHER / LCOTHER ) .	0
Differences were found for serum FBG , FINS , HOMA - IR , and HOMA - beta , and placental LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER .	0
CONCLUSION : The present experimental findings substantiate the clinically observed LCOTHER potential of LCOTHER and LCOTHER . LCGeneOrGeneProduct LCGeneOrGeneProduct gene variants as susceptibility marker for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Seroreactivity of the SEREX clones were determined in sera from 75 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER , 75 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER , and 25 healthy donors .	0
A total of 167 LCOrganismTaxon receiving LCOTHER fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving LCChemicalEntity .	0
METHODS : DNA samples from 405 LCOTHER LCOTHER , 97 LCDiseaseOrPhenotypicFeature LCOTHER , 113 LCOTHER LCOTHER , and 431 healthy controls were genotyped for the LCOTHER LCSequenceVariant LCSequenceVariant .	0
The age and sex of the control subjects did not differ from those of the LCChemicalEntity dependence LCOrganismTaxon .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCGeneOrGeneProduct and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
Furthermore , our global analysis of gene expression , which was focused on genes involved in the molecular regulation of LCOTHER LCOTHER LCOTHER LCOTHER , showed enhancement of pro - apoptotic LCGeneOrGeneProduct and LCGeneOrGeneProduct after the combination of LCOTHER - LCOTHER and LCOTHER .	0
RESULTS : HAT adipose tissue demonstrated increased LCOTHER related genes for storage ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCGeneOrGeneProduct ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	0
LCOTHER - LCOTHER LCOTHER stimulated LCOrganismTaxon and LCOrganismTaxon LCOTHER cell migration and invasion in a concentration - dependent manner in three - dimensional migration assays , acting as a chemotactic factor .	0
In this study , 10 to 25 micromol / L LCOTHER inhibited LCOTHER - LCOTHER and LCOTHER LCOTHER LCOTHER cell growth , and this was accompanied by induction of apoptosis and decreased expression of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCOTHER and the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	0
Knockdown and overexpression of LCOTHER in LCOTHER LCOTHER cells was performed using specifically constructed plasmids , which either had anti - LCGeneOrGeneProduct ribozyme transgene or the full length LCOTHER LCGeneOrGeneProduct coding sequence .	0
Three LCOrganismTaxon were heterozygous for LCOTHER , LCSequenceVariant , and LCOTHER substitutions .	0
BACKGROUND / AIMS : LCOTHER LCOTHER ( LCOTHER ) is a rare disease characterized by LCOTHER - like substances in markedly LCOTHER LCOTHER LCOTHER and elevated plasma levels of LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) .	0
Immunohistochemical analysis of Grade 1 LCOTHER LCOTHER revealed aberrant LCGeneOrGeneProduct expression , with foci of elevated LCGeneOrGeneProduct staining , not observed in normal endometrium .	0
The AS isoform lacks exon 8 , and is deduced to contain 49 amino acid changes in the membrane - distal portion of the extracellular domain , where considerable amino acid changes are known in LCOTHER ( c ) allele associated with LCOrganismTaxon LCDiseaseOrPhenotypicFeature .	0
Plasma LCChemicalEntity LCChemicalEntity ( LCOTHER ) concentration and LCChemicalEntity reducing antioxidant power ( FRAP ) value were determined .	0
The adaptive metabolic changes caused by LCOTHER in control LCOTHER hearts were found to have occurred already in LCGeneOrGeneProduct - deficient ( LCOTHER ( - / - ) ) LCOTHER hearts and sustained function in LCDiseaseOrPhenotypicFeature despite an inability for further metabolic remodeling .	0
LCOTHER - LCOTHER - LCOTHER LCOTHER ( LCOTHER ) are LCOTHER / LCOTHER LCOTHER comprising six isoforms divided in two groups , group - I ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) / group - II ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) which play important roles in cell cytoskeletal dynamics , survival , secretion and proliferation and are activated by diverse stimuli .	0
CONCLUSION : Although an association with LCDiseaseOrPhenotypicFeature cannot be excluded , the LCOTHER LCSequenceVariant LCSequenceVariant does not seem to be a disease susceptibility genotype for LCOTHER , LCOTHER , or LCOTHER .	0
RESULTS : HAT adipose tissue demonstrated increased LCOTHER related genes for storage ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCGeneOrGeneProduct , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	0
A model of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature was developed by intrasplenic injection of LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER - LCOTHER ) into LCOTHER knockout LCOTHER ( LCOTHER ) and wild - type ( LCOTHER / LCOTHER ) LCOTHER ( WT ) .	0
In the LCOTHER gene , 2 novel mutations , LCOTHER - > LCOTHER ( LCOTHER ) and LCSequenceVariant ( LCOTHER ) , were found in 2 LCOrganismTaxon .	0
In summary , our findings demonstrate for the first time that mutations in LCOTHER are associated with an S - LCDiseaseOrPhenotypicFeature phenotype including LCOTHER , thereby further extending the clinical spectrum of phenotypes associated with LCOTHER mutations . Genetic investigation of the LCOTHER gene in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCGeneOrGeneProduct ( LCOTHER - LCOTHER LCOTHER ) , LCGeneOrGeneProduct and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
This study showed that LCOTHER was more likely to be LCOTHER susceptibility gene at Chr . 1q31 based on the finding that the LCOTHER and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCOTHER in a white population in LCOTHER , LCOTHER , and LCGeneOrGeneProduct genes showed a significant association with LCOTHER . Seven novel and six de novo LCOTHER gene mutations in LCOrganismTaxon with LCOTHER LCOTHER .	0
The LCGeneOrGeneProduct and LCGeneOrGeneProduct deletion was not polymorphic in the Chinese population and was not associated with wet LCOTHER or LCOTHER .	0
Future studies remain necessary to develop effective personalized therapeutic strategies for LCOTHER variant allele carriers and other individuals at risk for LCChemicalEntity nonresponsiveness . LCOTHER enhances LCOTHER - LCOTHER LCOTHER signaling in LCOTHER B cells and confers resistance to LCGeneOrGeneProduct inhibition .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCGeneOrGeneProduct / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER ) .	0
The LCOTHER contains a highly conserved LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct phosphorylation site and the LCGeneOrGeneProduct subunit contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site which make them strong candidates for future mutation detection studies in LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER . The LCOTHER mutation database : an online database of LCOTHER LCOTHER mutations involved in the LCOTHER ( LCOTHER ) LCOTHER LCOTHER and congenital LCOTHER LCOTHER .	0
A unique set of LCOTHER - regulated survival factors included LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER LCOTHER .	0
Moreover , LCGeneOrGeneProduct agonist and LCGeneOrGeneProduct - siRNA significantly reduced the above changes .	0
Adipocyte cell culture revealed that endogenous and synthetic LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct - and LCOTHER - selective agonists , as well as a synthetic LCOTHER LCOTHER LCOTHER agonist , efficiently reduced LCOTHER expression , whereas LCGeneOrGeneProduct expression only increased with LCOTHER agonists .	0
It is concluded that oxidative tubular damage plays an important role in the LCOTHER - induced LCDiseaseOrPhenotypicFeature and the modulation of oxidative stress with LCOTHER reduces the LCOTHER - induced LCOTHER LCOTHER both at the biochemical and histological levels . LCOTHER LCOTHER LCOTHER - LCOTHER interacts with LCGeneOrGeneProduct and LCOTHER to modulate LCOTHER secretion in LCOTHER gonadotrophs .	0
LCOTHER is a multi - copper LCChemicalEntity that is secreted into plasma and facilitates cellular LCOTHER export and LCChemicalEntity binding to LCOTHER .	0
This study supports the hypothesis that LCOTHER is involved in LCOTHER LCOTHER and that sequence variation within the LCOTHER - LCOTHER gene influence the risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Glutamatergic neurotransmission mediated by LCOTHER LCOTHER in the inferior colliculus can modulate LCOTHER - induced LCDiseaseOrPhenotypicFeature .	0
Mechanistic studies revealed that LCOTHER LCOTHER are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER , ( 3 ) decreased plasma LCGeneOrGeneProduct levels , ( 4 ) decreased cardiac LCOTHER - LCOTHER oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCDiseaseOrPhenotypicFeature ) , ( 5 ) decreased mitochondrial LCOTHER - LCOTHER LCOTHER LCOTHER , and ( 6 ) 86% drop in cardiac LCOTHER levels accompanied by decreased LCOTHER / LCOTHER ratio after LCOTHER administration .	0
These studies have produced intriguing but inconsistent results , potentially because the known functional variants : LCOTHER LCSequenceVariant and LCOTHER , LCGeneOrGeneProduct LCOTHER and LCOTHER , and LCOTHER LCOTHER provided an incomplete picture of the total functional diversity at these genes .	0
Together with previously reported cases , our LCOrganismTaxon suggests that LCOTHER - LCOTHER LCOTHER might occur in certain vulnerable individuals during treatment with atypical LCOTHER such as LCOTHER , LCOTHER , or LCChemicalEntity . Context - and cell - dependent effects of LCOTHER - LCOTHER LCOTHER targeting in the bone marrow microenvironment .	0
DNA analysis revealed compound heterozygosity for mutations of LCGeneOrGeneProduct , including a previously reported LCSequenceVariant mutation and a novel duplication of a nucleotide in exon 9 ( LCOTHER ) , the latter resulting in a frameshift and a premature stop codon .	0
Our findings indicated that LCOTHER might be a very upstream key molecule regulating EMT involved in LCOTHER / LCOTHER - LCOTHER signaling pathway . LCOTHER LCOTHER LCOTHER protects high LCOTHER - induced energy LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature via blocking LCGeneOrGeneProduct - ubiquitin proteasome pathway .	0
Neutralizing anti - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) IgG or control IgG was administered to a group of wild - type animals prior to LCOTHER LCOTHER .	0
Genetic analysis of LCOTHER seems to be of limited significance in the differential diagnosis of LCOTHER without LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . High LCOTHER diet - fed LCOTHER LCOTHER are highly sensitive to LCOTHER - induced LCDiseaseOrPhenotypicFeature .	0
SNPs within LCGeneOrGeneProduct associated with LCOTHER LCOTHER mortality were LCSequenceVariant ( fixed effects hazard ratio , HRfixed = 0 . 78 ; 95% confidence interval ( 95%CI ) : 0 . 66 , 0 . 91 ; p values = 0 . 002 ) ; LCOTHER , HRfixed = 0 . 76 ; 95%CI : 0 . 64 , 0 . 91 ; p values = 0 . 003 ) ; and LCOTHER ( HRfixed = 0 . 76 ; 95%CI : 0 . 64 , 0 . 91 ; p values = 0 . 002 ) .	0
Our observation of frequent LCOTHER gene abnormalities ( 90% ) and inactivation ( 40 - 60% ) was in striking contrast to the same pathological subtype of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in which LCOTHER gene abnormalities and inactivation were infrequent , suggesting a difference in LCDiseaseOrPhenotypicFeature between LCOTHER and LCOTHER LCOTHER . LCOTHER LCOTHER LCOTHER LCOTHER in LCOTHER users and their neural correlates during a face - learning task .	0
No adverse effects of LCOTHER LCOTHER were observed in the behavioral / EEG patterns studied , including sleep / wakefulness cycle , at the doses studied . Hypomorphic mutations in LCGeneOrGeneProduct ( LCGeneOrGeneProduct / LCOTHER ) cause LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
METHODS : LCOTHER peripheral blood mononuclear cells ( PBMCs ) were isolated from a Taiwanese LCOTHER family bearing the LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant in the LCOTHER gene , corresponding to a LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) in the LCGeneOrGeneProduct - LCGeneOrGeneProduct protein .	0
The data suggest that in LCGeneOrGeneProduct ( - / - ) LCOrganismTaxon with LCOTHER LCOTHER , LCOTHER mediators are increased above that observed in WT with LCOTHER .	0
In LCChemicalEntity - induced LCOTHER LCOTHER , the protection of LCOTHER was associated with reduced leukocyte infiltration into the brain and microglial production of LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER .	0
The authors report here a LCOTHER LCOTHER comorbid with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature who developed LCOTHER after LCOTHER had been added to his LCChemicalEntity therapy .	0
Compound 1 is a potent LCChemicalEntity ( LCChemicalEntity ) / LCChemicalEntity ( LCChemicalEntity ) LCChemicalEntity LCChemicalEntity in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of LCOTHER ' LCOTHER LCOTHER including LCOTHER and LCOTHER models of LCOTHER - induced LCOTHER , LCOTHER model of LCOTHER - induced LCOTHER , LCOTHER LCChemicalEntity - LCChemicalEntity ( LCOTHER - LCOTHER ) lesion model of drug - induced rotation , and LCOTHER - treated non - LCOTHER primate model . Coincidence of mutations in different connexin genes in Hungarian LCOTHER .	0
RESULTS : In a pooled analysis of 1460 LCDiseaseOrPhenotypicFeature and 3817 LCOTHER / LCOTHER , LCOTHER were more frequent in LCOTHER vs LCOTHER / LCDiseaseOrPhenotypicFeature in all treatment groups , but the excess increased from 2 . 8 ( odds ratio ; range , 2 . 3 - 3 . 5 ) in nonantithrombotic users to 5 . 7 ( range , 3 . 4 - 9 . 7 ) in antiplatelet users and 8 . 0 ( range , 3 . 5 - 17 . 8 ) in LCOTHER users ( P difference = 0 . 01 ) .	0
CONCLUSIONS : LCChemicalEntity treatment is effective in controlling the LCOTHER LCOTHER , LCOTHER , LCOTHER , and LCOTHER in this child case , wherein LCSequenceVariant LCSequenceVariant plays a key role in the proper formation of the ligand - binding pocket and the AF - 2 surface of the LCOTHER LCOTHER LBD . Inactivation of LCOTHER / LCOTHER / LCOTHER LCOTHER LCOTHER LCOTHER triggers senescence and inhibits LCOTHER - induced immortalization .	0
In the present study , we found that a very low concentration of LCOTHER , an LCOTHER inhibitor , potentiated the antitumor activity of LCOTHER - LCOTHER ( LCChemicalEntity - LCChemicalEntity ) in a LCOTHER LCOTHER LCOTHER cell model using LCOTHER - LCOTHER , LCCellLine , and LCOTHER cells via the inhibition of colony formation ability or cellular viability .	0
Our findings offer new opportunities to understand the molecular mechanisms accounting for the B - cell growth - promoting activity of vp17s . Mutation analysis of LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER genes in LCOTHER LCOTHER LCOTHER / LCOTHER LCOTHER LCOrganismTaxon .	0
CONCLUSION : As LCOTHER exacerbated LCOTHER LCOTHER LCOTHER LCOTHER without an improvement in LCOTHER LCOTHER and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to LCOTHER in day surgery . LCOTHER - induced LCChemicalEntity + overload causes LCOTHER and triggers apoptosis through LCOTHER LCOTHER signaling pathway in LCOrganismTaxon .	0
We used wild - type ( WT ) and LCGeneOrGeneProduct knockout ( LCOTHER - KO ) LCOTHER hippocampal cultures , modeled in vitro following exposure to LCOTHER LCChemicalEntity deprivation ( OGD ) , and in vivo neonatal ( P9 - 10 ) LCOTHER model of LCOTHER LCOTHER LCOTHER .	0
Whole cell recordings from non - transfected LCOTHER cells and cells expressing LCOrganismTaxon LCOTHER revealed the presence of a basal inward current in both types of cells when the internal solution contained 0 . 1 mm LCChemicalEntity and 100 nm ( i ) or if the cytosolic LCOTHER ( LCOTHER + ) buffering remained undisturbed in perforated patch - clamp experiments .	0
The following gene polymorphisms were determined in genomic DNA : LCOTHER - LCOTHER LCOTHER insertion / deletion polymorphism ( I / D LCGeneOrGeneProduct ) , LCOTHER gene polymorphism ( LCOTHER LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) polymorphism ( LCOTHER LCOTHER ) , and polymorphism of LCOTHER LCOTHER gene ( LCGeneOrGeneProduct ) . Heart rate variability during HUT was assessed in 5 - minute intervals by low frequency , high frequency , standard deviation of the normal - to - normal ( SDNN ) , and root mean square successive difference parameters .	0
Both baseline and LCOTHER - LCOTHER LCOTHER - induced migration were LCOTHER - dependent and required the action of LCOTHER LCOTHER / LCOTHER , LCOTHER / LCGeneOrGeneProduct , LCOTHER - LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER and LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCGeneOrGeneProduct .	0
To prepare a vaccine candidate , a previously described LCOTHER LCOTHER LCOTHER ( LCSequenceVariant ) in the 3 ' untranslated region of LCOTHER - LCOTHER has been engineered into the LCOrganismTaxon - LCOrganismTaxon isolate .	0
BACKGROUND : Increase of the expression of LCOTHER - LCOTHER gene and high production of LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) in LCOTHER - LCOTHER LCOTHER is widely accepted as associated with a milder or even asymptomatic disease .	0
Furthermore , our global analysis of gene expression , which was focused on genes involved in the molecular regulation of LCOTHER LCOTHER LCOTHER LCOTHER , showed enhancement of pro - apoptotic LCGeneOrGeneProduct and LCOTHER after the combination of LCChemicalEntity - LCChemicalEntity and LCOTHER .	0
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCDiseaseOrPhenotypicFeature ( 874 LCOTHER ' LCOTHER LCOTHER , 259 LCOTHER LCOTHER , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER / LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER .	0
LCOTHER / LCOTHER phosphorylation induced by LCGeneOrGeneProduct - LCGeneOrGeneProduct , indicating activation of LCOTHER signalling , was the same whether LCGeneOrGeneProduct - LCGeneOrGeneProduct was used alone or combined with LCOTHER + / - LCOTHER .	0
BACKGROUND AND PURPOSE : LCOTHER LCOTHER ( LCOTHER ) are potential risk factors for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) , but it is unclear if they are a contraindication to using LCOTHER LCOTHER .	0
Because all heterozygous LCOTHER mutations that have been described are localized in the signal sequence , screening of the LCOTHER gene for LCOrganismTaxon with LCOTHER with LCOTHER and LCDiseaseOrPhenotypicFeature may best be focused on sequencing of exon 1 , which encodes the signal peptide . A Critical Role for the LCOTHER LCOTHER LCOTHER LCOTHER in Virus - Induced LCOTHER LCOTHER in LCOTHER .	0
This study aimed at investigating the potential antipsychotic - like properties of LCOTHER , with a particular focus on models of LCOTHER , involving either drug challenge ( ie , LCOTHER and LCOTHER - LCOTHER ) or transgenic LCOrganismTaxon ( ie , LCGeneOrGeneProduct LCGeneOrGeneProduct ( neo - / - ) and LCOTHER ( - / - ) ) .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCGeneOrGeneProduct [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
The results in this study significantly improve our understanding of the durability of LCOTHER - LCOTHER - producing LCOTHER ( + ) T cells postinfection and provide information on how LCOTHER - LCOTHER may contribute to optimized parasite control and prevention of immune - mediated pathology during repeated LCOTHER LCOTHER . LCOTHER as a LCOTHER LCOTHER : the role of critical LCOTHER groups in LCChemicalEntity LCDiseaseOrPhenotypicFeature .	0
Pulmonary LCGeneOrGeneProduct - LCGeneOrGeneProduct protein content increased , but LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER and LCGeneOrGeneProduct content , and lung histopathology , were not affected .	0
CONCLUSIONS : Our study shows that LCGeneOrGeneProduct is expressed locally in LCOTHER LCOTHER and that the gene polymorphism influences metastatic behavior . LCGeneOrGeneProduct mutations associated with LCOTHER ' LCOTHER and LCOTHER LCOTHER LCOTHER .	0
These data suggest that LCOTHER produced antiarrhythmic actions on LCOTHER LCOTHER and LCOTHER LCOTHER models induced by LCOTHER or LCChemicalEntity via stimulating the cardiac LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct .	0
Homozygous or compound heterozygous mutations in LCOTHER ( LCOTHER ) cause LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , which is characterized by LCOTHER in utero due to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER .	0
LCDiseaseOrPhenotypicFeature LCGeneOrGeneProduct LCOTHER allele ( frequency of allelic loss , 36% ) was protective ( for each allele with the deletion , based on an additive model , HR = 0 . 42 ; 95% CI , 0 . 22 to 0 . 82 ; P = . 0034 ) .	0
Collectively , our findings present a new approach for identifying ciliary proteins , and unveil LCGeneOrGeneProduct , a LCOTHER most closely related to the LCOTHER protein LCOTHER / LCOTHER , as an IFT - associated cargo with LCOTHER - dependent cell autonomous and non - autonomous functions at the ciliary base . Compound heterozygous mutations in the LCOTHER gene exon 4 in a LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER of Chinese origin .	0
These data lend further support to the proposal that cognitive processes mediated by the prefrontal cortex may be impaired by recreational LCChemicalEntity use . Successful therapy with LCOTHER for superior mesenteric LCOTHER LCOTHER in a LCOrganismTaxon with LCOTHER LCOTHER LCOTHER .	0
RESULTS : Carrier frequency of the LCOTHER - 93 variant was higher in LCOTHER who developed therapy related LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( t - LCOTHER ) ( 75 . 0% , n = 12 ) or LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( 53 . 3% .	0
For in vitro experiments , cardiomyocytes were isolated from both LCGeneOrGeneProduct knockout ( KO ) and wile - type ( WT ) LCOrganismTaxon , and the apoptotic ratios were evaluated after a 48 - h ischaemic insult .	0
Thus , LCOTHER appears to play a critical oncogenic function in LCDiseaseOrPhenotypicFeature microenvironment and may be a potential target for developing therapeutic and preventive strategies against LCOTHER . Effects of the LCOTHER - LCOTHER specific inhibitor LCOTHER versus LCOTHER LCOTHER LCOTHER and placebo on cardiovascular LCOTHER events in LCOrganismTaxon with LCOTHER .	0
RESULTS : Nontoxic doses of LCOTHER reduced LCOTHER and LCOTHER LCOTHER from LCChemicalEntity and LCOTHER in LCOTHER and antagonized their antiproliferative effects in the colony assay ; however , LCOTHER neither reduced LCOTHER , LCOTHER LCOTHER , nor the in vitro LCDiseaseOrPhenotypicFeature from LCOTHER .	0
RESULTS : HAT adipose tissue demonstrated increased LCOTHER related genes for storage ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCGeneOrGeneProduct ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCGeneOrGeneProduct - specific LCOTHER .	0
Thus , LCOTHER plays a role in the pathogenesis of LCDiseaseOrPhenotypicFeature in Japan . Endothelial LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct mediates LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER - induced intravitreal neovascularization in a LCOTHER model of LCOTHER LCOTHER LCOTHER .	0
These additional genes notably included LCOTHER ( LCGeneOrGeneProduct ) and LCGeneOrGeneProduct , supporting previous findings of their association with LCOTHER pathogenesis .	0
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) are LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature which appear most frequently in young LCOTHER , including at puberty , when LCOTHER has well - recognized proliferative actions on the breast .	0
LCGeneOrGeneProduct genotype frequencies were not significantly different between LCOTHER LCOrganismTaxon ( CC : 57 . 3% , CT : 36 . 7% , TT : 5 . 8% ) and control subjects ( CC : 60 . 9% , CT : 33 . 5% , TT 5 . 6% ; p = 0 . 35 ) .	0
LCOTHER and LCOTHER expression was not increased by treatment of LCCellLine cells with LCOTHER and LCOTHER inhibitors , suggesting that LCOTHER regulates LCOTHER expression independently of LCOTHER and LCGeneOrGeneProduct .	0
The LCOTHER LCOTHER LCOTHER is a rare LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER characterized by early LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER , borderline mental development , and a high tendency to LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Acidification , which slowed the reaction of LCOTHER with LCChemicalEntity donors , could also attenuate effects of LCChemicalEntity on LCOTHER markers , LCOTHER depletion and LCOTHER LCOTHER inhibition in living cells .	0
Collectively , our findings present a new approach for identifying ciliary proteins , and unveil LCOTHER , a LCOTHER most closely related to the LCOTHER protein LCGeneOrGeneProduct / LCOTHER , as an IFT - associated cargo with LCOTHER - dependent cell autonomous and non - autonomous functions at the ciliary base . Compound heterozygous mutations in the LCGeneOrGeneProduct gene exon 4 in a LCOTHER LCOTHER LCOTHER of Chinese origin .	0
These studies have produced intriguing but inconsistent results , potentially because the known functional variants : LCOTHER LCSequenceVariant and LCOTHER , LCOTHER LCOTHER and LCOTHER , and LCOTHER LCSequenceVariant provided an incomplete picture of the total functional diversity at these genes .	0
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in the ECG of LCOTHER with LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) has been reported in LCOTHER users .	0
Moreover , using RNA interference with small inhibitory RNAs for LCGeneOrGeneProduct , LCOTHER , and LCOTHER , we observed that LCOTHER - dependent inhibition of LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - dependent genes , such as LCOTHER - LCOTHER , LCOTHER , and LCOTHER LCOTHER , was also due , in part , to loss of LCGeneOrGeneProduct proteins .	0
Pulmonary LCOTHER - LCOTHER protein content increased , but LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct and LCOTHER content , and lung histopathology , were not affected .	0
A 74 - year - old LCOTHER with LCOTHER LCOTHER was admitted to a LCDiseaseOrPhenotypicFeature hospital due to LCOTHER , LCOTHER LCOTHER LCOTHER , exhaustion , and LCDiseaseOrPhenotypicFeature .	0
A new LCGeneOrGeneProduct homolog cDNA , LCOTHER , was discovered by a hypermethylated DNA fragment probe that was isolated from a LCOrganismTaxon multidrug resistant ( MDR ) LCOTHER LCOTHER cell line , LCOTHER / LCOTHER , by the methylation sensitive - representational difference analysis ( MS - RDA ) technique .	0
LCOTHER LCOTHER LCOTHER is one of the most common causes of LCOTHER LCOTHER in males , and LCOrganismTaxon with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature occasionally develop LCOTHER .	0
Immunofluorescent staining revealed that LCGeneOrGeneProduct is the most sensitive among the structures connecting the LCGeneOrGeneProduct in the cardiomyocyte cytoskeleton and the extracellular matrix .	0
Oral LCOrganismTaxon LCGeneOrGeneProduct ( 30 , 100 , 300 mg / kg ) was given from day 8 to 14 in a reversal study .	0
Common > or = grade 3 events were LCDiseaseOrPhenotypicFeature , LCDiseaseOrPhenotypicFeature , LCOTHER , LCOTHER , and LCOTHER .	0
A total of 10 novel variants was recognized , among them four variants in the adjacent 5 ' - region of the LCOTHER coding exon 2 ( LCSequenceVariant . LCSequenceVariant - LCSequenceVariant > LCSequenceVariant , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER ) , a 6 base - pair deletion ( LCOTHER . LCOTHER [ LCOTHER . LCOTHER ] ) , a variant leading to a stop codon ( LCOTHER . LCOTHER > LCOTHER [ LCSequenceVariant . LCSequenceVariant ] ) , synonymous variants ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , and one non - synonymous variant ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) .	0
Similarly , attenuation of LCGeneOrGeneProduct expression in LCCellLine cells , which have high endogenous levels , decreased LCOTHER in the same model .	0
The decreased capacity to concentrate urine is likely due to LCOTHER acutely disrupting the LCChemicalEntity pathway and chronically reducing LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER - LCOTHER ) and water channel ( LCOTHER ) expression in the inner medulla .	0
We report a case of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) in a dizygotic twin who presented at 12 years of age with LCOTHER LCOTHER , LCOTHER LCOTHER , LCOTHER and LCOTHER with inappropriate kaliuresis , and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with LCOTHER LCOTHER ( LCOTHER LCOTHER ) .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature can occur with low doses of LCOTHER . Upregulation of LCOTHER LCOTHER LCOTHER is associated with unfavorable prognosis and LCDiseaseOrPhenotypicFeature invasion in LCOTHER LCOTHER LCOTHER .	0
Here we show that LCOTHER blockade with monoclonal antibodies perturbs the BM vascular niche of sub - lethally irradiated LCOTHER , resulting in increased LCGeneOrGeneProduct ( + ) , LCGeneOrGeneProduct - LCGeneOrGeneProduct ( + ) and LCOTHER - LCOTHER ( + ) vessel density , and also increased megakaryocytes , whereas LCOTHER ( + ) , LCOTHER ( + ) , LCOTHER ( + ) and LCOTHER ( + ) vessel density remained unaltered .	0
Our findings show that microinjection of LCOTHER into the CA1 region of the hippocampus improves the LCOTHER - induced LCDiseaseOrPhenotypicFeature . LCOTHER : A LCOTHER LCOTHER LCOTHER LCOTHER candidate susceptibility gene? The chromosomal region 12q24 has been previously implicated by linkage studies of both LCOTHER LCOTHER and LCOTHER LCOTHER LCOTHER and we have reported two pedigrees segregating both LCOTHER LCOTHER and LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature that show linkage across this region .	0
In summary , we found four independent signals in the LCOTHER region associated with risk of LCDiseaseOrPhenotypicFeature in African American LCOTHER . Polymorphic LCOTHER and risk of LCOTHER after methylating chemotherapy for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Very recently , mutations of the LCOTHER gene in exons 2 - 9 have been found in LCDiseaseOrPhenotypicFeature LCOrganismTaxon , suggesting that this gene plays an important role in orofacial development .	0
Furthermore , LCOTHER treatment significantly decreases the release of LCOTHER cytokines and inhibits the LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCGeneOrGeneProduct signaling pathways .	0
The LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant ( AA ) into the LCGeneOrGeneProduct protein .	0
on newborn females and adult female controls , we found no departure from Hardy - Weinberg equilibrium in the distribution of LCSequenceVariant alleles for our female LCGeneOrGeneProduct carriers .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
EXPERIMENTAL DESIGN : Because of their widespread use , the LCOTHER LCOTHER following coadministration of LCChemicalEntity and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of LCOTHER and LCOTHER blood progenitor cells to LCOTHER , LCOTHER , and LCChemicalEntity + / - LCOTHER was determined in granulocyte - macrophage colony forming assays .	0
Moreover , consistent with previous results , we also show that LCOTHER was required for efficient LCGeneOrGeneProduct and LCGeneOrGeneProduct activation in response to LCOTHER engagement .	0
This study showed that LCOTHER was more likely to be LCOTHER susceptibility gene at Chr . 1q31 based on the finding that the LCOTHER and LCOTHER deletion was not polymorphic in the cohort of this study , and none of the SNPs that were significantly associated with LCDiseaseOrPhenotypicFeature in a white population in LCOTHER , LCGeneOrGeneProduct , and LCOTHER genes showed a significant association with LCOTHER . Seven novel and six de novo LCOTHER gene mutations in LCOTHER with LCOTHER LCOTHER .	0
In some families LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature also forms a component of the complex and as such has been described as LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature : LCOTHER LCOTHER ) .	0
In conclusion , HFD - induced LCOTHER LCOrganismTaxon are highly sensitized to LCOTHER - induced LCOTHER by substantially downregulating cardiac mitochondrial LCOTHER generation , increasing oxidative stress and downregulating the LCOTHER / LCOTHER pathway . Risks and benefits of LCOTHER - LCOTHER LCOTHER vs non - selective LCChemicalEntity : does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study .	0
In contrast , LCChemicalEntity failed to affect LCOTHER induced by LCOTHER or naturally observed in LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ( - / - ) ) knockout LCOTHER ( 10 - 30 mg / kg p . o . ) .	0
Silencing of LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) expression in LCOTHER cells had a greater impact on LCOTHER - inducible cytokines than LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , and LCOTHER expression .	0
Based on recent papers describing the prognostic roles of the polymorphisms and the LCOTHER functions on LCDiseaseOrPhenotypicFeature development , we sought to determine if Japanese LCOTHER LCOTHER LCOrganismTaxon were affected by the LCOTHER - 31 / - 511 and LCOTHER - 670 polymorphisms .	0
A total of 10 novel variants was recognized , among them four variants in the adjacent 5 ' - region of the LCOTHER coding exon 2 ( LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER ) , a 6 base - pair deletion ( LCOTHER . LCOTHER [ LCOTHER . LCOTHER ] ) , a variant leading to a stop codon ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , synonymous variants ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant [ LCSequenceVariant . LCSequenceVariant ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , and one non - synonymous variant ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) .	0
CONCLUSION : Taken together , the profile of LCOTHER receptor , LCOTHER gene expression and metabolic factors in adipose tissue from morbidly LCDiseaseOrPhenotypicFeature HAT subjects suggests a compensatory response associated with the increased plasma LCOTHER and LCOTHER . LCOTHER region and risk of LCOTHER LCOTHER LCOTHER in African American LCOrganismTaxon .	0
LCOTHER prevented the LCChemicalEntity - induced decrease in antioxidant enzymes in the heart and increased the rate of LCChemicalEntity - stimulated LCOTHER uptake and respiratory coupling ratio .	0
The single family with a LCGeneOrGeneProduct mutation had the LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
In particular , the drug prevents the decrease in LCGeneOrGeneProduct - , LCOTHER - , LCOTHER - , LCGeneOrGeneProduct - , and LCOTHER - immunoreactivity ( IR ) and the increase in LCOTHER - , and LCOTHER - IR .	0
CONCLUSION : This study showed that SNPs LCOTHER ( P = 0 . 0276 ) , LCOTHER ( P = 0 . 0266 ) , LCOTHER ( P = 0 . 00514 ) , and LCSequenceVariant ( P = 0 . 0089 ) , but not LCOTHER , LCOTHER , or LCSequenceVariant , in LCOTHER were significantly associated with wet LCOTHER in a mainland Han Chinese population .	0
Using whole - organism RNA - Seq libraries , we discovered a signature expression profile highly enriched for transcripts of known ciliary proteins , including LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCGeneOrGeneProduct orthologue ) , LCOTHER - LCOTHER ( LCOTHER ) , and LCOTHER - LCOTHER ( LCOTHER / LCOTHER ) , which we confirm are cilium - localised in worms .	0
CONCLUSIONS : Our results suggest that common variation in the putative LCOTHER LCOTHER susceptibility gene , LCOTHER , or its inhibitor does not contribute significantly to LCOTHER LCOTHER risk in this Afro - Caribbean population . Hepatic but not brain LCOTHER is rapidly chelated by LCChemicalEntity in LCDiseaseOrPhenotypicFeature due to a novel gene mutation .	0
In this study , we generated endothelial cell - specific LCOTHER - knockout ( LCGeneOrGeneProduct ( endo - / - ) ) LCOrganismTaxon by crossbreeding LCOTHER LCOTHER - LCOTHER - Cre LCOTHER with LCOTHER ( flox / flox ) LCOTHER .	0
Meanwhile apoptosis related proteins LCOTHER and LCGeneOrGeneProduct were involved in LCOTHER LCOTHER and LCOTHER LCOTHER model , but not LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct or LCOTHER . LCOTHER and LCOTHER are closely relevant in the tissue splices of deminopathies LCOTHER and LCOTHER with LCOTHER at protein lever .	0
Our data support potential interactions between the LCOTHER , LCOTHER - LCGeneOrGeneProduct and LCOTHER - LCOTHER pathways , and possible influence by LCOTHER or LCOTHER mutation on therapy or chemoprevention targeting LCOTHER . Identification of novel type LCOTHER LCOTHER gene mutations resulting in severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
LCOrganismTaxon who develop LCOTHER have a higher preoperative and 1 - year serum LCOTHER and are more likely to have LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Experimental EMT induced by LCOTHER plasmid transfection proved LCOTHER protein overexpression could enhance the cell scratch wound - healing and transwell ability and significantly upregulated mesenchymal marker proteins , LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER and concurrently downregulated epithelial marker of LCGeneOrGeneProduct - LCGeneOrGeneProduct .	0
CONCLUSION : This study showed that SNPs LCSequenceVariant ( P = 0 . 0276 ) , LCOTHER ( P = 0 . 0266 ) , LCOTHER ( P = 0 . 00514 ) , and LCOTHER ( P = 0 . 0089 ) , but not LCOTHER , LCOTHER , or LCSequenceVariant , in LCOTHER were significantly associated with wet LCOTHER in a mainland Han Chinese population .	0
Using a LCOrganismTaxon model , we tested whether the rapid reversal of anticoagulation using LCOTHER LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) can reduce hemorrhagic blood volume .	0
In contrast , LCChemicalEntity failed to affect LCOTHER induced by LCOTHER or naturally observed in LCOTHER LCOTHER ( LCOTHER ( - / - ) ) knockout LCOrganismTaxon ( 10 - 30 mg / kg p . o . ) .	0
Among LCOTHER with a LCGeneOrGeneProduct mutation detected in both types of specimens , the concordance between LCGeneOrGeneProduct mutation genotypes was 100% .	0
LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER LCOTHER LCOTHER ) are two members of this group that have been described in LCOrganismTaxon , LCOTHER , and LCOTHER .	0
Our results confirmed a previous study on the relationship between LCOTHER and LCOTHER in Caucasians . Does LCChemicalEntity potentiate LCChemicalEntity - associated LCOTHER LCOTHER LCOTHER There is now evidence to suggest a central role for the dopaminergic system in LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
Among the family members , LCOrganismTaxon with the homozygous LCOTHER ( previously known as ARS component B ) mutation are prone to LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , which might link to defective T - cell function as well as a derangement of epidermal homeostasis .	0
The present study aimed to evaluate the LCOTHER effects at doses of 25 , 50 or 75 mg / kg on LCOTHER parameters to determine their anticonvulsant activity and its effects on amino acid ( LCChemicalEntity - LCChemicalEntity LCChemicalEntity ( LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ) levels as well as on LCOTHER ( LCGeneOrGeneProduct ) activity in LCOTHER hippocampus after LCOTHER .	0
METHOD : Using five tagging SNPs ( LCSequenceVariant , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) , we conducted a genetic association analysis of case - control samples ( 197 LCOTHER - induced LCOTHER LCOrganismTaxon and 337 controls ) in the Japanese population .	0
LCOTHER markedly lowered LCOTHER - induced elevation in the levels of LCGeneOrGeneProduct mRNA , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) , and LCOTHER LCOTHER ( LCOTHER - LCOTHER ) in the heart tissues .	0
None of the SNPs in LCOTHER showed a significant association with LCDiseaseOrPhenotypicFeature , and none of the SNPs in LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER showed a significant association with either wet LCOTHER or LCOTHER in the cohort of this study .	0
Our data demonstrate that the LCOTHER - causing mutations strongly affect LCOTHER cellular functions which suggest a central role for perturbed LCOTHER signalling in LCOTHER LCDiseaseOrPhenotypicFeature . LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature : frequent abnormalities and inactivation of LCOTHER LCOTHER suppressor gene .	0
Certain concepts concerning LCOTHER / LCGeneOrGeneProduct action modes have been challenged by in vivo studies : LCGeneOrGeneProduct - LCGeneOrGeneProduct levels are elevated in maturing erythroblasts , but not in their progenitors ; truncated LCOTHER alleles that lack a major LCOTHER / LCOTHER recruitment site nonetheless promote LCOTHER ; and LCOTHER disruption unexpectedly bolsters erythropoiesis .	0
We propose that a cis - acting regulatory polymorphism has arisen close to LCOTHER - LCOTHER in the recessive founder , which decreases LCDiseaseOrPhenotypicFeature susceptibility in heterozygotes and slows disease progression . LCOTHER LCOTHER inhibit LCOTHER growth in a LCOTHER - LCOTHER LCOTHER LCOTHER - dependent manner by altering the cytokine milieu from LCOTHER - LCOTHER / LCOTHER - LCOTHER to LCGeneOrGeneProduct - LCGeneOrGeneProduct .	0
The signal transduction target upon LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) stimulation , the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) activation , supports LCOTHER development , signal transduction in which is mediated by LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) signaling .	0
Of these , LCGeneOrGeneProduct and LCOTHER have been reported to contribute to intravitreal neovascularization ( IVNV ) in LCOTHER - induced LCDiseaseOrPhenotypicFeature ( LCOTHER ) models .	0
These results indicate that LCGeneOrGeneProduct is involved in drug resistance in LCOTHER / LCOTHER cells . Genome - wide loss - of - function genetic screening identifies LCOTHER LCOTHER LCOTHER as a key regulator of LCOTHER - LCOTHER resistance in pediatric LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Our recent study showed that LCOTHER / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCGeneOrGeneProduct and LCOTHER , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCGeneOrGeneProduct and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	0
LCOTHER increased LCGeneOrGeneProduct , LCGeneOrGeneProduct and LCOTHER mRNA content two - to fourfold , but only the protein content for LCOTHER ( 20 % decrease ) differed significantly .	0
LCOrganismTaxon were divided into three groups : Controls , no LCDiseaseOrPhenotypicFeature or LCOTHER , n = 748 ; LCOTHER , sustained serum LCOTHER > 2 . 5 mg / dl , n = 41 ; and LCOTHER , n = 45 .	0
Compared to many other ethnic groups , LCDiseaseOrPhenotypicFeature - associated variants of the coding region of LCOTHER are rare in Sudan and Kenya , suggesting a role of other genetic , or epigenetic factors as a cause for LCOTHER in these countries . A novel point mutation in helix 10 of the LCOTHER LCOTHER LCOTHER causes generalized LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature by disrupting the structure of the ligand - binding domain .	0
Our findings indicated that LCGeneOrGeneProduct might be a very upstream key molecule regulating EMT involved in LCOTHER / LCOTHER - LCOTHER signaling pathway . LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct protects high LCOTHER - induced energy LCOTHER LCOTHER via blocking LCOTHER - ubiquitin proteasome pathway .	0
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCOTHER . LCOTHER ] have been reported in Japanese LCOrganismTaxon , but not in LCOTHER LCOTHER from other ethnic groups .	0
CONCLUSION : Our results did not lend strong support to the view that the genetic variation of the LCOTHER gene plays a major role in the individually variable adverse effect induced by LCChemicalEntity , at least in Chinese LCOrganismTaxon with LCOTHER .	0
LCOTHER is likely to be an LCOTHER - susceptibility gene and LCOTHER mutations may increase the risk of developing a LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature rather than being a direct causative mutation . The differential effects of LCOTHER and LCOTHER on LCOTHER LCOTHER release , LCOTHER gene expression and LCOTHER in a clinical LCDiseaseOrPhenotypicFeature model .	0
CONCLUSION : Taken together with previous studies of LCOTHER LCOTHER mutations , these findings suggest that LCOTHER - LCOTHER deficiency due either to haploinsufficiency or to substantial activity loss due to dominant negative interference of the normal allele product ' s function can each contribute to the LCDiseaseOrPhenotypicFeature phenotype . Cytostatic and anti - angiogenic effects of LCOTHER in refractory LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Loss of LCOTHER expression in LCOTHER altered the LCOTHER induction of LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER - LCOTHER .	0
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCDiseaseOrPhenotypicFeature WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	0
The adaptive metabolic changes caused by LCOTHER in control LCOTHER hearts were found to have occurred already in LCGeneOrGeneProduct - deficient ( LCOTHER ( - / - ) ) LCOrganismTaxon hearts and sustained function in LCOTHER despite an inability for further metabolic remodeling .	0
In this report the distribution of the exonic LCSequenceVariant / LCSequenceVariant single nucleotide polymorphism ( SNP ) in LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene , resulting in the amino acid substitution LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , was investigated in a large population of LCOTHER LCOTHER ( n = 321 ) and non - demented control ( n = 208 ) .	0
CONCLUSIONS : The LCSequenceVariant ( AA ) , H1 , H2 , and H3 are genetic predictors for postoperative persistence of LCOTHER for Chinese LCOrganismTaxon treated by adrenalectomy with LCOTHER .	0
BACKGROUND : Markers of fibrinolysis , LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , and LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) levels were studied for the evaluation of short - term effects of LCOTHER administration in postmenopausal LCOTHER .	0
We report mutation analysis of the LCGeneOrGeneProduct gene in 39 kindreds with LCOTHER and LCOTHER who previously tested negative for mutations in the LCOTHER ( LCOTHER ) and LCGeneOrGeneProduct ( LCOTHER LCOTHER LCOTHER LCOTHER ) genes .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCGeneOrGeneProduct signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
Both LCGeneOrGeneProduct knockout ( LCGeneOrGeneProduct ( - / - ) ) LCOTHER and db / db LCOTHER that were administered LCOTHER monoclonal antibody displayed lower LCOTHER LCOTHER levels accompanied by elevated plasma LCOTHER levels .	0
These data suggest that while LCOTHER deficiency increases oxidative stress and sympathetic activity in both arterial and venous vessels , the impact on veins does not make a major contribution to this form of LCDiseaseOrPhenotypicFeature . LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature after LCOTHER and LCOTHER - containing regimen in an elderly LCOTHER of LCOTHER LCOTHER .	0
Inhibition of LCOTHER LCOTHER LCOTHER LCOTHER LCGeneOrGeneProduct / LCGeneOrGeneProduct / LCGeneOrGeneProduct / LCGeneOrGeneProduct responsible for phosphorylation of LCOTHER / LCOTHER / LCOTHER reduced the hyperproliferation seen in LCSequenceVariant . LCSequenceVariant fibroblasts .	0
LCOTHER regulated the production of LCOTHER factors , cell proliferation , migration and invasion of LCOTHER FLS , which was mediated by the LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCGeneOrGeneProduct pathways .	0
METHOD : Using five tagging SNPs ( LCOTHER , LCSequenceVariant , LCOTHER , LCOTHER and LCSequenceVariant ) , we conducted a genetic association analysis of case - control samples ( 197 LCOTHER - induced LCOTHER LCOTHER and 337 controls ) in the Japanese population .	0
CONCLUSION : LCGeneOrGeneProduct and LCOTHER were identified as novel LCDiseaseOrPhenotypicFeature - associated genes with a high degree of significance , suggesting new directions in understanding the pathogenesis of LCOTHER .	0
LCOTHER enhanced the EC barrier and protected against barrier dysfunction caused by vasoactive peptide LCOTHER and LCDiseaseOrPhenotypicFeature bacterial wall LCOTHER ( LCChemicalEntity ) .	0
Our results reveal that dominant mutations in LCGeneOrGeneProduct hyperactivate LCOTHER motility and suggest that an imbalance of minus versus plus end - directed microtubule motility in neurons may underlie LCOTHER LCOTHER LCOTHER . LCOTHER metabolism in patients with LCDiseaseOrPhenotypicFeature treated with atypical LCOTHER LCOTHER : a frequently sampled intravenous LCOTHER tolerance test and minimal model analysis .	0
We generated LCGeneOrGeneProduct subunit - deficient LEW . 1WR1 LCOrganismTaxon using CRISPR - Cas9 ( clustered regularly interspaced short palindromic repeats - associated protein 9 ) genome editing and confirmed functional disruption of the LCOTHER gene .	0
Our results suggest the importance of routine screening for the rather frequent - 3170G > A mutation ( in addition to LCOTHER . LCOTHER ) in LCOTHER with LCOTHER LCOTHER . LCDiseaseOrPhenotypicFeature LCOTHER LCOTHER LCSequenceVariant genotype as a prognostic factor in LCOTHER LCOTHER LCOTHER receiving LCOTHER - based adjuvant treatment .	0
Our findings reveal a novel role of LCOTHER in regulating meiotic G2 / M transition by acting via the LCOTHER / LCOTHER ( LCGeneOrGeneProduct ) - LCOTHER LCOTHER pathway . The LCOTHER LCOTHER LCSequenceVariant > LCSequenceVariant polymorphism is not associated with LCOTHER LCOTHER LCOTHER .	0
Here we investigated the role of LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER in cellular senescence and immortalization of LCOTHER embryonic fibroblasts ( MEFs ) and report that LCOTHER is required for proper cell proliferation and LCOTHER ( LCSequenceVariant ) - induced immortalization .	0
OBJECTIVE : To evaluate longitudinal changes in the LCDiseaseOrPhenotypicFeature resistance genotype and phenotype along with strain - specific variability in a LCOrganismTaxon with LCOTHER - LCOTHER ' LCOTHER LCOTHER in whom successive anti - LCOTHER treatments failed .	0
Of note , injection of anti - LCGeneOrGeneProduct - LCGeneOrGeneProduct antibody in LCOTHER - bearing C3H / HeN LCOrganismTaxon in the absence of LCOTHER LCOTHER markedly suppressed LCOTHER growth and augmented LCOTHER - LCOTHER responses .	0
LCOTHER LCOTHER is characterized by prolonged LCDiseaseOrPhenotypicFeature after the use of LCOTHER LCOTHER ( LCChemicalEntity or LCOTHER ) in LCOTHER who have mutations in the LCOTHER gene .	0
Administration of parenteral LCOTHER must be done carefully and with good observation because of its pro - LCDiseaseOrPhenotypicFeature effect , especially in older patients who have LCOTHER LCOTHER or patients with LCOTHER LCOTHER ( LCOTHER ) which frequently occurs due to LCOTHER and or LCOTHER in LCOTHER cases . Low frequency of LCOTHER - associated LCOTHER variants in Kenya and Sudan and novel LCGeneOrGeneProduct variants .	0
Compared with a normoxic , chow - fed control LCOTHER heart , LCOTHER decreased LCOTHER expression , LCChemicalEntity LCChemicalEntity oxidation , and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) levels , while increasing glycolysis , all of which served to maintain normal LCOTHER concentrations ( [ LCOTHER ] ) and thereby , ejection fractions .	0
We identified one kindred with a novel LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER in the LCOTHER complementary DNA , corresponding to a LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , which is found within the signal sequence ( LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ; LCSequenceVariant . LCSequenceVariant ) .	0
LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) regulates protein LCOTHER - LCOTHER , an essential and dynamic post - translational modification .	0
Female carriers of the less frequent C allele of LCSequenceVariant had a 1 . 7 - fold elevated risk [ 95% confidence interval ( CI ) 1 . 09 - 2 . 66 ; P = 0 . 020 ] for the conversion to LCOTHER compared to LCOTHER with the common genotype after the adjustment for age , treatment group ( placebo or LCChemicalEntity ) , smoking , weight at baseline , and weight change .	0
A derivative of LCOTHER , designated LCOrganismTaxon - LCSequenceVariant , was generated by incorporation of a point mutation previously identified in the LCOTHER gene of LCOrganismTaxon - LCOrganismTaxon and was found to be more attenuated than LCOTHER in LCOTHER - LCOTHER - LCOTHER LCOTHER .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCGeneOrGeneProduct / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
We evaluated cardiovascular event data for LCOTHER , a new LCGeneOrGeneProduct - LCGeneOrGeneProduct - specific inhibitor in approximately 8000 LCOrganismTaxon with LCOTHER and LCOTHER LCOTHER treated with this agent in randomized clinical trials .	0
Clarifying the functional relevance of polymorphisms associated with susceptibility to a complex disorder such as LCOTHER LCOTHER provides a foundation for clinical association studies . LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct deficiency in a Canadian kindred with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER .	0
She had profound LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER , severe LCOTHER and relapsing LCOTHER , while her pre - pubescent daughter had normal fat distribution but elevated plasma LCOTHER and LCOTHER - LCOTHER and depressed LCChemicalEntity - LCChemicalEntity LCChemicalEntity LCChemicalEntity .	0
Polymerase chain reaction performed with DNA isolated from somatic LCOTHER - rodent cell hybrids containing defined LCOrganismTaxon chromosomes as template gave a LCOTHER - specific signal which mapped the LCOTHER and LCGeneOrGeneProduct subunits to chromosomes 1 and 11 , respectively .	0
By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic LCChemicalEntity and the active S - isomer , were quantitated in EMs and PMs in terms of IC50 values , representing LCChemicalEntity plasma concentrations resulting in half - maximum receptor occupancy .	0
The present study aimed to evaluate the LCOTHER effects at doses of 25 , 50 or 75 mg / kg on LCOTHER parameters to determine their anticonvulsant activity and its effects on amino acid ( LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCChemicalEntity and LCOTHER ) levels as well as on LCGeneOrGeneProduct ( LCOTHER ) activity in LCOTHER hippocampus after LCOTHER .	0
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCGeneOrGeneProduct transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	0
We aimed to compare the risks of hospitalization for LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature among elderly patients using LCChemicalEntity - LCChemicalEntity LCChemicalEntity , NS - LCOTHER and LCOTHER .	0
The factors regulating LCOTHER in a setting devoid of LCOTHER and LCGeneOrGeneProduct function remain unclear but may include the hormone LCGeneOrGeneProduct .	0
By identifying genes mis - expressed in LCOTHER mutants , we demonstrate that LCGeneOrGeneProduct represses genes associated with stress - related LCOTHER and LCOTHER LCOTHER hormone signaling pathways which have known roles in coordinating lateral growth of the LCOrganismTaxon stem .	0
PURPOSE : We present a case of a LCOTHER who developed LCOTHER shortly after initiating treatment with LCOTHER and to discuss the potential drug - drug interactions related to the inhibition of LCOTHER LCOTHER ( LCOTHER ) LCOTHER in this case , as well as in other cases , of LCChemicalEntity - induced LCDiseaseOrPhenotypicFeature .	0
Silencing of LCOTHER prevented LCChemicalEntity inhibition of LCOTHER - LCOTHER - LCOTHER cell growth and ablated LCOTHER effects on LCGeneOrGeneProduct / LCGeneOrGeneProduct phosphorylation .	0
Not only is LCGeneOrGeneProduct release controlled by LCOTHER but also LCGeneOrGeneProduct has many actions that can raise or reduce falls in LCOTHER LCOTHER level .	0
Viruses were evaluated for replication in SCID LCOTHER transplanted with LCOrganismTaxon LCOTHER cells ( LCOTHER - LCOTHER - LCOTHER LCOrganismTaxon ) , in mosquitoes , and in LCOTHER LCOTHER .	0
BACKGROUND : The LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) proteins and their genetic variants have been suggested to play a role in regulating LCOTHER LCOTHER .	0
There have been concerns that the risk of cardiovascular LCOTHER events may be higher with LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct - specific inhibitors than nonselective LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCOTHER ) .	0
To investigate effects of LCOTHER on LCOTHER LCOTHER , we performed LCDiseaseOrPhenotypicFeature assay in neonatal LCOrganismTaxon ventricular myocytes ( NRVMs ) , as well as measured LCOTHER LCOTHER level in the culture medium of NRVMs and activities of serum cardiac enzymes in LCOTHER .	0
RESULTS : LCOTHER LCOTHER significantly increased the levels of LCGeneOrGeneProduct , LCOTHER , phosphorylated ( p ) - LCOTHER , p - LCOTHER , and p - LCOTHER ; triggered LCGeneOrGeneProduct mRNA splicing ; and enhanced ER chaperone gene expression in WT embryos .	0
Recently , LCOrganismTaxon LCOTHER / LCOTHER , the ortholog of LCOTHER LCOTHER , has been identified as a new assembly factor for LCGeneOrGeneProduct .	0
A decrease of LCOTHER expression in addition to an up - regulation of LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , retinoid signaling , and LCOTHER LCOTHER response element signaling was selectively observed in WAT of LCOrganismTaxon fed a normal - LCOTHER LCOTHER , high - fat diet .	0
In this study , we establish the LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) or LCOTHER LCOTHER ( LCChemicalEntity ) - induced LCOTHER LCOTHER LCOTHER LCOTHER in vivo and the LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER - stimulated LCOTHER proximal tubular epithelial cell ( LCOTHER - LCOTHER ) model in vitro .	0
At puberty ( P40 ) , half the LCChemicalEntity - treated LCOTHER and half the saline - treated LCOrganismTaxon began treatment with LCOTHER ( LCOTHER , 5 mg / kg , 5 days / week ) .	0
Fasting serum LCOTHER concentrations differed among groups ( F ( 33 ) = 3 . 35 ; P = . 047 ) ( LCOTHER > LCOTHER > LCChemicalEntity ) with significant differences between LCOTHER and LCOTHER ( t ( 33 ) = 2 . 32 ; P = . 03 ) and LCChemicalEntity and LCOTHER ( t ( 33 ) = 2 . 15 ; P = . 04 ) .	0
The mechanism may be related to the improvement of LCOTHER ( LCOTHER + ) handling . LCGeneOrGeneProduct LCGeneOrGeneProduct deletion in myeloid cells affects the LCOTHER response in allergic LCDiseaseOrPhenotypicFeature , but not lung mechanics , in female LCOTHER .	0
The present study examined the influence of excitatory amino acid - mediated mechanisms in the IC on the LCOTHER induced by the LCGeneOrGeneProduct LCGeneOrGeneProduct blocker LCOTHER administered systemically ( 1 or 0 . 5 mg / kg ) in LCOrganismTaxon .	0
LCOTHER is likely to be an LCDiseaseOrPhenotypicFeature - susceptibility gene and LCOTHER mutations may increase the risk of developing a LCOTHER LCOTHER rather than being a direct causative mutation . The differential effects of LCOTHER and LCChemicalEntity on LCOTHER LCOTHER release , LCOTHER gene expression and LCOTHER in a clinical LCOTHER model .	0
Our data underscore the major role of LCOTHER in regulation of hepatic LCChemicalEntity and xenobiotic metabolism in LCOrganismTaxon liver and reveal a marked immuno - suppressive / anti - LCOTHER effect of LCOTHER in LCOTHER liver slices that may be therapeutically relevant for LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER decreases LCOTHER LCOTHER expression in LCOTHER LCOTHER cells .	0
LCChemicalEntity ( LCOTHER ) is a metabolite of the LCOTHER LCOTHER LCChemicalEntity ( LCOTHER ) and putatively responsible for LCOTHER LCOTHER following anti - LCOTHER therapy with LCOTHER .	0
In the present study , we describe the proinflammatory effects of LCOTHER on local LCOTHER LCOTHER ( LCOTHER ) production and LCGeneOrGeneProduct ( LCOTHER ) gene expression that increases LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER subjects .	0
Upon stimulation with various LCOTHER agonists , LCOTHER - treated DCs showed markedly increased LCGeneOrGeneProduct - LCGeneOrGeneProduct production through activation of the LCOTHER LCOTHER and LCOTHER - LCOTHER signaling pathways without altering the levels of LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER , indicating the LCOTHER - mediated induction of tolerogenic DCs .	0
RESULTS : HAT adipose tissue demonstrated increased LCOTHER related genes for storage ( LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCGeneOrGeneProduct , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	0
In conclusion , our data suggest that LCOTHER may influence in epileptogenesis and promote anticonvulsant actions in LCOTHER model by modulating the LCOTHER and LCChemicalEntity contents and of LCGeneOrGeneProduct activity in seized LCOTHER hippocampus .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCGeneOrGeneProduct / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
In conclusion , HFD - induced LCOTHER LCOrganismTaxon are highly sensitized to LCOTHER - induced LCDiseaseOrPhenotypicFeature by substantially downregulating cardiac mitochondrial LCOTHER generation , increasing oxidative stress and downregulating the LCOTHER / LCOTHER pathway . Risks and benefits of LCOTHER - LCOTHER LCOTHER vs non - selective LCOTHER : does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study .	0
The serum levels of LCOTHER varied widely among the LCOrganismTaxon with LCDiseaseOrPhenotypicFeature , and no significant difference was found when compared with those of the healthy controls .	0
No adverse effects of LCChemicalEntity LCChemicalEntity were observed in the behavioral / EEG patterns studied , including sleep / wakefulness cycle , at the doses studied . Hypomorphic mutations in LCOTHER ( LCOTHER / LCGeneOrGeneProduct ) cause LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
When examining a worldwide cohort of 62 independent LCOTHER with LCOTHER and associated LCOTHER LCOTHER we identified altogether four novel mutations ( LCOTHER . LCOTHER , LCSequenceVariant . LCSequenceVariant , LCOTHER . LCOTHER , and LCSequenceVariant . LCSequenceVariant ) in five of them .	0
LCOTHER chelation with LCOTHER was effective in mobilizing hepatic LCChemicalEntity but has no effect on brain LCOTHER . Aberrant LCGeneOrGeneProduct - LCGeneOrGeneProduct - mediated LCOTHER signaling and proliferation identified by analysis of LCOTHER LCOTHER LCOTHER mutation ( LCOTHER . LCOTHER ) in LCOTHER fibroblasts : a new perspective on the mechanism of LCOTHER LCOTHER .	0
Previously , three LCOTHER - LCOTHER genes ( LCGeneOrGeneProduct , LCOTHER and LCGeneOrGeneProduct ) were resequenced , identifying polymorphisms that were used in genetic association studies of LCOTHER LCOTHER LCOTHER LCOTHER .	0
We reviewed the genotype of LCOTHER cases from Japan , India , China and Taiwan , and found that LCGeneOrGeneProduct is a major causative gene for LCOTHER in Asian . LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER induces epithelial - mesenchymal transition via LCOTHER / LCOTHER - LCOTHER signaling pathway in LCOrganismTaxon LCOTHER LCOTHER .	0
METHODS : We performed a systematic review of published and unpublished data from cohorts with LCOTHER or LCOTHER to compare the presence of LCDiseaseOrPhenotypicFeature in : ( 1 ) antithrombotic users vs nonantithrombotic users with LCOTHER ; ( 2 ) antithrombotic users vs nonusers with LCOTHER / LCDiseaseOrPhenotypicFeature ; and ( 3 ) LCOTHER vs LCOTHER events stratified by antithrombotic use .	0
Hence , our results suggest that LCOTHER significantly aggravates LCOTHER ( LCOTHER + ) overload and causes LCOTHER and finally promotes apoptotic development via phosphorylation of LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct . LCChemicalEntity LCChemicalEntity treatment ameliorates acute LCOTHER LCOTHER in LCOTHER .	0
Taken together , our results suggest that LCChemicalEntity induces immune - suppressive tolerogenic DCs in LCChemicalEntity LCChemicalEntity - induced LCOTHER conditions via abundant LCOTHER - LCOTHER production , thereby skewing Th cell differentiation towards Th2 and Tr1 cells .	0
Expression of LCGeneOrGeneProduct protects the lung from LCOTHER LCOTHER and enhanced pathology during LCOTHER LCOTHER . Assessment of a new non - invasive index of cardiac performance for detection of LCOTHER - induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
In addition , each affected child was heterozygous for the LCOTHER mutation in exon 7 that led to an LCOTHER substitution in LCOTHER , within the linker region of the protein . LCOTHER LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCGeneOrGeneProduct are functionally redundant in regulating patterning of the dorsoventral axis .	0
Of them , two LCOrganismTaxon carrying LCOTHER mutation were from two generations in one family with LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	0
Previous studies have shown that genetic disorders of LCOTHER may contribute to the pathogenesis of LCOTHER , but LCDiseaseOrPhenotypicFeature may not be caused by LCGeneOrGeneProduct gene mutations in Chinese LCOTHER .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
LCGeneOrGeneProduct expression was not significantly related with LCOrganismTaxon survival , prognosis , or clinical outcome .	0
The fact that no truncation or frame shift mutations have been found in any of the LCOTHER LCOTHER , coupled with our recent finding that some breeding pairs of LCOTHER LCOTHER knockout LCOTHER yield litters that show not only LCOTHER , but also severe LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOrganismTaxon . Midline B3 LCOTHER nerves in LCOTHER medulla are involved in LCOTHER effect of LCOTHER .	0
RESULTS : LCOTHER was associated with LCChemicalEntity - induced LCOTHER LCOrganismTaxon in the allele / genotype - wise analysis .	0
Our data suggested that the LCOTHER LCOTHER , but not LCOTHER or LCOTHER , may contribute toward reversal of LCOTHER . Association study of LCOTHER LCOTHER LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct , and LCOTHER and LCOTHER - LCOTHER LCOTHER LCOTHER in a Han Chinese population .	0
We hypothesized that mutations in acetylcholine receptor - related genes might also result in a LCOTHER / LCOTHER LCOTHER phenotype and so we analyzed 15 cases of lethal LCOTHER / LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature without LCOTHER mutations for mutations in the LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER ( LCOTHER ) genes .	0
The experience of this case , together with a review of the literature , suggests that LCChemicalEntity is related to LCChemicalEntity - LCChemicalEntity - induced LCOTHER .	0
Alteration of LCOTHER protein levels may contribute to invasion and LCOTHER LCOTHER LCOTHER , which may occur through activation of LCGeneOrGeneProduct signaling and promotion of LCGeneOrGeneProduct - LCGeneOrGeneProduct expression . The number of LCOTHER LCOTHER LCOTHER in LCOTHER LCOTHER correlates with the LCOTHER LCOTHER - LCOTHER LCOTHER gene insertion / deletion polymorphism .	0
Transfection into LCOTHER LCOTHER ovary cells of a cDNA representing only the coding region of LCOTHER , carrying LCOTHER , LCOTHER , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , resulted in 1 . 5 - fold lower mRNA levels only for LCGeneOrGeneProduct - LCSequenceVariant , and more than 10 - fold lower LCOTHER protein levels , measured by Western blotting and receptor binding assay .	0
We observed slightly reduced levels of LCOTHER protein and reduced levels of its opposing enzyme LCGeneOrGeneProduct - LCGeneOrGeneProduct in both LCOrganismTaxon - derived fibroblasts , but global LCOTHER - LCOTHER levels appeared to be unaffected .	0
METHODS : LCCellLine , primary LCOTHER small airway epithelial ( LCOTHER ) cells and wild - type , LCOTHER - LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) and LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) knockout ( KO ) LCOTHER were infected with LCOTHER and cytokine responses were investigated by ELISA , multiplex analysis and qPCR .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
The aim of this study was therefore to investigate the influence of mutations in these LCOTHER LCOTHER LCOTHER genes ( LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER / LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCGeneOrGeneProduct , LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
CONCLUSION : These findings suggest that the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCOTHER LCOTHER allele is significantly associated with the development of LCOTHER LCOTHER , suggesting a role for LCOTHER - LCOTHER in the pathogenesis of LCOTHER LCOTHER . Identification of the LCOTHER LCSequenceVariant mutation in LCOTHER LCOTHER LCOTHER .	0
LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) is a polygenic and multifactorial complex disease , whose etiopathology is still unclear , however several genetic factors have shown to increase the risk of developing the disease .	0
Collectively , our findings present a new approach for identifying ciliary proteins , and unveil LCOTHER , a LCOTHER most closely related to the LCOTHER protein LCOTHER / LCOTHER , as an IFT - associated cargo with LCOTHER - dependent cell autonomous and non - autonomous functions at the ciliary base . Compound heterozygous mutations in the LCGeneOrGeneProduct gene exon 4 in a LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER of Chinese origin .	0
Additionally , LCOTHER also reduces the levels of serum biochemical markers ( serum LCOTHER , Scr ; blood LCChemicalEntity LCChemicalEntity , BUN ; and LCOTHER LCOTHER , LCOTHER ) and decreases the release of LCOTHER cytokines ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) .	0
Thus , LCOTHER appears to play a critical oncogenic function in LCOTHER microenvironment and may be a potential target for developing therapeutic and preventive strategies against LCDiseaseOrPhenotypicFeature . Effects of the LCOTHER - LCOTHER specific inhibitor LCChemicalEntity versus LCOTHER LCOTHER LCOTHER and placebo on cardiovascular LCOTHER events in LCOTHER with LCOTHER .	0
The LCOTHER were assigned into four groups ( n = 10 per group ) , as follows : Control LCOTHER ; LCOTHER + LCOTHER ; LCOTHER + LCChemicalEntity ; LCOrganismTaxon + LCOTHER + LCOTHER .	0
Administration of LCOTHER LCOTHER suppressed LCOTHER growth in C3H / HeN LCOrganismTaxon , but not in LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) - mutant C3H / HeJ LCOrganismTaxon , by reducing serum levels of LCOTHER - LCOTHER and LCOTHER - LCOTHER , while increasing LCOTHER ( LCOTHER ) - LCOTHER levels .	0
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCOTHER , LCSequenceVariant , LCOTHER , LCOTHER , LCOTHER and LCSequenceVariant ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCOTHER LCOTHER LCOTHER , and one with LCOTHER LCOTHER LCOTHER ) .	0
The - 930G allele carriers are particularly at risk of consequences of LCOTHER and LCOTHER smoke exposure . Segregation of a LCSequenceVariant mutation of the LCOTHER / LCOTHER LCOTHER ( LCOTHER / LCOTHER ) gene with polyostotic LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in an Italian family .	0
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCSequenceVariant ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) and LCSequenceVariant . LCSequenceVariant ] have been reported in Japanese LCOTHER , but not in LCOTHER LCOTHER from other ethnic groups .	0
Both LCOTHER knockout ( LCOTHER ( - / - ) ) LCOTHER and db / db LCOTHER that were administered LCGeneOrGeneProduct monoclonal antibody displayed lower LCOTHER LCOTHER levels accompanied by elevated plasma LCGeneOrGeneProduct levels .	0
These findings firmly establish that alterations in innate immunity influence the course of LCOTHER LCOTHER and support the use of targeted strategies to limit or prevent the development of LCOTHER LCOTHER LCOTHER . Anticonvulsant effect of LCOTHER LCOTHER ( LCOTHER LCOTHER - LCOTHER ) on LCDiseaseOrPhenotypicFeature induced by microperfusion of LCChemicalEntity in the hippocampus of freely moving LCOTHER .	0
The authors report here a LCOTHER LCOTHER comorbid with LCOTHER LCOTHER who developed LCDiseaseOrPhenotypicFeature after LCChemicalEntity had been added to his LCOTHER therapy .	0
These findings provide the first in vivo evidence in a mammalian system that LCOTHER is required for LCGeneOrGeneProduct signalling and functions as an upstream activating kinase for LCGeneOrGeneProduct / LCGeneOrGeneProduct / LCGeneOrGeneProduct in addition to its known role in regulating LCOTHER LCOTHER pathways .	0
Loss of LCOTHER expression in LCOTHER altered the LCOTHER induction of LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct and LCOTHER - LCOTHER .	0
LCOTHER ( LCOTHER ) is a metabolite of the LCOTHER LCOTHER LCChemicalEntity ( LCChemicalEntity ) and putatively responsible for LCOTHER LCOTHER following anti - LCOTHER therapy with LCOTHER .	0
This shift in balance may contribute to increased LCOTHER LCOTHER in LCOTHER ( - / - ) LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and altered neurochemical expression in micturition pathways . LCOTHER associated with LCChemicalEntity : case presentation and literature review .	0
CONCLUSIONS : LCOTHER treatment is effective in controlling the LCOTHER LCOTHER , LCOTHER , LCOTHER , and LCOTHER in this child case , wherein LCOTHER LCOTHER plays a key role in the proper formation of the ligand - binding pocket and the AF - 2 surface of the LCOTHER LCOTHER LBD . Inactivation of LCGeneOrGeneProduct / LCGeneOrGeneProduct / LCOTHER LCOTHER LCOTHER LCOTHER triggers senescence and inhibits LCOTHER - induced immortalization .	0
Five of them [ LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCOTHER ) , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER ) , LCOTHER . LCOTHER > LCOTHER ( LCSequenceVariant ) and LCOTHER . LCOTHER ] have been reported in Japanese LCOTHER , but not in LCOTHER LCOTHER from other ethnic groups .	0
The LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER ) enzymes synthesize the LCOTHER LCChemicalEntity LCChemicalEntity - LCChemicalEntity ( LCChemicalEntity ( LCChemicalEntity ) LCChemicalEntity ) , which has been detected at the Golgi complex and endosomal compartments and recruits LCOTHER adaptors .	0
A total of 10 novel variants was recognized , among them four variants in the adjacent 5 ' - region of the LCOTHER coding exon 2 ( LCSequenceVariant . LCSequenceVariant - LCSequenceVariant > LCSequenceVariant , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER ) , a 6 base - pair deletion ( LCOTHER . LCOTHER [ LCSequenceVariant . LCSequenceVariant ] ) , a variant leading to a stop codon ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , synonymous variants ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , and one non - synonymous variant ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) .	0
Materials and METHODS : A cohort of 1163 unrelated LCOrganismTaxon with LCOTHER ( 874 LCOTHER ' LCOTHER LCOTHER , 259 LCOTHER LCOTHER , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER / LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER and LCOTHER .	0
PURPOSE : The purpose of this study was to analyze the value of germline and LCOTHER LCOTHER LCOTHER ( LCOTHER ) genotyping as a prognostic marker in a series of LCOTHER LCOTHER LCOrganismTaxon receiving adjuvant LCOTHER ( LCChemicalEntity ) - based treatment .	0
Modulation of LCOTHER by LCGeneOrGeneProduct LCGeneOrGeneProduct may be important in regulating LCOTHER growth . The LCOTHER LCOTHER LCOTHER LCOTHER polymorphism is associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in LCOTHER ' LCOTHER LCOTHER LCOTHER .	0
There were a significant dilatation of tubular lumens , extensive epithelial cell vacuolization , LCOTHER , LCDiseaseOrPhenotypicFeature , and LCOTHER in LCChemicalEntity - treated LCOTHER more than those of the control and the LCOTHER groups .	0
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCOTHER ( 874 LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , 259 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER / LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER .	0
LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) is the most common and lethal histologic type of LCOTHER LCOTHER LCOTHER .	0
Another LCDiseaseOrPhenotypicFeature LCOTHER of African origin showed a homozygous nucleotide change in the tenth of LCOTHER gene that led to an alteration of the amino acid composition of the protein ( LCSequenceVariant ) .	0
We present the case of a 31 - year - old LCOTHER with bilateral LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER after excessive LCChemicalEntity and intranasal LCChemicalEntity use .	0
Recently , heterozygous LCOTHER mutations were shown to result in early - onset LCDiseaseOrPhenotypicFeature , LCOTHER , and LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	0
In addition to these new mutations , this investigation reveals the prevalence of LCOTHER substitution among a subset of African - Brazilian LCOrganismTaxon and presents evidences of the recurrence of already known mutations . Effects of LCOTHER on LCOTHER - induced LCDiseaseOrPhenotypicFeature in LCOTHER .	0
LCOTHER could protect LCOTHER LCOTHER LCOTHER and maintain the microvasculature integration in acute LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature of LCOTHER induced by LCOTHER / LCChemicalEntity - LCChemicalEntity .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
CONCLUSIONS : The utilization of LCOTHER to correct LCOTHER induced by anesthesia has a negative impact on S ( c ) O ( 2 ) while LCOTHER maintains frontal lobe oxygenation potentially related to an increase in CO . LCOTHER LCOTHER ( LCOTHER - LCOTHER ) and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) Single Nucleotide Polymorphisms ( SNPs ) , LCOTHER and Metabolism in LCOTHER LCOTHER LCOTHER in Inner Mongolia .	0
Of particular interest are genes involved in defense against LCOTHER LCOTHER LCOTHER ( LCChemicalEntity ) because LCChemicalEntity are thought to cause DNA damage and contribute to the pathogenesis of LCOTHER .	0
BACKGROUND : Markers of fibrinolysis , LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , and LCOTHER LCOTHER LCOTHER - LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct ) levels were studied for the evaluation of short - term effects of LCOTHER administration in postmenopausal LCOrganismTaxon .	0
Thus , it may extend the current findings on the interaction between LCOTHER and LCChemicalEntity . Behavioral effects of pubertal LCChemicalEntity LCChemicalEntity LCChemicalEntity exposure in male LCOTHER with low LCOTHER .	0
Since healthy relatives of the LCOTHER probands are not reliable negative controls for LCDiseaseOrPhenotypicFeature , we used a population of 90 race - matched , healthy individuals , unrelated to the LCDiseaseOrPhenotypicFeature LCOTHER , as controls to perform an association study .	0
In LCOTHER - LCOTHER - LCOTHER cells stimulated with ( LCOTHER ) - ( LCOTHER ) - ( - ) - LCOTHER LCOTHER ( LCOTHER ) , we measured ( a ) cell growth , ( b ) LCOTHER ( LCOTHER ) and LCChemicalEntity LCChemicalEntity levels , and ( c ) phosphorylation of LCGeneOrGeneProduct and LCOTHER - LCOTHER LCOTHER LCOTHER isoforms .	0
The following gene polymorphisms were determined in genomic DNA : LCOTHER - LCOTHER LCOTHER insertion / deletion polymorphism ( I / D LCOTHER ) , LCOTHER gene polymorphism ( LCOTHER LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) polymorphism ( LCSequenceVariant LCSequenceVariant ) , and polymorphism of LCOTHER LCOTHER gene ( LCOTHER ) . Heart rate variability during HUT was assessed in 5 - minute intervals by low frequency , high frequency , standard deviation of the normal - to - normal ( SDNN ) , and root mean square successive difference parameters .	0
RESULTS : The results indicate that LCChemicalEntity - and LCChemicalEntity - treated LCOTHER showed LCOTHER LCOTHER in comparison to control LCOTHER in all the parameters studied .	0
LCOTHER treatment significantly ( p < or = 0 . 001 ) increased expression of LCOTHER and LCOTHER - LCOTHER in the urinary bladder of WT and LCOTHER ( - / - ) LCOTHER , but expression in LCGeneOrGeneProduct ( - / - ) LCOrganismTaxon with LCOTHER treatment was significantly ( p < or = 0 . 001 ) greater ( 4 . 2 - to 13 - fold increase ) than that observed in WT urinary bladder ( 3 . 6 - to 5 - fold increase ) .	0
A model of LCOTHER LCOTHER was developed by intrasplenic injection of LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER - LCOTHER ) into LCGeneOrGeneProduct knockout LCOTHER ( LCOTHER ) and wild - type ( LCOTHER / LCOTHER ) LCOTHER ( WT ) .	0
Despite the absence of functional LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) protein in LCOTHER cells , LCOTHER knockdown reduced LCOTHER phosphorylation at LCOTHER LCOTHER and concomitantly inhibited phosphorylation of the LCGeneOrGeneProduct target , LCOTHER LCOTHER LCOTHER - LCOTHER ( LCOTHER - LCOTHER ) .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCOTHER with LCGeneOrGeneProduct and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCDiseaseOrPhenotypicFeature .	0
Also , it records a novel deletion in exon 1 of LCOTHER gene in a LCOTHER with severe LCOTHER . People aged over 75 in LCOTHER LCOTHER on LCOTHER : the rate of major LCOTHER and LCDiseaseOrPhenotypicFeature in more than 500 LCOrganismTaxon - years of follow - up .	0
Serum concentrations of LCOTHER , LCChemicalEntity and LCOTHER - LCOTHER as markers of LCOTHER and LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	0
The LCOTHER agonist LCOTHER - LCOTHER dose - dependently inhibited LCOTHER activity in LCOTHER cells stably expressing the LCOTHER LCGeneOrGeneProduct ; effects were reversed by LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist .	0
LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) blockade has been proposed as an alternative to LCOTHER monotherapy for treating LCOTHER LCOTHER LCOTHER since deletion or inhibition of LCOTHER corrects LCOTHER in models of LCOTHER .	0
Thus , our results support the notion that LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER / LCOTHER - LCOTHER mutually regulate Th17 and Th1 responses in LCOTHER - bearing hosts , and LCOTHER LCChemicalEntity modulates the balance of the LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER - LCOTHER axis towards LCOTHER - LCOTHER production , which leads to LCOTHER inhibition .	0
LCOTHER / LCGeneOrGeneProduct is a novel disease gene , causing LCOTHER - LCOTHER , early onset , severe LCOTHER LCOTHER . cDNA sequence and chromosomal localization of the remaining three LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct : the LCOTHER LCOTHER fraction is completed .	0
It is concluded that oxidative tubular damage plays an important role in the LCOTHER - induced LCOTHER and the modulation of oxidative stress with LCOTHER reduces the LCOTHER - induced LCOTHER LCOTHER both at the biochemical and histological levels . LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct interacts with LCOTHER and LCOTHER to modulate LCGeneOrGeneProduct secretion in LCOTHER gonadotrophs .	0
PURPOSE : This study was designed to establish a LCOTHER model of LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) by LCOTHER LCOTHER ( LCOTHER ( LCOTHER ) ) - induced LCOTHER LCOTHER and to explore the potential role of LCOTHER LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER LCOTHER ( LCOTHER ) and their endogenous inhibitors ( TIMPs ) in LCOTHER formation .	0
Effects on LCChemicalEntity LCChemicalEntity are similar to those noted for the LCOrganismTaxon LCOTHER LCOTHER LCOTHER .	0
LCOTHER administration to control LCOTHER significantly increased renal LCOTHER ( LCOTHER ) and urinary LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER , a marker of LCOTHER LCOTHER LCOTHER ) excretion but decreased LCOTHER LCOTHER ( LCOTHER ) and LCGeneOrGeneProduct ( LCOTHER ) activities .	0
We identified the minimal region of the LCOTHER promoter that confers inducibility by LCChemicalEntity to a 133 base pair region containing an Anti - oxidant Response Element ( ARE ) and showed the essential role of the transcription factor LCOTHER ( LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ) .	0
METHODS : Stage IIIb or IV LCDiseaseOrPhenotypicFeature LCOTHER , with two or fewer prior chemotherapy regimens , one LCOTHER based ( stratum 1 ) or both chemotherapy and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER inhibitors ( stratum 2 ) , received LCOTHER 10 mg / day until progression or unacceptable LCDiseaseOrPhenotypicFeature .	0
Compared to that in the normal control , more severe LCOTHER LCOTHER and hepatocyte apoptosis , worse hepatic LCOTHER peroxidation demonstrated by the increased ASAFR , . LCOTHER and LCChemicalEntity , but decreased LCOTHER and LCOTHER , increased LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCGeneOrGeneProduct activities and LCOTHER - LCOTHER , LCOTHER - LCOTHER and LCOTHER expressions , which revealed obvious LCOTHER LCOTHER and scaffold structure broken , were shown in the model control .	0
In this study , we establish the LCOTHER LCOTHER LCOTHER ( LCOTHER ) or LCOTHER LCOTHER ( LCOTHER ) - induced LCOrganismTaxon LCOTHER LCOTHER LCOTHER in vivo and the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct - stimulated LCOTHER proximal tubular epithelial cell ( LCOTHER - LCOTHER ) model in vitro .	0
Loss of LCOTHER expression in LCOrganismTaxon altered the LCOTHER induction of LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER - LCOTHER .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCGeneOrGeneProduct and LCOTHER , LCGeneOrGeneProduct , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental LCOTHER . Exaggerated expression of LCOTHER mediators in LCOTHER LCOTHER LCOTHER knockout ( LCOTHER - / - ) LCOTHER with LCOTHER ( LCChemicalEntity ) - induced LCDiseaseOrPhenotypicFeature .	0
Our recent study showed that LCOTHER / LCOTHER LCOTHER LCOTHER LCOTHER regulates apoptosis and vasculogenesis by promoting degradation of LCOTHER and LCGeneOrGeneProduct , and co - operates with LCOTHER to promote LCOTHER LCOTHER by activating LCGeneOrGeneProduct and LCOTHER pathways via targeted degradation of LCOTHER suppressive substrates including LCOTHER , LCOTHER , LCOTHER and LCOTHER .	0
These results illustrate that LCOTHER is a distinctive LCDiseaseOrPhenotypicFeature suppressor , which does not only suppress growth of LCOTHER cells but also regulates LCOTHER - mediated LCOTHER - initiating activity of LCDiseaseOrPhenotypicFeature cells . LCOTHER LCOTHER LCOTHER resulting from a new nonsense mutation , LCOTHER . LCOTHER , in the LCOTHER gene .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
The incidence of cardiovascular LCOTHER events ( cardiac , cerebrovascular and peripheral vascular , or arterial LCOTHER ) was determined by analyzing pooled LCOTHER ( 10 - 80 mg daily ) , nonselective LCChemicalEntity ( LCOTHER 75 mg bid , LCOTHER 800 mg tid , or LCOTHER 500 mg bid ) and placebo data from 10 randomized LCOTHER and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature trials that were 6 - 52 weeks in duration .	0
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCOTHER cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCGeneOrGeneProduct is required for the synergistic action of LCOTHER - LCOTHER and LCChemicalEntity , and that LCOTHER loss promotes LCOTHER cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	0
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) messenger RNA ( mRNA ) splicing .	0
Of these , LCOTHER : LCSequenceVariant > LCSequenceVariant in an intron of the LCOTHER gene ( LCOTHER ) was within a novel putative auxiliary LCGeneOrGeneProduct - binding motif , which is enriched in the neighborhood of canonical LCOTHER - responsive elements .	0
In this study , we developed a new LCDiseaseOrPhenotypicFeature - responsive reporter vector using a LCOTHER - responsive element of the 5 ' LCOTHER LCOTHER LCOTHER LCOTHER untranslated region and generated a novel LCOTHER - sensing transgenic LCOrganismTaxon .	0
The homeostasis model assessment of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( LCChemicalEntity > LCOTHER > LCOTHER ) ( LCOTHER vs LCOTHER , t ( 33 ) = 2 . 94 ; P = . 006 ; LCOTHER vs LCOTHER , t ( 33 ) = 2 . 42 ; P = . 02 ) .	0
LCOTHER LCOTHER - LCOTHER was found to attenuate LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in both LCOrganismTaxon models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the LCOTHER LCOTHER LCOTHER ( LCOTHER - LCOTHER ) - infused LCOTHER .	0
CONCLUSIONS : The LCOTHER and LCOTHER - LCOTHER viruses can be considered for evaluation in LCOrganismTaxon and for inclusion in a tetravalent LCOTHER vaccine . The effects of short - term LCChemicalEntity therapy on fibrinolysis markers : LCOTHER , LCOTHER , and LCOTHER - LCOTHER .	0
A comparison of genotypes , LCOTHER activities , and clinical data on 4 individuals carrying the allele of 81 LCOTHER with LCDiseaseOrPhenotypicFeature examined , further validates the concept that different degrees of residual LCOTHER activity are the basis of phenotypical variation in LCOTHER . Families with the risk allele of LCGeneOrGeneProduct reveal a link between LCOTHER and another component of the same molecular pathway , LCOTHER .	0
LCOTHER with both a LCOTHER deletion allele and low LCChemicalEntity intake ( < 400 microg / d from diet plus supplements ) had a significantly greater risk of LCOTHER LCOTHER ( AOR : 5 . 5 ; 95% CI : 1 . 5 , 20 . 4 ; P = 0 . 01 ) and a significantly greater risk of having an infant with a low birth weight ( AOR : 8 . 3 ; 95% CI : 1 . 8 , 38 . 6 ; P = 0 . 01 ) than did LCOTHER without a deletion allele and with a LCChemicalEntity intake > / = 400 microg / d .	0
RESULTS : In the case - control design , the frequencies of the TT genotype for SNP LCOTHER and the homozygous deletion variant ( LCSequenceVariant ) in the fourth exon of the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene were higher among LCOTHER with LCOTHER with LCOTHER compared with the controls ( odds ratio [ OR ] , 2 . 779 , P = . 016 ; and OR , 3 . 09 , P = . 022 , respectively ) .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCGeneOrGeneProduct ( goblet cell markers ) , and LCOTHER - specific LCGeneOrGeneProduct .	0
LCGeneOrGeneProduct , secreted from the endometrial glands ( GEs ) , binds to the LCOTHER , activating the LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER ( LCOTHER - LCGeneOrGeneProduct ) signaling pathway in the LE .	0
We hypothesized that mutations in acetylcholine receptor - related genes might also result in a LCOTHER / LCOTHER LCOTHER phenotype and so we analyzed 15 cases of lethal LCOTHER / LCOTHER LCOTHER without LCGeneOrGeneProduct mutations for mutations in the LCOTHER , LCOTHER , LCOTHER , and LCGeneOrGeneProduct ( LCOTHER ) genes .	0
Very recently , mutations of the LCGeneOrGeneProduct gene in exons 2 - 9 have been found in LCOTHER LCOrganismTaxon , suggesting that this gene plays an important role in orofacial development .	0
The fact that no truncation or frame shift mutations have been found in any of the LCOTHER LCOTHER , coupled with our recent finding that some breeding pairs of LCOTHER LCOTHER knockout LCOrganismTaxon yield litters that show not only LCOTHER , but also severe LCOTHER and LCOTHER LCOTHER , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOTHER . Midline B3 LCOTHER nerves in LCOrganismTaxon medulla are involved in LCOTHER effect of LCOTHER .	0
AIMS : Individuals with both LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) and the LCOTHER ( LCOTHER ) 2 - 2 genotype are at increased risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
We herein report the case of a 70 - year - old LCOrganismTaxon with LCOTHER - LCOTHER - induced LCDiseaseOrPhenotypicFeature , in whom a high serum level of LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCOTHER ) was observed .	0
We hypothesized that LCGeneOrGeneProduct and / or LCOTHER pathways may be modulated by LCOTHER - LCOTHER , but neither the LCOTHER - stimulated phosphorylation of LCOTHER / LCOTHER nor the LCOTHER - induced LCGeneOrGeneProduct / LCGeneOrGeneProduct or LCOTHER LCOTHER LCOTHER - LCOTHER phosphorylation were modified .	0
Results showed that LCOTHER ( 10 - 30 mg / kg p . o . ) blocked LCOTHER induced by the non - competitive LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist , LCOTHER - LCOTHER and partially reversed spontaneous LCOTHER of LCOTHER LCOTHER ( neo - / - ) LCOrganismTaxon .	0
Viruses were evaluated for replication in SCID LCOTHER transplanted with LCOTHER LCDiseaseOrPhenotypicFeature cells ( LCOTHER - LCOTHER - LCOTHER LCOTHER ) , in mosquitoes , and in LCOrganismTaxon LCOrganismTaxon .	0
Enzyme activity assays with recombinant LCOTHER isoforms ( LCOTHER LCOTHER and LCOTHER LCSequenceVariant ) and the LCOTHER substrate LCChemicalEntity were used to investigate the functional impact of the LCOTHER LCOTHER polymorphism .	0
An MspI polymorphism , producing a 3 . 7 kb band , may prove useful in assessing this gene ' s involvement in LCOTHER LCOTHER involving opiatergic systems . An LCGeneOrGeneProduct - LCGeneOrGeneProduct LCSequenceVariant - > LCSequenceVariant gene polymorphism associated with LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER gene and high LCOTHER LCOTHER production .	0
This increase was not associated with a change in LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , or LCGeneOrGeneProduct phosphorylation .	0
Next to the LCOTHER mutations we noted 2 cases of deletion in LCOTHER [ Delta ( LCGeneOrGeneProduct - D13S1830 ) ] and 3 ( 2 new and 1 described ) base substitutions in LCOTHER [ LCOTHER . LCOTHER > LCOTHER , LCOTHER . LCOTHER > LCOTHER and LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER . LCOTHER ) ] which are unlikely disease - causing .	0
This retrospective study examines the incidence and treatment of LCOTHER and LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) in OLTX LCOrganismTaxon .	0
These LCChemicalEntity - specific effects may be related to the vulnerability of isocortical and allocortical regions to the LCOTHER effects of LCChemicalEntity . Variation in the LCOTHER gene ( LCOTHER ) is not associated with susceptibility to LCOTHER LCOTHER .	0
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCGeneOrGeneProduct transgenic male and LCDiseaseOrPhenotypicFeature WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	0
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCGeneOrGeneProduct / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCGeneOrGeneProduct genes in LCOTHER with LCOTHER / LCOTHER .	0
Consistent with impaired growth , LCOTHER knockdown increased levels of the LCOTHER - LCOTHER LCOTHER ( LCOTHER ) inhibitors LCOTHER ( LCOTHER / LCOTHER ) ( LCGeneOrGeneProduct ) and LCOTHER ( LCGeneOrGeneProduct ) ( LCOTHER ) .	0
These data suggest that when LCOTHER activity is blocked in the setting of LCOTHER LCOTHER LCOTHER , the plasma LCOTHER level rises , preventing LCDiseaseOrPhenotypicFeature . LCGeneOrGeneProduct - LCGeneOrGeneProduct , a LCOTHER ( LCOTHER ) LCOTHER , functions as a LCOTHER suppressor in an orthotopic LCOTHER LCOTHER LCOTHER model .	0
Improving the understanding of LCGeneOrGeneProduct - LCGeneOrGeneProduct in LCOTHER LCOTHER could lead to the development of clinically useful therapeutic modalities for treatment of LCOTHER LCOTHER or even allow identification of preventive strategies . LCGeneOrGeneProduct is an essential regulator of LCOTHER signalling in cartilage .	0
Our findings reveal a novel role of LCOTHER in regulating meiotic G2 / M transition by acting via the LCOTHER / LCOTHER ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct LCGeneOrGeneProduct pathway . The LCOTHER LCOTHER LCOTHER > LCOTHER polymorphism is not associated with LCOTHER LCOTHER LCOTHER .	0
Here , we report two maternal cousins with an apparently LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , LCOTHER , LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER , and LCOTHER LCOTHER .	0
METHODS : LCOTHER , primary LCOTHER small airway epithelial ( LCOTHER ) cells and wild - type , LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) and LCOTHER LCOTHER - LCOTHER LCOTHER ( LCOTHER ) knockout ( KO ) LCOrganismTaxon were infected with LCOTHER and cytokine responses were investigated by ELISA , multiplex analysis and qPCR .	0
Since the first molecular characterization of an LCOTHER mutation by Bourgeron et al in 1994 , a series of reports of both LCOTHER LCOTHER LCOTHER and LCOTHER with LCDiseaseOrPhenotypicFeature / LCDiseaseOrPhenotypicFeature have described 107 variants , of which 93 are thought to be pathogenic .	0
Alteration of LCOTHER protein levels may contribute to invasion and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , which may occur through activation of LCOTHER signaling and promotion of LCOTHER - LCOTHER expression . The number of LCOTHER LCOTHER LCOTHER in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature correlates with the LCOTHER LCOTHER - LCOTHER LCOTHER gene insertion / deletion polymorphism .	0
These LCOrganismTaxon - inducible cytokines were also observed in the airways of LCOrganismTaxon during an LCOTHER .	0
In vitro - differentiated LCOTHER [ - / - ] myotubes exhibit a higher resting [ LCOTHER + ] i than do wild - type myotubes because of an altered open probability of voltage - dependent l - type LCChemicalEntity + and LCChemicalEntity + channels .	0
Here , we report a case of prolonged LCOTHER LCOTHER after administration of LCChemicalEntity leading to the discovery of a novel LCOTHER variant ( LCOTHER . LCOTHER > LCOTHER , LCSequenceVariant . LCSequenceVariant ) .	0
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER / LCGeneOrGeneProduct - LCGeneOrGeneProduct ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	0
Based on these data , it can be speculated that pubertal LCChemicalEntity users with low central LCOTHER - LCOTHER may be especially prone to exhibit LCOTHER LCOTHER . DNA damage and repair in LCOTHER LCOTHER - - a correlation with the LCOTHER and LCGeneOrGeneProduct genes polymorphisms .	0
LCOTHER ( LCChemicalEntity ) is a metabolite of the LCOTHER LCOTHER LCChemicalEntity ( LCOTHER ) and putatively responsible for LCOTHER LCOTHER following anti - LCOTHER therapy with LCOTHER .	0
Here , we report two maternal cousins with an apparently LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER , and LCOTHER LCOTHER .	0
Compared to many other ethnic groups , LCDiseaseOrPhenotypicFeature - associated variants of the coding region of LCOTHER are rare in Sudan and Kenya , suggesting a role of other genetic , or epigenetic factors as a cause for LCOTHER in these countries . A novel point mutation in helix 10 of the LCOrganismTaxon LCOTHER LCOTHER causes generalized LCOTHER LCOTHER by disrupting the structure of the ligand - binding domain .	0
Taken together , our results demonstrated that LCOTHER is a LCGeneOrGeneProduct ( LCSequenceVariant ) - cooperating oncogene required for LCOTHER ( LCOTHER ) - induced immortalization and transformation , and targeting LCOTHER - LCOTHER LCOTHER LCOTHER may , therefore , have therapeutic value for senescence - based LCOTHER treatment . In vivo evidences suggesting the role of oxidative stress in pathogenesis of LCOTHER - induced LCOTHER : protection by LCOTHER .	0
Consistent with this premise , LCOrganismTaxon LCOTHER cells with relatively high levels of LCGeneOrGeneProduct are more sensitive to LCOTHER - LCOTHER treatment compared to LCOTHER - depleted LCOTHER cells , further indicating that LCOTHER loss has a crucial role in LCOTHER - LCOTHER resistance in LCOTHER LCOTHER .	0
Another LCDiseaseOrPhenotypicFeature LCOrganismTaxon of African origin showed a homozygous nucleotide change in the tenth of LCOTHER gene that led to an alteration of the amino acid composition of the protein ( LCOTHER ) .	0
LCGeneOrGeneProduct - activation of LCGeneOrGeneProduct showed several novel features being dependent on both receptor - activation states , having LCOTHER - and LCOTHER - dependent / independent components and LCOTHER - LCOTHER - dependent / independent components .	0
Two silent mutations , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER ) and LCOTHER . LCOTHER > LCOTHER ( LCSequenceVariant ) , respectively , occurred in the coding region of exon 2 , again in both LCOTHER and normal controls .	0
A model of LCOTHER LCOTHER was developed by intrasplenic injection of LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER - LCOTHER ) into LCOTHER knockout LCOTHER ( LCGeneOrGeneProduct ) and wild - type ( LCOTHER / LCOTHER ) LCOTHER ( WT ) .	0
We hypothesized that mutations in acetylcholine receptor - related genes might also result in a LCOTHER / LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature phenotype and so we analyzed 15 cases of lethal LCOTHER / LCOTHER LCOTHER without LCOTHER mutations for mutations in the LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER ) genes .	0
Compared with a normoxic , chow - fed control LCOTHER heart , LCOTHER decreased LCOTHER expression , LCOTHER LCOTHER oxidation , and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) levels , while increasing glycolysis , all of which served to maintain normal LCOTHER concentrations ( [ LCOTHER ] ) and thereby , ejection fractions .	0
RESULTS : The results show that the LCSequenceVariant polymorphism is present in LCOTHER - LCOTHER LCOTHER in the 5 ' UTR sequence ( + 25 ) of the LCGeneOrGeneProduct - LCGeneOrGeneProduct gene , known to affect the LCOTHER ( LCOTHER homologue of LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER ) binding site 5 ' - GGTTAT - 3 ' .	0
Modulation of LCOTHER by LCOTHER LCOTHER may be important in regulating LCDiseaseOrPhenotypicFeature growth . The LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct polymorphism is associated with LCOTHER LCOTHER in LCOTHER ' LCOTHER LCOTHER LCOTHER .	0
CONCLUSIONS : The LCOTHER mutation status was highly concordant between endoscopic biopsy and surgically resected specimens from the same LCOTHER , suggesting that endoscopic biopsy specimens can be clinically used to detect LCOTHER mutations in LCOrganismTaxon with LCDiseaseOrPhenotypicFeature . LCOTHER LCOTHER polymorphisms and survival .	0
There was no LCOTHER or LCOTHER effect on the protein content for LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER LCOTHER - LCOTHER , LCGeneOrGeneProduct , LCOTHER or LCOTHER in muscle .	0
Oxidative stress was assessed by determining plasma and liver levels of LCChemicalEntity - LCChemicalEntity ( LCChemicalEntity ) - LCChemicalEntity , LCOTHER LCOTHER ( LCOTHER ) , and LCChemicalEntity LCChemicalEntity LCChemicalEntity LCChemicalEntity ( LCOTHER ) .	0
METHODS : DNA was collected from 191 LCOrganismTaxon ( mean age 44 + / - 18 years , 61 LCOTHER , 130 LCOrganismTaxon ) .	0
Thus , LCGeneOrGeneProduct appears to play a critical oncogenic function in LCOTHER microenvironment and may be a potential target for developing therapeutic and preventive strategies against LCOTHER . Effects of the LCOTHER - LCOTHER specific inhibitor LCChemicalEntity versus LCOTHER LCOTHER LCOTHER and placebo on cardiovascular LCOTHER events in LCOTHER with LCOTHER .	0
LCOTHER was activated by some LCOTHER LCOTHER - LCOTHER [ LCGeneOrGeneProduct , LCOTHER , LCOTHER ] , by secretagogues activating LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) [ LCOTHER , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCOTHER [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	0
In a multivariate logistic regression analysis including age , sex , smoking , LCOTHER , arterial LCOTHER and LCOTHER , the LCGeneOrGeneProduct LCSequenceVariant LCSequenceVariant variant was not significantly associated with the presence of LCOTHER ( Odds ratio 1 . 07 , 95% confidence interval 0 . 84 - 1 . 37 ; p = 0 . 60 ) .	0
Further study revealed that the effect of LCOTHER on LCOTHER LCOTHER LCOTHER is associated with the lower expression of LCOTHER , p - LCGeneOrGeneProduct , p - LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , both in vivo and in vitro .	0
As LCOTHER LCOTHER is the only modifiable factor , its administration , particularly in doses exceeding 80 mg . kg ( - 1 ) , should be weighed against the risk of postoperative LCOTHER . A LCGeneOrGeneProduct ligand attenuates LCOTHER LCOTHER after LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Our result expands the mutation spectrum of LCOTHER and contributes to the study of the molecular pathogenesis of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . LCOTHER polymorphisms associated with alternative splicing modify susceptibility to LCOTHER LCOTHER LCOTHER LCOTHER through epistatic interaction with LCGeneOrGeneProduct .	0
Therefore , we screened 47 Hungarian LCOTHER - heterozygous ( one mutation in coding exon of the LCGeneOrGeneProduct gene ) LCOTHER with LCOTHER LCOTHER for DNA changes in two further connexin genes ( LCGeneOrGeneProduct and LCOTHER ) and in the 5 ' non - coding region of LCOTHER including the splice sites .	0
The novel proteins LCOTHER and LCOTHER were both reduced , suggesting roles in LCDiseaseOrPhenotypicFeature , whereas LCGeneOrGeneProduct - LCGeneOrGeneProduct was unchanged . Intronic deletions in the LCOTHER gene cause LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER .	0
Next to the LCOTHER mutations we noted 2 cases of deletion in LCGeneOrGeneProduct [ Delta ( LCOTHER - D13S1830 ) ] and 3 ( 2 new and 1 described ) base substitutions in LCOTHER [ LCOTHER . LCOTHER > LCOTHER , LCOTHER . LCOTHER > LCOTHER and LCOTHER . LCOTHER > LCOTHER ( LCSequenceVariant . LCSequenceVariant ) ] which are unlikely disease - causing .	0
Although treatment with the pancreatic b - cell toxin LCOTHER induced LCDiseaseOrPhenotypicFeature and raised plasma LCOTHER levels in wild - type LCOTHER , LCDiseaseOrPhenotypicFeature was averted in similarly treated LCOTHER ( - / - ) LCOTHER and the plasma LCOTHER level was further increased .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
Reduced LCOTHER expression after high - fat diet is associated with selective up - regulation of LCGeneOrGeneProduct and further LCOTHER LCOTHER LCOTHER signaling in adipose tissue . Effect of the abrogation of LCOTHER - LCOTHER by antisense LCOTHER on the expression of LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct in isolated fibroblasts from LCOTHER LCOTHER .	0
Our results confirmed a previous study on the relationship between LCOTHER and LCOTHER in Caucasians . Does LCOTHER potentiate LCChemicalEntity - associated LCOTHER LCOTHER LCOTHER There is now evidence to suggest a central role for the dopaminergic system in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	0
BACKGROUND / AIMS : LCOTHER LCOTHER ( LCOTHER ) is a rare disease characterized by LCDiseaseOrPhenotypicFeature - like substances in markedly LCOTHER LCOTHER LCOTHER and elevated plasma levels of LCOTHER LCOTHER ( LCGeneOrGeneProduct ) .	0
The aim of this study was therefore to investigate the influence of mutations in these LCOTHER LCOTHER LCOTHER genes ( LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER / LCOTHER LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER - LCOTHER LCOTHER ( LCOTHER ) LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct and LCOTHER ) on the development of antimicrobial and antiglycan antibodies in LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
LCOTHER chelation with LCOTHER was effective in mobilizing hepatic LCOTHER but has no effect on brain LCOTHER . Aberrant LCGeneOrGeneProduct - LCGeneOrGeneProduct - mediated LCGeneOrGeneProduct signaling and proliferation identified by analysis of LCOTHER LCOTHER LCOTHER mutation ( LCOTHER . LCOTHER ) in LCOTHER fibroblasts : a new perspective on the mechanism of LCOTHER LCOTHER .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER / LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
The levels of serum LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) were measured as well .	0
Loss - of - function experiments demonstrate that LCOTHER serves as a LCOTHER antagonist with functions that overlap and are redundant with those of LCOTHER in forming the dorsoventral axis . Polymorphic forms of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct and their interaction with LCGeneOrGeneProduct LCGeneOrGeneProduct trinucleotide repeats in LCOTHER LCOTHER .	0
EXPERIMENTAL DESIGN : Because of their widespread use , the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature following coadministration of LCOTHER and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of LCOTHER and LCOTHER blood progenitor cells to LCOTHER , LCChemicalEntity , and LCOTHER + / - LCOTHER was determined in granulocyte - macrophage colony forming assays .	0
The binding of LCGeneOrGeneProduct , LCGeneOrGeneProduct and LCOTHER to LCOTHER did not differ for control and septic muscle in the basal condition ; however , the LCOTHER - induced decrease in LCOTHER LCOTHER and increase in LCOTHER LCOTHER seen in control muscle was absent in LCOTHER .	0
METHODS : Nine LCOrganismTaxon with LCDiseaseOrPhenotypicFeature from six families were recruited into the study .	0
One possibility might be that individuals who are compound heterozygotes for LCGeneOrGeneProduct mutations are more common than we realize . Omitting LCOTHER reduces LCOTHER and LCOTHER , without increasing LCDiseaseOrPhenotypicFeature , after LCOTHER for day surgery .	0
RESULTS Distribution frequency of LCGeneOrGeneProduct - LCGeneOrGeneProduct - LCSequenceVariant ( OR = 3 . 316 , 95% CI = 1 . 092 - 8 . 304 , p = 0 . 025 ) in LCOTHER with LCOTHER pregnancies were obviously higher than that in LCOrganismTaxon with healthy pregnancies .	0
LCOTHER is likely to be an LCOTHER - susceptibility gene and LCOTHER mutations may increase the risk of developing a LCOTHER LCOTHER rather than being a direct causative mutation . The differential effects of LCOTHER and LCOTHER on LCOTHER LCOTHER release , LCOTHER gene expression and LCDiseaseOrPhenotypicFeature in a clinical LCDiseaseOrPhenotypicFeature model .	0
We investigated whether the LCGeneOrGeneProduct polymorphisms within the promoter region ( LCOTHER LCOTHER LCOTHER / LCOTHER ) and the 3 ' - UTR ( LCSequenceVariant - LCSequenceVariant / LCSequenceVariant ) , which have been reported to influence LCOTHER - LCOTHER synthesis , are associated with the outcome of LCOTHER LCOTHER .	0
Serum concentrations of LCOTHER , LCOTHER and LCOTHER - LCOTHER as markers of LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER and LCOTHER , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	0
Mechanistic studies revealed that LCOTHER LCOTHER are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER , ( 3 ) decreased plasma LCOTHER levels , ( 4 ) decreased cardiac LCOTHER - LCOTHER oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCOTHER ) , ( 5 ) decreased mitochondrial LCOTHER - LCOTHER LCOTHER LCOTHER , and ( 6 ) 86% drop in cardiac LCOTHER levels accompanied by decreased LCChemicalEntity / LCChemicalEntity ratio after LCOTHER administration .	0
Moreover , we confirm previous results that a short LCSequenceVariant LCSequenceVariant in conjunction with GG genotype significantly increases the risk of LCOTHER LCOTHER . A homozygous mutation in LCOTHER / LCOTHER associated with early onset LCOTHER , LCOTHER LCOTHER , and severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature activity .	0
Administration of parenteral LCOTHER must be done carefully and with good observation because of its pro - LCOTHER effect , especially in older patients who have LCOTHER LCOTHER or patients with LCOTHER LCOTHER ( LCOTHER ) which frequently occurs due to LCDiseaseOrPhenotypicFeature and or LCDiseaseOrPhenotypicFeature in LCOTHER cases . Low frequency of LCOTHER - associated LCOTHER variants in Kenya and Sudan and novel LCOTHER variants .	0
Here , we tested the hypothesis that LCOTHER rises to prevent LCDiseaseOrPhenotypicFeature in the absence of LCGeneOrGeneProduct function .	0
RESULTS : HAT adipose tissue demonstrated increased LCOTHER related genes for storage ( LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCGeneOrGeneProduct , LCOTHER ) .	0
Low activity of LCOrganismTaxon plasma LCOTHER with LCOTHER ( LCOTHER ) and LCChemicalEntity , and values of LCOTHER and LCOTHER numbers fit with heterozygous atypical silent genotype .	0
Urinary LCOTHER , LCOTHER and LCOTHER were elevated in LCOTHER - fed WT but not in LCOTHER - fed LCGeneOrGeneProduct KO LCOrganismTaxon .	0
Sequencing analysis detected 17 different LCOTHER gene mutations , and 7 of these were identified as novel : 3 missense mutations , including LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 3 , LCOTHER . LCOTHER > LCOTHER ( LCSequenceVariant . LCSequenceVariant ) in exon 3 and LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 7 ; 2 deletion mutations , including LCOTHER . LCOTHER ( LCSequenceVariant . LCSequenceVariant ) in exon 5 and LCOTHER . LCOTHER ( LCOTHER . LCOTHER ) in exon 11 ; and 2 alternative splicing mutations , including LCOTHER . LCOTHER + LCOTHER in intron 4 at splicing donor sites and LCOTHER . LCOTHER - LCOTHER > LCOTHER in intron 13 at splicing acceptor sites .	0
OBJECTIVE : The goal of this study was to determine whether mutations of meiotic genes , such as disrupted meiotic cDNA ( LCGeneOrGeneProduct ) , LCOTHER homolog ( LCOTHER ) , LCGeneOrGeneProduct , and LCOTHER .	0
CONCLUSIONS LCOTHER - LCOTHER - LCOTHER / LCOTHER SNP , hs - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , and LCOTHER - LCOTHER / LCOTHER - LCOTHER were associated with LCOTHER in LCOTHER from Inner Mongolia , as was serious LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER . LCOTHER prevents LCOTHER LCOTHER accumulation in macrophages induced by the LCOTHER LCOTHER inhibitor LCChemicalEntity .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCGeneOrGeneProduct and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCGeneOrGeneProduct and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
A 74 - year - old LCOTHER with LCOTHER LCOTHER was admitted to a LCOTHER hospital due to LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER LCOTHER , exhaustion , and LCDiseaseOrPhenotypicFeature .	0
Thus , it may extend the current findings on the interaction between LCOTHER and LCOTHER . Behavioral effects of pubertal LCChemicalEntity LCChemicalEntity LCChemicalEntity exposure in male LCOrganismTaxon with low LCOTHER .	0
METHODS : LCOTHER , primary LCOTHER small airway epithelial ( LCCellLine ) cells and wild - type , LCOTHER - LCOTHER - LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) and LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) knockout ( KO ) LCOTHER were infected with LCOTHER and cytokine responses were investigated by ELISA , multiplex analysis and qPCR .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCSequenceVariant variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCGeneOrGeneProduct / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER ) .	0
On admission , laboratory examination showed LCOrganismTaxon LCOrganismTaxon ( + + + + ) , total LCOTHER 8 . 25 mg / dL , conjugated LCOTHER 4 . 36 mg / dL , unconjugated LCOTHER 3 . 89 mg / dL , LCOTHER 3 . 52 meq / L Patient was diagnosed as LCOTHER LCOTHER with LCDiseaseOrPhenotypicFeature and got LCOTHER infusion in LCOTHER 5% 500 mg / 8 hour .	0
METHOD : Using five tagging SNPs ( LCOTHER , LCSequenceVariant , LCSequenceVariant , LCOTHER and LCOTHER ) , we conducted a genetic association analysis of case - control samples ( 197 LCOTHER - induced LCOTHER LCOTHER and 337 controls ) in the Japanese population .	0
We analyzed for LCOTHER and LCOTHER mutations and LINE - 1 methylation by Pyrosequencing , microsatellite instability ( MSI ) , and DNA methylation ( epigenetic changes ) in eight CpG island methylator phenotype ( CIMP ) - specific promoters [ LCOTHER , LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct , and LCOTHER ] by MethyLight ( real - time PCR ) .	0
* 469 C > A , SNP LCSequenceVariant ) was also detected in 2 of the 34 LCOrganismTaxon .	0
The sG145R mutation strongly reduced LCOTHER levels and was able to fully restore the impaired replication of LCChemicalEntity - resistant LCOTHER mutants to the levels of wild - type LCOTHER , and LCGeneOrGeneProduct or BCP mutations further enhanced viral replication .	0
As such , the proposed implications of LCGeneOrGeneProduct in invasion , disease progression and as a potential therapeutic target warrant further investigation . Influence of LCOTHER LCOTHER ( LCOTHER ) polymorphisms on spontaneous and treatment - induced recovery from LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCOTHER ( 874 LCOTHER ' LCOTHER LCOTHER , 259 LCOTHER LCOTHER , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCOTHER , LCGeneOrGeneProduct / LCOTHER / LCOTHER , LCOTHER / LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct .	0
Hence , while alterations in select LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct are not associated with development of LCOTHER - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCGeneOrGeneProduct and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	0
PURPOSE : Mutations in the LCOTHER and LCGeneOrGeneProduct genes have been reported in LCOrganismTaxon with LCOTHER and / or LCOTHER .	0
CONCLUSIONS : These results , together with other studies on this gene and the CCTTT - microsatellite , establish , for the first time , a genetic association of LCOTHER with LCDiseaseOrPhenotypicFeature and suggest a regulatory function for the microsatellite . Severe form of LCOTHER LCOTHER LCOTHER in a LCOTHER with homozygous / hemizygous mutation of LCGeneOrGeneProduct LCGeneOrGeneProduct gene .	0
In contrast , the mutations detected here in LCOTHER with LCDiseaseOrPhenotypicFeature and associated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature are exclusively missense mutations .	0
Numerous aspects of LCOrganismTaxon LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature pathogenesis are recapitulated in the LEW . 1WR1 LCOTHER model .	0
The current data showed that LCOTHER significantly delayed onset of LCOTHER , decreased the time course of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , reduced LCDiseaseOrPhenotypicFeature score , and increased the survival time of LCOTHER LCOTHER and LCOTHER LCOTHER .	0
LCGeneOrGeneProduct - stimulated hRMVEC proliferation was measured following transfection with LCGeneOrGeneProduct siRNA or LCOTHER siRNA , or respective controls .	0
Thus , targeting LCOTHER may provide novel therapeutic options in LCOTHER LCOTHER . Common LCGeneOrGeneProduct variants and modification of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature risk in LCOTHER mutation carriers .	0
In LCOrganismTaxon 2 , sequence analysis revealed a compound heterozygosis for the already reported LCOTHER ( LCOTHER ) mutation and for a second novel mutation in exon 3 , substituting LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant , resulting in a LCOTHER change .	0
These findings suggested that LCGeneOrGeneProduct - LCGeneOrGeneProduct possesses LCOTHER - suppressing activity and can be a valuable target for developing new LCOTHER therapeutic strategies . Chronic treatment with LCChemicalEntity suppresses LCOTHER - LCOTHER LCOTHER LCOTHER signaling and attenuates LCOTHER LCOTHER LCOTHER following LCOTHER LCOTHER .	0
The LCOTHER mutation LCSequenceVariant on one allele was found in 3 of 270 LCOTHER with LCOTHER and 2 of 212 children and adolescents with LCOTHER ; no carrier was found among 63 LCOrganismTaxon with LCOTHER LCOTHER ( LCOTHER ) .	0
RESULTS : The results indicate that LCOTHER - and LCOTHER - treated LCOrganismTaxon showed LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature in comparison to control LCOTHER in all the parameters studied .	0
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCGeneOrGeneProduct / LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) messenger RNA ( mRNA ) splicing .	0
This study investigated the possible association between three functional polymorphisms in the promoter region of the LCOTHER LCOTHER LCOTHER ( LCOTHER ) gene and LCDiseaseOrPhenotypicFeature , LCOTHER , and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
The LCChemicalEntity peroxidation indicators including antisuperoxideanion ( ASAFR ) , LCOTHER LCOTHER LCOTHER ( . LCOTHER ) , LCOTHER LCOTHER ( LCOTHER ) , LCOTHER and LCOTHER LCOTHER - LCOTHER ( LCOTHER ) were determined with kits , and LCOTHER LCOTHER - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCGeneOrGeneProduct ) activities in liver were analyzed with gelatin zymography and in situ fluorescent zymography respectively .	0
There was no LCOTHER or LCOTHER effect on the protein content for LCOTHER - LCOTHER , LCOTHER - LCOTHER LCOTHER - LCOTHER , LCGeneOrGeneProduct , LCOTHER or LCGeneOrGeneProduct in muscle .	0
Therefore , our results indicate that LCDiseaseOrPhenotypicFeature B cells have already acquired enhanced survival and growth capabilities before transformation , and that elevated LCGeneOrGeneProduct levels confer resistance to pharmacologic inhibitors of LCOTHER signaling , which has significant implications for LCOTHER - LCOTHER treatment . Genetic investigation of four meiotic genes in LCOTHER with LCOTHER LCOTHER LCOTHER .	0
Consistent with this premise , LCOTHER LCDiseaseOrPhenotypicFeature cells with relatively high levels of LCOTHER are more sensitive to LCOTHER - LCOTHER treatment compared to LCOTHER - depleted LCOTHER cells , further indicating that LCGeneOrGeneProduct loss has a crucial role in LCOTHER - LCOTHER resistance in LCOTHER LCOTHER .	0
A LCGeneOrGeneProduct ligand attenuates LCOTHER LCOTHER after LCOTHER LCOTHER . Mechanisms of LCDiseaseOrPhenotypicFeature induced by LCOTHER LCOTHER ( LCOTHER ) deficiency : focus on venous function .	0
BACKGROUND : A LCOTHER LCOTHER LCOTHER LCOTHER ( LCOrganismTaxon - LCOrganismTaxon Tonga / 74 ) isolated from a 1974 epidemic was characterized by mild illness and belongs to the American genotype of LCOrganismTaxon - LCOrganismTaxon viruses .	0
Therefore , we screened 47 Hungarian LCOTHER - heterozygous ( one mutation in coding exon of the LCOTHER gene ) LCOrganismTaxon with LCOTHER LCOTHER for DNA changes in two further connexin genes ( LCOTHER and LCOTHER ) and in the 5 ' non - coding region of LCGeneOrGeneProduct including the splice sites .	0
Thus , LCOTHER appears to play a critical oncogenic function in LCDiseaseOrPhenotypicFeature microenvironment and may be a potential target for developing therapeutic and preventive strategies against LCOTHER . Effects of the LCOTHER - LCOTHER specific inhibitor LCOTHER versus LCOTHER LCOTHER LCOTHER and placebo on cardiovascular LCOTHER events in LCOTHER with LCDiseaseOrPhenotypicFeature .	0
LCOTHER ( LCOTHER ) LCOrganismTaxon displayed severe LCDiseaseOrPhenotypicFeature with runting , impaired formation of secondary centres of ossification , and LCOTHER LCOTHER including LCOTHER LCOTHER and LCOTHER LCOTHER .	0
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	0
Here , we report a case of prolonged LCOTHER LCOTHER after administration of LCOTHER leading to the discovery of a novel LCOTHER variant ( LCSequenceVariant . LCSequenceVariant > LCSequenceVariant , LCSequenceVariant . LCSequenceVariant ) .	0
Three LCOTHER - LCOTHER LCOTHER with LCGeneOrGeneProduct mutations demonstrated a durable response and one small LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER with LCGeneOrGeneProduct LCOTHER mutation showed progression after LCOTHER treatment .	0
Similar to B cells with targeted LCOTHER deletion , LCCellLine - LCCellLine LCOrganismTaxon show expanded marginal zone B cell population and have constitutive LCOTHER LCOTHER - LCOTHER processing .	0
LCOTHER also decreased LCOTHER LCOTHER growth in athymic nude LCOTHER bearing LCCellLine cells as xenografts and this was accompanied by decreased LCGeneOrGeneProduct , LCOTHER , and LCOTHER protein levels in LCOTHER .	0
Notably , administration of a LCGeneOrGeneProduct LCGeneOrGeneProduct antagonist further reduced LCOTHER LCOTHER levels into the markedly hypoglycemic range in overnight - fasted , LCOTHER - treated LCOTHER ( - / - ) LCOrganismTaxon .	0
We found that the common allele is preferentially expressed in normal lymphocytes , normal breast , and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature compared with the rare allele , but there were no differences in total levels of LCGeneOrGeneProduct mRNA across genotypes .	0
Instead , a selective increase in phosphorylation of LCOTHER and its downstream substrates , LCOTHER and LCGeneOrGeneProduct was detected in LCOTHER - fed LCOrganismTaxon .	0
Pretreatment of LCOTHER , at a dose of 0 . 5 mL / 100 g bodyweight per day , orally for 30 days , prevented the increase in LCOTHER peroxidation and activity of marker enzymes observed in LCChemicalEntity - induced LCOrganismTaxon ( 85 mg kg ( - 1 ) s .	0
The present results demonstrate that LCChemicalEntity - LCChemicalEntity attenuates the effect of LCOTHER on hippocampal LTP through LCOTHER LCOTHER and suggest an ameliorative function of LCOTHER - LCOTHER on LCOTHER - induced LCOTHER LCOTHER . Distinct patterns of germ - line deletions in LCOTHER and LCOTHER : the implication of Alu repetitive element in the genetic etiology of LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	0
One - hundred and fifty LCOTHER ( 90 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature [ LCOTHER ] and 60 LCOTHER LCOTHER LCOTHER [ LCOTHER ] ) LCOTHER and 165 age - and sex - matched normal healthy controls without known LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER were included in the study .	0
A 74 - year - old LCOTHER with LCOTHER LCOTHER was admitted to a LCOTHER hospital due to LCDiseaseOrPhenotypicFeature , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , exhaustion , and LCOTHER .	0
RESULTS : LCOrganismTaxon with LCDiseaseOrPhenotypicFeature had higher serum LCOTHER and LCOTHER ( P < 0 . 001 for LCOTHER , LCOTHER , LCOTHER and LCOTHER ) and lower LCOTHER ( P = 0 . 008 ) levels than LCOTHER LCOTHER without LCOTHER .	0
Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental LCOTHER . Exaggerated expression of LCOTHER mediators in LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct knockout ( LCOTHER - / - ) LCOTHER with LCOTHER ( LCChemicalEntity ) - induced LCOTHER .	0
LCOTHER - deficient LCGeneOrGeneProduct / LCGeneOrGeneProduct - treated females differed from males in a more pronounced decline of arginine - metabolizing and - transporting genes , higher plasma arginine levels , a smaller LCOTHER - specific LCOTHER response , and no improvement of peripheral lung function .	0
Thus , LCChemicalEntity reduced LCOTHER burden through associated cytostatic and anti - angiogenic effects . This dual effect of LCOTHER on LCOTHER tissue could contribute to its recently reported efficiency in refractory LCDiseaseOrPhenotypicFeature resistant to conventional chemotherapy . Rapid reversal of anticoagulation reduces LCOTHER volume in a LCOTHER model of LCOTHER - associated LCOTHER LCOTHER .	0
RESULTS : HAT adipose tissue demonstrated increased LCOTHER related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCGeneOrGeneProduct , LCOTHER , LCOTHER ) .	0
We report a case of LCOTHER LCOTHER ( LCOTHER ) in a dizygotic twin who presented at 12 years of age with LCOTHER LCOTHER , LCOTHER LCOTHER , LCOTHER and LCOTHER with inappropriate kaliuresis , and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature with LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	0
Thus , LCOTHER reduced LCOTHER burden through associated cytostatic and anti - angiogenic effects . This dual effect of LCOTHER on LCDiseaseOrPhenotypicFeature tissue could contribute to its recently reported efficiency in refractory LCOTHER resistant to conventional chemotherapy . Rapid reversal of anticoagulation reduces LCOTHER volume in a LCOTHER model of LCOTHER - associated LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
The goal of this study was to perform LCOTHER - LCOTHER - LCOTHER LCOTHER LCOTHER gene ( LCGeneOrGeneProduct ) analysis in a LCOTHER LCOTHER ( LCOTHER ) LCOTHER with normal LCChemicalEntity ( LCOTHER ) production and normal LCOTHER LCOTHER ( LCOTHER ) gene coding sequences .	0
To the best of our knowledge , this is the first study to report that the combination of LCOTHER - LCOTHER and LCOTHER induces LCOrganismTaxon LCOTHER LCOTHER cell apoptosis in a concerted manner with the induction of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene expression . LCOTHER is required for cambium homeostasis in LCOTHER .	0
Thus the present study indicates that individuals with the variant w1 / m1 genotype exhibit an increased risk while those with w2 / m2 genotype exhibit a decreased risk for LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature . Four novel mutations in the LCOTHER - sensitive LCOTHER - LCOTHER LCOTHER - LCOTHER gene in Japanese LCOTHER with LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Patients taking LCOTHER and LCChemicalEntity must be examined for LCOTHER LCOTHER and its consequences . LCChemicalEntity phenotype and the pharmacokinetics and LCOTHER - LCOTHER LCOTHER pharmacodynamics of LCOTHER and its enantiomers .	0
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCOTHER ( 874 LCOTHER ' LCOTHER LCOTHER , 259 LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCOTHER , LCOTHER / LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER and LCOTHER .	0
AIM : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) is most commonly affected by typical LCOTHER LCOTHER that have a high affinity with the LCOTHER LCOTHER .	0
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER LCOTHER LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER LCOTHER - LCOTHER LCOTHER - LCOTHER ( LCOTHER ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	0
LCOTHER , an agonist of LCOTHER , enhances the sensitivity of parental LCDiseaseOrPhenotypicFeature cells , but not LCOTHER - depleted cells , to LCOTHER - LCOTHER treatment , indicating that LCOTHER is required for the synergistic action of LCOTHER - LCOTHER and LCOTHER , and that LCOTHER loss promotes LCDiseaseOrPhenotypicFeature cell survival likely through downregulation of the LCOTHER - mediated apoptotic pathway .	0
In contrast , the mutations detected here in LCOrganismTaxon with LCDiseaseOrPhenotypicFeature and associated LCOTHER LCOTHER are exclusively missense mutations .	0
In recent years working LCOTHER LCOTHER have been reported in users of LCChemicalEntity ( LCOTHER , LCOTHER - LCOTHER , LCChemicalEntity ) .	0
We originally described a LCSequenceVariant - - > LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant ( LCOTHER ) of exon 8 , in the ubiquitin protein - binding domain of LCOTHER / LCOTHER gene in an Italian LCOTHER LCOrganismTaxon .	0
PARTICIPANTS : Two hundred thirty - five LCOrganismTaxon aged 76 and older admitted to a major healthcare network between July 1 , 2001 , and June 30 , 2002 , with LCOTHER LCOTHER on LCChemicalEntity were enrolled .	0
We investigated also the expression of angiocrine genes upon LCOTHER treatment in vivo , and demonstrate that LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct and LCOTHER - LCOTHER are upregulated , while LCOTHER and LCOTHER are reduced .	0
This data suggests that LCOTHER modifies the expression of LCOTHER at the level of protein expression in monocyte - derived macrophages resulting in reduced LCChemicalEntity LCChemicalEntity accumulation following LCOTHER treatment . Single - strand conformation polymorphism analysis of the LCOTHER gene in LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER children in Japan .	0
Taking these in vitro and in vivo results together , our study suggests that LCChemicalEntity LCChemicalEntity - LCChemicalEntity is a potentially effective candidate against LCOTHER ' LCOTHER LCOTHER that is characterized by wide spread LCOTHER LCOTHER and progressive LCOTHER LCOTHER LCOTHER LCOTHER . Anticipation in familial LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER with LCOTHER mutation in the LCGeneOrGeneProduct ( LCOTHER ) gene .	0
The results in this study significantly improve our understanding of the durability of LCGeneOrGeneProduct - LCGeneOrGeneProduct - producing LCOTHER ( + ) T cells postinfection and provide information on how LCOTHER - LCOTHER may contribute to optimized parasite control and prevention of immune - mediated pathology during repeated LCOTHER LCOTHER . LCOTHER as a LCOTHER LCOTHER : the role of critical LCChemicalEntity groups in LCOTHER LCOTHER .	0
RESULTS : Three pathogenic mutations were identified ; two mutations , LCOTHER and LCSequenceVariant , were novel and found in three LCOrganismTaxon .	0
BACKGROUND : LCGeneOrGeneProduct LCGeneOrGeneProduct ( HGNC approved gene symbol - LCGeneOrGeneProduct ) , also known as LCOTHER , is an enzyme of the LCOTHER LCOTHER ( LCOTHER ) cycle , involved in fundamental cellular energy production .	0
Here , we show that a single LCOTHER ( LCOTHER ) LCOTHER LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOTHER LCOTHER in the refp17 backbone ( LCOTHER ) , as in the LCOTHER variant , is per se sufficient to confer a B - cell clonogenic potential to the viral protein and modulate , through activation of the LCOTHER / LCOTHER / LCOTHER signaling pathway , different molecules involved in apoptosis inhibition ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct ) , cell cycle promotion and LCOTHER progression ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER - LCOTHER LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER ) .	0
Our data show that ablation of LCOTHER preserves LCOTHER and LCOTHER - LCOTHER protein expression and localization in LCChemicalEntity - induced LCOTHER , and prevents the development of the severe LCOTHER associated with LCOTHER therapy . LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - mediated activation of LCOTHER LCOTHER LCOTHER inhibits the growth of LCOTHER in vitro and in vivo .	0
A LCOTHER - LCOTHER inhibitor , LCOTHER , selectively depleted LCOTHER ( + ) cells , suppressed LCGeneOrGeneProduct and LCGeneOrGeneProduct , induced LCOTHER , inhibited LCOTHER growthin vivo , and sensitized LCOTHER ( + ) cells to radiation .	0
Chronic administration of LCOTHER strongly reduced the blood pressure and production of LCChemicalEntity and improved antioxidant capacity in LCChemicalEntity - induced LCOTHER , suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LCOTHER . Role of LCOTHER LCOTHER LCOTHER LCOTHER in LCOTHER and migration of fibroblast - like synoviocytes in LCOTHER LCOTHER .	0
A comparison of genotypes , LCOTHER activities , and clinical data on 4 individuals carrying the allele of 81 LCOrganismTaxon with LCOTHER examined , further validates the concept that different degrees of residual LCOTHER activity are the basis of phenotypical variation in LCOTHER . Families with the risk allele of LCOTHER reveal a link between LCOTHER and another component of the same molecular pathway , LCGeneOrGeneProduct .	0
BACKGROUND : LCGeneOrGeneProduct LCGeneOrGeneProduct ( HGNC approved gene symbol - LCOTHER ) , also known as LCGeneOrGeneProduct , is an enzyme of the LCOTHER LCOTHER ( LCOTHER ) cycle , involved in fundamental cellular energy production .	0
LCOTHER was up - regulated in LCOTHER ( + ) cells from brains of LCOTHER with LCOTHER and in LCGeneOrGeneProduct ( + ) LCOTHER ( int ) cells from LCOTHER subjected to LCChemicalEntity - induced LCOTHER .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER .	0
PURPOSE : Mutations of the LCGeneOrGeneProduct gene , a novel family member of the LCOTHER LCOTHER genes on chromosome 4q35 , have recently been identified in LCOTHER with LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) .	0
We reviewed the genotype of LCOTHER cases from Japan , India , China and Taiwan , and found that LCOTHER is a major causative gene for LCDiseaseOrPhenotypicFeature in Asian . LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER induces epithelial - mesenchymal transition via LCOTHER / LCOTHER - LCOTHER signaling pathway in LCOrganismTaxon LCOTHER LCOTHER .	0
PURPOSE : Genes in the complement pathway , including LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct / LCGeneOrGeneProduct , and LCGeneOrGeneProduct , have been reported to be associated with LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
Crossing LCOTHER - Cre LCOTHER with LCOTHER flx / flx LCOTHER generated LCGeneOrGeneProduct flx / D : LCGeneOrGeneProduct Cre / + females that were overtly normal but infertile .	0
This LCOTHER presented with symptoms of LCOTHER LCOTHER LCOTHER ( LCOTHER ) , thus demonstrating that LCDiseaseOrPhenotypicFeature - like symptoms can occur after combined LCChemicalEntity and LCOTHER treatment .	0
Collectively , our findings present a new approach for identifying ciliary proteins , and unveil LCGeneOrGeneProduct , a LCOTHER most closely related to the LCOTHER protein LCOTHER / LCOTHER , as an IFT - associated cargo with LCOTHER - dependent cell autonomous and non - autonomous functions at the ciliary base . Compound heterozygous mutations in the LCOTHER gene exon 4 in a LCOTHER LCOTHER LCOrganismTaxon of Chinese origin .	0
A total of 10 novel variants was recognized , among them four variants in the adjacent 5 ' - region of the LCOTHER coding exon 2 ( LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER ) , a 6 base - pair deletion ( LCOTHER . LCOTHER [ LCOTHER . LCOTHER ] ) , a variant leading to a stop codon ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , synonymous variants ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCSequenceVariant . LCSequenceVariant ] , LCOTHER . LCOTHER > LCOTHER [ LCSequenceVariant . LCSequenceVariant ] ) , and one non - synonymous variant ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) .	0
LCOTHER signalling was markedly impaired in LCOTHER - deficient chondrocytes as evidenced by reduced expression of known LCOTHER target genes as well as reduced phosphorylation of LCGeneOrGeneProduct / LCGeneOrGeneProduct / LCGeneOrGeneProduct and LCOTHER / LCOTHER / LCOTHER LCGeneOrGeneProduct LCGeneOrGeneProduct .	0
Materials and METHODS : A cohort of 1163 unrelated LCOTHER with LCOTHER ( 874 LCOTHER ' LCOTHER LCOTHER , 259 LCOTHER LCOTHER , 30 indeterminate LCOTHER ) and 312 controls were analysed for anti - LCOTHER LCOTHER antibodies ( gASCA ) IgG , anti - laminaribioside antibodies ( ALCA ) IgG , anti - chitobioside antibodies ( ACCA ) IgA , anti - mannobioside antibodies ( AMCA ) IgG and outer membrane porin ( Omp ) IgA and were genotyped for variants in LCOTHER / LCOTHER , LCOTHER / LCOTHER / LCGeneOrGeneProduct , LCOTHER / LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCGeneOrGeneProduct .	0
Furthermore , we established a small amplicon genotyping ( SAG ) method for detecting three high frequency coding - region SNPs ( LCOTHER : LCOTHER > LCOTHER , LCOTHER : LCOTHER > LCOTHER , and LCSequenceVariant : LCSequenceVariant > LCSequenceVariant ) in LCOTHER to differentiate mutations before sequencing .	0
CONCLUSIONS : The LCOTHER and LCOrganismTaxon - LCSequenceVariant viruses can be considered for evaluation in LCOTHER and for inclusion in a tetravalent LCDiseaseOrPhenotypicFeature vaccine . The effects of short - term LCOTHER therapy on fibrinolysis markers : LCOTHER , LCOTHER , and LCOTHER - LCOTHER .	0
Here , we demonstrated that HG decreased the expression of LCGeneOrGeneProduct , mitochondrial fusion proteins ( LCOTHER , LCOTHER ) , cell gap junction related proteins ( LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct ) , and intracellular LCOTHER concentration .	0
IMPORTANCE OF THE FIELD : LCOTHER , in particular LCChemicalEntity - LCChemicalEntity ( LCChemicalEntity - LCChemicalEntity ) , have been the mainstay of treatment for several solid LCOTHER , including LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , for > 40 years .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCGeneOrGeneProduct [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCGeneOrGeneProduct ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCOTHER LCOTHER LCOTHER participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
The aims of this study were to examine LCOTHER ( LCChemicalEntity ) - induced oxidative stress that promotes production of LCOTHER LCOTHER LCOTHER ( LCOTHER ) and to investigate the role of LCOTHER , an expectorant agent , which has also LCOTHER properties , on kidney tissue against the possible LCOTHER - induced LCOTHER LCOTHER in LCOrganismTaxon .	0
RESULTS : Quantitative PCR indicated that LCOTHER is well expressed in LCOrganismTaxon liver and LCOTHER liver slices and that the classical LCGeneOrGeneProduct targets LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER are robustly induced by LCOTHER activation .	0
This retrospective study investigated the combination of LCOTHER ( 1 . 3 mg / m ( 2 ) on days 1 , 4 , 8 , and 11 every 3 weeks ) and LCChemicalEntity ( 20 mg on the day of and the day after LCOTHER ) as salvage treatment in 85 LCOrganismTaxon with R / R LCOTHER after prior autologous stem cell transplantation or conventional chemotherapy .	0
LCOTHER - LCOTHER may be administered safely to LCOTHER with LCOTHER - LCOTHER - induced LCDiseaseOrPhenotypicFeature . Hypoglycemic Effect of Combined LCGeneOrGeneProduct and LCOTHER LCOTHER Blockade .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCOTHER - related gene , including LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
LCOTHER - LCOTHER was an effective salvage treatment for LCOTHER LCOrganismTaxon , particularly for those in first relapse . LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct gene ( LCOTHER ) variants may increase LCOTHER LCOTHER and LCOTHER in LCOTHER LCOTHER LCOTHER .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCGeneOrGeneProduct and LCOTHER , LCOTHER , LCGeneOrGeneProduct , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
The LCDiseaseOrPhenotypicFeature / LCOTHER LCOTHER of LCChemicalEntity was similar to that of LCOTHER and seemed to be better than those of LCOTHER and NS - LCOTHER .	0
RESULTS : LCOTHER with LCOTHER had higher serum LCOTHER and LCGeneOrGeneProduct ( P < 0 . 001 for LCOTHER , LCGeneOrGeneProduct , LCOTHER and LCOTHER ) and lower LCOTHER ( P = 0 . 008 ) levels than LCOTHER LCOTHER without LCOTHER .	0
On the second day the patient had LCOTHER , LCDiseaseOrPhenotypicFeature , LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
One possibility might be that individuals who are compound heterozygotes for LCOTHER mutations are more common than we realize . Omitting LCChemicalEntity reduces LCOTHER and LCOTHER , without increasing LCOTHER , after LCChemicalEntity for day surgery .	0
STUDY DESIGN : Wild - type ( WT ) and LCOTHER LCOTHER LCOTHER ( LCOTHER ) - overexpressing day 8 . 75 embryos from nondiabetic WT control with LCOTHER transgenic male and LCOTHER WT female with LCOTHER transgenic male were analyzed for ER stress markers : LCOTHER / LCOTHER - LCOTHER LCOTHER ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER LCOTHER LCOTHER ( LCOTHER ) , LCOTHER LCOTHER LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct - LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) , and the LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) messenger RNA ( mRNA ) splicing .	0
These data suggest that when LCOTHER activity is blocked in the setting of LCOTHER LCOTHER LCOTHER , the plasma LCGeneOrGeneProduct level rises , preventing LCOTHER . LCOTHER - LCOTHER , a LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) LCGeneOrGeneProduct , functions as a LCOTHER suppressor in an orthotopic LCOTHER LCOTHER LCOTHER model .	0
LCOrganismTaxon cDNA analysis revealed that the entire exon 5 of the LCGeneOrGeneProduct gene was lacking ; this new mutation was identified as LCOTHER . LCOTHER - LCOTHER .	0
No significant effect of the LCOTHER LCOTHER on disease severity was demonstrated . LCOTHER causes LCOTHER LCOTHER LCOTHER LCOTHER in LCOrganismTaxon : involvement of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct and oxidative stress , and prevention by LCOTHER .	0
OBJECTIVE : To assess and characterise the risk of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and its relation to LCOTHER , in LCOrganismTaxon with LCOTHER ' LCOTHER LCOTHER .	0
Similarly , LCOTHER ' LCOTHER LCOTHER LCOrganismTaxon carrying LCOTHER / LCOTHER indel had a higher prevalence of gASCA antibodies than wild - type LCOrganismTaxon ( 63 . 8% versus 55 . 2% , p = 0 . 014 ) , also with a gene dosage effect .	0
We used wild - type ( WT ) and LCOTHER knockout ( LCOTHER - KO ) LCOTHER hippocampal cultures , modeled in vitro following exposure to LCOTHER LCChemicalEntity deprivation ( OGD ) , and in vivo neonatal ( P9 - 10 ) LCOrganismTaxon model of LCOTHER LCOTHER LCOTHER .	0
On the whole , our findings indicate that the absence of LCGeneOrGeneProduct plays a cardioprotective role in LCOTHER LCOTHER LCOTHER by promoting changes in LCOTHER / LCOTHER signalling . Long - Lived LCOTHER + LCOTHER - LCOTHER + T Cells rather than Short - Lived LCOTHER + LCOTHER - LCOTHER + LCOTHER - LCOTHER + T Cells Initiate Rapid LCOTHER - LCOTHER Production To Suppress Anamnestic T Cell Responses during Secondary LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
LCGeneOrGeneProduct - activation of LCOTHER showed several novel features being dependent on both receptor - activation states , having LCOTHER - and LCOTHER - dependent / independent components and LCGeneOrGeneProduct - LCGeneOrGeneProduct - dependent / independent components .	0
The ability of LCOTHER to block LCOTHER - LCOTHER LCOTHER ( LCOTHER + ) LCOTHER , also expressed by enteric neurons , might represent a possible mechanism through which LCOTHER exerts its actions . Lack of association of LCOTHER - LCOTHER LCOTHER LCOTHER LCOTHER LCSequenceVariant LCSequenceVariant status with LCOTHER LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , LCOTHER LCOTHER , and disease severity .	0
A derivative of LCOTHER , designated LCOTHER - LCOTHER , was generated by incorporation of a point mutation previously identified in the LCOTHER gene of LCOrganismTaxon - LCOrganismTaxon and was found to be more attenuated than LCOTHER in LCCellLine - LCCellLine - LCCellLine LCOTHER .	0
In addition , the previously described variants LCOTHER . LCOTHER ( commonly designated LCOTHER or LCOTHER LCOTHER ) , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant [ LCSequenceVariant . LCSequenceVariant ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , and LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] were identified .	0
Many genes induced by LCOTHER activation were involved in LCOTHER metabolism ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER ) , xenobiotic metabolism ( LCOTHER , LCOTHER , LCGeneOrGeneProduct ) or the unfolded protein response , whereas most of the downregulated genes were involved in immune - related pathways .	0
LCOTHER was not implicated with LCOTHER / LCOTHER in our LCOTHER cohort . Combination of the LCOTHER LCOTHER inhibitor LCOTHER and LCOTHER - LCOTHER upregulates LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER and LCOTHER genes and activates LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCGeneOrGeneProduct in LCOTHER LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER - LCOTHER cells .	0
A total of 10 novel variants was recognized , among them four variants in the adjacent 5 ' - region of the LCOTHER coding exon 2 ( LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER , LCOTHER . LCOTHER - LCOTHER > LCOTHER ) , a 6 base - pair deletion ( LCOTHER . LCOTHER [ LCOTHER . LCOTHER ] ) , a variant leading to a stop codon ( LCOTHER . LCOTHER > LCOTHER [ LCSequenceVariant . LCSequenceVariant ] ) , synonymous variants ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] , LCSequenceVariant . LCSequenceVariant > LCSequenceVariant [ LCOTHER . LCOTHER ] , LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) , and one non - synonymous variant ( LCOTHER . LCOTHER > LCOTHER [ LCOTHER . LCOTHER ] ) .	0
This study supports the hypothesis that LCDiseaseOrPhenotypicFeature is involved in LCOTHER LCOTHER and that sequence variation within the LCOTHER - LCOTHER gene influence the risk of LCOTHER LCOTHER . Glutamatergic neurotransmission mediated by LCOTHER LCOTHER in the inferior colliculus can modulate LCOTHER - induced LCDiseaseOrPhenotypicFeature .	0
Analyses of markers associated with the LCGeneOrGeneProduct pathway were carried out on archival LCDiseaseOrPhenotypicFeature from a subgroup using immunohistochemistry ( IHC ) and direct mutation sequencing .	0
LCChemicalEntity - induced LCOTHER was challenged with prior intracollicular microinjections of LCOTHER LCOTHER LCOTHER antagonists , LCChemicalEntity - LCChemicalEntity ( 15 or 30 mmol / 0 . 5 microl ) and LCOTHER ( 10 or 20 nmol / 0 . 5 microl ) , or of the LCOTHER LCOTHER agonist LCOTHER - LCOTHER - LCOTHER - LCOTHER ( LCOTHER , 20 or 30 nmol / 0 . 5 microl ) .	0
Serum concentrations of LCOTHER , LCOTHER and LCOTHER - LCOTHER as markers of LCOTHER and LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct , LCOTHER LCOTHER and LCGeneOrGeneProduct , LCOTHER , LCOTHER - LCOTHER ( M65 ) and LCOTHER fragment ( M30 ) and a panel of LCOTHER LCOTHER ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER - LCOTHER ) were measured .	0
Gene expression analysis revealed that LCSequenceVariant exerted the greatest influence on LCGeneOrGeneProduct transcript levels .	0
This may be a gene - environment interaction . LCOTHER ( LCChemicalEntity - LCChemicalEntity ) reverses LCOTHER - induced LCDiseaseOrPhenotypicFeature of a passive avoidance response : delayed emergence of the memory retention effects .	0
The high penetrance of the LCOTHER trait in this family together with the study of the asymptomatic gene carriers will allow us to confirm the proposed genotype - phenotype correlation and to evaluate the potential use of mutational analysis of the LCOTHER / LCGeneOrGeneProduct gene in the early detection of relatives at risk for LCOTHER . LCOTHER LCOTHER LCOTHER LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and LCOTHER associated with mutations in exon 49 of LCOTHER .	0
Further study is required to validate this finding . Disruption of a LCGeneOrGeneProduct ( LCOTHER ) associated with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Thus , our results support the notion that LCGeneOrGeneProduct - LCGeneOrGeneProduct and LCOTHER - LCOTHER / LCOTHER - LCOTHER mutually regulate Th17 and Th1 responses in LCOTHER - bearing hosts , and LCOTHER LCOTHER modulates the balance of the LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER - LCOTHER axis towards LCOTHER - LCOTHER production , which leads to LCDiseaseOrPhenotypicFeature inhibition .	0
Although uncommon , point mutations in the LCOTHER gene may be a cause of LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER in Japanese LCOrganismTaxon . Homozygously deleted gene LCOTHER regulates LCOTHER - initiating activity of LCOTHER cells .	0
Three LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature - LCOTHER , LCOTHER , and LCOTHER - accounted for 51% , 20% , and 11% of the identified mutations , respectively . Allelic expression imbalance of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) caused by variant LCSequenceVariant .	0
In vivo induction of airway LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ( LCOTHER ) , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct / LCOTHER , LCOTHER - LCOTHER , LCOTHER / LCOTHER and LCOTHER were dependent on LCOTHER expression in LCOTHER .	0
We report a case of a 76 - year - old LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature who suffered LCOTHER LCOTHER without LCDiseaseOrPhenotypicFeature after the combination treatment with LCOTHER , high - dose LCOTHER and LCOTHER .	0
We observed slightly reduced levels of LCOTHER protein and reduced levels of its opposing enzyme LCOTHER - LCOTHER in both LCOrganismTaxon - derived fibroblasts , but global LCGeneOrGeneProduct - LCGeneOrGeneProduct levels appeared to be unaffected .	0
We investigated whether the LCOTHER LCOTHER is associated with disease susceptibility in a population of LCOTHER with LCOTHER LCOTHER ( LCOTHER ) , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) , and LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) ; and whether it is associated with disease severity .	0
The LCOTHER - 93 variant allele was also over - represented in t - LCDiseaseOrPhenotypicFeature cases when compared to de novo LCOTHER cases ( 36 . 9% , n = 420 ) and healthy controls ( 36 . 3% , n = 952 ) , and was associated with a significantly increased risk of developing t - LCDiseaseOrPhenotypicFeature ( odds ratio 5 . 31 , 95% confidence interval 1 . 40 to 20 . 15 ) , but only in LCOTHER previously treated with a methylating agent .	0
The LCGeneOrGeneProduct contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site and the LCOTHER subunit contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site which make them strong candidates for future mutation detection studies in LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER . The LCOTHER mutation database : an online database of LCOTHER LCOTHER mutations involved in the LCOTHER ( LCOTHER ) LCOTHER LCOTHER and congenital LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
Previously , we showed that following LCChemicalEntity ( LCChemicalEntity ) treatment LCOTHER LCOTHER LCOTHER - LCOTHER cells undergo a LCOTHER - dependent upregulation of LCOTHER and LCOTHER ( governing self - renewal and regulating cell cycle inhibition and senescence , respectively ) .	0
A comparison of genotypes , LCOTHER activities , and clinical data on 4 individuals carrying the allele of 81 LCOrganismTaxon with LCOTHER examined , further validates the concept that different degrees of residual LCOTHER activity are the basis of phenotypical variation in LCOTHER . Families with the risk allele of LCOTHER reveal a link between LCDiseaseOrPhenotypicFeature and another component of the same molecular pathway , LCOTHER .	0
LCOTHER mediated barrier - protective effects of LCOTHER by activating LCOTHER / LCOTHER LCOTHER and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct targets at cell adhesions and cytoskeleton : LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCOTHER , and LCGeneOrGeneProduct .	0
LCOTHER LCOTHER ( LCOTHER ) is a common LCDiseaseOrPhenotypicFeature where LCDiseaseOrPhenotypicFeature is directly linked to LCOTHER survival .	0
Our data show that in pre - malignant B cells , LCGeneOrGeneProduct overexpression is sufficient to activate LCOTHER and LCOTHER / LCGeneOrGeneProduct signaling pathways and further enhances signaling following LCOTHER ligation .	0
CONCLUSION : The results indicate a dose - response relationship between LCOTHER and the risk of LCOTHER LCOTHER , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before LCOTHER ' LCOTHER LCOTHER . Mutation analysis of LCOTHER in LCOrganismTaxon with LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) in combination with LCOTHER LCOTHER .	0
We conducted a screening of the LCOTHER region for 1 , 536 single nucleotide polymorphisms ( SNPs ) and the deletion of the LCGeneOrGeneProduct gene in a LCOTHER case - control study ( 380 cases , 765 age - matched controls ) nested within the prospective Black LCOrganismTaxon ' s Health Study .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCGeneOrGeneProduct and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCGeneOrGeneProduct - specific LCOTHER .	0
Our data show that ablation of LCOTHER preserves LCOTHER and LCOTHER - LCOTHER protein expression and localization in LCOTHER - induced LCOTHER , and prevents the development of the severe LCOTHER associated with LCOTHER therapy . LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct - mediated activation of LCOTHER LCOTHER LCOTHER inhibits the growth of LCDiseaseOrPhenotypicFeature in vitro and in vivo .	0
Moreover , in studies of 238 middle - aged LCChemicalEntity tolerant subjects , of 226 LCChemicalEntity tolerant offspring of LCOTHER LCOTHER LCOTHER LCOTHER and of 367 young healthy subjects , the carriers of the polymorphism did not differ from non - carriers in LCOTHER induced serum LCOTHER or LCOTHER - LCOTHER responses .	0
A new LCOTHER homolog cDNA , LCGeneOrGeneProduct , was discovered by a hypermethylated DNA fragment probe that was isolated from a LCOrganismTaxon multidrug resistant ( MDR ) LCOTHER LCOTHER cell line , LCOTHER / LCOTHER , by the methylation sensitive - representational difference analysis ( MS - RDA ) technique .	0
The LCOrganismTaxon had a LCOTHER ( 38 . 2 degrees C ) , fluctuating blood pressure ( between 165 / 90 and 130 / 70 mg mm Hg ) , and severe LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
The LCOTHER contains a highly conserved LCOTHER LCOTHER LCOTHER phosphorylation site and the LCOTHER subunit contains a highly conserved LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct phosphorylation site which make them strong candidates for future mutation detection studies in LCOTHER LCOTHER LCOTHER - LCOTHER LCOTHER . The LCOTHER mutation database : an online database of LCOTHER LCOTHER mutations involved in the LCOTHER ( LCOTHER ) LCOTHER LCOTHER and congenital LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) was widely used for a variety of diseases including LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , the current study aims to investigate the protective effects of LCOTHER on liver sinusoidal endothelial cells ( LSECs ) in acute LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and related action mechanisms .	0
Nine distinct mutations including one small deletion mutation ( LCSequenceVariant ) , two small insertion mutations ( LCOTHER - LCOTHER and LCSequenceVariant - LCSequenceVariant ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCOTHER LCOTHER LCOTHER , and one with LCOTHER LCOTHER LCOTHER ) .	0
Dysregulated expression of LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) is found in the cells of LCOTHER who have LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) , a genetic disorder of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature and progressive LCOTHER LCOTHER .	0
CONCLUSIONS : Our study shows that LCOTHER is expressed locally in LCOTHER LCOTHER and that the gene polymorphism influences metastatic behavior . LCGeneOrGeneProduct mutations associated with LCDiseaseOrPhenotypicFeature ' LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER LCOTHER .	0
In a baby LCOrganismTaxon with early onset , severe LCOTHER , LCOTHER LCOTHER and profound , isolated LCOTHER LCOTHER in skeletal muscle , we identified a disease - segregating homozygous mutation ( LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ) in LCOTHER / LCOTHER , predicting a drastic change in a highly conserved amino - acid residue ( LCOTHER . LCOTHER ) .	0
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCOTHER - LCOTHER ) , and six non - synonymous mutations ( LCSequenceVariant , LCOTHER , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) were identified in 12 of the 486 LCOrganismTaxon ( nine with LCOTHER LCOTHER LCOTHER , two with LCOTHER LCOTHER LCOTHER , and one with LCOTHER LCOTHER LCOTHER ) .	0
LCOTHER were excised and evaluated for proliferation , apoptosis , and expression of LCOTHER , LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) - LCGeneOrGeneProduct , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER LCOTHER LCOTHER , and LCOTHER LCOTHER LCOTHER .	0
Here , we demonstrated that HG decreased the expression of LCOTHER , mitochondrial fusion proteins ( LCOTHER , LCGeneOrGeneProduct ) , cell gap junction related proteins ( LCOTHER , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) , and intracellular LCChemicalEntity concentration .	0
An opposite effect was observed for the LCOTHER LCOTHER and LCGeneOrGeneProduct LCSequenceVariant variants , with a lower prevalence of ACCA antibodies ( 23 . 4% versus 35% , p = 0 . 013 ) and Omp antibodies ( 20 . 5% versus 34 . 6% , p = 0 . 009 ) , respectively .	0
In LCOrganismTaxon , neither IMT nor plaque index was associated with LCSequenceVariant .	0
All new LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOrganismTaxon could receive appropriate preventive care , which should significantly improve their life expectancy and prognosis . LCOTHER / LCOTHER regulates molecular lineage identity , LCOTHER LCOTHER trimethylation and genomic imprinting during preimplantation development .	0
LCOTHER depletion caused increased LCOTHER - LCOTHER trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of LCOTHER - LCOTHER with membranes containing the endosomal markers LCOTHER and LCGeneOrGeneProduct but increased localization with the exocytic LCGeneOrGeneProduct .	0
Mechanistic studies revealed that LCOTHER LCOrganismTaxon are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER , ( 2 ) downregulation of cardiac LCOTHER LCOTHER LCOTHER LCOTHER - LCOTHER , ( 3 ) decreased plasma LCOTHER levels , ( 4 ) decreased cardiac LCChemicalEntity - LCChemicalEntity oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in LCOTHER ) , ( 5 ) decreased mitochondrial LCOTHER - LCOTHER LCOTHER LCOTHER , and ( 6 ) 86% drop in cardiac LCOTHER levels accompanied by decreased LCOTHER / LCOTHER ratio after LCOTHER administration .	0
PURPOSE : LCOTHER ( LCDiseaseOrPhenotypicFeature ) is a rare LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature caused by the mutations of the LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) gene .	0
Eleven subjects presented LCOTHER homozygous single - base mutations ( two first cousins and four unrelated LCOTHER with LCOTHER , two with LCOTHER , one with LCOTHER , one with LCOTHER , and one with LCOTHER plus the LCOTHER variant in heterozygosis ) , whereas four were compound heterozygotes ( one with LCOTHER / LCSequenceVariant + LCSequenceVariant > LCSequenceVariant , one with LCOTHER / LCOTHER , and two brothers with LCOTHER / LCSequenceVariant ) .	0
Constitutive activity of LCGeneOrGeneProduct ( LCSequenceVariant ) in the breast sample from a LCOTHER was supported by increased LCOTHER signaling .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCOTHER - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCGeneOrGeneProduct ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCGeneOrGeneProduct ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCOTHER - specific LCOTHER .	0
Here , we report two maternal cousins with an apparently LCDiseaseOrPhenotypicFeature - LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) , LCOTHER , LCOTHER LCOTHER , LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and LCOTHER LCOTHER .	0
Lipolytic enzymes ( LCGeneOrGeneProduct and LCGeneOrGeneProduct phosphorylation ) were increased and lipogenic regulators ( LCOTHER and LCOTHER / LCOTHER ) were decreased in eWAT by LCOTHER .	0
In 2002 , the Multiple LCOTHER Consortium identified heterozygous germline mutations of LCOTHER in LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , ( LCOTHER : LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ) .	0
We document a loss of LCGeneOrGeneProduct LCGeneOrGeneProduct LCOTHER LCOTHER trimethylation ( LCOTHER ) in LCOTHER - deficient embryos and confirm that knockdown of either LCOTHER or LCGeneOrGeneProduct results in similar phenotypes .	0
LCOTHER - LCOTHER LCOTHER , LCOTHER LCOTHER ( LCOTHER ) ( LCOTHER # LCOTHER ) is an LCOTHER LCOTHER LCOTHER caused by LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct gene ( LCGeneOrGeneProduct ) mutations .	0
Constitutive activity of LCGeneOrGeneProduct ( LCOTHER ) in the breast sample from a LCOrganismTaxon was supported by increased LCOTHER signaling .	0
Although treatment with the pancreatic b - cell toxin LCOTHER induced LCOTHER and raised plasma LCOTHER levels in wild - type LCOTHER , LCDiseaseOrPhenotypicFeature was averted in similarly treated LCOTHER ( - / - ) LCOrganismTaxon and the plasma LCOTHER level was further increased .	0
Sequencing analysis detected 17 different LCOTHER gene mutations , and 7 of these were identified as novel : 3 missense mutations , including LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 3 , LCOTHER . LCOTHER > LCOTHER ( LCOTHER . LCOTHER ) in exon 3 and LCSequenceVariant . LCSequenceVariant > LCSequenceVariant ( LCOTHER . LCOTHER ) in exon 7 ; 2 deletion mutations , including LCOTHER . LCOTHER ( LCOTHER . LCOTHER ) in exon 5 and LCOTHER . LCOTHER ( LCOTHER . LCOTHER ) in exon 11 ; and 2 alternative splicing mutations , including LCOTHER . LCOTHER + LCOTHER in intron 4 at splicing donor sites and LCSequenceVariant . LCSequenceVariant - LCSequenceVariant > LCSequenceVariant in intron 13 at splicing acceptor sites .	0
Relationships between LCDiseaseOrPhenotypicFeature and LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) remain unclear .	0
The LCOTHER mutation LCOTHER on one allele was found in 3 of 270 LCOrganismTaxon with LCOTHER and 2 of 212 children and adolescents with LCOTHER ; no carrier was found among 63 LCOTHER with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) .	0
Inactivating mutations in LCGeneOrGeneProduct - LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) have been identified as a cause of LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ; LCOTHER LCOTHER ) .	0
In this study , we establish the LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCOTHER ) or LCOTHER LCOTHER ( LCChemicalEntity ) - induced LCOTHER LCOTHER LCOTHER LCOTHER in vivo and the LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER - stimulated LCOTHER proximal tubular epithelial cell ( LCOTHER - LCOTHER ) model in vitro .	0
Of 13 documented LCDiseaseOrPhenotypicFeature , 3 occurred after LCOTHER and LCOTHER were started , and none occurred in LCOTHER with LCDiseaseOrPhenotypicFeature .	0
Mutations in the LCGeneOrGeneProduct gene are known to result in LCDiseaseOrPhenotypicFeature , a more severe phenotype than LCOTHER , with earlier onset , more extensive fat loss and biochemical changes , more severe LCOTHER LCOTHER , and more severe LCOTHER .	0
Among 12 LCOTHER - LCOTHER , eight showed mutations of more than one LCDiseaseOrPhenotypicFeature - related gene , including LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , and LCOTHER .	0
Several risk factors for LCOTHER should be noted in elderly LCOTHER LCOTHER whose symptoms often include LCDiseaseOrPhenotypicFeature , LCDiseaseOrPhenotypicFeature , LCOTHER , and exhaustion .	0
METHODS : We identified seven SNP ( single nucleotide polymorphism ) ( - 141Cins > del , TaqIB , TaqID , LCOTHER , LCOTHER , LCOTHER and TaqIA ) in the LCOTHER gene in 146 LCOTHER LCOTHER ( 59 with LCDiseaseOrPhenotypicFeature and 87 without LCOTHER according to the Simpson - Angus Scale ) treated with LCChemicalEntity after 8 weeks .	0
We performed a case - control study to test the association between two polymorphisms in the LCOTHER gene : an LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER producing an LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( the LCOTHER polymorphism ) and a LCOTHER - - > LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER resulting in a LCSequenceVariant - - > LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant LCSequenceVariant ( the LCSequenceVariant polymorphism ) and LCOTHER LCOTHER risk and LCOTHER progression .	0
LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) is an LCOTHER - binding LCOTHER with antihypertensive properties .	0
In the LCGeneOrGeneProduct gene , 2 novel mutations , LCOTHER - > LCOTHER ( LCOTHER ) and LCOTHER ( LCOTHER ) , were found in 2 LCOrganismTaxon .	0
LCOTHER AND METHODS : We examined associations between 54 polymorphisms that tag the known common variants ( minor allele frequency > 0 . 05 ) in 10 genes involved in oxidative damage repair ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCOTHER , LCOTHER , and LCGeneOrGeneProduct ) and survival in 4 , 470 LCOTHER with LCOTHER LCOTHER .	0
Results showed that LCChemicalEntity ( 10 - 30 mg / kg p . o . ) blocked LCOTHER induced by the non - competitive LCOTHER LCOTHER antagonist , LCChemicalEntity - LCChemicalEntity and partially reversed spontaneous LCOTHER of LCOTHER LCOTHER ( neo - / - ) LCOTHER .	0
LCOTHER LCOTHER LCOTHER ( LCOTHER ) comprise a group of multiple LCOTHER LCOTHER LCOTHER characterized by webbing ( pterygia ) of the neck , elbows , and / or knees and LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) .	0
The fact that no truncation or frame shift mutations have been found in any of the LCDiseaseOrPhenotypicFeature LCOTHER , coupled with our recent finding that some breeding pairs of LCOTHER LCOTHER knockout LCOTHER yield litters that show not only LCOTHER , but also severe LCDiseaseOrPhenotypicFeature and LCOTHER LCOTHER , raises the possibility that major LCOTHER mutations could be embryonically or postnatally lethal in LCOTHER . Midline B3 LCOTHER nerves in LCOTHER medulla are involved in LCOTHER effect of LCOTHER .	0
Given the marked degree of efficacy of subcutaneous LCChemicalEntity treatment in fluctuating LCOTHER ' LCOTHER LCOTHER , this approach seems to deserve more widespread clinical use . LCGeneOrGeneProduct - LCGeneOrGeneProduct gene polymorphism in LCOTHER with LCOTHER LCOTHER LCOTHER .	0
The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters ( LCOTHER , LCOTHER , LCChemicalEntity and LCOTHER ) of LCChemicalEntity - ( LCChemicalEntity - LCChemicalEntity ) LCChemicalEntity ( LCOTHER ) in comparison to its parent compound , LCOTHER LCOTHER ( LCOTHER ) .	0
In this report the distribution of the exonic LCOTHER / LCOTHER single nucleotide polymorphism ( SNP ) in LCOTHER LCOTHER LCOTHER ( LCGeneOrGeneProduct ) gene , resulting in the amino acid substitution LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) , was investigated in a large population of LCOTHER LCOrganismTaxon ( n = 321 ) and non - demented control ( n = 208 ) .	0
EXPERIMENTAL DESIGN : Because of their widespread use , the LCOTHER LCOTHER following coadministration of LCOTHER and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of LCOrganismTaxon and LCOTHER blood progenitor cells to LCOTHER , LCChemicalEntity , and LCOTHER + / - LCOTHER was determined in granulocyte - macrophage colony forming assays .	0
CONCLUSIONS : The LCOTHER - LCOTHER polymorphism of the LCOTHER LCOTHER gene is associated with LCDiseaseOrPhenotypicFeature and may be a potential regulatory site . Protective effects of LCOTHER on LCOTHER LCOTHER LCDiseaseOrPhenotypicFeature in LCOTHER .	0
We investigated the effect of LCGeneOrGeneProduct in the LCOTHER microenvironment of LCOTHER with liver parenchymal cell - specific LCOTHER ablation ( LCOTHER - Cre ; LCGeneOrGeneProduct ( f / f ) ) and LCOTHER deletion both in liver parenchymal and non - parenchymal cells ( LCOTHER - Cre ; LCOTHER ( f / f ) ) .	0
RESULTS : Person - years of exposure among non - users of LCOTHER were : 75 , 761 to LCChemicalEntity , 42 , 671 to LCChemicalEntity 65 , 860 to LCOTHER , and 37 , 495 to NS - LCOTHER .	0
These data suggest that while LCOTHER deficiency increases oxidative stress and sympathetic activity in both arterial and venous vessels , the impact on veins does not make a major contribution to this form of LCOTHER . LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature after LCChemicalEntity and LCOTHER - containing regimen in an elderly LCOTHER of LCOTHER LCOTHER .	0
Here we show that LCOTHER blockade with monoclonal antibodies perturbs the BM vascular niche of sub - lethally irradiated LCOTHER , resulting in increased LCOTHER ( + ) , LCOTHER - LCOTHER ( + ) and LCOTHER - LCOTHER ( + ) vessel density , and also increased megakaryocytes , whereas LCOTHER ( + ) , LCGeneOrGeneProduct ( + ) , LCGeneOrGeneProduct ( + ) and LCOTHER ( + ) vessel density remained unaltered .	0
Nine distinct mutations including one small deletion mutation ( LCOTHER ) , two small insertion mutations ( LCOTHER - LCOTHER and LCSequenceVariant - LCSequenceVariant ) , and six non - synonymous mutations ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCSequenceVariant and LCOTHER ) were identified in 12 of the 486 LCOTHER ( nine with LCOTHER LCOTHER LCOTHER , two with LCOTHER LCOTHER LCOTHER , and one with LCOTHER LCOTHER LCOTHER ) .	0
Inhibition of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCOTHER / LCOTHER / LCOTHER / LCOTHER responsible for phosphorylation of LCOTHER / LCOTHER / LCOTHER reduced the hyperproliferation seen in LCSequenceVariant . LCSequenceVariant fibroblasts .	0
METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( LCOTHER , LCOTHER , LCOTHER , LCOTHER , LCOTHER [ LCOTHER ] , LCOTHER , LCOTHER , LCGeneOrGeneProduct [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER , LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , LCOTHER [ LCOTHER ] , and LCOTHER [ LCOTHER ] ) and survival among LCOTHER diagnosed with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) LCOTHER LCOTHER study .	0
Isoforms of LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct , LCOTHER , and LCOTHER are reported to be expressed in endothelial cells ( ECs ) .	0
MAIN OUTCOME MEASURES : Fasting plasma LCOTHER and fasting serum LCChemicalEntity levels , insulin sensitivity index , homeostasis model assessment of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature , and LCOTHER effectiveness .	0
LCDiseaseOrPhenotypicFeature were excised and evaluated for proliferation , apoptosis , and expression of LCOTHER , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) - LCOTHER , LCOTHER - LCOTHER , LCOTHER LCOTHER LCOTHER , and LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct .	0
The LCOTHER were assigned into four groups ( n = 10 per group ) , as follows : Control LCOTHER ; LCOTHER + LCOTHER ; LCOrganismTaxon + LCOTHER ; LCOTHER + LCChemicalEntity + LCOTHER .	0
The LCOTHER LCOTHER intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the LCOTHER in the predisposed myocardium of this LCOrganismTaxon . LCOTHER and LCOTHER are Essential for Proliferation and Radiation Resistance of LCOTHER Stem - Like Cells in LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature .	0
LCOrganismTaxon were divided into three groups : sham , LCChemicalEntity and LCOTHER plus LCOTHER .	0
The genotype frequencies of LCOrganismTaxon did not differ significantly from controls ( LCOTHER / LCSequenceVariant , LCOTHER / LCOTHER : LCOTHER 18 . 3% and 1 . 2% , respectively ; LCOTHER 17 . 5% and 2 . 1% ; LCOTHER 13 . 3% and 1 . 8% ; controls 20 . 0% and 2 . 8% ) .	0
Genetic analysis of LCOTHER seems to be of limited significance in the differential diagnosis of LCOTHER without LCOTHER LCOTHER LCOTHER LCOTHER . High LCOTHER diet - fed LCOTHER LCOrganismTaxon are highly sensitive to LCChemicalEntity - induced LCOTHER .	0
PURPOSE : The aim of the study was to evaluate the LCGeneOrGeneProduct - LCOTHER system and LCOTHER LCOTHER gene polymorphisms in relation to hemodynamic parameters and heart rate variability during a head - up tilt test ( HUT ) in LCOrganismTaxon with LCOTHER LCOTHER .	0
In agreement with the expectation that this mutation alters the LCGeneOrGeneProduct binding activity , we found that the LCOTHER ( + LCOTHER LCOTHER - > LCOTHER ) and LCOTHER - LCOTHER - XmnI polymorphisms are associated with high LCOTHER in erythroid precursor cells isolated from LCOTHER ( LCOTHER ) LCOTHER / LCOTHER ( LCOTHER ) LCOTHER LCOTHER LCOrganismTaxon .	0
LCOTHER LCOTHER ( LCOTHER ) , the most prevalent LCOTHER LCOTHER in adults , is caused by ( CTG ) n - repeat expansion in a gene encoding a protein kinase ( LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ; LCGeneOrGeneProduct ) and involves changes in cytoarchitecture and ion homeostasis .	0
LCOTHER levels were not significantly affected by any of the treatments , indicating that the effects seen were attributable to inhibition of LCGeneOrGeneProduct - LCGeneOrGeneProduct , but not LCGeneOrGeneProduct - LCGeneOrGeneProduct .	0
The severe phenotype with seriously LCOTHER LCOTHER LCOTHER , LCOTHER behaviour , LCOTHER , LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature is probably due to the dominant negative effect of the LCOTHER mutant protein and the absence of any functional LCOTHER - LCOTHER . The LCGeneOrGeneProduct LCGeneOrGeneProduct confers protection against diet - induced LCOTHER , LCOTHER , and LCOTHER in female LCOTHER .	0
LCGeneOrGeneProduct genotype frequencies were not significantly different between LCDiseaseOrPhenotypicFeature LCOTHER ( CC : 57 . 3% , CT : 36 . 7% , TT : 5 . 8% ) and control subjects ( CC : 60 . 9% , CT : 33 . 5% , TT 5 . 6% ; p = 0 . 35 ) .	0
LCOTHER on either day induced LCOTHER LCOTHER ; LCOTHER LCOTHER at P45 resulted in LCCellLine cell loss and spontaneous LCOTHER , whereas P20 LCOrganismTaxon had no cell loss or spontaneous LCOTHER .	0
LCGeneOrGeneProduct was up - regulated in LCOTHER ( + ) cells from brains of LCOTHER with LCOTHER and in LCGeneOrGeneProduct ( + ) LCOTHER ( int ) cells from LCOTHER subjected to LCOTHER - induced LCOTHER .	0
PURPOSE : The purpose of this study was to analyze the value of germline and LCOTHER LCOTHER LCOTHER ( LCOTHER ) genotyping as a prognostic marker in a series of LCOTHER LCOTHER LCOrganismTaxon receiving adjuvant LCChemicalEntity ( LCOTHER ) - based treatment .	0
Differences in LCDiseaseOrPhenotypicFeature , body weight , and LCOTHER levels between LCGeneOrGeneProduct and control LCOTHER were abolished in LCOTHER that were ovariectomized before puberty , consistent with a protective action of ovarian LCOTHER mediated via the LCOTHER .	0
A single dose of LCChemicalEntity LCChemicalEntity ( LCChemicalEntity ) , which is a widely used LCOTHER LCOTHER , is associated with oxidative stress in LCOTHER , as recently demonstrated by elevated levels of LCOTHER - LCOTHER ( LCOTHER ) - LCOTHER ( LCOTHER - LCOTHER ( LCOTHER ) - LCOTHER ) .	0
Thus , our results support the notion that LCOTHER - LCOTHER and LCOTHER - LCOTHER / LCOTHER - LCOTHER mutually regulate Th17 and Th1 responses in LCOTHER - bearing hosts , and LCOrganismTaxon LCOTHER modulates the balance of the LCOTHER - LCOTHER - LCOTHER - LCOTHER / LCOTHER - LCOTHER axis towards LCGeneOrGeneProduct - LCGeneOrGeneProduct production , which leads to LCOTHER inhibition .	0
LCChemicalEntity on either day induced LCOTHER LCOTHER ; LCOTHER LCOTHER at P45 resulted in LCCellLine cell loss and spontaneous LCOTHER , whereas P20 LCOTHER had no cell loss or spontaneous LCOTHER .	0
LCOTHER administration would be effective in the treatment of LCOTHER LCOTHER LCOTHER with LCOTHER LCOTHER . Mutational analysis of LCGeneOrGeneProduct in LCDiseaseOrPhenotypicFeature LCOTHER using denaturing high performance liquid chromatography .	0
These results suggested that resident hepatic macrophages induced LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature formation by induction of LCOTHER - LCOTHER through LCOTHER signaling . LCOTHER induces primary loss of LCGeneOrGeneProduct in LCOTHER hearts : correlation with LCOTHER LCOTHER .	0
As a species comparison with our previous results , we used LCOTHER cells to investigate the effects of LCOTHER - LCOTHER on LCGeneOrGeneProduct mRNA and secretion modulated by LCGeneOrGeneProduct and LCOTHER .	0
This sole substitution was sufficient to confer constitutive activity to the receptor variant ( LCOTHER ( LCSequenceVariant ) ) , as assessed in three reconstituted cell models ( LCOTHER / LCOTHER , LCCellLine and LCOTHER - LCOTHER cells ) by LCOTHER - independent ( i ) LCOTHER tyrosine phosphorylation , ( ii ) activation of LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER ) signaling , ( iii ) transcriptional activity toward a LCOTHER - responsive reporter gene , and ( iv ) cell proliferation and protection from cell death .	0
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCOTHER with LCGeneOrGeneProduct and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCChemicalEntity to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCOTHER and LCOTHER genes in LCOTHER with LCOTHER / LCOTHER .	0
Together with previously reported cases , our LCOTHER suggests that LCOTHER - LCOTHER LCOTHER might occur in certain vulnerable individuals during treatment with atypical LCOTHER such as LCChemicalEntity , LCChemicalEntity , or LCOTHER . Context - and cell - dependent effects of LCOTHER - LCOTHER LCOTHER targeting in the bone marrow microenvironment .	0
There were a significant dilatation of tubular lumens , extensive epithelial cell vacuolization , LCDiseaseOrPhenotypicFeature , LCOTHER , and LCOTHER in LCChemicalEntity - treated LCOTHER more than those of the control and the LCOTHER groups .	0
PURPOSE : Genes in the complement pathway , including LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) , LCOTHER / LCOTHER , and LCOTHER , have been reported to be associated with LCOTHER - LCOTHER LCOTHER LCOTHER ( LCOTHER ) .	0
Although treatment with the pancreatic b - cell toxin LCOTHER induced LCDiseaseOrPhenotypicFeature and raised plasma LCOTHER levels in wild - type LCOTHER , LCOTHER was averted in similarly treated LCGeneOrGeneProduct ( - / - ) LCOTHER and the plasma LCOTHER level was further increased .	0
LCOTHER was activated by some LCOTHER LCOTHER - LCOTHER [ LCOTHER , LCOTHER , LCGeneOrGeneProduct ] , by secretagogues activating LCOTHER - LCOTHER ( LCGeneOrGeneProduct ) [ LCOTHER , LCOTHER , LCOTHER ] and by post - receptor stimulants activating LCOTHER [ LCOTHER ] , but not agents only mobilizing cellular LCOTHER or increasing LCOTHER LCOTHER .	0
The present results demonstrate that LCOTHER - LCOTHER attenuates the effect of LCChemicalEntity on hippocampal LTP through LCOTHER LCOTHER and suggest an ameliorative function of LCOTHER - LCOTHER on LCChemicalEntity - induced LCOTHER LCOTHER . Distinct patterns of germ - line deletions in LCOTHER and LCOTHER : the implication of Alu repetitive element in the genetic etiology of LCOTHER LCOTHER ( LCOTHER ) .	0
The expression analysis of LCOTHER ( LCOTHER + ) handling proteins demonstrated that LCOTHER promoted LCChemicalEntity ( LCChemicalEntity + ) overload through the expression regulation of LCChemicalEntity ( LCChemicalEntity + ) handling proteins .	0
PURPOSE : LCOTHER ( LCOTHER ) is a rare LCOTHER LCOTHER LCOTHER caused by the mutations of the LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCGeneOrGeneProduct ) gene .	0
To determine the physiologic LCGeneOrGeneProduct LCGeneOrGeneProduct ( LCOTHER ) - dependent actions of LCOTHER on LCOTHER in female LCOTHER , we generated female LCOTHER - knockout ( LCOTHER ) LCOrganismTaxon on an LCOTHER - prone LCOTHER LCOTHER ( LCOTHER ) - deficient background .	0
Hence , while alterations in select LCOTHER LCOTHER LCOTHER are not associated with development of LCOTHER - induced LCOTHER resistance , the LCOTHER - stimulated binding of LCOTHER with LCOTHER and the recruitment of LCOTHER / LCOTHER to the endosome - lysosomal compartment may partially explain the inability of LCOTHER to fully activate LCOTHER and muscle protein synthesis . Identification of novel mutations and sequence variants in the LCGeneOrGeneProduct and LCOTHER genes in LCOrganismTaxon with LCOTHER / LCOTHER .	0
However , few studies have focused on the association of LCOTHER - LCOTHER - LCOTHER / LCOTHER and LCOTHER - LCOTHER - LCOTHER / LCOTHER single nucleotide polymorphisms ( SNPs ) , LCDiseaseOrPhenotypicFeature biomarkers , and metabolic indexes in LCOTHER with LCDiseaseOrPhenotypicFeature , especially in the Inner Mongolia population .	0
PURPOSE : To identify the mutation in the LCOTHER - LCOTHER gene ( LCOTHER ) in a Chinese family with LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature ( LCDiseaseOrPhenotypicFeature ) .	0
MAIN OUTCOME MEASURES : Fasting plasma LCOTHER and fasting serum LCChemicalEntity levels , insulin sensitivity index , homeostasis model assessment of LCOTHER LCOTHER , and LCChemicalEntity effectiveness .	0
LCOTHER was up - regulated in LCOTHER ( + ) cells from brains of LCOTHER with LCOTHER and in LCGeneOrGeneProduct ( + ) LCOTHER ( int ) cells from LCOTHER subjected to LCOTHER - induced LCDiseaseOrPhenotypicFeature .	0
LCOTHER ( + ) LCOTHER cells produced activated LCOTHER ( LCGeneOrGeneProduct ) and generated LCOTHER ( - ) cells that expressed LCOTHER as well as neural differentiation factors LCGeneOrGeneProduct , LCOTHER , and LCOTHER .	0
RESULTS : HAT adipose tissue demonstrated increased LCOTHER related genes for storage ( LCOTHER , LCOTHER , LCOTHER , LCGeneOrGeneProduct , LCGeneOrGeneProduct , and LCOTHER ) , lipolysis ( LCOTHER , LCOTHER , LCOTHER ) , LCOTHER LCOTHER LCOTHER LCOTHER ( LCOTHER , LCOTHER ) and adipocyte differentiation markers ( LCOTHER , LCOTHER , LCOTHER ) .	0
Using the two Asian cohorts , significant association of LCOTHER - LCSequenceVariant / Thr with LCOTHER was observed only in the presence of LCOTHER - * 1 / * 1 genotype ( OR 4 . 63 , 95% CI 1 . 47 - 14 . 6 , P = 0 . 009 versus LCGeneOrGeneProduct - LCOTHER / Ile plus LCOTHER - * 2 / * 2 ) .	0
Expression of some lineage specific factors is markedly reduced in LCOTHER knockdown embryos , including LCOTHER , LCOTHER and LCGeneOrGeneProduct , while others are inappropriately expressed ( LCGeneOrGeneProduct , LCOTHER , LCOTHER , LCOTHER and LCOTHER ) .	0
Extensive literature search revealed multiple cases of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature secondary to LCOTHER , but none of the cases were associated with LCOTHER . Characterization of LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCDiseaseOrPhenotypicFeature LCOTHER with LCOTHER mutations .	0
Although LCOTHER , LCOTHER - LCOTHER ( LCChemicalEntity or LCChemicalEntity ) has been shown to damage brain LCOTHER ( LCOTHER - LCOTHER ) neurons in animals and possibly LCOTHER , little is known about the long - term consequences of LCOTHER - induced LCOTHER - LCOTHER LCOTHER LCOTHER on functions in which LCOTHER - LCOTHER is involved , such as cognitive function .	0
However , we did not find significant association of this polymorphism with LCOTHER . LCGeneOrGeneProduct induces LCOTHER activation in LCDiseaseOrPhenotypicFeature microenvironment and LCOTHER resistance in LCOTHER LCOTHER .	0
RESULTS : LCOTHER ablation had no influence on the development of LCOTHER - induced AHR , but attenuated LCGeneOrGeneProduct - induced increases in expression of LCOTHER and LCOTHER , LCOTHER , LCOTHER , and LCOTHER ( LCOTHER LCOTHER ) , LCOTHER , LCOTHER and LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( LCOTHER ) , LCOTHER ( LCOTHER - LCOTHER LCOTHER ) , LCOTHER and LCOTHER ( goblet cell markers ) , and LCGeneOrGeneProduct - specific LCOTHER .	0
LCOTHER is a rare complication occurring during LCChemicalEntity - LCChemicalEntity ( LCChemicalEntity - LCChemicalEntity ) treatment for LCOTHER .	0
Newborn LCOrganismTaxon pups and dams were placed into an LCOTHER model that cycled LCChemicalEntity concentration between 50% and 10% every 24 h for 14 days , and then were placed in room air ( RA ) for an additional 4 days ( LCOTHER LCOTHER model ) .	0
LCOTHER biomarkers in serum ( hs - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio ) and placental ( LCOTHER - LCOTHER , LCOTHER - LCOTHER , LCGeneOrGeneProduct - LCGeneOrGeneProduct , LCOTHER - LCOTHER / LCOTHER - LCOTHER ratio , LCOTHER - LCOTHER , LCOTHER - LCOTHER ) were significantly different ( p < 0 . 05 ) between LCOTHER with LCOTHER and LCOTHER with healthy pregnancies .	0
CONTEXT : LCOTHER LCOTHER LCOTHER LCOTHER LCOTHER ( LCDiseaseOrPhenotypicFeature ) is a rare LCOTHER LCOTHER , characterized by LCOTHER and LCOTHER / LCDiseaseOrPhenotypicFeature with increased serum LCOTHER , LCOTHER - LCOTHER LCOTHER [ LCOTHER , LCOTHER - ( LCOTHER ) ( LCOTHER ) LCOTHER ] resulting in LCOTHER .	0
